Key,Virtual Compound Preferred Name,EUbOPEN Compound ID,Compound SMILES,Compound InChi,Compound InChi Key,Protein Family,Target ID,NCBI Gene ID,UniProt ID,Synonyms,Mode of Action,Negative Control (In Case of Probe),Affinity Biochemical (nM),Affinity Biochemical Definition,Affinity Biochemical Assay Type,Affinity Biochemical Source Knowledge,Affinity Biochemical Relation,Affinity On-target Cellular (nM),Affinity On-target Cellular Definition,Affinity On-target Cellular Assay Type,Affinity on-target cellular Source Knowledge,Affinity On-target Cellular Relation,Selectivity Number of Off-targets,Selectivity Platform,Selectivity Platform Number of Targets,Selectivity Remarks,Selectivity Source Knowledge,CG-Set,Recommended Concentration
EUB0000326a_EP300@Acetyltransferase,A-486,EUB0000326a,C[C@H](N(C(CN1C([C@]2(OC1=O)CCC3=C2C=C(NC(NC)=O)C=C3)=O)=O)CC4=CC=C(F)C=C4)C(F)(F)F,"InChI=1S/C25H24F4N4O5/c1-14(25(27,28)29)32(12-15-3-6-17(26)7-4-15)20(34)13-33-21(35)24(38-23(33)37)10-9-16-5-8-18(11-19(16)24)31-22(36)30-2/h3-8,11,14H,9-10,12-13H2,1-2H3,(H2,30,31,36)/t14-,24-/m0/s1",MTTJOZOOUCZVHO-BSEYFRJRSA-N,HAT,EP300@Acetyltransferase,2033,Q09472,"p300, KAT3B",Negative control for A-485,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-485,,,,,,,,,,,,Epigenetic set,1 µM
EUB0000326a_CREBBP@Acetyltransferase,A-486,EUB0000326a,C[C@H](N(C(CN1C([C@]2(OC1=O)CCC3=C2C=C(NC(NC)=O)C=C3)=O)=O)CC4=CC=C(F)C=C4)C(F)(F)F,"InChI=1S/C25H24F4N4O5/c1-14(25(27,28)29)32(12-15-3-6-17(26)7-4-15)20(34)13-33-21(35)24(38-23(33)37)10-9-16-5-8-18(11-19(16)24)31-22(36)30-2/h3-8,11,14H,9-10,12-13H2,1-2H3,(H2,30,31,36)/t14-,24-/m0/s1",MTTJOZOOUCZVHO-BSEYFRJRSA-N,HAT,CREBBP@Acetyltransferase,1387,Q92793,"RTS, CBP, KAT3A",Negative control for A-485,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-485,,,,,,,,,,,,Epigenetic set,1 µM
EUB0000327a_MYST3@Acetyltransferase,WM-2474,EUB0000327a,FC1=CC=C(C2=CC=NN=C2)C=C1C(NNS(C3=CC=CC=C3)(=O)=O)=O,"InChI=1S/C17H13FN4O3S/c18-16-7-6-12(13-8-9-19-20-11-13)10-15(16)17(23)21-22-26(24,25)14-4-2-1-3-5-14/h1-11,22H,(H,21,23)",WYMCVPPNOFFNGE-UHFFFAOYSA-N,HAT,MYST3@Acetyltransferase,7994,Q92794,"MOZ, ZC2HC6A",Negative control for WM-1119,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/WM-1119,,,,,,,,,,,,Epigenetic set,1 µM
EUB0000327a_MYST4@Acetyltransferase,WM-2474,EUB0000327a,FC1=CC=C(C2=CC=NN=C2)C=C1C(NNS(C3=CC=CC=C3)(=O)=O)=O,"InChI=1S/C17H13FN4O3S/c18-16-7-6-12(13-8-9-19-20-11-13)10-15(16)17(23)21-22-26(24,25)14-4-2-1-3-5-14/h1-11,22H,(H,21,23)",WYMCVPPNOFFNGE-UHFFFAOYSA-N,HAT,MYST4@Acetyltransferase,23522,Q8WYB5,"querkopf, qkf, Morf, MOZ2, ZC2HC6B",Negative control for WM-1119,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/WM-1119,,,,,,,,,,,,Epigenetic set,1 µM
EUB0000328a_EP300@Acetyltransferase,A-485,EUB0000328a,C[C@H](N(C(CN1C([C@]2(OC1=O)CCC3=CC(NC(NC)=O)=CC=C23)=O)=O)CC4=CC=C(F)C=C4)C(F)(F)F,"InChI=1S/C25H24F4N4O5/c1-14(25(27,28)29)32(12-15-3-5-17(26)6-4-15)20(34)13-33-21(35)24(38-23(33)37)10-9-16-11-18(7-8-19(16)24)31-22(36)30-2/h3-8,11,14H,9-10,12-13H2,1-2H3,(H2,30,31,36)/t14-,24-/m0/s1",VRVJKILQRBSEAG-BSEYFRJRSA-N,HAT,EP300@Acetyltransferase,2033,Q09472,"p300, KAT3B",Inhibitor,A-486,10,IC50,TR-FRET assay (BHC domains),"https://doi.org/10.1038/nature24028, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-485",=,,,,,,,,,"Selective against other available HATs (MYST3, MYST4, PCAF, HAT1, TIP60 and GCN5L2); Screened in KinomeScan (DiscoverX) against 468 targets at 10 µM, clostest targets as % of contr.: PRKCE (22%), LATS2 (47%), ABL1(H396P)-nonphosphorylated (49%); Screened against 45 GPCR targets, closest targets: Ki(SLC6A4) = 223.27 nM, Ki(GABA/PBR) = 1107.62 nM, Ki(HTR2B) = 1292.04 nM, Ki(SLC6A3) = 1817.04;Cerep ligand profiling against 83 targets, at 10 µM, closest targets as % inhibition: SLC6A4 (99%), SLC6A3 (94%);","https://doi.org/10.1038/nature24028, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-485",Epigenetic set,1 µM
EUB0000328a_CREBBP@Acetyltransferase,A-485,EUB0000328a,C[C@H](N(C(CN1C([C@]2(OC1=O)CCC3=CC(NC(NC)=O)=CC=C23)=O)=O)CC4=CC=C(F)C=C4)C(F)(F)F,"InChI=1S/C25H24F4N4O5/c1-14(25(27,28)29)32(12-15-3-5-17(26)6-4-15)20(34)13-33-21(35)24(38-23(33)37)10-9-16-11-18(7-8-19(16)24)31-22(36)30-2/h3-8,11,14H,9-10,12-13H2,1-2H3,(H2,30,31,36)/t14-,24-/m0/s1",VRVJKILQRBSEAG-BSEYFRJRSA-N,HAT,CREBBP@Acetyltransferase,1387,Q92793,"RTS, CBP, KAT3A",Inhibitor,A-486,3,IC50,TR-FRET assay (BHC domains),"https://doi.org/10.1038/nature24028, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-485",=,,,,,,,,,"Selective against other available HATs (MYST3, MYST4, PCAF, HAT1, TIP60 and GCN5L2); Screened in KinomeScan (DiscoverX) against 468 targets at 10 µM, clostest targets as % of contr.: PRKCE (22%), LATS2 (47%), ABL1(H396P)-nonphosphorylated (49%); Screened against 45 GPCR targets, closest targets: Ki(SLC6A4) = 223.27 nM, Ki(GABA/PBR) = 1107.62 nM, Ki(HTR2B) = 1292.04 nM, Ki(SLC6A3) = 1817.04;Cerep ligand profiling against 83 targets, at 10 µM, closest targets as % inhibition: SLC6A4 (99%), SLC6A3 (94%);","https://doi.org/10.1038/nature24028, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-485",Epigenetic set,1 µM
EUB0000329a_MYST3@Acetyltransferase,WM-1119,EUB0000329a,FC1=CC=CC=C1S(NNC(C2=CC(F)=CC(C3=NC=CC=C3)=C2)=O)(=O)=O,"InChI=1S/C18H13F2N3O3S/c19-14-10-12(16-6-3-4-8-21-16)9-13(11-14)18(24)22-23-27(25,26)17-7-2-1-5-15(17)20/h1-11,23H,(H,22,24)",QLXULUNLCRKWRD-UHFFFAOYSA-N,HAT,MYST3@Acetyltransferase,7994,Q92794,"MOZ, ZC2HC6A",Inhibitor,WM-2474,2,Kd,Surface plasmon resonance (SPR),"https://doi.org/10.1021/acs.jmedchem.9b02071, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/WM-1119",=,,,,,,0,"HAT panel, literature",6,"> 200-fold selective on all other HATs tested; No significant activity on 166 targets at 10 µM (kinases, GPCRs, HDACs, phosphatases etc.), no target was affected by more than 50%, closest hits in the GPCR scan: Ki(DRD2) = 397.52 nM, GABAA/BZP (75.65 % inhibition)",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/WM-1119,Epigenetic set,1 µM
EUB0000329a_MYST4@Acetyltransferase,WM-1119,EUB0000329a,FC1=CC=CC=C1S(NNC(C2=CC(F)=CC(C3=NC=CC=C3)=C2)=O)(=O)=O,"InChI=1S/C18H13F2N3O3S/c19-14-10-12(16-6-3-4-8-21-16)9-13(11-14)18(24)22-23-27(25,26)17-7-2-1-5-15(17)20/h1-11,23H,(H,22,24)",QLXULUNLCRKWRD-UHFFFAOYSA-N,HAT,MYST4@Acetyltransferase,23522,Q8WYB5,"querkopf, qkf, Morf, MOZ2, ZC2HC6B",Inhibitor,WM-2474,,,,,,6.3,IC50,HAT binding assay,,=,0,"HAT panel, literature",6,"> 200-fold selective on all other HATs tested; No significant activity on 166 targets at 10 ?M (Kinases, GPCRs, HDACs, phosphatases etc.), no target was affected by more than 50%, closest hits in the GPCR scan: Ki(DRD2) = 397.52 nM, GABAA/BZP (75.65 % inhibition)",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/WM-1119,Epigenetic set,1 µM
EUB0000195c_CREBBP@BRD,I-CBP112,EUB0000195c,CCC(=O)N1CCOc2c(cc(-c3ccc(OC)c(OC)c3)cc2OC[C@H]2CCCN(C)C2)C1,"InChI=1S/C27H36N2O5/c1-5-26(30)29-11-12-33-27-22(17-29)13-21(20-8-9-23(31-3)24(14-20)32-4)15-25(27)34-18-19-7-6-10-28(2)16-19/h8-9,13-15,19H,5-7,10-12,16-18H2,1-4H3/t19-/m0/s1",YKNAKDFZAWQEEO-IBGZPJMESA-N,Bromodomain,CREBBP@BRD,1387,Q92793,"RTS, CBP, KAT3A",Inhibitor,,151,Kd,ITC,"https://aacrjournals.org/cancerres/article/75/23/5106/606315/Generation-of-a-Selective-Small-Molecule-Inhibitor, https://www.thesgc.org/chemical-probes/I-CBP112",=,600,IC50,NanoBRET assay (HEK293T cells),,=,0,"Bromodomain panel, literature",42,"Screened at 2 µM via biolayer interferometry (BLI), weak inhibition of BET bromodomains at 2.0 µM (BRD2, BRD3, BRD4, BRDT on both BD1 and BD2), clean at screen with 200 nM; DSF assay screen against 43 bromodomain family members, closest targets: dTM(BRD2, BD1) = 1.35 K, dTM(BRD3, BD1) = 1.55 K, dTM(BRD4, BD1) = 2.09 K, dTm(BRD4, BD2) = 0.58 K; In vitro follow-up (ITC): Kd(BRD4, BD1) = 5.6 µM, Kd(BRD4, BD2) = 20 µM; Screened in CEREP selectivity panel against 104 targets (nuclear receptors, ion channels, and 32 enzyme assays (including 10 kinases, 9 proteases, and 5 phosphodiesterases) at 10 µM, closest targets as % of inhibition: a1A (89%), M2 (67%);",https://doi.org/10.1158/0008-5472.CAN-15-0236,Epigenetic set,1 µM
EUB0000195c_EP300@BRD,I-CBP112,EUB0000195c,CCC(=O)N1CCOc2c(cc(-c3ccc(OC)c(OC)c3)cc2OC[C@H]2CCCN(C)C2)C1,"InChI=1S/C27H36N2O5/c1-5-26(30)29-11-12-33-27-22(17-29)13-21(20-8-9-23(31-3)24(14-20)32-4)15-25(27)34-18-19-7-6-10-28(2)16-19/h8-9,13-15,19H,5-7,10-12,16-18H2,1-4H3/t19-/m0/s1",YKNAKDFZAWQEEO-IBGZPJMESA-N,Bromodomain,EP300@BRD,2033,Q09472,"p300, KAT3B",Inhibitor,,625,Kd,ITC,"https://aacrjournals.org/cancerres/article/75/23/5106/606315/Generation-of-a-Selective-Small-Molecule-Inhibitor, https://www.thesgc.org/chemical-probes/I-CBP112",=,,,,,,0,"Bromodomain panel, literature",42,"Screened at 2 µM via biolayer interferometry (BLI), weak inhibition of BET bromodomains at 2.0 µM (BRD2, BRD3, BRD4, BRDT on both BD1 and BD2), clean at screen with 200 nM; DSF assay screen against 43 bromodomain family members, closest targets: dTM(BRD2, BD1) = 1.35 K, dTM(BRD3, BD1) = 1.55 K, dTM(BRD4, BD1) = 2.09 K, dTm(BRD4, BD2) = 0.58 K; In vitro follow-up (ITC): Kd(BRD4, BD1) = 5.6 µM, Kd(BRD4, BD2) = 20 µM; Screened in CEREP selectivity panel against 104 targets (nuclear receptors, ion channels, and 32 enzyme assays (including 10 kinases, 9 proteases, and 5 phosphodiesterases) at 10 µM, closest targets as % of inhibition: a1A (89%), M2 (67%);",https://doi.org/10.1158/0008-5472.CAN-15-0236,Epigenetic set,1 µM
EUB0000208c_CREBBP@BRD,SGC-CBP30,EUB0000208c,COc1ccc(CCc2nc3cc(-c4c(C)noc4C)ccc3n2C[C@H](C)N2CCOCC2)cc1Cl,"InChI=1S/C28H33ClN4O3/c1-18(32-11-13-35-14-12-32)17-33-25-8-7-22(28-19(2)31-36-20(28)3)16-24(25)30-27(33)10-6-21-5-9-26(34-4)23(29)15-21/h5,7-9,15-16,18H,6,10-14,17H2,1-4H3/t18-/m0/s1",GEPYBHCJBORHCE-SFHVURJKSA-N,Bromodomain,CREBBP@BRD,1387,Q92793,"RTS, CBP, KAT3A",Inhibitor,BDOIA513,21,Kd,ITC,"https://doi.org/10.1073/pnas.1501956112, https://www.thesgc.org/chemical-probes/CBP30",=,,,,,,0,"Bromodomain panel, literature",45,"Screened at 10 µM in DSF assay, dTM (CREBBPA/EP300A) = 9.6/ 10.4 K, closest targets: dTM(BRD4) = 2.0 K, dTM(BRD3) = 1.9 K, dTm(BRD2) = 1.4 K, dTm (BRD3) = 1.2 K; Follow-up Kds via ITC: Kd(BRD4 at BD1/ BD2) = 0.854/ 4.88 µM, Ki(BRD3 at BD1/ BD2) = 1.09/ 2.19 µM, Kd(BRD2 at BD1/BD2) = 1.01/ 1.76 µM, Kd(BRD3 at BD1/BD2) = 1.09/ 2.19µM; Screened in CEREP panel against 104 receptors, ion channels and other enzymes, closest targets: Ki(alpha2A) = 570 nM, Ki(alpha2C) = 110 nM, Ki(PAF) = 540 nM;","https://doi.org/10.1073/pnas.1501956112, https://www.thesgc.org/chemical-probes/CBP30",Epigenetic set,1 µM
EUB0000208c_EP300@BRD,SGC-CBP30,EUB0000208c,COc1ccc(CCc2nc3cc(-c4c(C)noc4C)ccc3n2C[C@H](C)N2CCOCC2)cc1Cl,"InChI=1S/C28H33ClN4O3/c1-18(32-11-13-35-14-12-32)17-33-25-8-7-22(28-19(2)31-36-20(28)3)16-24(25)30-27(33)10-6-21-5-9-26(34-4)23(29)15-21/h5,7-9,15-16,18H,6,10-14,17H2,1-4H3/t18-/m0/s1",GEPYBHCJBORHCE-SFHVURJKSA-N,Bromodomain,EP300@BRD,2033,Q09472,"p300, KAT3B",Inhibitor,BDOIA513,38,Kd,ITC,"https://doi.org/10.1073/pnas.1501956112, https://www.thesgc.org/chemical-probes/CBP30",=,,,,,,0,"Bromodomain panel, literature",45,"Screened at 10 µM in DSF assay, dTM (CREBBPA/EP300A) = 9.6/ 10.4 K, closest targets: dTM(BRD4) = 2.0 K, dTM(BRD3) = 1.9 K, dTm(BRD2) = 1.4 K, dTm (BRD3) = 1.2 K; Follow-up Kds via ITC: Kd(BRD4 at BD1/ BD2) = 0.854/ 4.88 µM, Ki(BRD3 at BD1/ BD2) = 1.09/ 2.19 µM, Kd(BRD2 at BD1/BD2) = 1.01/ 1.76 µM, Kd(BRD3 at BD1/BD2) = 1.09/ 2.19µM; Screened in CEREP panel against 104 receptors, ion channels and other enzymes, closest targets: Ki(alpha2A) = 570 nM, Ki(alpha2C) = 110 nM, Ki(PAF) = 540 nM;","https://doi.org/10.1073/pnas.1501956112, https://www.thesgc.org/chemical-probes/CBP30",Epigenetic set,1 µM
EUB0000218c_KAT2B@BRD,L-Moses,EUB0000218c,Cc1nnc2c3ccccc3c(N[C@@H](C)[C@H](c3ccccc3)N(C)C)nn12,"InChI=1S/C21H24N6/c1-14(19(26(3)4)16-10-6-5-7-11-16)22-20-17-12-8-9-13-18(17)21-24-23-15(2)27(21)25-20/h5-14,19H,1-4H3,(H,22,25)/t14-,19+/m0/s1",MSFPLTWUFWOKBX-IFXJQAMLSA-N,Bromodomain,KAT2B@BRD,8850,Q92831,"P/CAF, GCN5, GCN5L",Inhibitor,D-Moses,48,IC50,BROMOscan assay (DiscoverX),https://www.thesgc.org/chemical-probes/L-Moses,=,660,IC50,Competing pull-down assay (full-length PCAF from cell lysates using immobilized L-Moses),,=,0,"Bromodomain panel, literature",48,"Screened in DSF assay at 10 µM: highly selective, other targets <2 K; Screened against 130 enzymes (GPCR panel and Eurofins panel) at 10 µM, closest targets: opioid receptors, Ki(MU) = 100 nM, Ki(OPRL1) = 840 nM, Ki(kappa) = 1100 nM, and 5-HAT transporter, Ki = 220 nM","https://doi.org/10.1002/anie.201610816, https://www.thesgc.org/chemical-probes/L-Moses",Epigenetic set,1 µM
EUB0000218c_KAT2A@BRD,L-Moses,EUB0000218c,Cc1nnc2c3ccccc3c(N[C@@H](C)[C@H](c3ccccc3)N(C)C)nn12,"InChI=1S/C21H24N6/c1-14(19(26(3)4)16-10-6-5-7-11-16)22-20-17-12-8-9-13-18(17)21-24-23-15(2)27(21)25-20/h5-14,19H,1-4H3,(H,22,25)/t14-,19+/m0/s1",MSFPLTWUFWOKBX-IFXJQAMLSA-N,Bromodomain,KAT2A@BRD,2648,Q92830,"GCN5, PCAF-b",Inhibitor,D-Moses,220,IC50,BROMOscan assay (DiscoverX),https://www.thesgc.org/chemical-probes/L-Moses,=,220,IC50,Competing pull-down assay (full-length GCN5 from cell lysates using immobilized L-Moses),,=,0,"Bromodomain panel, literature",48,"Screened in DSF assay at 10 µM: highly selective, other targets <2 K; Screened against 130 enzymes (GPCR panel and Eurofins panel) at 10 µM, closest targets: opioid receptors, Ki(MU) = 100 nM, Ki(OPRL1) = 840 nM, Ki(kappa) = 1100 nM, and 5-HAT transporter, Ki = 220 nM","https://doi.org/10.1002/anie.201610816, https://www.thesgc.org/chemical-probes/L-Moses",Epigenetic set,1 µM
EUB0000004c_BRD7@BRD,BI-9564,EUB0000004c,COc1cc(-c2cn(C)c(=O)c3cnccc23)c(OC)cc1CN(C)C,"InChI=1S/C20H23N3O3/c1-22(2)11-13-8-19(26-5)15(9-18(13)25-4)17-12-23(3)20(24)16-10-21-7-6-14(16)17/h6-10,12H,11H2,1-5H3",BJFSUDWKXGMUKA-UHFFFAOYSA-N,Bromodomain,BRD7@BRD,29117,Q9NPI1,"CELTIX1, BP75",Inhibitor,,73,Kd,Competition binding assay (DiscoverX),"https://doi.org/10.1021/acs.jmedchem.5b01865, https://www.thesgc.org/chemical-probes/BI-9564",=,1000,IC50,Recovery After Photobleaching (FRAP) assay U2OS cells,,<,0,"Bromodomain panel, literature",48,"Screened at 10 µM in DSF assays, dTm(BRD7) = 6.47 K, dTm(BRD9) = 9.21 K, closest target: dTm(CERC2) = 5.61 K, all other bromodomains <2 K; In vitro follow up of closest target: Kd(CERC2, ITC) = 200 nM; Screened against 32 bromodomains at 10 µM (Bromoscan and BromoMax",https://doi.org/10.1021/acs.jmedchem.5b01865,Epigenetic set,1 µM
EUB0000004c_BRD9@BRD,BI-9564,EUB0000004c,COc1cc(-c2cn(C)c(=O)c3cnccc23)c(OC)cc1CN(C)C,"InChI=1S/C20H23N3O3/c1-22(2)11-13-8-19(26-5)15(9-18(13)25-4)17-12-23(3)20(24)16-10-21-7-6-14(16)17/h6-10,12H,11H2,1-5H3",BJFSUDWKXGMUKA-UHFFFAOYSA-N,Bromodomain,BRD9@BRD,65980,Q9H8M2,FLJ13441,Inhibitor,,5.9,Kd,Competition binding assay (DiscoverX),"https://doi.org/10.1021/acs.jmedchem.5b01865, https://www.thesgc.org/chemical-probes/BI-9564",=,100,IC50,Recovery After Photobleaching (FRAP) assay U2OS cells,,<,0,"Bromodomain panel, literature",48,"Screened at 10 µM in DSF assays, dTm(BRD7) = 6.47 K, dTm(BRD9) = 9.21 K, closest target: dTm(CERC2) = 5.61 K, all other bromodomains <2 K; In vitro follow up of closest target: Kd(CERC2, ITC) = 200 nM; Screened against 32 bromodomains at 10 µM (Bromoscan and BromoMax",https://doi.org/10.1021/acs.jmedchem.5b01865,Epigenetic set,1 µM
EUB0000330a_BRD4@BD1,(+)-JQ1,EUB0000330a,O=C(C[C@@H]1N=C(C2=C(N3C1=NN=C3C)SC(C)=C2C)C4=CC=C(C=C4)Cl)OC(C)(C)C,"InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m0/s1",DNVXATUJJDPFDM-KRWDZBQOSA-N,Bromodomain,BRD4@BD1,23476,O60885,"HUNKI, MCAP, CAP, HUNK1",Inhibitor,(-)-JQ1,49,Kd,Isothermal titration calorimetry (ITC),"https://doi.org/10.1038/nature09504, https://www.thesgc.org/chemical-probes/JQ1",=,,,,,,0,"Bromodomain panel, literature",37,"Screened at 10 µM in DSF-assay, closest target: dTM(CREBBP) = 1.04 K, inactive in CEREP assay; Screened at 1 µM in CEREP panel against 55 ligand receptors, ion channels and transporters, clean profile;",https://www.thesgc.org/chemical-probes/JQ1,Epigenetic set,1 µM
EUB0000330a_BRD4@BD2,(+)-JQ1,EUB0000330a,O=C(C[C@@H]1N=C(C2=C(N3C1=NN=C3C)SC(C)=C2C)C4=CC=C(C=C4)Cl)OC(C)(C)C,"InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m0/s1",DNVXATUJJDPFDM-KRWDZBQOSA-N,Bromodomain,BRD4@BD2,23476,O60885,"HUNKI, MCAP, CAP, HUNK1",Inhibitor,(-)-JQ1,90.1,Kd,Isothermal titration calorimetry (ITC),"https://doi.org/10.1038/nature09504, https://www.thesgc.org/chemical-probes/JQ1",=,,,,,,0,"Bromodomain panel, literature",37,"Screened at 10 µM in DSF-assay, closest target: dTM(CREBBP) = 1.04 K, inactive in CEREP assay; Screened at 1 µM in CEREP panel against 55 ligand receptors, ion channels and transporters, clean profile;",https://www.thesgc.org/chemical-probes/JQ1,Epigenetic set,1 µM
EUB0000330a_BRD2@BD1,(+)-JQ1,EUB0000330a,O=C(C[C@@H]1N=C(C2=C(N3C1=NN=C3C)SC(C)=C2C)C4=CC=C(C=C4)Cl)OC(C)(C)C,"InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m0/s1",DNVXATUJJDPFDM-KRWDZBQOSA-N,Bromodomain,BRD2@BD1,6046,P25440,"KIAA9001, RING3, D6S113E, NAT, FSRG1",Inhibitor,(-)-JQ1,128.4,Kd,Isothermal titration calorimetry (ITC),"https://doi.org/10.1038/nature09504, https://www.thesgc.org/chemical-probes/JQ1",=,,,,,,0,"Bromodomain panel, literature",37,"Screened at 10 µM in DSF-assay, closest target: dTM(CREBBP) = 1.04 K, inactive in CEREP assay; Screened at 1 µM in CEREP panel against 55 ligand receptors, ion channels and transporters, clean profile;",https://www.thesgc.org/chemical-probes/JQ1,Epigenetic set,1 µM
EUB0000330a_BRD2@BD2,(+)-JQ1,EUB0000330a,O=C(C[C@@H]1N=C(C2=C(N3C1=NN=C3C)SC(C)=C2C)C4=CC=C(C=C4)Cl)OC(C)(C)C,"InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m0/s1",DNVXATUJJDPFDM-KRWDZBQOSA-N,Bromodomain,BRD2@BD2,6046,P25440,"KIAA9001, RING3, D6S113E, NAT, FSRG1",Inhibitor,(-)-JQ1,,,,,,,,,,,0,"Bromodomain panel, literature",37,"Screened at 10 µM in DSF-assay, closest target: dTM(CREBBP) = 1.04 K, inactive in CEREP assay; Screened at 1 µM in CEREP panel against 55 ligand receptors, ion channels and transporters, clean profile;",https://www.thesgc.org/chemical-probes/JQ1,Epigenetic set,1 µM
EUB0000330a_BRD3@BD1,(+)-JQ1,EUB0000330a,O=C(C[C@@H]1N=C(C2=C(N3C1=NN=C3C)SC(C)=C2C)C4=CC=C(C=C4)Cl)OC(C)(C)C,"InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m0/s1",DNVXATUJJDPFDM-KRWDZBQOSA-N,Bromodomain,BRD3@BD1,8019,Q15059,"RING3L, ORFX, KIAA0043",Inhibitor,(-)-JQ1,59.5,Kd,Isothermal titration calorimetry (ITC),"https://doi.org/10.1038/nature09504, https://www.thesgc.org/chemical-probes/JQ1",=,,,,,,0,"Bromodomain panel, literature",37,"Screened at 10 µM in DSF-assay, closest target: dTM(CREBBP) = 1.04 K, inactive in CEREP assay; Screened at 1 µM in CEREP panel against 55 ligand receptors, ion channels and transporters, clean profile;",https://www.thesgc.org/chemical-probes/JQ1,Epigenetic set,1 µM
EUB0000330a_BRD3@BD2,(+)-JQ1,EUB0000330a,O=C(C[C@@H]1N=C(C2=C(N3C1=NN=C3C)SC(C)=C2C)C4=CC=C(C=C4)Cl)OC(C)(C)C,"InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m0/s1",DNVXATUJJDPFDM-KRWDZBQOSA-N,Bromodomain,BRD3@BD2,8019,Q15059,"RING3L, ORFX, KIAA0043",Inhibitor,(-)-JQ1,82,Kd,Isothermal titration calorimetry (ITC),"https://doi.org/10.1038/nature09504, https://www.thesgc.org/chemical-probes/JQ1",=,,,,,,0,"Bromodomain panel, literature",37,"Screened at 10 µM in DSF-assay, closest target: dTM(CREBBP) = 1.04 K, inactive in CEREP assay; Screened at 1 µM in CEREP panel against 55 ligand receptors, ion channels and transporters, clean profile;",https://www.thesgc.org/chemical-probes/JQ1,Epigenetic set,1 µM
EUB0000330a_BRDT@BD1,(+)-JQ1,EUB0000330a,O=C(C[C@@H]1N=C(C2=C(N3C1=NN=C3C)SC(C)=C2C)C4=CC=C(C=C4)Cl)OC(C)(C)C,"InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m0/s1",DNVXATUJJDPFDM-KRWDZBQOSA-N,Bromodomain,BRDT@BD1,676,Q58F21,"BRD6, CT9",Inhibitor,(-)-JQ1,190.1,Kd,Isothermal titration calorimetry (ITC),"https://doi.org/10.1038/nature09504, https://www.thesgc.org/chemical-probes/JQ1",=,,,,,,0,"Bromodomain panel, literature",37,"Screened at 10 µM in DSF-assay, closest target: dTM(CREBBP) = 1.04 K, inactive in CEREP assay; Screened at 1 µM in CEREP panel against 55 ligand receptors, ion channels and transporters, clean profile;",https://www.thesgc.org/chemical-probes/JQ1,Epigenetic set,1 µM
EUB0000330a_BRDT@BD2,(+)-JQ1,EUB0000330a,O=C(C[C@@H]1N=C(C2=C(N3C1=NN=C3C)SC(C)=C2C)C4=CC=C(C=C4)Cl)OC(C)(C)C,"InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m0/s1",DNVXATUJJDPFDM-KRWDZBQOSA-N,Bromodomain,BRDT@BD2,676,Q58F21,"BRD6, CT9",Inhibitor,(-)-JQ1,,,,,,,,,,,0,"Bromodomain panel, literature",37,"Screened at 10 µM in DSF-assay, closest target: dTM(CREBBP) = 1.04 K, inactive in CEREP assay; Screened at 1 µM in CEREP panel against 55 ligand receptors, ion channels and transporters, clean profile;",https://www.thesgc.org/chemical-probes/JQ1,Epigenetic set,1 µM
EUB0000191c_BRD1@BRD,BAY-299,EUB0000191c,Cc1cc2c(cc1N1C(=O)c3cccc4c(CCCO)ccc(c34)C1=O)n(C)c(=O)n2C,"InChI=1S/C25H23N3O4/c1-14-12-20-21(27(3)25(32)26(20)2)13-19(14)28-23(30)17-8-4-7-16-15(6-5-11-29)9-10-18(22(16)17)24(28)31/h4,7-10,12-13,29H,5-6,11H2,1-3H3",OFWWWKWUCDUISA-UHFFFAOYSA-N,Bromodomain,BRD1@BRD,23774,O95696,"BRL, BRPF2",Inhibitor,BAY-364,67,IC50,TR-FRET assay,https://doi.org/10.1021/acs.jmedchem.7b00306,=,503,IC50,NanoBRET assay (HEK293T cells),,=,0,CEREP panel (LeadProfilingScreen Eurofins),68,"Screened at 10 µM against receptors, ion channels and enzymes, closest targets as % of contr.: A1 receptor (48%), Cl- channel (GABA-gated) (23%), PDE2A1 (49%), PDE5 (2%), >10000-fold selective; In vitro activity of closest targets (TR-FRET assays): IC50(BRPF1) = 3.15 µM, IC50(BRPF3) = 5.55 µM, IC50(TAF1L, BD2) = 0.106 µM, IC50(BRD4, BD1) >15 µM, IC50(BRD4,BD2) >20 µM; Screened in DSF assay against 48 bromodomains at 10 µM, closest targets: dTm(CECR2) = 3.5 K, dTm(EP300) = 3.5 K, dTm(BRD7) = 2.3 K; In vitro follow up ITC: Kd(CECR2) = 1.39 µM; Screened against31 bromodomains in (BROMOscan DiscoverX) at 100 nM, closest targets as % contr.: CREBBP (30%), TAF1L(BD2) (0.7%); Screened against 300 kinases at 10 µM, >10000-fold selective (PMID: 28402630)","https://doi.org/10.1021/acs.jmedchem.7b00306, https://www.thesgc.org/chemical-probes/BAY-299",Epigenetic set,1 µM
EUB0000191c_TAF1@BD2,BAY-299,EUB0000191c,Cc1cc2c(cc1N1C(=O)c3cccc4c(CCCO)ccc(c34)C1=O)n(C)c(=O)n2C,"InChI=1S/C25H23N3O4/c1-14-12-20-21(27(3)25(32)26(20)2)13-19(14)28-23(30)17-8-4-7-16-15(6-5-11-29)9-10-18(22(16)17)24(28)31/h4,7-10,12-13,29H,5-6,11H2,1-3H3",OFWWWKWUCDUISA-UHFFFAOYSA-N,Bromodomain,TAF1@BD2,6872,P21675,"NSCL2, TAFII250, KAT4, DYT3/TAF1",Inhibitor,BAY-364,8,IC50,TR-FRET assay,https://doi.org/10.1021/acs.jmedchem.7b00306,=,970,IC50,NanoBRET assay (HEK293T cells),,=,0,CEREP panel (LeadProfilingScreen Eurofins),68,"Screened at 10 µM against receptors, ion channels and enzymes, closest targets as % of contr.: A1 receptor (48%), Cl- channel (GABA-gated) (23%), PDE2A1 (49%), PDE5 (2%), >10000-fold selective; In vitro activity of closest targets (TR-FRET assays): IC50(BRPF1) = 3.15 µM, IC50(BRPF3) = 5.55 µM, IC50(TAF1L, BD2) = 0.106 µM, IC50(BRD4, BD1) >15 µM, IC50(BRD4,BD2) >20 µM; Screened in DSF assay against 48 bromodomains at 10 µM, closest targets: dTm(CECR2) = 3.5 K, dTm(EP300) = 3.5 K, dTm(BRD7) = 2.3 K; In vitro follow up ITC: Kd(CECR2) = 1.39 µM; Screened against31 bromodomains in (BROMOscan DiscoverX) at 100 nM, closest targets as % contr.: CREBBP (30%), TAF1L(BD2) (0.7%); Screened against 300 kinases at 10 µM, >10000-fold selective (PMID: 28402630)","https://doi.org/10.1021/acs.jmedchem.7b00306, https://www.thesgc.org/chemical-probes/BAY-299",Epigenetic set,1 µM
EUB0000192d_BAZ2A@BRD,BAZ2-ICR,EUB0000192d,Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(C#N)cc2)cn1,"InChI=1S/C20H19N7/c1-25-12-16(10-23-25)7-8-27-14-22-19(18-11-24-26(2)13-18)20(27)17-5-3-15(9-21)4-6-17/h3-6,10-14H,7-8H2,1-2H3",RRZVGDGTWNQAPW-UHFFFAOYSA-N,Bromodomain,BAZ2A@BRD,11176,Q9UIF9,"KIAA0314, TIP5, WALp3",Inhibitor,,109,Kd,ITC,"https://doi.org/10.1021/jm501963e, https://www.thesgc.org/chemical-probes/BAZ2-ICR",=,1000,EC50,FRAP assay (utilizing GFP-tagged BAZ2A full length protein transfected into U2OS cells),,<,1,"Bromodomain panel, literature",47,"Screeed at 10 µM in thermal shift assays, dTm(BAZ2A) = 5.2 K, dTm(BAZ2B) = 3.8 K, dTm(CECR2) = 2.0 K; Follow-up in vitro potency (ITC): Kd(CECR2) = 1.55 µM (15-fold selective); Greater 100-fold selective for BRD4 (IC50 >50 µM, BRD4 AlphaScreen assay); Clean profile in CEREP screen against 55 targets (receptors, ion chanels) at 10 µM;",https://doi.org/10.1021/jm501963e,Epigenetic set,1 µM
EUB0000192d_BAZ2B@BRD,BAZ2-ICR,EUB0000192d,Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(C#N)cc2)cn1,"InChI=1S/C20H19N7/c1-25-12-16(10-23-25)7-8-27-14-22-19(18-11-24-26(2)13-18)20(27)17-5-3-15(9-21)4-6-17/h3-6,10-14H,7-8H2,1-2H3",RRZVGDGTWNQAPW-UHFFFAOYSA-N,Bromodomain,BAZ2B@BRD,29994,Q9UIF8,WALp4,Inhibitor,,170,Kd,ITC,"https://doi.org/10.1021/jm501963e, https://www.thesgc.org/chemical-probes/BAZ2-ICR",=,1000,EC50,FRAP assay (utilizing GFP-tagged BAZ2A full length protein transfected into U2OS cells),,<,1,"Bromodomain panel, literature",47,"Screeed at 10 µM in thermal shift assays, dTm(BAZ2A) = 5.2 K, dTm(BAZ2B) = 3.8 K, dTm(CECR2) = 2.0 K; Follow-up in vitro potency (ITC): Kd(CECR2) = 1.55 µM (15-fold selective); Greater 100-fold selective for BRD4 (IC50 >50 µM, BRD4 AlphaScreen assay); Clean profile in CEREP screen against 55 targets (receptors, ion chanels) at 10 µM;",https://doi.org/10.1021/jm501963e,Epigenetic set,1 µM
EUB0000199c_PBRM1@BRD,PFI-3,EUB0000199c,O=C(/C=C/N1C[C@H]2C[C@@H]1CN2c1ccccn1)c1ccccc1O,"InChI=1S/C19H19N3O2/c23-17-6-2-1-5-16(17)18(24)8-10-21-12-15-11-14(21)13-22(15)19-7-3-4-9-20-19/h1-10,14-15,23H,11-13H2/b10-8+/t14-,15-/m1/s1",INAICWLVUAKEPB-QSTFCLMHSA-N,Bromodomain,PBRM1@BRD,55193,Q86U86,"BAF180, PB1",Inhibitor,PFI-3oMet,48,Kd,ITC,https://www.thesgc.org/chemical-probes/PFI-3,=,1000,EC50,FRAP assay in U2OS cells full-length PB1 protein,,<,0,"Bromodomain panel, literature",48,"Screened in DSF assay at 10 µM, dTm(PBRM1,BD5) = 9.1 K, dTm(SMARCA2) = 8.2 K, dTM(SMARCA4) = 7.0 K, other targets dTm <1 K; Screened in CEREP panel against 102 cellular receptors and 30 enzymes, closest targets: IC50(A1A) = 0.44 µM, IC50(A1B) = 3.6 µM, IC50(kKOP) = 13 µM, IC50(5-HAT2B) = 4.0 µM;",https://doi.org/10.1021/acs.jmedchem.6b00012,Epigenetic set,1 µM
EUB0000199c_SMARCA2@BRD,PFI-3,EUB0000199c,O=C(/C=C/N1C[C@H]2C[C@@H]1CN2c1ccccn1)c1ccccc1O,"InChI=1S/C19H19N3O2/c23-17-6-2-1-5-16(17)18(24)8-10-21-12-15-11-14(21)13-22(15)19-7-3-4-9-20-19/h1-10,14-15,23H,11-13H2/b10-8+/t14-,15-/m1/s1",INAICWLVUAKEPB-QSTFCLMHSA-N,Bromodomain,SMARCA2@BRD,6595,P51531,"BAF190, hSNF2a, hBRM, Sth1p, SNF2LA, BRM, SNF2, SWI2",Inhibitor,PFI-3oMet,89,Kd,ITC,https://www.thesgc.org/chemical-probes/PFI-3,=,1000,EC50,FRAP assay in U2OS cells full-length SMARCA2 protein,,<,0,"Bromodomain panel, literature",48,"Screened in DSF assay at 10 µM, dTm(PBRM1,BD5) = 9.1 K, dTm(SMARCA2) = 8.2 K, dTM(SMARCA4) = 7.0 K, other targets dTm <1 K; Screened in CEREP panel against 102 cellular receptors and 30 enzymes, closest targets: IC50(A1A) = 0.44 µM, IC50(A1B) = 3.6 µM, IC50(kKOP) = 13 µM, IC50(5-HAT2B) = 4.0 µM;",https://doi.org/10.1021/acs.jmedchem.6b00012,Epigenetic set,1 µM
EUB0000199c_SMARCA4@BRD,PFI-3,EUB0000199c,O=C(/C=C/N1C[C@H]2C[C@@H]1CN2c1ccccn1)c1ccccc1O,"InChI=1S/C19H19N3O2/c23-17-6-2-1-5-16(17)18(24)8-10-21-12-15-11-14(21)13-22(15)19-7-3-4-9-20-19/h1-10,14-15,23H,11-13H2/b10-8+/t14-,15-/m1/s1",INAICWLVUAKEPB-QSTFCLMHSA-N,Bromodomain,SMARCA4@BRD,6597,P51532,"hSNF2b, BRG1, BAF190, SNF2, SWI2, SNF2-BETA, SNF2LB, FLJ39786",Inhibitor,PFI-3oMet,,,,,,1000,EC50,FRAP assay in U2OS cells full-length SMARCA4 protein,,<,0,"Bromodomain panel, literature",48,"Screened in DSF assay at 10 µM, dTm(PBRM1,BD5) = 9.1 K, dTm(SMARCA2) = 8.2 K, dTM(SMARCA4) = 7.0 K, other targets dTm <1 K; Screened in CEREP panel against 102 cellular receptors and 30 enzymes, closest targets: IC50(A1A) = 0.44 µM, IC50(A1B) = 3.6 µM, IC50(kKOP) = 13 µM, IC50(5-HAT2B) = 4.0 µM;",https://doi.org/10.1021/acs.jmedchem.6b00012,Epigenetic set,1 µM
EUB0000201c_CECR2@BRD,NVS-CECR2-1,EUB0000201c,CCCS(=O)(=O)c1nc(NC2CC2)cc(-c2ccc3c(ccn3C3CC(C)(C)NC(C)(C)C3)c2)n1,"InChI=1S/C27H37N5O2S/c1-6-13-35(33,34)25-29-22(15-24(30-25)28-20-8-9-20)18-7-10-23-19(14-18)11-12-32(23)21-16-26(2,3)31-27(4,5)17-21/h7,10-12,14-15,20-21,31H,6,8-9,13,16-17H2,1-5H3,(H,28,29,30)",XVECNLUKQDKOST-UHFFFAOYSA-N,Bromodomain,CECR2@BRD,27443,Q9BXF3,KIAA1740,Inhibitor,NVS-CECR2-C,80,Kd,ITC,https://www.thesgc.org/chemical-probes/NVS-CECR2-1,=,255,IC50,NanoBRET assay (dose-dependent displacement from histone H3.3 in HEK293T cells),,=,0,"Bromodomain panel, literature",48,"DSF-assay, dTm(CECR2) = 12.52 K, closest targets, dTM 1-2 K: BRD4(BD2), BRD7, FALZ, SMARCA4, TAF1 (BD2);",https://www.thesgc.org/chemical-probes/NVS-CECR2-1,Epigenetic set,1 µM
EUB0000205c_BRPF1@BRD,NI-57,EUB0000205c,COc1cc(C#N)ccc1S(=O)(=O)Nc1ccc2c(c1)cc(C)c(=O)n2C,"InChI=1S/C19H17N3O4S/c1-12-8-14-10-15(5-6-16(14)22(2)19(12)23)21-27(24,25)18-7-4-13(11-20)9-17(18)26-3/h4-10,21H,1-3H3",UEMQPCYDWCSVCU-UHFFFAOYSA-N,Bromodomain,BRPF1@BRD,7862,P55201,BR140,Inhibitor,NI-198,114,IC50,AlphaScreen,www.thesgc.org/chemical-probes/NI-57,=,70,IC50,NanoBRET assay (HEK293T cells),,=,1,"Bromodomain panel, literature",47,"No targets confirmed outside BRD family; Screened in BROMOscan panel against 46 targets, closest target: IC50(TRIM24) = 1600 nM, 500-fold selective; Clean profile in CEREP screen against 55 ligand receptors, ion channels and transporters, at 10 µM","https://doi.org/10.1021/acs.jmedchem.7b00611, www.thesgc.org/chemical-probes/NI-57",Epigenetic set,1 µM
EUB0000205c_BRD1@BRD,NI-57,EUB0000205c,COc1cc(C#N)ccc1S(=O)(=O)Nc1ccc2c(c1)cc(C)c(=O)n2C,"InChI=1S/C19H17N3O4S/c1-12-8-14-10-15(5-6-16(14)22(2)19(12)23)21-27(24,25)18-7-4-13(11-20)9-17(18)26-3/h4-10,21H,1-3H3",UEMQPCYDWCSVCU-UHFFFAOYSA-N,Bromodomain,BRD1@BRD,23774,O95696,"BRL, BRPF2",Inhibitor,NI-198,619,IC50,AlphaScreen,www.thesgc.org/chemical-probes/NI-57,=,,,,,,1,"Bromodomain panel, literature",47,"No targets confirmed outside BRD family; Screened in BROMOscan panel against 46 targets, closest target: IC50(TRIM24) = 1600 nM, 500-fold selective; Clean profile in CEREP screen against 55 ligand receptors, ion channels and transporters, at 10 µM","28714688, www.thesgc.org/chemical-probes/NI-57",Epigenetic set,1 µM
EUB0000205c_BRPF3@BRD,NI-57,EUB0000205c,COc1cc(C#N)ccc1S(=O)(=O)Nc1ccc2c(c1)cc(C)c(=O)n2C,"InChI=1S/C19H17N3O4S/c1-12-8-14-10-15(5-6-16(14)22(2)19(12)23)21-27(24,25)18-7-4-13(11-20)9-17(18)26-3/h4-10,21H,1-3H3",UEMQPCYDWCSVCU-UHFFFAOYSA-N,Bromodomain,BRPF3@BRD,27154,Q9ULD4,KIAA1286,Inhibitor,NI-198,1010,IC50,AlphaScreen,www.thesgc.org/chemical-probes/NI-57,=,,,,,,1,"Bromodomain panel, literature",47,"No targets confirmed outside BRD family; Screened in BROMOscan panel against 46 targets, closest target: IC50(TRIM24) = 1600 nM, 500-fold selective; Clean profile in CEREP screen against 55 ligand receptors, ion channels and transporters, at 10 µM","https://doi.org/10.1021/acs.jmedchem.7b00611, www.thesgc.org/chemical-probes/NI-57",Epigenetic set,1 µM
EUB0000222b_BAZ2A@BRD,GSK2801,EUB0000222b,CCCOc1ccn2c(C(C)=O)cc(-c3ccccc3S(C)(=O)=O)c2c1,"InChI=1S/C20H21NO4S/c1-4-11-25-15-9-10-21-18(14(2)22)13-17(19(21)12-15)16-7-5-6-8-20(16)26(3,23)24/h5-10,12-13H,4,11H2,1-3H3",KHWCPNJRJCNVRI-UHFFFAOYSA-N,Bromodomain,BAZ2A@BRD,11176,Q9UIF9,"KIAA0314, TIP5, WALp3",Inhibitor,GSK8573,400,IC50,AlphaScreen assay,https://doi.org/10.1021/acs.jmedchem.5b00209,=,3981,Kd,Chemoproteomic competition binding assay (endogenous full-length BAZ2A from HuT78 extracts),,=,0,"Bromodomain panel, literature",46,"Screened at 10 µM in DSF assays, dTm(BAZ2A) = 4.1 K, dTm(BAZ2B) = 2.7 K, closest targets: dTm(TAF1L) = 3.4 K, dTm(BRD9) = 2.3 K; In vitro follow up (biolayer interferometry experiment) at 0.2 µM: Kd(BAZ2B) = 0.1 µM, Kd(BRD9) = 1.2 µM, Kd(TAF1L) = 3.19 µM, (ITC experiment): Kd(TAF1L) = 3.2 µM, Kd(BRD9) = 1.1 µM; Screened in CEREP panel against 55 receptors and ion channels at 10 µM, closest target as % of contr.: Melatonin (MT-1) receptor(4%)","https://doi.org/10.1021/acs.jmedchem.5b00209, https://www.thesgc.org/chemical-probes/GSK2801",Epigenetic set,1 µM
EUB0000222b_BAZ2B@BRD,GSK2801,EUB0000222b,CCCOc1ccn2c(C(C)=O)cc(-c3ccccc3S(C)(=O)=O)c2c1,"InChI=1S/C20H21NO4S/c1-4-11-25-15-9-10-21-18(14(2)22)13-17(19(21)12-15)16-7-5-6-8-20(16)26(3,23)24/h5-10,12-13H,4,11H2,1-3H3",KHWCPNJRJCNVRI-UHFFFAOYSA-N,Bromodomain,BAZ2B@BRD,29994,Q9UIF8,WALp4,Inhibitor,GSK8573,430,IC50,AlphaScreen assay,https://doi.org/10.1021/acs.jmedchem.5b00209,=,3162,Kd,Chemoproteomic competition binding assay (endogenous full-length BAZ2B captured on the GSK2801 affinity matrix from HuT-78 cell lysate) ,,=,0,"Bromodomain panel, literature",46,"Screened at 10 µM in DSF assays, dTm(BAZ2A) = 4.1 K, dTm(BAZ2B) = 2.7 K, closest targets: dTm(TAF1L) = 3.4 K, dTm(BRD9) = 2.3 K; In vitro follow up (biolayer interferometry experiment) at 0.2 µM: Kd(BAZ2B) = 0.1 µM, Kd(BRD9) = 1.2 µM, Kd(TAF1L) = 3.19 µM, (ITC experiment): Kd(TAF1L) = 3.2 µM, Kd(BRD9) = 1.1 µM; Screened in CEREP panel against 55 receptors and ion channels at 10 µM, closest target as % of contr.: Melatonin (MT-1) receptor(4%)","https://doi.org/10.1021/acs.jmedchem.5b00209, https://www.thesgc.org/chemical-probes/GSK2801",Epigenetic set,1 µM
EUB0000224d_BRPF1@BRD,GSK6853,EUB0000224d,COc1ccccc1C(=O)Nc1cc2c(cc1N1CCCC1)n(C)c(=O)n2C,"InChI=1S/C21H24N4O3/c1-23-17-12-15(22-20(26)14-8-4-5-9-19(14)28-3)16(25-10-6-7-11-25)13-18(17)24(2)21(23)27/h4-5,8-9,12-13H,6-7,10-11H2,1-3H3,(H,22,26)",QCIJLRJBZDBVDB-UHFFFAOYSA-N,Bromodomain,BRPF1@BRD,7862,P55201,BR140,Inhibitor,GSK9311,7.9,IC50,TR-FRET assay,https://doi.org/10.1021/acsmedchemlett.6b00092,=,20,IC50,NanoBRET assay (HEK293T cells),,=,0,BROMOscan™ panel (DiscoverX),35,">1600-fold selective, closest targets: pKd(BRPF2/BRD2) = 6.29, pKd(BRPF3) = 6.00, pKd(BRD9) = 6.00, pKd(BRD7) = 6.09; Screened against 48 ion channels, GPCRs and other enzymes, all pXC50 <5, compound is highly selective;",https://doi.org/10.1021/acsmedchemlett.6b00092,Epigenetic set,1 µM
EUB0000231c_BRD9@BRD,TP-472,EUB0000231c,CC(=O)c1cc(-c2cc(C(=O)NC3CC3)ccc2C)c2ncccn12,"InChI=1S/C20H19N3O2/c1-12-4-5-14(20(25)22-15-6-7-15)10-16(12)17-11-18(13(2)24)23-9-3-8-21-19(17)23/h3-5,8-11,15H,6-7H2,1-2H3,(H,22,25)",RPBMXJHQYJLPDN-UHFFFAOYSA-N,Bromodomain,BRD9@BRD,65980,Q9H8M2,FLJ13441,Inhibitor,TP-472N,33,Kd,ITC,https://www.thesgc.org/chemical-probes/TP-472,=,320,EC50,NanoBRET assay (HEK293T cells),,=,0,Eurofins CEREP Diversity Profiling,96,"Screened against 71 receptors and ion channels and against 25 other enzymes at 10 µM, closest targets as % of contr.: Adenosine A1 receptor (14%), Benzodiazepine receptor (47%), PDE2A1 (h) (25%), PDE3A (h) (48%) and PDE4D2 (h) (28%); Selectivity >30 fold over all other bromodomain family members except BRD7: Kd(BRD7) = 340 nM (ITC)",https://www.thesgc.org/chemical-probes/TP-472,Epigenetic set,1 µM
EUB0000224e_BRPF1@BRD,PFI-4,EUB0000224e,COc1ccccc1C(O)=Nc1cc2c(cc1N1CCCC1)n(C)c(=O)n2C,"InChI=1S/C21H24N4O3/c1-23-17-12-15(22-20(26)14-8-4-5-9-19(14)28-3)16(25-10-6-7-11-25)13-18(17)24(2)21(23)27/h4-5,8-9,12-13H,6-7,10-11H2,1-3H3,(H,22,26)",QCIJLRJBZDBVDB-UHFFFAOYSA-N,Bromodomain,BRPF1@BRD,7862,P55201,BR140,Inhibitor,,13,Kd,ITC,https://www.thesgc.org/chemical-probes/PFI-4,=,242,IC50,NanoBRET assay (HEK293T cells),,=,1,"Bromodomain panel, literature",48,"Screened in DSF assay at 10 µM, closest target: dTm(CECR2) = 2 K, follow up in Alpha Screen: IC50(CECR2) = 2.32 µM ",https://www.thesgc.org/chemical-probes/PFI-4,Epigenetic set,1 µM
EUB0000224e_BRD1@BRD,PFI-4,EUB0000224e,COc1ccccc1C(O)=Nc1cc2c(cc1N1CCCC1)n(C)c(=O)n2C,"InChI=1S/C21H24N4O3/c1-23-17-12-15(22-20(26)14-8-4-5-9-19(14)28-3)16(25-10-6-7-11-25)13-18(17)24(2)21(23)27/h4-5,8-9,12-13H,6-7,10-11H2,1-3H3,(H,22,26)",QCIJLRJBZDBVDB-UHFFFAOYSA-N,Bromodomain,BRD1@BRD,23774,O95696,"BRL, BRPF2",Inhibitor,,775,Kd,ITC,https://www.thesgc.org/chemical-probes/PFI-4,=,,,,,,1,"Bromodomain panel, literature",48,"Screened in DSF assay at 10 µM, closest target: dTm(CECR2) = 2 K, follow up in Alpha Screen: IC50(CECR2) = 2.32 µM ",https://www.thesgc.org/chemical-probes/PFI-4,Epigenetic set,1 µM
EUB0000247b_BRD9@BRD,I-BRD9 (GSK602),EUB0000247b,CCn1cc(-c2cccc(C(F)(F)F)c2)c2sc(C(N)=NC3CCS(=O)(=O)CC3)cc2c1=O,"InChI=1S/C22H22F3N3O3S2/c1-2-28-12-17(13-4-3-5-14(10-13)22(23,24)25)19-16(21(28)29)11-18(32-19)20(26)27-15-6-8-33(30,31)9-7-15/h3-5,10-12,15H,2,6-9H2,1H3,(H2,26,27)",WRUWGLUCNBMGPS-UHFFFAOYSA-N,Bromodomain,BRD9@BRD,65980,Q9H8M2,FLJ13441,Inhibitor,,50.1,IC50,Time-Resolved FRET assay,"https://doi.org/10.1021/acs.jmedchem.5b00256, https://www.thesgc.org/chemical-probes/I-BRD9",=,79.4,IC50,Western Blot (chemoproteomic competition binding assay in HUT-78 cell lysate),,=,0,BROMOscan™ (DiscoverX),34,">70-fold selective over other bromodomains tested, closest targets: Kd(CECR2) = 140 nM, Kd(BRD7) = 390 nM, Kd(CREBBP) = 740 nM, Kd(EP300) = 770 nM, others >1.5 µM; Inactive against a panel of 49 human receptors, ion channels, kinases and other enzymes","https://doi.org/10.1021/acs.jmedchem.5b00256, https://www.thesgc.org/chemical-probes/I-BRD9",Epigenetic set,1 µM
EUB0000253b_BPTF@BRD,NVS-BPTF-1,EUB0000253b,Cc1c(Nc2ccc(S(=O)(=O)N3CCN(C)CC3)cc2F)nc2ccc(-c3cnn(C4CC4)c3)cn2c1=O,"InChI=1S/C26H28FN7O3S/c1-17-25(29-23-7-6-21(13-22(23)27)38(36,37)32-11-9-31(2)10-12-32)30-24-8-3-18(15-33(24)26(17)35)19-14-28-34(16-19)20-4-5-20/h3,6-8,13-16,20,29H,4-5,9-12H2,1-2H3",JYTISQGEFSHUIR-UHFFFAOYSA-N,Bromodomain,BPTF@BRD,2186,Q12830,"FAC1, NURF301",Inhibitor,NVS-BPTF-C,71,Kd,BioLayer Interferometry assay (BLI),"https://doi.org/10.1016/j.bmcl.2021.128208, https://www.thesgc.org/chemical-probes/NVS-BPTF-1",=,16,IC50,NanoBRET assay (HEK293T cells),,=,3,BROMOscan,32,"Screened at 1 µM, closest targets: Kd(CERC2) = 66 nM, Kd(GCN5L2) = 62 nM, Kd(PCAF) = 74 nM; Follow-up IC50s in cellular NanoBRET assay: IC50(CERC2/GCN5L2/PCAF) >10 µM; DSF screen against 48 human bromodomains, dTm(BPTF) = 6.16 K, closest targets: dTm(CERC2) = 2.48 K, dTm(BRD7) = 1.95 K, dTM(PCAF) = 1.53 K; Screened in NIBR principial panel against 12 GPCRs, 3 nuclear receptors, 3 transporters and 7 other enzymes, closest tagets: IC50(Ad3) = 4.9 µM, IC50(D3) = 3.5 µM, IC50(H3) = 4 µM, others >30 µM, Screened in NIBR kinase panel against 48 kinases, no target with IC50 <30 µM;",https://www.thesgc.org/chemical-probes/NVS-BPTF-1,Epigenetic set,1 µM
EUB0000254b_BPTF@BRD,NVS-BPTF-C,EUB0000254b,Cc1c(Nc2ccc(S(=O)(=O)N3CCN(C)CC3)cc2F)nc2ccc(Nc3cnn(C4CC4)c3)cn2c1=O,"InChI=1S/C26H29FN8O3S/c1-17-25(30-23-7-6-21(13-22(23)27)39(37,38)33-11-9-32(2)10-12-33)31-24-8-3-18(15-34(24)26(17)36)29-19-14-28-35(16-19)20-4-5-20/h3,6-8,13-16,20,29-30H,4-5,9-12H2,1-2H3",BFSKPRUNBBMNCF-UHFFFAOYSA-N,Bromodomain,BPTF@BRD,2186,Q12830,"FAC1, NURF301",Negative control for NVS-BPTF-1,,,Negative Control,,https://www.thesgc.org/chemical-probes/NVS-BPTF-1,,,,,,,,,,,,Epigenetic set,1 µM
EUB0000256b_KAT2B@BRD,GSK4027,EUB0000256b,CN1C[C@H](Nc2cnn(C)c(=O)c2Br)C[C@H](c2ccccc2)C1,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,Bromodomain,KAT2B@BRD,8850,Q92831,"P/CAF, GCN5, GCN5L",Inhibitor,GSK4028,1.4,Ki,Bromoscan assay(DiscoverX),"https://doi.org/10.1021/acs.jmedchem.6b01566, https://www.thesgc.org/chemical-probes/GSK4027",=,60,IC50,NanoBRET assay (HEK293T cells),,=,1,BROMOscan panel (DiscoverX),34,"Closest targets: Ki(BRPF3) = 100 nM, Kd(BRD1) = 110 nM, Kd(FALZ) = 130 nM, Kd(BRPF1) = 140 nM, Kd(BAZB) = 840 nM, Kd(BRD7) = 1500 nM, Kd(BRD9) = 1400 nM, others >20 µM; Screened against 50 receptors, ion channels and other enzymes (internal GSK panel), closest target: XC50(AChEase) = 3.2 µM, others >4 µM",https://doi.org/10.1021/acs.jmedchem.6b01566,Epigenetic set,1 µM
EUB0000256b_KAT2A@BRD,GSK4027,EUB0000256b,CN1C[C@H](Nc2cnn(C)c(=O)c2Br)C[C@H](c2ccccc2)C1,"InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1",VZAFGXCWAWRULT-UONOGXRCSA-N,Bromodomain,KAT2A@BRD,2648,Q92830,"GCN5, PCAF-b",Inhibitor,GSK4028,1.4,Ki,Bromoscan assay(DiscoverX),"https://doi.org/10.1021/acs.jmedchem.6b01566, https://www.thesgc.org/chemical-probes/GSK4027",=,,,,,,1,BROMOscan panel (DiscoverX),34,"Closest targets: Ki(BRPF3) = 100 nM, Kd(BRD1) = 110 nM, Kd(FALZ) = 130 nM, Kd(BRPF1) = 140 nM, Kd(BAZB) = 840 nM, Kd(BRD7) = 1500 nM, Kd(BRD9) = 1400 nM, others >20 µM; Screened against 50 receptors, ion channels and other enzymes (internal GSK panel), closest target: XC50(AChEase) = 3.2 µM, others >4 µM",https://doi.org/10.1021/acs.jmedchem.6b01566,Epigenetic set,1 µM
EUB0000267b_BAZ2A@BRD,GSK8573,EUB0000267b,CCCOc1ccn2c(C(C)=O)cc(-c3cccc(OC)c3)c2c1,"InChI=1S/C20H21NO3/c1-4-10-24-17-8-9-21-19(14(2)22)13-18(20(21)12-17)15-6-5-7-16(11-15)23-3/h5-9,11-13H,4,10H2,1-3H3",QQBGNWWJANJWNY-UHFFFAOYSA-N,Bromodomain,BAZ2A@BRD,11176,Q9UIF9,"KIAA0314, TIP5, WALp3",Negative control for GSK2801,,,Negative Control,,https://www.thesgc.org/chemical-probes/GSK2801,,,,,,,,,,,,Epigenetic set,1 µM
EUB0000267b_BAZ2B@BRD,GSK8573,EUB0000267b,CCCOc1ccn2c(C(C)=O)cc(-c3cccc(OC)c3)c2c1,"InChI=1S/C20H21NO3/c1-4-10-24-17-8-9-21-19(14(2)22)13-18(20(21)12-17)15-6-5-7-16(11-15)23-3/h5-9,11-13H,4,10H2,1-3H3",QQBGNWWJANJWNY-UHFFFAOYSA-N,Bromodomain,BAZ2B@BRD,29994,Q9UIF8,WALp4,Negative control for GSK2801,,,Negative Control,,https://www.thesgc.org/chemical-probes/GSK2801,,,,,,,,,,,,Epigenetic set,1 µM
EUB0000323b_BRPF1@BRD,OF-1,EUB0000323b,COC1=CC(N2C)=C(C=C1NS(=O)(C3=CC=C(C=C3C)Br)=O)N(C)C2=O,"InChI=1S/C17H18BrN3O4S/c1-10-7-11(18)5-6-16(10)26(23,24)19-12-8-13-14(9-15(12)25-4)21(3)17(22)20(13)2/h5-9,19H,1-4H3",YUNQZQREIHWDQT-UHFFFAOYSA-N,Bromodomain,BRPF1@BRD,7862,P55201,BR140,Inhibitor,,101,Kd,ITC,"https://doi.org/10.1021/acschembio.7b00481, https://www.thesgc.org/chemical-probes/OF-1",=,80,IC50,NanoBRET assay (HEK293T cells),,=,1,"Bromodomain panel, literature",49,"Screened in DSF-panel, closest target: dTm(BRD4, BD1) = 2.1 K; In vitro follow-up with AlphaScreen: IC50(BRD4, BD1) >10 µM, ITC: Kd(BRD4, BD1) = 3.9 µM; Screened in CEREB panel against 56 GPCRs, ion channels and transporters at 10 µM, closest targtes as % inhibition: A1 (82%), 5-HT6 (54%), A3 (53%);",https://doi.org/10.1021/acschembio.7b00481,Epigenetic set,1 µM
EUB0000323b_BRD1@BRD,OF-1,EUB0000323b,COC1=CC(N2C)=C(C=C1NS(=O)(C3=CC=C(C=C3C)Br)=O)N(C)C2=O,"InChI=1S/C17H18BrN3O4S/c1-10-7-11(18)5-6-16(10)26(23,24)19-12-8-13-14(9-15(12)25-4)21(3)17(22)20(13)2/h5-9,19H,1-4H3",YUNQZQREIHWDQT-UHFFFAOYSA-N,Bromodomain,BRD1@BRD,23774,O95696,"BRL, BRPF2",Inhibitor,,505,Kd,ITC,"https://doi.org/10.1021/acschembio.7b00481, https://www.thesgc.org/chemical-probes/OF-1",=,,,,,,1,"Bromodomain panel, literature",49,"Screened in DSF-panel, closest target: dTm(BRD4, BD1) = 2.1 K; In vitro follow-up with AlphaScreen: IC50(BRD4, BD1) >10 µM, ITC: Kd(BRD4, BD1) = 3.9 µM; Screened in CEREB panel against 56 GPCRs, ion channels and transporters at 10 µM, closest targtes as % inhibition: A1 (82%), 5-HT6 (54%), A3 (53%);",https://doi.org/10.1021/acschembio.7b00481,Epigenetic set,1 µM
EUB0000323b_BRPF3@BRD,OF-1,EUB0000323b,COC1=CC(N2C)=C(C=C1NS(=O)(C3=CC=C(C=C3C)Br)=O)N(C)C2=O,"InChI=1S/C17H18BrN3O4S/c1-10-7-11(18)5-6-16(10)26(23,24)19-12-8-13-14(9-15(12)25-4)21(3)17(22)20(13)2/h5-9,19H,1-4H3",YUNQZQREIHWDQT-UHFFFAOYSA-N,Bromodomain,BRPF3@BRD,27154,Q9ULD4,KIAA1286,Inhibitor,,2406,Kd,ITC,"https://doi.org/10.1021/acschembio.7b00481, https://www.thesgc.org/chemical-probes/OF-1",=,,,,,,1,"Bromodomain panel, literature",49,"Screened in DSF-panel, closest target: dTm(BRD4, BD1) = 2.1 K; In vitro follow-up with AlphaScreen: IC50(BRD4, BD1) >10 µM, ITC: Kd(BRD4, BD1) = 3.9 µM; Screened in CEREB panel against 56 GPCRs, ion channels and transporters at 10 µM, closest targtes as % inhibition: A1 (82%), 5-HT6 (54%), A3 (53%);",https://doi.org/10.1021/acschembio.7b00481,Epigenetic set,1 µM
EUB0000240b_LHCGR,BAY-899,EUB0000240b,O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1,"InChI=1S/C25H19F2N5O2/c26-17-5-3-16(4-6-17)23-21-2-1-12-28-22(21)11-13-32(23)25(33)31-19-14-29-24(30-15-19)34-20-9-7-18(27)8-10-20/h1-10,12,14-15,23H,11,13H2,(H,31,33)/t23-/m0/s1",VKQBTIMLSDGNLG-QHCPKHFHSA-N,GPCR,LHCGR,3973,P22888,"LHR, LCGR, LGR2, ULG5",Inhibitor,BAY-897,,,,,,185,IC50,Cell-based assay (LH Antagonism),,=,0,"GPCR panel (Eurofins, Bayer)",25,"Screened at 10 µM, closest targets in the GPCR scan: Ki(SIGMAR1) = 1431.53 nM, Ki(TMEM97) = 2051.16 nM, Ki(OPRK1) = 7634.84 nM; hTSH antagonism: IC50 = 24 µM; hFSH antagonism: IC50 > 16 µM; Screened against 468 kinases (KinomeScan (DiscoverX)) at 1 µM, closest target as % of contr.: CDKL2 (33%)","https://doi.org/10.1021/acs.jmedchem.9b01382, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-899",GPCR set,1 µM
EUB0000252b_CHRM1,MSD-M1PAM,EUB0000252b,N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1,"InChI=1S/C22H20N4O3/c23-15-22(19-6-1-3-9-24-19)7-11-25(12-8-22)14-16-13-17(21(28)29)20(27)26-10-4-2-5-18(16)26/h1-6,9-10,13H,7-8,11-12,14H2,(H,28,29)",RJTJRVASUFIDQM-UHFFFAOYSA-N,GPCR,CHRM1,1128,P11229,,Positive allosteric modulator,CHRM1,,,,,,136,Potentiation inflection oint,Fold potentiation assay (addition of EC20 acetylcholine; in human M1 expressing Chinese hamster ovary (CHO) cells; using calcium mobilization readout on a fluorometric imaging plate reader (FLIPR384)),,=,0,GPCR screen (PDSP),45,"Screened at 10 µM, > 700-fold selective for CHRM2, CHRM3, CHRM4; Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: PIK3CB (36%), TGFBR1 (41%), BLK (49%); Panlabs screen at 10 µM against 140 targets, closest target: IC50( PTPN2) = 10 µM;",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/MSD-M1PAM,GPCR set,1 µM
EUB0000274bCl_P2RY14,PPTN,EUB0000274bCl,Cl.O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1,"InChI=1S/C29H24F3NO2.ClH/c30-29(31,32)25-8-5-19(6-9-25)22-7-10-26-23(15-22)16-24(28(34)35)17-27(26)21-3-1-18(2-4-21)20-11-13-33-14-12-20;/h1-10,15-17,20,33H,11-14H2,(H,34,35);1H",FKMVYPCBLWYNAV-UHFFFAOYSA-N,GPCR,P2RY14,9934,Q15391,KIAA0001,Antagonist,PPTN-NC,0.5,IC50,FLIPR assay,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/PPTN,=,7.96,IC50,Fluorescence binding assay (using flow cytometry in hP2Y14R-expressing CHO cells),,=,0,GPCR screen (PDSP),45,"Screened at 10 µM, >10,000-fold selectivity over other P2RY* receptors, closest targets: Ki(DRD3) = 884.3 nM, Ki(TMEM97) = 1120.99 nM, Ki(SIGMAR1) = 1180.59 nM, Ki(ADRA2B) = 2561.53 nM; Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest target: MAPKAPK2 (51% of contr.); Screened in Eurofins-Panlabs enzyme assay against 40 targets at 10 µM, closest targets: IC50(INSR) = 4.31 µM, IC50(EGFR) = 4.59 µM; Screened in Eurofins-Panlabs radioligand binding assay against 125 targets at 1 µM and 10 µM, closest targets: IC50(CYSLTR1) = 560 nM, IC50(HRH2) = 1390 nM, IC50(SLC6A3) = 2310 nM; Screened in PDSP screen against 45 receptors, ion channels and transporters at 10 µM, closest targets: Ki(D3 dopamine receptor) = 6.79 µM, Ki(d-opioid receptor) = 2.75 µM","https://doi.org/10.1021/acs.jmedchem.8b00168, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/PPTN",GPCR set,100 nM
EUB0000291b_F2R,BAY-386,EUB0000291b,O=C(N1CCS(=O)(=O)CC1)N1C[C@@](S)(c2ccc(OC(F)(F)F)cc2)C[C@@](S)(c2nc(C3CC3)no2)C1,"InChI=1S/C22H25F3N4O5S3/c23-22(24,25)33-16-5-3-15(4-6-16)20(35)11-21(36,18-26-17(27-34-18)14-1-2-14)13-29(12-20)19(30)28-7-9-37(31,32)10-8-28/h3-6,14,35-36H,1-2,7-13H2/t20-,21+/m1/s1",FWONKSVKZWQNPN-RTWAWAEBSA-N,GPCR,F2R,2149,P25116,"TR, CF2R, PAR1, PAR-1",Antagonist,BAY-448,56,IC50,Binding assay (platelet membranes),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-386,=,10,IC50,Functional cellular assay in HEK cells expressing F2R,,=,0,Eurofins-Panlabs radioligand binding assay,68,"Screened at 10 µM, closest target as % of inhibition: CNR1 (88 %); CNR1 functional test (GTPyS binding): IC50 = 10.6 µM; Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest target: Ki(TMEM97) = 1203.22 nM; Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: CDK11A (0%), DCLK2(0%), MAP3K12(0%), CDK18(0%), CDK4(18%), TYK2(53%);",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-386,GPCR set,100 nM
EUB0000296b_CNR1,MRL-650,EUB0000296b,CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12,"InChI=1S/C25H18Cl3N3O3/c1-12(32)21-23(29-13(2)33)19-11-18(14-4-6-15(26)7-5-14)22(30-24(19)31(3)25(21)34)17-9-8-16(27)10-20(17)28/h4-11H,1-3H3,(H,29,33)",VHSIAYLBCLUAFT-UHFFFAOYSA-N,GPCR,CNR1,1268,P21554,"CB1K5, CB-R, CB1, CANN6, CB1A",Inverse agonist,MRL-CB1-NC,7.5,IC50,Radioligand binding assay,"https://doi.org/10.1021/acs.jmedchem.9b01460, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/MRL-650",=,4.9,EC50,Radioimmunoassay (hCB1r functional activation assay on recombinant hCB1r CHO cells),,=,0,GPCR screen (PDSP),45,"Screened at 10 µM, closest targets: Ki(GABA/PBR) = 82 nM, Ki(TMEM97) = 605 nM, Ki(SIGMAR1) = 1158 nM; Radioligand binding assay: IC50(CNR2) = 4.1 µM (PMID: 31859507); Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % contr.: DYRK1B (35%), STK11 (43%), EIF2AK4 (48%), PIK3C2B (48%), PRKCE (48%); Screened against 168 enzymes and receptors (MSD Pharma/Taiwan screen) at 10 µM, closest targets: IC50(ALOX5) = 1.34 µM, IC50(EGFR) = 3.26 µM, IC50(MAPK14) = 3.68 µM, IC50(MAPK3) = 8.61 µM; Radioligand binding assays (MDS Pharma Service): Ki(SLC18A2) = 0.648 µM, Ki(ADORA3) = 0.773 µM, Ki(SLC6A3) = 0.799 µM, Ki(ADRA2C) = 1.13 µM;",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/MRL-650,GPCR set,1 µM
EUB0000297b_PTGDR2,CRTH2,EUB0000297b,CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1,"InChI=1S/C21H21FN2O4S/c1-23(29(27,28)16-9-6-14(22)7-10-16)15-8-11-20-18(12-21(25)26)17-4-2-3-5-19(17)24(20)13-15/h2-7,9-10,15H,8,11-13H2,1H3,(H,25,26)/t15-/m1/s1",JTCAGRAKUAAYDY-OAHLLOKOSA-N,GPCR,PTGDR2,11251,Q9Y5Y4,"CRTH2, CD294, DP2",Antagonist,CRTH2 negative control,2.5,Ki,Prostanoid receptor binding assay,"https://doi.org/10.1016/j.bmcl.2010.11.015, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/CRTH%3Csub%3E2%3C/sub%3E%20antagonist",=,3,IC50,cAMP functional assay in HEK-hCRTH2 cells,,=,0,GPCR screen (PDSP),45,"Screened at 10 µM, closest targets: Ki(SLC6A3) = 283 nM, Ki(GABA/PBR) = 1115 nM, Ki(DRD2) = 3746 nM; Prostanoid receptor binding assay: Ki(TBXA2R)= 3804 nM, >100-fold selective against related receptors; Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contrl.: ROCK1 (34%), DYRK1B (44%)",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/CRTH%3Csub%3E2%3C/sub%3E%20antagonist,GPCR set,100 nM
EUB0000317b_GPR52,TP-024,EUB0000317b,Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O,"InChI=1S/C19H16F4N4O/c1-10-5-15(3-4-16(10)18(24)28)27-11(2)25-17(26-27)8-12-6-13(19(21,22)23)9-14(20)7-12/h3-7,9H,8H2,1-2H3,(H2,24,28)",TYXSIXOYTBHZFA-UHFFFAOYSA-N,GPCR,GPR52,9293,Q9Y2T5,,Agonist,TP-024n,,,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-024,,93,EC50,Cell-based cAMP assay,,=,0,GPCR screen (PDSP),45,"Screened at 10 µM, closest target as % of inhibition: HTR7 (21%); Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest target as % of contr.: STK38L (49%); Clean in Diversity panel screen (by Ricerca) against>100 targets, at 10 µM",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-024,GPCR set,1 µM
EUB0000290bCl_DRD4,ABT-724,EUB0000290bCl,[H]Cl.[H]Cl.[H]Cl.N1(CCN(C2=NC=CC=C2)CC1)CC3=NC4=CC=CC=C4N3,"InChI=1S/C17H19N5.3ClH/c1-2-6-15-14(5-1)19-16(20-15)13-21-9-11-22(12-10-21)17-7-3-4-8-18-17;;;/h1-8H,9-13H2,(H,19,20);3*1H",AZFUVPBLKQGSRI-UHFFFAOYSA-N,GPCR,DRD4,1815,P21917,,Partial agonist,,,,,,,12.3,EC50,Agonist activity at human D4.4 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR,,=,,,,,,,
EUB0000332a_DRD4,A-769,EUB0000332a,CSc1ccncc1N2CCN(Cc3nc4ccccc4[nH]3)CC2,"InChI=1S/C18H21N5S/c1-24-17-6-7-19-12-16(17)23-10-8-22(9-11-23)13-18-20-14-4-2-3-5-15(14)21-18/h2-7,12H,8-11,13H2,1H3,(H,20,21)",MGBNTFOCYSALPQ-UHFFFAOYSA-N,GPCR,DRD4,1815,P21917,,Negative control for ABT-724,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/ABT-724,,,,,,,,,,,,GPCR set,100 nM
EUB0000333a_F2R,BAY-448,EUB0000333a,Cc1nc([C@H]2C[C@H](CN(C2)C(N2CCS(C2)(=O)=O)=O)c2ccc(cc2)C(F)(F)F)on1,"InChI=1S/C19H21F3N4O4S/c1-12-23-17(30-24-12)15-8-14(13-2-4-16(5-3-13)19(20,21)22)9-26(10-15)18(27)25-6-7-31(28,29)11-25/h2-5,14-15H,6-11H2,1H3/t14-,15+/m1/s1",BCJOKAFRZRDMFV-CABCVRRESA-N,GPCR,F2R,2149,P25116,"TR, CF2R, PAR1, PAR-1",Negative control for BAY-386,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-386,,,,,,,,,,,,GPCR set,100 nM
EUB0000316b_CNR1,MRL-CB1-NC,EUB0000316b,[O-][N+](C1=CC(Cl)=C(NC2=CC(CCC(N3)=O)=C3C=C2)C=C1OC4CCOCC4)=O,"InChI=1S/C20H20ClN3O5/c21-15-10-18(24(26)27)19(29-14-5-7-28-8-6-14)11-17(15)22-13-2-3-16-12(9-13)1-4-20(25)23-16/h2-3,9-11,14,22H,1,4-8H2,(H,23,25)",RRELDGDKULRRDM-UHFFFAOYSA-N,GPCR,CNR1,1268,P21554,"CB1K5, CB-R, CB1, CANN6, CB1A",Negative control for MRL-650,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/MRL-650,,,,,,,,,,,,GPCR set,1 µM
EUB0000334a_PTGDR2,CRTH2 negative control,EUB0000334a,CN([C@@H]1CCc2c(CC(O)=O)c3cc(ccc3n2C1)S(C)(=O)=O)S(c1ccc(cc1)F)(=O)=O,"InChI=1S/C22H23FN2O6S2/c1-24(33(30,31)16-6-3-14(23)4-7-16)15-5-9-20-19(12-22(26)27)18-11-17(32(2,28)29)8-10-21(18)25(20)13-15/h3-4,6-8,10-11,15H,5,9,12-13H2,1-2H3,(H,26,27)/t15-/m1/s1",BEMUNJONNGSREM-OAHLLOKOSA-N,GPCR,PTGDR2,11251,Q9Y5Y4,"CRTH2, CD294, DP2",Negative control for CRTH2,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/CRTH%3Csub%3E2%3C/sub%3E%20antagonist,,,,,,,,,,,,GPCR set,100 nM
EUB0000335a_GNRHR,BAY-786,EUB0000335a,C1CC1[C@@H]1C2(CCS(CC2)(=O)=O)c2cc(ccc2N1S(c1ccc(cc1)F)(=O)=O)C(NCc1c(cc(cn1)C(F)(F)F)[Cl])=O,"InChI=1S/C29H26ClF4N3O5S2/c30-23-14-19(29(32,33)34)15-35-24(23)16-36-27(38)18-3-8-25-22(13-18)28(9-11-43(39,40)12-10-28)26(17-1-2-17)37(25)44(41,42)21-6-4-20(31)5-7-21/h3-8,13-15,17,26H,1-2,9-12,16H2,(H,36,38)/t26-/m1/s1",PZGSYNNVPNLHQG-AREMUKBSSA-N,GPCR,GNRHR,2798,P30968,LHRHR,Negative control for BAY-784,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-784,,,,,,,,,,,,GPCR set,1 µM
EUB0000289bCl_EDNRA,A-545,EUB0000289bCl,CCCCN(C(CN1C[C@@H](C2=CC(OC)=C3OCOC3=C2)[C@H](C(O)=O)[C@H]1CC(C)(CCC)C)=O)CCCC.Cl,"InChI=1S/C30H48N2O6.ClH/c1-7-10-13-31(14-11-8-2)26(33)19-32-18-22(21-15-24(36-6)28-25(16-21)37-20-38-28)27(29(34)35)23(32)17-30(4,5)12-9-3;/h15-16,22-23,27H,7-14,17-20H2,1-6H3,(H,34,35);1H/t22-,23+,27-;/m0./s1",KMKKFZCVBRAWNX-GSAMTNRBSA-N,GPCR,EDNRA,1909,P25101,"ET-A, ETA-R, hET-AR",Negative control for ABT-546,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/ABT-546,,,,,,,,,,,,GPCR set,100 nM
EUB0000336a_GPR52,TP-024n,EUB0000336a,CC1=C(C2=CC=C(C(N)=O)N=C2)SC(CC3=CC=CC(C(F)(F)F)=C3)=N1,"InChI=1S/C18H14F3N3OS/c1-10-16(12-5-6-14(17(22)25)23-9-12)26-15(24-10)8-11-3-2-4-13(7-11)18(19,20)21/h2-7,9H,8H2,1H3,(H2,22,25)",LEEQPBKUBIMCLS-UHFFFAOYSA-N,GPCR,GPR52,9293,Q9Y2T5,,Negative control for TP-024,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-024,,,,,,,,,,,,GPCR set,1 µM
EUB0000337aCl_P2RY14,PPTN-NC,EUB0000337aCl,CC1=C(C(O)=O)C=C(C2=C1C=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C4=CC=C(C5CCNCC5)C=C4.Cl,"InChI=1S/C30H26F3NO2.ClH/c1-18-26-16-23(20-6-9-24(10-7-20)30(31,32)33)8-11-25(26)28(17-27(18)29(35)36)22-4-2-19(3-5-22)21-12-14-34-15-13-21;/h2-11,16-17,21,34H,12-15H2,1H3,(H,35,36);1H",FWPPUDHURRAJHH-UHFFFAOYSA-N,GPCR,P2RY14,9934,Q15391,KIAA0001,Negative control for PPTN,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/PPTN,,,,,,,,,,,,GPCR set,100 nM
EUB0000338a_DRD4,UCSF924NC,EUB0000338a,CC1=CC(C(C=C(N2)CNCCCC3=CC=NC=C3)=O)=C2C=C1,"InChI=1S/C19H21N3O/c1-14-4-5-18-17(11-14)19(23)12-16(22-18)13-21-8-2-3-15-6-9-20-10-7-15/h4-7,9-12,21H,2-3,8,13H2,1H3,(H,22,23)",PALPPRFQCFXPCD-UHFFFAOYSA-N,GPCR,DRD4,1815,P21917,,Negative control for UCSF924,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/UCSF924,,,,,,,,,,,,GPCR set,1 µM
EUB0000339a_EDNRB,A-1806262,EUB0000339a,CCCOC1=CC=C([C@@H]2[C@H]([C@H](C3=CC=C4C(OCO4)=C3)CN2CC(NC5=C(C=CC=C5CC)CC)=O)C(O)=O)C=C1,"InChI=1S/C33H38N2O6/c1-4-16-39-25-13-10-23(11-14-25)32-30(33(37)38)26(24-12-15-27-28(17-24)41-20-40-27)18-35(32)19-29(36)34-31-21(5-2)8-7-9-22(31)6-3/h7-15,17,26,30,32H,4-6,16,18-20H2,1-3H3,(H,34,36)(H,37,38)/t26-,30-,32+/m0/s1",LQEHCKYYIXQEBM-WXALXNGTSA-N,GPCR,EDNRB,1910,P24530,ETB,Negative control for A-192621,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-192621,,,,,,,,,,,,GPCR set,100 nM
EUB0000340a_LHCGR,BAY-897,EUB0000340a,FC(C=C1)=CC=C1OC2=CC=C(C=C2)NC(N3CCC4=C(C=CC=N4)[C@H]3C5=CC=C(F)C=C5)=O,"InChI=1S/C27H21F2N3O2/c28-19-5-3-18(4-6-19)26-24-2-1-16-30-25(24)15-17-32(26)27(33)31-21-9-13-23(14-10-21)34-22-11-7-20(29)8-12-22/h1-14,16,26H,15,17H2,(H,31,33)/t26-/m1/s1",AEOSDPHCSPJLGL-AREMUKBSSA-N,GPCR,LHCGR,3973,P22888,"LHR, LCGR, LGR2, ULG5",Negative control for BAY-899,,,Negative Control,,"https://doi.org/10.1021/acs.jmedchem.9b01382, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-899",,,,,,,,,,,,GPCR set,1 µM
EUB0000341aCl_ADRA1D,(S)-9s,EUB0000341aCl,C[C@@H](C1=CC=CC(C#N)=C1)N2C=C(C=C(C2=N)C(N)=O)Cl.[H]Cl,"InChI=1S/C15H13ClN4O.ClH/c1-9(11-4-2-3-10(5-11)7-17)20-8-12(16)6-13(14(20)18)15(19)21;/h2-6,8-9,18H,1H3,(H2,19,21);1H/t9-;/m0./s1",XUCZRJDRBBJCTE-FVGYRXGTSA-N,GPCR,ADRA1D,146,P25100,"ADRA1R, ADRA1A, ADRA1",Negative control for (R)-9s,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/(R)-9s,,,,,,,,,,,,GPCR set,1 µM
EUB0000342a_PTGER2,PF-04475866,EUB0000342a,FC(C=C1)=CC=C1C(N2CC(COC3=CC=C(Br)C=C3)(C(O)=O)C2)=O,"InChI=1S/C18H15BrFNO4/c19-13-3-7-15(8-4-13)25-11-18(17(23)24)9-21(10-18)16(22)12-1-5-14(20)6-2-12/h1-8H,9-11H2,(H,23,24)",KBYIQQODUSXDFL-UHFFFAOYSA-N,GPCR,PTGER2,5732,P43116,EP2,Negative control for PF-04418948,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/PF-04418948,,,,,,,,,,,,GPCR set,100 nM
EUB0000343a_CCR1,BI-9307,EUB0000343a,CS(C1=CC([C@@H](NC(C2=CN=CC3=C2C=NN3C4=CC=C(F)C=C4)=O)CCNS(C)(=O)=O)=CC=N1)(=O)=O,"InChI=1S/C23H23FN6O5S2/c1-36(32,33)22-11-15(7-9-26-22)20(8-10-28-37(2,34)35)29-23(31)19-12-25-14-21-18(19)13-27-30(21)17-5-3-16(24)4-6-17/h3-7,9,11-14,20,28H,8,10H2,1-2H3,(H,29,31)/t20-/m0/s1",WNEINSVFBXZUFH-FQEVSTJZSA-N,GPCR,CCR1,1230,P32246,"CKR-1, MIP1aR, CD191",Negative control for BI-639667,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI%20639667,,,,,,,,,,,,GPCR set,100 nM
EUB0000344a_CHRM1,MSD-M1PAM-NC,EUB0000344a,N#CC(CC1)(C2=CC=CC=N2)CCN1CC3=C4C=CC=CN4C(C(C(N5CCCC5)=O)=C3)=O,"InChI=1S/C26H27N5O2/c27-19-26(23-8-1-3-11-28-23)9-15-29(16-10-26)18-20-17-21(24(32)30-12-5-6-13-30)25(33)31-14-4-2-7-22(20)31/h1-4,7-8,11,14,17H,5-6,9-10,12-13,15-16,18H2",ASAKPTPDFNXOQN-UHFFFAOYSA-N,GPCR,CHRM1,1128,P11229,,Negative control for MSD-M1PAM,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/MSD-M1PAM,,,,,,,,,,,,GPCR set,1 µM
EUB0000345a_MRGPRX2,(S)-ZINC 3573,EUB0000345a,CN([C@H]1CCN(C2=CC(C3=CC=CC=C3)=NC4=CC=NN24)C1)C,"InChI=1S/C18H21N5/c1-21(2)15-9-11-22(13-15)18-12-16(14-6-4-3-5-7-14)20-17-8-10-19-23(17)18/h3-8,10,12,15H,9,11,13H2,1-2H3/t15-/m0/s1",XKBSPAZCFAIBJL-HNNXBMFYSA-N,GPCR,MRGPRX2,117194,Q96LB1,MRGX2,Negative control for (R)-ZINC 3573,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/(R)-ZINC-3573,,,,,,,,,,,,GPCR set,1 µM
EUB0000346a_GPR68,ZINC32547799,EUB0000346a,OCC1=CC=CC(C2=NC(N)=NC(NCC3=CC=CC=C3)=N2)=C1,"InChI=1S/C17H17N5O/c18-16-20-15(14-8-4-7-13(9-14)11-23)21-17(22-16)19-10-12-5-2-1-3-6-12/h1-9,23H,10-11H2,(H3,18,19,20,21,22)",RVKAHYFWSKSSQQ-UHFFFAOYSA-N,GPCR,GPR68,8111,Q15743,OGR1,Negative control for Ogerin,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/Ogerin,,,,,,,,,,,,GPCR set,1 µM
EUB0000347a_GNRHR,BAY-784,EUB0000347a,C1CC1[C@H]1C2(CCS(CC2)(=O)=O)c2cc(ccc2N1S(c1ccc(cc1)F)(=O)=O)C(NCc1c(cc(cn1)C(F)(F)F)[Cl])=O,"InChI=1S/C29H26ClF4N3O5S2/c30-23-14-19(29(32,33)34)15-35-24(23)16-36-27(38)18-3-8-25-22(13-18)28(9-11-43(39,40)12-10-28)26(17-1-2-17)37(25)44(41,42)21-6-4-20(31)5-7-21/h3-8,13-15,17,26H,1-2,9-12,16H2,(H,36,38)/t26-/m0/s1",PZGSYNNVPNLHQG-SANMLTNESA-N,GPCR,GNRHR,2798,P30968,LHRHR,Antagonist,BAY-786,27,IC50,Tag Lite binding assay (human GnRH-R binding),"https://doi.org/10.1021/acs.jmedchem.0c01076, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-784",=,21,IC50,"Mechanistic biochemical IP1 assay (CHO cells stably expressing human GnRH-R, snythetic agonist Buserelin at EC80)",,=,0,GPCR panel (PDSP),45,"Screened at 10 µM, closest target: Ki(TMEM97) = 1107.9 nM; Screened against 122 enzymes, receptors, transporters and ion channels (Leadprofiling screen, Ricerca) at 10 µM, closest targets: IC50(MAPK3) = 4.87 µM, IC50(MAPK14) = 10.7 µM, IC50(CNR1) = 3.44 µM; Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % contr.: CDK5 (0%), CLK4 (0%), MAP3K13(0%), PRKAA1(39%)",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-784,GPCR set,1 µM
EUB0000348aPTSA_EDNRA,ABT-546,EUB0000348aPTSA,COC1=CC([C@@H]2[C@H]([C@@H](N(C2)CC(N(CCCC)CCCC)=O)CC(C)(CCC)C)C(O)=O)=CC3=C1OCO3.CC4=CC=C(S(=O)(O)=O)C=C4,"InChI=1S/C30H48N2O6.C7H8O3S/c1-7-10-13-31(14-11-8-2)26(33)19-32-18-22(21-15-24(36-6)28-25(16-21)37-20-38-28)27(29(34)35)23(32)17-30(4,5)12-9-3;1-6-2-4-7(5-3-6)11(8,9)10/h15-16,22-23,27H,7-14,17-20H2,1-6H3,(H,34,35);2-5H,1H3,(H,8,9,10)/t22-,23+,27-;/m1./s1",AADJQCRYJYCVDO-KQQHTNMISA-N,GPCR,EDNRA,1909,P25101,"ET-A, ETA-R, hET-AR",Antagonist,A-545,0.46,Ki,[125I]-endothelin-1 saturation binding assay,"https://doi.org/10.1016/s0014-2999(98)00891-7, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/ABT-546",=,0.59,IC50,Endothelin-1-evoked phosphatidylinositol hydrolysis in MMQ cells,,=,0,CEREP panel (Eurofins),75,"Screened at 10 µM against 75 receptors, ion channels and other enzymes, closest targets as % inhibition: EDNRB (56%), OPRD1 (62 %); in vitro follow up: Ki(EDNRB) = 13000 nM; Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest target as % inhibition: HRH1(54%); In vitro follow up: Ki(HRH1) >10 µM; Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets: CDK5 (0%), CLK4 (0%), MAP3K13 (0%); ",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/ABT-546,GPCR set,100 nM
EUB0000349a_KISS1R,KISS1-305,EUB0000349a,CC(C[C@H](NC(NNC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](NC([C@H](N)CC1=CC=C(O)C=C1)=O)CC2=CC=NC=C2)=O)CC(N)=O)=O)CO)=O)CC3=CC=CC=C3)=O)=O)C(N[C@H](C(N[C@H](C(N)=O)CC4=CC=CC=C4)=O)CCCNC(NC)=N)=O)C,"InChI=1S/C56H76N16O12/c1-32(2)25-41(50(79)64-39(15-10-22-63-55(60)61-3)49(78)65-40(47(59)76)27-33-11-6-4-7-12-33)70-56(84)72-71-54(83)43(28-34-13-8-5-9-14-34)67-53(82)45(31-73)69-52(81)44(30-46(58)75)68-51(80)42(29-36-20-23-62-24-21-36)66-48(77)38(57)26-35-16-18-37(74)19-17-35/h4-9,11-14,16-21,23-24,32,38-45,73-74H,10,15,22,25-31,57H2,1-3H3,(H2,58,75)(H2,59,76)(H,64,79)(H,65,78)(H,66,77)(H,67,82)(H,68,80)(H,69,81)(H,71,83)(H3,60,61,63)(H2,70,72,84)/t38-,39+,40+,41+,42-,43+,44+,45+/m1/s1",YSVWFFNZZGLLAI-XNTOLAJGSA-N,GPCR,KISS1R,84634,Q969F8,"HOT7T175, AXOR12",Agonist,KISS1-543,0.089,Ki,Binding assay (used membrane fraction of human KISS1R-expressing cells),"http://pubs.acs.org/doi/10.1021/jm401056w, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/KISS1-305",=,,,,,,1,GPCR screen (PDSP),45,"Screened at 1 µM, closest target: Ki(OPRD1) = 47.5 nM; Potency against NPFFR2 (GPR74) and NPFFR1 (GPR147) >30 fold;",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/KISS1-305,GPCR set,1 µM
EUB0000350a_EDNRB,A-192621,EUB0000350a,CCCOC1=CC=C([C@H]2[C@@H]([C@@H](C3=CC(OCO4)=C4C=C3)CN2CC(NC5=C(C=CC=C5CC)CC)=O)C(O)=O)C=C1,"InChI=1S/C33H38N2O6/c1-4-16-39-25-13-10-23(11-14-25)32-30(33(37)38)26(24-12-15-27-28(17-24)41-20-40-27)18-35(32)19-29(36)34-31-21(5-2)8-7-9-22(31)6-3/h7-15,17,26,30,32H,4-6,16,18-20H2,1-3H3,(H,34,36)(H,37,38)/t26-,30-,32+/m1/s1",LQEHCKYYIXQEBM-FUKIBTTHSA-N,GPCR,EDNRB,1910,P24530,ETB,Antagonist,A-1806262,4.5,IC50,Inhibition of 125I labeled ET-3 binding,"https://doi.org/10.1042/CS103S107S, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-192621",=,0.8,IC50,EDNRB-dependent phosphatidylinositol hydrolysis assay (CHO cells transfected with human EDNRBA),,=,1,CEREP panel (Eurofins),71,"Screened at 10 µM (binding assay), closest targets as % inhibition: EDNRA (97.1%), BZD peripheral (72.1%), CCK (63.1%), Cl- channel (77.4%); In vitro follow up of closest target: IC50(EDNRA) = 4.28 µM (>600-fold selective, EDNRB- dependent phosphatidylinositol hydrolysis assay in MMQ cells); Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets: FLT3(ITD,F691L) (13%), NEK5(29%); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest target as % inhibition: HRH1 (36%); Screened in Eurofins-Cerep panel against 7 targets at 10 µM (enzymes and uptake assays): clean profile;",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-192621,GPCR set,100 nM
EUB0000351a_PTGER2,PF-04418948,EUB0000351a,COC1=CC2=C(C=C(OCC3(C(O)=O)CN(C(C4=CC=C(F)C=C4)=O)C3)C=C2)C=C1,"InChI=1S/C23H20FNO5/c1-29-19-8-4-17-11-20(9-5-16(17)10-19)30-14-23(22(27)28)12-25(13-23)21(26)15-2-6-18(24)7-3-15/h2-11H,12-14H2,1H3,(H,27,28)",LWJGMYMNSNVCEM-UHFFFAOYSA-N,GPCR,PTGER2,5732,P43116,EP2,Antagonist,PF-04475866,5,IC50,Enzymatic inhibition assay,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/PF-04418948,=,1.8,Kd,Functional reporter assay (prostaglandin E2 (PGE2)-induced increase in cAMP in CHO cells expressing EP2 receptors),,=,0,GPCR screen (PDSP),45,"Screened at 10 µM, no target >50% of inhibition; F-04418948 displayed >2000-fold functional selectivity for the human EP2 receptor over antagonist activity against the human EP1, EP3, EP4, DP1 and CRTH2 receptors; Selectivity over human IP, FP, TP and LTB4 receptors; Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: PRKAA2 (28%), TAOK3 (35%), PIK3CA (42%); Screened in CEREP ligand profiling (at 10 µM, against 125 targets), closest targets: IC50(NQO2) = 0.53 µM, IC50(PDE3) = 3.5 µM, IC50(LTB4R) = 9.7 µM","https://doi.org/10.1111/j.1476-5381.2011.01495.x, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/PF-04418948",GPCR set,100 nM
EUB0000352a_CCR1,BI-639667,EUB0000352a,CS(C1=CC(C2(NC(C3=CN=CC4=C3C=NN4C5=CC=C(F)C=C5)=O)CC2)=CC=N1)(=O)=O,"InChI=1S/C22H18FN5O3S/c1-32(30,31)20-10-14(6-9-25-20)22(7-8-22)27-21(29)18-11-24-13-19-17(18)12-26-28(19)16-4-2-15(23)3-5-16/h2-6,9-13H,7-8H2,1H3,(H,27,29)",PXQATVYJKMMHAU-UHFFFAOYSA-N,GPCR,CCR1,1230,P32246,"CKR-1, MIP1aR, CD191",Antagonist,BI-9307,5.4,IC50,Scintillation Proximity Assay (SPA),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI%20639667,=,2.4,IC50,Chemotaxis in THP-1 cells,,=,0,GPCR panel (PDSP),45,"Screened at 10 µM, closest target: Ki(ADRB1) = 1.88 µM; Screened in CEREP panel of CCRs at 10 µM: >1000-fold selective over other CCRs (CCR10, CCR9, CCR6, CCR4, all >90% of control); Screened against 69 receptors (Eurofins-Panlabs screen) at 10 µM, closest target as % inhibition: DATRANS (71%); Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: NRD2 (34%), LRRK2 (43%)",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI%20639667,GPCR set,100 nM
EUB0000353a_MRGPRX2,(R)-ZINC 3573,EUB0000353a,CN(C)[C@@H]1CCN(C1)c1cc(c2ccccc2)nc2ccnn12,"InChI=1S/C18H21N5/c1-21(2)15-9-11-22(13-15)18-12-16(14-6-4-3-5-7-14)20-17-8-10-19-23(17)18/h3-8,10,12,15H,9,11,13H2,1-2H3/t15-/m1/s1",XKBSPAZCFAIBJL-OAHLLOKOSA-N,GPCR,MRGPRX2,117194,Q96LB1,MRGX2,Agonist,(S)-ZINC 3573,,,,,,740,EC50,PRESTO-Tango concentration response assay (by the NIMH-PDSP),,=,0,PRESTO-Tango GPCRome screening,315,"Closest targets: Ki(DRD2) = 369.37 nM, Ki(TMEM97) = 489.44 nM, Ki(HTR6) = 748.23 nM; Screened against 45 GPCR targets (PDSD screen) at 10 µM, closest targets: Ki(D2) = 369.37 nM, Ki(5-HT6)= 748.23 nM, Ki(Sigma2) = 489.44 nM, Ki(DAT) = 1109 nM; Screened against 468 kinases (KINOMEscan DiscoverX) at 10 µM, closest targets: Kd(BTK) = 27 µM, Kd(MAPK8) = 19 µM, Kd(MAPK10) >30 µM, PMID: 28288109;",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/(R)-ZINC-3573,GPCR set,1 µM
EUB0000354a_GPR68,Ogerin,EUB0000354a,OCC1=CC=CC=C1C2=NC(N)=NC(NCC3=CC=CC=C3)=N2,"InChI=1S/C17H17N5O/c18-16-20-15(14-9-5-4-8-13(14)11-23)21-17(22-16)19-10-12-6-2-1-3-7-12/h1-9,23H,10-11H2,(H3,18,19,20,21,22)",MDGIEDNDSFMSLP-UHFFFAOYSA-N,GPCR,GPR68,8111,Q15743,OGR1,Allosteric modulator,ZINC32547799,,,,,,148,EC50 ,FLIPR-TETRA assay,,=,0,GPCR screen (PDSP),45,"Highly selective in GPCR screen at 10 µM, clostest target: Ki(5-HT1A) = 849.9 nM","https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/Ogerin, https://doi.org/10.1038/nature15699",GPCR set,1 µM
EUB0000356a_GRM8,DL-AP4,EUB0000356a,NC(CCP(O)(O)=O)C(O)=O,"InChI=1S/C4H10NO5P/c5-3(4(6)7)1-2-11(8,9)10/h3H,1-2,5H2,(H,6,7)(H2,8,9,10)",DDOQBQRIEWHWBT-UHFFFAOYSA-N,GPCR,GRM8,2918,O00222,"GLUR8, GPRC1H, mGlu8, MGLUR8",Agonist,,5.13,IC50,Inhibitory concentration against [3H]1 binding to recombinant human Metabotropic glutamate receptor 8,15603952,=,,,,,,,,,,,,
EUB0000357aCl_ADRB2,rel-RITODRINE,EUB0000357aCl,[H]Cl.C[C@H]([C@H](C1=CC=C(C=C1)O)O)NCCC2=CC=C(C=C2)O,"InChI=1S/C17H21NO3.ClH/c1-12(17(21)14-4-8-16(20)9-5-14)18-11-10-13-2-6-15(19)7-3-13;/h2-9,12,17-21H,10-11H2,1H3;1H/t12-,17-;/m1./s1",IDLSITKDRVDKRV-JSUROZADSA-N,GPCR,ADRB2,154,P07550,"ADRBR, BAR, B2AR",Agonist,,0.5,Kd,Binding affinity to beta-2 adrenergic receptor (unknown origin) at 1 to 10000 nM,23954364,=,,,,,,,,,,,,
EUB0000359aCl_DRD1,A-77636,EUB0000359aCl,[H]Cl.NC[C@@H]1O[C@H](C23CC4CC(C3)CC(C2)C4)CC5=C1C=CC(O)=C5O,"InChI=1S/C20H27NO3.ClH/c21-10-17-14-1-2-16(22)19(23)15(14)6-18(24-17)20-7-11-3-12(8-20)5-13(4-11)9-20;/h1-2,11-13,17-18,22-23H,3-10,21H2;1H/t11?,12?,13?,17-,18-,20?;/m0./s1",BWHPNJVKFAPVOG-QYFJGNGUSA-N,GPCR,DRD1,1812,P21728,,Agonist,,7.94,EC50,Adenylate cyclase assay carried out in LTK cells transfected with human Dopamine receptor D1,7658429,=,,,,,,,,,,,,
EUB0000363a_TACR1,CP-96345,EUB0000363a,COC1=CC=CC=C1CN[C@H]1C2CCN(CC2)[C@H]1C(C1=CC=CC=C1)C1=CC=CC=C1,"InChI=1S/C28H32N2O/c1-31-25-15-9-8-14-24(25)20-29-27-23-16-18-30(19-17-23)28(27)26(21-10-4-2-5-11-21)22-12-6-3-7-13-22/h2-15,23,26-29H,16-20H2,1H3/t27-,28-/m0/s1",FLNYLINBEZROPL-NSOVKSMOSA-N,GPCR,TACR1,6869,P25103,"SPR, NK1R, NKIR",Antagonist,,1.48,Ki,Binding affinity towards Tachykinin receptor 1 expressed in CHO cells using [3H][Pro9]-SP as radioligand,11266164,=,0.79,Kd,Antagonist activity against Tachykinin receptor 1 in dog isolated carotid artery,,=,,,,,,,
EUB0000365aCl_OPRK1,BRL-52537,EUB0000365aCl,[H]Cl.O=C(CC1=CC(Cl)=C(Cl)C=C1)N2CCCC[C@H]2CN3CCCC3,"InChI=1S/C18H24Cl2N2O.ClH/c19-16-7-6-14(11-17(16)20)12-18(23)22-10-2-1-5-15(22)13-21-8-3-4-9-21;/h6-7,11,15H,1-5,8-10,12-13H2;1H/t15-;/m0./s1",NGVLSOWJSUUYDE-RSAXXLAASA-N,GPCR,OPRK1,4986,P41145,"KOR, OPRK",Agonist,,,,,,,10.96,IC50,Kappa-opioid receptor agonist potency in vitro using rabbit vas deferens(LVD) preparation,,=,,,,,,,
EUB0000366a_HTR2A,FANANSERIN,EUB0000366a,FC1=CC=C(C=C1)N1CCN(CCCN2C3=C4C(=CC=CC4=CC=C3)S2(=O)=O)CC1,"InChI=1S/C23H24FN3O2S/c24-19-8-10-20(11-9-19)26-16-14-25(15-17-26)12-3-13-27-21-6-1-4-18-5-2-7-22(23(18)21)30(27,28)29/h1-2,4-11H,3,12-17H2",VGIGHGMPMUCLIQ-UHFFFAOYSA-N,GPCR,HTR2A,3356,P28223,5-HT2A,Antagonist,,0.12,Ki,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,11784153,=,,,,,,,,,,,,
EUB0000366a_HTR2C,FANANSERIN,EUB0000366a,FC1=CC=C(C=C1)N1CCN(CCCN2C3=C4C(=CC=CC4=CC=C3)S2(=O)=O)CC1,"InChI=1S/C23H24FN3O2S/c24-19-8-10-20(11-9-19)26-16-14-25(15-17-26)12-3-13-27-21-6-1-4-18-5-2-7-22(23(18)21)30(27,28)29/h1-2,4-11H,3,12-17H2",VGIGHGMPMUCLIQ-UHFFFAOYSA-N,GPCR,HTR2C,3358,P28335,"5-HT2C, 5HTR2C",,,1,Ki,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,11784153,=,,,,,,,,,,,,
EUB0000366a_DRD4,FANANSERIN,EUB0000366a,FC1=CC=C(C=C1)N1CCN(CCCN2C3=C4C(=CC=CC4=CC=C3)S2(=O)=O)CC1,"InChI=1S/C23H24FN3O2S/c24-19-8-10-20(11-9-19)26-16-14-25(15-17-26)12-3-13-27-21-6-1-4-18-5-2-7-22(23(18)21)30(27,28)29/h1-2,4-11H,3,12-17H2",VGIGHGMPMUCLIQ-UHFFFAOYSA-N,GPCR,DRD4,1815,P21917,,,,2.88,Ki,Displacement of [3H]spiperone from cloned human dopamine D4.2 receptor in HEK298 cells,16168646,=,,,,,,,,,,,,
EUB0000367a_CCKAR,DEVAZEPIDE,EUB0000367a,CN1C2=C(C=CC=C2)C(=N[C@H](NC(=O)C2=CC3=CC=CC=C3N2)C1=O)C1=CC=CC=C1,"InChI=1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1",NFHRQQKPEBFUJK-HSZRJFAPSA-N,GPCR,CCKAR,886,P32238,,Antagonist,,0.2,Ki,Displacement of [3H]L-364718 from human recombinant CCK1 receptor expressed in PC3 cell line,16570921,=,,,,,,,,,,,,
EUB0000370a_LTB4R,LY223982,EUB0000370a,COC1=CC=C(\C=C\CCCCOC2=C(CCC(O)=O)C=C(C=C2)C(=O)C2=CC(=CC=C2)C(O)=O)C=C1,"InChI=1S/C30H30O7/c1-36-26-14-10-21(11-15-26)7-4-2-3-5-18-37-27-16-12-24(19-22(27)13-17-28(31)32)29(33)23-8-6-9-25(20-23)30(34)35/h4,6-12,14-16,19-20H,2-3,5,13,17-18H2,1H3,(H,31,32)(H,34,35)/b7-4+",SYZSSLLFRVDRHL-QPJJXVBHSA-N,GPCR,LTB4R,1241,Q15722,"BLTR, P2Y7, LTB4R1",Antagonist,,7.76,IC50,Inhibition of [3H]LTB4 binding to Leukotriene B4 receptor in the guinea pig spleen membranes,1333011,=,113.5,IC50,Inhibition of LTB4-induced elastase release in human polymorphonuclear leukocytes,,=,,,,,,,
EUB0000372aCl_OPRK1,NORBINALTORPHIMINE,EUB0000372aCl,[H]Cl.OC1=C2O[C@H]3C4=C(C5=C([C@@H]6OC7=C(C=CC8=C7[C@@]69CCN([C@@H]([C@@]9(C5)O)C8)CC%10CC%10)O)N4)C[C@]%11([C@H]%12CC(C=C1)=C2[C@@]3%11CCN%12CC%13CC%13)O,"InChI=1S/C40H43N3O6.ClH/c44-25-7-5-21-13-27-39(46)15-23-24-16-40(47)28-14-22-6-8-26(45)34-30(22)38(40,10-12-43(28)18-20-3-4-20)36(49-34)32(24)41-31(23)35-37(39,29(21)33(25)48-35)9-11-42(27)17-19-1-2-19;/h5-8,19-20,27-28,35-36,41,44-47H,1-4,9-18H2;1H/t27-,28-,35+,36+,37+,38+,39-,40-;/m1./s1",SQNOQAMOMUBPHK-FFZCCNEYSA-N,GPCR,OPRK1,4986,P41145,"KOR, OPRK",Antagonist,,0.35,Ki,Binding affinity using [3H]diprenorphine as the radioligand against E297A mutant Opioid receptor kappa 1 in COS-7 cells,10780914,=,3.01,Ki,"Compound was evaluated for its binding affinity by displacing [3H]U-69593 to human cloned Kappa opioid receptor transfected into CHO cells using [35S]GTP-gamma-S, assay",,=,,,,,,,
EUB0000372aCl_OPRD1,NORBINALTORPHIMINE,EUB0000372aCl,[H]Cl.OC1=C2O[C@H]3C4=C(C5=C([C@@H]6OC7=C(C=CC8=C7[C@@]69CCN([C@@H]([C@@]9(C5)O)C8)CC%10CC%10)O)N4)C[C@]%11([C@H]%12CC(C=C1)=C2[C@@]3%11CCN%12CC%13CC%13)O,"InChI=1S/C40H43N3O6.ClH/c44-25-7-5-21-13-27-39(46)15-23-24-16-40(47)28-14-22-6-8-26(45)34-30(22)38(40,10-12-43(28)18-20-3-4-20)36(49-34)32(24)41-31(23)35-37(39,29(21)33(25)48-35)9-11-42(27)17-19-1-2-19;/h5-8,19-20,27-28,35-36,41,44-47H,1-4,9-18H2;1H/t27-,28-,35+,36+,37+,38+,39-,40-;/m1./s1",SQNOQAMOMUBPHK-FFZCCNEYSA-N,GPCR,OPRD1,4985,P41143,,,,,,,,,11.09,Ki,"Compound was evaluated for functional opioid activity by stimulation of [35S]GTP-gamma-S, in cloned human Opioid receptor delta 1 transfected into CHO cells",,=,,,,,,,
EUB0000383a_CCKBR,L-365260,EUB0000383a,CN1C2=C(C=CC=C2)C(=N[C@@H](NC(=O)NC2=CC(C)=CC=C2)C1=O)C1=CC=CC=C1,"InChI=1S/C24H22N4O2/c1-16-9-8-12-18(15-16)25-24(30)27-22-23(29)28(2)20-14-7-6-13-19(20)21(26-22)17-10-4-3-5-11-17/h3-15,22H,1-2H3,(H2,25,27,30)/t22-/m0/s1",KDFQABSFVYLGPM-QFIPXVFZSA-N,GPCR,CCKBR,887,P32239,,Antagonist,,3.98,Ki,Inhibition by displacing [3H]CCK-8S against Cholecystokinin type B receptor of guinea pig,11020274,=,,,,,,,,,,,,
EUB0000385a_NTSR1,REMINERTANT,EUB0000385a,COC1=CC=CC(OC)=C1C1=CC(=NN1C1=C2C=CC(Cl)=CC2=NC=C1)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O,"InChI=1S/C32H31ClN4O5/c1-41-27-4-3-5-28(42-2)29(27)26-16-24(36-37(26)25-8-9-34-23-15-21(33)6-7-22(23)25)30(38)35-32(31(39)40)19-11-17-10-18(13-19)14-20(32)12-17/h3-9,15-20H,10-14H2,1-2H3,(H,35,38)(H,39,40)",DYLJVOXRWLXDIG-UHFFFAOYSA-N,GPCR,NTSR1,4923,P30989,NTR,Antagonist,,20.89,Kd,Displacement of [3H]SR48692 from wild type human NTR1 expressed in HEK293 cells,18809332,=,,,,,,,,,,,,
EUB0000385a_NTSR2,REMINERTANT,EUB0000385a,COC1=CC=CC(OC)=C1C1=CC(=NN1C1=C2C=CC(Cl)=CC2=NC=C1)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O,"InChI=1S/C32H31ClN4O5/c1-41-27-4-3-5-28(42-2)29(27)26-16-24(36-37(26)25-8-9-34-23-15-21(33)6-7-22(23)25)30(38)35-32(31(39)40)19-11-17-10-18(13-19)14-20(32)12-17/h3-9,15-20H,10-14H2,1-2H3,(H,35,38)(H,39,40)",DYLJVOXRWLXDIG-UHFFFAOYSA-N,GPCR,NTSR2,23620,O95665,NTR2,,,416.87,Ki,Binding affinity to NTR2 (unknown origin),23721919,=,,,,,,,,,,,,
EUB0000386aBDA_HRH1,DEXCHLORPHENIRAMINE,EUB0000386aBDA,OC(/C=C\C(O)=O)=O.CN(CC[C@H](C1=NC=CC=C1)C2=CC=C(C=C2)Cl)C,"InChI=1S/C16H19ClN2.C4H4O4/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13;5-3(6)1-2-4(7)8/h3-9,11,15H,10,12H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t15-;/m0./s1",DBAKFASWICGISY-DASCVMRKSA-N,GPCR,HRH1,3269,P35367,,Antagonist,,2.14,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",,=,,,,,,,,,,,,
EUB0000387a_ADRA1B,PHENYLEPHRINE,EUB0000387a,CNC[C@H](O)C1=CC(O)=CC=C1,"InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1",SONNWYBIRXJNDC-VIFPVBQESA-N,GPCR,ADRA1B,147,P35368,,Agonist,,2.24,EC50,Agonist activity at alpha-1B adrenergic receptor (unknown origin) after 5 hrs by CCF4-AM staining-based cellular assay,25813897,=,,,,,,,,,,,,
EUB0000387a_ADRA1A,PHENYLEPHRINE,EUB0000387a,CNC[C@H](O)C1=CC(O)=CC=C1,"InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1",SONNWYBIRXJNDC-VIFPVBQESA-N,GPCR,ADRA1A,148,P35348,ADRA1L1,,,56.23,EC50,Intrinsic activity at alpha1A adrenergic receptor (unknown origin) after 5 hrs in presence of CCF4-AM by cell based beta lactamase reporter gene assay,27658792,=,,,,,,,,,,,,
EUB0000393aCl_TACR1,CP-122721,EUB0000393aCl,[H]Cl.[H]Cl.COC1=C(C=C(C=C1)OC(F)(F)F)CN[C@H]2CCCN[C@H]2C3=CC=CC=C3,"InChI=1S/C20H23F3N2O2.2ClH/c1-26-18-10-9-16(27-20(21,22)23)12-15(18)13-25-17-8-5-11-24-19(17)14-6-3-2-4-7-14;;/h2-4,6-7,9-10,12,17,19,24-25H,5,8,11,13H2,1H3;2*1H/t17-,19-;;/m0../s1",AVTRGAPFNJEOTQ-FFUVTKDNSA-N,GPCR,TACR1,6869,P25103,"SPR, NK1R, NKIR",Antagonist,,0.14,IC50,Displacement of [125I]-labeled substance P from cloned human NK1 receptor expressed in CHO cells,16307878,=,0.19,IC50,Antagonist activity for Tachykinin receptor 1 as displacement of [3H]-Substance P in human IM-9 cells,,=,,,,,,,
EUB0000394a_DRD2,"L-741,626",EUB0000394a,OC1(CCN(CC2=CNC3=CC=CC=C23)CC1)C1=CC=C(Cl)C=C1,"InChI=1S/C20H21ClN2O/c21-17-7-5-16(6-8-17)20(24)9-11-23(12-10-20)14-15-13-22-19-4-2-1-3-18(15)19/h1-8,13,22,24H,9-12,14H2",LLBLNMUONVVVPG-UHFFFAOYSA-N,GPCR,DRD2,1813,P14416,,Antagonist,,8.71,Ki,Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting,19155177,=,4.46,EC50,Antagonist activity at human dopamine D2 receptor expressed in CHO cells assessed as inhibition of quinpirole stimulated mitogenesis,,=,,,,,,,
EUB0000394a_DRD3,"L-741,626",EUB0000394a,OC1(CCN(CC2=CNC3=CC=CC=C23)CC1)C1=CC=C(Cl)C=C1,"InChI=1S/C20H21ClN2O/c21-17-7-5-16(6-8-17)20(24)9-11-23(12-10-20)14-15-13-22-19-4-2-1-3-18(15)19/h1-8,13,22,24H,9-12,14H2",LLBLNMUONVVVPG-UHFFFAOYSA-N,GPCR,DRD3,1814,P35462,,,,93.33,Ki,Displacement of [125I]iodosulpiride from human Dopamine receptor D3 expressed in CHO cells,14521403,=,91.2,EC50,Antagonist activity at human dopamine D3 receptor expressed in CHO cells assessed as inhibition of quinpirole stimulated mitogenesis,,=,,,,,,,
EUB0000400a_NTSR1,SR 142948,EUB0000400a,COC1=CC=CC(OC)=C1C1=CC(=NN1C1=C(C=C(C=C1)C(=O)N(C)CCCN(C)C)C(C)C)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O,"InChI=1S/C39H51N5O6/c1-23(2)29-21-26(37(46)43(5)15-9-14-42(3)4)12-13-31(29)44-32(35-33(49-6)10-8-11-34(35)50-7)22-30(41-44)36(45)40-39(38(47)48)27-17-24-16-25(19-27)20-28(39)18-24/h8,10-13,21-25,27-28H,9,14-20H2,1-7H3,(H,40,45)(H,47,48)",LWULHXVBLMWCHO-UHFFFAOYSA-N,GPCR,NTSR1,4923,P30989,NTR,Antagonist,,3.16,Ki,Displacement of [3H]neurotensin from human NTS1 receptor expressed in CHO cells,24160350,=,,,,,,,,,,,,
EUB0000400a_NTSR2,SR 142948,EUB0000400a,COC1=CC=CC(OC)=C1C1=CC(=NN1C1=C(C=C(C=C1)C(=O)N(C)CCCN(C)C)C(C)C)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O,"InChI=1S/C39H51N5O6/c1-23(2)29-21-26(37(46)43(5)15-9-14-42(3)4)12-13-31(29)44-32(35-33(49-6)10-8-11-34(35)50-7)22-30(41-44)36(45)40-39(38(47)48)27-17-24-16-25(19-27)20-28(39)18-24/h8,10-13,21-25,27-28H,9,14-20H2,1-7H3,(H,40,45)(H,47,48)",LWULHXVBLMWCHO-UHFFFAOYSA-N,GPCR,NTSR2,23620,O95665,NTR2,,,74.13,Ki,Displacement of [3H]NT(8 to 13) from human NTS2 receptor expressed in HEK293 cells,24160350,=,,,,,,,,,,,,
EUB0000404aCl_ADRA1D,DEXMEDETOMIDINE,EUB0000404aCl,[H]Cl.C[C@H](C1=CN=CN1)C1=C(C)C(C)=CC=C1,"InChI=1S/C13H16N2.ClH/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13;/h4-8,11H,1-3H3,(H,14,15);1H/t11-;/m0./s1",VPNGEIHDPSLNMU-MERQFXBCSA-N,GPCR,ADRA1D,146,P25100,"ADRA1R, ADRA1A, ADRA1",Agonist,,0.02,Ki,In vitro binding affinity against alpha-2D adrenergic receptor of male Wistar rat,11300868,=,,,,,,,,,,,,
EUB0000404aCl_ADRA2A,DEXMEDETOMIDINE,EUB0000404aCl,[H]Cl.C[C@H](C1=CN=CN1)C1=C(C)C(C)=CC=C1,"InChI=1S/C13H16N2.ClH/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13;/h4-8,11H,1-3H3,(H,14,15);1H/t11-;/m0./s1",VPNGEIHDPSLNMU-MERQFXBCSA-N,GPCR,ADRA2A,150,P08913,ADRAR,,,,,,,,1.51,EC50,Agonist activity at human recombinant alpha2A adrenergic receptor expressed in CHO cells assessed as induction of [35S]GTPgammaS binding after 60 mins by scintillation counting,,=,,,,,,,
EUB0000405a_PTGFR,DINOPROST,EUB0000405a,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,"InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1",PXGPLTODNUVGFL-YNNPMVKQSA-N,GPCR,PTGFR,5737,P43088,FP,Agonist,,7.08,IC50,Affinity for human Prostanoid FP receptor expressed in COS-7 cells,10715159,=,44.15,EC50,"Functional activity in RAT-1cells, transiently-transfected with human FP-receptor (% of control ligand, fluprostenol=75%)",,=,,,,,,,
EUB0000405a_PTGER3,DINOPROST,EUB0000405a,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,"InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1",PXGPLTODNUVGFL-YNNPMVKQSA-N,GPCR,PTGER3,5733,P43115,"EP3, lnc003875",,,188.36,IC50,Affinity for Prostanoid EP3 receptor expressed in CHO cell line,10715159,=,,,,,,,,,,,,
EUB0000405a_PTGER1,DINOPROST,EUB0000405a,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,"InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1",PXGPLTODNUVGFL-YNNPMVKQSA-N,GPCR,PTGER1,5731,P34995,EP1,,,,,,,,602.55,EC50,"Functional activity in RAT-1cells, transiently-transfected with human Prostaglandin E receptor EP1 (% of control ligand, 17-phi-PGE2=80%)",,=,,,,,,,
EUB0000406aCl_HRH1,IMIPRAMINE,EUB0000406aCl,[H]Cl.CN(C)CCCN1C2=C(CCC3=C1C=CC=C3)C=CC=C2,"InChI=1S/C19H24N2.ClH/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21;/h3-6,8-11H,7,12-15H2,1-2H3;1H",XZZXIYZZBJDEEP-UHFFFAOYSA-N,GPCR,HRH1,3269,P35367,,Antagonist,,26.92,IC50,Binding affinity to histamine H1 receptor (unknown origin) by radioligand binding assay,23919353,=,,,,,,,,,,,,
EUB0000406aCl_HTR2A,IMIPRAMINE,EUB0000406aCl,[H]Cl.CN(C)CCCN1C2=C(CCC3=C1C=CC=C3)C=CC=C2,"InChI=1S/C19H24N2.ClH/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21;/h3-6,8-11H,7,12-15H2,1-2H3;1H",XZZXIYZZBJDEEP-UHFFFAOYSA-N,GPCR,HTR2A,3356,P28223,5-HT2A,,,158.49,Ki,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,11266163,=,,,,,,,,,,,,
EUB0000406aCl_HTR2C,IMIPRAMINE,EUB0000406aCl,[H]Cl.CN(C)CCCN1C2=C(CCC3=C1C=CC=C3)C=CC=C2,"InChI=1S/C19H24N2.ClH/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21;/h3-6,8-11H,7,12-15H2,1-2H3;1H",XZZXIYZZBJDEEP-UHFFFAOYSA-N,GPCR,HTR2C,3358,P28335,"5-HT2C, 5HTR2C",,,158.49,Ki,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,15081025,=,,,,,,,,,,,,
EUB0000406aCl_DRD2,IMIPRAMINE,EUB0000406aCl,[H]Cl.CN(C)CCCN1C2=C(CCC3=C1C=CC=C3)C=CC=C2,"InChI=1S/C19H24N2.ClH/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21;/h3-6,8-11H,7,12-15H2,1-2H3;1H",XZZXIYZZBJDEEP-UHFFFAOYSA-N,GPCR,DRD2,1813,P14416,,,,543.25,Ki,Binding affinity towards dopamine receptor D2 using [3H]spiperone as radioligand,15081025,=,,,,,,,,,,,,
EUB0000407a_CYSLTR1,Zafirlukast,EUB0000407a,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=CC=CC=C1C,"InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)",YEEZWCHGZNKEEK-UHFFFAOYSA-N,GPCR,CYSLTR1,10800,Q9Y271,"CysLT1, CysLT(1), CYSLT1R",Antagonist,,1.82,IC50,Antagonist activity at human CysLT1,26200813,=,,,,,,,,,,,,
EUB0000408aCl_CASR,TECALCET,EUB0000408aCl,[H]Cl.COC1=CC(=CC=C1)[C@@H](C)NCCCC1=CC=CC=C1Cl,"InChI=1S/C18H22ClNO.ClH/c1-14(16-8-5-10-17(13-16)21-2)20-12-6-9-15-7-3-4-11-18(15)19;/h3-5,7-8,10-11,13-14,20H,6,9,12H2,1-2H3;1H/t14-;/m1./s1",YJXUXANREVNZLH-PFEQFJNWSA-N,GPCR,CASR,846,P41180,"FHH, NSHPT, GPRC2A",Positive allosteric modulator,,79.43,EC50,Activity at human CaSR expressed in HEK293 cells assessed as calcium release by FLIPR assay,19835382,=,,,,,,,,,,,,
EUB0000410aCl_HTR1B,Oxymetazoline,EUB0000410aCl,[H]Cl.CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C,"InChI=1S/C16H24N2O.ClH/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14;/h8,19H,6-7,9H2,1-5H3,(H,17,18);1H",BEEDODBODQVSIM-UHFFFAOYSA-N,GPCR,HTR1B,3351,P28222,"S12, 5-HT1B, HTR1D2, 5-HT1DB",Agonist,,0.3,Ki,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,9632357,=,,,,,,,,,,,,
EUB0000410aCl_HTR1D,Oxymetazoline,EUB0000410aCl,[H]Cl.CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C,"InChI=1S/C16H24N2O.ClH/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14;/h8,19H,6-7,9H2,1-5H3,(H,17,18);1H",BEEDODBODQVSIM-UHFFFAOYSA-N,GPCR,HTR1D,3352,P28221,"RDC4, HT1DA, 5-HT1D",,,0.4,Ki,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,9632357,=,,,,,,,,,,,,
EUB0000410aCl_ADRA2A,Oxymetazoline,EUB0000410aCl,[H]Cl.CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C,"InChI=1S/C16H24N2O.ClH/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14;/h8,19H,6-7,9H2,1-5H3,(H,17,18);1H",BEEDODBODQVSIM-UHFFFAOYSA-N,GPCR,ADRA2A,150,P08913,ADRAR,,,8.71,Ki,Affinity to human Alpha-2A adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells,12014961,=,3.31,EC50,Agonist potency at Alpha-2A stably expressed in CHO cells.,,=,,,,,,,
EUB0000410aCl_HTR1A,Oxymetazoline,EUB0000410aCl,[H]Cl.CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C,"InChI=1S/C16H24N2O.ClH/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14;/h8,19H,6-7,9H2,1-5H3,(H,17,18);1H",BEEDODBODQVSIM-UHFFFAOYSA-N,GPCR,HTR1A,3350,P08908,5-hydroxytryptamine receptor 1A,,,,,,,,69.18,EC50,"PUBCHEM_BIOASSAY: Dose Response assay for agonists of 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1A (5HT1A). (Class of assay: confirmatory) [Related pubchem assays: 567, 574 ]",,=,,,,,,,
EUB0000410aCl_ADRA1A,Oxymetazoline,EUB0000410aCl,[H]Cl.CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C,"InChI=1S/C16H24N2O.ClH/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14;/h8,19H,6-7,9H2,1-5H3,(H,17,18);1H",BEEDODBODQVSIM-UHFFFAOYSA-N,GPCR,ADRA1A,148,P35348,ADRA1L1,,,,,,,,83.17,EC50,In vitro activation of human alpha-1A receptor expressed in rat-1 fibroblasts via calcium mobilization through the Gq coupled PLC pathway as functional assay,,=,,,,,,,
EUB0000413a_AVPR2,TOLVAPTAN,EUB0000413a,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2,"InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)",GYHCTFXIZSNGJT-UHFFFAOYSA-N,GPCR,AVPR2,554,P30518,V2R,Antagonist,,0.43,Ki,Concentration which inhibit [3H]AVP binding to human Vasopressin V2 receptor coded HeLa cells by 50%,11087564,=,,,,,,,,,,,,
EUB0000415a_AGTR2,Telmisartan,EUB0000415a,CCCC1=NC2=C(C)C=C(C=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O)C1=NC2=CC=CC=C2N1C,"InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)",RMMXLENWKUUMAY-UHFFFAOYSA-N,GPCR,AGTR2,186,P50052,"AT2, MRX88",Antagonist,,0.33,IC50,Displacement of [125I]Sar1 Ile8-Ang 2 from angiotensin 2 AT2 receptor after 180 mins by gamma counting,22309912,=,,,,,,,,,,,,
EUB0000415a_AGTR1,Telmisartan,EUB0000415a,CCCC1=NC2=C(C)C=C(C=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O)C1=NC2=CC=CC=C2N1C,"InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)",RMMXLENWKUUMAY-UHFFFAOYSA-N,GPCR,AGTR1,185,P30556,"AT1, AT2R1, AGTR1A, AT2R1A, HAT1R, AG2S, AT2R1B, AT1B",,,2,IC50,Inhibition of AT1 receptor,20079636,=,,,,,,,,,,,,
EUB0000417a_ADORA2A,ZM-241385,EUB0000417a,NC1=NC(NCCC2=CC=C(O)C=C2)=NC2=NC(=NN12)C1=CC=CO1,"InChI=1S/C16H15N7O2/c17-14-20-15(18-8-7-10-3-5-11(24)6-4-10)21-16-19-13(22-23(14)16)12-2-1-9-25-12/h1-6,9,24H,7-8H2,(H3,17,18,19,20,21,22)",PWTBZOIUWZOPFT-UHFFFAOYSA-N,GPCR,ADORA2A,135,P29274,RDC8,Antagonist,,0.92,Ki,Binding affinity towards human Adenosine A2a receptor expressed in HEK293 cells using 6 nM [3H]CGS-21680,16250647,=,1.39,Ki,Inhibition of human recombinant adenosine receptor A2a,,=,,,,,,,
EUB0000418aCl_ADRB2,PROPRANOLOL,EUB0000418aCl,[H]Cl.CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1,"InChI=1S/C16H21NO2.ClH/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16;/h3-9,12,14,17-18H,10-11H2,1-2H3;1H",ZMRUPTIKESYGQW-UHFFFAOYSA-N,GPCR,ADRB2,154,P07550,"ADRBR, BAR, B2AR",Antagonist,,0.76,Kd,Binding affinity to human adrenergic beta2 receptor,19168263,=,0.23,Kd,Antagonist activity at human beta-2 adrenergic receptor expressed in salbutamol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,,=,,,,,,,
EUB0000418aCl_ADRB1,PROPRANOLOL,EUB0000418aCl,[H]Cl.CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1,"InChI=1S/C16H21NO2.ClH/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16;/h3-9,12,14,17-18H,10-11H2,1-2H3;1H",ZMRUPTIKESYGQW-UHFFFAOYSA-N,GPCR,ADRB1,153,P08588,,,,3.89,IC50,Tested for Beta-1 adrenergic receptor selectivity in canine cardiac tissue in anesthetized dogs,1976812,=,,,,,,,,,,,,
EUB0000420aCl_ADRB2,CGP-12177,EUB0000420aCl,[H]Cl.CC(C)(C)NCC(O)COC1=C2NC(=O)NC2=CC=C1,"InChI=1S/C14H21N3O3.ClH/c1-14(2,3)15-7-9(18)8-20-11-6-4-5-10-12(11)17-13(19)16-10;/h4-6,9,15,18H,7-8H2,1-3H3,(H2,16,17,19);1H",YQVFCYCTITZLSX-UHFFFAOYSA-N,GPCR,ADRB2,154,P07550,"ADRBR, BAR, B2AR",Antagonist,,1.95,Kd,Displacement of [3H]DHA from inactive/G protein-uncoupled human beta2-AR expressed in CHO cell membranes by liquid scintillation counting,27239696,=,,,,,,,,,,,,
EUB0000420aCl_ADRB1,CGP-12177,EUB0000420aCl,[H]Cl.CC(C)(C)NCC(O)COC1=C2NC(=O)NC2=CC=C1,"InChI=1S/C14H21N3O3.ClH/c1-14(2,3)15-7-9(18)8-20-11-6-4-5-10-12(11)17-13(19)16-10;/h4-6,9,15,18H,7-8H2,1-3H3,(H2,16,17,19);1H",YQVFCYCTITZLSX-UHFFFAOYSA-N,GPCR,ADRB1,153,P08588,,,,,,,,,12.3,EC50,Partial agonist activity at human beta1 adrenoceptor expressed in CHOK1 cells assessed as induction of [3H]cAMP accumulation after 5 hrs,,=,,,,,,,
EUB0000423aNa_CYSLTR1,MONTELUKAST,EUB0000423aNa,CC(C)(O)C(C=CC=C1)=C1CC[C@@H](SCC2(CC2)CC([O-])=O)C3=CC(/C=C/C4=NC5=CC(Cl)=CC=C5C=C4)=CC=C3.[Na+],"InChI=1S/C35H36ClNO3S.Na/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29;/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39);/q;+1/p-1/b15-10+;/t32-;/m1./s1",LBFBRXGCXUHRJY-HKHDRNBDSA-M,GPCR,CYSLTR1,10800,Q9Y271,"CysLT1, CysLT(1), CYSLT1R",Antagonist,,2.29,IC50,Antagonist activity at human CysLT1,26200813,=,72.44,EC50,Antagonist activity at CysLT1 receptor in human dU937 cells assessed as inhibition of LTD4-induced increase of calcium level treated 30 mins before LTD4 challenge,,=,,,,,,,
EUB0000425aMSA_GHSR,IBUTAMOREN,EUB0000425aMSA,O=C(N1CCC2(C(C=CC=C3)=C3N(S(C)(=O)=O)C2)CC1)[C@H](NC(C(C)(N)C)=O)COCC4=CC=CC=C4.OS(=O)(C)=O,"InChI=1S/C27H36N4O5S.CH4O3S/c1-26(2,28)25(33)29-22(18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27(14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27;1-5(2,3)4/h4-12,22H,13-19,28H2,1-3H3,(H,29,33);1H3,(H,2,3,4)/t22-;/m1./s1",DUGMCDWNXXFHDE-VZYDHVRKSA-N,GPCR,GHSR,2693,Q92847,,Agonist,,0.57,IC50,Binding affinity for human growth hormone GH secretagogue (hGHsr) receptor,10636230,=,1.31,EC50,Functional potency measured as intracellular calcium elevation in Hek-293 cells expressing hGHSR1a,,=,,,,,,,
EUB0000426aCl_HTR7,SB-269970,EUB0000426aCl,[H]Cl.CC1CCN(CC[C@H]2CCCN2S(=O)(=O)C2=CC=CC(O)=C2)CC1,"InChI=1S/C18H28N2O3S.ClH/c1-15-7-11-19(12-8-15)13-9-16-4-3-10-20(16)24(22,23)18-6-2-5-17(21)14-18;/h2,5-6,14-16,21H,3-4,7-13H2,1H3;1H/t16-;/m1./s1",XQCJOYZLWFNDIO-PKLMIRHRSA-N,GPCR,HTR7,3363,P34969,5-HT7,Antagonist,,1.55,Ki,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,12392747,=,0.91,IC50,Antagonist activity at human 5-HT7 receptor expressed in HEK293 cells assessed as inhibition of Gs protein-mediated cAMP accumulation by luminescence-based assay,,=,,,,,,,
EUB0000427aCl_OPRL1,JTC-801,EUB0000427aCl,[H]Cl.CCC1=CC=C(OCC2=CC=CC=C2C(=O)NC2=CC3=C(N)C=C(C)N=C3C=C2)C=C1,"InChI=1S/C26H25N3O2.ClH/c1-3-18-8-11-21(12-9-18)31-16-19-6-4-5-7-22(19)26(30)29-20-10-13-25-23(15-20)24(27)14-17(2)28-25;/h4-15H,3,16H2,1-2H3,(H2,27,28)(H,29,30);1H",NQLIYKXNAXKMBL-UHFFFAOYSA-N,GPCR,OPRL1,4987,P41146,"NOCIR, ORL1, OOR, KOR-3, NOPr",Antagonist,,15.67,Ki,"Binding affinity for opioid receptor like type, human Opioid receptor like 1 expressed in membrane homogenates of COS-1 or CHO cells",12431062,=,,,,,,,,,,,,
EUB0000427aCl_OPRM1,JTC-801,EUB0000427aCl,[H]Cl.CCC1=CC=C(OCC2=CC=CC=C2C(=O)NC2=CC3=C(N)C=C(C)N=C3C=C2)C=C1,"InChI=1S/C26H25N3O2.ClH/c1-3-18-8-11-21(12-9-18)31-16-19-6-4-5-7-22(19)26(30)29-20-10-13-25-23(15-20)24(27)14-17(2)28-25;/h4-15H,3,16H2,1-2H3,(H2,27,28)(H,29,30);1H",NQLIYKXNAXKMBL-UHFFFAOYSA-N,GPCR,OPRM1,4988,P35372,MOR1,,,102.33,Ki,Inhibition of [3H]diprenorphine (0.33 nM) binding from human Opioid receptor mu 1 expressed in CHO-K1 cells.,11101358,=,,,,,,,,,,,,
EUB0000428aCl_ADRA2A,Fluoxetine,EUB0000428aCl,[H]Cl.CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,"InChI=1S/C17H18F3NO.ClH/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20;/h2-10,16,21H,11-12H2,1H3;1H",GIYXAJPCNFJEHY-UHFFFAOYSA-N,GPCR,ADRA2A,150,P08913,ADRAR,,,6.31,Ki,Binding affinity for human alpha-2 adrenergic receptor expressed in CHO cell,11262089,=,,,,,,,,,,,,
EUB0000428aCl_HTR2C,Fluoxetine,EUB0000428aCl,[H]Cl.CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,"InChI=1S/C17H18F3NO.ClH/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20;/h2-10,16,21H,11-12H2,1H3;1H",GIYXAJPCNFJEHY-UHFFFAOYSA-N,GPCR,HTR2C,3358,P28335,"5-HT2C, 5HTR2C",,,93.33,Ki,Binding affinity to human 5HT2C receptor by radioligand displacement assay,22520153,=,,,,,,,,,,,,
EUB0000428aCl_HTR2A,Fluoxetine,EUB0000428aCl,[H]Cl.CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,"InChI=1S/C17H18F3NO.ClH/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20;/h2-10,16,21H,11-12H2,1H3;1H",GIYXAJPCNFJEHY-UHFFFAOYSA-N,GPCR,HTR2A,3356,P28223,5-HT2A,,,194.98,IC50,Displacement of [3H]ketanserin from 5HT2A receptor (unknown origin) by cell based radioligand competitive binding analysis,31889666,=,,,,,,,,,,,,
EUB0000429a_GRM8,DCPG,EUB0000429a,N[C@H](C(O)=O)C1=CC=C(C(O)=O)C(=C1)C(O)=O,"InChI=1S/C10H9NO6/c11-7(10(16)17)4-1-2-5(8(12)13)6(3-4)9(14)15/h1-3,7H,11H2,(H,12,13)(H,14,15)(H,16,17)/t7-/m0/s1",IJVMOGKBEVRBPP-ZETCQYMHSA-N,GPCR,GRM8,2918,O00222,"GLUR8, GPRC1H, mGlu8, MGLUR8",Agonist,,30.9,EC50,Agonist activity at mGlu8 (unknown origin) expressed in HEK293 cells coexpressing chimeric Gq/i protein assessed as [3H]inositol phosphate accumulation after 30 mins by scintillation and luminescence counting method,29397723,=,,,,,,,,,,,,
EUB0000435a_CXCR2,SB 332235,EUB0000435a,NS(=O)(=O)C1=C(Cl)C=CC(NC(=O)NC2=C(Cl)C(Cl)=CC=C2)=C1O,"InChI=1S/C13H10Cl3N3O4S/c14-6-2-1-3-8(10(6)16)18-13(21)19-9-5-4-7(15)12(11(9)20)24(17,22)23/h1-5,20H,(H2,17,22,23)(H2,18,19,21)",WTLRWOHEKQGKDS-UHFFFAOYSA-N,GPCR,CXCR2,3579,P25025,"CMKAR2, CD182",Antagonist,,25.12,IC50,Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation,27096048,=,,,,,,,,,,,,
EUB0000437aCl_CASR,CINACALCET,EUB0000437aCl,[H]Cl.C[C@@H](NCCCC1=CC=CC(=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12,"InChI=1S/C22H22F3N.ClH/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25;/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3;1H/t16-;/m1./s1",QANQWUQOEJZMLL-PKLMIRHRSA-N,GPCR,CASR,846,P41180,"FHH, NSHPT, GPRC2A",Positive allosteric modulator,,39.81,EC50,Positive allosteric modulation of calcium sensing receptor by cell based assay,20727747,=,177.83,EC50,Agonist activity at human CaSR expressed in CHO cells assessed as increase in intracellular calcium mobilization after 1 hr by Fura-2 dye-based fluorescence assay,,=,,,,,,,
EUB0000439a_HCRTR1,SB-408124,EUB0000439a,CN(C)C1=CC=C(NC(=O)NC2=C3C=C(F)C=C(F)C3=NC(C)=C2)C=C1,"InChI=1S/C19H18F2N4O/c1-11-8-17(15-9-12(20)10-16(21)18(15)22-11)24-19(26)23-13-4-6-14(7-5-13)25(2)3/h4-10H,1-3H3,(H2,22,23,24,26)",JTARFZSNUAGHRB-UHFFFAOYSA-N,GPCR,HCRTR1,3061,O43613,OX1R,Antagonist,,23.44,Kd,Binding affinity to OX1 receptor,19199652,=,,,,,,,,,,,,
EUB0000439a_HTR2B,SB-408124,EUB0000439a,CN(C)C1=CC=C(NC(=O)NC2=C3C=C(F)C=C(F)C3=NC(C)=C2)C=C1,"InChI=1S/C19H18F2N4O/c1-11-8-17(15-9-12(20)10-16(21)18(15)22-11)24-19(26)23-13-4-6-14(7-5-13)25(2)3/h4-10H,1-3H3,(H2,22,23,24,26)",JTARFZSNUAGHRB-UHFFFAOYSA-N,GPCR,HTR2B,3357,P41595,"5-HT(2B), 5-HT2B",,,316.23,Ki,Binding affinity to 5HT2B receptor (unknown origin),23891187,=,,,,,,,,,,,,
EUB0000441a_S1PR1,SEW 2871,EUB0000441a,FC(F)(F)C1=C(C=C(S1)C1=NC(=NO1)C1=CC(=CC=C1)C(F)(F)F)C1=CC=CC=C1,"InChI=1S/C20H10F6N2OS/c21-19(22,23)13-8-4-7-12(9-13)17-27-18(29-28-17)15-10-14(11-5-2-1-3-6-11)16(30-15)20(24,25)26/h1-10H",OYMNPJXKQVTQTR-UHFFFAOYSA-N,GPCR,S1PR1,1901,P21453,"edg-1, D1S3362, CD363",Agonist,,21.88,IC50,Displacement of [33P]S1P from human S1P1R expressed in CHO cell membranes,24900286,=,,,,,,,,,,,,
EUB0000447aCl_OPRM1,LOPERAMIDE,EUB0000447aCl,[H]Cl.CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1,"InChI=1S/C29H33ClN2O2.ClH/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23;/h3-16,34H,17-22H2,1-2H3;1H",PGYPOBZJRVSMDS-UHFFFAOYSA-N,GPCR,OPRM1,4988,P35372,MOR1,Agonist,,0.92,IC50,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,11585443,=,,,,,,,,,,,,
EUB0000447aCl_OPRD1,LOPERAMIDE,EUB0000447aCl,[H]Cl.CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1,"InChI=1S/C29H33ClN2O2.ClH/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23;/h3-16,34H,17-22H2,1-2H3;1H",PGYPOBZJRVSMDS-UHFFFAOYSA-N,GPCR,OPRD1,4985,P41143,,,,,,,,,154.88,EC50,Inhibition of delta opioid receptor mediated GTPgammaS binding to CHO cell membranes,,=,,,,,,,
EUB0000449a_GPER1,ESTRADIOL,EUB0000449a,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O,"InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1",VOXZDWNPVJITMN-ZBRFXRBCSA-N,GPCR,GPER1,2852,Q99527,"FEG-1, GPCR-Br, LERGU, LERGU2, DRY12, LyGPR, CEPR",Agonist,,3.94,Ki,Inhibition of estrogen binding to GPR30 (unknown origin),23672690,=,0.3,EC50,Agonist activity at GPR30 (unknown origin) by calcium mobilization assay,,=,,,,,,,
EUB0000453a_GRM5,FENOBAM,EUB0000453a,CN1CC(=O)N=C1NC(=O)NC1=CC(Cl)=CC=C1,"InChI=1S/C11H11ClN4O2/c1-16-6-9(17)14-10(16)15-11(18)13-8-4-2-3-7(12)5-8/h2-5H,6H2,1H3,(H2,13,14,15,17,18)",DWPQODZAOSWNHB-UHFFFAOYSA-N,GPCR,GRM5,2915,P41594,"MGLUR5, GPRC1E, mGlu5, PPP1R86",,,36.31,IC50,Displacement of [3H]MPEP from mGlu5 receptor,17196387,=,42.66,IC50,Inhibition of glutamate-induced calcium influx in human mGluR5d by FLIPR,,=,,,,,,,
EUB0000453a_GRM1,FENOBAM,EUB0000453a,CN1CC(=O)N=C1NC(=O)NC1=CC(Cl)=CC=C1,"InChI=1S/C11H11ClN4O2/c1-16-6-9(17)14-10(16)15-11(18)13-8-4-2-3-7(12)5-8/h2-5H,6H2,1H3,(H2,13,14,15,17,18)",DWPQODZAOSWNHB-UHFFFAOYSA-N,GPCR,GRM1,2911,Q13255,"GPRC1A, mGlu1, MGLUR1, PPP1R85",Negative allosteric modulator,,,,,,,6.76,Ki,Antagonist activity at human mGLUR1,,=,,,,,,,
EUB0000454a_GRM2,BINA,EUB0000454a,CC1=C(C)C(OCC2=CC(=CC=C2)C2=CC=C(C=C2)C(O)=O)=CC2=C1C(=O)C(C2)C1CCCC1,"InChI=1S/C30H30O4/c1-18-19(2)28-25(15-26(29(28)31)22-7-3-4-8-22)16-27(18)34-17-20-6-5-9-24(14-20)21-10-12-23(13-11-21)30(32)33/h5-6,9-14,16,22,26H,3-4,7-8,15,17H2,1-2H3,(H,32,33)",KMKBEESNZAPKMP-UHFFFAOYSA-N,GPCR,GRM2,2912,Q14416,"GPRC1B, mGlu2, MGLUR2",Positive allosteric modulator,,93.33,Kd,Binding affinity to human metabotropic glutamate receptor 2 expressed in CHOK1 cell membranes by scintillation proximity assay,28704052,=,27.54,EC50,Allosteric modulation of human mGluR2 expressed in CHO cells by [35S]GTPgammaS binding assay,,=,,,,,,,
EUB0000459a_PTGDR,LAROPIPRANT,EUB0000459a,CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1,"InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1",NXFFJDQHYLNEJK-CYBMUJFWSA-N,GPCR,PTGDR,5729,Q13258,"DP, DP1, PTGDR1",Antagonist,,0.58,Ki,Binding affinity to human DP receptor expressed in HEK293 cells,17300164,=,0.6,IC50,Activity at human DP receptor in washed platelets assessed as inhibition of PGD2-induced cAMP accumulation,,=,,,,,,,
EUB0000459a_TBXA2R,LAROPIPRANT,EUB0000459a,CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1,"InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1",NXFFJDQHYLNEJK-CYBMUJFWSA-N,GPCR,TBXA2R,6915,P21731,,,,5.69,Ki,Binding affinity to human TP receptor expressed in HEK293 cells,17300164,=,,,,,,,,,,,,
EUB0000460a_ADORA2B,BAY 60-6583,EUB0000460a,NC(=O)CSC1=C(C#N)C(C2=CC=C(OCC3CC3)C=C2)=C(C#N)C(N)=N1,"InChI=1S/C19H17N5O2S/c20-7-14-17(12-3-5-13(6-4-12)26-9-11-1-2-11)15(8-21)19(24-18(14)23)27-10-16(22)25/h3-6,11H,1-2,9-10H2,(H2,22,25)(H2,23,24)",ZTYHZMAZUWOXNC-UHFFFAOYSA-N,GPCR,ADORA2B,136,P29275,,Agonist,,,,,,,30.9,EC50,Agonist activity at human adenosine A2B receptor expressed in CHO cell membranes assessed as induction of cAMP accumulation by AlphaScreen assay,,=,,,,,,,
EUB0000464a_LPAR2,LPA2 Antagonist 1,EUB0000464a,C[C@@H](CN1CCN(CC1)S(=O)(=O)C1=CC=C(Cl)C(Cl)=C1)NC1=C2SC=C(C)C2=NC=N1,"InChI=1S/C20H23Cl2N5O2S2/c1-13-11-30-19-18(13)23-12-24-20(19)25-14(2)10-26-5-7-27(8-6-26)31(28,29)15-3-4-16(21)17(22)9-15/h3-4,9,11-12,14H,5-8,10H2,1-2H3,(H,23,24,25)/t14-/m0/s1",BPRNMVDTWIHULJ-AWEZNQCLSA-N,GPCR,LPAR2,9170,Q9HBW0,"EDG-4, LPA2",Antagonist,,,,,,,16.98,IC50,Antagonist activity at LPA2 expressed in RH7777 cells with Gi4-protein and aequorin by calcium mobilization assay,,=,,,,,,,
EUB0000469a_F2RL1,AC 264613,EUB0000469a,C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)C1=CC=CC=C1)C1=CC=CC(Br)=C1,"InChI=1S/C19H18BrN3O2/c1-12(14-8-5-9-15(20)10-14)22-23-19(25)17-16(11-21-18(17)24)13-6-3-2-4-7-13/h2-10,16-17H,11H2,1H3,(H,21,24)(H,23,25)/b22-12+/t16-,17-/m0/s1",RQKXQCSEZPQBNZ-QSBCOWLBSA-N,GPCR,F2RL1,2150,P55085,PAR2,Agonist,,30.2,EC50,Agonist activity at human PAR2 expressed in HEK293T cells assessed as stimulation of phosphatidylinositol hydrolysis after 45 mins by scintillation counting analysis,23895492,=,30.9,EC50,Agonist activity at human PAR2 expressed in HEK293T cells assessed as effect on intracellular calcium mobilization by R-SAT assay,,=,,,,,,,
EUB0000472aNa_GNRHR,ELAGOLIX,EUB0000472aNa,O=C(N(CC1=C(F)C=CC=C1C(F)(F)F)C(C)=C2C3=C(F)C(OC)=CC=C3)N(C[C@H](NCCCC([O-])=O)C4=CC=CC=C4)C2=O.[Na+],"InChI=1S/C32H30F5N3O5.Na/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33;/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42);/q;+1/p-1/t25-;/m0./s1",DQYGXRQUFSRDCH-UQIIZPHYSA-M,GPCR,GNRHR,2798,P30968,LHRHR,Antagonist,,0.89,Ki,"Displacement of [125I-Tyr5,DLeu6,NMeLeu7,Pro9-NEt-]GnRH from human GnRH receptor expressed in HEK293 cells by liquid scintillation counting",19006286,=,1.51,IC50,Antagonist activity at human GnRH receptor expressed in RBL1 cells assessed as inhibition of GnRH-stimulated inositol phosphate production,,=,,,,,,,
EUB0000474aCl_CCR2,PLERIXAFOR,EUB0000474aCl,[H]Cl.C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1,"InChI=1S/C28H54N8.ClH/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36;/h5-8,29-34H,1-4,9-26H2;1H",VZVSLNRDUPMOSZ-UHFFFAOYSA-N,GPCR,CCR2,729230,P41597,"CC-CKR-2, CKR2, MCP-1-R, CD192, FLJ78302",Antagonist,,0.06,IC50,Displacement of [125I]MCP1 from CCR2/CXCR4 expressed in CHOK1 cells,17715128,=,,,,,,,,,,,,
EUB0000475aCl_HRH3,PITOLISANT,EUB0000475aCl,[H]Cl.ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1,"InChI=1S/C17H26ClNO.ClH/c18-17-9-7-16(8-10-17)6-4-14-20-15-5-13-19-11-2-1-3-12-19;/h7-10H,1-6,11-15H2;1H",XLFKECRRMPOAQS-UHFFFAOYSA-N,GPCR,HRH3,11255,Q9Y5N1,GPCR97,Inverse agonist,,2.6,Ki,Displacement of [125I]iodoproxyfan from human recombinant histamine H3 receptor expressed in CHO-K1 cells,18774720,=,12.02,IC50,Antagonist activity at human cloned histamine H3 receptor expressed in CHO-K1 cells assessed as inhibition of R-alpha-methylhistamine-induced [35S]GTPgammaS binding,,=,,,,,,,
EUB0000477aCl_HRH1,FEXOFENADINE,EUB0000477aCl,[H]Cl.CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,"InChI=1S/C32H39NO4.ClH/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27;/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36);1H",RRJFVPUCXDGFJB-UHFFFAOYSA-N,GPCR,HRH1,3269,P35367,,Antagonist,,26.92,Ki,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,19660947,=,,,,,,,,,,,,
EUB0000480a_HTR7,LATREPIRDINE,EUB0000480a,CN1CCC2=C(C1)C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1,"InChI=1S/C21H25N3/c1-15-4-7-20-18(12-15)19-14-23(3)10-9-21(19)24(20)11-8-17-6-5-16(2)22-13-17/h4-7,12-13H,8-11,14H2,1-3H3",JNODQFNWMXFMEV-UHFFFAOYSA-N,GPCR,HTR7,3363,P34969,5-HT7,Antagonist,,7.94,Ki,Binding affinity to 5HT7 receptor by radioligand displacement assay,19939513,=,,,,,,,,,,,,
EUB0000480a_HTR6,LATREPIRDINE,EUB0000480a,CN1CCC2=C(C1)C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1,"InChI=1S/C21H25N3/c1-15-4-7-20-18(12-15)19-14-23(3)10-9-21(19)24(20)11-8-17-6-5-16(2)22-13-17/h4-7,12-13H,8-11,14H2,1-3H3",JNODQFNWMXFMEV-UHFFFAOYSA-N,GPCR,HTR6,3362,P50406,"5-HT6, 5-HT6R",,,33.88,Ki,Binding affinity to human recombinant 5HT6 receptor by radioligand displacement assay,19939513,=,1011.58,IC50,Antagonist activity at human recombinant 5HT6 receptor expressed in HEK293 cells assessed as inhibition of serotonin-induced cAMP production by LANCE assay,,=,,,,,,,
EUB0000480a_ADRA1A,LATREPIRDINE,EUB0000480a,CN1CCC2=C(C1)C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1,"InChI=1S/C21H25N3/c1-15-4-7-20-18(12-15)19-14-23(3)10-9-21(19)24(20)11-8-17-6-5-16(2)22-13-17/h4-7,12-13H,8-11,14H2,1-3H3",JNODQFNWMXFMEV-UHFFFAOYSA-N,GPCR,ADRA1A,148,P35348,ADRA1L1,,,60.26,Ki,Binding affinity to adrenergic alpha1A receptor by radioligand displacement assay,19945877,=,,,,,,,,,,,,
EUB0000480a_HTR2A,LATREPIRDINE,EUB0000480a,CN1CCC2=C(C1)C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1,"InChI=1S/C21H25N3/c1-15-4-7-20-18(12-15)19-14-23(3)10-9-21(19)24(20)11-8-17-6-5-16(2)22-13-17/h4-7,12-13H,8-11,14H2,1-3H3",JNODQFNWMXFMEV-UHFFFAOYSA-N,GPCR,HTR2A,3356,P28223,5-HT2A,,,61.66,Ki,Displacement of [3H]Ketanserin from human recombinant 5HT2A receptor expressed in CHO-K1 cells,19945877,=,,,,,,,,,,,,
EUB0000480a_HTR2C,LATREPIRDINE,EUB0000480a,CN1CCC2=C(C1)C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1,"InChI=1S/C21H25N3/c1-15-4-7-20-18(12-15)19-14-23(3)10-9-21(19)24(20)11-8-17-6-5-16(2)22-13-17/h4-7,12-13H,8-11,14H2,1-3H3",JNODQFNWMXFMEV-UHFFFAOYSA-N,GPCR,HTR2C,3358,P28335,"5-HT2C, 5HTR2C",,,75.86,Ki,Binding affinity to 5HT2C receptor by radioligand displacement assay,19939513,=,,,,,,,,,,,,
EUB0000480a_ADRA2A,LATREPIRDINE,EUB0000480a,CN1CCC2=C(C1)C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1,"InChI=1S/C21H25N3/c1-15-4-7-20-18(12-15)19-14-23(3)10-9-21(19)24(20)11-8-17-6-5-16(2)22-13-17/h4-7,12-13H,8-11,14H2,1-3H3",JNODQFNWMXFMEV-UHFFFAOYSA-N,GPCR,ADRA2A,150,P08913,ADRAR,,,109.65,Ki,Displacement of [3H]MK-912 from human recombinant adrenergic alpha2A receptor expressed in insect Sf9 cells,19945877,=,,,,,,,,,,,,
EUB0000480a_HRH1,LATREPIRDINE,EUB0000480a,CN1CCC2=C(C1)C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1,"InChI=1S/C21H25N3/c1-15-4-7-20-18(12-15)19-14-23(3)10-9-21(19)24(20)11-8-17-6-5-16(2)22-13-17/h4-7,12-13H,8-11,14H2,1-3H3",JNODQFNWMXFMEV-UHFFFAOYSA-N,GPCR,HRH1,3269,P35367,,,,,,,,,158.49,IC50,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,,=,,,,,,,
EUB0000482aCl_ADRB2,Zinterol,EUB0000482aCl,[H]Cl.CC(C)(CC1=CC=CC=C1)NCC(O)C1=CC=C(O)C(NS(C)(=O)=O)=C1,"InChI=1S/C19H26N2O4S.ClH/c1-19(2,12-14-7-5-4-6-8-14)20-13-18(23)15-9-10-17(22)16(11-15)21-26(3,24)25;/h4-11,18,20-23H,12-13H2,1-3H3;1H",LVNUBJDWJFOMKH-UHFFFAOYSA-N,GPCR,ADRB2,154,P07550,"ADRBR, BAR, B2AR",Agonist,,,,,,,0.05,EC50,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,,=,,,,,,,
EUB0000493aCl_DRD3,CARIPRAZINE,EUB0000493aCl,[H]Cl.CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1,"InChI=1S/C21H32Cl2N4O.ClH/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23;/h3-5,16-17H,6-15H2,1-2H3,(H,24,28);1H/t16-,17-;",GPPJWWMREQHLQT-BHQIMSFRSA-N,GPCR,DRD3,1814,P35462,,Antagonist,,0.09,Ki,Binding affinity to human dopamine D3 receptor,22537450,=,5.75,EC50,Agonist activity at human dopamine D3 receptor transiently expressed in HEK293 cells co-expressing Galphao1 after 30 mins by [35S]GTPgammaS binding assay,,=,,,,,,,
EUB0000493aCl_DRD2,CARIPRAZINE,EUB0000493aCl,[H]Cl.CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1,"InChI=1S/C21H32Cl2N4O.ClH/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23;/h3-5,16-17H,6-15H2,1-2H3,(H,24,28);1H/t16-,17-;",GPPJWWMREQHLQT-BHQIMSFRSA-N,GPCR,DRD2,1813,P14416,,,,0.81,Ki,Binding affinity to human dopamine D2L receptor,22537450,=,110.92,EC50,Agonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells co-expressing Galphai2 after 30 mins by [35S]GTPgammaS binding assay,,=,,,,,,,
EUB0000493aCl_HTR1A,CARIPRAZINE,EUB0000493aCl,[H]Cl.CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1,"InChI=1S/C21H32Cl2N4O.ClH/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23;/h3-5,16-17H,6-15H2,1-2H3,(H,24,28);1H/t16-,17-;",GPPJWWMREQHLQT-BHQIMSFRSA-N,GPCR,HTR1A,3350,P08908,5-hydroxytryptamine receptor 1A,,,2.82,Ki,Displacement of [3H]8-OH-DPAT from recombinant human 5-HT1A receptor expressed in HEK293 cell membranes after 60 mins by scintillation counting method,27487565,=,,,,,,,,,,,,
EUB0000499a_ADRB2,INDACATEROL,EUB0000499a,CCC1=CC2=C(CC(C2)NC[C@H](O)C2=C3C=CC(=O)NC3=C(O)C=C2)C=C1CC,"InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1",QZZUEBNBZAPZLX-QFIPXVFZSA-N,GPCR,ADRB2,154,P07550,"ADRBR, BAR, B2AR",Agonist,,39.35,Ki,Displacement of [125I]cyanopindolol from human recombinant beta2 adrenergic receptor expressed in CHO cells by filtration assay,20402514,=,10.96,EC50,Agonist activity at human beta2 adrenergic receptor assessed as increase in cAMP level by whole cell assay,,=,,,,,,,
EUB0000499a_ADRB1,INDACATEROL,EUB0000499a,CCC1=CC2=C(CC(C2)NC[C@H](O)C2=C3C=CC(=O)NC3=C(O)C=C2)C=C1CC,"InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1",QZZUEBNBZAPZLX-QFIPXVFZSA-N,GPCR,ADRB1,153,P08588,,,,91.2,Ki,Displacement of [3H]CGP12177 from human beta-1 adrenoceptor,20655218,=,,,,,,,,,,,,
EUB0000499a_DRD3,INDACATEROL,EUB0000499a,CCC1=CC2=C(CC(C2)NC[C@H](O)C2=C3C=CC(=O)NC3=C(O)C=C2)C=C1CC,"InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1",QZZUEBNBZAPZLX-QFIPXVFZSA-N,GPCR,DRD3,1814,P35462,,,,1047.13,Ki,Displacement of [125I]7-HO-PIPAT from human D3R expressed in HEK cells,25065493,=,,,,,,,,,,,,
EUB0000501a_S1PR1,NIBR0213,EUB0000501a,C[C@H](NC(=O)C1=C(C)C=C(C=C1C)C1=CC(N[C@H](C)C2=CC(C)=C(Cl)C=C2)=CC=C1)C(O)=O,"InChI=1S/C27H29ClN2O3/c1-15-11-20(9-10-24(15)28)18(4)29-23-8-6-7-21(14-23)22-12-16(2)25(17(3)13-22)26(31)30-19(5)27(32)33/h6-14,18-19,29H,1-5H3,(H,30,31)(H,32,33)/t18-,19+/m1/s1",KYHUARFFBDLROH-MOPGFXCFSA-N,GPCR,S1PR1,1901,P21453,"edg-1, D1S3362, CD363",Antagonist,,,,,,,2,IC50,Antagonist activity at human S1P1 receptor expressed in CHO cells after 120 mins by [35S]GTPgammaS binding assay,,=,,,,,,,
EUB0000519a_FFAR4,GPR120 Compound A,EUB0000519a,OC(=O)CC1CCC2(CC1)CCN(CC2)C1=CC(OC(F)(F)F)=CC=C1Cl,"InChI=1S/C19H23ClF3NO3/c20-15-2-1-14(27-19(21,22)23)12-16(15)24-9-7-18(8-10-24)5-3-13(4-6-18)11-17(25)26/h1-2,12-13H,3-11H2,(H,25,26)",WUJVPELCYCESAP-UHFFFAOYSA-N,GPCR,FFAR4,338557,Q5NUL3,PGR4,Agonist,,80.35,EC50,Agonist activity at ARMS2-PK2 -tagged human GPR120 short isoform expressed in CHOK1 cells assessed as induction of beta-arrestin2 recruitment after 90 mins by luminescence assay,28105274,=,,,,,,,,,,,,
EUB0000521a_FFAR2,GLPG-0974,EUB0000521a,C[C@@]1(CCN1C(=O)C1=CSC2=CC=CC=C12)C(=O)N(CCCC(O)=O)CC1=CC(Cl)=CC=C1,"InChI=1S/C25H25ClN2O4S/c1-25(11-13-28(25)23(31)20-16-33-21-9-3-2-8-19(20)21)24(32)27(12-5-10-22(29)30)15-17-6-4-7-18(26)14-17/h2-4,6-9,14,16H,5,10-13,15H2,1H3,(H,29,30)/t25-/m1/s1",MPMKMQHJHDHPBE-RUZDIDTESA-N,GPCR,FFAR2,2867,O15552,FFA2R,Antagonist,,,,,,,10.35,IC50,Antagonist activity against human FFA2 receptor expressed in HEK293 cells assessed as inhibition of sodium acetate-induced calcium mobilization,,=,,,,,,,
EUB0000524a_S1PR5,A 971432,EUB0000524a,OC(=O)C1CN(CC2=CC=C(OCC3=CC(Cl)=C(Cl)C=C3)C=C2)C1,"InChI=1S/C18H17Cl2NO3/c19-16-6-3-13(7-17(16)20)11-24-15-4-1-12(2-5-15)8-21-9-14(10-21)18(22)23/h1-7,14H,8-11H2,(H,22,23)",WAAWETUDFSIYSD-UHFFFAOYSA-N,GPCR,S1PR5,53637,Q9H228,Edg-8,Agonist,,5.75,EC50,Agonist activity at S1P5 receptor (unknown origin) expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation by GTPgammaS binding assay,26509640,=,,,,,,,,,,,,
EUB0000526a_SMO,CYCLOPAMINE,EUB0000526a,C[C@H]1C[C@@H]2[C@H]([C@H]([C@]3(O2)CC[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@]6([C@H]5CC4=C3C)C)O)C)NC1,"InChI=1S/C27H41NO2/c1-15-11-24-25(28-14-15)17(3)27(30-24)10-8-20-21-6-5-18-12-19(29)7-9-26(18,4)23(21)13-22(20)16(27)2/h5,15,17,19-21,23-25,28-29H,6-14H2,1-4H3/t15-,17+,19-,20-,21-,23-,24+,25-,26-,27-/m0/s1",QASFUMOKHFSJGL-LAFRSMQTSA-N,GPCR,SMO,6608,Q99835,FZD11,Antagonist,,64.57,IC50,Antagonist activity at human Smo receptor expressed in CHO cells by [3H]Hh-Ag binding assay,19091559,=,,,,,,,,,,,,
EUB0000529a_TSHR,PURVALANOL A,EUB0000529a,CC(C)[C@H](CO)NC1=NC(NC2=CC=CC(Cl)=C2)=C2N=CN(C(C)C)C2=N1,"InChI=1S/C19H25ClN6O/c1-11(2)15(9-27)23-19-24-17(22-14-7-5-6-13(20)8-14)16-18(25-19)26(10-21-16)12(3)4/h5-8,10-12,15,27H,9H2,1-4H3,(H2,22,23,24,25)/t15-/m0/s1",PMXCMJLOPOFPBT-HNNXBMFYSA-N,GPCR,TSHR,7253,P16473,LGR3,,,,,,,,12.59,EC50,PUBCHEM_BIOASSAY: qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor. (Class of assay: confirmatory) ,,=,,,,,,,
EUB0000531a_TSHR,FLUMAZENIL,EUB0000531a,CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1,"InChI=1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3",OFBIFZUFASYYRE-UHFFFAOYSA-N,GPCR,TSHR,7253,P16473,LGR3,,,,,,,,31.62,EC50,PUBCHEM_BIOASSAY: qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor. (Class of assay: confirmatory) ,,=,,,,,,,
EUB0000534a_GCGR,SB-203580,EUB0000534a,CS(=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=NC=C1)C1=CC=C(F)C=C1,"InChI=1S/C21H16FN3OS/c1-27(26)18-8-4-16(5-9-18)21-24-19(14-2-6-17(22)7-3-14)20(25-21)15-10-12-23-13-11-15/h2-13H,1H3,(H,24,25)",CDMGBJANTYXAIV-UHFFFAOYSA-N,GPCR,GCGR,2642,P47871,GGR,Antagonist,,37.15,IC50,Antagonist activity at human glucagon receptor,10.1007/s00044-013-0801-3,=,,,,,,,,,,,,
EUB0000537a_TSHR,ML351,EUB0000537a,CNC1=C(N=C(O1)C1=C2C=CC=CC2=CC=C1)C#N,"InChI=1S/C15H11N3O/c1-17-15-13(9-16)18-14(19-15)12-8-4-6-10-5-2-3-7-11(10)12/h2-8,17H,1H3",DYXYXTDIFMDJIR-UHFFFAOYSA-N,GPCR,TSHR,7253,P16473,LGR3,,,,,,,,100,EC50,PUBCHEM_BIOASSAY: qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor. (Class of assay: confirmatory) ,,=,,,,,,,
EUB0000537a_HCRTR1,ML351,EUB0000537a,CNC1=C(N=C(O1)C1=C2C=CC=CC2=CC=C1)C#N,"InChI=1S/C15H11N3O/c1-17-15-13(9-16)18-14(19-15)12-8-4-6-10-5-2-3-7-11(10)12/h2-8,17H,1H3",DYXYXTDIFMDJIR-UHFFFAOYSA-N,GPCR,HCRTR1,3061,O43613,OX1R,,,,,,,,1757.92,IC50,"PUBCHEM_BIOASSAY: Homogeneous Time Resolved Fluorescence (HTRF)-based cell-based high throughput dose response assay for antagonists of the orexin 1 receptor (OX1R; HCRTR1). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID434989, AID435008, AID463079, AID485270, AID492963, AID492964, AID492965, AID493232, AID504717, AID504718]",,=,,,,,,,
EUB0000300bCl_ADRA1D,(R)-9s,EUB0000300bCl,C[C@@H](c1cccc(CN)c1)n1cc(Cl)cc(C(N)=O)c1=N.Cl,"InChI=1S/C15H17ClN4O.ClH/c1-9(11-4-2-3-10(5-11)7-17)20-8-12(16)6-13(14(20)18)15(19)21;/h2-6,8-9,18H,7,17H2,1H3,(H2,19,21);1H/t9-;/m0./s1",PIRKVXKOMRREFI-FVGYRXGTSA-N,GPCR,ADRA1D,146,P25100,"ADRA1R, ADRA1A, ADRA1",Antagonist,(S)-9s,1.6,Ki,Binding assay,"https://doi.org/10.1021/acs.jmedchem.5b01528, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/(R)-9s",=,,,,,,0,GPCR screen (PDSP),45,"Screened at 10 µM, closest targets as % inhibition: ADRA1A (84%), ADRA2B (80%); In vitro follow up: Ki(ADRA1A) >2.7 µM (> 1700 fold), Ki(ADRA1B) >1.2 µM (>750 fold); Screened against 468 kinases (KinomeScan, DiscoverX) at 1 µM, closest targets as % contr.: MAPK6 (0%), TYRO3 (33%);",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/(R)-9s,GPCR set,1 µM
EUB0000539a_DRD4,UCSF924,EUB0000539a,Cc1ccc2c(c1)C(C=C(CNCCCOc1ccccc1)N2)=O,"InChI=1S/C20H22N2O2/c1-15-8-9-19-18(12-15)20(23)13-16(22-19)14-21-10-5-11-24-17-6-3-2-4-7-17/h2-4,6-9,12-13,21H,5,10-11,14H2,1H3,(H,22,23)",RPHDOVLXDYWDGF-UHFFFAOYSA-N,GPCR,DRD4,1815,P21917,,Agonist,UCSF924NC,3,Ki,Radioligand binding assay,"https://doi.org/10.1126/science.aan5468, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/UCSF924",=,4.2,EC50,Split luciferase based cAMP receptor assay (HEK293T cells),,=,0,PRESTO-Tango GPCR-ome screening,320,"Screened at 1 µM (activity assay in HTLA cells), closest targets: Ki(DRD4 )= 4.9 nM, Ki(HTR1A) = 223 nM, Ki(HTR2B) = 236.67 nM, Ki(NMDA) = 1004 nM, Ki(HRH2) = 1909.67, Ki(SLC6A3) = 2116.67 nM; Screened against D2-like family: > 3300-fold selective (DRD2 Ki > 10 µM, DRD3 Ki >10 µM)","https://doi.org/10.1126/science.aan5468, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/UCSF924",GPCR set,1 µM
EUB0000306b_FAAH,PF-04457845,EUB0000306b,O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1,"InChI=1S/C23H20F3N5O2/c24-23(25,26)18-6-7-21(27-15-18)33-19-4-1-3-17(14-19)13-16-8-11-31(12-9-16)22(32)29-20-5-2-10-28-30-20/h1-7,10,13-15H,8-9,11-12H2,(H,29,30,32)",BATCTBJIJJEPHM-UHFFFAOYSA-N,Hydrolase,FAAH,2166,O00519,"FAAH, FAAH1",Covalent inhibitor,PF-04875474,7.2,IC50,Glutamate dehydrogenase-coupled FAAH assay (preincubation time 60 min),"https://doi.org/10.1124/jpet.111.180257, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/PF-04457845",=,,,,,,0,"Serine hydrolase panel, literature",200,"Functional proteomic screen, testet at 10 µM and 100 µM, PF-04457845 showed exquisite selectivity for FAAH relative to other mammalian serine hydrolases (no targets up to 100 µM); Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: KIT(L576P) (0%), TAOK3 (42%), PIK3CA (45%); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest targets: Ki(HTR2A) = 248.71 nM, Ki(TMEM97) = 436.72 nM, Ki(SIGMAR1) = 472.06 nM, Ki(ADRA2C) = 595.66 nM, Ki(GABA/ PBR) = 1140.08 nM; Screened in CEREP ligand profiling, panel of 68 ion channels, GPCRS and transporters at 10 µM, closest target: Ki(HTR2A) =1.6 µM;","https://doi.org/10.1124/jpet.111.180257, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/PF-04457845",Other targets,1 µM
EUB0000540a_FAAH,PF-04875474,EUB0000540a,FC(F)(F)c1cnc(Oc2nc(/C=C/CC3CN(C(Nc4nnccc4)=O)C3)cnc2)cc1,"InChI=1S/C21H18F3N7O2/c22-21(23,24)15-6-7-18(26-9-15)33-19-11-25-10-16(28-19)4-1-3-14-12-31(13-14)20(32)29-17-5-2-8-27-30-17/h1-2,4-11,14H,3,12-13H2,(H,29,30,32)/b4-1+",WBFGOFIEIRLCBO-DAFODLJHSA-N,Hydrolase,FAAH,2166,O00519,"FAAH, FAAH1",Negative control for PF-04457845,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/PF-04457845,,,,,,,,,,,,Other targets,1 µM
EUB0000541a_EPHX2@Protease,BI-2049,EUB0000541a,FC1=C(C2=CC=CC=C2)C=CC(C(NC3=CC=C(N4N=C(C5=CC=CN=C5)C=C4C(F)(F)F)C=N3)=O)=C1,"InChI=1S/C27H17F4N5O/c28-22-13-18(8-10-21(22)17-5-2-1-3-6-17)26(37)34-25-11-9-20(16-33-25)36-24(27(29,30)31)14-23(35-36)19-7-4-12-32-15-19/h1-16H,(H,33,34,37)",QPQWTXYSJPGPST-UHFFFAOYSA-N,Protease,EPHX2@Protease,2053,P34913,"ABHD20, CEH, SEH",Negative control for BI-1935,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-1935,,,,,,,,,,,,Other targets,100 nM
EUB0000542a_EPHX2@Protease,BI-1935,EUB0000542a,CCOCCN1C=C(C=CC1=O)C(Nc1ccc(cn1)n1c(cc(c2cccnc2)n1)C(F)(F)F)=O,"InChI=1S/C24H21F3N6O3/c1-2-36-11-10-32-15-17(5-8-22(32)34)23(35)30-21-7-6-18(14-29-21)33-20(24(25,26)27)12-19(31-33)16-4-3-9-28-13-16/h3-9,12-15H,2,10-11H2,1H3,(H,29,30,35)",KMESAVNRPDKZCQ-UHFFFAOYSA-N,Protease,EPHX2@Protease,2053,P34913,"ABHD20, CEH, SEH",Inhibitor,BI-2049,7,IC50,Human soluble epoxide hydrolase inhibition,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-1935,=,1,IC50,ELISA (inhibition of sEH in human Hep G2 cells),,<,,,,"Screened against human CYP epoxygenases (Boehringer panel) CYP2J2, CYP2C9, CYP2C19 and IL2: IC50 >1 µM for related targets (> 100-fold selective); Screened against 67 targets (Eurofins-Panlabs) at 10 µM, closest targets: TBXAS1 (96% inhibition, IC50 = 132 nM), 5-Lipoxygenase (66% inhibition, IC50 = 5.92 µM); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest targets: Ki(SLC6A3) = 4.48 µM, Ki(SIGMAR1) = 6.28 µM; Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: CHEK2 (0%), TYRO3 (0%), JAK1 (JH2domain-pseudokinase) (37%) ",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-1935,Other targets,100 nM
EUB0000213bCl_KDM1A/LSD1@Demethylase,GSK-LSD1,EUB0000213bCl,Cl.Cl.c1ccc([C@@H]2C[C@H]2NC2CCNCC2)cc1,"InChI=1S/C14H20N2.2ClH/c1-2-4-11(5-3-1)13-10-14(13)16-12-6-8-15-9-7-12;;/h1-5,12-16H,6-10H2;2*1H/t13-,14+;;/m0../s1",PJFZOGMSPBHPNS-WICJZZOFSA-N,KDM,KDM1A/LSD1@Demethylase,23028,O60341,"KIAA0601, BHC110, LSD1","Irreversible, mechanism based inhibitor",,16,IC50,Enzyme inhibition assay,https://www.thesgc.org/chemical-probes/GSK-LSD1,=,,,,,,0,CEREP ExpressProfile selectivity/specificity profile,55,"Screened against 55 human recombinant receptors at 10 µM, closest targets as % inhibition: 5-HT1A (49%), 5-HAT (74%), dopamine transporter (39%); Screened against 45 other enzymes (GPCRs, kinases, transporters, ion channels, nuclear receptors), >1000-fold selective over other closely related FAD utilizing enzymes (i.e. LSD2, MAO-A, MAO-B)","https://doi.org/10.1016/j.ccell.2015.06.002, https://www.thesgc.org/chemical-probes/GSK-LSD1",Other targets,100 nM
EUB0000217b_KDM6A/UTX@Demethylase,GSK-J4,EUB0000217b,CCOC(=O)CCNc1cc(N2CCc3ccccc3CC2)nc(-c2ccccn2)n1,"InChI=1S/C24H27N5O2/c1-2-31-23(30)10-14-26-21-17-22(28-24(27-21)20-9-5-6-13-25-20)29-15-11-18-7-3-4-8-19(18)12-16-29/h3-9,13,17H,2,10-12,14-16H2,1H3,(H,26,27,28)",WBKCKEHGXNWYMO-UHFFFAOYSA-N,KDM,KDM6A/UTX@Demethylase,7403,O15550,,Pro-drug of GSK-J1,GSK-J5,6600,IC50,AlphaLISA based assay,https://doi.org/10.1038/nature13688,=,,,,,,,,,,,Other targets,100 nM
EUB0000265b_KDM6A/UTX@Demethylase,GSK-J5,EUB0000265b,CCOC(=O)CCNc1cc(N2CCc3ccccc3CC2)nc(-c2cccnc2)n1,"InChI=1S/C24H27N5O2/c1-2-31-23(30)9-13-26-21-16-22(28-24(27-21)20-8-5-12-25-17-20)29-14-10-18-6-3-4-7-19(18)11-15-29/h3-8,12,16-17H,2,9-11,13-15H2,1H3,(H,26,27,28)",LQPGVGSKBNXQDU-UHFFFAOYSA-N,KDM,KDM6A/UTX@Demethylase,7403,O15550,,Negative control for GSK-J5,,,Negative Control,,https://www.thesgc.org/chemical-probes/GSKJ1,,,,,,,,,,,,Other targets,100 nM
EUB0000214b_L3MBTL3@MBT1,UNC1215,EUB0000214b,O=C(c1ccc(C(=O)N2CCC(N3CCCC3)CC2)c(Nc2ccccc2)c1)N1CCC(N2CCCC2)CC1,"InChI=1S/C32H43N5O2/c38-31(36-20-12-27(13-21-36)34-16-4-5-17-34)25-10-11-29(30(24-25)33-26-8-2-1-3-9-26)32(39)37-22-14-28(15-23-37)35-18-6-7-19-35/h1-3,8-11,24,27-28,33H,4-7,12-23H2",PQOOIERVZAXHBP-UHFFFAOYSA-N,MBT,L3MBTL3@MBT1,84456,Q96JM7,KIAA1798,Antagonist,UNC1079,40,IC50,AlphaScreen assay,"https://doi.org/10.1038/nchembio.1157, https://www.thesgc.org/chemical-probes/UNC1215",=,,,,,,0,"Kme reader domain panel, literature",200,"Selective; <50% inhibition at 250 mM against 10 HMT targets; >50-fold selective against other members of human MBT family: IC50(L3MBTL1) = 2 µM, IC50(L3MBTL4) = 11 µM, IC50(SFMBT) >30 µM, IC50(MBTD1) = 6 µM (Alphascreen assay); Histone demethylases: < 50% inhibition at 10 mM versus 35 targets; Bromodomains: Tm shift < 0.5 °C at 10 mM versus 12 targets (DSF assay); Kinases: < 15% inhibition at 10 mM versus 49 kinases, closest target as % of contr.: FLT3 (64%); NIMH Psychoactive Drug Screening Program Selectivity Panel (Radioligand binding assay): Ki(M1) = 97 nM, Ki(M2) = 72 nM, Ki(M3) = 890 nM, Ki(M4) = 400 nM, Ki(M5) = 4.3 µM, Ki(Alpha 2C) = 860 nM","https://doi.org/10.1038/nchembio.1157, https://www.thesgc.org/chemical-probes/UNC1215",Epigenetic set,1 µM
EUB0000251b_SLC2A1,BAY-588,EUB0000251b,Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1,"InChI=1S/C27H25F4N5O2/c1-14-22(34-25(38)19-12-21(24(32)37)33-20-11-17(28)9-10-18(19)20)23(27(29,30)31)35-36(14)13-15-5-7-16(8-6-15)26(2,3)4/h5-12H,13H2,1-4H3,(H2,32,37)(H,34,38)",DNGZBWVQLFNTRT-UHFFFAOYSA-N,SLC,SLC2A1,6513,P11166,CSE DYT17 DYT18 DYT9 EIG12 GLUT GLUT-1 GLUT1 GLUT1DS HTLVR PED SDCHCN,Negative control for BAY-876,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-876,,,,,,,,,,,,Ion Channel,1 µM
EUB0000544a_CFTR,A-1596586,EUB0000544a,COc1ccc2c(c1)O[C@@H](C[C@@H]2NC(C1(CC1)c1ccc2c(c1)OC(O2)(F)F)=O)c1ccc(c(c1)OC)OC,"InChI=1S/C29H27F2NO7/c1-34-18-6-7-19-20(15-23(37-24(19)14-18)16-4-8-21(35-2)25(12-16)36-3)32-27(33)28(10-11-28)17-5-9-22-26(13-17)39-29(30,31)38-22/h4-9,12-14,20,23H,10-11,15H2,1-3H3,(H,32,33)/t20-,23-/m0/s1",KDOQEEMQPHIANX-REWPJTCUSA-N,ABC transporter,CFTR,1080,P13569,"CFTR, ABCC7",Corrector,A-1596584,,,,,,28,EC50,CFTR Restoration Trans-Epithelial Current Clamp (TECC) assay (in HBE cells from F508del CF patients),,=,0,CEREP panel (Eurofins),71,"Screened at 10 µM (binding assay), closest targets as % inhibition: BZD peripheral (95.5%), ADORA3 (63.9%) and ADRA2B (63.5%); Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest target: HIPK4 (51%); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest targets: Ki(GABA/PBR) = 19.59 nM, Ki(SIGMAR1) = 314.63 nM, Ki(TMEM97) = 1192.34;Screened in Eurofins-Cerep panel against 7 targets at 10 µM (enzymes and uptake assays): clean profile;",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-1596586,Ion Channel,1 µM
EUB0000304b_TRPM8,PF-05105679,EUB0000304b,C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1,"InChI=1S/C26H21FN2O3/c1-17(19-9-11-23(27)12-10-19)29(16-18-5-4-7-21(13-18)26(31)32)25(30)22-14-20-6-2-3-8-24(20)28-15-22/h2-15,17H,16H2,1H3,(H,31,32)/t17-/m1/s1",BXNMZRPTQFVRFA-QGZVFWFLSA-N,TRP channel,TRPM8,79054,Q7Z2W7,"TRPM8, LTRPC6, TRPP8",Antagonist,PF-05257137,181,IC50,FLIPR assay,"https://doi.org/10.1021/ml500479v, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/PF-05105679",=,103,IC50,Clamp electrophysiology (Ephys) assay (inhibition of voltage-induced current in HEK-293 cells expressing human TRPM8 channel),,=,0,"CEREP Wide Ligand screening panel, literature",90,"Screened at 10 µM, panel of ion channels, receptors, enzymes, > 100-fold selective (including closely related TRPV1, TRPA1 channels); Clean in CardiacProfiler ion channel panel (Millipore) at 10 µM; Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: MAPK14 (0%), GRK3 (40%), TAOK3 (41%), PIK3CA(Q546K) (42%); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest target: Ki (GABA/PBR) = 1022.12 nM","https://doi.org/10.1021/ml500479v, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/PF-05105679",Ion Channel,1 µM
EUB0000307b_SLC2A1,BAY-876,EUB0000307b,Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1,"InChI=1S/C24H16F4N6O2/c1-12-20(21(24(26,27)28)33-34(12)11-14-4-2-13(10-29)3-5-14)32-23(36)17-9-19(22(30)35)31-18-8-15(25)6-7-16(17)18/h2-9H,11H2,1H3,(H2,30,35)(H,32,36)",BKLJDIJJOOQUFG-UHFFFAOYSA-N,SLC,SLC2A1,6513,P11166,CSE DYT17 DYT18 DYT9 EIG12 GLUT GLUT-1 GLUT1 GLUT1DS HTLVR PED SDCHCN,Inhibitor,BAY-588,,,,,,2,IC50,CellTiter-Glo® Luminescent Cell Viability Assay (DLD1 cells; Promega),,=,0,"Glucose transporter panel, literature",4,"Selectivity against other glucose transporters (CellTiter-Glo® Luminescent Cell Viability Assay, Promega): IC50(SLC2A4) = 270 nM, IC50(SLC2A3) = 1.6 µM, IC50(SLC2A2) = 9.4 µM, >100-fold selective; Screened against 468 targets in KinomeScan (DiscoverX) at 1 µM, closest targets as % of contr.: WNK4 (0%), DDR1 (1.5%); Screened against 45 GPCRs (PDSP screen) at 10 µM, closest target: Ki(HRH2) = 8078 nM; Screened in Eurofins-Panlabs radioligand binding assay against 68 enzymes, closest targets: IC50(ADORA3) =1.14 µM, IC50(PTGER4) = 1.12 µM;","https://doi.org/10.1002/cmdc.201600276, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-876",Ion Channel,1 µM
EUB0000308b_TRPA1,A-079,EUB0000308b,Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl,"InChI=1S/C13H9Cl2N5/c14-11-5-1-4-10(12(11)15)13-17-18-19-20(13)8-9-3-2-6-16-7-9/h1-7H,8H2",MMPAULQSJLVKHP-UHFFFAOYSA-N,TRP channel,TRPA1,8989,O75762,"TRPA1, ANKTM1",Antagonist,A-226,67,IC50,FLIPR-based Ca2+ assay (activated by 30 µM AITC),"https://doi.org/10.1124/jpet.111.189902,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-079",=,51,IC50,"Electrophysiological assay (inhibition of AITC (allylthiocyanate, 100 µmol/L)-evoked currents in HEK293F cells transiently overexpressing hTRPA1)",,=,0,CEREP panel (Eurofins),75,"Screened at 10 µM (radioligand binding assay) against 75 enzymes, GPCRS, transporters, and ion channels, closest targets as % inhibition: to SLC6A3 (43%), SLC6A2 (32%), MTNR1A (31%), >1000-fold selective over other TRP channels (TRPV1, TRPV3, TRPV4, or TRPM8); Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest target as % of contr.: ULK2 (46%) ; Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest targets: Ki(SIGMAR1) =505.48 nM;","https://doi.org/10.1016/j.pain.2011.01.049, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-079",Ion Channel,1 µM
EUB0000309b_P2RX4,BAY-1797,EUB0000309b,NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1,"InChI=1S/C20H17ClN2O4S/c21-15-7-4-8-17(12-15)27-18-10-9-16(13-19(18)28(22,25)26)23-20(24)11-14-5-2-1-3-6-14/h1-10,12-13H,11H2,(H,23,24)(H2,22,25,26)",CSJYMAFXYMYNCK-UHFFFAOYSA-N,P2X receptors,P2RX4,5025,Q99571,P2RX4,Inhibitor,BAY-207,,,,,,211,IC50,"FLIPR assay (inhibition of ATP-induced calcium influx in HEK cells, stably transfected with human P2X4 receptor)",,=,0,Lead profiling screen (Eurofins),67,"Screened against 67 GPCRs, ion channels, kinases and transporters at 10 µM, closest targets: IC50(SLC6A3) = 2.17 µM, IC50(P2RX1) >50 µM, IC50(P2RX2) >30 µM, IC50(P2RX3) = 8.3 µM, IC50(P2RX7) = 10.6 µM; Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: WNK2 (0%), WNK4 (0%), BUB1 (1.6%), EGFR(L747-T751del,Sins) (47%); Screened against 45 GPCR targets at 10 µM (PDPS screen), closest targets: Ki(TMEM97) = 4.34 µM, Ki(ADRA2B) = 4.58 µM, Ki(HTR2C) = 6.52 µM;","https://doi.org/10.1021/acs.jmedchem.9b01304, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-1797",Ion Channel,1 µM
EUB0000310b_ITGAL,BI-1950,EUB0000310b,C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1,"InChI=1S/C32H26Cl2FN7O3/c1-18(27(43)40-32(10-11-32)25-5-3-4-12-37-25)39-28(44)24-17-38-30-41(21-13-22(33)26(35)23(34)14-21)29(45)31(2,42(24)30)15-19-6-8-20(16-36)9-7-19/h3-9,12-14,17-18H,10-11,15H2,1-2H3,(H,39,44)(H,40,43)/t18-,31+/m0/s1",JZTTUZXIQIRVAB-FZEVHQGJSA-N,Integrin,ITGAL,3683,P20701,"ITGAL, CD11A",Inhibitor,BI-9446,9,Kd,ITGAL binding assay (inhibition of LFA-1 binding to ICAM-1),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-1950,=,,,,,,0,Eurofins Panlabs panel,47,"Screened against 47 receptors, ion channel and other enzymes at 10 µM, closest target as % inhibition: CACNA1C (72%), >1000 fold selective against closely related ITGB2 and ITGB1; Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: STK39 (24%), EIF2AK2 (34%), STK38L (49%); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest target: TMEM97 (26%); ",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-1950,Ion Channel,100 nM
EUB0000545a_SLC9A1,BI-0054,EUB0000545a,CC(=O)N1CCC(CC1)c2ccc(cc2C(F)(F)F)C(=O)NC3=NCCN3,"InChI=1S/C18H21F3N4O2/c1-11(26)25-8-4-12(5-9-25)14-3-2-13(10-15(14)18(19,20)21)16(27)24-17-22-6-7-23-17/h2-3,10,12H,4-9H2,1H3,(H2,22,23,24,27)",UPJRPOWMFLBSKZ-UHFFFAOYSA-N,SLC,SLC9A1,6548,P19634,APNH LIKNS NHE-1 NHE1 PPP1R143,Negative control for BI-9627,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!orderview/BI-9627,,,,,,,,,,,,Ion Channel,1 µM
EUB0000546a_TRPM8,PF-05257137,EUB0000546a,C[C@H](C1=CC=C(C=C1)F)N(C(C2=CC3=CC=CC=C3N=C2)=O)CC4=CC(C(O)=O)=C(Cl)C=C4,"InChI=1S/C26H20ClFN2O3/c1-16(18-7-9-21(28)10-8-18)30(15-17-6-11-23(27)22(12-17)26(32)33)25(31)20-13-19-4-2-3-5-24(19)29-14-20/h2-14,16H,15H2,1H3,(H,32,33)/t16-/m1/s1",KDAYMLCFQCRZOT-MRXNPFEDSA-N,TRP channel,TRPM8,79054,Q7Z2W7,"TRPM8, LTRPC6, TRPP8",Negative control for PF-05105679,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/PF-05105679,,,,,,,,,,,,Ion Channel,1 µM
EUB0000547a_TRPA1,A-226,EUB0000547a,CCC(/C(C)=C/c1cc(C)c(F)cc1)=N\O,"InChI=1S/C13H16FNO/c1-4-13(15-16)10(3)8-11-5-6-12(14)9(2)7-11/h5-8,16H,4H2,1-3H3/b10-8+,15-13+",WRHHATMLNUQQTB-MZRBSKCNSA-N,TRP channel,TRPA1,8989,O75762,"TRPA1, ANKTM1",Negative control for A-079,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-079,,,,,,,,,,,,Ion Channel,1 µM
EUB0000548a_P2RX4,BAY-207,EUB0000548a,C1CC1(C(Nc1ccc(c(c1)S(N)(=O)=O)Oc1cccc(c1)[Cl])=O)c1ccccc1[Cl],"InChI=1S/C22H18Cl2N2O4S/c23-14-4-3-5-16(12-14)30-19-9-8-15(13-20(19)31(25,28)29)26-21(27)22(10-11-22)17-6-1-2-7-18(17)24/h1-9,12-13H,10-11H2,(H,26,27)(H2,25,28,29)",JXAOITUGCKTSTF-UHFFFAOYSA-N,P2X receptors,P2RX4,5025,Q99571,P2RX4,Negative control for BAY-1797,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-1797,,,,,,,,,,,,Ion Channel,1 µM
EUB0000549a_ITGAL,BI-9446,EUB0000549a,C[C@@]1(Cc2ccc(C#N)cc2)C(N(c2cc(cc(c2)[Cl])[Cl])c2ncc(C(NC3(CC3)c3nc(C4CCC4)no3)=O)n12)=O,"InChI=1S/C30H25Cl2N7O3/c1-29(14-17-5-7-18(15-33)8-6-17)27(41)38(22-12-20(31)11-21(32)13-22)28-34-16-23(39(28)29)25(40)36-30(9-10-30)26-35-24(37-42-26)19-3-2-4-19/h5-8,11-13,16,19H,2-4,9-10,14H2,1H3,(H,36,40)/t29-/m1/s1",VATLFUUMDRXLTK-GDLZYMKVSA-N,Integrin,ITGAL,3683,P20701,"ITGAL, CD11A",Negative control for BI-1950,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-1950,,,,,,,,,,,,Ion Channel,100 nM
EUB0000264b_CFTR,A-1596584,EUB0000264b,COc1ccc2c(c1)O[C@H](C[C@H]2NC(C1(CC1)c1ccc2c(c1)OC(O2)(F)F)=O)c1ccc(c(c1)OC)OC,"InChI=1S/C29H27F2NO7/c1-34-18-6-7-19-20(15-23(37-24(19)14-18)16-4-8-21(35-2)25(12-16)36-3)32-27(33)28(10-11-28)17-5-9-22-26(13-17)39-29(30,31)38-22/h4-9,12-14,20,23H,10-11,15H2,1-3H3,(H,32,33)/t20-,23-/m1/s1",KDOQEEMQPHIANX-NFBKMPQASA-N,ABC transporter,CFTR,1080,P13569,"CFTR, ABCC7",Negative control for A-1596586,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-1596586,,,,,,,,,,,,Ion Channel,1 µM
EUB0000282b_SLC13A5,BI01383298,EUB0000282b,O=C(NCc1ccc(F)cc1)C1CCN(S(=O)(=O)c2cc(Cl)cc(Cl)c2)CC1,"InChI=1S/C19H19Cl2FN2O3S/c20-15-9-16(21)11-18(10-15)28(26,27)24-7-5-14(6-8-24)19(25)23-12-13-1-3-17(22)4-2-13/h1-4,9-11,14H,5-8,12H2,(H,23,25)",VUOYAALVGSMUHC-UHFFFAOYSA-N,SLC,SLC13A5,284111,Q86YT5,EIEE25 INDY NACT mIndy,Inhibitor,BI01372674,,,,,,24,IC50,Citrate uptake inhibition assay (HepG2 cells expressing endogenous SLC13A5),,=,0,SafetyScreen44™ (Eurofins),44,"Screened at 10 µM against a panel of ion channels, GPCRs, hydrolases and other enzymes, closest target as % of contr.: NA+/SITE2/R (48%, voltage-gated ion channel) 1000-fold selective over closest family members: human SLC13A2 and SLC13A3 that share physiological substrates citrate and succinate",https://opnme.com/molecules/slc13a5-bi01383298#,Ion Channel,1 µM
EUB0000295b_SLC9A1,BI-9627,EUB0000295b,CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1,"InChI=1S/C16H19F3N4O2/c1-9(24)23-6-4-10(5-7-23)12-3-2-11(14(25)22-15(20)21)8-13(12)16(17,18)19/h2-3,8,10H,4-7H2,1H3,(H4,20,21,22,25)",QMHRLXNEGYTSRV-UHFFFAOYSA-N,SLC,SLC9A1,6548,P19634,APNH LIKNS NHE-1 NHE1 PPP1R143,Antagonist,,6,IC50,pHi change assay,https://www.sgc-ffm.uni-frankfurt.de/#!orderview/BI-9627,=,,,,,,,,,"Solute carrier family 9 isoform selectivity: > 30-fold selective versus SLC9A2 (IC50 = 231 nM) and >1000-fold versus SLC9A3 (IC50 >16 µM); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest target: Ki(DAT) = 1523 nM; Selective in KinomeScan (DiscoverX) against 468 targets at 1 µM; Screened in Eurofins-Panlabs panel (68 targets), closest target M2 (67 % inhibition at 10 µM)","https://pubs.acs.org/doi/10.1021/jm300601d, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-9627",Ion Channel,1 µM
EUB0000193b_SUV420H1@Methyltransferase,A-196,EUB0000193b,Clc1cc2c(NC3CCCC3)nnc(-c3ccncc3)c2cc1Cl,"InChI=1S/C18H16Cl2N4/c19-15-9-13-14(10-16(15)20)18(22-12-3-1-2-4-12)24-23-17(13)11-5-7-21-8-6-11/h5-10,12H,1-4H2,(H,22,24)",ABGOSOMRWSYAOB-UHFFFAOYSA-N,HMT,SUV420H1@Methyltransferase,51111,Q4FZB7,CGI-85,Inhibitor,"A-197,SGC2043",25,IC50,Scintillation proximity assay (SPA),"https://doi.org/10.1038/nchembio.2282, https://www.thesgc.org/chemical-probes/A-196",=,,,,,,0,"Epigenetic methyltransferases panel, literature",29,"Highly selective in methyltransferase screen at 1 µM and 10 µM; Inactive against protein arginine methyltransferases and DNA methyltransferases; Selective against a panel of 9 epigenetic readers and chromatin binders; Screened against 125 nonepigenetic targets (CEREP panel: GPCRS, ion channels, transporters) at 10 µM, closest targets >50% inhibition: Adenosin A1 receptor (98%, Ki = 21 nM), Adenosin A2A receptor (98%, Ki = 28 nM), Cl-chanel (GABA-gated, 90%, Ki = 1.8 µM), Adenosin A2 receptor (74%, 2 µM), kappa (KOP, 62%, Ki >10 µM), NK2 (61%, Ki = 4.1 µM), delta2 (DOP, 51%, Ki = 9 µM)","https://doi.org/10.1038/nchembio.2282, https://www.thesgc.org/chemical-probes/A-196",Epigenetic set,1 µM
EUB0000193b_SUV420H2@Methyltransferase,A-196,EUB0000193b,Clc1cc2c(NC3CCCC3)nnc(-c3ccncc3)c2cc1Cl,"InChI=1S/C18H16Cl2N4/c19-15-9-13-14(10-16(15)20)18(22-12-3-1-2-4-12)24-23-17(13)11-5-7-21-8-6-11/h5-10,12H,1-4H2,(H,22,24)",ABGOSOMRWSYAOB-UHFFFAOYSA-N,HMT,SUV420H2@Methyltransferase,84787,Q86Y97,MGC2705,Inhibitor,"A-197,SGC2043",144,IC50,Scintillation proximity assay (SPA),"https://doi.org/10.1038/nchembio.2282, https://www.thesgc.org/chemical-probes/A-196",=,,,,,,0,"Epigenetic methyltransferases panel, literature",29,"Highly selective in methyltransferase screen at 1 µM and 10 µM; Inactive against protein arginine methyltransferases and DNA methyltransferases; Selective against a panel of 9 epigenetic readers and chromatin binders; Screened against 125 nonepigenetic targets (CEREP panel: GPCRS, ion channels, transporters) at 10 µM, closest targets >50% inhibition: Adenosin A1 receptor (98%, Ki = 21 nM), Adenosin A2A receptor (98%, Ki = 28 nM), Cl-chanel (GABA-gated, 90%, Ki = 1.8 µM), Adenosin A2 receptor (74%, 2 µM), kappa (KOP, 62%, Ki >10 µM), NK2 (61%, Ki = 4.1 µM), delta2 (DOP, 51%, Ki = 9 µM)","https://doi.org/10.1038/nchembio.2282, https://www.thesgc.org/chemical-probes/A-196",Epigenetic set,1 µM
EUB0000194b_EHMT1/GLP@Methyltransferase,UNC0642,EUB0000194b,COc1cc2c(NC3CCN(C(C)C)CC3)nc(N3CCC(F)(F)CC3)nc2cc1OCCCN1CCCC1,"InChI=1S/C29H44F2N6O2/c1-21(2)36-14-7-22(8-15-36)32-27-23-19-25(38-3)26(39-18-6-13-35-11-4-5-12-35)20-24(23)33-28(34-27)37-16-9-29(30,31)10-17-37/h19-22H,4-18H2,1-3H3,(H,32,33,34)",RNAMYOYQYRYFQY-UHFFFAOYSA-N,HMT,EHMT1/GLP@Methyltransferase,79813,Q9H9B1,"Eu-HMTase1, FLJ12879, KIAA1876, bA188C12.1, KMT1D, FLJ40292",Inhibitor,,2.5,IC50,Enzymatic activity assay,"https://doi.org/10.1021/jm401480r, https://www.thesgc.org/chemical-probes/UNC0642",<,,,,,,0,"HMT panel, literature",16,">100-fold selective against other HMTs, selective against 44 GPCRS, ion channels and transporters at 1 µM, closest targets as % of contr.: H3 (93%, Ki = 45 nM), µ opioid (74%, Ki >10 µM), a2C (67%, Ki > 10 µM), a1D (59%, Ki = 4.5 µM); Selective against 50 kinases at 10 µM",https://doi.org/10.1021/jm401480r,Epigenetic set,1 µM
EUB0000194b_EHMT2/G9a@Methyltransferase,UNC0642,EUB0000194b,COc1cc2c(NC3CCN(C(C)C)CC3)nc(N3CCC(F)(F)CC3)nc2cc1OCCCN1CCCC1,"InChI=1S/C29H44F2N6O2/c1-21(2)36-14-7-22(8-15-36)32-27-23-19-25(38-3)26(39-18-6-13-35-11-4-5-12-35)20-24(23)33-28(34-27)37-16-9-29(30,31)10-17-37/h19-22H,4-18H2,1-3H3,(H,32,33,34)",RNAMYOYQYRYFQY-UHFFFAOYSA-N,HMT,EHMT2/G9a@Methyltransferase,10919,Q96KQ7,"G9A, Em:AF134726.3, NG36/G9a, KMT1C",Inhibitor,,2.5,IC50,Enzymatic activity assay,"https://doi.org/10.1021/jm401480r, https://www.thesgc.org/chemical-probes/UNC0642",<,,,,,,0,"HMT panel, literature",16,">100-fold selective against other HMTs, selective against 44 GPCRS, ion channels and transporters at 1 µM, closest targets as % of contr.: H3 (93%, Ki = 45 nM), µ opioid (74%, Ki >10 µM), a2C (67%, Ki > 10 µM), a1D (59%, Ki = 4.5 µM); Selective against 50 kinases at 10 µM",https://doi.org/10.1021/jm401480r,Epigenetic set,1 µM
EUB0000198b_PRMT5,GSK591,EUB0000198b,O=C(NC[C@H](O)CN1CCc2ccccc2C1)c1ccnc(NC2CCC2)c1,"InChI=1S/C22H28N4O2/c27-20(15-26-11-9-16-4-1-2-5-18(16)14-26)13-24-22(28)17-8-10-23-21(12-17)25-19-6-3-7-19/h1-2,4-5,8,10,12,19-20,27H,3,6-7,9,11,13-15H2,(H,23,25)(H,24,28)/t20-/m0/s1",TWKYXZSXXXKKJU-FQEVSTJZSA-N,HMT,PRMT5,10419,O14744,"HRMT1L5, HSL7, IBP72, JBP1, SKB1, SKB1Hs",Inhibitor,SGC2096,4,IC50,HTRF assay (monomethylation of H4R3 on a histone H4 peptide by PRMT5:MEP50),https://doi.org/10.1021/acsmedchemlett.5b00380,=,3,IC50,In-Cell Western (ICW) format assay (inhibition of symmetric arginine methylation of SmD3 in Z-138 cells),,=,0,"Methyltransferase panel, literature",32,"Screened at 1 and 10 µM, closest target NSD3 (75% at 10 µM), GSK591 is highly selective",https://www.thesgc.org/chemical-probes/GSK591,Epigenetic set,1 µM
EUB0000209b_EZH1@Methyltransferase,UNC1999,EUB0000209b,CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(-c2ccc(N3CCN(C(C)C)CC3)nc2)cc2c1cnn2C(C)C,"InChI=1S/C33H43N7O2/c1-7-8-24-15-23(6)37-33(42)28(24)19-35-32(41)27-16-26(17-30-29(27)20-36-40(30)22(4)5)25-9-10-31(34-18-25)39-13-11-38(12-14-39)21(2)3/h9-10,15-18,20-22H,7-8,11-14,19H2,1-6H3,(H,35,41)(H,37,42)",DPJNKUOXBZSZAI-UHFFFAOYSA-N,HMT,EZH1@Methyltransferase,2145,Q92800,"KIAA0388, KMT6B",Inhibitor,UNC2400,45,IC50,Radiometric kinase assay,"https://doi.org/10.1021/cb400133j, https://www.thesgc.org/chemical-probes/UNC1999",=,,,,,,0,"HMT panel, literature",16,"Selective over 15 other lysine, arginine, and DNA methyltransferases; Less than 20% inhibition on 50 kinase targets at 10 µM; Tested in PDSP screen: less than 50% inhibition on 40 7TM targets at 10 µM, greater than 50% inhibition of 4 7TM targets at 10 µM, closest targets: Ki(H3) = 300 nM, Ki(NET) = 1500nM, Ki(Sigma 1) =4700 nM, Ki(Sigma 2) = 65 nM (Radioligand binding assay);",https://doi.org/10.1021/cb400133j,Epigenetic set,1 µM
EUB0000209b_EZH2@Methyltransferase,UNC1999,EUB0000209b,CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(-c2ccc(N3CCN(C(C)C)CC3)nc2)cc2c1cnn2C(C)C,"InChI=1S/C33H43N7O2/c1-7-8-24-15-23(6)37-33(42)28(24)19-35-32(41)27-16-26(17-30-29(27)20-36-40(30)22(4)5)25-9-10-31(34-18-25)39-13-11-38(12-14-39)21(2)3/h9-10,15-18,20-22H,7-8,11-14,19H2,1-6H3,(H,35,41)(H,37,42)",DPJNKUOXBZSZAI-UHFFFAOYSA-N,HMT,EZH2@Methyltransferase,2146,Q15910,"EZH1, ENX-1, KMT6, KMT6A",Inhibitor,UNC2400,2,IC50,Radiometric kinase assay,"https://doi.org/10.1021/cb400133j, https://www.thesgc.org/chemical-probes/UNC1999",=,,,,,,0,"HMT panel, literature",16,"Selective over 15 other lysine, arginine, and DNA methyltransferases; Less than 20% inhibition on 50 kinase targets at 10 µM; Tested in PDSP screen: less than 50% inhibition on 40 7TM targets at 10 µM, greater than 50% inhibition of 4 7TM targets at 10 µM, closest targets: Ki(H3) = 300 nM, Ki(NET) = 1500nM, Ki(Sigma 1) =4700 nM, Ki(Sigma 2) = 65 nM (Radioligand binding assay);",https://doi.org/10.1021/cb400133j,Epigenetic set,1 µM
EUB0000215b_EZH2@Methyltransferase,GSK343,EUB0000215b,CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(-c2ccnc(N3CCN(C)CC3)c2)cc2c1cnn2C(C)C,"InChI=1S/C31H39N7O2/c1-6-7-23-14-21(4)35-31(40)26(23)18-33-30(39)25-15-24(16-28-27(25)19-34-38(28)20(2)3)22-8-9-32-29(17-22)37-12-10-36(5)11-13-37/h8-9,14-17,19-20H,6-7,10-13,18H2,1-5H3,(H,33,39)(H,35,40)",ULNXAWLQFZMIHX-UHFFFAOYSA-N,HMT,EZH2@Methyltransferase,2146,Q15910,"EZH1, ENX-1, KMT6, KMT6A",Inhibitor,,1.2,"Ki,app",Enzyme inhibition assay,https://doi.org/10.1021/ml3003346,=,174,IC50,Immunofluorescence (inhibition of H3K27 methylation in HCC1806 cells),,=,0,"Methyltransferase panel (HotSpot screen, Reaction Biology)",19,"Selective over other methyltransferases (radioisotope-based filter binding assays), closest target: IC50(EZH1) = 240 nM, others <60 µM; Screened against 44 receptors and enzymes (internal screening at GSK), closest target: IC50(A1b) = 10 µM, others >10 µM, >100-fold selective","https://doi.org/10.1021/ml3003346, https://www.thesgc.org/chemical-probes/GSK343",Epigenetic set,1 µM
EUB0000216b_DOT1L@Methyltransferase,SGC0946,EUB0000216b,CC(C)N(CCCNC(=O)Nc1ccc(C(C)(C)C)cc1)C[C@H]1O[C@@H](n2cc(Br)c3c(N)ncnc32)[C@H](O)[C@@H]1O,"InChI=1S/C28H40BrN7O4/c1-16(2)35(12-6-11-31-27(39)34-18-9-7-17(8-10-18)28(3,4)5)14-20-22(37)23(38)26(40-20)36-13-19(29)21-24(30)32-15-33-25(21)36/h7-10,13,15-16,20,22-23,26,37-38H,6,11-12,14H2,1-5H3,(H2,30,32,33)(H2,31,34,39)/t20-,22-,23-,26-/m1/s1",IQCKJUKAQJINMK-HUBRGWSESA-N,HMT,DOT1L@Methyltransferase,84444,Q8TEK3,"KIAA1814, DOT1, KMT4",Inhibitor,SGC0649,0.3,IC50,Radioactive enzyme assay,"https://doi.org/10.1038/ncomms2304, https://www.thesgc.org/chemical-probes/SGC0946",=,2.6,IC50,Westen Blot (reduction of H3K79 dimethylation in A431 cells by DOT1L),,=,0,"Methyltransferase panel, literature",12,"Screened against G9a, EHMT1, PRMT3/5, SETDB1, SETD7/8, MLL, EZH2, SUV39H2, SUV420H2; Clean profile in Ricerca selectivity panel at 1 µM against 29 diverse receptors","https://doi.org/10.1038/ncomms2304, https://www.thesgc.org/chemical-probes/SGC0946",Epigenetic set,1 µM
EUB0000226b_PRMT5,LLY-283,EUB0000226b,Nc1ncnc2c1ccn2[C@@H]1O[C@H]([C@H](O)c2ccccc2)[C@@H](O)[C@H]1O,"InChI=1S/C17H18N4O4/c18-15-10-6-7-21(16(10)20-8-19-15)17-13(24)12(23)14(25-17)11(22)9-4-2-1-3-5-9/h1-8,11-14,17,22-24H,(H2,18,19,20)/t11-,12+,13-,14-,17-/m1/s1",WWOOWAHTEXIWBO-QFRSUPTLSA-N,HMT,PRMT5,10419,O14744,"HRMT1L5, HSL7, IBP72, JBP1, SKB1, SKB1Hs",Inhibitor,LLY-284,22,IC50,Radioactivity-based assay (measuring transfer of the methyl group from 3H-SAM to peptide substrate),"https://doi.org/10.1021/acsmedchemlett.8b00014, https://www.thesgc.org/chemical-probes/LLY-283",=,25,IC50,Western Blot (monitoring SmBB-Rme2s levels in MCF7 cells),,=,0,"Methyltransferase panel, literature",32,"Screened at 1 µM and 10 µM, selective over other targets including closely related arginine methyltransferases PRMT4, PRMT6, PRMT7;",https://doi.org/10.1021/acsmedchemlett.8b00014,Epigenetic set,1 µM
EUB0000234b_PRDM9,MRK-740,EUB0000234b,COc1cc(OC)cc(-c2noc(N3CCN(C)C4(CCN(c5ccnc(C)c5)CC4)C3)n2)c1,"InChI=1S/C25H32N6O3/c1-18-13-20(5-8-26-18)30-9-6-25(7-10-30)17-31(12-11-29(25)2)24-27-23(28-34-24)19-14-21(32-3)16-22(15-19)33-4/h5,8,13-16H,6-7,9-12,17H2,1-4H3",NZYTZRHHBAJPKN-UHFFFAOYSA-N,HMT,PRDM9,56979,Q9NQV7,"KMT8B, MEISETZ, MSBP3, PFM6, ZNF899",Inhibitor,MRK-740-NC,80,IC50,Scintillation proximity assay (SPA),"https://doi.org/10.1038/s41467-019-13652-x, https://www.thesgc.org/chemical-probes/MRK-740",=,800,IC50,Western Blot (inhibition of PRDM9-dependent trimethylation of ectopic H3K4 in HEK293T cells),,=,0,"Methyltransferase panel, literature",45,"Screened in DSF assay at 10µM, dTm(PRDMT9) = 5.2K, closest target dTm(PRDMT7) = 5.0K; Screened against 108 enzymes and receptors (Eurofins Panlabs Discovery Services), closest targets>50% at 10µM: MOR, A2AB, M2, H3; In vitro follow up with GloSensor assay (PDSP screen): EC50>10µM for all targets",https://doi.org/10.1038/s41467-019-13652-x,Epigenetic set,1 µM
EUB0000034d_PRMT1@Methyltransferase,MS023,EUB0000034d,CC(C)Oc1ccc(-c2c[nH]cc2CN(C)CCN)cc1,"InChI=1S/C17H25N3O/c1-13(2)21-16-6-4-14(5-7-16)17-11-19-10-15(17)12-20(3)9-8-18/h4-7,10-11,13,19H,8-9,12,18H2,1-3H3",FMTVWAGUJRUAKE-UHFFFAOYSA-N,HMT,PRMT1@Methyltransferase,3276,Q99873,"HCP1, ANM1",Inhibitor,MS094,30,IC50,Scintillation proximity assay (SPA) ,"https://doi.org/10.1021/acschembio.5b00839, https://www.thesgc.org/chemical-probes/MS023",=,9,IC50,Western Blot (inhibition of PRMT1 methyltransferase activity in MCF7 cells),,=,0,"Methyltransferase panel, literature",25,"Screened at 1 µM and 10 µM, highly selective within methyltransferase family; Selective over 9 reader proteins (UHRF1, BRPF1, WDR5, HGDF2, TDRD3, RBBP1, FXR1, EED, and SND1) in DSF assays: all enzymes dTm <2 K;",https://doi.org/10.1021/acschembio.5b00839,Epigenetic set,1 µM
EUB0000034d_PRMT3@Methyltransferase,MS023,EUB0000034d,CC(C)Oc1ccc(-c2c[nH]cc2CN(C)CCN)cc1,"InChI=1S/C17H25N3O/c1-13(2)21-16-6-4-14(5-7-16)17-11-19-10-15(17)12-20(3)9-8-18/h4-7,10-11,13,19H,8-9,12,18H2,1-3H3",FMTVWAGUJRUAKE-UHFFFAOYSA-N,HMT,PRMT3@Methyltransferase,10196,O60678,,Inhibitor,MS094,119,IC50,Scintillation proximity assay (SPA) ,"https://doi.org/10.1021/acschembio.5b00839, https://www.thesgc.org/chemical-probes/MS023",=,1000,IC50,Western Blot (inhibition of PRMT3 methyltransferase activity in MCF7 cells),,=,0,"Methyltransferase panel, literature",25,"Screened at 1 µM and 10 µM, highly selective within methyltransferase family; Selective over 9 reader proteins (UHRF1, BRPF1, WDR5, HGDF2, TDRD3, RBBP1, FXR1, EED, and SND1) in DSF assays: all enzymes dTm <2 K;",https://doi.org/10.1021/acschembio.5b00839,Epigenetic set,1 µM
EUB0000034d_CARM1@Methyltransferase,MS023,EUB0000034d,CC(C)Oc1ccc(-c2c[nH]cc2CN(C)CCN)cc1,"InChI=1S/C17H25N3O/c1-13(2)21-16-6-4-14(5-7-16)17-11-19-10-15(17)12-20(3)9-8-18/h4-7,10-11,13,19H,8-9,12,18H2,1-3H3",FMTVWAGUJRUAKE-UHFFFAOYSA-N,HMT,CARM1@Methyltransferase,10498,Q86X55,PRMT4,Inhibitor,MS094,83,IC50,Scintillation proximity assay (SPA) ,"https://doi.org/10.1021/acschembio.5b00839, https://www.thesgc.org/chemical-probes/MS023",=,,,,,,0,"Methyltransferase panel, literature",25,"Screened at 1 µM and 10 µM, highly selective within methyltransferase family; Selective over 9 reader proteins (UHRF1, BRPF1, WDR5, HGDF2, TDRD3, RBBP1, FXR1, EED, and SND1) in DSF assays: all enzymes dTm <2 K;",https://doi.org/10.1021/acschembio.5b00839,Epigenetic set,1 µM
EUB0000034d_PRMT6@Methyltransferase,MS023,EUB0000034d,CC(C)Oc1ccc(-c2c[nH]cc2CN(C)CCN)cc1,"InChI=1S/C17H25N3O/c1-13(2)21-16-6-4-14(5-7-16)17-11-19-10-15(17)12-20(3)9-8-18/h4-7,10-11,13,19H,8-9,12,18H2,1-3H3",FMTVWAGUJRUAKE-UHFFFAOYSA-N,HMT,PRMT6@Methyltransferase,55170,Q96LA8,FLJ10559,Inhibitor,MS094,4,IC50,Scintillation proximity assay (SPA) ,"https://doi.org/10.1021/acschembio.5b00839, https://www.thesgc.org/chemical-probes/MS023",=,56,IC50,Western Blot (inhibition of PRMT6 methyltransferase activity in HEK293 cells),,=,0,"Methyltransferase panel, literature",25,"Screened at 1 µM and 10 µM, highly selective within methyltransferase family; Selective over 9 reader proteins (UHRF1, BRPF1, WDR5, HGDF2, TDRD3, RBBP1, FXR1, EED, and SND1) in DSF assays: all enzymes dTm <2 K;",https://doi.org/10.1021/acschembio.5b00839,Epigenetic set,1 µM
EUB0000034d_PRMT8@Methyltransferase,MS023,EUB0000034d,CC(C)Oc1ccc(-c2c[nH]cc2CN(C)CCN)cc1,"InChI=1S/C17H25N3O/c1-13(2)21-16-6-4-14(5-7-16)17-11-19-10-15(17)12-20(3)9-8-18/h4-7,10-11,13,19H,8-9,12,18H2,1-3H3",FMTVWAGUJRUAKE-UHFFFAOYSA-N,HMT,PRMT8@Methyltransferase,56341,Q9NR22,,Inhibitor,MS094,5,IC50,Scintillation proximity assay (SPA) ,"https://doi.org/10.1021/acschembio.5b00839, https://www.thesgc.org/chemical-probes/MS023",=,,,,,,0,"Methyltransferase panel, literature",25,"Screened at 1 µM and 10 µM, highly selective within methyltransferase family; Selective over 9 reader proteins (UHRF1, BRPF1, WDR5, HGDF2, TDRD3, RBBP1, FXR1, EED, and SND1) in DSF assays: all enzymes dTm <2 K;",https://doi.org/10.1021/acschembio.5b00839,Epigenetic set,1 µM
EUB0000103c_CARM1@Methyltransferase,MS049 hydrochloride,EUB0000103c,CNCCN1CCC(OCc2ccccc2)CC1,"InChI=1S/C15H24N2O/c1-16-9-12-17-10-7-15(8-11-17)18-13-14-5-3-2-4-6-14/h2-6,15-16H,7-13H2,1H3",HBOJWAYLSJLULG-UHFFFAOYSA-N,HMT,CARM1@Methyltransferase,10498,Q86X55,PRMT4,Inhibitor,MS049N,34,IC50,Biochemical assay (measuring transfer of the methyl group from 3H-SAM to the peptide substrates),https://doi.org/10.1021/acs.jmedchem.6b01033,=,1400,IC50,Western Blot (PRMT4 dependent cellular asymmetric arginine dimethylation of Med12 (Med12-Rme2a) in HEK293 cells),,=,0,"Methyltransferase panel, literature",25,"Screened at 10 µM and 50 µM: MS049 is highly selective and showed no inhibition of any enzyme in the panel; Screened in CEREP panel against 100 enzymes (GPCRs, ion channels, transporters, kinases) at 10 µM, clean profile; Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest targets (radioligand binding assays): Ki(H3) = 87 nM, Ki(Sigma 1) = 64 nM, Ki(Sigma 2) = 574 nM;",https://doi.org/10.1021/acs.jmedchem.6b01033,Epigenetic set,1 µM
EUB0000103c_PRMT6@Methyltransferase,MS049 hydrochloride,EUB0000103c,CNCCN1CCC(OCc2ccccc2)CC1,"InChI=1S/C15H24N2O/c1-16-9-12-17-10-7-15(8-11-17)18-13-14-5-3-2-4-6-14/h2-6,15-16H,7-13H2,1H3",HBOJWAYLSJLULG-UHFFFAOYSA-N,HMT,PRMT6@Methyltransferase,55170,Q96LA8,FLJ10559,Inhibitor,MS049N,43,IC50,Biochemical assay (measuring transfer of the methyl group from 3H-SAM to the peptide substrates),https://doi.org/10.1021/acs.jmedchem.6b01033,=,970,IC50,Western Blot (PRMT6 dependent asymmetric dimethylation of histone H3 arginine 2 (H3R2me2a) in HEK293 cells),,=,0,"Methyltransferase panel, literature",25,"Screened at 10 µM and 50 µM: MS049 is highly selective and showed no inhibition of any enzyme in the panel; Screened in CEREP panel against 100 enzymes (GPCRs, ion channels, transporters, kinases) at 10 µM, clean profile; Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest targets (radioligand binding assays): Ki(H3) = 87 nM, Ki(Sigma 1) = 64 nM, Ki(Sigma 2) = 574 nM;",https://doi.org/10.1021/acs.jmedchem.6b01033,Epigenetic set,1 µM
EUB0000196bCl_SETD7,PFI-2,EUB0000196bCl,Cl.O=C([C@@H](Cc1cccc(C(F)(F)F)c1)NS(=O)(=O)c1cc(F)c2c(c1)CCNC2)N1CCCC1,"InChI=1S/C23H25F4N3O3S.ClH/c24-20-13-18(12-16-6-7-28-14-19(16)20)34(32,33)29-21(22(31)30-8-1-2-9-30)11-15-4-3-5-17(10-15)23(25,26)27;/h3-5,10,12-13,21,28-29H,1-2,6-9,11,14H2;1H/t21-;/m1./s1",ZADKZNVAJGEFLC-ZMBIFBSDSA-N,HMT,SETD7,80854,Q8WTS6,"KMT7, SET7, SET7/9, SET9",Inhibitor,(S)-PFI-2,2,IC50,Scintillation proximity assay (SPA) ,"https://doi.org/10.1073/pnas.1407358111, https://www.thesgc.org/chemical-probes/PFI-2",=,10000,EC50,Immunoblot (increase in nuclear YAP levels by treatment of MEFs (from Setd7+/+ mice) with 10 µM PFI-2),,<,0,"Methyltransferase panel, literature",19,"Screened at 50 µM, >1000-fold selective over other methyltransferases (G9a, EZH2, EHMT1, SUV39H2, EZH1, SUV420H1, SUV420H2, SETD8, SETD2, PRMT1, PRMT3, PRMT5, PRMT8, SETDB1, MLL1, DOT1L, WHSC1, SMYD2, DNMT1); Screened against 137 ion channels, GPCRs, and enzymes at 10 µM, closest targets: Ki(A2B) = 1.3 µM, Ki(BB3) = 8.1 µM, Ki(motilin) = 7.2 µM, Ki(KOP) = 3.8 µM",https://doi.org/10.1073/pnas.1407358111,Epigenetic set,1 µM
EUB0000197b_PRMT3@Methyltransferase,SGC707,EUB0000197b,O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1,"InChI=1S/C16H18N4O2/c21-15(20-7-1-2-8-20)11-18-16(22)19-14-4-3-13-10-17-6-5-12(13)9-14/h3-6,9-10H,1-2,7-8,11H2,(H2,18,19,22)",DMIDPTCQPIJYFE-UHFFFAOYSA-N,HMT,PRMT3@Methyltransferase,10196,O60678,,Allosteric inhibitor,XY1,85,Kd,SPR,"https://doi.org/10.1002/anie.201412154, https://www.thesgc.org/chemical-probes/SGC707",=,91,IC50,Western Blot assay (measuring H4R3me2a levels in HEK293 cells co-transfected with FLAG tagged PRMT3 (wt)),,=,0,"Methyltransferase panel, literature",31,"Screened at 1 µM, 5 µM and 20 µM, closest target at 20 µM: METTL21a (60% of contr.); Selective against panel of 250 enzymes (kinases, GPCRs, ion channels, transporters) at 10 µM, closest targets as % of contr.: 5HT2B (69%, Ki >15 µM), BRSK1 (56%), DLK1 (60%), MSK2 (55%), PKG2 (58%), PRKX (61%);","https://doi.org/10.1002/anie.201412154, https://www.thesgc.org/chemical-probes/SGC707",Epigenetic set,1 µM
EUB0000212b_EHMT1/GLP@Methyltransferase,A-366,EUB0000212b,COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1,"InChI=1S/C19H27N3O2/c1-23-16-12-14-15(21-18(20)19(14)6-4-7-19)13-17(16)24-11-5-10-22-8-2-3-9-22/h12-13H,2-11H2,1H3,(H2,20,21)",BKCDJTRMYWSXMC-UHFFFAOYSA-N,HMT,EHMT1/GLP@Methyltransferase,79813,Q9H9B1,"Eu-HMTase1, FLJ12879, KIAA1876, bA188C12.1, KMT1D, FLJ40292",Inhibitor,,38,IC50,Scintillation proximity assay (SPA),"https://doi.org/10.1021/ml400496h, https://www.thesgc.org/chemical-probes/A-366",=,,,,,,0,"Methyltransferade panel, literature",21,"Selectivity on methyltransferases measured by scintillation proximity assay (SPA), selective <50 µM","https://doi.org/10.1021/ml400496h, https://www.thesgc.org/chemical-probes/A-366",Epigenetic set,1 µM
EUB0000212b_EHMT2/G9a@Methyltransferase,A-366,EUB0000212b,COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1,"InChI=1S/C19H27N3O2/c1-23-16-12-14-15(21-18(20)19(14)6-4-7-19)13-17(16)24-11-5-10-22-8-2-3-9-22/h12-13H,2-11H2,1H3,(H2,20,21)",BKCDJTRMYWSXMC-UHFFFAOYSA-N,HMT,EHMT2/G9a@Methyltransferase,10919,Q96KQ7,"G9A, Em:AF134726.3, NG36/G9a, KMT1C",Inhibitor,,3,IC50,Scintillation proximity assay (SPA),"https://doi.org/10.1021/ml400496h, https://www.thesgc.org/chemical-probes/A-366",=,,,,,,0,"Methyltransferade panel, literature",21,"Selectivity on methyltransferases measured by scintillation proximity assay (SPA), selective <50 µM","https://doi.org/10.1021/ml400496h, https://www.thesgc.org/chemical-probes/A-366",Epigenetic set,1 µM
EUB0000221b_SMYD3@Methyltransferase,BAY-6035,EUB0000221b,C[C@H]1CC(=O)Nc2cc(C(=O)NCCC3CC3)ccc2N1C(=O)N1CC2CC2C1,"InChI=1S/C22H28N4O3/c1-13-8-20(27)24-18-10-15(21(28)23-7-6-14-2-3-14)4-5-19(18)26(13)22(29)25-11-16-9-17(16)12-25/h4-5,10,13-14,16-17H,2-3,6-9,11-12H2,1H3,(H,23,28)(H,24,27)/t13-,16?,17?/m0/s1",CKFRXCBNKKOFGO-IGEOTXOUSA-N,HMT,SMYD3@Methyltransferase,64754,Q9H7B4,KMT3E,Peptide-competitive inhibitor,BAY-444,88,IC50,Scintillation proximity assay (SPA),https://www.thesgc.org/chemical-probes/BAY-6035,=,,,,,,0,"Methyltransferase panel, literature ",34,"Screened at 1 µM and 10 µM, highly selective for SMYD3 with no activity on other methyltransferases; Screened against 31 kinases in enzyme assays, closest target T-Fyn (HTRF assay) = 5.71 µM, others >20 µM;",https://doi.org/10.1177/24725552211019409,Epigenetic set,1 µM
EUB0000551aCl_NR1I3,Meclizine dihydrochloride,EUB0000551aCl,CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl.Cl.Cl,"InChI=1S/C25H27ClN2.2ClH/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23;;/h2-13,18,25H,14-17,19H2,1H3;2*1H",VCTHNOIYJIXQLV-UHFFFAOYSA-N,Nuclear-receptor,NR1I3,9970,Q14994,"MB67, CAR1, CAR",Antagonist,,,,,,,63,IC50,cell-based,,=,,in house,,"inactive at 1 µM for VDR, NR1I2, VP16 and RXRA",in house,NR,
EUB0000040b_RORC,T0901317,EUB0000040b,C1=CC=C(C=C1)S(=O)(=O)N(CC(F)(F)F)C2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O,"InChI=1S/C17H12F9NO3S/c18-14(19,20)10-27(31(29,30)13-4-2-1-3-5-13)12-8-6-11(7-9-12)15(28,16(21,22)23)17(24,25)26/h1-9,28H,10H2",SGIWFELWJPNFDH-UHFFFAOYSA-N,Nuclear-receptor,RORC,6097,P51449,"RZRG, RORG, NR1F3, TOR",Inverse Agonist,,,,,,,460,IC50,cell-based,,=,3,literature; in house,,"IC50 at 2600 nM for RORA, IC50 at >5000 nM for NR1F2, EC50 at 1300 nM for NR1H4; inactive at 1 µM for VDR, NR1I3, VP16 and RXRA","https://doi.org/10.1021/jm401901d, https://doi.org/10.1016/j.bmcl.2013.10.054, https://doi.org/10.1021/acs.jmedchem.9b00327, https://doi.org/10.1016/j.bmcl.2014.09.053, in house",NR,
EUB0000040b_NR1H2,T0901317,EUB0000040b,C1=CC=C(C=C1)S(=O)(=O)N(CC(F)(F)F)C2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O,"InChI=1S/C17H12F9NO3S/c18-14(19,20)10-27(31(29,30)13-4-2-1-3-5-13)12-8-6-11(7-9-12)15(28,16(21,22)23)17(24,25)26/h1-9,28H,10H2",SGIWFELWJPNFDH-UHFFFAOYSA-N,Nuclear-receptor,NR1H2,7376,P55055,"NER, NER-I, RIP15, LXR-b, LXRb",Agonist,,,,,,,160,EC50,cell-based,,=,3,literature; in house,,"IC50 at 2600 nM for RORA, IC50 at >5000 nM for NR1F2, EC50 at 1300 nM for NR1H4; inactive at 1 µM for VDR, NR1I3, VP16 and RXRA","https://doi.org/10.1021/jm401901d, https://doi.org/10.1016/j.bmcl.2013.10.054, https://doi.org/10.1021/acs.jmedchem.9b00327, https://doi.org/10.1016/j.bmcl.2014.09.053, in house",NR,
EUB0000040b_NR1H3,T0901317,EUB0000040b,C1=CC=C(C=C1)S(=O)(=O)N(CC(F)(F)F)C2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O,"InChI=1S/C17H12F9NO3S/c18-14(19,20)10-27(31(29,30)13-4-2-1-3-5-13)12-8-6-11(7-9-12)15(28,16(21,22)23)17(24,25)26/h1-9,28H,10H2",SGIWFELWJPNFDH-UHFFFAOYSA-N,Nuclear-receptor,NR1H3,10062,Q13133,"LXR-a, RLD-1, LXRa",Agonist,,,,,,,370,EC50,cell-based,,=,3,literature; in house,,"IC50 at 2600 nM for RORA, IC50 at >5000 nM for NR1F2, EC50 at 1300 nM for NR1H4; inactive at 1 µM for VDR, NR1I3, VP16 and RXRA","https://doi.org/10.1021/jm401901d, https://doi.org/10.1016/j.bmcl.2013.10.054, https://doi.org/10.1021/acs.jmedchem.9b00327, https://doi.org/10.1016/j.bmcl.2014.09.053, in house",NR,
EUB0000040b_NR1I2,T0901317,EUB0000040b,C1=CC=C(C=C1)S(=O)(=O)N(CC(F)(F)F)C2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O,"InChI=1S/C17H12F9NO3S/c18-14(19,20)10-27(31(29,30)13-4-2-1-3-5-13)12-8-6-11(7-9-12)15(28,16(21,22)23)17(24,25)26/h1-9,28H,10H2",SGIWFELWJPNFDH-UHFFFAOYSA-N,Nuclear-receptor,NR1I2,8856,O75469,"ONR1, PXR, BXR, SXR, PAR2",Agonist,,,,,,,36,EC50,cell-based,,=,3,literature; in house,,"IC50 at 2600 nM for RORA, IC50 at >5000 nM for NR1F2, EC50 at 1300 nM for NR1H4; inactive at 1 µM for VDR, NR1I3, VP16 and RXRA","https://doi.org/10.1021/jm401901d, https://doi.org/10.1016/j.bmcl.2013.10.054, https://doi.org/10.1021/acs.jmedchem.9b00327, https://doi.org/10.1016/j.bmcl.2014.09.053, in house",NR,
EUB0000555a_THRA,T3,EUB0000555a,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O,"InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1",AUYYCJSJGJYCDS-LBPRGKRZSA-N,Nuclear-receptor,THRA,7067,P10827,"EAR-7.1/EAR-7.2, THRA3, AR7, ERBA, NR1A1",Agonist,,,,,,,2,EC50,cell-based,,=,,in house,,inactive at 1 µM for VP16 and RXRA,in house,NR,
EUB0000555a_THRB,T3,EUB0000555a,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O,"InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1",AUYYCJSJGJYCDS-LBPRGKRZSA-N,Nuclear-receptor,THRB,7068,P10828,"THRB1, THRB2, NR1A2, THR1, ERBA-BETA, GRTH",Agonist,,,,,,,2,EC50,cell-based,,=,,in house,,inactive at 1 µM for VP16 and RXRA,in house,NR,
EUB0000563a_RARB,Tazarotene,EUB0000563a,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,"InChI=1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3",OGQICQVSFDPSEI-UHFFFAOYSA-N,Nuclear-receptor,RARB,5915,P10826,"HAP, NR1B2, RRB2",Agonist,,,,,,,0.8,EC50,cell-based,,=,,in house,,inactive at 1 µM for VP16 and RXRA,in house,NR,
EUB0000563a_RARA,Tazarotene,EUB0000563a,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,"InChI=1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3",OGQICQVSFDPSEI-UHFFFAOYSA-N,Nuclear-receptor,RARA,5914,P10276,"RAR, NR1B1",Agonist,,,,,,,63,EC50,cell-based,,=,,in house,,inactive at 1 µM for VP16 and RXRA,in house,NR,
EUB0000563a_RARG,Tazarotene,EUB0000563a,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,"InChI=1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3",OGQICQVSFDPSEI-UHFFFAOYSA-N,Nuclear-receptor,RARG,5916,P13631,"RARC, NR1B3",Agonist,,,,,,,40,EC50,cell-based,,=,,in house,,inactive at 1 µM for VP16 and RXRA,in house,NR,
EUB0000564a_RARB,Adapalene,EUB0000564a,COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5,"InChI=1S/C28H28O3/c1-31-26-7-6-23(21-2-3-22-12-24(27(29)30)5-4-20(22)11-21)13-25(26)28-14-17-8-18(15-28)10-19(9-17)16-28/h2-7,11-13,17-19H,8-10,14-16H2,1H3,(H,29,30)",LZCDAPDGXCYOEH-UHFFFAOYSA-N,Nuclear-receptor,RARB,5915,P10826,"HAP, NR1B2, RRB2",Agonist,,,,,,,2,EC50,cell-based,,=,,in house,,inactive at 1 µM for VP16 and RXRA,in house,NR,
EUB0000564a_RARA,Adapalene,EUB0000564a,COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5,"InChI=1S/C28H28O3/c1-31-26-7-6-23(21-2-3-22-12-24(27(29)30)5-4-20(22)11-21)13-25(26)28-14-17-8-18(15-28)10-19(9-17)16-28/h2-7,11-13,17-19H,8-10,14-16H2,1H3,(H,29,30)",LZCDAPDGXCYOEH-UHFFFAOYSA-N,Nuclear-receptor,RARA,5914,P10276,"RAR, NR1B1",Agonist,,,,,,,22,EC50,cell-based,,=,,in house,,inactive at 1 µM for VP16 and RXRA,in house,NR,
EUB0000564a_RARG,Adapalene,EUB0000564a,COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5,"InChI=1S/C28H28O3/c1-31-26-7-6-23(21-2-3-22-12-24(27(29)30)5-4-20(22)11-21)13-25(26)28-14-17-8-18(15-28)10-19(9-17)16-28/h2-7,11-13,17-19H,8-10,14-16H2,1H3,(H,29,30)",LZCDAPDGXCYOEH-UHFFFAOYSA-N,Nuclear-receptor,RARG,5916,P13631,"RARC, NR1B3",Agonist,,,,,,,3,EC50,cell-based,,=,,in house,,inactive at 1 µM for VP16 and RXRA,in house,NR,
EUB0000565a_RARA,BMS753,EUB0000565a,CC1(C2=C(C=C(C=C2)C(=O)NC3=CC=C(C=C3)C(=O)O)C(C1=O)(C)C)C,"InChI=1S/C21H21NO4/c1-20(2)15-10-7-13(11-16(15)21(3,4)19(20)26)17(23)22-14-8-5-12(6-9-14)18(24)25/h5-11H,1-4H3,(H,22,23)(H,24,25)",KFBPBWUZXBYJDG-UHFFFAOYSA-N,Nuclear-receptor,RARA,5914,P10276,"RAR, NR1B1",Agonist,,,,,,,,EC50,cell-based,,=,2,in house,,"13 fold activation for RARB, 2 fold activation for RARG, inactive at 1 µM for VP16 and RXRA",in house,NR,
EUB0000566a_RARB,Tamibarotene,EUB0000566a,CC1(CCC(C2=C1C=CC(=C2)NC(=O)C3=CC=C(C=C3)C(=O)O)(C)C)C,"InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)",MUTNCGKQJGXKEM-UHFFFAOYSA-N,Nuclear-receptor,RARB,5915,P10826,"HAP, NR1B2, RRB2",Agonist,,,,,,,235,EC50,cell-based,,=,,in house,,inactive at 1 µM for VP16 and RXRA,in house,NR,
EUB0000566a_RARA,Tamibarotene,EUB0000566a,CC1(CCC(C2=C1C=CC(=C2)NC(=O)C3=CC=C(C=C3)C(=O)O)(C)C)C,"InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)",MUTNCGKQJGXKEM-UHFFFAOYSA-N,Nuclear-receptor,RARA,5914,P10276,"RAR, NR1B1",Agonist,,,,,,,45,EC50,cell-based,,=,,in house,,inactive at 1 µM for VP16 and RXRA,in house,NR,
EUB0000566a_RARG,Tamibarotene,EUB0000566a,CC1(CCC(C2=C1C=CC(=C2)NC(=O)C3=CC=C(C=C3)C(=O)O)(C)C)C,"InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)",MUTNCGKQJGXKEM-UHFFFAOYSA-N,Nuclear-receptor,RARG,5916,P13631,"RARC, NR1B3",Agonist,,,,,,,591,EC50,cell-based,,=,,in house,,inactive at 1 µM for VP16 and RXRA,in house,NR,
EUB0000567a_RARB,Ro 40-6055,EUB0000567a,CC1(CCC(C2=C1C=CC(=C2)C(=O)NC3=CC=C(C=C3)C(=O)O)(C)C)C,"InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-15(7-10-17(18)21)19(24)23-16-8-5-14(6-9-16)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)",SZWKGOZKRMMLAJ-UHFFFAOYSA-N,Nuclear-receptor,RARB,5915,P10826,"HAP, NR1B2, RRB2",Agonist,,,,,,,8.6,EC50,cell-based,,=,,in house,,inactive at 1 µM for VP16 and RXRA,in house,NR,
EUB0000567a_RARA,Ro 40-6055,EUB0000567a,CC1(CCC(C2=C1C=CC(=C2)C(=O)NC3=CC=C(C=C3)C(=O)O)(C)C)C,"InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-15(7-10-17(18)21)19(24)23-16-8-5-14(6-9-16)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)",SZWKGOZKRMMLAJ-UHFFFAOYSA-N,Nuclear-receptor,RARA,5914,P10276,"RAR, NR1B1",Agonist,,,,,,,0.3,EC50,cell-based,,=,,in house,,inactive at 1 µM for VP16 and RXRA,in house,NR,
EUB0000567a_RARG,Ro 40-6055,EUB0000567a,CC1(CCC(C2=C1C=CC(=C2)C(=O)NC3=CC=C(C=C3)C(=O)O)(C)C)C,"InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-15(7-10-17(18)21)19(24)23-16-8-5-14(6-9-16)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)",SZWKGOZKRMMLAJ-UHFFFAOYSA-N,Nuclear-receptor,RARG,5916,P13631,"RARC, NR1B3",Agonist,,,,,,,13,EC50,cell-based,,=,,in house,,inactive at 1 µM for VP16 and RXRA,in house,NR,
EUB0000568a_RARG,AHPN,EUB0000568a,C1C2CC3CC1CC(C2)(C3)C4=C(C=CC(=C4)C5=CC6=C(C=C5)C=C(C=C6)C(=O)O)O,"InChI=1S/C27H26O3/c28-25-6-5-22(20-1-2-21-11-23(26(29)30)4-3-19(21)10-20)12-24(25)27-13-16-7-17(14-27)9-18(8-16)15-27/h1-6,10-12,16-18,28H,7-9,13-15H2,(H,29,30)",LDGIHZJOIQSHPB-UHFFFAOYSA-N,Nuclear-receptor,RARG,5916,P13631,"RARC, NR1B3",Agonist,,,,,,,50,EC50,cell-based,,=,1,literature; in house,,EC50 at >10000 nM for RARA; inactive at 1 µM for VP16 and RXRA,"https://doi.org/10.1016/j.bmcl.2018.04.036, in house",NR,
EUB0000568a_RARB,AHPN,EUB0000568a,C1C2CC3CC1CC(C2)(C3)C4=C(C=CC(=C4)C5=CC6=C(C=C5)C=C(C=C6)C(=O)O)O,"InChI=1S/C27H26O3/c28-25-6-5-22(20-1-2-21-11-23(26(29)30)4-3-19(21)10-20)12-24(25)27-13-16-7-17(14-27)9-18(8-16)15-27/h1-6,10-12,16-18,28H,7-9,13-15H2,(H,29,30)",LDGIHZJOIQSHPB-UHFFFAOYSA-N,Nuclear-receptor,RARB,5915,P10826,"HAP, NR1B2, RRB2",Agonist,,,,,,,226,EC50,cell-based,,=,1,literature; in house,,EC50 at >10000 nM for RARA; inactive at 1 µM for VP16 and RXRA,"https://doi.org/10.1016/j.bmcl.2018.04.036, in house",NR,
EUB0000185b_PPARA,GW7647,EUB0000185b,CC(C)(C(=O)O)SC1=CC=C(C=C1)CCN(CCCCC2CCCCC2)C(=O)NC3CCCCC3,"InChI=1S/C29H46N2O3S/c1-29(2,27(32)33)35-26-18-16-24(17-19-26)20-22-31(28(34)30-25-14-7-4-8-15-25)21-10-9-13-23-11-5-3-6-12-23/h16-19,23,25H,3-15,20-22H2,1-2H3,(H,30,34)(H,32,33)",PKNYXWMTHFMHKD-UHFFFAOYSA-N,Nuclear-receptor,PPARA,5465,Q07869,"hPPAR, NR1C1",Agonist,,,,,,,6.3,EC50,cell-based,,=,2,literature; in house,,"EC50 at 6200 nM for PPARD, EC50 at 1000 nM for PPARG; inactive at 1 µM for VP16 and RXRA","https://doi.org/10.1016/s0960-894x(01)00188-3, in house",NR,
EUB0000569a_PPARD,GW0742,EUB0000569a,CC1=C(C=CC(=C1)SCC2=C(N=C(S2)C3=CC(=C(C=C3)C(F)(F)F)F)C)OCC(=O)O,"InChI=1S/C21H17F4NO3S2/c1-11-7-14(4-6-17(11)29-9-19(27)28)30-10-18-12(2)26-20(31-18)13-3-5-15(16(22)8-13)21(23,24)25/h3-8H,9-10H2,1-2H3,(H,27,28)",HWVNEWGKWRGSRK-UHFFFAOYSA-N,Nuclear-receptor,PPARD,5467,Q03181,"NUC1, NUCII, FAAR, NR1C2",Agonist,,,,,,,1,EC50,cell-based,,=,2,literature; in house,,"EC50 at 1100 nM for PPARA, EC50 at 2000 nM for PPARG; inactive at 1 µM for VP16 and RXRA","https://doi.org/10.1016/s0960-894x(03)00207-5, in house",NR,
EUB0000570a_PPARG,GW1929 hydrate,EUB0000570a,CN(C1=CC=CC=N1)CCOC2=CC=C(C[C@H](NC3=CC=CC=C3C(C4=CC=CC=C4)=O)C(O)=O)C=C2.[H]O[H],"InChI=1S/C30H29N3O4.H2O/c1-33(28-13-7-8-18-31-28)19-20-37-24-16-14-22(15-17-24)21-27(30(35)36)32-26-12-6-5-11-25(26)29(34)23-9-3-2-4-10-23;/h2-18,27,32H,19-21H2,1H3,(H,35,36);1H2/t27-;/m0./s1",XSITZVFUXCLFMK-YCBFMBTMSA-N,Nuclear-receptor,PPARG,5468,P37231,"PPARG1, PPARG2, NR1C3, PPARgamma",Agonist,,,,,,,4,EC50,cell-based,,=,,literature; in house,,inactive for PPARA and PPARD; inactive at 1 µM for VP16 and RXRA,"https://doi.org/10.2337/diabetes.48.7.1415, in house",NR,
EUB0000571a_PPARG,S26948,EUB0000571a,COC(=O)C(CC1=CC=C(C=C1)OCCN2C3=C(C=C(C=C3)C(=O)C4=CC=CC=C4)SC2=O)C(=O)OC,"InChI=1S/C28H25NO7S/c1-34-26(31)22(27(32)35-2)16-18-8-11-21(12-9-18)36-15-14-29-23-13-10-20(17-24(23)37-28(29)33)25(30)19-6-4-3-5-7-19/h3-13,17,22H,14-16H2,1-2H3",NSMJEHGOMXSLCW-UHFFFAOYSA-N,Nuclear-receptor,PPARG,5468,P37231,"PPARG1, PPARG2, NR1C3, PPARgamma",Agonist,,,,,,,40,EC50,cell-based,,=,,literature; in house,,inactive for PPARA and PPARD; inactive at 1 µM for VP16 and RXRA,"https://doi.org/10.2337/db06-1734, in house",NR,
EUB0000572aCl_NR1H2,GW3965,EUB0000572aCl,C1=CC=C(C=C1)C(CN(CCCOC2=CC=CC(=C2)CC(=O)O)CC3=C(C(=CC=C3)C(F)(F)F)Cl)C4=CC=CC=C4.Cl,"InChI=1S/C33H31ClF3NO3.ClH/c34-32-27(15-8-17-30(32)33(35,36)37)22-38(18-9-19-41-28-16-7-10-24(20-28)21-31(39)40)23-29(25-11-3-1-4-12-25)26-13-5-2-6-14-26;/h1-8,10-17,20,29H,9,18-19,21-23H2,(H,39,40);1H",NMPUWJFHNOUNQU-UHFFFAOYSA-N,Nuclear-receptor,NR1H2,7376,P55055,"NER, NER-I, RIP15, LXR-b, LXRb",Agonist,,,,,,,30,EC50,cell-based,,=,1,in house,,"2 fold activation for NR1H4, inactive at 1 µM for VP16 and RXRA",in house,NR,
EUB0000572aCl_NR1H3,GW3965,EUB0000572aCl,C1=CC=C(C=C1)C(CN(CCCOC2=CC=CC(=C2)CC(=O)O)CC3=C(C(=CC=C3)C(F)(F)F)Cl)C4=CC=CC=C4.Cl,"InChI=1S/C33H31ClF3NO3.ClH/c34-32-27(15-8-17-30(32)33(35,36)37)22-38(18-9-19-41-28-16-7-10-24(20-28)21-31(39)40)23-29(25-11-3-1-4-12-25)26-13-5-2-6-14-26;/h1-8,10-17,20,29H,9,18-19,21-23H2,(H,39,40);1H",NMPUWJFHNOUNQU-UHFFFAOYSA-N,Nuclear-receptor,NR1H3,10062,Q13133,"LXR-a, RLD-1, LXRa",Agonist,,,,,,,190,EC50,cell-based,,=,1,in house,,"2 fold activation for NR1H4, inactive at 1 µM for VP16 and RXRA",in house,NR,
EUB0000184b_NR1H4,GW4064,EUB0000184b,CC(C)C1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)COC3=CC(=C(C=C3)/C=C/C4=CC(=CC=C4)C(=O)O)Cl,"InChI=1S/C28H22Cl3NO4/c1-16(2)27-21(26(32-36-27)25-22(29)7-4-8-23(25)30)15-35-20-12-11-18(24(31)14-20)10-9-17-5-3-6-19(13-17)28(33)34/h3-14,16H,15H2,1-2H3,(H,33,34)/b10-9+",BYTNEISLBIENSA-MDZDMXLPSA-N,Nuclear-receptor,NR1H4,9971,Q96RI1,"FXR, RIP14, HRR1, HRR-1",Agonist,,,,,,,70,EC50,cell-based,,=,,in house,,"inactive at 1 µM for NR1H2, NR1H3, VP16 and RXRA",in house,NR,
EUB0000573a_NR1H4,XL335,EUB0000573a,CC(C)OC(=O)C1=CN(CC(C2=C1NC3=CC=CC=C32)(C)C)C(=O)C4=CC(=C(C=C4)F)F,"InChI=1S/C25H24F2N2O3/c1-14(2)32-24(31)17-12-29(23(30)15-9-10-18(26)19(27)11-15)13-25(3,4)21-16-7-5-6-8-20(16)28-22(17)21/h5-12,14,28H,13H2,1-4H3",INASOKQDNHHMRE-UHFFFAOYSA-N,Nuclear-receptor,NR1H4,9971,Q96RI1,"FXR, RIP14, HRR1, HRR-1",Agonist,,,,,,,15,EC50,cell-based,,=,,in house,,"inactive at 1 µM for NR1H2, NR1H3, VP16 and RXRA",in house,NR,
EUB0000574a_NR1I2,Rifampicin,EUB0000574a,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,"InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1",JQXXHWHPUNPDRT-WLSIYKJHSA-N,Nuclear-receptor,NR1I2,8856,O75469,"ONR1, PXR, BXR, SXR, PAR2",Agonist,,,,,,,1335,EC50,cell-based,,=,1,in house,,"1.6 fold activation for VDR, inacitve at 1 µM for NR1I3, VP16 and RXRA",in house,NR,
EUB0000575a_NR1I2,Lovastatin,EUB0000575a,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,"InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1",PCZOHLXUXFIOCF-BXMDZJJMSA-N,Nuclear-receptor,NR1I2,8856,O75469,"ONR1, PXR, BXR, SXR, PAR2",Agonist,,,,,,,2300,EC50,cell-based,,=,1,in house,,"1.2 fold activation for VDR, active at 1 µM for VP16, inacitve at 1 µM for NR1I3 and RXRA",in house,NR,
EUB0000576a_NR1I2,SR12813,EUB0000576a,CCOP(=O)(C(=CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C)P(=O)(OCC)OCC)OCC,"InChI=1S/C24H42O7P2/c1-11-28-32(26,29-12-2)21(33(27,30-13-3)31-14-4)17-18-15-19(23(5,6)7)22(25)20(16-18)24(8,9)10/h15-17,25H,11-14H2,1-10H3",YQLJDECYQDRSBI-UHFFFAOYSA-N,Nuclear-receptor,NR1I2,8856,O75469,"ONR1, PXR, BXR, SXR, PAR2",Agonist,,,,,,,137,EC50,cell-based,,=,,in house,,"inactive at 1 µM for VDR, NR1I3, VP16 and RXRA",in house,NR,
EUB0000581a_PPARA,CP 775146,EUB0000581a,CC(C)C1=CC=C(C=C1)CC(=O)N2CCC[C@H](C2)C3=CC(=CC=C3)OC(C)(C)C(=O)O,"InChI=1S/C26H33NO4/c1-18(2)20-12-10-19(11-13-20)15-24(28)27-14-6-8-22(17-27)21-7-5-9-23(16-21)31-26(3,4)25(29)30/h5,7,9-13,16,18,22H,6,8,14-15,17H2,1-4H3,(H,29,30)/t22-/m1/s1",OISHBINQIFNIPV-JOCHJYFZSA-N,Nuclear-receptor,PPARA,5465,Q07869,"hPPAR, NR1C1",Agonist,,,,,,,50,EC50,cell-based,,=,1,in house,,"3 fold activation for PPARG, inactive at 1 µM for PPARD, VP16 and RXRA",in house,NR,
EUB0000183b_NR1H2,GSK2033,EUB0000183b,CC1=CC(=C(C(=C1)C)S(=O)(=O)N(CC2=CC=C(C=C2)C3=CC(=CC=C3)S(=O)(=O)C)CC4=CC=C(O4)C(F)(F)F)C,"InChI=1S/C29H28F3NO5S2/c1-19-14-20(2)28(21(3)15-19)40(36,37)33(18-25-12-13-27(38-25)29(30,31)32)17-22-8-10-23(11-9-22)24-6-5-7-26(16-24)39(4,34)35/h5-16H,17-18H2,1-4H3",PSOXOVKYGWBTPB-UHFFFAOYSA-N,Nuclear-receptor,NR1H2,7376,P55055,"NER, NER-I, RIP15, LXR-b, LXRb",Antagonist,,,,,,,31,IC50,cell-based,,=,,in house,,"inactive at 1 µM for NR1H4, VP16 and RXRA",in house,NR,
EUB0000183b_NR1H3,GSK2033,EUB0000183b,CC1=CC(=C(C(=C1)C)S(=O)(=O)N(CC2=CC=C(C=C2)C3=CC(=CC=C3)S(=O)(=O)C)CC4=CC=C(O4)C(F)(F)F)C,"InChI=1S/C29H28F3NO5S2/c1-19-14-20(2)28(21(3)15-19)40(36,37)33(18-25-12-13-27(38-25)29(30,31)32)17-22-8-10-23(11-9-22)24-6-5-7-26(16-24)39(4,34)35/h5-16H,17-18H2,1-4H3",PSOXOVKYGWBTPB-UHFFFAOYSA-N,Nuclear-receptor,NR1H3,10062,Q13133,"LXR-a, RLD-1, LXRa",Antagonist,,,,,,,100,IC50,cell-based,,=,,in house,,"inactive at 1 µM for NR1H4, VP16 and RXRA",in house,NR,
EUB0000182b_NR1H4,Fexaramine,EUB0000182b,CN(C)C1=CC=C(C=C1)C2=CC=C(C=C2)CN(C3=CC=CC(=C3)/C=C/C(=O)OC)C(=O)C4CCCCC4,"InChI=1S/C32H36N2O3/c1-33(2)29-19-17-27(18-20-29)26-15-12-25(13-16-26)23-34(32(36)28-9-5-4-6-10-28)30-11-7-8-24(22-30)14-21-31(35)37-3/h7-8,11-22,28H,4-6,9-10,23H2,1-3H3/b21-14+",VLQTUNDJHLEFEQ-KGENOOAVSA-N,Nuclear-receptor,NR1H4,9971,Q96RI1,"FXR, RIP14, HRR1, HRR-1",Agonist,,,,,,,25,EC50,cell-based,,=,,in house,,"inactive at 1 µM for NR1H2, NR1H3, VP16 and RXRA",in house,NR,
EUB0000582a_VDR,Seocalcitol,EUB0000582a,CCC(CC)(/C=C/C=C/[C@@H](C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C)O,"InChI=1S/C30H46O3/c1-6-30(33,7-2)18-9-8-11-21(3)26-15-16-27-23(12-10-17-29(26,27)5)13-14-24-19-25(31)20-28(32)22(24)4/h8-9,11,13-14,18,21,25-28,31-33H,4,6-7,10,12,15-17,19-20H2,1-3,5H3/b11-8+,18-9+,23-13+,24-14-/t21-,25-,26-,27+,28+,29-/m1/s1",LVLLALCJVJNGQQ-SEODYNFXSA-N,Nuclear-receptor,VDR,7421,P11473,"NR1I1, PPP1R163",Agonist,,,,,,,0.6,EC50,cell-based,,=,,in house,,"inactive at 1 µM for NR1I2, NR1I3, VP16 and RXRA",in house,NR,
EUB0000583a_VDR,Doxercalciferol,EUB0000583a,C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C,"InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1",HKXBNHCUPKIYDM-CGMHZMFXSA-N,Nuclear-receptor,VDR,7421,P11473,"NR1I1, PPP1R163",Agonist,,,,,,,960,EC50,cell-based,,=,,in house,,"inactive at 1 µM for NR1I2, NR1I3, VP16 and RXRA",in house,NR,
EUB0000585a_THRA,Sobetirome,EUB0000585a,CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OCC(=O)O,"InChI=1S/C20H24O4/c1-12(2)17-9-15(5-6-19(17)21)10-18-13(3)7-16(8-14(18)4)24-11-20(22)23/h5-9,12,21H,10-11H2,1-4H3,(H,22,23)",QNAZTOHXCZPOSA-UHFFFAOYSA-N,Nuclear-receptor,THRA,7067,P10827,"EAR-7.1/EAR-7.2, THRA3, AR7, ERBA, NR1A1",Agonist,,,,,,,3,EC50,cell-based,,=,,in house,,inactive at 1 µM for VP16 and RXRA,in house,NR,
EUB0000585a_THRB,Sobetirome,EUB0000585a,CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OCC(=O)O,"InChI=1S/C20H24O4/c1-12(2)17-9-15(5-6-19(17)21)10-18-13(3)7-16(8-14(18)4)24-11-20(22)23/h5-9,12,21H,10-11H2,1-4H3,(H,22,23)",QNAZTOHXCZPOSA-UHFFFAOYSA-N,Nuclear-receptor,THRB,7068,P10828,"THRB1, THRB2, NR1A2, THR1, ERBA-BETA, GRTH",Agonist,,,,,,,18,EC50,cell-based,,=,,in house,,inactive at 1 µM for VP16 and RXRA,in house,NR,
EUB0000314b_NR3C1,BI-653048,EUB0000314b,CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1,"InChI=1S/C23H25F4N3O4S/c1-4-35(33,34)19-8-13-7-15(30-18(13)11-29-19)10-22(32,23(25,26)27)12-21(2,3)17-6-5-14(24)9-16(17)20(28)31/h5-9,11,30,32H,4,10,12H2,1-3H3,(H2,28,31)/t22-/m0/s1",AUIFRJWXYUNPPV-QFIPXVFZSA-N,Nuclear-receptor,NR3C1,2908,P04150,GR,Agonist,BI-3047,55,IC50,Fluorescence polarization assay,"https://doi.org/10.1021/ml500387y, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI%20653048",=,,,,,,,,,"> 100 fold selective against related nuclear receptors (PGR, NR3C2, ESR1, AR); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest target as % of contr: DRD5 (34%); Screened against 49 targets (Eurofins-Panlabs panel at Boehringer Ingelheim) at 10 µM: clean profile; Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: LATS2(40%)","https://doi.org/10.1021/ml500387y, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI%20653048",NR set,1 µM
EUB0000586a_NR3C1,BI-3047,EUB0000586a,CCS(C1=NC=C2NC(C[C@@](O)(CC(C3=CC=C(C=C3C(N)=O)F)(C)C)C(F)(F)F)=CC2=C1)(=O)=O,"InChI=1S/C23H25F4N3O4S/c1-4-35(33,34)19-8-13-7-15(30-18(13)11-29-19)10-22(32,23(25,26)27)12-21(2,3)17-6-5-14(24)9-16(17)20(28)31/h5-9,11,30,32H,4,10,12H2,1-3H3,(H2,28,31)/t22-/m1/s1",AUIFRJWXYUNPPV-JOCHJYFZSA-N,Nuclear-receptor,NR3C1,2908,P04150,GR,Negative control for BI-653048,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI%20653048,,,,,,,,,,,,NR set,1 µM
EUB0000190b_PPARG,Rosiglitazone,EUB0000190b,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,"InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)",YASAKCUCGLMORW-UHFFFAOYSA-N,Nuclear-receptor,PPARG,5468,P37231,"PPARG1, PPARG2, NR1C3, PPARgamma",Agonist,,,,,,,30,EC50,cell-based,,=,2,literature; in house,,"EC50 at 15000 nM for PPARA, EC50 at 8600 nM for PPARD; inactive at 1 µM for VP16 and RARB","https://doi.org/10.1002/cmdc.201100598, in house",NR,
EUB0000302b_NUDT1,BAY-707,EUB0000302b,CCNC(=O)c1cc2c(N3CCOC[C@H]3C)ccnc2[nH]1,"InChI=1S/C15H20N4O2/c1-3-16-15(20)12-8-11-13(4-5-17-14(11)18-12)19-6-7-21-9-10(19)2/h4-5,8,10H,3,6-7,9H2,1-2H3,(H,16,20)(H,17,18)/t10-/m1/s1",RPMGXDCRCWWCRY-SNVBAGLBSA-N,Nudix hydrolase family,NUDT1,4521,P36639,,Inhibitor,BAY-604,2.3,IC50,PPiLight Biochemical Assay (full-length human NUDT1),"https://doi.org/10.1021/acschembio.7b00370, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-707",=,7.6,EC50,CETSA (cellular thermal shift assay in K562 cells),,=,,,,"Selective across the Nudix family when tested in Tm shift assay; Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest target: Ki(GABAA/BZP) = 1527 nM; Screened against 30 kinases at 40 µM (Bayer in-house kinase panel), all targets IC50 >8 µM (PMID: 28679043)",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-707,Other targets,1 µM
EUB0000587a_NUDT1,BAY-604,EUB0000587a,CCNC(=O)c1cc2c(ccnc2n1C)N3CCOC[C@H]3C,"InChI=1S/C16H22N4O2/c1-4-17-16(21)14-9-12-13(5-6-18-15(12)19(14)3)20-7-8-22-10-11(20)2/h5-6,9,11H,4,7-8,10H2,1-3H3,(H,17,21)/t11-/m1/s1",SYYSMZCCSNLTHZ-LLVKDONJSA-N,Nudix hydrolase family,NUDT1,4521,P36639,,Negative control for BAY-707,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-707,,,,,,,,,,,,Other targets,1 µM
EUB0000232b_LIMK1,TH-257,EUB0000232b,CCCCN(Cc1ccccc1)C(=O)c1ccc(S(=O)(=O)Nc2ccccc2)cc1,"InChI=1S/C24H26N2O3S/c1-2-3-18-26(19-20-10-6-4-7-11-20)24(27)21-14-16-23(17-15-21)30(28,29)25-22-12-8-5-9-13-22/h4-17,25H,2-3,18-19H2,1H3",VNCIWNGCMAKKEO-UHFFFAOYSA-N,Protein Kinase,LIMK1,3984,P53667,LIMK,Allosteric inhibitor,TH-263,84,IC50,RapidFire MS assay,https://www.thesgc.org/chemical-probes/TH-257,=,250,IC50,NanoBRET assay (HEK293T cells),,=,0,KinomeScan (DiscoverX),448,"Screened at 1 µM, no significant activities below 50%",https://www.thesgc.org/chemical-probes/TH-257,Kinase set,1 µM
EUB0000232b_LIMK2,TH-257,EUB0000232b,CCCCN(Cc1ccccc1)C(=O)c1ccc(S(=O)(=O)Nc2ccccc2)cc1,"InChI=1S/C24H26N2O3S/c1-2-3-18-26(19-20-10-6-4-7-11-20)24(27)21-14-16-23(17-15-21)30(28,29)25-22-12-8-5-9-13-22/h4-17,25H,2-3,18-19H2,1H3",VNCIWNGCMAKKEO-UHFFFAOYSA-N,Protein Kinase,LIMK2,3985,P53671,,Allosteric inhibitor,TH-263,39,IC50,RapidFire MS assay,https://www.thesgc.org/chemical-probes/TH-257,=,150,IC50,NanoBRET assay (HEK293T cells),,=,0,KinomeScan (DiscoverX),448,"Screened at 1 µM, no significant activities below 50%",https://www.thesgc.org/chemical-probes/TH-257,Kinase set,1 µM
EUB0000285b_LIMK1,TH-263,EUB0000285b,O=C(NCc1ccccc1)c1ccc(S(=O)(=O)NCc2ccccc2)cc1,"InChI=1S/C21H20N2O3S/c24-21(22-15-17-7-3-1-4-8-17)19-11-13-20(14-12-19)27(25,26)23-16-18-9-5-2-6-10-18/h1-14,23H,15-16H2,(H,22,24)",QDGVJMITKNOVTP-UHFFFAOYSA-N,Protein Kinase,LIMK1,3984,P53667,LIMK,Negative control for TH-257,,,Negative Control,,https://www.thesgc.org/chemical-probes/TH-257,,,,,,,,,,,,Kinase set,1 µM
EUB0000285b_LIMK2,TH-263,EUB0000285b,O=C(NCc1ccccc1)c1ccc(S(=O)(=O)NCc2ccccc2)cc1,"InChI=1S/C21H20N2O3S/c24-21(22-15-17-7-3-1-4-8-17)19-11-13-20(14-12-19)27(25,26)23-16-18-9-5-2-6-10-18/h1-14,23H,15-16H2,(H,22,24)",QDGVJMITKNOVTP-UHFFFAOYSA-N,Protein Kinase,LIMK2,3985,P53671,,Negative control for TH-257,,,Negative Control,,https://www.thesgc.org/chemical-probes/TH-257,,,,,,,,,,,,Kinase set,1 µM
EUB0000589aTFA_IKBKB,BMS-345541 (ditrifluoroacetate),EUB0000589aTFA,CC1=CN=C2N1C3=C(C=CC(C)=C3)N=C2NCCN.FC(F)(C(O)=O)F.FC(F)(C(O)=O)F,"InChI=1S/C14H17N5.2C2HF3O2/c1-9-3-4-11-12(7-9)19-10(2)8-17-14(19)13(18-11)16-6-5-15;2*3-2(4,5)1(6)7/h3-4,7-8H,5-6,15H2,1-2H3,(H,16,18);2*(H,6,7)",OWHLFAMVTWAXBL-UHFFFAOYSA-N,Protein Kinase,IKBKB,3551,O14920,"IKK2, NFKBIKB, IKK-beta, IKKB",Allosteric inhibitor,,130,Kd,Competition binding assay,https://doi.org/10.1038/nbt.1990,=,,,,,,9,"Competition binding assay, literature",442,"In vitro follow up of closest targets: Kd(IKKB) = 170 nM, Kd(YSK4) = 200 nM, Kd(CDK11A) = 399 nM, Kd(CDK11B) = 420 nM, Kd(CDK13) = 800 nM, Kd(CDK7) = 680 nM, Kd(MYLK4) = 700 nM; S(300nM) = 0.0052, S(3µM) = 0.0440;",https://doi.org/10.1038/nbt.1990,Kinase set,1 µM
EUB0000154b_PRKCA,Enzastaurin,EUB0000154b,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,"InChI=1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)",AXRCEOKUDYDWLF-UHFFFAOYSA-N,Protein Kinase,PRKCA,5578,P17252,PKCalpha,Inhibitor,,39,IC50,Filter-binding assays,https://doi.org/10.1158/0008-5472.CAN-05-0071,=,,,,,,10,KinomeScan (DiscoverX),456,"Screened at 1 µM, follow-up Kds for closest targets: Kd(GSK3B) = 8.3 nM, Kd(PRKCD) = 25 nM, Kd(RSK4) = 25 nM, Kd(PRKCQ) = 36 nM, Kd(FLT3(D835Y)) = 40 nM, Kd(PRKCH) = 46 nM, Kd(FLT3(D835H)) = 49 nM, Kd(FLT3(ITD)) = 72 nM, Kd(MAPK15) = 76 nM, Kd(RSK2Kd) = 87 nM, 18 other targets with Kd 0.1-1 µM;",https://www.guidetopharmacology.org/GRAC/LigandScreenDisplayForward?ligandId=5693&screenId=2,Kinase set,100 nM
EUB0000154b_PRKCB,Enzastaurin,EUB0000154b,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,"InChI=1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)",AXRCEOKUDYDWLF-UHFFFAOYSA-N,Protein Kinase,PRKCB,5579,P05771,PKCbeta,Inhibitor,,6,IC50,Filter-binding assays,https://doi.org/10.1158/0008-5472.CAN-05-0071,=,,,,,,10,KinomeScan (DiscoverX),456,"Screened at 1 µM, follow-up Kds for closest targets: Kd(GSK3B) = 8.3 nM, Kd(PRKCD) = 25 nM, Kd(RSK4) = 25 nM, Kd(PRKCQ) = 36 nM, Kd(FLT3(D835Y)) = 40 nM, Kd(PRKCH) = 46 nM, Kd(FLT3(D835H)) = 49 nM, Kd(FLT3(ITD)) = 72 nM, Kd(MAPK15) = 76 nM, Kd(RSK2Kd) = 87 nM, 18 other targets with Kd 0.1-1 µM;",https://www.guidetopharmacology.org/GRAC/LigandScreenDisplayForward?ligandId=5693&screenId=2,Kinase set,100 nM
EUB0000154b_PRKCG,Enzastaurin,EUB0000154b,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,"InChI=1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)",AXRCEOKUDYDWLF-UHFFFAOYSA-N,Protein Kinase,PRKCG,5582,P05129,"PKCCy, MGC57564, PKCgamma",Inhibitor,,83,IC50,Filter-binding assays,https://doi.org/10.1158/0008-5472.CAN-05-0071,=,,,,,,10,KinomeScan (DiscoverX),456,"Screened at 1 µM, follow-up Kds for closest targets: Kd(GSK3B) = 8.3 nM, Kd(PRKCD) = 25 nM, Kd(RSK4) = 25 nM, Kd(PRKCQ) = 36 nM, Kd(FLT3(D835Y)) = 40 nM, Kd(PRKCH) = 46 nM, Kd(FLT3(D835H)) = 49 nM, Kd(FLT3(ITD)) = 72 nM, Kd(MAPK15) = 76 nM, Kd(RSK2Kd) = 87 nM, 18 other targets with Kd 0.1-1 µM;",https://www.guidetopharmacology.org/GRAC/LigandScreenDisplayForward?ligandId=5693&screenId=2,Kinase set,100 nM
EUB0000154b_PRKCE,Enzastaurin,EUB0000154b,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,"InChI=1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)",AXRCEOKUDYDWLF-UHFFFAOYSA-N,Protein Kinase,PRKCE,5581,Q02156,,Inhibitor,,110,IC50,Filter-binding assays,https://doi.org/10.1158/0008-5472.CAN-05-0071,=,,,,,,10,KinomeScan (DiscoverX),456,"Screened at 1 µM, follow-up Kds for closest targets: Kd(GSK3B) = 8.3 nM, Kd(PRKCD) = 25 nM, Kd(RSK4) = 25 nM, Kd(PRKCQ) = 36 nM, Kd(FLT3(D835Y)) = 40 nM, Kd(PRKCH) = 46 nM, Kd(FLT3(D835H)) = 49 nM, Kd(FLT3(ITD)) = 72 nM, Kd(MAPK15) = 76 nM, Kd(RSK2Kd) = 87 nM, 18 other targets with Kd 0.1-1 µM;",https://www.guidetopharmacology.org/GRAC/LigandScreenDisplayForward?ligandId=5693&screenId=2,Kinase set,100 nM
EUB0000134b_ROCK1,GSK429286A,EUB0000134b,CC1=C(C(=O)Nc2cc3cn[nH]c3cc2F)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1,"InChI=1S/C21H16F4N4O2/c1-10-19(20(31)28-17-6-12-9-26-29-16(12)8-15(17)22)14(7-18(30)27-10)11-2-4-13(5-3-11)21(23,24)25/h2-6,8-9,14H,7H2,1H3,(H,26,29)(H,27,30)(H,28,31)",OLIIUAHHAZEXEX-UHFFFAOYSA-N,Protein Kinase,ROCK1,6093,Q13464,p160ROCK,Inhibitor,,14,IC50,Scintillation Proximity Assay (SPA),"https://doi.org/10.1021/jm0609014, https://doi.org/10.1042/BJ20091035 ",=,,,,,,3,KinomeScan,317,"Screened at 10 µM, closest targets as % contr.: JAK3(JH1 catalytic domain) (3.2%), PRKACA (4.2%), PRKACB (6.4%); Additionally screened against 85 kinase targets at 1 µM, closest target as % of contr.: RPS6KA2 (20%), PMID: 19740074;",https://lincs.hms.harvard.edu/db/sm/10012-101/,Kinase set,1 µM
EUB0000134b_ROCK2,GSK429286A,EUB0000134b,CC1=C(C(=O)Nc2cc3cn[nH]c3cc2F)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1,"InChI=1S/C21H16F4N4O2/c1-10-19(20(31)28-17-6-12-9-26-29-16(12)8-15(17)22)14(7-18(30)27-10)11-2-4-13(5-3-11)21(23,24)25/h2-6,8-9,14H,7H2,1H3,(H,26,29)(H,27,30)(H,28,31)",OLIIUAHHAZEXEX-UHFFFAOYSA-N,Protein Kinase,ROCK2,9475,O75116,,Inhibitor,,63,IC50,Enzymatic inhibition assay (100 µM ATP),"https://doi.org/10.1021/jm0609014, https://doi.org/10.1042/BJ20091035 ",=,,,,,,3,KinomeScan,317,"Screened at 10 µM, closest targets as % contr.: JAK3(JH1 catalytic domain) (3.2%), PRKACA (4.2%), PRKACB (6.4%); Additionally screened against 85 kinase targets at 1 µM, closest target as % of contr.: RPS6KA2 (20%), PMID: 19740074;",https://lincs.hms.harvard.edu/db/sm/10012-101/,Kinase set,1 µM
EUB0000596aBDA_EGFR,Afatinib (dimaleate),EUB0000596aBDA,CN(C/C=C/C(=O)NC1=C(C=C2N=CN=C(C2=C1)NC3=CC(=C(C=C3)F)Cl)O[C@@H]4COCC4)C.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,"InChI=1S/C24H25ClFN5O3.2C4H4O4/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15;2*5-3(6)1-2-4(7)8/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29);2*1-2H,(H,5,6)(H,7,8)/b4-3+;2*2-1-/t16-;;/m0../s1",USNRYVNRPYXCSP-JUGPPOIOSA-N,Protein Kinase,EGFR,1956,P00533,ERBB1,Covalent inhibitor,,0.3,Kd,Competition binding assay (DiscoverX),https://lincs.hms.harvard.edu/db/datasets/20172/results,=,13,EC50,EGFR-phosphorylation in A431 cells,,=,1,KinomeScan (DiscoverX),442,"Closest targets: Kd(GAK) = 79 nM, Kd(BLK) = 220 nM, Kd(ABL,F317L) = 230 nM, Kd(IRAK1) = 240 nM, KD(EPHA6) = 340 nM, Kd(HIPK4) = 360 nM, Kd(ABL,Q252H) = 380 nM, Kd(ABL,E255K) = 420 nM, Kd(PHKG2) = 470 nM,Kd(ABL,H396P) = 500 nM, Kd(ABL,phos.) = 570 nM, Kd(LCK) = 570 nM, Kd(ABL,F317L, nonphos.) = 580 nM, Kd(ABL,F317I, phos.) = 750 nM, Kd(ABL,Q252H, nonphos.) = 790 nM, Kd(ABL,Y253F, phos.) = 830 nM, Kd(ABL,T315I, phos.) = 870 nM, Kd(DYRK1A) = 970 nM, others >1 µM; Screened also against 52 kinases, closest targets: IC50(LYN) = 736 nM, IC50(ABL,T315I)= 1180 nM, others >2 µM (PMID: 18408761)",https://lincs.hms.harvard.edu/db/sm/10133-999/,Kinase set,100 nM
EUB0000596aBDA_ERBB2,Afatinib (dimaleate),EUB0000596aBDA,CN(C/C=C/C(=O)NC1=C(C=C2N=CN=C(C2=C1)NC3=CC(=C(C=C3)F)Cl)O[C@@H]4COCC4)C.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,"InChI=1S/C24H25ClFN5O3.2C4H4O4/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15;2*5-3(6)1-2-4(7)8/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29);2*1-2H,(H,5,6)(H,7,8)/b4-3+;2*2-1-/t16-;;/m0../s1",USNRYVNRPYXCSP-JUGPPOIOSA-N,Protein Kinase,ERBB2,2064,P04626,"NEU, HER-2, CD340, HER2",Covalent inhibitor,,5,Kd,Competition binding assay (DiscoverX),https://lincs.hms.harvard.edu/db/datasets/20172/results,=,35,EC50,HER2-phosphorylation in BT-474 cells,,=,1,KinomeScan (DiscoverX),442,"Closest targets: Kd(GAK) = 79 nM, Kd(BLK) = 220 nM, Kd(ABL,F317L) = 230 nM, Kd(IRAK1) = 240 nM, KD(EPHA6) = 340 nM, Kd(HIPK4) = 360 nM, Kd(ABL,Q252H) = 380 nM, Kd(ABL,E255K) = 420 nM, Kd(PHKG2) = 470 nM,Kd(ABL,H396P) = 500 nM, Kd(ABL,phos.) = 570 nM, Kd(LCK) = 570 nM, Kd(ABL,F317L, nonphos.) = 580 nM, Kd(ABL,F317I, phos.) = 750 nM, Kd(ABL,Q252H, nonphos.) = 790 nM, Kd(ABL,Y253F, phos.) = 830 nM, Kd(ABL,T315I, phos.) = 870 nM, Kd(DYRK1A) = 970 nM, others >1 µM; Screened also against 52 kinases, closest targets: IC50(LYN) = 736 nM, IC50(ABL,T315I)= 1180 nM, others >2 µM (PMID: 18408761)",https://lincs.hms.harvard.edu/db/sm/10133-999/,Kinase set,100 nM
EUB0000596aBDA_ERBB4,Afatinib (dimaleate),EUB0000596aBDA,CN(C/C=C/C(=O)NC1=C(C=C2N=CN=C(C2=C1)NC3=CC(=C(C=C3)F)Cl)O[C@@H]4COCC4)C.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,"InChI=1S/C24H25ClFN5O3.2C4H4O4/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15;2*5-3(6)1-2-4(7)8/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29);2*1-2H,(H,5,6)(H,7,8)/b4-3+;2*2-1-/t16-;;/m0../s1",USNRYVNRPYXCSP-JUGPPOIOSA-N,Protein Kinase,ERBB4,2066,Q15303,"ALS19, HER4",Covalent inhibitor,,6.3,Kd,Competition binding assay (DiscoverX),https://lincs.hms.harvard.edu/db/datasets/20172/results,=,,,,,,1,KinomeScan (DiscoverX),442,"Closest targets: Kd(GAK) = 79 nM, Kd(BLK) = 220 nM, Kd(ABL,F317L) = 230 nM, Kd(IRAK1) = 240 nM, KD(EPHA6) = 340 nM, Kd(HIPK4) = 360 nM, Kd(ABL,Q252H) = 380 nM, Kd(ABL,E255K) = 420 nM, Kd(PHKG2) = 470 nM,Kd(ABL,H396P) = 500 nM, Kd(ABL,phos.) = 570 nM, Kd(LCK) = 570 nM, Kd(ABL,F317L, nonphos.) = 580 nM, Kd(ABL,F317I, phos.) = 750 nM, Kd(ABL,Q252H, nonphos.) = 790 nM, Kd(ABL,Y253F, phos.) = 830 nM, Kd(ABL,T315I, phos.) = 870 nM, Kd(DYRK1A) = 970 nM, others >1 µM; Screened also against 52 kinases, closest targets: IC50(LYN) = 736 nM, IC50(ABL,T315I)= 1180 nM, others >2 µM (PMID: 18408761)",https://lincs.hms.harvard.edu/db/sm/10133-999/,Kinase set,100 nM
EUB0000598a_CSF1R,GW 2580,EUB0000598a,NC1=NC(N)=C(CC2=CC(OC)=C(OCC3=CC=C(OC)C=C3)C=C2)C=N1,"InChI=1S/C20H22N4O3/c1-25-16-6-3-13(4-7-16)12-27-17-8-5-14(10-18(17)26-2)9-15-11-23-20(22)24-19(15)21/h3-8,10-11H,9,12H2,1-2H3,(H4,21,22,23,24)",MYQAUKPBNJWPIE-UHFFFAOYSA-N,Protein Kinase,CSF1R,1436,P07333,"C-FMS, CSFR, CD115",Inhibitor,,60,IC50,Enzymatic inhibition assay,https://doi.org/10.1073/pnas.0502000102,=,,,,,,3,KinomeScan (DiscoverX),468,"Closest targets with Kd <100 nM: NTRK2, targets with 100 nM < Kd < 1 µM: NTRK1, NTRK3, others >1 µM",https://lincs.hms.harvard.edu/db/sm/10401-101/,Kinase set,1 µM
EUB0000599a_MAP2K1,CI-1040,EUB0000599a,C1CC1CONC(=O)C2=C(C(=C(C=C2)F)F)NC3=C(C=C(C=C3)I)Cl,"InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)",GFMMXOIFOQCCGU-UHFFFAOYSA-N,Protein Kinase,MAP2K1,5604,Q02750,"MEK1, MAPKK1",Inhibitor,,120,Kd,Competition binding assay,https://doi.org/10.1038/nbt.1990,=,46,IC50,ELISA (mouse colon 26 carcinoma cells),,=,0,"Competition binding assay by Davis et.al., literature",442,"S(Kd < 300 nM) =0.0026, S(Kd < 3µM) = 0.0078",https://doi.org/10.1038/nbt.1990,Kinase set,100 nM
EUB0000599a_MAP2K2,CI-1040,EUB0000599a,C1CC1CONC(=O)C2=C(C(=C(C=C2)F)F)NC3=C(C=C(C=C3)I)Cl,"InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)",GFMMXOIFOQCCGU-UHFFFAOYSA-N,Protein Kinase,MAP2K2,5605,P36507,MEK2,Inhibitor,,370,Kd,Competition binding assay,https://doi.org/10.1038/nbt.1990,=,,,,,,0,"Competition binding assay by Davis et.al., literature",442,"S(Kd < 300 nM) =0.0026, S(Kd < 3µM) = 0.0078",https://doi.org/10.1038/nbt.1990,Kinase set,100 nM
EUB0000135b_BRAF,GDC-0879,EUB0000135b,OCCn1cc(-c2ccc3c(c2)CCC3=NO)c(-c2ccncc2)n1,"InChI=1S/C19H18N4O2/c24-10-9-23-12-17(19(21-23)13-5-7-20-8-6-13)15-1-3-16-14(11-15)2-4-18(16)22-25/h1,3,5-8,11-12,24-25H,2,4,9-10H2",DEZZLWQELQORIU-UHFFFAOYSA-N,Protein Kinase,BRAF,673,P15056,BRAF1,Inhibitor,,0.13,IC50,Radiometric assay,https://doi.org/10.1016/j.bmcl.2008.07.002,=,,,,,,1,"Kinase panel, literature",212,"Screened at 1 µM, closest target as % of contr.: RAF1 (8%)",https://doi.org/10.1016/j.bmcl.2008.07.002,Kinase set,100 nM
EUB0000603a_PLK1,GSK461364,EUB0000603a,CN1CCN(CC1)CC2=CC3=C(C=C2)N=CN3C4=CC(O[C@H](C)C5=C(C(F)(F)F)C=CC=C5)=C(S4)C(N)=O,"InChI=1S/C27H28F3N5O2S/c1-17(19-5-3-4-6-20(19)27(28,29)30)37-23-14-24(38-25(23)26(31)36)35-16-32-21-8-7-18(13-22(21)35)15-34-11-9-33(2)10-12-34/h3-8,13-14,16-17H,9-12,15H2,1-2H3,(H2,31,36)/t17-/m1/s1",ZHJGWYRLJUCMRT-QGZVFWFLSA-N,Protein Kinase,PLK1,5347,P53350,,Inhibitor,,0.5,Ki,Enzymatic Z'-LITE assay (Invitrogen),https://doi.org/10.1158/0008-5472.CAN-09-0945,<,,,,,,6,Kinase Profiler (Millipore),262,"Screened at 10 µM, closest targets as % inhibition: PDGFRA(V561D) (96%), RPS6KA6 (92%), RPS6KA3(92%), PKN2(92%), RPS6KA1(91%), PIM1 (90%); Screened against 48 kinases (GlaxoSmithKline panel), closest target: IC50(NEK2) = 158 nM;",https://doi.org/10.1158/0008-5472.CAN-09-0945,Kinase set,100 nM
EUB0000056c_MAPKAPK2,PF 3644022,EUB0000056c,O=C(N[C@H](C)CN4)C3=C4C1=C(S3)C=CC2=C1C=CC(C5=CC=C(C)N=C5)=N2,"InChI=1S/C21H18N4OS/c1-11-3-4-13(10-22-11)15-6-5-14-16(25-15)7-8-17-18(14)19-20(27-17)21(26)24-12(2)9-23-19/h3-8,10,12,23H,9H2,1-2H3,(H,24,26)/t12-/m1/s1",CMWRPDHVGMHLSZ-GFCCVEGCSA-N,Protein Kinase,MAPKAPK2,9261,P49137,MK2,Inhibitor,,5,IC50,Enzymatic activity assay (Ustate kinase profiler Service; Millipore),https://doi.org/10.1124/jpet.110.166173,=,201,IC50,Western Blot (phosphorylation of the MK2 substrate HSP27 in U937 cells),,=,6,Upstate Kinase Profiler service (Millipore),170,"Screened at 1 µM, closest targets: IC50(AMPK) = 117 nM, IC50(BRSK1) = 187 nM, IC50(BRSK2) = 90 nM, IC50(CAMK2B) = 70 nM, IC50(DRAK1) = 71 nM, IC50(MNK2) = 148 nM, IC50(PHKG2) = 528 nM , IC50(PIM1) = 88 nM ,IC50(CDK1) = 354 nM, IC50(CDK5) = 902 nM, IC50(MAP3K5) = 60 nM, IC50(AXL) = 428 nM, IC50(MERTK) = 76 nM, IC50(RIPK2) = 590 nM;",https://doi.org/10.1124/jpet.110.166173,Kinase set,1 µM
EUB0000056c_MAPKAPK3,PF 3644022,EUB0000056c,O=C(N[C@H](C)CN4)C3=C4C1=C(S3)C=CC2=C1C=CC(C5=CC=C(C)N=C5)=N2,"InChI=1S/C21H18N4OS/c1-11-3-4-13(10-22-11)15-6-5-14-16(25-15)7-8-17-18(14)19-20(27-17)21(26)24-12(2)9-23-19/h3-8,10,12,23H,9H2,1-2H3,(H,24,26)/t12-/m1/s1",CMWRPDHVGMHLSZ-GFCCVEGCSA-N,Protein Kinase,MAPKAPK3,7867,Q16644,"3pK, MAPKAP3, 3PK, MK-3, MK3",Inhibitor,,53,IC50,Enzymatic activity assay (Ustate kinase profiler Service; Millipore),https://doi.org/10.1124/jpet.110.166173,=,,,,,,6,Upstate Kinase Profiler service (Millipore),170,"Screened at 1 µM, closest targets: IC50(AMPK) = 117 nM, IC50(BRSK1) = 187 nM, IC50(BRSK2) = 90 nM, IC50(CAMK2B) = 70 nM, IC50(DRAK1) = 71 nM, IC50(MNK2) = 148 nM, IC50(PHKG2) = 528 nM , IC50(PIM1) = 88 nM ,IC50(CDK1) = 354 nM, IC50(CDK5) = 902 nM, IC50(MAP3K5) = 60 nM, IC50(AXL) = 428 nM, IC50(MERTK) = 76 nM, IC50(RIPK2) = 590 nM;",https://doi.org/10.1124/jpet.110.166173,Kinase set,1 µM
EUB0000056c_MAPKAPK5,PF 3644022,EUB0000056c,O=C(N[C@H](C)CN4)C3=C4C1=C(S3)C=CC2=C1C=CC(C5=CC=C(C)N=C5)=N2,"InChI=1S/C21H18N4OS/c1-11-3-4-13(10-22-11)15-6-5-14-16(25-15)7-8-17-18(14)19-20(27-17)21(26)24-12(2)9-23-19/h3-8,10,12,23H,9H2,1-2H3,(H,24,26)/t12-/m1/s1",CMWRPDHVGMHLSZ-GFCCVEGCSA-N,Protein Kinase,MAPKAPK5,8550,Q8IW41,"PRAK, MK5",Inhibitor,,5,IC50,Enzymatic activity assay (Ustate kinase profiler Service; Millipore),https://doi.org/10.1124/jpet.110.166173,=,,,,,,6,Upstate Kinase Profiler service (Millipore),170,"Screened at 1 µM, closest targets: IC50(AMPK) = 117 nM, IC50(BRSK1) = 187 nM, IC50(BRSK2) = 90 nM, IC50(CAMK2B) = 70 nM, IC50(DRAK1) = 71 nM, IC50(MNK2) = 148 nM, IC50(PHKG2) = 528 nM , IC50(PIM1) = 88 nM ,IC50(CDK1) = 354 nM, IC50(CDK5) = 902 nM, IC50(MAP3K5) = 60 nM, IC50(AXL) = 428 nM, IC50(MERTK) = 76 nM, IC50(RIPK2) = 590 nM;",https://doi.org/10.1124/jpet.110.166173,Kinase set,1 µM
EUB0000608a_TTK,Mps1-IN-2,EUB0000608a,OC1CCN(C2=CC(OCC)=C(NC3=NC=C(N(C)C(CCN4C5CCCC5)=O)C4=N3)C=C2)CC1,"InChI=1S/C26H36N6O3/c1-3-35-23-16-19(31-13-10-20(33)11-14-31)8-9-21(23)28-26-27-17-22-25(29-26)32(18-6-4-5-7-18)15-12-24(34)30(22)2/h8-9,16-18,20,33H,3-7,10-15H2,1-2H3,(H,27,28,29)",WELBJLUKWAJOQV-UHFFFAOYSA-N,Protein Kinase,TTK,7272,P33981,"MPS1, MPS1L1, CT96, MPH1",Inhibitor,,12,Kd,Ambit Competition binding assay,https://doi.org/10.1038/nchembio.345,=,,,,,,1,Ambit kinase binding assay panel,352,"Screened at 10 µM, closest targets as % of contr.: PLK1(4.3%); In vitro follow up of closest targets: IC50(GAK) = 140 nM, IC50(PLK1/3/4) = 61/ 1600/ 3100 nM, IC50(STK33) = 5000 nM",https://doi.org/10.1038/nchembio.345,Kinase set,1 µM
EUB0000608a_PLK1,Mps1-IN-2,EUB0000608a,OC1CCN(C2=CC(OCC)=C(NC3=NC=C(N(C)C(CCN4C5CCCC5)=O)C4=N3)C=C2)CC1,"InChI=1S/C26H36N6O3/c1-3-35-23-16-19(31-13-10-20(33)11-14-31)8-9-21(23)28-26-27-17-22-25(29-26)32(18-6-4-5-7-18)15-12-24(34)30(22)2/h8-9,16-18,20,33H,3-7,10-15H2,1-2H3,(H,27,28,29)",WELBJLUKWAJOQV-UHFFFAOYSA-N,Protein Kinase,PLK1,5347,P53350,,Inhibitor,,61,Kd,Ambit Competition binding assay,https://doi.org/10.1038/nchembio.345,=,,,,,,1,Ambit kinase binding assay panel,352,"Screened at 10 µM, closest targets as % of contr.: PLK1(4.3%); In vitro follow up of closest targets: IC50(GAK) = 140 nM, IC50(PLK1/3/4) = 61/ 1600/ 3100 nM, IC50(STK33) = 5000 nM",https://doi.org/10.1038/nchembio.345,Kinase set,1 µM
EUB0000609a_TTK,Mps1-IN-1,EUB0000609a,COC1=C(NC2=CC(NC3=CC=CC=C3S(C(C)C)(=O)=O)=C(C=CN4)C4=N2)C=CC(N5CCC(O)CC5)=C1,"InChI=1S/C28H33N5O4S/c1-18(2)38(35,36)26-7-5-4-6-23(26)30-24-17-27(32-28-21(24)10-13-29-28)31-22-9-8-19(16-25(22)37-3)33-14-11-20(34)12-15-33/h4-10,13,16-18,20,34H,11-12,14-15H2,1-3H3,(H3,29,30,31,32)",NMJMRSQTDLRCRQ-UHFFFAOYSA-N,Protein Kinase,TTK,7272,P33981,"MPS1, MPS1L1, CT96, MPH1",Inhibitor,,27,Kd,Ambit Competition binding assay,https://doi.org/10.1038/nchembio.345,=,,,,,,13,Ambit kinase binding assay panel,352,"Screened at 10 µM, closest targets as % of contr.: ALK(8.9%), CLK1(7.3%), ERK2(6%), GAK(5.4%), IGF1R(0.9%), INSR(0.15%), INSRR(2%), JNK1(5.2%), LTK(1.2%), MEK4(6.2%), PRK2(0.1%), PTK2B(0.5%), RIOK3(0.5%); In vitro follow up of closest targets: IC50(ALK) = 21 nM, IC50(CLK1) = 1900 nM, IC50(ERK2) = 2900 nM, IC50(FAK) = 440 nM, IC50(GAK) = 1100 nM, IC50(IGF1R) = 750 nM, IC50(INSR) = 470 nM, IC50(INSRR) = 1200 nM, IC50(LTK) = 29 nM, IC50(PYK2) = 280 nM, IC50(TNK1) = 2600 nM, IC50(TNK2) = 3100 nM;",https://doi.org/10.1038/nchembio.345,Kinase set,1 µM
EUB0000143b_EPHA2,NVP-BHG712,EUB0000143b,Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1Nc1nc(-c2cccnc2)nc2c1cnn2C,"InChI=1S/C26H20F3N7O/c1-15-8-9-16(25(37)32-19-7-3-6-18(12-19)26(27,28)29)11-21(15)33-23-20-14-31-36(2)24(20)35-22(34-23)17-5-4-10-30-13-17/h3-14H,1-2H3,(H,32,37)(H,33,34,35)",ZCCPLJOKGAACRT-UHFFFAOYSA-N,Protein Kinase,EPHA2,1969,P29317,,Inhibitor,,13,IC50,Microscale thermophoresis (MST) assay,https://doi.org/10.1002/cmdc.201800398,=,3,IC50,NanoBRET assay (HEK293T cells),,=,1,"Kinobeads competition assays (Proteomics), literature",1483,"Closest targets: Kd(EPHA5) = 37.9 nM, other targets with low Kd values determined, however targets areof low- to no confidence; Cellular potency of closely related targets (NanoBRET assay in HEK293T cells): IC50(EPHA1) = 330 nM, IC50(EPHA3) = 1000 nM, IC50(EPHA4) = 100 nM, IC50(EPHA5) = 37 nM, IC50(EPHA6) = 2000 nM, IC50(EPHA7) = 2000 nM, IC50(EPHA8) = 12 nM, IC50(EPHB1) = 1000 nM, IC50(EPHB2) = 37 nM, IC50(EPHB3) = 330 nM, IC50(EPHB6) = 330 nM;Screened against 40 kinases in TR-FRET-based LanthaScreen™ and Caliper mobility shift assays, closest targets: IC50(RAF1) = 395 nM, IC50(c-Sarc) = 1266 nM, IC50(c-ABL) = 1667 nM, others >10 µM (PMID: 20803239)",https://doi.org/10.1002/cmdc.201800398,Kinase set,100 nM
EUB0000143b_EPHB4,NVP-BHG712,EUB0000143b,Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1Nc1nc(-c2cccnc2)nc2c1cnn2C,"InChI=1S/C26H20F3N7O/c1-15-8-9-16(25(37)32-19-7-3-6-18(12-19)26(27,28)29)11-21(15)33-23-20-14-31-36(2)24(20)35-22(34-23)17-5-4-10-30-13-17/h3-14H,1-2H3,(H,32,37)(H,33,34,35)",ZCCPLJOKGAACRT-UHFFFAOYSA-N,Protein Kinase,EPHB4,2050,P54760,Tyro11,Inhibitor,,6,IC50,Microscale thermophoresis (MST) assay,https://doi.org/10.1002/cmdc.201800398,=,3,IC50,NanoBRET assay (HEK293T cells),,=,1,"Kinobeads competition assays (Proteomics), literature",1483,"Closest targets: Kd(EPHA5) = 37.9 nM, other targets with low Kd values determined, however targets areof low- to no confidence; Cellular potency of closely related targets (NanoBRET assay in HEK293T cells): IC50(EPHA1) = 330 nM, IC50(EPHA3) = 1000 nM, IC50(EPHA4) = 100 nM, IC50(EPHA5) = 37 nM, IC50(EPHA6) = 2000 nM, IC50(EPHA7) = 2000 nM, IC50(EPHA8) = 12 nM, IC50(EPHB1) = 1000 nM, IC50(EPHB2) = 37 nM, IC50(EPHB3) = 330 nM, IC50(EPHB6) = 330 nM;Screened against 40 kinases in TR-FRET-based LanthaScreen™ and Caliper mobility shift assays, closest targets: IC50(RAF1) = 395 nM, IC50(c-Sarc) = 1266 nM, IC50(c-ABL) = 1667 nM, others >10 µM (PMID: 20803239)",https://doi.org/10.1002/cmdc.201800398,Kinase set,100 nM
EUB0000153b_PDPK1,GSK2334470,EUB0000153b,CNc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2C[C@@H](C(=O)NC3CCCCC3)CC[C@H]2C)n1,"InChI=1S/C25H34N8O/c1-15-8-9-17(24(34)28-18-6-4-3-5-7-18)14-33(15)22-13-20(29-25(27-2)30-22)16-10-11-19-21(12-16)31-32-23(19)26/h10-13,15,17-18H,3-9,14H2,1-2H3,(H,28,34)(H3,26,31,32)(H,27,29,30)/t15-,17+/m1/s1",QLPHOXTXAKOFMU-WBVHZDCISA-N,Protein Kinase,PDPK1,5170,O15530,PDK1,Inhibitor,,2.5,IC50,Enzymatic inhibition assay,https://doi.org/10.1021/jm101527u,=,,,,,,7,Kinase panel (Millipore),285,"Screened at 10 µM, closest targets as % of contr.: SGK2 (0%), PRKX (4%), RSK4 (12%), SGK (13%), RSK3 (14%), NUAK1 (16%), ROCK2 (17%); Screened against panel of 13 kinases (PDK, AKT1, ALK5, ASK1, AURA, AURB, EGFR, GSK3B, IKK1, PIK3CG, ROCK1, SYK, VEGFR2): IC50(ODK) = 2.5 nM, IC50(AURB) = 3162 nM, IC50(ROCK1) = 7943 nM, others >10 µM;",https://doi.org/10.1021/jm101527u,Kinase set,1 µM
EUB0000613a_CSNK2A1,CX-4945,EUB0000613a,OC(C1=CC2=NC(NC3=CC(Cl)=CC=C3)=C(C=CN=C4)C4=C2C=C1)=O,"InChI=1S/C19H12ClN3O2/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18/h1-10H,(H,22,23)(H,24,25)",MUOKSQABCJCOPU-UHFFFAOYSA-N,Protein Kinase,CSNK2A1,1457,P68400,"Cka1, Cka2",Inhibitor,,1,IC50,Radiometric activity assay (15 µM ATP),https://doi.org/10.1021/jm101251q,=,,,,,,7,Kinase panel (Millipore),238,"Screened at 0.5 µM, closest targets: IC50(DAPK3) = 17 nM, IC50(FLT3) = 35 nM, IC50(TBK1) = 35 nM, IC50(CLK3) = 41 nM, IC50(HIPK3) = 45 nM, IC50(PIM1) = 46 nM, IC50(CDK1/cyclinB) = 56 nM (radiometric filter-binding assay, conc. ATP = Km); Follow-up in cellular assays: IC50(FLT3/ PIM1/ CDK1) >10 µM;",https://doi.org/10.1021/jm101251q,Kinase set,1 µM
EUB0000614a_IGF1R,Linsitinib,EUB0000614a,NC1=NC=CN2C1=C(C3=CC(N=C(C4=CC=CC=C4)C=C5)=C5C=C3)N=C2[C@H]6C[C@@](C)(O)C6,"InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)/t19-,26+",PKCDDUHJAFVJJB-VLZXCDOPSA-N,Protein Kinase,IGF1R,3480,P08069,"JTK13, CD221, IGFIR, MGC18216, IGFR",Inhibitor,,35,IC50,Radiometric kinase assay (100 µM ATP),https://doi.org/10.4155/fmc.09.89,=,24,IC50,Immunoblot (IGF-1-dependent autophosphorylation of IGF-1R in LISN cells),,=,2,"Kinobeads, literature",224,"Screened at 1 µM, closest targets as % inhibition: MAP4K2 (99%), MET(86%); Screened also with ProfilerPro® Kinase Selectivity Assay Kit (Caliper Life Sciences) at 1 µM, 88 kinases <50% inhibition, clean in IC50 follow up assay: IC50 >10 µM (PMID: 21425998)",https://doi.org/10.1126/science.aan4368,Kinase set,1 µM
EUB0000614a_INSR,Linsitinib,EUB0000614a,NC1=NC=CN2C1=C(C3=CC(N=C(C4=CC=CC=C4)C=C5)=C5C=C3)N=C2[C@H]6C[C@@](C)(O)C6,"InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)/t19-,26+",PKCDDUHJAFVJJB-VLZXCDOPSA-N,Protein Kinase,INSR,3643,P06213,CD220,Inhibitor,,75,IC50,Radiometric kinase assay (100 µM ATP),https://doi.org/10.4155/fmc.09.89,=,,,,,,2,"Kinobeads, literature",224,"Screened at 1 µM, closest targets as % inhibition: MAP4K2 (99%), MET(86%); Screened also with ProfilerPro® Kinase Selectivity Assay Kit (Caliper Life Sciences) at 1 µM, 88 kinases <50% inhibition, clean in IC50 follow up assay: IC50 >10 µM (PMID: 21425998)",https://doi.org/10.1126/science.aan4368,Kinase set,1 µM
EUB0000614a_INSRR,Linsitinib,EUB0000614a,NC1=NC=CN2C1=C(C3=CC(N=C(C4=CC=CC=C4)C=C5)=C5C=C3)N=C2[C@H]6C[C@@](C)(O)C6,"InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)/t19-,26+",PKCDDUHJAFVJJB-VLZXCDOPSA-N,Protein Kinase,INSRR,3645,P14616,IRR,Inhibitor,,75,IC50,Radiometric kinase assay (100 µM ATP),https://doi.org/10.4155/fmc.09.89,=,,,,,,2,"Kinobeads, literature",224,"Screened at 1 µM, closest targets as % inhibition: MAP4K2 (99%), MET(86%); Screened also with ProfilerPro® Kinase Selectivity Assay Kit (Caliper Life Sciences) at 1 µM, 88 kinases <50% inhibition, clean in IC50 follow up assay: IC50 >10 µM (PMID: 21425998)",https://doi.org/10.1126/science.aan4368,Kinase set,1 µM
EUB0000619a_MET,PF-04217903,EUB0000619a,OCCN(N=C1)C=C1C2=CN=C3C(N(CC4=CC=C5C(C=CC=N5)=C4)N=N3)=N2,"InChI=1S/C19H16N8O/c28-7-6-26-12-15(9-22-26)17-10-21-18-19(23-17)27(25-24-18)11-13-3-4-16-14(8-13)2-1-5-20-16/h1-5,8-10,12,28H,6-7,11H2",PDMUGYOXRHVNMO-UHFFFAOYSA-N,Protein Kinase,MET,4233,P08581,"HGFR, RCCP2, DFNB97",Inhibitor,,4.8,Ki,Continuous-coupled spectrophotometric assay (detecting ADP production),https://doi.org/10.1158/1535-7163.MCT-11-0839,=,5,IC50,ELISA (c-Met phosphorylation in HT29 cells),,=,0,Kinase panel (Invitrogen),125,"Screened at 1 µM and 10 µM, no target >50% inhibition; Screened in Dundee panel (51 kinases at 10 µM), no target >50% inhibition; Screened in Pfizer panel (48 kinases), no target >50% inhibition; Screened in Millipore panel (105 kinases at 1 µM an 10 µM), closest targets: ALK, EpHB2, INSR; IC50 follow-up showed all IC50 >10 µM; PF-04217903 is >1000-fold selective for c-Met;",https://doi.org/10.1021/bi900438w,Kinase set,1 µM
EUB0000622a_LRRK2,GSK2578215A,EUB0000622a,O=C(C1=C(OCC2=CC=CC=C2)C=CC(C3=CC(F)=NC=C3)=C1)NC4=CC=CN=C4,"InChI=1S/C24H18FN3O2/c25-23-14-19(10-12-27-23)18-8-9-22(30-16-17-5-2-1-3-6-17)21(13-18)24(29)28-20-7-4-11-26-15-20/h1-15H,16H2,(H,28,29)",WCIGMFCFPXZRMQ-UHFFFAOYSA-N,Protein Kinase,LRRK2,120892,Q5S007,"ROCO2, DKFZp434H2111, FLJ45829, RIPK7",Inhibitor,,10.9,IC50,HTRF assay,https://doi.org/10.1016/j.bmcl.2012.06.104,=,,,,,,3,KinomScan Ambit,329,"Screened at 10 µM, Ambit score <10 at 10 µM, off-targets with PoC <50%",https://doi.org/10.1016/j.bmcl.2012.06.104,Kinase set,1 µM
EUB0000624a_MST1R,BMS 777607,EUB0000624a,CCOC1=C(C(=O)N(C=C1)C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C(=NC=C4)N)Cl)F,"InChI=1S/C25H19ClF2N4O4/c1-2-35-19-10-12-32(16-6-3-14(27)4-7-16)25(34)21(19)24(33)31-15-5-8-18(17(28)13-15)36-20-9-11-30-23(29)22(20)26/h3-13H,2H2,1H3,(H2,29,30)(H,31,33)",VNBRGSXVFBYQNN-UHFFFAOYSA-N,Protein Kinase,MST1R,4486,Q04912,"CDw136, CD136",Inhibitor,,1.8,IC50,Enzyme activity assay,https://doi.org/10.1021/jm801586s ,=,,,,,,20,Ambit kinome screening platform,200,"Screened at 10 µM (Ambit phage-based competition binding assay), closest targets as % of contr.: FRK (0.55%), FLT4 (0.85%), FLT3 (0.05%), EPHA3 (0.1%), CSF1R (0.8%), BLK (0.35%), STK10 (0%), AURKB (0%), KIT (0%), LCK (0.2%), MUSK (0%), PDGFRA/B (0.2/0.7%), TEK (0.15%), NTRK1/2/3 (0.55/ 0.1/ 0.1%), KDR (0.2%), MKNK2 (0.75%); In vitro follow up of closest targets: IC50(MERTK) = 14 nM, IC50(FLT3) = 16 nM, IC50(AURKB) = 78 nM, IC50(LCK) = 120 nM, IC50(KDR) = 180 nM, IC50(NTRK1/2) = 290/ 190 nM, IC50(PKA) = 550, IC50 >2 µM for: BTK, CDK2E, EGFR, GSK3B, IGFR1R, IKK1/2, INSR, JAK2, MAPKAPK2, MAPK14, PIM1, PLK1/3",https://doi.org/10.1021/jm801586s ,Kinase set,1 µM
EUB0000624a_MET,BMS 777607,EUB0000624a,CCOC1=C(C(=O)N(C=C1)C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C(=NC=C4)N)Cl)F,"InChI=1S/C25H19ClF2N4O4/c1-2-35-19-10-12-32(16-6-3-14(27)4-7-16)25(34)21(19)24(33)31-15-5-8-18(17(28)13-15)36-20-9-11-30-23(29)22(20)26/h3-13H,2H2,1H3,(H2,29,30)(H,31,33)",VNBRGSXVFBYQNN-UHFFFAOYSA-N,Protein Kinase,MET,4233,P08581,"HGFR, RCCP2, DFNB97",Inhibitor,,3.9,IC50,Enzyme activity assay,https://doi.org/10.1021/jm801586s ,=,,,,,,20,Ambit kinome screening platform,200,"Screened at 10 µM (Ambit phage-based competition binding assay), closest targets as % of contr.: FRK (0.55%), FLT4 (0.85%), FLT3 (0.05%), EPHA3 (0.1%), CSF1R (0.8%), BLK (0.35%), STK10 (0%), AURKB (0%), KIT (0%), LCK (0.2%), MUSK (0%), PDGFRA/B (0.2/0.7%), TEK (0.15%), NTRK1/2/3 (0.55/ 0.1/ 0.1%), KDR (0.2%), MKNK2 (0.75%); In vitro follow up of closest targets: IC50(MERTK) = 14 nM, IC50(FLT3) = 16 nM, IC50(AURKB) = 78 nM, IC50(LCK) = 120 nM, IC50(KDR) = 180 nM, IC50(NTRK1/2) = 290/ 190 nM, IC50(PKA) = 550, IC50 >2 µM for: BTK, CDK2E, EGFR, GSK3B, IGFR1R, IKK1/2, INSR, JAK2, MAPKAPK2, MAPK14, PIM1, PLK1/3",https://doi.org/10.1021/jm801586s ,Kinase set,1 µM
EUB0000624a_TYRO3,BMS 777607,EUB0000624a,CCOC1=C(C(=O)N(C=C1)C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C(=NC=C4)N)Cl)F,"InChI=1S/C25H19ClF2N4O4/c1-2-35-19-10-12-32(16-6-3-14(27)4-7-16)25(34)21(19)24(33)31-15-5-8-18(17(28)13-15)36-20-9-11-30-23(29)22(20)26/h3-13H,2H2,1H3,(H2,29,30)(H,31,33)",VNBRGSXVFBYQNN-UHFFFAOYSA-N,Protein Kinase,TYRO3,7301,Q06418,"Dtk, Brt, Tif, Sky, Etk-2, Rek",Inhibitor,,4.3,IC50,Enzyme activity assay,https://doi.org/10.1021/jm801586s ,=,,,,,,20,Ambit kinome screening platform,200,"Screened at 10 µM (Ambit phage-based competition binding assay), closest targets as % of contr.: FRK (0.55%), FLT4 (0.85%), FLT3 (0.05%), EPHA3 (0.1%), CSF1R (0.8%), BLK (0.35%), STK10 (0%), AURKB (0%), KIT (0%), LCK (0.2%), MUSK (0%), PDGFRA/B (0.2/0.7%), TEK (0.15%), NTRK1/2/3 (0.55/ 0.1/ 0.1%), KDR (0.2%), MKNK2 (0.75%); In vitro follow up of closest targets: IC50(MERTK) = 14 nM, IC50(FLT3) = 16 nM, IC50(AURKB) = 78 nM, IC50(LCK) = 120 nM, IC50(KDR) = 180 nM, IC50(NTRK1/2) = 290/ 190 nM, IC50(PKA) = 550, IC50 >2 µM for: BTK, CDK2E, EGFR, GSK3B, IGFR1R, IKK1/2, INSR, JAK2, MAPKAPK2, MAPK14, PIM1, PLK1/3",https://doi.org/10.1021/jm801586s ,Kinase set,1 µM
EUB0000624a_AXL,BMS 777607,EUB0000624a,CCOC1=C(C(=O)N(C=C1)C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C(=NC=C4)N)Cl)F,"InChI=1S/C25H19ClF2N4O4/c1-2-35-19-10-12-32(16-6-3-14(27)4-7-16)25(34)21(19)24(33)31-15-5-8-18(17(28)13-15)36-20-9-11-30-23(29)22(20)26/h3-13H,2H2,1H3,(H2,29,30)(H,31,33)",VNBRGSXVFBYQNN-UHFFFAOYSA-N,Protein Kinase,AXL,558,P30530,"UFO, JTK11, Tyro7, ARK",Inhibitor,,1.1,IC50,Enzyme activity assay,https://doi.org/10.1021/jm801586s ,=,,,,,,20,Ambit kinome screening platform,200,"Screened at 10 µM (Ambit phage-based competition binding assay), closest targets as % of contr.: FRK (0.55%), FLT4 (0.85%), FLT3 (0.05%), EPHA3 (0.1%), CSF1R (0.8%), BLK (0.35%), STK10 (0%), AURKB (0%), KIT (0%), LCK (0.2%), MUSK (0%), PDGFRA/B (0.2/0.7%), TEK (0.15%), NTRK1/2/3 (0.55/ 0.1/ 0.1%), KDR (0.2%), MKNK2 (0.75%); In vitro follow up of closest targets: IC50(MERTK) = 14 nM, IC50(FLT3) = 16 nM, IC50(AURKB) = 78 nM, IC50(LCK) = 120 nM, IC50(KDR) = 180 nM, IC50(NTRK1/2) = 290/ 190 nM, IC50(PKA) = 550, IC50 >2 µM for: BTK, CDK2E, EGFR, GSK3B, IGFR1R, IKK1/2, INSR, JAK2, MAPKAPK2, MAPK14, PIM1, PLK1/3",https://doi.org/10.1021/jm801586s ,Kinase set,1 µM
EUB0000626a_JAK1@kinase 1,Filgotinib,EUB0000626a,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,"InChI=1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27)",RIJLVEAXPNLDTC-UHFFFAOYSA-N,Protein Kinase,JAK1@kinase 1,3716,P23458,"JAK1A, JTK3",Inhibitor,,10,IC50,Radiometric kinase assay (incorporation of phosphate into an ULight-JAK-1(Tyr1023) peptide using an europium-labeled anti-phosphotyrosine Ab),https://doi.org/10.4049/jimmunol.1201348,=,,,,,,4,Radioactive biochemical assays (Millipore and Galapagos N.V.),175,"Screened at 1 µM, closest targets: IC50( FLT3) = 338 nM, IC50(FLT4) = 274 nM, IC50(CSF1R) = 488.9 nM, IC50(TYK2) = 116 nM",https://doi.org/10.4049/jimmunol.1201348,Kinase set,1 µM
EUB0000626a_JAK2@kinase 1,Filgotinib,EUB0000626a,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,"InChI=1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27)",RIJLVEAXPNLDTC-UHFFFAOYSA-N,Protein Kinase,JAK2@kinase 1,3717,O60674,JTK10,Inhibitor,,28,IC50,Radiometric kinase assay (incorporation of phosphate into an ULight-JAK-1(Tyr1023) peptide using an europium-labeled anti-phosphotyrosine Ab),https://doi.org/10.4049/jimmunol.1201348,=,,,,,,4,Radioactive biochemical assays (Millipore and Galapagos N.V.),175,"Screened at 1 µM, closest targets: IC50( FLT3) = 338 nM, IC50(FLT4) = 274 nM, IC50(CSF1R) = 488.9 nM, IC50(TYK2) = 116 nM",https://doi.org/10.4049/jimmunol.1201348,Kinase set,1 µM
EUB0000627a_NUAK1,WZ4003,EUB0000627a,CN1CCN(C2=CC=C(NC3=NC=C(Cl)C(OC4=CC=CC(NC(CC)=O)=C4)=N3)C(OC)=C2)CC1,"InChI=1S/C25H29ClN6O3/c1-4-23(33)28-17-6-5-7-19(14-17)35-24-20(26)16-27-25(30-24)29-21-9-8-18(15-22(21)34-3)32-12-10-31(2)11-13-32/h5-9,14-16H,4,10-13H2,1-3H3,(H,28,33)(H,27,29,30)",SDGJBAUIGHSMRI-UHFFFAOYSA-N,Protein Kinase,NUAK1,9891,O60285,"ARK5, KIAA0537",Inhibitor,,20,IC50,Radiometric kinase assay,https://doi.org/10.1042/BJ20131152,=,,,,,,0,Kinase panel (international centre for protein kinase profiling),140,"Screened at1 µM, closest targets as % of kinase activity.: STK33 (33%), ULK2 (37%)",https://doi.org/10.1042/BJ20131152,Kinase set,1 µM
EUB0000627a_NUAK2,WZ4003,EUB0000627a,CN1CCN(C2=CC=C(NC3=NC=C(Cl)C(OC4=CC=CC(NC(CC)=O)=C4)=N3)C(OC)=C2)CC1,"InChI=1S/C25H29ClN6O3/c1-4-23(33)28-17-6-5-7-19(14-17)35-24-20(26)16-27-25(30-24)29-21-9-8-18(15-22(21)34-3)32-12-10-31(2)11-13-32/h5-9,14-16H,4,10-13H2,1-3H3,(H,28,33)(H,27,29,30)",SDGJBAUIGHSMRI-UHFFFAOYSA-N,Protein Kinase,NUAK2,81788,Q9H093,"SNARK, FLJ90349",Inhibitor,,100,IC50,Radiometric kinase assay,https://doi.org/10.1042/BJ20131152,=,,,,,,0,Kinase panel (international centre for protein kinase profiling),140,"Screened at1 µM, closest targets as % of kinase activity.: STK33 (33%), ULK2 (37%)",https://doi.org/10.1042/BJ20131152,Kinase set,1 µM
EUB0000629a_LRRK2,GNE-9605,EUB0000629a,CNC1=C(C(F)(F)F)C=NC(NC2=C(Cl)N([C@H]3CCN(C4COC4)C[C@@H]3F)N=C2)=N1,"InChI=1S/C17H20ClF4N7O/c1-23-15-10(17(20,21)22)4-24-16(27-15)26-12-5-25-29(14(12)18)13-2-3-28(6-11(13)19)9-7-30-8-9/h4-5,9,11,13H,2-3,6-8H2,1H3,(H2,23,24,26,27)/t11-,13-/m0/s1",PUXPEQJKNAWNQA-AAEUAGOBSA-N,Protein Kinase,LRRK2,120892,Q5S007,"ROCO2, DKFZp434H2111, FLJ45829, RIPK7",Inhibitor,,2,Ki,Biochemical assay,https://doi.org/10.1021/jm401654j,=,19,IC50,Cellular assay (LRRK2 phosphorylation),,=,1,KinomeScan (Invitrogen),178,"Screened at 0.1 µM, closest targets with PoC <50%, TAK1-TAB1",https://doi.org/10.1021/jm401654j,Kinase set,100 nM
EUB0000147b_MERTK,LDC1267,EUB0000147b,CCOc1cn(-c2ccc(F)cc2C)nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1,"InChI=1S/C30H26F2N4O5/c1-5-40-28-16-36(23-8-6-18(31)12-17(23)2)35-29(28)30(37)34-19-7-9-25(21(32)13-19)41-24-10-11-33-22-15-27(39-4)26(38-3)14-20(22)24/h6-16H,5H2,1-4H3,(H,34,37)",ISPBCAXOSOLFME-UHFFFAOYSA-N,Protein Kinase,MERTK,10461,Q12866,"mer, RP38, c-Eyk, Tyro12",Inhibitor,,5,IC50,HTRF assay,https://doi.org/0.1038/nature12998,=,,,,,,29,KinomeScan (DiscoverX),465,"Screened at 1 µM, closest targets with <10% of contr.: ABL1, BLK, DDR1, FLT3, KIT, LCK, STK10, MAP2K5, MET, HIPK4, AURKB/C, FER, HCK, MST1R, CDK19, FRK, SRC, TIE1, CHEK2, MUSK, CDK8, CSF1R, EPHB6, PDGFRB, ROS1, NRTK1/3, MAP4K5, and mutants; Cellular selectivity (quantitative chemical proteomics, cell-based phosphorylation and proliferation assays in Hs578t cells), closest targets: Kd(cMET) = 13 nM,Kd(FER) = 107 nM, Kd(MAP2K5) = 124 nM, Kd(ABL1) = 154 nM, Kd(SRC) = 217 nM;",https://doi.org/0.1038/nature12998,Kinase set,100 nM
EUB0000147b_TYRO3,LDC1267,EUB0000147b,CCOc1cn(-c2ccc(F)cc2C)nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1,"InChI=1S/C30H26F2N4O5/c1-5-40-28-16-36(23-8-6-18(31)12-17(23)2)35-29(28)30(37)34-19-7-9-25(21(32)13-19)41-24-10-11-33-22-15-27(39-4)26(38-3)14-20(22)24/h6-16H,5H2,1-4H3,(H,34,37)",ISPBCAXOSOLFME-UHFFFAOYSA-N,Protein Kinase,TYRO3,7301,Q06418,"Dtk, Brt, Tif, Sky, Etk-2, Rek",Inhibitor,,8,IC50,HTRF assay,https://doi.org/0.1038/nature12998,=,,,,,,29,KinomeScan (DiscoverX),465,"Screened at 1 µM, closest targets with <10% of contr.: ABL1, BLK, DDR1, FLT3, KIT, LCK, STK10, MAP2K5, MET, HIPK4, AURKB/C, FER, HCK, MST1R, CDK19, FRK, SRC, TIE1, CHEK2, MUSK, CDK8, CSF1R, EPHB6, PDGFRB, ROS1, NRTK1/3, MAP4K5, and mutants; Cellular selectivity (quantitative chemical proteomics, cell-based phosphorylation and proliferation assays in Hs578t cells), closest targets: Kd(cMET) = 13 nM,Kd(FER) = 107 nM, Kd(MAP2K5) = 124 nM, Kd(ABL1) = 154 nM, Kd(SRC) = 217 nM;",https://doi.org/0.1038/nature12998,Kinase set,100 nM
EUB0000147b_AXL,LDC1267,EUB0000147b,CCOc1cn(-c2ccc(F)cc2C)nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1,"InChI=1S/C30H26F2N4O5/c1-5-40-28-16-36(23-8-6-18(31)12-17(23)2)35-29(28)30(37)34-19-7-9-25(21(32)13-19)41-24-10-11-33-22-15-27(39-4)26(38-3)14-20(22)24/h6-16H,5H2,1-4H3,(H,34,37)",ISPBCAXOSOLFME-UHFFFAOYSA-N,Protein Kinase,AXL,558,P30530,"UFO, JTK11, Tyro7, ARK",Inhibitor,,29,IC50,HTRF assay,https://doi.org/0.1038/nature12998,=,19,Kd,Quantitative chemical proteomics in Hs578t cells,,=,29,KinomeScan (DiscoverX),465,"Screened at 1 µM, closest targets with <10% of contr.: ABL1, BLK, DDR1, FLT3, KIT, LCK, STK10, MAP2K5, MET, HIPK4, AURKB/C, FER, HCK, MST1R, CDK19, FRK, SRC, TIE1, CHEK2, MUSK, CDK8, CSF1R, EPHB6, PDGFRB, ROS1, NRTK1/3, MAP4K5, and mutants; Cellular selectivity (quantitative chemical proteomics, cell-based phosphorylation and proliferation assays in Hs578t cells), closest targets: Kd(cMET) = 13 nM,Kd(FER) = 107 nM, Kd(MAP2K5) = 124 nM, Kd(ABL1) = 154 nM, Kd(SRC) = 217 nM;",https://doi.org/0.1038/nature12998,Kinase set,100 nM
EUB0000238b_MAP4K2,TL4-12,EUB0000238b,CNc1cc(Oc2cc(C(=O)Nc3cc(N4CCN(C)CC4)cc(C(F)(F)F)c3)ccc2C)ncn1,"InChI=1S/C25H27F3N6O2/c1-16-4-5-17(10-21(16)36-23-14-22(29-2)30-15-31-23)24(35)32-19-11-18(25(26,27)28)12-20(13-19)34-8-6-33(3)7-9-34/h4-5,10-15H,6-9H2,1-3H3,(H,32,35)(H,29,30,31)",HXKJJIMUMNPQQY-UHFFFAOYSA-N,Protein Kinase,MAP4K2,5871,Q12851,"GCK, BL44",Inhibitor,,37,IC50,Enzymatic inhibition assay,https://doi.org/10.1021/jm500480k,=,,,,,,0,KiNativ profiling (A375 live cells treatment assays),220,"Screened at 1 µM, closest targets as % inhibition: ABL1(49%) and ABL2 (49%);",https://doi.org/10.1021/jm500480k,Kinase set,1 µM
EUB0000631a_PIK3C3,Vps34-IN-1,EUB0000631a,OC(C)(C)CNC1=NC(CC2CC2)=C(C3=CC=NC(NC4=CC=NC(Cl)=C4)=N3)C=N1,"InChI=1S/C21H24ClN7O/c1-21(2,30)12-26-19-25-11-15(17(29-19)9-13-3-4-13)16-6-8-24-20(28-16)27-14-5-7-23-18(22)10-14/h5-8,10-11,13,30H,3-4,9,12H2,1-2H3,(H,25,26,29)(H,23,24,27,28)",AWNXKZVIZARMME-UHFFFAOYSA-N,lipid-kinase,PIK3C3,5289,Q8NEB9,Vps34,Inhibitor,,25,IC50,Radioactive liposome kinase assay,https://doi.org/10.1042/BJ20140889,=,,,,,,0,Kinase panel (ProQinase),300,"Screened at 1 µM, >1000-fold selective against other targets; Screened in Dundee panel against 140 kinases and 19 lipid kinases at 1 µM, >1000-fold selective; Screened in AstraZeneca panel against 8 lipid kinases, closest target: IC50(PIP5K1C) = 382 µM, IC50(PI4K3B) = 1.069 µM, IC50(PI3Kd) = 1.896 µM, others >2 µM; Screened in ProQuinase panel against 13 lipid kinases at 1 µM, closest targets: IC50(PIP5K1A) = 4.93 µM, IC50(PIP5K1C) = 3.37 µM;",https://doi.org/10.1042/BJ20140889,Kinase set,1 µM
EUB0000632a_RIPK3,GSK872,EUB0000632a,CC(C)S(C1=CC(C(NC2=CC=C(SC=N3)C3=C2)=CC=N4)=C4C=C1)(=O)=O,"InChI=1S/C19H17N3O2S2/c1-12(2)26(23,24)14-4-5-16-15(10-14)17(7-8-20-16)22-13-3-6-19-18(9-13)21-11-25-19/h3-12H,1-2H3,(H,20,22)",ZCDBTQNFAPKACC-UHFFFAOYSA-N,Protein Kinase,RIPK3,11035,Q9Y572,RIP3,Inhibitor,,1.3,IC50,ADP-Glo assay,https://doi.org/10.1016/j.molcel.2014.10.021,=,,,,,,0,HotSpot assay platform (Reaction Biology),300,"Screened at 1 µM, closest targets as % of contr.: ABL (12%), BRK (13%), FYN (18%), KDR (17%)",https://doi.org/10.1016/j.molcel.2014.10.021,Kinase set,1 µM
EUB0000634a_TTK,BAY 12-17389,EUB0000634a,CC1=C(C=CC(=C1)C2=CN=C3N2N=C(C=C3NCCC(F)(F)F)OC4=C(C(=C(C=C4)OC)F)F)C(=O)NC5CC5,"InChI=1S/C27H24F5N5O3/c1-14-11-15(3-6-17(14)26(38)35-16-4-5-16)19-13-34-25-18(33-10-9-27(30,31)32)12-22(36-37(19)25)40-21-8-7-20(39-2)23(28)24(21)29/h3,6-8,11-13,16,33H,4-5,9-10H2,1-2H3,(H,35,38)",WNEILUNVMHVMPH-UHFFFAOYSA-N,Protein Kinase,TTK,7272,P33981,"MPS1, MPS1L1, CT96, MPH1",Inhibitor,,0.63,IC50,TR-FRET-based in vitro kinase assays,https://doi.org/10.1158/1535-7163.MCT-15-0500,=,,,,,,3,KinomeScan (DiscoverX),395,"Screened at 1 µM, closest targets as % of contr.: JNK2(4%), KIT(2%), PDGFRB(0%)",https://doi.org/10.1158/1535-7163.MCT-15-0500,Kinase set,1 µM
EUB0000636a_CHEK1,CCT245737,EUB0000636a,FC(F)(F)C(C=N1)=C(NC[C@@H]2OCCNC2)C=C1NC3=CN=C(C#N)C=N3,"InChI=1S/C16H16F3N7O/c17-16(18,19)12-8-25-14(26-15-9-22-10(4-20)5-24-15)3-13(12)23-7-11-6-21-1-2-27-11/h3,5,8-9,11,21H,1-2,6-7H2,(H2,23,24,25,26)/t11-/m1/s1",YBYYWUUUGCNAHQ-LLVKDONJSA-N,Protein Kinase,CHEK1,1111,O14757,CHK1,Inhibitor,,1.3,IC50,Microfluid assay (CALIPER),https://doi.org/10.1021/acs.jmedchem.5b01938,=,,,,,,6,Kinase panel (Dundee),124,"Screened at 10 µM, closest targets: IC50(MAPK15) = 130 nM, IC50(RPS6KA3) = 361 nM, IC50(RPS6KA2) = 362 nM; IC50(FLT3) = 582 nM, IC50(NUAK1) = 711 nM, IC50(CLK2) = 1370 nM (Z’-Lyte assay)",https://doi.org/10.1021/acs.jmedchem.5b01938,Kinase set,100 nM
EUB0000178b_STK3,XMU-MP-1,EUB0000178b,CN1C(=O)c2sccc2N(C)c2nc(Nc3ccc(S(N)(=O)=O)cc3)ncc21,"InChI=1S/C17H16N6O3S2/c1-22-12-7-8-27-14(12)16(24)23(2)13-9-19-17(21-15(13)22)20-10-3-5-11(6-4-10)28(18,25)26/h3-9H,1-2H3,(H2,18,25,26)(H,19,20,21)",YRDHKIFCGOZTGD-UHFFFAOYSA-N,Protein Kinase,STK3,6788,Q13188,"MST2, KRS1",Inhibitor,,11,Kd,Competition binding assay (DiscoverX),https://doi.org/10.1126/scitranslmed.aaf2304,=,,,,,,20,KinomeScan (DiscoverX),468,"Screened at 1 µM, S(10) = 0.05, closest targets as % of contr.: ABL (M351T phosph.) (5.5%), ABL (Q252H phosph.) (6.8%), ABL (T315I phosph.) (1.6%), AURKA (0.05%), AURKB (3.4%), DCAMKL1 (8.3%), MAP3K2 (2.6%), MAP3K3 (2%), JAK1 (JH2 pseudokinase domain) (4.3%), STK24 (0.9%), STK26 (0.6%), PIK3CG (0.15%), PIP5K1C (10%), PIP5K2C (8%), RIPK4 (9.5%), TAOK1 (2.6%), TAOK2 (3.4%), TAOK3 (4.5%), TYK2 (JH1 catalytic domain, 2.7%), ULK2 (4.8%); Follow-up Kds and IC50s: Kd/IC50(ABL, M351T phosph.) = 42/ 17.6 nM, KD/IC50(ABL (Q252H phosph.) = 24/ 11.6 nM, Kd/IC50(ABL, T315I phosph.) = 14/ 16.6 nM, Kd/IC50 (AURKA) = 13/ 19.4 nM, Kd/IC50(AURKB) = 40/ 19.4 nM, Kd/IC50(DCAMKL1) = 25/ 27.9 nM, Kd/IC50(MAP3K2) = 19/ 79.6 nM, Kd/IC50(MAP3K3) = 27/ 38.4 nM, Kd/IC50(JAK1, JH2 pseudokinase domain) = 22/ 38.7 nM, Kd/IC50(STK24) = 18/ 44.8 nM, Kd/IC50(STK26) = 16/ 27.3 nM, Kd/IC50(PIK3CG) = 4.8/ 38.4 nM, Kd/IC50(PIP5K1C) = 77/ 436 nM, Kd(PIP5K2C) = 34 nM, Kd(RIPK4) = 140 nM, Kd/IC50(TAOK1) = 180/ 165 nM, Kd/IC50(TAOK2) = 100/ 134 nM, Kd/IC50(TAOK3) = 610/ 254 nM, Kd/IC50(TYK2, JH1 catalytic domain) = 610/ 254 nM, Kd/IC50(ULK2) = 35/ 41.5 nM;",https://doi.org/10.1126/scitranslmed.aaf2304,Kinase set,100 nM
EUB0000178b_STK4,XMU-MP-1,EUB0000178b,CN1C(=O)c2sccc2N(C)c2nc(Nc3ccc(S(N)(=O)=O)cc3)ncc21,"InChI=1S/C17H16N6O3S2/c1-22-12-7-8-27-14(12)16(24)23(2)13-9-19-17(21-15(13)22)20-10-3-5-11(6-4-10)28(18,25)26/h3-9H,1-2H3,(H2,18,25,26)(H,19,20,21)",YRDHKIFCGOZTGD-UHFFFAOYSA-N,Protein Kinase,STK4,6789,Q13043,"MST1, KRS2, YSK3",Inhibitor,,17,Kd,Competition binding assay (DiscoverX),https://doi.org/10.1126/scitranslmed.aaf2304,=,,,,,,20,KinomeScan (DiscoverX),468,"Screened at 1 µM, S(10) = 0.05, closest targets as % of contr.: ABL (M351T phosph.) (5.5%), ABL (Q252H phosph.) (6.8%), ABL (T315I phosph.) (1.6%), AURKA (0.05%), AURKB (3.4%), DCAMKL1 (8.3%), MAP3K2 (2.6%), MAP3K3 (2%), JAK1 (JH2 pseudokinase domain) (4.3%), STK24 (0.9%), STK26 (0.6%), PIK3CG (0.15%), PIP5K1C (10%), PIP5K2C (8%), RIPK4 (9.5%), TAOK1 (2.6%), TAOK2 (3.4%), TAOK3 (4.5%), TYK2 (JH1 catalytic domain, 2.7%), ULK2 (4.8%); Follow-up Kds and IC50s: Kd/IC50(ABL, M351T phosph.) = 42/ 17.6 nM, KD/IC50(ABL (Q252H phosph.) = 24/ 11.6 nM, Kd/IC50(ABL, T315I phosph.) = 14/ 16.6 nM, Kd/IC50 (AURKA) = 13/ 19.4 nM, Kd/IC50(AURKB) = 40/ 19.4 nM, Kd/IC50(DCAMKL1) = 25/ 27.9 nM, Kd/IC50(MAP3K2) = 19/ 79.6 nM, Kd/IC50(MAP3K3) = 27/ 38.4 nM, Kd/IC50(JAK1, JH2 pseudokinase domain) = 22/ 38.7 nM, Kd/IC50(STK24) = 18/ 44.8 nM, Kd/IC50(STK26) = 16/ 27.3 nM, Kd/IC50(PIK3CG) = 4.8/ 38.4 nM, Kd/IC50(PIP5K1C) = 77/ 436 nM, Kd(PIP5K2C) = 34 nM, Kd(RIPK4) = 140 nM, Kd/IC50(TAOK1) = 180/ 165 nM, Kd/IC50(TAOK2) = 100/ 134 nM, Kd/IC50(TAOK3) = 610/ 254 nM, Kd/IC50(TYK2, JH1 catalytic domain) = 610/ 254 nM, Kd/IC50(ULK2) = 35/ 41.5 nM;",https://doi.org/10.1126/scitranslmed.aaf2304,Kinase set,100 nM
EUB0000637a_AKT1,BAY1125976,EUB0000637a,C1CC(C1)(C2=CC=C(C=C2)C3=C(N4C(=N3)C=CC(=N4)C(=O)N)C5=CC=CC=C5)N,"InChI=1S/C23H21N5O/c24-22(29)18-11-12-19-26-20(21(28(19)27-18)16-5-2-1-3-6-16)15-7-9-17(10-8-15)23(25)13-4-14-23/h1-3,5-12H,4,13-14,25H2,(H2,24,29)",JBGYKRAZYDNCNV-UHFFFAOYSA-N,Protein Kinase,AKT1,207,P31749,"RAC, PKB, PRKBA, AKT, RAC-alpha",Allosteric Inhibitor,,5.2,IC50,TR-FRET-based in vitro kinase assays (10 µM ATP),https://doi.org/10.1002/ijc.30457 ,=,0.9,IC50,TR-FRET assay (inhibition of AKT1-T308 phosphorylation in KPL-4 cells),,=,4,KinomeScan (DiscoverX),468,"Screened at 10 µM, follow-up Kds and IC50s of closest targets: Kd(FLT1,D835Y) = 210 nM, Kd(CKL1) = 310 nM, Kd(MKNK2) = 330 nM, IC50(AKT3) = 427 nM.",https://doi.org/10.1002/ijc.30457 ,Kinase set,100 nM
EUB0000637a_AKT2,BAY1125976,EUB0000637a,C1CC(C1)(C2=CC=C(C=C2)C3=C(N4C(=N3)C=CC(=N4)C(=O)N)C5=CC=CC=C5)N,"InChI=1S/C23H21N5O/c24-22(29)18-11-12-19-26-20(21(28(19)27-18)16-5-2-1-3-6-16)15-7-9-17(10-8-15)23(25)13-4-14-23/h1-3,5-12H,4,13-14,25H2,(H2,24,29)",JBGYKRAZYDNCNV-UHFFFAOYSA-N,Protein Kinase,AKT2,208,P31751,PKBb,Allosteric Inhibitor,,18,IC50,TR-FRET-based in vitro kinase assays (10 µM ATP),https://doi.org/10.1002/ijc.30457 ,=,,,,,,4,KinomeScan (DiscoverX),468,"Screened at 10 µM, follow-up Kds and IC50s of closest targets: Kd(FLT1,D835Y) = 210 nM, Kd(CKL1) = 310 nM, Kd(MKNK2) = 330 nM, IC50(AKT3) = 427 nM.",https://doi.org/10.1002/ijc.30457 ,Kinase set,100 nM
EUB0000638a_BTK,Acalabrutinib,EUB0000638a,O=C(NC1=CC=CC=N1)C(C=C2)=CC=C2C3=C(C(N)=NC=C4)N4C([C@@H]5CCCN5C(C#CC)=O)=N3,"InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1",WDENQIQQYWYTPO-IBGZPJMESA-N,Protein Kinase,BTK,695,Q06187,"ATK, XLA, PSCTK1",Covalent inhibitor,,5.1,IC50,IMAP (immobilized metal ion affinity-based fluorescence polarization) assay,https://doi.org/10.1056/NEJMoa1509981,=,,,,,,3,KinomeScan (DiscoverX),395,"Screened at 1 µM, closest targets as % of contr.: ERBB2 (2.1%), ERBB4 (4.3%), TEC (6.4%); Inhibits kinases containing conserved cystein residue: IC50(BMX) = 46 nM, IC50(ERBB4) = 16 nM, IC50(TEC) = 93 nM, IC50(TXK) = 368 nM, IC50(ERBB2) = 1000 nM (Z’-LYTE assay), PMID: 26641137;",https://doi.org/10.1158/1078-0432.CCR-16-0463,Kinase set,1 µM
EUB0000640a_NTRK1,LOXO-195,EUB0000640a,O=C(N[C@H](C)CCC1=NC=C(F)C=C1[C@]2([H])N3CCC2)C4=C5N(N=C4)C=CC3=N5,"InChI=1S/C20H21FN6O/c1-12-4-5-16-14(9-13(21)10-22-16)17-3-2-7-26(17)18-6-8-27-19(25-18)15(11-23-27)20(28)24-12/h6,8-12,17H,2-5,7H2,1H3,(H,24,28)/t12-,17-/m1/s1",OEBIHOVSAMBXIB-SJKOYZFVSA-N,Protein Kinase,NTRK1,4914,P04629,"TRK, TRKA, MTC",Inhibitor,,3.7,IC50,LanthaScreenTM Eu,https://doi.org/10.1158/2159-8290.CD-17-0507,=,1.6,IC50,Phospho-TRKA ELISA (inhibition of NTRK1 phosphorylation in NIH 3T3 cells),,=,4,KinaseProfiler™ (Millipore),228,"Screened at 1 µM, closest targets as % of contr.: BMX (15%), ROS1 (12%), TXK (14%), TNK2(10%)",https://doi.org/10.1158/2159-8290.CD-17-0507,Kinase set,1 µM
EUB0000640a_NTRK2,LOXO-195,EUB0000640a,O=C(N[C@H](C)CCC1=NC=C(F)C=C1[C@]2([H])N3CCC2)C4=C5N(N=C4)C=CC3=N5,"InChI=1S/C20H21FN6O/c1-12-4-5-16-14(9-13(21)10-22-16)17-3-2-7-26(17)18-6-8-27-19(25-18)15(11-23-27)20(28)24-12/h6,8-12,17H,2-5,7H2,1H3,(H,24,28)/t12-,17-/m1/s1",OEBIHOVSAMBXIB-SJKOYZFVSA-N,Protein Kinase,NTRK2,4915,Q16620,TRKB,Inhibitor,,1.9,IC50,LanthaScreenTM Eu,https://doi.org/10.1158/2159-8290.CD-17-0507,=,,,,,,4,KinaseProfiler™ (Millipore),228,"Screened at 1 µM, closest targets as % of contr.: BMX (15%), ROS1 (12%), TXK (14%), TNK2(10%)",https://doi.org/10.1158/2159-8290.CD-17-0507,Kinase set,1 µM
EUB0000640a_NTRK3,LOXO-195,EUB0000640a,O=C(N[C@H](C)CCC1=NC=C(F)C=C1[C@]2([H])N3CCC2)C4=C5N(N=C4)C=CC3=N5,"InChI=1S/C20H21FN6O/c1-12-4-5-16-14(9-13(21)10-22-16)17-3-2-7-26(17)18-6-8-27-19(25-18)15(11-23-27)20(28)24-12/h6,8-12,17H,2-5,7H2,1H3,(H,24,28)/t12-,17-/m1/s1",OEBIHOVSAMBXIB-SJKOYZFVSA-N,Protein Kinase,NTRK3,4916,Q16288,TRKC,Inhibitor,,1.4,IC50,LanthaScreenTM Eu,https://doi.org/10.1158/2159-8290.CD-17-0507,=,2,IC50,Flow cytometry for ETV6-TRKC (inhibition of ERK phosphorylation in NIH 3T3 cells),,=,4,KinaseProfiler™ (Millipore),228,"Screened at 1 µM, closest targets as % of contr.: BMX (15%), ROS1 (12%), TXK (14%), TNK2(10%)",https://doi.org/10.1158/2159-8290.CD-17-0507,Kinase set,1 µM
EUB0000642a_TTK,CC-671,EUB0000642a,CC1=NC2=C(O1)C=C(C=C2)C3=CNC4=C3C(=NC(=N4)NC5=C(C=C(C=C5)C(=O)NC)OC)OC6CCCC6,"InChI=1S/C28H28N6O4/c1-15-31-21-10-8-16(12-23(21)37-15)19-14-30-25-24(19)27(38-18-6-4-5-7-18)34-28(33-25)32-20-11-9-17(26(35)29-2)13-22(20)36-3/h8-14,18H,4-7H2,1-3H3,(H,29,35)(H2,30,32,33,34)",CWJLAVRXVFHDSJ-UHFFFAOYSA-N,Protein Kinase,TTK,7272,P33981,"MPS1, MPS1L1, CT96, MPH1",Inhibitor,,5,IC50,LanthaScreen Eu kinase binding assay,https://doi.org/10.1021/acs.jmedchem.7b01223,=,,,,,,5,KinomeScan (Invitrogen),255,"Screened at 3 µM, closest targets as % inhibition: CLK1 (99%), DYRK1A/B (94/98%), DYRK3 (95%), PHKG (96%); In vitro follow-up (Invitrogen): IC50(DYRK3) = 99 nM, IC50(DYRK1A/B) = 104/157 nM, IC50(PHKG) = 136 nM, IC50(CLK3) = 300 nM; Cellular selectivity: IC50(JNK1/2/3) = 0.68 µM, IC50(CAMKK2) = 1.10 µM, IC50(PIP4K2C) = 1.30 µM (ActivX KiNative profiling assay (in HCT-116 cell line (CRL-1619))",https://doi.org/10.1021/acs.jmedchem.7b01223,Kinase set,100 nM
EUB0000642a_CLK2,CC-671,EUB0000642a,CC1=NC2=C(O1)C=C(C=C2)C3=CNC4=C3C(=NC(=N4)NC5=C(C=C(C=C5)C(=O)NC)OC)OC6CCCC6,"InChI=1S/C28H28N6O4/c1-15-31-21-10-8-16(12-23(21)37-15)19-14-30-25-24(19)27(38-18-6-4-5-7-18)34-28(33-25)32-20-11-9-17(26(35)29-2)13-22(20)36-3/h8-14,18H,4-7H2,1-3H3,(H,29,35)(H2,30,32,33,34)",CWJLAVRXVFHDSJ-UHFFFAOYSA-N,Protein Kinase,CLK2,1196,P49760,,Inhibitor,,6,IC50,LanthaScreen Eu kinase binding assay,https://doi.org/10.1021/acs.jmedchem.7b01223,=,15,IC50,ActivX KiNative profiling assay (in HCT-116 cell line (CRL-1619)),,=,5,KinomeScan (Invitrogen),255,"Screened at 3 µM, closest targets as % inhibition: CLK1 (99%), DYRK1A/B (94/98%), DYRK3 (95%), PHKG (96%); In vitro follow-up (Invitrogen): IC50(DYRK3) = 99 nM, IC50(DYRK1A/B) = 104/157 nM, IC50(PHKG) = 136 nM, IC50(CLK3) = 300 nM; Cellular selectivity: IC50(JNK1/2/3) = 0.68 µM, IC50(CAMKK2) = 1.10 µM, IC50(PIP4K2C) = 1.30 µM (ActivX KiNative profiling assay (in HCT-116 cell line (CRL-1619))",https://doi.org/10.1021/acs.jmedchem.7b01223,Kinase set,100 nM
EUB0000645a_AKT1,Borussertib,EUB0000645a,C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1,"InChI=1S/C36H32N6O3/c1-2-33(43)38-26-12-13-31-32(20-26)42(36(45)40-31)27-15-18-41(19-16-27)22-23-8-10-25(11-9-23)34-28(24-6-4-3-5-7-24)21-29-30(39-34)14-17-37-35(29)44/h2-14,17,20-21,27H,1,15-16,18-19,22H2,(H,37,44)(H,38,43)(H,40,45)",HXBRBOYWXDLHDC-UHFFFAOYSA-N,Protein Kinase,AKT1,207,P31749,"RAC, PKB, PRKBA, AKT, RAC-alpha",Covalent-allosteric inhibitor,,0.8,IC50,HTFR assay,https://doi.org/10.1002/anie.201909857,=,21,IC50,NanoBRET assay (HEK293T cells),,=,1,SelectScreen® Kinase Profiling (activity based Z’LYTE® assay),100,"Closest target: AKT3 (83% of ctrl.); Follow up in vitro activity: IC50(AKT3) = 618 nM (HTFR assay, PMID: 31584233), IC50(AKT3) = 4.3 µM (NanoBRET assay)",https://doi.org/10.1039/c8sc05212c,Kinase set,1 µM
EUB0000645a_AKT2,Borussertib,EUB0000645a,C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1,"InChI=1S/C36H32N6O3/c1-2-33(43)38-26-12-13-31-32(20-26)42(36(45)40-31)27-15-18-41(19-16-27)22-23-8-10-25(11-9-23)34-28(24-6-4-3-5-7-24)21-29-30(39-34)14-17-37-35(29)44/h2-14,17,20-21,27H,1,15-16,18-19,22H2,(H,37,44)(H,38,43)(H,40,45)",HXBRBOYWXDLHDC-UHFFFAOYSA-N,Protein Kinase,AKT2,208,P31751,PKBb,Covalent-allosteric inhibitor,,59,IC50,HTFR assay,https://doi.org/10.1002/anie.201909857,=,68,IC50,NanoBRET assay (HEK293T cells),,=,1,SelectScreen® Kinase Profiling (activity based Z’LYTE® assay),100,"Closest target: AKT3 (83% of ctrl.); Follow up in vitro activity: IC50(AKT3) = 618 nM (HTFR assay, PMID: 31584233), IC50(AKT3) = 4.3 µM (NanoBRET assay)",https://doi.org/10.1039/c8sc05212c,Kinase set,1 µM
EUB0000646a_BTK,Zanubrutinib,EUB0000646a,O=C(C=C)N1CCC([C@]2([H])CCNC3=C(C(N)=O)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1,"InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1",RNOAOAWBMHREKO-QFIPXVFZSA-N,Protein Kinase,BTK,695,Q06187,"ATK, XLA, PSCTK1",Covalent inhibitor,,0.3,IC50,33P-ATP and filter-binding assay (Reaction Biology),https://doi.org/10.1021/acs.jmedchem.9b00687,=,1.8,IC50,HTRF-based assay (Cisbio; phosphorylation of BTK on Y223),,=,1,Kinase panel (Reaction Biology),342,"Screened at 1 µM, 33P-ATP and filter-binding assay, closest target as % inhibition: BRK (99%), others >90%; In vitro potencies of closest 12 targets (33P-ATP and filter-binding assay (Reaction Biology)): IC50(ITK) = 56 nM, IC50(TEC) = 2.0 nM, IC50(JAK3) = 580 nM, IC50(EGFR) = 2.6 nM, IC50(HER2) = 530 nM, IC50(BRK) = 33 nM, IC50(FGR) = 155 nM, IC50(FRK/PTK5) = 379 nM, IC50(LCK) = 187 nM; Cellular selectivity: IC50(EGFR) = 606 nM (337-fold, p-EGFR HTRF assay), IC50(ITK) = 3477 nM (1932-fold, p-PLCg1 assay), IC50(TEC) = 204.7 nM (114-fold, p-TEC MSD assay), other targets not tested;",https://doi.org/10.1021/acs.jmedchem.9b00687,Kinase set,1 µM
EUB0000646a_BLK,Zanubrutinib,EUB0000646a,O=C(C=C)N1CCC([C@]2([H])CCNC3=C(C(N)=O)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1,"InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1",RNOAOAWBMHREKO-QFIPXVFZSA-N,Protein Kinase,BLK,640,P51451,MGC10442,Covalent inhibitor,,1.13,IC50,33P-ATP and filter-binding assay (Reaction Biology),https://doi.org/10.1021/acs.jmedchem.9b00687,=,,,,,,1,Kinase panel (Reaction Biology),342,"Screened at 1 µM, 33P-ATP and filter-binding assay, closest target as % inhibition: BRK (99%), others >90%; In vitro potencies of closest 12 targets (33P-ATP and filter-binding assay (Reaction Biology)): IC50(ITK) = 56 nM, IC50(TEC) = 2.0 nM, IC50(JAK3) = 580 nM, IC50(EGFR) = 2.6 nM, IC50(HER2) = 530 nM, IC50(BRK) = 33 nM, IC50(FGR) = 155 nM, IC50(FRK/PTK5) = 379 nM, IC50(LCK) = 187 nM; Cellular selectivity: IC50(EGFR) = 606 nM (337-fold, p-EGFR HTRF assay), IC50(ITK) = 3477 nM (1932-fold, p-PLCg1 assay), IC50(TEC) = 204.7 nM (114-fold, p-TEC MSD assay), other targets not tested;",https://doi.org/10.1021/acs.jmedchem.9b00687,Kinase set,1 µM
EUB0000646a_BMX,Zanubrutinib,EUB0000646a,O=C(C=C)N1CCC([C@]2([H])CCNC3=C(C(N)=O)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1,"InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1",RNOAOAWBMHREKO-QFIPXVFZSA-N,Protein Kinase,BMX,660,P51813,"ETK, PSCTK3",Covalent inhibitor,,0.62,IC50,33P-ATP and filter-binding assay (Reaction Biology),https://doi.org/10.1021/acs.jmedchem.9b00687,=,,,,,,1,Kinase panel (Reaction Biology),342,"Screened at 1 µM, 33P-ATP and filter-binding assay, closest target as % inhibition: BRK (99%), others >90%; In vitro potencies of closest 12 targets (33P-ATP and filter-binding assay (Reaction Biology)): IC50(ITK) = 56 nM, IC50(TEC) = 2.0 nM, IC50(JAK3) = 580 nM, IC50(EGFR) = 2.6 nM, IC50(HER2) = 530 nM, IC50(BRK) = 33 nM, IC50(FGR) = 155 nM, IC50(FRK/PTK5) = 379 nM, IC50(LCK) = 187 nM; Cellular selectivity: IC50(EGFR) = 606 nM (337-fold, p-EGFR HTRF assay), IC50(ITK) = 3477 nM (1932-fold, p-PLCg1 assay), IC50(TEC) = 204.7 nM (114-fold, p-TEC MSD assay), other targets not tested;",https://doi.org/10.1021/acs.jmedchem.9b00687,Kinase set,1 µM
EUB0000646a_ERBB4,Zanubrutinib,EUB0000646a,O=C(C=C)N1CCC([C@]2([H])CCNC3=C(C(N)=O)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1,"InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1",RNOAOAWBMHREKO-QFIPXVFZSA-N,Protein Kinase,ERBB4,2066,Q15303,"ALS19, HER4",Covalent inhibitor,,1.58,IC50,33P-ATP and filter-binding assay (Reaction Biology),https://doi.org/10.1021/acs.jmedchem.9b00687,=,,,,,,1,Kinase panel (Reaction Biology),342,"Screened at 1 µM, 33P-ATP and filter-binding assay, closest target as % inhibition: BRK (99%), others >90%; In vitro potencies of closest 12 targets (33P-ATP and filter-binding assay (Reaction Biology)): IC50(ITK) = 56 nM, IC50(TEC) = 2.0 nM, IC50(JAK3) = 580 nM, IC50(EGFR) = 2.6 nM, IC50(HER2) = 530 nM, IC50(BRK) = 33 nM, IC50(FGR) = 155 nM, IC50(FRK/PTK5) = 379 nM, IC50(LCK) = 187 nM; Cellular selectivity: IC50(EGFR) = 606 nM (337-fold, p-EGFR HTRF assay), IC50(ITK) = 3477 nM (1932-fold, p-PLCg1 assay), IC50(TEC) = 204.7 nM (114-fold, p-TEC MSD assay), other targets not tested;",https://doi.org/10.1021/acs.jmedchem.9b00687,Kinase set,1 µM
EUB0000646a_TXK,Zanubrutinib,EUB0000646a,O=C(C=C)N1CCC([C@]2([H])CCNC3=C(C(N)=O)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1,"InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1",RNOAOAWBMHREKO-QFIPXVFZSA-N,Protein Kinase,TXK,7294,P42681,"TKL, PSCTK5, BTKL, RLK",Covalent inhibitor,,2.95,IC50,33P-ATP and filter-binding assay (Reaction Biology),https://doi.org/10.1021/acs.jmedchem.9b00687,=,,,,,,1,Kinase panel (Reaction Biology),342,"Screened at 1 µM, 33P-ATP and filter-binding assay, closest target as % inhibition: BRK (99%), others >90%; In vitro potencies of closest 12 targets (33P-ATP and filter-binding assay (Reaction Biology)): IC50(ITK) = 56 nM, IC50(TEC) = 2.0 nM, IC50(JAK3) = 580 nM, IC50(EGFR) = 2.6 nM, IC50(HER2) = 530 nM, IC50(BRK) = 33 nM, IC50(FGR) = 155 nM, IC50(FRK/PTK5) = 379 nM, IC50(LCK) = 187 nM; Cellular selectivity: IC50(EGFR) = 606 nM (337-fold, p-EGFR HTRF assay), IC50(ITK) = 3477 nM (1932-fold, p-PLCg1 assay), IC50(TEC) = 204.7 nM (114-fold, p-TEC MSD assay), other targets not tested;",https://doi.org/10.1021/acs.jmedchem.9b00687,Kinase set,1 µM
EUB0000656a_PIK3CA,ZSTK474,EUB0000656a,FC(F)C1=NC(C=CC=C2)=C2N1C3=NC(N4CCOCC4)=NC(N5CCOCC5)=N3,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,Protein Kinase,PIK3CA,5290,P42336,PI3K,Inhibitor,,16,IC50,HTRF-based inhibition assay,https://doi.org/10.1038/aps.2010.150,=,,,,,,0,"Kinase panel, literature",139,"Screened at 30 µM, highly specific",https://doi.org/10.1093/jnci/djj133,Kinase set,1 µM
EUB0000656a_PIK3CB,ZSTK474,EUB0000656a,FC(F)C1=NC(C=CC=C2)=C2N1C3=NC(N4CCOCC4)=NC(N5CCOCC5)=N3,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,Protein Kinase,PIK3CB,5291,P42338,,Inhibitor,,44,IC50,HTRF-based inhibition assay,https://doi.org/10.1038/aps.2010.150,=,,,,,,0,"Kinase panel, literature",139,"Screened at 30 µM, highly specific",https://doi.org/10.1093/jnci/djj133,Kinase set,1 µM
EUB0000656a_PIK3CG,ZSTK474,EUB0000656a,FC(F)C1=NC(C=CC=C2)=C2N1C3=NC(N4CCOCC4)=NC(N5CCOCC5)=N3,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,Protein Kinase,PIK3CG,5294,P48736,,Inhibitor,,49,IC50,HTRF-based inhibition assay,https://doi.org/10.1038/aps.2010.150,=,,,,,,0,"Kinase panel, literature",139,"Screened at 30 µM, highly specific",https://doi.org/10.1093/jnci/djj133,Kinase set,1 µM
EUB0000656a_PIK3CD,ZSTK474,EUB0000656a,FC(F)C1=NC(C=CC=C2)=C2N1C3=NC(N4CCOCC4)=NC(N5CCOCC5)=N3,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,Protein Kinase,PIK3CD,5293,O00329,p110D,Inhibitor,,5,IC50,HTRF-based inhibition assay,https://doi.org/10.1038/aps.2010.150,=,,,,,,0,"Kinase panel, literature",139,"Screened at 30 µM, highly specific",https://doi.org/10.1093/jnci/djj133,Kinase set,1 µM
EUB0000129b_MAP2K1,Selumetinib,EUB0000129b,CN(C=N1)C2=C1C(F)=C(NC3=CC=C(Br)C=C3Cl)C(C(NOCCO)=O)=C2,"InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",CYOHGALHFOKKQC-UHFFFAOYSA-N,Protein Kinase,MAP2K1,5604,Q02750,"MEK1, MAPKK1",Inhibitor,,99,Kd,Competition binding assay,https://doi.org/10.1038/nbt.1990,=,14,IC50,Inhibition of MEK1 human HeLa-Ma Tu matched pair cells,,=,0,"Kinase panel, literature",442,"Kinases screened via competition binding assays: S(Kd < 300 nM) = 0.0026, S(Kd < 3µM) = 0.0052",https://doi.org/10.1038/nbt.1990,Kinase set,1 µM
EUB0000129b_MAP2K2,Selumetinib,EUB0000129b,CN(C=N1)C2=C1C(F)=C(NC3=CC=C(Br)C=C3Cl)C(C(NOCCO)=O)=C2,"InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",CYOHGALHFOKKQC-UHFFFAOYSA-N,Protein Kinase,MAP2K2,5605,P36507,MEK2,Inhibitor,,530,Kd,Competition binding assay,https://doi.org/10.1038/nbt.1990,=,,,,,,0,"Kinase panel, literature",442,"Kinases screened via competition binding assays: S(Kd < 300 nM) = 0.0026, S(Kd < 3µM) = 0.0052",https://doi.org/10.1038/nbt.1990,Kinase set,1 µM
EUB0000014b_PIKFYVE,YM-201636,EUB0000014b,O=C(C1=CC=C(N)N=C1)NC2=CC(C3=NC4=C(OC5=C4C=CC=N5)C(N6CCOCC6)=N3)=CC=C2,"InChI=1S/C25H21N7O3/c26-19-7-6-16(14-28-19)24(33)29-17-4-1-3-15(13-17)22-30-20-18-5-2-8-27-25(18)35-21(20)23(31-22)32-9-11-34-12-10-32/h1-8,13-14H,9-12H2,(H2,26,28)(H,29,33)",YBPIBGNBHHGLEB-UHFFFAOYSA-N,lipid-kinase,PIKFYVE,200576,Q9Y2I7,"CFD, FAB1, HEL37, PIP5K, PIP5K3, ZFYVE29",Inhibitor,,33,IC50,Radiometric assay (50 µM ATP),https://doi.org/10.1038/sj.embor.7401155,=,,,,,,1,KinomeScan (DiscoverX),448,"Screened at 1 µM, closest target as % of contr. PIK3CB (9.8%); Selective over PI3P, PI4P, PI34P, PI45P at 800 nM (radiolabel incorporation assay in NIH3T3 cells)",https://doi.org/10.1038/sj.embor.7401155,Kinase set,1 µM
EUB0000665a_CHEK1,PF-477736,EUB0000665a,O=C([C@H](N)C1CCCCC1)NC2=CC3=C4C(NC(C5=CN(C)N=C5)=C4C=NNC3=O)=C2,"InChI=1S/C22H25N7O2/c1-29-11-13(9-25-29)20-16-10-24-28-21(30)15-7-14(8-17(27-20)18(15)16)26-22(31)19(23)12-5-3-2-4-6-12/h7-12,19,27H,2-6,23H2,1H3,(H,26,31)(H,28,30)/t19-/m1/s1",NDEXUOWTGYUVGA-LJQANCHMSA-N,Protein Kinase,CHEK1,1111,O14757,CHK1,Inhibitor,,0.49,Ki,Biochemical activity-based assay (0.15 mM ATP),https://doi.org/ 10.1158/1535-7163.MCT-07-2391,=,,,,,,7,"Kinase panel, literature",100,"Screened at 1 µM or 10 µM (iknase panel literature or Upstate/Millipore); Closest targets: Ki(VEGFR2) = 8 nM, IC50(YES) = 14 nM, IC50(FMS) = 10 nM, IC50(AURKA) = 23nM, IC50(FGFR3) = 23 nM, IC50(FLT3) = 25 nM, IC50(RET) = 39 nM;",https://doi.org/ 10.1158/1535-7163.MCT-07-2391,Kinase set,100 nM
EUB0000665a_CHEK2,PF-477736,EUB0000665a,O=C([C@H](N)C1CCCCC1)NC2=CC3=C4C(NC(C5=CN(C)N=C5)=C4C=NNC3=O)=C2,"InChI=1S/C22H25N7O2/c1-29-11-13(9-25-29)20-16-10-24-28-21(30)15-7-14(8-17(27-20)18(15)16)26-22(31)19(23)12-5-3-2-4-6-12/h7-12,19,27H,2-6,23H2,1H3,(H,26,31)(H,28,30)/t19-/m1/s1",NDEXUOWTGYUVGA-LJQANCHMSA-N,Protein Kinase,CHEK2,11200,O96017,"CDS1, CHK2, HuCds1, PP1425, bA444G7",Inhibitor,,47,Ki,Biochemical activity-based assay (0.15 mM ATP),https://doi.org/ 10.1158/1535-7163.MCT-07-2391,=,,,,,,7,"Kinase panel, literature",100,"Screened at 1 µM or 10 µM (Kinase panel literature or Upstate/Millipore); Closest targets: Ki(VEGFR2) = 8 nM, IC50(YES) = 14 nM, IC50(FMS) = 10 nM, IC50(AURKA) = 23nM, IC50(FGFR3) = 23 nM, IC50(FLT3) = 25 nM, IC50(RET) = 39 nM;",https://doi.org/ 10.1158/1535-7163.MCT-07-2391,Kinase set,100 nM
EUB0000666a_MAP2K1,PD0325901,EUB0000666a,FC1=C(F)C(NC2=CC=C(I)C=C2F)=C(C(NOC[C@H](O)CO)=O)C=C1,"InChI=1S/C16H14F3IN2O4/c17-11-3-2-10(16(25)22-26-7-9(24)6-23)15(14(11)19)21-13-4-1-8(20)5-12(13)18/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m1/s1",SUDAHWBOROXANE-SECBINFHSA-N,Protein Kinase,MAP2K1,5604,Q02750,"MEK1, MAPKK1",Inhibitor,,82,IC50,Enzymatic inhibition assay,https://doi.org/10.1021/acs.jmedchem.9b01528,=,0.33,IC50,Whole cell assay (murine colon 26 (C26) carcinoma cells),,=,0,KinomeScan (DiscoverX),451,"Screened at 10 µM, none target within 10-fold, closest target as % of contr.: PIK3CA (I800L, 33%)",http://identifiers.org/lincs.data/LDS-1066,Kinase set,100 nM
EUB0000666a_MAP2K2,PD0325901,EUB0000666a,FC1=C(F)C(NC2=CC=C(I)C=C2F)=C(C(NOC[C@H](O)CO)=O)C=C1,"InChI=1S/C16H14F3IN2O4/c17-11-3-2-10(16(25)22-26-7-9(24)6-23)15(14(11)19)21-13-4-1-8(20)5-12(13)18/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m1/s1",SUDAHWBOROXANE-SECBINFHSA-N,Protein Kinase,MAP2K2,5605,P36507,MEK2,Inhibitor,,110,IC50,Enzymatic inhibition assay,https://doi.org/10.1021/acs.jmedchem.9b01528,=,,,,,,0,KinomeScan (DiscoverX),451,"Screened at 10 µM, none target within 10-fold, closest target as % of contr.: PIK3CA (I800L, 33%)",http://identifiers.org/lincs.data/LDS-1066,Kinase set,100 nM
EUB0000669a_PLK1,Volasertib,EUB0000669a,CC[C@@H]1C(N(C)C2=CN=C(NC3=C(OC)C=C(C(N[C@@H]4CC[C@@H](N5CCN(CC6CC6)CC5)CC4)=O)C=C3)N=C2N1C(C)C)=O,"InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25-,26-,28-/m1/s1",SXNJFOWDRLKDSF-STROYTFGSA-N,Protein Kinase,PLK1,5347,P53350,,Inhibitor,,0.87,IC50,Radiometric kinase assay (7.5 µM ATP),https://doi.org/10.1158/1078-0432.CCR-08-2445,=,,,,,,0,"Kinase panel, literature",255,"Kinases screened in Kinobeads assay,closest target: Kd(CAMKK2) = 195 nM; Kd (BRD4) = 79 nM.",https://doi.org/10.1126/science.aan4368,Kinase set,100 nM
EUB0000669a_PLK2,Volasertib,EUB0000669a,CC[C@@H]1C(N(C)C2=CN=C(NC3=C(OC)C=C(C(N[C@@H]4CC[C@@H](N5CCN(CC6CC6)CC5)CC4)=O)C=C3)N=C2N1C(C)C)=O,"InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25-,26-,28-/m1/s1",SXNJFOWDRLKDSF-STROYTFGSA-N,Protein Kinase,PLK2,10769,Q9NYY3,SNK,Inhibitor,,5,IC50,Radiometric kinase assay (7.5 µM ATP),https://doi.org/10.1158/1078-0432.CCR-08-2445,=,,,,,,0,"Kinase panel, literature",255,"Kinases screened in Kinobeads assay,closest target: Kd(CAMKK2) = 195 nM; Kd (BRD4) = 79 nM.",https://doi.org/10.1126/science.aan4368,Kinase set,100 nM
EUB0000669a_PLK3,Volasertib,EUB0000669a,CC[C@@H]1C(N(C)C2=CN=C(NC3=C(OC)C=C(C(N[C@@H]4CC[C@@H](N5CCN(CC6CC6)CC5)CC4)=O)C=C3)N=C2N1C(C)C)=O,"InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25-,26-,28-/m1/s1",SXNJFOWDRLKDSF-STROYTFGSA-N,Protein Kinase,PLK3,1263,Q9H4B4,"FNK, PRK",Inhibitor,,56,IC50,Radiometric kinase assay (7.5 µM ATP),https://doi.org/10.1158/1078-0432.CCR-08-2445,=,,,,,,0,"Kinase panel, literature",255,"Kinases screened in Kinobeads assay,closest target: Kd(CAMKK2) = 195 nM; Kd (BRD4) = 79 nM.",https://doi.org/10.1126/science.aan4368,Kinase set,100 nM
EUB0000049b_PIK3CA,Pictilisib (GDC-0941),EUB0000049b,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,"InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)",LHNIIDJUOCFXAP-UHFFFAOYSA-N,Protein Kinase,PIK3CA,5290,P42336,PI3K,Inhibitor,,0.76,Kd,ScanMax technology (DiscoverX),https://doi.org/10.1021/acs.jmedchem.7b00930,=,,,,,,0,KinomeScan (DiscoverX),468,"Screened at 10 µM, closest targets as % of contr.: CLK2 (25%), PIK3C2G (27%); Kd(mTOR) = 48 nM, Kd(PI3KC2b) = 40 nM (Kds by DiscoverX, PMID:28829592)",https://doi.org/10.1021/acs.jmedchem.7b00930,Kinase set,1 µM
EUB0000049b_PIK3CB,Pictilisib (GDC-0941),EUB0000049b,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,"InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)",LHNIIDJUOCFXAP-UHFFFAOYSA-N,Protein Kinase,PIK3CB,5291,P42338,,Inhibitor,,2.1,Kd,ScanMax technology (DiscoverX),https://doi.org/10.1021/acs.jmedchem.7b00930,=,,,,,,0,KinomeScan (DiscoverX),468,"Screened at 10 µM, closest targets as % of contr.: CLK2 (25%), PIK3C2G (27%); Kd(mTOR) = 48 nM, Kd(PI3KC2b) = 40 nM (Kds by DiscoverX, PMID:28829592)",https://doi.org/10.1021/acs.jmedchem.7b00930,Kinase set,1 µM
EUB0000049b_PIK3CG,Pictilisib (GDC-0941),EUB0000049b,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,"InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)",LHNIIDJUOCFXAP-UHFFFAOYSA-N,Protein Kinase,PIK3CG,5294,P48736,,Inhibitor,,7.7,Kd,ScanMax technology (DiscoverX),https://doi.org/10.1021/acs.jmedchem.7b00930,=,,,,,,0,KinomeScan (DiscoverX),468,"Screened at 10 µM, closest targets as % of contr.: CLK2 (25%), PIK3C2G (27%); Kd(mTOR) = 48 nM, Kd(PI3KC2b) = 40 nM (Kds by DiscoverX, PMID:28829592)",https://doi.org/10.1021/acs.jmedchem.7b00930,Kinase set,1 µM
EUB0000049b_PIK3CD,Pictilisib (GDC-0941),EUB0000049b,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,"InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)",LHNIIDJUOCFXAP-UHFFFAOYSA-N,Protein Kinase,PIK3CD,5293,O00329,p110D,Inhibitor,,3.3,Kd,ScanMax technology (DiscoverX),https://doi.org/10.1021/acs.jmedchem.7b00930,=,,,,,,0,KinomeScan (DiscoverX),468,"Screened at 10 µM, closest targets as % of contr.: CLK2 (25%), PIK3C2G (27%); Kd(mTOR) = 48 nM, Kd(PI3KC2b) = 40 nM (Kds by DiscoverX, PMID:28829592)",https://doi.org/10.1021/acs.jmedchem.7b00930,Kinase set,1 µM
EUB0000674a_AURKB,GSK1070916,EUB0000674a,CN(C)CC1=CC=CC(C2=CC3=C(C4=CN(CC)N=C4C5=CC=C(NC(N(C)C)=O)C=C5)C=CN=C3N2)=C1,"InChI=1S/C30H33N7O/c1-6-37-19-26(28(34-37)21-10-12-23(13-11-21)32-30(38)36(4)5)24-14-15-31-29-25(24)17-27(33-29)22-9-7-8-20(16-22)18-35(2)3/h7-17,19H,6,18H2,1-5H3,(H,31,33)(H,32,38)",QTBWCSQGBMPECM-UHFFFAOYSA-N,Protein Kinase,AURKB,9212,Q96GD4,"Aik2, IPL1, AurB, AIM-1, ARK2, STK5, PPP1R48",Inhibitor,,5,IC50,Enzymatic activity assay,https://doi.org/10.1021/jm901870q,=,,,,,,5,"Kinase panel, literature",328,"In vitro activity of closest targets:IC50(FLT1/4) = 42/74 nM, IC50(TIE2) = 59 nM, IC50(SIK) = 70 nM, IC50(FGFR1) = 78 nM",https://doi.org/10.1158/1535-7163.MCT-09-0041,Kinase set,1 µM
EUB0000674a_AURKC,GSK1070916,EUB0000674a,CN(C)CC1=CC=CC(C2=CC3=C(C4=CN(CC)N=C4C5=CC=C(NC(N(C)C)=O)C=C5)C=CN=C3N2)=C1,"InChI=1S/C30H33N7O/c1-6-37-19-26(28(34-37)21-10-12-23(13-11-21)32-30(38)36(4)5)24-14-15-31-29-25(24)17-27(33-29)22-9-7-8-20(16-22)18-35(2)3/h7-17,19H,6,18H2,1-5H3,(H,31,33)(H,32,38)",QTBWCSQGBMPECM-UHFFFAOYSA-N,Protein Kinase,AURKC,6795,Q9UQB9,"AurC, ARK3",Inhibitor,,6.5,IC50,Enzymatic activity assay,https://doi.org/10.1021/jm901870q,=,,,,,,5,"Kinase panel, literature",328,"In vitro activity of closest targets:IC50(FLT1/4) = 42/74 nM, IC50(TIE2) = 59 nM, IC50(SIK) = 70 nM, IC50(FGFR1) = 78 nM",https://doi.org/10.1158/1535-7163.MCT-09-0041,Kinase set,1 µM
EUB0000130bCl_AKT1,MK-2206 2HCl,EUB0000130bCl,Cl.Cl.NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1,"InChI=1S/C25H21N5O.2ClH/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31;;/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31);2*1H",HWUHTJIKQZZBRA-UHFFFAOYSA-N,Protein Kinase,AKT1,207,P31749,"RAC, PKB, PRKBA, AKT, RAC-alpha",Allosteric inhibitor,,8,IC50,Enzyme activity assay,https://cancerres.aacrjournals.org/content/69/9_Supplement/DDT01-1,=,,,,,,0,"Kinase panel, literature",250,"Screened at 1 µM, highly selective allosteric inhibitor",https://cancerres.aacrjournals.org/content/69/9_Supplement/DDT01-1,Kinase set,1 µM
EUB0000130bCl_AKT2,MK-2206 2HCl,EUB0000130bCl,Cl.Cl.NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1,"InChI=1S/C25H21N5O.2ClH/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31;;/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31);2*1H",HWUHTJIKQZZBRA-UHFFFAOYSA-N,Protein Kinase,AKT2,208,P31751,PKBb,Allosteric inhibitor,,12,IC50,Enzyme activity assay,https://cancerres.aacrjournals.org/content/69/9_Supplement/DDT01-1,=,,,,,,0,"Kinase panel, literature",250,"Screened at 1 µM, highly selective allosteric inhibitor",https://cancerres.aacrjournals.org/content/69/9_Supplement/DDT01-1,Kinase set,1 µM
EUB0000130bCl_AKT3,MK-2206 2HCl,EUB0000130bCl,Cl.Cl.NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1,"InChI=1S/C25H21N5O.2ClH/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31;;/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31);2*1H",HWUHTJIKQZZBRA-UHFFFAOYSA-N,Protein Kinase,AKT3,10000,Q9Y243,"PKBG, RAC-gamma, PRKBG",Allosteric inhibitor,,65,IC50,Enzyme activity assay,https://cancerres.aacrjournals.org/content/69/9_Supplement/DDT01-1,=,,,,,,0,"Kinase panel, literature",250,"Screened at 1 µM, highly selective allosteric inhibitor",https://cancerres.aacrjournals.org/content/69/9_Supplement/DDT01-1,Kinase set,1 µM
EUB0000122b_MAPK7,XMD8-92,EUB0000122b,OC1CCN(C2=CC(OCC)=C(NC3=NC=C(N(C)C(C(C=CC=C4)=C4N5C)=O)C5=N3)C=C2)CC1,"InChI=1S/C26H30N6O3/c1-4-35-23-15-17(32-13-11-18(33)12-14-32)9-10-20(23)28-26-27-16-22-24(29-26)30(2)21-8-6-5-7-19(21)25(34)31(22)3/h5-10,15-16,18,33H,4,11-14H2,1-3H3,(H,27,28,29)",QAPAJIZPZGWAND-UHFFFAOYSA-N,Protein Kinase,MAPK7,5598,Q13164,"BMK1, ERK5",Inhibitor,,80,KD,ATP-binding displacement assay,https://doi.org/10.1016/j.ccr.2010.08.008,=,1500,IC50,KiNativ assay (HeLa cell lysate),,=,3,"Kinase panel, literature",402,"Screened at 10 µM, ATP-site competition binding assay, S(10) = 0.012, closest targets: Kd(BMK1) = 80 nM, Kd(DCAMKL2) = 190 nM, Kd(TNK1) = 890 nM, Kd(PLK4) = 600 nM; Cellular selectivity profiling using KiNativ method against 181 kinases in HeLa cells, closest targets: IC50(TNK1/2) = 10/ 18 µM, IC50(RSK1/2) = 29/ 47 µM, IC50(FAK) = 39 µM, IC50(PIK4CA/L) = 36 µM, others >50 µM;",https://doi.org/10.1016/j.ccr.2010.08.008,Kinase set,1 µM
EUB0000677a_PLK1,NMS-1286937,EUB0000677a,CN1CCN(C2=CC=C(OC(F)(F)F)C(NC3=NC=C(CCC4=C5N(CCO)N=C4C(N)=O)C5=N3)=C2)CC1,"InChI=1S/C24H27F3N8O3/c1-33-6-8-34(9-7-33)15-3-5-18(38-24(25,26)27)17(12-15)30-23-29-13-14-2-4-16-20(22(28)37)32-35(10-11-36)21(16)19(14)31-23/h3,5,12-13,36H,2,4,6-11H2,1H3,(H2,28,37)(H,29,30,31)",QHLVBNKYJGBCQJ-UHFFFAOYSA-N,Protein Kinase,PLK1,5347,P53350,,Inhibitor,,2,IC50,Radiometric kinase assay,https://doi.org/10.1016/j.bmcl.2011.03.054,=,,,,,,3,Kinase Profiler (Millipore),296,"Screened at 1 µM, closest targets as % of contr.: CDK9 (10%), FLT3(D835Y) (9%), PLK1 (3%); Screened additionally against 58 kinases (radiometric kinase assay), closesttargets: IC50(FLT3) = 510 nM, IC50(MELK) = 744 nM, IC50(CK2) = 826 nM, other targets IC50 >10 µM (PMID: 21470862)",https://doi.org/10.1158/1535-7163.MCT-11-0765,Kinase set,100 nM
EUB0000679a_RPS6KA3@kinase 1,BIX 02565,EUB0000679a,C[C@@H]1CCNC(=O)C2=CC3=C(N12)C=C(C=C3)C(=O)NC4=NC5=CC=CC=C5N4CCCN(C)C,"InChI=1S/C26H30N6O2/c1-17-11-12-27-25(34)23-15-18-9-10-19(16-22(18)32(17)23)24(33)29-26-28-20-7-4-5-8-21(20)31(26)14-6-13-30(2)3/h4-5,7-10,15-17H,6,11-14H2,1-3H3,(H,27,34)(H,28,29,33)/t17-/m1/s1",ZHMXXVNQAFCXKK-QGZVFWFLSA-N,Protein Kinase,RPS6KA3@kinase 1,6197,P51812,"RSK2, HU-3",Inhibitor,,1.1,IC50,Kinase Glo Plus assay (Promega; 0.75 µM ATP),"https://doi.org/10.1016/j.bmcl.2011.10.029, https://patents.google.com/patent/WO2011071716A1/en",=,,,,,,10,SelectScreen (Invitrogen),200,"Screened at 1 µM, closest targets: IC50(PRKD2) = 139 nM, IC50(PRKD3) = 219 nM, IC50(RET) = 161 nM, IC50(FLT3) = 714 nM, IC50(LRRK2) =16 nM, IC50(PRKD1) = 35 nM, IC50(CLK1/2) = 512/ 112 nM, IC50(FGFR2) = 320 nM, IC50(PDGFRA) = 956 nM; Screened against panel of 68 receptors, ion channels and protein targets, at 10 µM, closest targets: IC50(A1A) = 914 nM, IC50(A1B) = 52 nM, IC50(A1D) = NA, IC50(A2A) = 1420 nM, IC50(AB2) = 1820 nM, IC50(imidazoline I2) = 97 nM (PMID: 22128344)",https://doi.org/10.1016/j.bmcl.2011.10.029,Kinase set,100 nM
EUB0000684a_MAP2K1,Cobimetinib,EUB0000684a,FC1=C(NC2=CC=C(I)C=C2F)C(C(N3CC([C@@H]4CCCCN4)(O)C3)=O)=CC=C1F,"InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1",BSMCAPRUBJMWDF-KRWDZBQOSA-N,Protein Kinase,MAP2K1,5604,Q02750,"MEK1, MAPKK1",Inhibitor,,4.2,IC50,Enzymatic inhibition assay,https://doi.org/10.1158/0008-5472.CAN-11-1515,=,,,,,,0,"Kinase panel, literature",259," In vitro inhibition (biochemical potency): >100 fold selective for MEK, other targets >10µM",https://doi.org/10.1126/science.aan4368,Kinase set,1 µM
EUB0000685a_PIK3CA,Taselisib,EUB0000685a,CC1=NN(C(C)C)C(C2=CN(CCO3)C(C4=C3C=C(C5=CN(C(C)(C)C(N)=O)N=C5)C=C4)=N2)=N1,"InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33)",BEUQXVWXFDOSAQ-UHFFFAOYSA-N,Protein Kinase,PIK3CA,5290,P42336,PI3K,Inhibitor,,0.29,Ki,Enzymatic fluorescence polarization assay,https://doi.org/10.1021/jm4003632,=,,,,,,0,SelectScreen panel (Invitrogen),235,"Screened at 1 µM, closest targets as % of cont.: PIK3C2B (80.4%), PIK3CA (98.6%), PIK3CD (97.9%), PIK3CG (90.6%), PIK3C3 (69.9%); IC50 follow-up of closest targets: IC50(PIK3C2B) = 292 nM, IC50(PIK3C3) = 374 nM, >1000-fold selective",https://doi.org/10.1021/jm4003632,Kinase set,100 nM
EUB0000685a_PIK3CB,Taselisib,EUB0000685a,CC1=NN(C(C)C)C(C2=CN(CCO3)C(C4=C3C=C(C5=CN(C(C)(C)C(N)=O)N=C5)C=C4)=N2)=N1,"InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33)",BEUQXVWXFDOSAQ-UHFFFAOYSA-N,Protein Kinase,PIK3CB,5291,P42338,,Inhibitor,,9.1,Ki,Enzymatic fluorescence polarization assay,https://doi.org/10.1021/jm4003632,=,,,,,,0,SelectScreen panel (Invitrogen),235,"Screened at 1 µM, closest targets as % of cont.: PIK3C2B (80.4%), PIK3CA (98.6%), PIK3CD (97.9%), PIK3CG (90.6%), PIK3C3 (69.9%); IC50 follow-up of closest targets: IC50(PIK3C2B) = 292 nM, IC50(PIK3C3) = 374 nM, >1000-fold selective",https://doi.org/10.1021/jm4003632,Kinase set,100 nM
EUB0000685a_PIK3CD,Taselisib,EUB0000685a,CC1=NN(C(C)C)C(C2=CN(CCO3)C(C4=C3C=C(C5=CN(C(C)(C)C(N)=O)N=C5)C=C4)=N2)=N1,"InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33)",BEUQXVWXFDOSAQ-UHFFFAOYSA-N,Protein Kinase,PIK3CD,5293,O00329,p110D,Inhibitor,,0.12,Ki,Enzymatic fluorescence polarization assay,https://doi.org/10.1021/jm4003632,=,,,,,,0,SelectScreen panel (Invitrogen),235,"Screened at 1 µM, closest targets as % of cont.: PIK3C2B (80.4%), PIK3CA (98.6%), PIK3CD (97.9%), PIK3CG (90.6%), PIK3C3 (69.9%); IC50 follow-up of closest targets: IC50(PIK3C2B) = 292 nM, IC50(PIK3C3) = 374 nM, >1000-fold selective",https://doi.org/10.1021/jm4003632,Kinase set,100 nM
EUB0000685a_PIK3CG,Taselisib,EUB0000685a,CC1=NN(C(C)C)C(C2=CN(CCO3)C(C4=C3C=C(C5=CN(C(C)(C)C(N)=O)N=C5)C=C4)=N2)=N1,"InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33)",BEUQXVWXFDOSAQ-UHFFFAOYSA-N,Protein Kinase,PIK3CG,5294,P48736,,Inhibitor,,0.97,Ki,Enzymatic fluorescence polarization assay,https://doi.org/10.1021/jm4003632,=,,,,,,0,SelectScreen panel (Invitrogen),235,"Screened at 1 µM, closest targets as % of cont.: PIK3C2B (80.4%), PIK3CA (98.6%), PIK3CD (97.9%), PIK3CG (90.6%), PIK3C3 (69.9%); IC50 follow-up of closest targets: IC50(PIK3C2B) = 292 nM, IC50(PIK3C3) = 374 nM, >1000-fold selective",https://doi.org/10.1021/jm4003632,Kinase set,100 nM
EUB0000686a_CDK4,Ribociclib,EUB0000686a,O=C(N(C)C)C(N1C2CCCC2)=CC(C1=N3)=CN=C3NC(C=C4)=NC=C4N5CCNCC5,"InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)",RHXHGRAEPCAFML-UHFFFAOYSA-N,Protein Kinase,CDK4,1019,P11802,PSK-J3,Inhibitor,,10,IC50,Enzymatic activity assay,https://doi.org/10.1038/s41523-019-0121-y,=,,,,,,1,KinomeScan (DiscoverX),468,"Screened at 1 µM, closest target with PoC <10%: ABL2 (5.8%)",https://lincs.hms.harvard.edu/db/datasets/20330/,Kinase set,1 µM
EUB0000686a_CDK6,Ribociclib,EUB0000686a,O=C(N(C)C)C(N1C2CCCC2)=CC(C1=N3)=CN=C3NC(C=C4)=NC=C4N5CCNCC5,"InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)",RHXHGRAEPCAFML-UHFFFAOYSA-N,Protein Kinase,CDK6,1021,Q00534,PLSTIRE,Inhibitor,,39,IC50,Enzymatic activity assay,https://doi.org/10.1038/s41523-019-0121-y,=,,,,,,1,KinomeScan (DiscoverX),468,"Screened at 1 µM, closest target with PoC <10%: ABL2 (5.8%)",https://lincs.hms.harvard.edu/db/datasets/20330/,Kinase set,1 µM
EUB0000687a_MAPK7,XMD17-109,EUB0000687a,CN1CCN(C2CCN(C(C3=CC(OCC)=C(NC4=NC=C(N(C)C(C(C=CC=C5)=C5N6C7CCCC7)=O)C6=N4)C=C3)=O)CC2)CC1,"InChI=1S/C36H46N8O3/c1-4-47-32-23-25(34(45)43-17-15-26(16-18-43)42-21-19-40(2)20-22-42)13-14-29(32)38-36-37-24-31-33(39-36)44(27-9-5-6-10-27)30-12-8-7-11-28(30)35(46)41(31)3/h7-8,11-14,23-24,26-27H,4-6,9-10,15-22H2,1-3H3,(H,37,38,39)",XVBGRTMNFNMINE-UHFFFAOYSA-N,Protein Kinase,MAPK7,5598,Q13164,"BMK1, ERK5",Inhibitor,,162,IC50,Radiometric assay,https://doi.org/10.1016/j.ejmech.2013.10.052,=,90,EC50,EGF-stimulated autophosphorylation of ERK5 in HeLa cells,,=,2,KinomeScan (Ambit),442,"Screened at 10 µM, S(10) = 0.007, closest targets as % of contr.: DCAMK2 (3.6%), PLK4 (5.1%); Cellular selectivity profiling at 10 µM using KiNativ method, only ERK5 inhibited with90 % higher target occupancy;",https://doi.org/10.1016/j.ejmech.2013.10.052,Kinase set,1 µM
EUB0000689a_PIK3CA,Alpelisib,EUB0000689a,CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,"InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1",STUWGJZDJHPWGZ-LBPRGKRZSA-N,Protein Kinase,PIK3CA,5290,P42336,PI3K,Inhibitor,,5,IC50,Enzymatic inhibition assay (Kinase-Glo® assay),https://doi.org/10.1016/j.bmcl.2013.05.007,=,,,,,,0,Kinase panel (literature + Ambit panel + Invitrogen panel),442,"Screened at 10 µM, > 50-fold selective",https://doi.org/10.1016/j.bmcl.2013.05.007,Kinase set,1 µM
EUB0000690a_ALK,Lorlatinib,EUB0000690a,FC1=CC=C(C(N(C)CC2=NN(C)C(C#N)=C32)=O)C([C@@H](C)OC4=C(N)N=CC3=C4)=C1,"InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1",IIXWYSCJSQVBQM-LLVKDONJSA-N,Protein Kinase,ALK,238,Q9UM73,CD246,Inhibitor,,0.07,Ki,Microfluidic mobility shift assay,https://doi.org/10.1073/pnas.1420785112 ,<,1.3,IC50,ELISA (ALK phosphoryaltion in 3T3-EML4-ALK engineered cell lines),,=,11,Z’-LYTE assays (SelectScreen Invitrogen),206,"Screened at 1 µM, closest targets: Ki(LTK) = 2.7 nM, Ki(FER) = 3.3 nM, Ki(FES) = 6 nM, Ki(PTK2B) = 14 nM, Ki(TNK2) = 17 nM, Ki(PTK2) = 17 nM, Ki(NTRK1) = 24 nM, Ki(NTKR2) = 23 nM, Ki(NTRK3) = 46 nM, Ki(FRK) = 53 nM, Ki(EGFR(L858R/T790M)) = 56 nM, Ki(EGFR(T790M) = 319 nM, Ki(JAK2) = 529 nM, others >75% inhibition at 1 µM",https://doi.org/10.1021/jm500261q,Kinase set,100 nM
EUB0000690a_ROS1,Lorlatinib,EUB0000690a,FC1=CC=C(C(N(C)CC2=NN(C)C(C#N)=C32)=O)C([C@@H](C)OC4=C(N)N=CC3=C4)=C1,"InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1",IIXWYSCJSQVBQM-LLVKDONJSA-N,Protein Kinase,ROS1,6098,P08922,"MCF3, ROS, c-ros-1",Inhibitor,,0.025,Ki,Microfluidic mobility shift assay,https://doi.org/10.1073/pnas.1420785112 ,<,0.53,IC50,Sandwich ELISA (cell-based ROS1-fusion assay),,<,11,Z’-LYTE assays (SelectScreen Invitrogen),206,"Screened at 1 µM, closest off-targets: Ki(LTK) = 2.7 nM, Ki(FER) = 3.3 nM, Ki(FES) = 6 nM, Ki(PTK2B) = 14 nM, Ki(TNK2) = 17 nM, Ki(PTK2) = 17 nM, Ki(NTRK1) = 24 nM, Ki(NTKR2) = 23 nM, Ki(NTRK3) = 46 nM, Ki(FRK) = 53 nM, Ki(EGFR(L858R/T790M)) = 56 nM, Ki(EGFR(T790M) = 319 nM, Ki(JAK2) = 529 nM, others >75% inhibition at 1 µM",https://doi.org/10.1021/jm500261q,Kinase set,100 nM
EUB0000691a_PIK3CA,Omipalisib,EUB0000691a,COC1=C(NS(C2=CC=C(F)C=C2F)(=O)=O)C=C(C3=CC(C(C4=CC=NN=C4)=CC=N5)=C5C=C3)C=N1,"InChI=1S/C25H17F2N5O3S/c1-35-25-23(32-36(33,34)24-5-3-18(26)12-21(24)27)11-17(13-29-25)15-2-4-22-20(10-15)19(7-8-28-22)16-6-9-30-31-14-16/h2-14,32H,1H3",CGBJSGAELGCMKE-UHFFFAOYSA-N,Protein Kinase,PIK3CA,5290,P42336,PI3K,Inhibitor,,0.019,Ki,HTRF-based inhibition assay,https://doi.org/10.1021/ml900028r,=,,,,,,6,KinomeScan (DiscoverX),442,"Screened at 10 µM, closest targets with < 10% of contr.: GAK, JAK1, STK16, TTK, PIK3C2G, MAP2K4; Screened against 240 kinases (Milipore panel): >10000-fold selective","https://lincs.hms.harvard.edu/db/datasets/20084/, https://doi.org/10.1021/ml900028r",Kinase set,100 nM
EUB0000691a_PIK3CB,Omipalisib,EUB0000691a,COC1=C(NS(C2=CC=C(F)C=C2F)(=O)=O)C=C(C3=CC(C(C4=CC=NN=C4)=CC=N5)=C5C=C3)C=N1,"InChI=1S/C25H17F2N5O3S/c1-35-25-23(32-36(33,34)24-5-3-18(26)12-21(24)27)11-17(13-29-25)15-2-4-22-20(10-15)19(7-8-28-22)16-6-9-30-31-14-16/h2-14,32H,1H3",CGBJSGAELGCMKE-UHFFFAOYSA-N,Protein Kinase,PIK3CB,5291,P42338,,Inhibitor,,0.13,Ki,HTRF-based inhibition assay,https://doi.org/10.1021/ml900028r,=,,,,,,6,KinomeScan (DiscoverX),442,"Screened at 10 µM, closest targets with < 10% of contr.: GAK, JAK1, STK16, TTK, PIK3C2G, MAP2K4; Screened against 240 kinases (Milipore panel): >10000-fold selective","https://lincs.hms.harvard.edu/db/datasets/20084/, https://doi.org/10.1021/ml900028r",Kinase set,100 nM
EUB0000691a_PIK3CD,Omipalisib,EUB0000691a,COC1=C(NS(C2=CC=C(F)C=C2F)(=O)=O)C=C(C3=CC(C(C4=CC=NN=C4)=CC=N5)=C5C=C3)C=N1,"InChI=1S/C25H17F2N5O3S/c1-35-25-23(32-36(33,34)24-5-3-18(26)12-21(24)27)11-17(13-29-25)15-2-4-22-20(10-15)19(7-8-28-22)16-6-9-30-31-14-16/h2-14,32H,1H3",CGBJSGAELGCMKE-UHFFFAOYSA-N,Protein Kinase,PIK3CD,5293,O00329,p110D,Inhibitor,,0.024,Ki,HTRF-based inhibition assay,https://doi.org/10.1021/ml900028r,=,,,,,,6,KinomeScan (DiscoverX),442,"Screened at 10 µM, closest targets with < 10% of contr.: GAK, JAK1, STK16, TTK, PIK3C2G, MAP2K4; Screened against 240 kinases (Milipore panel): >10000-fold selective","https://lincs.hms.harvard.edu/db/datasets/20084/, https://doi.org/10.1021/ml900028r",Kinase set,100 nM
EUB0000691a_PIK3CG,Omipalisib,EUB0000691a,COC1=C(NS(C2=CC=C(F)C=C2F)(=O)=O)C=C(C3=CC(C(C4=CC=NN=C4)=CC=N5)=C5C=C3)C=N1,"InChI=1S/C25H17F2N5O3S/c1-35-25-23(32-36(33,34)24-5-3-18(26)12-21(24)27)11-17(13-29-25)15-2-4-22-20(10-15)19(7-8-28-22)16-6-9-30-31-14-16/h2-14,32H,1H3",CGBJSGAELGCMKE-UHFFFAOYSA-N,Protein Kinase,PIK3CG,5294,P48736,,Inhibitor,,0.06,Ki,HTRF-based inhibition assay,https://doi.org/10.1021/ml900028r,=,,,,,,6,KinomeScan (DiscoverX),442,"Screened at 10 µM, closest targets with < 10% of contr.: GAK, JAK1, STK16, TTK, PIK3C2G, MAP2K4; Screened against 240 kinases (Milipore panel): >10000-fold selective","https://lincs.hms.harvard.edu/db/datasets/20084/, https://doi.org/10.1021/ml900028r",Kinase set,100 nM
EUB0000696a_PIK3CD,Umbralisib,EUB0000696a,C[C@@H](C1=C(C2=CC(F)=CC=C2)C(C3=CC(F)=CC=C3O1)=O)N4N=C(C5=CC=C(OC(C)C)C(F)=C5)C6=C(N)N=CN=C46,"InChI=1S/C31H24F3N5O3/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29/h4-16H,1-3H3,(H2,35,36,37)/t16-/m0/s1",IUVCFHHAEHNCFT-INIZCTEOSA-N,Protein Kinase,PIK3CD,5293,O00329,p110D,Inhibitor,,14,IC50,Enzymatic inhibition assay,https://doi.org/10.1021/acs.jmedchem.8b01298,=,,,,,,1,Radioisotope filter binding assay (Reaction Biology),359,"Screened at 1 µM, closest target as % of contr.: CSNK1E (39%)","https://doi.org/10.1021/acs.jmedchem.8b01298, https://patents.google.com/patent/WO2017079558A1/en",Kinase set,1 µM
EUB0000697a_CSF1R,PLX5622,EUB0000697a,CC1=CN=C(NC=C2CC3=C(F)N=C(NCC4=C(OC)N=CC(F)=C4)C=C3)C2=C1,"InChI=1S/C21H19F2N5O/c1-12-5-17-14(9-26-20(17)25-8-12)6-13-3-4-18(28-19(13)23)24-10-15-7-16(22)11-27-21(15)29-2/h3-5,7-9,11H,6,10H2,1-2H3,(H,24,28)(H,25,26)",NSMOZFXKTHCPTQ-UHFFFAOYSA-N,Protein Kinase,CSF1R,1436,P07333,"C-FMS, CSFR, CD115",Inhibitor,,16,IC50,Enzymatic inhibition assay (100 µM ATP),https://doi.org/10.1038/s41467-019-11674-z,=,,,,,,4,SelectScreen (Invitrogen),200,"Screened at 1 µM, closest targets: IC50(FLT3) = 390 nM, IC50(KIT) = 860 nM, IC50(AURKC) = 1000 nM, IC50(KDR) = 1100 nM (enzymatic assay with 100 µM ATP), other targets > 1 µM; Cellular selectivity: IC50(FLT3) > 10 µM (FLT3-ITD dependent proliferation of Ba/F3 cells); IC50(KIT) = 2.7 µM (BCR-KIT fusion dependent proliferation of Ba/F3 cells)",https://doi.org/10.1038/s41467-019-11674-z,Kinase set,1 µM
EUB0000698a_PLK1,GW843682X,EUB0000698a,COC1=C(OC)C=C(N=CN2C3=CC(OCC4=CC=CC=C4C(F)(F)F)=C(C(N)=O)S3)C2=C1,"InChI=1S/C22H18F3N3O4S/c1-30-16-7-14-15(8-17(16)31-2)28(11-27-14)19-9-18(20(33-19)21(26)29)32-10-12-5-3-4-6-13(12)22(23,24)25/h3-9,11H,10H2,1-2H3,(H2,26,29)",JSKUWFIZUALZLX-UHFFFAOYSA-N,Protein Kinase,PLK1,5347,P53350,,Inhibitor,,2.2,IC50,Radiometric kinase assay,https://pubmed.ncbi.nlm.nih.gov/7267659/,=,140,IC50,ELISA (PLK1 phosphorylation of Ser15-p53 in HeLa cells),,=,22,KinomeScan (DiscoverX),441,"Screened at 10 µM, closest targets as % of contr.: GAK(4.1%), RIOK1/3 (4.1/4.2%), PDGFRB (5.3%), FLT3(D835H)(1.4%), FLT4(1.4%), KIT(D816V)(1.4%), PIP5K2B(6.6%), MAPK3K1(1.6%), PIP5K2B(6.6%), DAPK1(8.6%), FLT3(N841I) (1.7%), ROCK1 (4.7%), MST2(1.8%), SRPK1(8.9%), EPHB6(9.9%), LOK(0.0%), PLK2(0.2%), SLK(0.3%), MP2K5(0.5%), BIKE(1.0%), PIP5K1C (10%); Screened against 30 kinases, closest targets: IC50(PDGFR1b) = 160 nM, IC50(VEGFR2) = 360 nM, IC50(AURA) = 4800 nM, IC50(CDK2/cyclinA) = 7600 nM, others IC50 >10 µM (PMID: 17267659)",https://lincs.hms.harvard.edu/db/datasets/20032/main,Kinase set,100 nM
EUB0000698a_PLK3,GW843682X,EUB0000698a,COC1=C(OC)C=C(N=CN2C3=CC(OCC4=CC=CC=C4C(F)(F)F)=C(C(N)=O)S3)C2=C1,"InChI=1S/C22H18F3N3O4S/c1-30-16-7-14-15(8-17(16)31-2)28(11-27-14)19-9-18(20(33-19)21(26)29)32-10-12-5-3-4-6-13(12)22(23,24)25/h3-9,11H,10H2,1-2H3,(H2,26,29)",JSKUWFIZUALZLX-UHFFFAOYSA-N,Protein Kinase,PLK3,1263,Q9H4B4,"FNK, PRK",Inhibitor,,9.1,IC50,Radiometric kinase assay,https://pubmed.ncbi.nlm.nih.gov/7267659/,=,,,,,,22,KinomeScan (DiscoverX),441,"Screened at 10 µM, closest targets as % of contr.: GAK(4.1%), RIOK1/3 (4.1/4.2%), PDGFRB (5.3%), FLT3(D835H)(1.4%), FLT4(1.4%), KIT(D816V)(1.4%), PIP5K2B(6.6%), MAPK3K1(1.6%), PIP5K2B(6.6%), DAPK1(8.6%), FLT3(N841I) (1.7%), ROCK1 (4.7%), MST2(1.8%), SRPK1(8.9%), EPHB6(9.9%), LOK(0.0%), PLK2(0.2%), SLK(0.3%), MP2K5(0.5%), BIKE(1.0%), PIP5K1C (10%); Screened against 30 kinases, closest targets: IC50(PDGFR1b) = 160 nM, IC50(VEGFR2) = 360 nM, IC50(AURA) = 4800 nM, IC50(CDK2/cyclinA) = 7600 nM, others IC50 >10 µM (PMID: 17267659)",https://lincs.hms.harvard.edu/db/datasets/20032/main,Kinase set,100 nM
EUB0000132b_MAPK14,SR318,EUB0000132b,Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1,"InChI=1S/C27H33N5O2/c28-25-24(19-31-32(25)23-11-5-2-6-12-23)27(34)30-18-21-13-15-22(16-14-21)26(33)29-17-7-10-20-8-3-1-4-9-20/h2,5-6,11-16,19-20H,1,3-4,7-10,17-18,28H2,(H,29,33)(H,30,34)",HXNUFFCHRIWTRZ-UHFFFAOYSA-N,Protein Kinase,MAPK14,1432,Q16539,"PRKM14, p38, Mxi2, PRKM15",Inhibitor,SR321,5,IC50,Radiometric activity assay (ProQinase),https://doi.org/10.1021/acs.jmedchem.9b01227,=,3.7,IC50,NanoBRET assay (HEK293T cells),,=,0,KinomeScan (DiscoverX),403,"Screened at 1 µM, closest targets in the screen: DDR1, DDR2, KIT, ZAK, RSK, MYLK4, but confirmed by NanoBRET as false positive (IC50s of 910-140000 nM)",https://doi.org/10.1021/acs.jmedchem.9b01227,Kinase set,1 µM
EUB0000132b_MAPK11,SR318,EUB0000132b,Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1,"InChI=1S/C27H33N5O2/c28-25-24(19-31-32(25)23-11-5-2-6-12-23)27(34)30-18-21-13-15-22(16-14-21)26(33)29-17-7-10-20-8-3-1-4-9-20/h2,5-6,11-16,19-20H,1,3-4,7-10,17-18,28H2,(H,29,33)(H,30,34)",HXNUFFCHRIWTRZ-UHFFFAOYSA-N,Protein Kinase,MAPK11,5600,Q15759,"p38-2, p38Beta, SAPK2",Inhibitor,SR321,32,IC50,Radiometric activity assay (ProQinase),https://doi.org/10.1021/acs.jmedchem.9b01227,=,10,IC50,NanoBRET assay (HEK293T cells),,=,0,KinomeScan (DiscoverX),403,"Screened at 1 µM, closest targets in the screen: DDR1, DDR2, KIT, ZAK, RSK, MYLK4, but confirmed by NanoBRET as false positive (IC50s of 910-140000 nM)",https://doi.org/10.1021/acs.jmedchem.9b01227,Kinase set,1 µM
EUB0000250b_MAPK7,BAY-885,EUB0000250b,CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1,"InChI=1S/C25H28F3N7O2/c1-33-8-10-34(11-9-33)17-12-21-23(30-14-17)22(32-15-31-21)16-4-6-35(7-5-16)24(36)19-3-2-18(13-20(19)29)37-25(26,27)28/h2-3,12-16H,4-11,29H2,1H3",QXURFIGBRGWPQD-UHFFFAOYSA-N,Protein Kinase,MAPK7,5598,Q13164,"BMK1, ERK5",Inhibitor,BAY-693,35,IC50,TR-FRET assay (250 µM ATP),"https://doi.org/10.1021/acs.jmedchem.8b01606, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-885",=,115,IC50,Cellular luciferase reporter assay (using the SN12C-MEF2-luc cell line and ONE-Glo),,=,0,KinomeScan (Eurofins),358,"Screened at 1 µM, closest targets as % of contr.: FER (38%), EPHB3 (42%), EPHA5 (57%); Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: EPHB6 (18%), EGFR(S752-I759del) (38%), LTK (49%); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest target: Ki(SIGMAR1) = 2.50 µM",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-885,Kinase set,1 µM
EUB0000293b_MET,BAY-474,EUB0000293b,CC1=C(C#N)C(c2ccc3[nH]nc(C)c3c2)C(C#N)=C(C)N1,"InChI=1S/C17H15N5/c1-9-14(7-18)17(15(8-19)10(2)20-9)12-4-5-16-13(6-12)11(3)21-22-16/h4-6,17,20H,1-3H3,(H,21,22)",QKVFMAAIXZONRN-UHFFFAOYSA-N,Protein Kinase,MET,4233,P08581,"HGFR, RCCP2, DFNB97",Inhibitor,BAY-827,1,IC50,Homogeneous Time Resolved Fluorescence Assay,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-474,<,2.9,IC50,Cellular mechanistic assay (phosphorylation of MET in NKM-45 cells),,=,0,Millipore panel,218,"Screened at 1 µM, closest target: IC50(RPS6KA3) = 0.9 µM, >1000 fold selective against all other kinases; Eurofins-Panlabs radioligand binding assay (screened against 68 targets, at 10 µM): clean profile; Screened against 45 GPCR targets (PDSP screen) at 10 µM: clean profile",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-474,Kinase set,1 µM
EUB0000321b_CLK1,T3-CLK,EUB0000321b,CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5ccncc5)ccc4n3)cc2)CC1,"InChI=1S/C28H30N6O2/c1-28(2,27(36)33-16-14-32(3)15-17-33)23-7-4-21(5-8-23)26(35)31-24-19-34-18-22(6-9-25(34)30-24)20-10-12-29-13-11-20/h4-13,18-19H,14-17H2,1-3H3,(H,31,35)",IEFFSHLHNYVSEF-UHFFFAOYSA-N,Protein Kinase,CLK1,1195,P49759,,Inhibitor,T3-CLK-N,0.67,IC50,Enzymatic inhibition assay,https://www.thesgc.org/chemical-probes/T3-CLK,=,4,IC50,NanoBRET assay (HEK293T cells),,=,2,KinomeScan (DiscoverX),468,"Screened at 100 nM, closest targets as % of contr.: DYRK1A (0.3%), DYRK1B (4.4%), MAP2K5 (4.9%), KIT (14%), MAP3K5 (19%), PDGFRB (24%), PDGFRA (29%); IC50 follow up in cellular NanoBRET assays: IC50(DYRK1A) = 32 nM, IC50(DYRK1B) = 67 nM, IC50(MAP2K5) >10 µM, IC50(KIT) = 2.44 µM, IC50(MAP3K5) >10 µM, IC50(PDGFRB) = 3 µM, IC50(PDGFRA) = 2.52 µM",https://www.thesgc.org/chemical-probes/T3-CLK,Kinase set,100 nM
EUB0000321b_CLK2,T3-CLK,EUB0000321b,CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5ccncc5)ccc4n3)cc2)CC1,"InChI=1S/C28H30N6O2/c1-28(2,27(36)33-16-14-32(3)15-17-33)23-7-4-21(5-8-23)26(35)31-24-19-34-18-22(6-9-25(34)30-24)20-10-12-29-13-11-20/h4-13,18-19H,14-17H2,1-3H3,(H,31,35)",IEFFSHLHNYVSEF-UHFFFAOYSA-N,Protein Kinase,CLK2,1196,P49760,,Inhibitor,T3-CLK-N,15,IC50,Enzymatic inhibition assay,https://www.thesgc.org/chemical-probes/T3-CLK,=,17,IC50,NanoBRET assay (HEK293T cells),,=,2,KinomeScan (DiscoverX),468,"Screened at 100 nM, closest targets as % of contr.: DYRK1A (0.3%), DYRK1B (4.4%), MAP2K5 (4.9%), KIT (14%), MAP3K5 (19%), PDGFRB (24%), PDGFRA (29%); IC50 follow up in cellular NanoBRET assays: IC50(DYRK1A) = 32 nM, IC50(DYRK1B) = 67 nM, IC50(MAP2K5) >10 µM, IC50(KIT) = 2.44 µM, IC50(MAP3K5) >10 µM, IC50(PDGFRB) = 3 µM, IC50(PDGFRA) = 2.52 µM",https://www.thesgc.org/chemical-probes/T3-CLK,Kinase set,100 nM
EUB0000321b_CLK3,T3-CLK,EUB0000321b,CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5ccncc5)ccc4n3)cc2)CC1,"InChI=1S/C28H30N6O2/c1-28(2,27(36)33-16-14-32(3)15-17-33)23-7-4-21(5-8-23)26(35)31-24-19-34-18-22(6-9-25(34)30-24)20-10-12-29-13-11-20/h4-13,18-19H,14-17H2,1-3H3,(H,31,35)",IEFFSHLHNYVSEF-UHFFFAOYSA-N,Protein Kinase,CLK3,1198,P49761,,Inhibitor,T3-CLK-N,110,IC50,Enzymatic inhibition assay,https://www.thesgc.org/chemical-probes/T3-CLK,=,,,,,,2,KinomeScan (DiscoverX),468,"Screened at 100 nM, closest targets as % of contr.: DYRK1A (0.3%), DYRK1B (4.4%), MAP2K5 (4.9%), KIT (14%), MAP3K5 (19%), PDGFRB (24%), PDGFRA (29%); IC50 follow up in cellular NanoBRET assays: IC50(DYRK1A) = 32 nM, IC50(DYRK1B) = 67 nM, IC50(MAP2K5) >10 µM, IC50(KIT) = 2.44 µM, IC50(MAP3K5) >10 µM, IC50(PDGFRB) = 3 µM, IC50(PDGFRA) = 2.52 µM",https://www.thesgc.org/chemical-probes/T3-CLK,Kinase set,100 nM
EUB0000321b_CLK4,T3-CLK,EUB0000321b,CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5ccncc5)ccc4n3)cc2)CC1,"InChI=1S/C28H30N6O2/c1-28(2,27(36)33-16-14-32(3)15-17-33)23-7-4-21(5-8-23)26(35)31-24-19-34-18-22(6-9-25(34)30-24)20-10-12-29-13-11-20/h4-13,18-19H,14-17H2,1-3H3,(H,31,35)",IEFFSHLHNYVSEF-UHFFFAOYSA-N,Protein Kinase,CLK4,57396,Q9HAZ1,,Inhibitor,T3-CLK-N,,,,,,2,IC50,NanoBRET assay (HEK293T cells),,=,2,KinomeScan (DiscoverX),468,"Screened at 100 nM, closest targets as % of contr.: DYRK1A (0.3%), DYRK1B (4.4%), MAP2K5 (4.9%), KIT (14%), MAP3K5 (19%), PDGFRB (24%), PDGFRA (29%); IC50 follow up in cellular NanoBRET assays: IC50(DYRK1A) = 32 nM, IC50(DYRK1B) = 67 nM, IC50(MAP2K5) >10 µM, IC50(KIT) = 2.44 µM, IC50(MAP3K5) >10 µM, IC50(PDGFRB) = 3 µM, IC50(PDGFRA) = 2.52 µM",https://www.thesgc.org/chemical-probes/T3-CLK,Kinase set,100 nM
EUB0000305b_TBK1,BAY-985,EUB0000305b,C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1,"InChI=1S/C27H30F3N9O/c1-17(38-8-10-39(11-9-38)25(40)15-27(28,29)30)18-6-7-31-23(13-18)36-26-34-20-5-4-19(12-22(20)35-26)21-14-24(37(2)3)33-16-32-21/h4-7,12-14,16-17H,8-11,15H2,1-3H3,(H2,31,34,35,36)/t17-/m1/s1",HZRJHVDNTDBTOZ-QGZVFWFLSA-N,Protein Kinase,TBK1,29110,Q9UHD2,NAK,Inhibitor,BAY-440,2,IC50,TR-FRET-based kinase activity inhibition assay (1 µM ATP),https://doi.org/10.1021/acs.jmedchem.9b01460 ,=,312,IC50,NanoBRET assay (HEK293T cells),,=,2,Kinome Scan (DiscoverX),468,"Screened at 100 nM, closest targets as % of contr.: MAP2K5 (8.5%), MAP3K19 (10%), SYK (31%), FLT3(D835V) (32%), STK17A (40%), TAOK3 (41%), PIK3CA(Q546K) (45%); In vitro follow-up of closest targets: IC50(FLT3) = 123 nM, IC50(MAP2K5) = 847 nM (Bayer in-house data), IC50(FLT3) = 123 nM, IC50(RPS6KA6) = 276 nM, IC50(DRAK1) = 311 nM, IC50(ULK1) = 7930 nM (PMID: 31859507); Kd(STK17A) = 74 nM, Kd(MAP3K19) = 9.6 nM (DiscoverX), IC50(STK17A) = 310 nM (Eurofins kinase panel); Cellular selectivity (NanoBRET assay, HEK293T cells): IC50(MAP3K19) >20 µM, IC50(STK17A) >20 µM, IC50(MAP2K5) >20 µM, IC50(FLT3) >20 µM; Screened against 45 GPCR targets (PDSP screen), closest targets: Ki(TMEM97) = 1155.57 nM , Ki(HTR2B) = 1305.2 nM;",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-985,Kinase set,1 µM
EUB0000305b_IKBKE,BAY-985,EUB0000305b,C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1,"InChI=1S/C27H30F3N9O/c1-17(38-8-10-39(11-9-38)25(40)15-27(28,29)30)18-6-7-31-23(13-18)36-26-34-20-5-4-19(12-22(20)35-26)21-14-24(37(2)3)33-16-32-21/h4-7,12-14,16-17H,8-11,15H2,1-3H3,(H2,31,34,35,36)/t17-/m1/s1",HZRJHVDNTDBTOZ-QGZVFWFLSA-N,Protein Kinase,IKBKE,9641,Q14164,"IKKE, IKK-i, KIAA0151",Inhibitor,BAY-440,2,IC50,TR-FRET-based kinase activity inhibition assay (1 µM ATP),https://doi.org/10.1021/acs.jmedchem.9b01460 ,=,1725,IC50,NanoBRET assay (HEK293T cells),,=,2,Kinome Scan (DiscoverX),468,"Screened at 100 nM, closest targets as % of contr.: MAP2K5 (8.5%), MAP3K19 (10%), SYK (31%), FLT3(D835V) (32%), STK17A (40%), TAOK3 (41%), PIK3CA(Q546K) (45%); In vitro follow-up of closest targets: IC50(FLT3) = 123 nM, IC50(MAP2K5) = 847 nM (Bayer in-house data), IC50(FLT3) = 123 nM, IC50(RPS6KA6) = 276 nM, IC50(DRAK1) = 311 nM, IC50(ULK1) = 7930 nM (PMID: 31859507); Kd(STK17A) = 74 nM, Kd(MAP3K19) = 9.6 nM (DiscoverX), IC50(STK17A) = 310 nM (Eurofins kinase panel); Cellular selectivity (NanoBRET assay, HEK293T cells): IC50(MAP3K19) >20 µM, IC50(STK17A) >20 µM, IC50(MAP2K5) >20 µM, IC50(FLT3) >20 µM; Screened against 45 GPCR targets (PDSP screen), closest targets: Ki(TMEM97) = 1155.57 nM , Ki(HTR2B) = 1305.2 nM;",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-985,Kinase set,1 µM
EUB0000312b_TGFBR1,TP-008,EUB0000312b,Cc1ncc(-c2cc(Cl)ccc2F)cc1-n1c(=O)n(CC(N)=O)c2cnccc21,"InChI=1S/C20H15ClFN5O2/c1-11-17(6-12(8-25-11)14-7-13(21)2-3-15(14)22)27-16-4-5-24-9-18(16)26(20(27)29)10-19(23)28/h2-9H,10H2,1H3,(H2,23,28)",HSCQDYRIKMDIJX-UHFFFAOYSA-N,Protein Kinase,TGFBR1,7046,P36897,"ALK-5, ACVRLK4, ALK5, TBRI, TBR-i",Inhibitor,Al11,25,IC50,Lathascreen (Takeda),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-008,=,245,IC50,Reporter gene assay,,=,0,KinomeScan (DiscoverX),70,"Screened at 1 µM, closest targets as % contr.: PIK3CA (33.9%), DDR1 (36.7%), JAK1 (38.6%), PNCK (39.5%), MAPK9 (39.6%), all >20 µM in NanoBRET cellular assays (HEK293T cells)",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-008,Kinase set,1 µM
EUB0000312b_ACVR1B,TP-008,EUB0000312b,Cc1ncc(-c2cc(Cl)ccc2F)cc1-n1c(=O)n(CC(N)=O)c2cnccc21,"InChI=1S/C20H15ClFN5O2/c1-11-17(6-12(8-25-11)14-7-13(21)2-3-15(14)22)27-16-4-5-24-9-18(16)26(20(27)29)10-19(23)28/h2-9H,10H2,1H3,(H2,23,28)",HSCQDYRIKMDIJX-UHFFFAOYSA-N,Protein Kinase,ACVR1B,91,P36896,"ALK4, SKR2, ActRIB",Inhibitor,Al11,126,IC50,Radioactive kinase assay (ACVR1B),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-008,=,526,IC50,Reporter gene assay,,=,0,KinomeScan (DiscoverX),70,"Screened at 1 µM, closest targets as % contr.: PIK3CA (33.9%), DDR1 (36.7%), JAK1 (38.6%), PNCK (39.5%), MAPK9 (39.6%), all >20 µM in NanoBRET cellular assays (HEK293T cells)",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-008,Kinase set,1 µM
EUB0000700a_MAPK3,ERKi-NC,EUB0000700a,C[C@@H](C1=CC=CC=N1)NC(NC2=NC(CO)=C3C=NNC3=C2)=O,"InChI=1S/C15H16N6O2/c1-9(11-4-2-3-5-16-11)18-15(23)20-14-6-12-10(7-17-21-12)13(8-22)19-14/h2-7,9,22H,8H2,1H3,(H,17,21)(H2,18,19,20,23)/t9-/m0/s1",XACXTPQNHGFQOD-VIFPVBQESA-N,Protein Kinase,MAPK3,5595,P27361,"ERK1, p44mapk, p44erk1",Negative control for ERKi,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/ERKi,,,,,,,,,,,,Kinase set,1 µM
EUB0000700a_MAPK1,ERKi-NC,EUB0000700a,C[C@@H](C1=CC=CC=N1)NC(NC2=NC(CO)=C3C=NNC3=C2)=O,"InChI=1S/C15H16N6O2/c1-9(11-4-2-3-5-16-11)18-15(23)20-14-6-12-10(7-17-21-12)13(8-22)19-14/h2-7,9,22H,8H2,1H3,(H,17,21)(H2,18,19,20,23)/t9-/m0/s1",XACXTPQNHGFQOD-VIFPVBQESA-N,Protein Kinase,MAPK1,5594,P28482,"ERK, ERK2, p41mapk, MAPK2",Negative control for ERKi,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/ERKi,,,,,,,,,,,,Kinase set,1 µM
EUB0000701a_TBK1,BAY-440,EUB0000701a,CN(C1=NC=NC(C2=CC=C3N=C(NC3=C2)NC4=CC(CN5CCN(C(CC(F)(F)F)=O)CC5)=CC=N4)=C1Cl)C,"InChI=1S/C26H27ClF3N9O/c1-37(2)24-22(27)23(32-15-33-24)17-3-4-18-19(12-17)35-25(34-18)36-20-11-16(5-6-31-20)14-38-7-9-39(10-8-38)21(40)13-26(28,29)30/h3-6,11-12,15H,7-10,13-14H2,1-2H3,(H2,31,34,35,36)",FNGNFKLDKUCGLD-UHFFFAOYSA-N,Protein Kinase,TBK1,29110,Q9UHD2,NAK,Negative control for BAY-985,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-985,,,,,,,,,,,,Kinase set,1 µM
EUB0000701a_IKBKE,BAY-440,EUB0000701a,CN(C1=NC=NC(C2=CC=C3N=C(NC3=C2)NC4=CC(CN5CCN(C(CC(F)(F)F)=O)CC5)=CC=N4)=C1Cl)C,"InChI=1S/C26H27ClF3N9O/c1-37(2)24-22(27)23(32-15-33-24)17-3-4-18-19(12-17)35-25(34-18)36-20-11-16(5-6-31-20)14-38-7-9-39(10-8-38)21(40)13-26(28,29)30/h3-6,11-12,15H,7-10,13-14H2,1-2H3,(H2,31,34,35,36)",FNGNFKLDKUCGLD-UHFFFAOYSA-N,Protein Kinase,IKBKE,9641,Q14164,"IKKE, IKK-i, KIAA0151",Negative control for BAY-985,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-985,,,,,,,,,,,,Kinase set,1 µM
EUB0000702a_PTK2,PF-00911705,EUB0000702a,CN(S(C)(=O)=O)C1=CC=NC(CNC2=C(C(F)(F)F)C=NC(NC3=CC(CC(N4)=O)=C4C=C3)=N2)=N1,"InChI=1S/C20H19F3N8O3S/c1-31(35(2,33)34)16-5-6-24-15(29-16)10-25-18-13(20(21,22)23)9-26-19(30-18)27-12-3-4-14-11(7-12)8-17(32)28-14/h3-7,9H,8,10H2,1-2H3,(H,28,32)(H2,25,26,27,30)",BJRRXLJCIAUKMM-UHFFFAOYSA-N,Protein Kinase,PTK2,5747,Q05397,"FAK, FADK, FAK1, PPP1R71",Negative control for PF-04554878,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/PF-04554878,,,,,,,,,,,,Kinase set,100 nM
EUB0000702a_PTK2B,PF-00911705,EUB0000702a,CN(S(C)(=O)=O)C1=CC=NC(CNC2=C(C(F)(F)F)C=NC(NC3=CC(CC(N4)=O)=C4C=C3)=N2)=N1,"InChI=1S/C20H19F3N8O3S/c1-31(35(2,33)34)16-5-6-24-15(29-16)10-25-18-13(20(21,22)23)9-26-19(30-18)27-12-3-4-14-11(7-12)8-17(32)28-14/h3-7,9H,8,10H2,1-2H3,(H,28,32)(H2,25,26,27,30)",BJRRXLJCIAUKMM-UHFFFAOYSA-N,Protein Kinase,PTK2B,2185,Q14289,"CAKB, PYK2, RAFTK, PTK, CADTK",Negative control for PF-04554878,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/PF-04554878,,,,,,,,,,,,Kinase set,100 nM
EUB0000703a_TIE1,BAY-309,EUB0000703a,O=C(C1=CC=CC(S(F)(F)(F)(F)F)=C1)NC2=CC(C)=CC(N3C=CN(C3=C4)N=C4C5=CN=CC=C5)=C2,"InChI=1S/C24H18F5N5OS/c1-16-10-19(31-24(35)17-4-2-6-21(12-17)36(25,26,27,28)29)13-20(11-16)33-8-9-34-23(33)14-22(32-34)18-5-3-7-30-15-18/h2-15H,1H3,(H,31,35)",MOONEVNPHKFNGV-UHFFFAOYSA-N,Protein Kinase,TIE1,7075,P35590,JTK14,Negative control for BAY-826,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-826,,,,,,,,,,,,Kinase set,100 nM
EUB0000703a_TEK,BAY-309,EUB0000703a,O=C(C1=CC=CC(S(F)(F)(F)(F)F)=C1)NC2=CC(C)=CC(N3C=CN(C3=C4)N=C4C5=CN=CC=C5)=C2,"InChI=1S/C24H18F5N5OS/c1-16-10-19(31-24(35)17-4-2-6-21(12-17)36(25,26,27,28)29)13-20(11-16)33-8-9-34-23(33)14-22(32-34)18-5-3-7-30-15-18/h2-15H,1H3,(H,31,35)",MOONEVNPHKFNGV-UHFFFAOYSA-N,Protein Kinase,TEK,7010,Q02763,"TIE2, TIE-2, VMCM1, CD202b",Negative control for BAY-826,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-826,,,,,,,,,,,,Kinase set,100 nM
EUB0000703a_DDR1,BAY-309,EUB0000703a,O=C(C1=CC=CC(S(F)(F)(F)(F)F)=C1)NC2=CC(C)=CC(N3C=CN(C3=C4)N=C4C5=CN=CC=C5)=C2,"InChI=1S/C24H18F5N5OS/c1-16-10-19(31-24(35)17-4-2-6-21(12-17)36(25,26,27,28)29)13-20(11-16)33-8-9-34-23(33)14-22(32-34)18-5-3-7-30-15-18/h2-15H,1H3,(H,31,35)",MOONEVNPHKFNGV-UHFFFAOYSA-N,Protein Kinase,DDR1,780,Q08345,"RTK6, CD167",Negative control for BAY-826,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-826,,,,,,,,,,,,Kinase set,100 nM
EUB0000703a_DDR2,BAY-309,EUB0000703a,O=C(C1=CC=CC(S(F)(F)(F)(F)F)=C1)NC2=CC(C)=CC(N3C=CN(C3=C4)N=C4C5=CN=CC=C5)=C2,"InChI=1S/C24H18F5N5OS/c1-16-10-19(31-24(35)17-4-2-6-21(12-17)36(25,26,27,28)29)13-20(11-16)33-8-9-34-23(33)14-22(32-34)18-5-3-7-30-15-18/h2-15H,1H3,(H,31,35)",MOONEVNPHKFNGV-UHFFFAOYSA-N,Protein Kinase,DDR2,4921,Q16832,TKT,Negative control for BAY-826,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-826,,,,,,,,,,,,Kinase set,100 nM
EUB0000704a_SYK,MRL-SYKi-NC,EUB0000704a,OC([C@H](C(C)(C)C1)CC[C@]1(O)C2=NC=C(S2)C3=CC(NC4=NC=CC(C)=N4)=CC(C)=C3)=O,"InChI=1S/C24H28N4O3S/c1-14-9-16(11-17(10-14)28-22-25-8-6-15(2)27-22)19-12-26-21(32-19)24(31)7-5-18(20(29)30)23(3,4)13-24/h6,8-12,18,31H,5,7,13H2,1-4H3,(H,29,30)(H,25,27,28)/t18-,24-/m1/s1",OYKPWSZSBLRRPL-HOYKHHGWSA-N,Protein Kinase,SYK,6850,P43405,,Negative control for MRL-SYKi,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/MRL-SYKi,,,,,,,,,,,,Kinase set,100 nM
EUB0000705a_CLK1,T3-CLK-N,EUB0000705a,CN1CCN(C(C(C)(C2=CC=C(C(NC3=CN4C=C(C5=CC(C(C)(C)C)=CC(C(C)(C)C)=C5)C=CC4=N3)=O)C=C2)C)=O)CC1,"InChI=1S/C37H47N5O2/c1-35(2,3)29-20-27(21-30(22-29)36(4,5)6)26-12-15-32-38-31(24-42(32)23-26)39-33(43)25-10-13-28(14-11-25)37(7,8)34(44)41-18-16-40(9)17-19-41/h10-15,20-24H,16-19H2,1-9H3,(H,39,43)",BNTGVINQADRYBE-UHFFFAOYSA-N,Protein Kinase,CLK1,1195,P49759,,Negative control for T3-CLK,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/T3-CLK,,,,,,,,,,,,Kinase set,100 nM
EUB0000705a_CLK2,T3-CLK-N,EUB0000705a,CN1CCN(C(C(C)(C2=CC=C(C(NC3=CN4C=C(C5=CC(C(C)(C)C)=CC(C(C)(C)C)=C5)C=CC4=N3)=O)C=C2)C)=O)CC1,"InChI=1S/C37H47N5O2/c1-35(2,3)29-20-27(21-30(22-29)36(4,5)6)26-12-15-32-38-31(24-42(32)23-26)39-33(43)25-10-13-28(14-11-25)37(7,8)34(44)41-18-16-40(9)17-19-41/h10-15,20-24H,16-19H2,1-9H3,(H,39,43)",BNTGVINQADRYBE-UHFFFAOYSA-N,Protein Kinase,CLK2,1196,P49760,,Negative control for T3-CLK,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/T3-CLK,,,,,,,,,,,,Kinase set,100 nM
EUB0000705a_CLK3,T3-CLK-N,EUB0000705a,CN1CCN(C(C(C)(C2=CC=C(C(NC3=CN4C=C(C5=CC(C(C)(C)C)=CC(C(C)(C)C)=C5)C=CC4=N3)=O)C=C2)C)=O)CC1,"InChI=1S/C37H47N5O2/c1-35(2,3)29-20-27(21-30(22-29)36(4,5)6)26-12-15-32-38-31(24-42(32)23-26)39-33(43)25-10-13-28(14-11-25)37(7,8)34(44)41-18-16-40(9)17-19-41/h10-15,20-24H,16-19H2,1-9H3,(H,39,43)",BNTGVINQADRYBE-UHFFFAOYSA-N,Protein Kinase,CLK3,1198,P49761,,Negative control for T3-CLK,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/T3-CLK,,,,,,,,,,,,Kinase set,100 nM
EUB0000705a_CLK4,T3-CLK-N,EUB0000705a,CN1CCN(C(C(C)(C2=CC=C(C(NC3=CN4C=C(C5=CC(C(C)(C)C)=CC(C(C)(C)C)=C5)C=CC4=N3)=O)C=C2)C)=O)CC1,"InChI=1S/C37H47N5O2/c1-35(2,3)29-20-27(21-30(22-29)36(4,5)6)26-12-15-32-38-31(24-42(32)23-26)39-33(43)25-10-13-28(14-11-25)37(7,8)34(44)41-18-16-40(9)17-19-41/h10-15,20-24H,16-19H2,1-9H3,(H,39,43)",BNTGVINQADRYBE-UHFFFAOYSA-N,Protein Kinase,CLK4,57396,Q9HAZ1,,Negative control for T3-CLK,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/T3-CLK,,,,,,,,,,,,Kinase set,100 nM
EUB0000706a_LRRK2,MLi-2-NC,EUB0000706a,C[C@H]1CN(C[C@@H](C)O1)C2=NC=NC(C3=NN(C4=C3C=C(C=C4)OC5(C)CC5)C)=C2,"InChI=1S/C22H27N5O2/c1-14-11-27(12-15(2)28-14)20-10-18(23-13-24-20)21-17-9-16(29-22(3)7-8-22)5-6-19(17)26(4)25-21/h5-6,9-10,13-15H,7-8,11-12H2,1-4H3/t14-,15+",YGCZGTCXWBPTDC-GASCZTMLSA-N,Protein Kinase,LRRK2,120892,Q5S007,"ROCO2, DKFZp434H2111, FLJ45829, RIPK7",Negative control for MLi-2,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/MLi-2,,,,,,,,,,,,Kinase set,100 nM
EUB0000707a_PRKAA1,BAY-974,EUB0000707a,CC1=C(C=CC=C1)C(NC2=NN(C3=CC=C(C=C23)C4C(C#N)=C(C)NC(C)=C4C#N)C)=O,"InChI=1S/C25H22N6O/c1-14-7-5-6-8-18(14)25(32)29-24-19-11-17(9-10-22(19)31(4)30-24)23-20(12-26)15(2)28-16(3)21(23)13-27/h5-11,23,28H,1-4H3,(H,29,30,32)",YJJMPAOJOSVSDB-UHFFFAOYSA-N,Protein Kinase,PRKAA1,5562,Q13131,AMPKa1,Negative control for BAY-3827,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-3827,,,,,,,,,,,,Kinase set,100 nM
EUB0000707a_RPS6KA1@kinase 1,BAY-974,EUB0000707a,CC1=C(C=CC=C1)C(NC2=NN(C3=CC=C(C=C23)C4C(C#N)=C(C)NC(C)=C4C#N)C)=O,"InChI=1S/C25H22N6O/c1-14-7-5-6-8-18(14)25(32)29-24-19-11-17(9-10-22(19)31(4)30-24)23-20(12-26)15(2)28-16(3)21(23)13-27/h5-11,23,28H,1-4H3,(H,29,30,32)",YJJMPAOJOSVSDB-UHFFFAOYSA-N,Protein Kinase,RPS6KA1@kinase 1,6196,Q15349,"RSK3, HU-2",Negative control for BAY-3827,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-3827,,,,,,,,,,,,Kinase set,100 nM
EUB0000708a_MAPK7,BAY-693,EUB0000708a,CC1=NC(C=C(N2CCN(CC2)C)C=N3)=C3C(C4CCN(C(C5=CC=C(OC(F)(F)F)C=C5N)=O)CC4)=N1,"InChI=1S/C26H30F3N7O2/c1-16-32-22-13-18(35-11-9-34(2)10-12-35)15-31-24(22)23(33-16)17-5-7-36(8-6-17)25(37)20-4-3-19(14-21(20)30)38-26(27,28)29/h3-4,13-15,17H,5-12,30H2,1-2H3",AROOGPVJRFLMEV-UHFFFAOYSA-N,Protein Kinase,MAPK7,5598,Q13164,"BMK1, ERK5",Negative control for BAY-885,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-885,,,,,,,,,,,,Kinase set,1 µM
EUB0000709a_ROCK1,BAY-4900,EUB0000709a,CN1C=C(Cl)C2=C1N=CC=C2OC3=C(F)C=C(NC4=NC(N)=NC(Cl)=C4)C=C3F,"InChI=1S/C18H12Cl2F2N6O/c1-28-7-9(19)15-12(2-3-24-17(15)28)29-16-10(21)4-8(5-11(16)22)25-14-6-13(20)26-18(23)27-14/h2-7H,1H3,(H3,23,25,26,27)",LQNZFNWBROGUOM-UHFFFAOYSA-N,Protein Kinase,ROCK1,6093,Q13464,p160ROCK,Negative control for BAY-549,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-549,,,,,,,,,,,,Kinase set,100 nM
EUB0000709a_ROCK2,BAY-4900,EUB0000709a,CN1C=C(Cl)C2=C1N=CC=C2OC3=C(F)C=C(NC4=NC(N)=NC(Cl)=C4)C=C3F,"InChI=1S/C18H12Cl2F2N6O/c1-28-7-9(19)15-12(2-3-24-17(15)28)29-16-10(21)4-8(5-11(16)22)25-14-6-13(20)26-18(23)27-14/h2-7H,1H3,(H3,23,25,26,27)",LQNZFNWBROGUOM-UHFFFAOYSA-N,Protein Kinase,ROCK2,9475,O75116,,Negative control for BAY-549,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-549,,,,,,,,,,,,Kinase set,100 nM
EUB0000710a_ACVR1B,Al11,EUB0000710a,O=C1N(C2=CC=CC=C2N1CC(N)=O)C3=CC(C4=C(C=CC(Cl)=C4)F)=CN=C3C,"InChI=1S/C21H16ClFN4O2/c1-12-19(8-13(10-25-12)15-9-14(22)6-7-16(15)23)27-18-5-3-2-4-17(18)26(21(27)29)11-20(24)28/h2-10H,11H2,1H3,(H2,24,28)",XNDYHEXTXJNCNG-UHFFFAOYSA-N,Protein Kinase,ACVR1B,91,P36896,"ALK4, SKR2, ActRIB",Negative control for TP-008,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-008,,,,,,,,,,,,Kinase set,1 µM
EUB0000710a_TGFBR1,Al11,EUB0000710a,O=C1N(C2=CC=CC=C2N1CC(N)=O)C3=CC(C4=C(C=CC(Cl)=C4)F)=CN=C3C,"InChI=1S/C21H16ClFN4O2/c1-12-19(8-13(10-25-12)15-9-14(22)6-7-16(15)23)27-18-5-3-2-4-17(18)26(21(27)29)11-20(24)28/h2-10H,11H2,1H3,(H2,24,28)",XNDYHEXTXJNCNG-UHFFFAOYSA-N,Protein Kinase,TGFBR1,7046,P36897,"ALK-5, ACVRLK4, ALK5, TBRI, TBR-i",Negative control for TP-008,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-008,,,,,,,,,,,,Kinase set,1 µM
EUB0000711a_MAPK11,SR321,EUB0000711a,FC(F)(F)C1=C(C=NN1C2=CC=CC=C2)C(NCC3=CC=C(C=C3)C(NCCCC4CCCCC4)=O)=O,"InChI=1S/C28H31F3N4O2/c29-28(30,31)25-24(19-34-35(25)23-11-5-2-6-12-23)27(37)33-18-21-13-15-22(16-14-21)26(36)32-17-7-10-20-8-3-1-4-9-20/h2,5-6,11-16,19-20H,1,3-4,7-10,17-18H2,(H,32,36)(H,33,37)",HMPXSYOFBMBHDF-UHFFFAOYSA-N,Protein Kinase,MAPK11,5600,Q15759,"p38-2, p38Beta, SAPK2",Negative control for SR318,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/SR-318,,,,,,,,,,,,Kinase set,1 µM
EUB0000711a_MAPK14,SR321,EUB0000711a,FC(F)(F)C1=C(C=NN1C2=CC=CC=C2)C(NCC3=CC=C(C=C3)C(NCCCC4CCCCC4)=O)=O,"InChI=1S/C28H31F3N4O2/c29-28(30,31)25-24(19-34-35(25)23-11-5-2-6-12-23)27(37)33-18-21-13-15-22(16-14-21)26(36)32-17-7-10-20-8-3-1-4-9-20/h2,5-6,11-16,19-20H,1,3-4,7-10,17-18H2,(H,32,36)(H,33,37)",HMPXSYOFBMBHDF-UHFFFAOYSA-N,Protein Kinase,MAPK14,1432,Q16539,"PRKM14, p38, Mxi2, PRKM15",Negative control for SR318,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/SR-318,,,,,,,,,,,,Kinase set,1 µM
EUB0000712a_DDR1,SR-302,EUB0000712a,CS(N1CCCC(NC([C@@H](NC(C2=CC=C(C=C2)CNC(C3=CN=C4C=CC=CN34)=O)=O)CCC5CCCCC5)=O)C1)(=O)=O,"InChI=1S/C32H42N6O5S/c1-44(42,43)37-18-7-10-26(22-37)35-31(40)27(17-14-23-8-3-2-4-9-23)36-30(39)25-15-12-24(13-16-25)20-34-32(41)28-21-33-29-11-5-6-19-38(28)29/h5-6,11-13,15-16,19,21,23,26-27H,2-4,7-10,14,17-18,20,22H2,1H3,(H,34,41)(H,35,40)(H,36,39)/t26?,27-/m0/s1",WGMNFJAFXXXRLZ-GEVKEYJPSA-N,Protein Kinase,DDR1,780,Q08345,"RTK6, CD167",Inhibitor,SR301,53.3,IC50,Enzyme kinetic assay (Reaction Biology),"https://doi.org/10.1021/acs.jmedchem.1c00868, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/SR-302",=,23,IC50,NanoBRET assay (HEK293T cells),,=,0,KinomeScan (DiscoverX),468,"Screened at 1 µM, closest targets as % of contr.: ABL1-nonphosphorylated (14%), RIPK2 (30%), RPS6KA5RPS6KA5(Kin.Dom.2-C-terminal) (35%), CHEK2 (37%), PIK3CA (37%), STK38L (40%); Follow-up IC50s in cellular NanoBRET assays: all targets IC50 >25 µM (>125-fold selective);","https://doi.org/10.1021/acs.jmedchem.1c00868, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/SR-302",Kinase set,100 nM
EUB0000712a_DDR2,SR-302,EUB0000712a,CS(N1CCCC(NC([C@@H](NC(C2=CC=C(C=C2)CNC(C3=CN=C4C=CC=CN34)=O)=O)CCC5CCCCC5)=O)C1)(=O)=O,"InChI=1S/C32H42N6O5S/c1-44(42,43)37-18-7-10-26(22-37)35-31(40)27(17-14-23-8-3-2-4-9-23)36-30(39)25-15-12-24(13-16-25)20-34-32(41)28-21-33-29-11-5-6-19-38(28)29/h5-6,11-13,15-16,19,21,23,26-27H,2-4,7-10,14,17-18,20,22H2,1H3,(H,34,41)(H,35,40)(H,36,39)/t26?,27-/m0/s1",WGMNFJAFXXXRLZ-GEVKEYJPSA-N,Protein Kinase,DDR2,4921,Q16832,TKT,Inhibitor,SR301,0.75,IC50,Enzyme kinetic assay (Reaction Biology),"https://doi.org/10.1021/acs.jmedchem.1c00868, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/SR-302",=,18,IC50,NanoBRET assay (HEK293T cells),,=,0,KinomeScan (DiscoverX),468,"Screened at 1 µM, closest targets as % of contr.: ABL1-nonphosphorylated (14%), RIPK2 (30%), RPS6KA5RPS6KA5(Kin.Dom.2-C-terminal) (35%), CHEK2 (37%), PIK3CA (37%), STK38L (40%); Follow-up IC50s in cellular NanoBRET assays: all targets IC50 >25 µM (>125-fold selective);","https://doi.org/10.1021/acs.jmedchem.1c00868, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/SR-302",Kinase set,100 nM
EUB0000712a_MAPK11,SR-302,EUB0000712a,CS(N1CCCC(NC([C@@H](NC(C2=CC=C(C=C2)CNC(C3=CN=C4C=CC=CN34)=O)=O)CCC5CCCCC5)=O)C1)(=O)=O,"InChI=1S/C32H42N6O5S/c1-44(42,43)37-18-7-10-26(22-37)35-31(40)27(17-14-23-8-3-2-4-9-23)36-30(39)25-15-12-24(13-16-25)20-34-32(41)28-21-33-29-11-5-6-19-38(28)29/h5-6,11-13,15-16,19,21,23,26-27H,2-4,7-10,14,17-18,20,22H2,1H3,(H,34,41)(H,35,40)(H,36,39)/t26?,27-/m0/s1",WGMNFJAFXXXRLZ-GEVKEYJPSA-N,Protein Kinase,MAPK11,5600,Q15759,"p38-2, p38Beta, SAPK2",Inhibitor,SR301,45.1,IC50,Enzyme kinetic assay (Reaction Biology),"https://doi.org/10.1021/acs.jmedchem.1c00868, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/SR-302",=,196,IC50,NanoBRET assay (HEK293T cells),,=,0,KinomeScan (DiscoverX),468,"Screened at 1 µM, closest targets as % of contr.: ABL1-nonphosphorylated (14%), RIPK2 (30%), RPS6KA5RPS6KA5(Kin.Dom.2-C-terminal) (35%), CHEK2 (37%), PIK3CA (37%), STK38L (40%); Follow-up IC50s in cellular NanoBRET assays: all targets IC50 >25 µM (>125-fold selective);","https://doi.org/10.1021/acs.jmedchem.1c00868, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/SR-302",Kinase set,100 nM
EUB0000712a_MAPK14,SR-302,EUB0000712a,CS(N1CCCC(NC([C@@H](NC(C2=CC=C(C=C2)CNC(C3=CN=C4C=CC=CN34)=O)=O)CCC5CCCCC5)=O)C1)(=O)=O,"InChI=1S/C32H42N6O5S/c1-44(42,43)37-18-7-10-26(22-37)35-31(40)27(17-14-23-8-3-2-4-9-23)36-30(39)25-15-12-24(13-16-25)20-34-32(41)28-21-33-29-11-5-6-19-38(28)29/h5-6,11-13,15-16,19,21,23,26-27H,2-4,7-10,14,17-18,20,22H2,1H3,(H,34,41)(H,35,40)(H,36,39)/t26?,27-/m0/s1",WGMNFJAFXXXRLZ-GEVKEYJPSA-N,Protein Kinase,MAPK14,1432,Q16539,"PRKM14, p38, Mxi2, PRKM15",Inhibitor,SR301,6.2,IC50,Enzyme kinetic assay (Reaction Biology),"https://doi.org/10.1021/acs.jmedchem.1c00868, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/SR-302",=,125,IC50,NanoBRET assay (HEK293T cells),,=,0,KinomeScan (DiscoverX),468,"Screened at 1 µM, closest targets as % of contr.: ABL1-nonphosphorylated (14%), RIPK2 (30%), RPS6KA5RPS6KA5(Kin.Dom.2-C-terminal) (35%), CHEK2 (37%), PIK3CA (37%), STK38L (40%); Follow-up IC50s in cellular NanoBRET assays: all targets IC50 >25 µM (>125-fold selective);","https://doi.org/10.1021/acs.jmedchem.1c00868, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/SR-302",Kinase set,100 nM
EUB0000138c_PTK2,PF-04554878,EUB0000138c,CNC(C1=CC=C(NC2=NC=C(C(F)(F)F)C(NCC3=C(N(S(C)(=O)=O)C)N=CC=N3)=N2)C=C1)=O,"InChI=1S/C20H21F3N8O3S/c1-24-18(32)12-4-6-13(7-5-12)29-19-28-10-14(20(21,22)23)16(30-19)27-11-15-17(26-9-8-25-15)31(2)35(3,33)34/h4-10H,11H2,1-3H3,(H,24,32)(H2,27,28,29,30)",FWLMVFUGMHIOAA-UHFFFAOYSA-N,Protein Kinase,PTK2,5747,Q05397,"FAK, FADK, FAK1, PPP1R71",Inhibitor,PF-00911705,0.2,IC50,Binding assay,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/PF-04554878,=,3,IC50,Inhibition of human PTK2 phosphorylation in A431 cells,,=,11,KinomeScan (DiscoverX),448,"Screened at 0.1 µM, closest targets as % of contr.: CLK2 (0%), FLT3(N841I) (0%), FLT3(D835V) (0.2%), YSK4 (1.7%), JAK2 (4.8%), FLT3(D835Y) (5.9%), STK16 (7.7%), JAK3 (8.2), TTK (8.3%), FLT3(ITD,F691L) (9%), FLT3(D835H) (9.8%); Screened in Invitrogen panel at 10 µM, closest targets: IC50(NTRK1) = 56 nM, IC50(MAP3K9) = 75.3 nM; Screened in CEREP panel against 122 human receptors, ion channels, enzymes, closest target: Ki(ADORA3) = 27 nM; Screened in GPCR screen against 45 targets at 10 µM, clean profile;",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/PF-04554878,Kinase set,100 nM
EUB0000138c_PTK2B,PF-04554878,EUB0000138c,CNC(C1=CC=C(NC2=NC=C(C(F)(F)F)C(NCC3=C(N(S(C)(=O)=O)C)N=CC=N3)=N2)C=C1)=O,"InChI=1S/C20H21F3N8O3S/c1-24-18(32)12-4-6-13(7-5-12)29-19-28-10-14(20(21,22)23)16(30-19)27-11-15-17(26-9-8-25-15)31(2)35(3,33)34/h4-10H,11H2,1-3H3,(H,24,32)(H2,27,28,29,30)",FWLMVFUGMHIOAA-UHFFFAOYSA-N,Protein Kinase,PTK2B,2185,Q14289,"CAKB, PYK2, RAFTK, PTK, CADTK",Inhibitor,PF-00911705,0.2,IC50,Binding assay,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/PF-04554878,=,,,,,,11,KinomeScan (DiscoverX),448,"Screened at 0.1 µM, closest targets as % of contr.: CLK2 (0%), FLT3(N841I) (0%), FLT3(D835V) (0.2%), YSK4 (1.7%), JAK2 (4.8%), FLT3(D835Y) (5.9%), STK16 (7.7%), JAK3 (8.2), TTK (8.3%), FLT3(ITD,F691L) (9%), FLT3(D835H) (9.8%); Screened in Invitrogen panel at 10 µM, closest targets: IC50(NTRK1) = 56 nM, IC50(MAP3K9) = 75.3 nM; Screened in CEREP panel against 122 human receptors, ion channels, enzymes, closest target: Ki(ADORA3) = 27 nM; Screened in GPCR screen against 45 targets at 10 µM, clean profile;",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/PF-04554878,Kinase set,100 nM
EUB0000713a_TIE1,BAY-826,EUB0000713a,N#CC1=CC(S(F)(F)(F)(F)F)=CC(C(NC2=C(C)C=C(C)C(N3C=CN(C3=C4)N=C4C5=CN=CC=C5)=C2)=O)=C1,"InChI=1S/C26H19F5N6OS/c1-16-8-17(2)24(36-6-7-37-25(36)13-23(35-37)19-4-3-5-33-15-19)12-22(16)34-26(38)20-9-18(14-32)10-21(11-20)39(27,28,29,30)31/h3-13,15H,1-2H3,(H,34,38)",MPASHPJAIUOWCK-UHFFFAOYSA-N,Protein Kinase,TIE1,7075,P35590,JTK14,Inhibitor,BAY-309,0.9,Kd,KdELECT (DiscoverX),"https://doi.org/10.1111/jnc.13877,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-826",=,5.4,IC50,NanoBRET assay (HEK293T cells),,=,0,Kinome Scan (DiscoverX),453,"Screened at 100 nM, closest targets: Kd(STK10) = 5.9 nM, Ki(EPHB6) = 25 nM, Ki(ABL-1, non-phosphorylated) = 38 nM, Ki(LYN) = 40 nM; Cellular selectivity, of closest targets in HEK293T cells (NanoBRET assay): IC50(STK10) = 210 ± 97 nM (n= 2), IC50(EPHB6) = 3.9 ± 0.3 µM (n= 2), IC50(LYN) = 8.2 ± 0.86 µM (n= 2); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest targets: Ki(OPRK1) = 124.61 nM, Ki(GABA/PBR) = 217.26 nM, Ki(TMEM97) = 983.68 nM, Ki(ADRB3) = 7099.67 nM","https://doi.org/10.1111/jnc.13877, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-826",Kinase set,100 nM
EUB0000713a_TEK,BAY-826,EUB0000713a,N#CC1=CC(S(F)(F)(F)(F)F)=CC(C(NC2=C(C)C=C(C)C(N3C=CN(C3=C4)N=C4C5=CN=CC=C5)=C2)=O)=C1,"InChI=1S/C26H19F5N6OS/c1-16-8-17(2)24(36-6-7-37-25(36)13-23(35-37)19-4-3-5-33-15-19)12-22(16)34-26(38)20-9-18(14-32)10-21(11-20)39(27,28,29,30)31/h3-13,15H,1-2H3,(H,34,38)",MPASHPJAIUOWCK-UHFFFAOYSA-N,Protein Kinase,TEK,7010,Q02763,"TIE2, TIE-2, VMCM1, CD202b",Inhibitor,BAY-309,1.6,Kd,KdELECT (DiscoverX),"https://doi.org/10.1111/jnc.13877,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-826",=,0.7,IC50,NanoBRET assay (HEK293T cells),,=,0,Kinome Scan (DiscoverX),453,"Screened at 100 nM, closest targets: Kd(STK10) = 5.9 nM, Ki(EPHB6) = 25 nM, Ki(ABL-1, non-phosphorylated) = 38 nM, Ki(LYN) = 40 nM; Cellular selectivity, of closest targets in HEK293T cells (NanoBRET assay): IC50(STK10) = 210 ± 97 nM (n= 2), IC50(EPHB6) = 3.9 ± 0.3 µM (n= 2), IC50(LYN) = 8.2 ± 0.86 µM (n= 2); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest targets: Ki(OPRK1) = 124.61 nM, Ki(GABA/PBR) = 217.26 nM, Ki(TMEM97) = 983.68 nM, Ki(ADRB3) = 7099.67 nM","https://doi.org/10.1111/jnc.13877, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-826",Kinase set,100 nM
EUB0000713a_DDR1,BAY-826,EUB0000713a,N#CC1=CC(S(F)(F)(F)(F)F)=CC(C(NC2=C(C)C=C(C)C(N3C=CN(C3=C4)N=C4C5=CN=CC=C5)=C2)=O)=C1,"InChI=1S/C26H19F5N6OS/c1-16-8-17(2)24(36-6-7-37-25(36)13-23(35-37)19-4-3-5-33-15-19)12-22(16)34-26(38)20-9-18(14-32)10-21(11-20)39(27,28,29,30)31/h3-13,15H,1-2H3,(H,34,38)",MPASHPJAIUOWCK-UHFFFAOYSA-N,Protein Kinase,DDR1,780,Q08345,"RTK6, CD167",Inhibitor,BAY-309,0.4,Kd,KdELECT (DiscoverX),"https://doi.org/10.1111/jnc.13877,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-826",=,0.9,IC50,NanoBRET assay (HEK293T cells),,=,0,Kinome Scan (DiscoverX),453,"Screened at 100 nM, closest targets: Kd(STK10) = 5.9 nM, Ki(EPHB6) = 25 nM, Ki(ABL-1, non-phosphorylated) = 38 nM, Ki(LYN) = 40 nM; Cellular selectivity, of closest targets in HEK293T cells (NanoBRET assay): IC50(STK10) = 210 ± 97 nM (n= 2), IC50(EPHB6) = 3.9 ± 0.3 µM (n= 2), IC50(LYN) = 8.2 ± 0.86 µM (n= 2); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest targets: Ki(OPRK1) = 124.61 nM, Ki(GABA/PBR) = 217.26 nM, Ki(TMEM97) = 983.68 nM, Ki(ADRB3) = 7099.67 nM","https://doi.org/10.1111/jnc.13877, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-826",Kinase set,100 nM
EUB0000713a_DDR2,BAY-826,EUB0000713a,N#CC1=CC(S(F)(F)(F)(F)F)=CC(C(NC2=C(C)C=C(C)C(N3C=CN(C3=C4)N=C4C5=CN=CC=C5)=C2)=O)=C1,"InChI=1S/C26H19F5N6OS/c1-16-8-17(2)24(36-6-7-37-25(36)13-23(35-37)19-4-3-5-33-15-19)12-22(16)34-26(38)20-9-18(14-32)10-21(11-20)39(27,28,29,30)31/h3-13,15H,1-2H3,(H,34,38)",MPASHPJAIUOWCK-UHFFFAOYSA-N,Protein Kinase,DDR2,4921,Q16832,TKT,Inhibitor,BAY-309,1.3,Kd,KdELECT (DiscoverX),"https://doi.org/10.1111/jnc.13877,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-826",=,3,IC50,NanoBRET assay (HEK293T cells),,=,0,Kinome Scan (DiscoverX),453,"Screened at 100 nM, closest targets: Kd(STK10) = 5.9 nM, Ki(EPHB6) = 25 nM, Ki(ABL-1, non-phosphorylated) = 38 nM, Ki(LYN) = 40 nM; Cellular selectivity, of closest targets in HEK293T cells (NanoBRET assay): IC50(STK10) = 210 ± 97 nM (n= 2), IC50(EPHB6) = 3.9 ± 0.3 µM (n= 2), IC50(LYN) = 8.2 ± 0.86 µM (n= 2); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest targets: Ki(OPRK1) = 124.61 nM, Ki(GABA/PBR) = 217.26 nM, Ki(TMEM97) = 983.68 nM, Ki(ADRB3) = 7099.67 nM","https://doi.org/10.1111/jnc.13877, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-826",Kinase set,100 nM
EUB0000714a_SYK,MRL-SYKi,EUB0000714a,OC([C@H](C(C)(C)C1)CC[C@]1(O)C2=NC=C(S2)C3=CC(NC4=CC=CC(C(F)(F)F)=N4)=C(C)C=C3)=O,"InChI=1S/C25H26F3N3O3S/c1-14-7-8-15(11-17(14)30-20-6-4-5-19(31-20)25(26,27)28)18-12-29-22(35-18)24(34)10-9-16(21(32)33)23(2,3)13-24/h4-8,11-12,16,34H,9-10,13H2,1-3H3,(H,30,31)(H,32,33)/t16-,24-/m1/s1",HUOXIXBCBFNFKF-VOIUYBSRSA-N,Protein Kinase,SYK,6850,P43405,,Inhibitor,MRL-SYKi-NC,0.9,IC50,Enzymatic inhibition assay,https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/MRL-SYKi,=,38,IC50,Cellular human mast cell degranulation assay,,=,0,KinomeScan (Invitrogen),265,"Screened at 1 µM, no targets within 10-fold, closest kinases IC50 >100-fold",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/MRL-SYKi,Kinase set,100 nM
EUB0000715a_LRRK2,MLi-2,EUB0000715a,[H][C@@]1(CN(C2=NC=NC(C3=NNC4=C3C=C(OC5(CC5)C)C=C4)=C2)C[C@@](C)(O1)[H])C,"InChI=1S/C21H25N5O2/c1-13-10-26(11-14(2)27-13)19-9-18(22-12-23-19)20-16-8-15(28-21(3)6-7-21)4-5-17(16)24-25-20/h4-5,8-9,12-14H,6-7,10-11H2,1-3H3,(H,24,25)/t13-,14+",ATUUNJCZCOMUKD-OKILXGFUSA-N,Protein Kinase,LRRK2,120892,Q5S007,"ROCO2, DKFZp434H2111, FLJ45829, RIPK7",Inhibitor,MLi-2-NC,0.76,IC50,LanthaScreen,https://doi.org/10.1124/jpet.115.227587,=,1.2,IC50,NanoBRET assay (HEK293T cells),,=,5,SelectScreen (Invitrogen),308,"Screened at 1 µM, >100-fold selective, closest targets: IC50(CLK4) = 225 nM, IC50(MAP3K14) = 244 nM, IC50(MAP3K5) = 428 nM, IC50(CLK2) = 605 nM, IC50(TTK) = 935 nM); PanLabs Profile showed 5 hits > 50% inhibition at 10 µM: IC50 (HTR2B) = 1.2 µM, IC50(SLC6A2) = 3.8 µM, IC50(CHRM2) = 6.4 µM, IC50(PPARG) = 6.5 µM, IC50(adenosine transporter) = 9.7 µM; Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest target: Ki(TMEM97) = 4600.45 nM ",https://doi.org/10.1124/jpet.115.227587,Kinase set,100 nM
EUB0000716a_ROCK1,BAY-549,EUB0000716a,Cc1c[nH]c2c1c(ccn2)Oc1c(cc(cc1F)Nc1cc(nc(N)n1)[Cl])F,"InChI=1S/C18H13ClF2N6O/c1-8-7-24-17-15(8)12(2-3-23-17)28-16-10(20)4-9(5-11(16)21)25-14-6-13(19)26-18(22)27-14/h2-7H,1H3,(H,23,24)(H3,22,25,26,27)",NRSGWEVTVGZDFC-UHFFFAOYSA-N,Protein Kinase,ROCK1,6093,Q13464,p160ROCK,Inhibitor,BAY-4900,0.6,IC50,Enzyme activity assay,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-549,=,,,,,,1,KinomeScan (DiscoverX),468,"Screened at 100 nM, closest targets as % of contr.: LATS2 (0.7%), PRKACA (28%), PRKACB (36%), LATS1 (42%), PRKG1 (49%); Screened in Upstate kinase panel against 114 kinases at 10 µM, >250 fold selective, closest targets: IC50(NTRK1) = 252 nM, IC50(FLT3) = 303 nM, IC50(PKA) = 734 nM; Screened against 45 GPCR targets (PDSP screen), closest targets: Ki(OPRK1) = 187.33 nM, Ki(SIGMAR1) = 6765.5 nM; Screened in Eurofins-Panlabs radioligand binding assay against 63 targets at 10 µM, closest targets: Ki(SLC6A3) = 0.039 µM, Ki(DAT2) = 0.027 µM;",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-549,Kinase set,100 nM
EUB0000716a_ROCK2,BAY-549,EUB0000716a,Cc1c[nH]c2c1c(ccn2)Oc1c(cc(cc1F)Nc1cc(nc(N)n1)[Cl])F,"InChI=1S/C18H13ClF2N6O/c1-8-7-24-17-15(8)12(2-3-23-17)28-16-10(20)4-9(5-11(16)21)25-14-6-13(19)26-18(22)27-14/h2-7H,1H3,(H,23,24)(H3,22,25,26,27)",NRSGWEVTVGZDFC-UHFFFAOYSA-N,Protein Kinase,ROCK2,9475,O75116,,Inhibitor,BAY-4900,1.1,IC50,Enzyme activity assay,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-549,=,,,,,,1,KinomeScan (DiscoverX),468,"Screened at 100 nM, closest targets as % of contr.: LATS2 (0.7%), PRKACA (28%), PRKACB (36%), LATS1 (42%), PRKG1 (49%); Screened in Upstate kinase panel against 114 kinases at 10 µM, >250 fold selective, closest targets: IC50(NTRK1) = 252 nM, IC50(FLT3) = 303 nM, IC50(PKA) = 734 nM; Screened against 45 GPCR targets (PDSP screen), closest targets: Ki(OPRK1) = 187.33 nM, Ki(SIGMAR1) = 6765.5 nM; Screened in Eurofins-Panlabs radioligand binding assay against 63 targets at 10 µM, closest targets: Ki(SLC6A3) = 0.039 µM, Ki(DAT2) = 0.027 µM;",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-549,Kinase set,100 nM
EUB0000717a_MAPK14,L-Skepinone,EUB0000717a,C1Cc2cc(ccc2C(c2cc(ccc12)OC[C@@H](CO)O)=O)Nc1ccc(cc1F)F,"InChI=1S/C24H21F2NO4/c25-16-4-8-23(22(26)10-16)27-17-5-7-20-15(9-17)2-1-14-3-6-19(11-21(14)24(20)30)31-13-18(29)12-28/h3-11,18,27-29H,1-2,12-13H2/t18-/m1/s1",HXMGCTFLLWPVFM-GOSISDBHSA-N,Protein Kinase,MAPK14,1432,Q16539,"PRKM14, p38, Mxi2, PRKM15",Inhibitor,,5,IC50,ELISA (cell free),https://doi.org/10.1038/nchembio.761,=,13.6,IC50,NanoBRET assay (HEK293T cells),,=,0,KINOMEscan (DiscoverX),403,"Screened at 1 µM, >1000-fold selective, off-targets with PoC <50%",https://doi.org/10.1038/nchembio.761,Kinase set,1 µM
EUB0000717a_MAPK11,L-Skepinone,EUB0000717a,C1Cc2cc(ccc2C(c2cc(ccc12)OC[C@@H](CO)O)=O)Nc1ccc(cc1F)F,"InChI=1S/C24H21F2NO4/c25-16-4-8-23(22(26)10-16)27-17-5-7-20-15(9-17)2-1-14-3-6-19(11-21(14)24(20)30)31-13-18(29)12-28/h3-11,18,27-29H,1-2,12-13H2/t18-/m1/s1",HXMGCTFLLWPVFM-GOSISDBHSA-N,Protein Kinase,MAPK11,5600,Q15759,"p38-2, p38Beta, SAPK2",Inhibitor,,,,,,,40.2,IC50,NanoBRET assay (HEK293T cells),,=,0,KINOMEscan (DiscoverX),403,"Screened at 1 µM, >1000-fold selective, off-targets with PoC <50%",https://doi.org/10.1038/nchembio.761,Kinase set,1 µM
EUB0000718a_MAPK14,FS-694,EUB0000718a,C1Cc2cc(ccc2C(c2cc(ccc12)C(NCCN1CCOCC1)=O)=O)Nc1ccc(c(c1)NC(c1ccccc1)=O)F,"InChI=1S/C35H33FN4O4/c36-31-13-11-28(22-32(31)39-35(43)24-4-2-1-3-5-24)38-27-10-12-29-25(20-27)8-6-23-7-9-26(21-30(23)33(29)41)34(42)37-14-15-40-16-18-44-19-17-40/h1-5,7,9-13,20-22,38H,6,8,14-19H2,(H,37,42)(H,39,43)",JWZSSEWMVYKYKW-UHFFFAOYSA-N,Protein Kinase,MAPK14,1432,Q16539,"PRKM14, p38, Mxi2, PRKM15",Inhibitor,FM-743,0.2,IC50,ELISA (cell free),https://doi.org/10.1021/acs.jmedchem.7b00745 ,=,14.9,IC50,NanoBRET assay (HEK293T cells),,=,5,KinomeScan (DiscoverX),441,Screened at 1 µM off-targets with PoC <35%,https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/FS-694,Kinase set,1 µM
EUB0000718a_MAPK11,FS-694,EUB0000718a,C1Cc2cc(ccc2C(c2cc(ccc12)C(NCCN1CCOCC1)=O)=O)Nc1ccc(c(c1)NC(c1ccccc1)=O)F,"InChI=1S/C35H33FN4O4/c36-31-13-11-28(22-32(31)39-35(43)24-4-2-1-3-5-24)38-27-10-12-29-25(20-27)8-6-23-7-9-26(21-30(23)33(29)41)34(42)37-14-15-40-16-18-44-19-17-40/h1-5,7,9-13,20-22,38H,6,8,14-19H2,(H,37,42)(H,39,43)",JWZSSEWMVYKYKW-UHFFFAOYSA-N,Protein Kinase,MAPK11,5600,Q15759,"p38-2, p38Beta, SAPK2",Inhibitor,FM-743,,,,,,16.9,IC50,NanoBRET assay (HEK293T cells),,=,5,KinomeScan (DiscoverX),441,Screened at 1 µM off-targets with PoC <35%,https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/FS-694,Kinase set,1 µM
EUB0000719a_RIPK1,TP_030_1,EUB0000719a,CN1C([C@@H](N2CCC3=CN(N=C3C2=O)CC4=CC=CC=C4)COC5=C1C=CC=C5)=O,"InChI=1S/C23H22N4O3/c1-25-18-9-5-6-10-20(18)30-15-19(22(25)28)27-12-11-17-14-26(24-21(17)23(27)29)13-16-7-3-2-4-8-16/h2-10,14,19H,11-13,15H2,1H3/t19-/m0/s1",MAHFVAHPQSLLJF-IBGZPJMESA-N,Protein Kinase,RIPK1,8737,Q13546,RIP,Allosteric inhibitor,TP_030_n,3.9,Ki,TR-FRET binding assay (Invitrogen),"https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-030-1, https://doi.org/10.1021/acs.jmedchem.7b01647",=,,,,,,0,Takeda global kinase panel,303,"Highly selective; screen against 45 GPCR targets, closest target: Ki(GABA/PBR) = 374.92 nM; clean in Eurofins-Panlabs radioligand binding assay, screen against 68 targets, at 10 µM",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-030-1,Kinase set,100 nM
EUB0000720a_RIPK1,TP_030_2,EUB0000720a,CN1C([C@@H](N2CCC3=C(Br)N(CC4=CC=CC=C4)N=C3C2=O)COC5=C1C=CC=C5)=O,"InChI=1S/C23H21BrN4O3/c1-26-17-9-5-6-10-19(17)31-14-18(22(26)29)27-12-11-16-20(23(27)30)25-28(21(16)24)13-15-7-3-2-4-8-15/h2-10,18H,11-14H2,1H3/t18-/m0/s1",KHVVJKLNKLQLJZ-SFHVURJKSA-N,Protein Kinase,RIPK1,8737,Q13546,RIP,Allosteric inhibitor,TP_030_n,0.43,Ki,TR-FRET binding assay (Invitrogen),"https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-030-2, https://doi.org/10.1021/acs.jmedchem.7b01647",=,,,,,,0,Takeda global kinase panel,303,"Highly selective; Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest targets: Ki(GABA/PBR) = 346.58 nM, Ki(HTR2A) = 2071.02 nM, Ki(ADRA2A) = 2355.74 nM; Screened in Eurofins-Panlabs radioligand binding assay against 68 targets at 10 µM: closest target: HTR2B (63 % of contr.)",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-030-2,Kinase set,100 nM
EUB0000721a_AKT1,RL2841,EUB0000721a,C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(C(=O)c4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1,"InChI=1S/C36H30N6O4/c1-2-32(43)38-25-12-13-30-31(20-25)42(36(46)40-30)26-15-18-41(19-16-26)35(45)24-10-8-23(9-11-24)33-27(22-6-4-3-5-7-22)21-28-29(39-33)14-17-37-34(28)44/h2-14,17,20-21,26H,1,15-16,18-19H2,(H,37,44)(H,38,43)(H,40,46)",DOWXJKCQWFHDRU-UHFFFAOYSA-N,Protein Kinase,AKT1,207,P31749,"RAC, PKB, PRKBA, AKT, RAC-alpha",Negative control for Borussertib,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/Borussertib,,,,,,,,,,,,Kinase set,1 µM
EUB0000721a_AKT2,RL2841,EUB0000721a,C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(C(=O)c4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1,"InChI=1S/C36H30N6O4/c1-2-32(43)38-25-12-13-30-31(20-25)42(36(46)40-30)26-15-18-41(19-16-26)35(45)24-10-8-23(9-11-24)33-27(22-6-4-3-5-7-22)21-28-29(39-33)14-17-37-34(28)44/h2-14,17,20-21,26H,1,15-16,18-19H2,(H,37,44)(H,38,43)(H,40,46)",DOWXJKCQWFHDRU-UHFFFAOYSA-N,Protein Kinase,AKT2,208,P31751,PKBb,Negative control for Borussertib,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/Borussertib,,,,,,,,,,,,Kinase set,1 µM
EUB0000721a_AKT3,RL2841,EUB0000721a,C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(C(=O)c4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1,"InChI=1S/C36H30N6O4/c1-2-32(43)38-25-12-13-30-31(20-25)42(36(46)40-30)26-15-18-41(19-16-26)35(45)24-10-8-23(9-11-24)33-27(22-6-4-3-5-7-22)21-28-29(39-33)14-17-37-34(28)44/h2-14,17,20-21,26H,1,15-16,18-19H2,(H,37,44)(H,38,43)(H,40,46)",DOWXJKCQWFHDRU-UHFFFAOYSA-N,Protein Kinase,AKT3,10000,Q9Y243,"PKBG, RAC-gamma, PRKBG",Negative control for Borussertib,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/Borussertib,,,,,,,,,,,,Kinase set,1 µM
EUB0000169b_PLK1,BI-2536,EUB0000169b,CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1,"InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1",XQVVPGYIWAGRNI-JOCHJYFZSA-N,Protein Kinase,PLK1,5347,P53350,,Inhibitor,,0.19,Kd,ITC,https://doi.org/ 10.1021/acs.jmedchem.8b01947 ,=,,,,,,8,KinomeScan (DiscoverX),468,"Screened at 1 µM, closest targets as % of contrl.: ALK(C1156Y) (0.3%), CAMKK1/2 (3.7/ 3.4%), PIP5K2C (4.2%), PLK2/3 (1.2/ 0.5%), RPS6KA4(KD2-C) (0.3%); follow-up IC50s of closest targets: IC50(PLK2) = 3.5 nM, IC50(PLK3) = 9 nM; Screened in Dundee panel against 30 kinases at 10 µM, clean profile; Screened in SafetyScreen44™ (Eurofins) against 64 targets (GPCRS, ion channels, transporters) at 10 µM, closest target as % of contr. ALPHA1A/R (13%);","https://doi.org/10.1016/j.cub.2006.12.046, https://opnme.com/molecules/plk1-bi-2536",Kinase set,1 µM
EUB0000169b_BRD4,BI-2536,EUB0000169b,CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1,"InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1",XQVVPGYIWAGRNI-JOCHJYFZSA-N,Bromodomain,BRD4,23476,O60885,"HUNKI, MCAP, CAP, HUNK1",Inhibitor,,37,Kd,ITC,https://doi.org/ 10.1021/acs.jmedchem.8b01947 ,=,300,IC50,NanoBRET assay (HEK293T cells),,=,8,KinomeScan (DiscoverX),468,"Screened at 1 µM, closest targets as % of contrl.: ALK(C1156Y) (0.3%), CAMKK1/2 (3.7/ 3.4%), PIP5K2C (4.2%), PLK2/3 (1.2/ 0.5%), RPS6KA4(KD2-C) (0.3%), follow-up IC50s of closest targets: IC50(PLK2) = 3.5 nM, IC50(PLK3) = 9 nM; Screened in Dundee panel against 30 kinases at 10 µM, clean profile; Screened in SafetyScreen44™ (Eurofins) against 64 targets (GPCRS, ion channels, transporters) at 10 µM, closest target as % of contr. ALPHA1A/R (13%);","https://doi.org/10.1016/j.cub.2006.12.046, https://opnme.com/molecules/plk1-bi-2536",Kinase set,1 µM
EUB0000722a_CASK,NR187,EUB0000722a,O=C(NCCCN1CCCC1=O)C2=CN=C(N(CC)CC3=CC=C(Cl)C=C3)N=C2NC4CCCC4,"InChI=1S/C26H35ClN6O2/c1-2-32(18-19-10-12-20(27)13-11-19)26-29-17-22(24(31-26)30-21-7-3-4-8-21)25(35)28-14-6-16-33-15-5-9-23(33)34/h10-13,17,21H,2-9,14-16,18H2,1H3,(H,28,35)(H,29,30,31)",AYRUNBYNKCLGFI-UHFFFAOYSA-N,Protein Kinase,CASK,8573,O14936,"LIN2, CAGH39, FGS4",Negative control for NR162,,,Negative Control,,"https://www.thesgc.org/chemical-probes/NR162, https://doi.org/10.1021/acs.jmedchem.1c00845",,,,,,,,,,,,Kinase set,1 µM
EUB0000005b_DDR1,DDR-TRK-1 (D2202-1),EUB0000005b,Cc1cn(-c2cc(NC(=O)c3ccc4c(c3)CN(c3cncnc3)C[C@@H]4C)cc(C(F)(F)F)c2)cn1,"InChI=1S/C26H23F3N6O/c1-16-11-34(23-9-30-14-31-10-23)13-19-5-18(3-4-24(16)19)25(36)33-21-6-20(26(27,28)29)7-22(8-21)35-12-17(2)32-15-35/h3-10,12,14-16H,11,13H2,1-2H3,(H,33,36)/t16-/m0/s1",CMJJZRAAQMUAFH-INIZCTEOSA-N,Protein Kinase,DDR1,780,Q08345,"RTK6, CD167",Inhibitor,DDR-TRK-1N (380079),27,IC50,Enzymatic inhibition assay,https://www.thesgc.org/chemical-probes/DDR-TRK-1,=,104,IC50,NanoBRET assay (HEK293T cells),,=,3,ScanMAX (DiscoverX),468,"Screened at 1 µM, in vitro activity of closest targets: Kd(CDK11) = 370 nM, Kd(EPHA8) = 550 nM, Kd(MUSK) = 530 nM",https://www.thesgc.org/chemical-probes/DDR-TRK-1,Kinase set,1 µM
EUB0000005b_DDR2,DDR-TRK-1 (D2202-1),EUB0000005b,Cc1cn(-c2cc(NC(=O)c3ccc4c(c3)CN(c3cncnc3)C[C@@H]4C)cc(C(F)(F)F)c2)cn1,"InChI=1S/C26H23F3N6O/c1-16-11-34(23-9-30-14-31-10-23)13-19-5-18(3-4-24(16)19)25(36)33-21-6-20(26(27,28)29)7-22(8-21)35-12-17(2)32-15-35/h3-10,12,14-16H,11,13H2,1-2H3,(H,33,36)/t16-/m0/s1",CMJJZRAAQMUAFH-INIZCTEOSA-N,Protein Kinase,DDR2,4921,Q16832,TKT,Inhibitor,DDR-TRK-1N (380079),3.5,IC50,Enzymatic inhibition assay,https://www.thesgc.org/chemical-probes/DDR-TRK-1,=,175,IC50,NanoBRET assay (HEK293T cells),,=,3,ScanMAX (DiscoverX),468,"Screened at 1 µM, in vitro activity of closest targets: Kd(CDK11) = 370 nM, Kd(EPHA8) = 550 nM, Kd(MUSK) = 530 nM",https://www.thesgc.org/chemical-probes/DDR-TRK-1,Kinase set,1 µM
EUB0000005b_NTRK1,DDR-TRK-1 (D2202-1),EUB0000005b,Cc1cn(-c2cc(NC(=O)c3ccc4c(c3)CN(c3cncnc3)C[C@@H]4C)cc(C(F)(F)F)c2)cn1,"InChI=1S/C26H23F3N6O/c1-16-11-34(23-9-30-14-31-10-23)13-19-5-18(3-4-24(16)19)25(36)33-21-6-20(26(27,28)29)7-22(8-21)35-12-17(2)32-15-35/h3-10,12,14-16H,11,13H2,1-2H3,(H,33,36)/t16-/m0/s1",CMJJZRAAQMUAFH-INIZCTEOSA-N,Protein Kinase,NTRK1,4914,P04629,"TRK, TRKA, MTC",Inhibitor,DDR-TRK-1N (380079),43,IC50,Enzymatic inhibition assay,https://www.thesgc.org/chemical-probes/DDR-TRK-1,=,448,IC50,NanoBRET assay (HEK293T cells),,=,3,ScanMAX (DiscoverX),468,"Screened at 1 µM, in vitro activity of closest targets: Kd(CDK11) = 370 nM, Kd(EPHA8) = 550 nM, Kd(MUSK) = 530 nM",https://www.thesgc.org/chemical-probes/DDR-TRK-1,Kinase set,1 µM
EUB0000005b_NTRK2,DDR-TRK-1 (D2202-1),EUB0000005b,Cc1cn(-c2cc(NC(=O)c3ccc4c(c3)CN(c3cncnc3)C[C@@H]4C)cc(C(F)(F)F)c2)cn1,"InChI=1S/C26H23F3N6O/c1-16-11-34(23-9-30-14-31-10-23)13-19-5-18(3-4-24(16)19)25(36)33-21-6-20(26(27,28)29)7-22(8-21)35-12-17(2)32-15-35/h3-10,12,14-16H,11,13H2,1-2H3,(H,33,36)/t16-/m0/s1",CMJJZRAAQMUAFH-INIZCTEOSA-N,Protein Kinase,NTRK2,4915,Q16620,TRKB,Inhibitor,DDR-TRK-1N (380079),3.6,IC50,Enzymatic inhibition assay,https://www.thesgc.org/chemical-probes/DDR-TRK-1,=,14,IC50,NanoBRET assay (HEK293T cells),,=,3,ScanMAX (DiscoverX),468,"Screened at 1 µM, in vitro activity of closest targets: Kd(CDK11) = 370 nM, Kd(EPHA8) = 550 nM, Kd(MUSK) = 530 nM",https://www.thesgc.org/chemical-probes/DDR-TRK-1,Kinase set,1 µM
EUB0000005b_NTRK3,DDR-TRK-1 (D2202-1),EUB0000005b,Cc1cn(-c2cc(NC(=O)c3ccc4c(c3)CN(c3cncnc3)C[C@@H]4C)cc(C(F)(F)F)c2)cn1,"InChI=1S/C26H23F3N6O/c1-16-11-34(23-9-30-14-31-10-23)13-19-5-18(3-4-24(16)19)25(36)33-21-6-20(26(27,28)29)7-22(8-21)35-12-17(2)32-15-35/h3-10,12,14-16H,11,13H2,1-2H3,(H,33,36)/t16-/m0/s1",CMJJZRAAQMUAFH-INIZCTEOSA-N,Protein Kinase,NTRK3,4916,Q16288,TRKC,Inhibitor,DDR-TRK-1N (380079),2.9,IC50,Enzymatic inhibition assay,https://www.thesgc.org/chemical-probes/DDR-TRK-1,=,,,,,,3,ScanMAX (DiscoverX),468,"Screened at 1 µM, in vitro activity of closest targets: Kd(CDK11) = 370 nM, Kd(EPHA8) = 550 nM, Kd(MUSK) = 530 nM",https://www.thesgc.org/chemical-probes/DDR-TRK-1,Kinase set,1 µM
EUB0000006b_JAK3@kinase 1,FM-381,EUB0000006b,CN(C)C(=O)/C(C#N)=C/c1ccc(-c2nc3cnc4[nH]ccc4c3n2C2CCCCC2)o1,"InChI=1S/C24H24N6O2/c1-29(2)24(31)15(13-25)12-17-8-9-20(32-17)23-28-19-14-27-22-18(10-11-26-22)21(19)30(23)16-6-4-3-5-7-16/h8-12,14,16H,3-7H2,1-2H3,(H,26,27)/b15-12+",GJMZWYLOARVASY-NTCAYCPXSA-N,Protein Kinase,JAK3@kinase 1,3718,P52333,"L-JAK, JAKL, LJAK, JAK3_HUMAN, JAK-3",Inhibitor,FM-479,0.154,IC50,Radiometric inhibition assay,"https://doi.org/10.1016/j.chembiol.2016.10.008, https://www.thesgc.org/chemical-probes/FM-381",=,100,IC50,NanoBRET assay (HEK293T cells),,=,0,Kinase panel (ProQinase),410,No targets with >70% inhibition at 100 nM and 500 nM,"https://doi.org/10.1016/j.chembiol.2016.10.008, https://www.thesgc.org/chemical-probes/FM-381",Kinase set,100 nM
EUB0000007b_JAK3@kinase 1,FM-479,EUB0000007b,CN(C)C(=O)/C(C#N)=C/c1ccc(-c2nc3cnc4c(ccn4C)c3n2C2CCCCC2)o1,"InChI=1S/C25H26N6O2/c1-29(2)25(32)16(14-26)13-18-9-10-21(33-18)24-28-20-15-27-23-19(11-12-30(23)3)22(20)31(24)17-7-5-4-6-8-17/h9-13,15,17H,4-8H2,1-3H3/b16-13+",RPIGHLXKDWUGDT-DTQAZKPQSA-N,Protein Kinase,JAK3@kinase 1,3718,P52333,"L-JAK, JAKL, LJAK, JAK3_HUMAN, JAK-3",Negative control for FM-381,,,Negative Control,,https://www.thesgc.org/chemical-probes/FM-381,,,,,,,,,,,,Kinase set,100 nM
EUB0000009b_CLK1,MU140,EUB0000009b,Cn1cc(-c2ccc3occ(-c4ccccc4-c4ccccc4)c3n2)cn1,"InChI=1S/C23H17N3O/c1-26-14-17(13-24-26)21-11-12-22-23(25-21)20(15-27-22)19-10-6-5-9-18(19)16-7-3-2-4-8-16/h2-15H,1H3",QSBNKGGRYOLZND-UHFFFAOYSA-N,Protein Kinase,CLK1,1195,P49759,,Negative control for MU1210,,,Negative Control,,https://www.thesgc.org/chemical-probes/MU1210,,,,,,,,,,,,Kinase set,1 µM
EUB0000009b_CLK2,MU140,EUB0000009b,Cn1cc(-c2ccc3occ(-c4ccccc4-c4ccccc4)c3n2)cn1,"InChI=1S/C23H17N3O/c1-26-14-17(13-24-26)21-11-12-22-23(25-21)20(15-27-22)19-10-6-5-9-18(19)16-7-3-2-4-8-16/h2-15H,1H3",QSBNKGGRYOLZND-UHFFFAOYSA-N,Protein Kinase,CLK2,1196,P49760,,Negative control for MU1210,,,Negative Control,,https://www.thesgc.org/chemical-probes/MU1210,,,,,,,,,,,,Kinase set,1 µM
EUB0000009b_CLK4,MU140,EUB0000009b,Cn1cc(-c2ccc3occ(-c4ccccc4-c4ccccc4)c3n2)cn1,"InChI=1S/C23H17N3O/c1-26-14-17(13-24-26)21-11-12-22-23(25-21)20(15-27-22)19-10-6-5-9-18(19)16-7-3-2-4-8-16/h2-15H,1H3",QSBNKGGRYOLZND-UHFFFAOYSA-N,Protein Kinase,CLK4,57396,Q9HAZ1,,Negative control for MU1210,,,Negative Control,,https://www.thesgc.org/chemical-probes/MU1210,,,,,,,,,,,,Kinase set,1 µM
EUB0000156b_DDR1,DDR-TRK-1N (380079),EUB0000156b,CN1CCN(Cc2cc(NC(=O)c3ccc4c(c3)CN(c3ccccc3)CC4)cc(C(F)(F)F)c2)CC1,"InChI=1S/C29H31F3N4O/c1-34-11-13-35(14-12-34)19-21-15-25(29(30,31)32)18-26(16-21)33-28(37)23-8-7-22-9-10-36(20-24(22)17-23)27-5-3-2-4-6-27/h2-8,15-18H,9-14,19-20H2,1H3,(H,33,37)",FWKRCZKMCJOFNG-UHFFFAOYSA-N,Protein Kinase,DDR1,780,Q08345,"RTK6, CD167",Negative control for DDR-TRK-1 (D2202-1),,,Negative Control,,https://www.thesgc.org/chemical-probes/DDR-TRK-1,,,,,,,,,,,,Kinase set,1 µM
EUB0000156b_DDR2,DDR-TRK-1N (380079),EUB0000156b,CN1CCN(Cc2cc(NC(=O)c3ccc4c(c3)CN(c3ccccc3)CC4)cc(C(F)(F)F)c2)CC1,"InChI=1S/C29H31F3N4O/c1-34-11-13-35(14-12-34)19-21-15-25(29(30,31)32)18-26(16-21)33-28(37)23-8-7-22-9-10-36(20-24(22)17-23)27-5-3-2-4-6-27/h2-8,15-18H,9-14,19-20H2,1H3,(H,33,37)",FWKRCZKMCJOFNG-UHFFFAOYSA-N,Protein Kinase,DDR2,4921,Q16832,TKT,Negative control for DDR-TRK-1 (D2202-1),,,Negative Control,,https://www.thesgc.org/chemical-probes/DDR-TRK-1,,,,,,,,,,,,Kinase set,1 µM
EUB0000156b_NTRK1,DDR-TRK-1N (380079),EUB0000156b,CN1CCN(Cc2cc(NC(=O)c3ccc4c(c3)CN(c3ccccc3)CC4)cc(C(F)(F)F)c2)CC1,"InChI=1S/C29H31F3N4O/c1-34-11-13-35(14-12-34)19-21-15-25(29(30,31)32)18-26(16-21)33-28(37)23-8-7-22-9-10-36(20-24(22)17-23)27-5-3-2-4-6-27/h2-8,15-18H,9-14,19-20H2,1H3,(H,33,37)",FWKRCZKMCJOFNG-UHFFFAOYSA-N,Protein Kinase,NTRK1,4914,P04629,"TRK, TRKA, MTC",Negative control for DDR-TRK-1 (D2202-1),,,Negative Control,,https://www.thesgc.org/chemical-probes/DDR-TRK-1,,,,,,,,,,,,Kinase set,1 µM
EUB0000156b_NTRK2,DDR-TRK-1N (380079),EUB0000156b,CN1CCN(Cc2cc(NC(=O)c3ccc4c(c3)CN(c3ccccc3)CC4)cc(C(F)(F)F)c2)CC1,"InChI=1S/C29H31F3N4O/c1-34-11-13-35(14-12-34)19-21-15-25(29(30,31)32)18-26(16-21)33-28(37)23-8-7-22-9-10-36(20-24(22)17-23)27-5-3-2-4-6-27/h2-8,15-18H,9-14,19-20H2,1H3,(H,33,37)",FWKRCZKMCJOFNG-UHFFFAOYSA-N,Protein Kinase,NTRK2,4915,Q16620,TRKB,Negative control for DDR-TRK-1 (D2202-1),,,Negative Control,,https://www.thesgc.org/chemical-probes/DDR-TRK-1,,,,,,,,,,,,Kinase set,1 µM
EUB0000156b_NTRK3,DDR-TRK-1N (380079),EUB0000156b,CN1CCN(Cc2cc(NC(=O)c3ccc4c(c3)CN(c3ccccc3)CC4)cc(C(F)(F)F)c2)CC1,"InChI=1S/C29H31F3N4O/c1-34-11-13-35(14-12-34)19-21-15-25(29(30,31)32)18-26(16-21)33-28(37)23-8-7-22-9-10-36(20-24(22)17-23)27-5-3-2-4-6-27/h2-8,15-18H,9-14,19-20H2,1H3,(H,33,37)",FWKRCZKMCJOFNG-UHFFFAOYSA-N,Protein Kinase,NTRK3,4916,Q16288,TRKC,Negative control for DDR-TRK-1 (D2202-1),,,Negative Control,,https://www.thesgc.org/chemical-probes/DDR-TRK-1,,,,,,,,,,,,Kinase set,1 µM
EUB0000164c_PAK1,NVS-PAK1-1,EUB0000164c,CC(C)NC(=O)N1CC[C@H](NC2=Nc3cc(F)ccc3N(CC(F)F)c3ccc(Cl)cc32)C1,"InChI=1S/C23H25ClF3N5O/c1-13(2)28-23(33)31-8-7-16(11-31)29-22-17-9-14(24)3-5-19(17)32(12-21(26)27)20-6-4-15(25)10-18(20)30-22/h3-6,9-10,13,16,21H,7-8,11-12H2,1-2H3,(H,28,33)(H,29,30)/t16-/m0/s1",OINGHOPGNMYCAB-INIZCTEOSA-N,Protein Kinase,PAK1,5058,Q13153,,Allosteric inhibitor,NVS-PAK1-C,6,IC50,Caliper in vitro assay,https://www.thesgc.org/chemical-probes/nvs-pak1-1,=,250,IC50,Western Blot (inhibition of autophosphorylation of PAK (S144) in Su86.86 cell line),,=,1,KinomeScan (DiscoverX),442,"Screened at 10 µM, S(10) = 0.003, closest target: IC50(PAK2) = 72 nM; Screened against 27 receptors (Novartis panel) at 10 µM, closest target: IC50(H1) = 13 µM, IC50(M1) = 13 µM; Screened against panel of 48 bromodomains at 10 µM in DSF-assay, all targets dTm < 1 K clean profile",https://www.thesgc.org/chemical-probes/nvs-pak1-1,Kinase set,1 µM
EUB0000165b_AAK1,SGC-AAK1-1,EUB0000165b,CCN(CC)S(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1,"InChI=1S/C21H25N5O3S/c1-3-26(4-2)30(28,29)25-17-7-5-6-15(12-17)16-10-11-18-19(13-16)23-24-20(18)22-21(27)14-8-9-14/h5-7,10-14,25H,3-4,8-9H2,1-2H3,(H2,22,23,24,27)",UCBIQZUJJSVQHL-UHFFFAOYSA-N,Protein Kinase,AAK1,22848,Q2M2I8,"KIAA1048, DKFZp686K16132",Inhibitor,SGC-AAK1-1N,9.1,Ki,TR-FRET binding-displacement assays,"https://doi.org/10.1021/acsmedchemlett.9b00399, https://www.thesgc.org/chemical-probes/SGC-AAK1-1",=,230,IC50,NanoBRET assay (HEK293T cells),,=,3,KinomeScan (DiscoverX),403,"Screened at 1 µM, S(10) = 0.02, follow-up Kds for closest targets: Kd(PIP5K1C) = 260 nM, Kd(RIOK1) = 72 nM, Kd(RIOK3) = 290 nM; Kd(RIOK3) = 290 nM, Kd(CDKL2) = 880 nM, Kd(MYLK2) = 960 nM;","https://doi.org/10.1021/acsmedchemlett.9b00399, https://www.thesgc.org/chemical-probes/SGC-AAK1-1",Kinase set,1 µM
EUB0000165b_BMP2K,SGC-AAK1-1,EUB0000165b,CCN(CC)S(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1,"InChI=1S/C21H25N5O3S/c1-3-26(4-2)30(28,29)25-17-7-5-6-15(12-17)16-10-11-18-19(13-16)23-24-20(18)22-21(27)14-8-9-14/h5-7,10-14,25H,3-4,8-9H2,1-2H3,(H2,22,23,24,27)",UCBIQZUJJSVQHL-UHFFFAOYSA-N,Protein Kinase,BMP2K,55589,Q9NSY1,"DKFZp434K0614, BIKe",Inhibitor,SGC-AAK1-1N,17,Ki,TR-FRET binding-displacement assays,"https://doi.org/10.1021/acsmedchemlett.9b00399, https://www.thesgc.org/chemical-probes/SGC-AAK1-1",=,1500,IC50,NanoBRET assay (HEK293T cells),,=,3,KinomeScan (DiscoverX),403,"Screened at 1 µM, S(10) = 0.02, follow-up Kds for closest targets: Kd(PIP5K1C) = 260 nM, Kd(RIOK1) = 72 nM, Kd(RIOK3) = 290 nM; Kd(RIOK3) = 290 nM, Kd(CDKL2) = 880 nM, Kd(MYLK2) = 960 nM;","https://doi.org/10.1021/acsmedchemlett.9b00399, https://www.thesgc.org/chemical-probes/SGC-AAK1-1",Kinase set,1 µM
EUB0000166b_AAK1,SGC-AAK1-1N,EUB0000166b,CC(C)C(=O)Nc1n[nH]c2cc(-c3cccc(NS(=O)(=O)C4CC4)c3)ccc12,"InChI=1S/C20H22N4O3S/c1-12(2)20(25)21-19-17-9-6-14(11-18(17)22-23-19)13-4-3-5-15(10-13)24-28(26,27)16-7-8-16/h3-6,9-12,16,24H,7-8H2,1-2H3,(H2,21,22,23,25)",RAIAORGFMNXPOV-UHFFFAOYSA-N,Protein Kinase,AAK1,22848,Q2M2I8,"KIAA1048, DKFZp686K16132",Negative control for SGC-AAK1-1,,,Negative Control,,"https://doi.org/10.1021/acsmedchemlett.9b00399, https://www.thesgc.org/chemical-probes/SGC-AAK1-1",,,,,,,,,,,,Kinase set,1 µM
EUB0000166b_BMP2K,SGC-AAK1-1N,EUB0000166b,CC(C)C(=O)Nc1n[nH]c2cc(-c3cccc(NS(=O)(=O)C4CC4)c3)ccc12,"InChI=1S/C20H22N4O3S/c1-12(2)20(25)21-19-17-9-6-14(11-18(17)22-23-19)13-4-3-5-15(10-13)24-28(26,27)16-7-8-16/h3-6,9-12,16,24H,7-8H2,1-2H3,(H2,21,22,23,25)",RAIAORGFMNXPOV-UHFFFAOYSA-N,Protein Kinase,BMP2K,55589,Q9NSY1,"DKFZp434K0614, BIKe",Negative control for SGC-AAK1-1,,,Negative Control,,"https://doi.org/10.1021/acsmedchemlett.9b00399, https://www.thesgc.org/chemical-probes/SGC-AAK1-1",,,,,,,,,,,,Kinase set,1 µM
EUB0000168b_CAMKK2,SGC-CAMKK2-1N (UNC-YL-83),EUB0000168b,O=C(O)c1ccc(-c2coc3ncc(-c4ccccc4)cc23)cc1Cl,"InChI=1S/C20H12ClNO3/c21-18-9-13(6-7-15(18)20(23)24)17-11-25-19-16(17)8-14(10-22-19)12-4-2-1-3-5-12/h1-11H,(H,23,24)",KHPDNSBTNDXSBL-UHFFFAOYSA-N,Protein Kinase,CAMKK2,10645,Q96RR4,"CAMKK, KIAA0787, CAMKKB, MGC15254",Negative control for SGC-CAMKK2-1 (UNC-YL-36),,,Negative Control,,https://www.thesgc.org/chemical-probes/SGC-CAMKK2-1,,,,,,,,,,,,Kinase set,1 µM
EUB0000723a_CASK,NR162,EUB0000723a,O=C(NCCCN1CCOC1=O)C2=CN=C(NCC3=CC(Br)=CC=C3Br)N=C2NC4CCCC4,"InChI=1S/C23H28Br2N6O3/c24-16-6-7-19(25)15(12-16)13-27-22-28-14-18(20(30-22)29-17-4-1-2-5-17)21(32)26-8-3-9-31-10-11-34-23(31)33/h6-7,12,14,17H,1-5,8-11,13H2,(H,26,32)(H2,27,28,29,30)",HOYFKJXFPMNFPM-UHFFFAOYSA-N,Protein Kinase,CASK,8573,O14936,"LIN2, CAGH39, FGS4",Inhibitor,NR187,22,Kd,ITC,"https://www.thesgc.org/chemical-probes/NR162, https://doi.org/10.1021/acs.jmedchem.1c00845",=,80,IC50,NanoBRET assay (HEK293T cells),,=,8,KinomeScan (DiscoverX),448,"Screened at 1 µM; 8 additional targets: AURKC, ABL1, RPS6KA6, PIKFYVE, ERBB3, RPS6KA5, LRRK2 and STK38L, initially identified, but confirmed as false positive by NanoBRET: closest targets: IC50(TYRO3) = 3.8 µM (47-fold selective), IC50(ERBB3) = 18.2 µM (227-fold selective), other targets >20 µM in NanoBRET assays.","https://www.thesgc.org/chemical-probes/NR162, https://doi.org/10.1021/acs.jmedchem.1c00845",Kinase set,1 µM
EUB0000298b_MAPK1,ERKi,EUB0000298b,C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1,"InChI=1S/C16H17N5O2/c1-10(11-5-3-2-4-6-11)18-16(23)20-15-7-13-12(8-17-21-13)14(9-22)19-15/h2-8,10,22H,9H2,1H3,(H,17,21)(H2,18,19,20,23)/t10-/m1/s1",RAXZSEGXMBWYQK-SNVBAGLBSA-N,Protein Kinase,MAPK1,5594,P28482,"ERK, ERK2, p41mapk, MAPK2",Inhibitor,ERKi-NC,4.8,Kd,KdELECT (DiscoverX),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/ERKi,=,850,IC50,NanoBRET assay (HEK293T cells),,=,10,ScanMAX (DiscoverX),486,"Screened at 0.1 µM, closest targets: Kd(LATS2) = 55 nM, Kd(MAPK15) = 30 nM, Kd(TGFBR2) = 54 nM, Kd(ROCK2) = 82 nM, Kd(ULK1) = 140 nM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/ERKi,Kinase set,1 µM
EUB0000298b_MAPK3,ERKi,EUB0000298b,C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1,"InChI=1S/C16H17N5O2/c1-10(11-5-3-2-4-6-11)18-16(23)20-15-7-13-12(8-17-21-13)14(9-22)19-15/h2-8,10,22H,9H2,1H3,(H,17,21)(H2,18,19,20,23)/t10-/m1/s1",RAXZSEGXMBWYQK-SNVBAGLBSA-N,Protein Kinase,MAPK3,5595,P27361,"ERK1, p44mapk, p44erk1",Inhibitor,ERKi-NC,1.5,Kd,KdELECT (DiscoverX),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/ERKi,=,6690,IC50,NanoBRET assay (HEK293T cells),,=,10,ScanMAX (DiscoverX),486,"Screened at 0.1 µM, closest targets: Kd(LATS2) = 55 nM, Kd(MAPK15) = 30 nM, Kd(TGFBR2) = 54 nM, Kd(ROCK2) = 82 nM, Kd(ULK1) = 140 nM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/ERKi,Kinase set,1 µM
EUB0000207b_GAK,SGC-GAK-1,EUB0000207b,COc1cc(Nc2ccnc3ccc(Br)cc23)cc(OC)c1OC,"InChI=1S/C18H17BrN2O3/c1-22-16-9-12(10-17(23-2)18(16)24-3)21-15-6-7-20-14-5-4-11(19)8-13(14)15/h4-10H,1-3H3,(H,20,21)",AUOSKLDNVNGKRR-UHFFFAOYSA-N,Protein Kinase,GAK,2580,O14976,DNAJC26,Inhibitor,SGC-GAK-1N,1.9,Kd,Competition binding assay (DiscoverX),https://doi.org/10.1021/acs.jmedchem.8b01213,=,120,IC50,NanoBRET assay (HEK293T cells),,=,4,KinomeScan (DiscoverX),468,"Screened at 1 µM, in vitro follow-up of closest targets: Kd(RIPK2) = 110 nM, Kd(ADCK3) = 190 nM, Kd(NLK) = 520 nM, Kd(ACVR1) = 980 nM; Cellular selectivity: IC50(RIPK2) = 360 nM (NanoBRET assay), others not tested;",https://doi.org/10.1021/acs.jmedchem.8b01213,Kinase set,1 µM
EUB0000724a_CLK1,SGC-CLK-1 (UNC-CAF-170 ),EUB0000724a,COC1=NN2N=CC(C3=NC(NC4=CC(C(F)(F)F)=CC(OC)=C4)=NC=C3)=C2C=C1,"InChI=1S/C19H15F3N6O2/c1-29-13-8-11(19(20,21)22)7-12(9-13)25-18-23-6-5-15(26-18)14-10-24-28-16(14)3-4-17(27-28)30-2/h3-10H,1-2H3,(H,23,25,26)",GJYVLTPTDBQQCY-UHFFFAOYSA-N,Protein Kinase,CLK1,1195,P49759,,Inhibitor,SGC-CLK-1N (UNC-CAF-225 ),41,IC50,Binding assays (Luceome Biotechniology),https://www.thesgc.org/chemical-probes/SGC-CLK-1,=,165,IC50,NanoBRET assay (HEK293T cells),,=,0,KinomeScan (DiscoverX),468,"Screened at 1 µM, closest targets as % of contr.: MAPK15 (21%), HIPK1 (31%), HIPK2 (34%), NEK7 (40%), PIP5K2B (50%), STK16 (53%), S(35) = 0.02; Follow-up IC50s in cellular NanoBRET assays: IC50(HIPK1/2) >10 µM, IC50(STK16) = 167 nM (partial inhibition), others NA;",https://www.thesgc.org/chemical-probes/SGC-CLK-1,Kinase set,1 µM
EUB0000724a_CLK2,SGC-CLK-1 (UNC-CAF-170 ),EUB0000724a,COC1=NN2N=CC(C3=NC(NC4=CC(C(F)(F)F)=CC(OC)=C4)=NC=C3)=C2C=C1,"InChI=1S/C19H15F3N6O2/c1-29-13-8-11(19(20,21)22)7-12(9-13)25-18-23-6-5-15(26-18)14-10-24-28-16(14)3-4-17(27-28)30-2/h3-10H,1-2H3,(H,23,25,26)",GJYVLTPTDBQQCY-UHFFFAOYSA-N,Protein Kinase,CLK2,1196,P49760,,Inhibitor,SGC-CLK-1N (UNC-CAF-225 ),36,IC50,Binding assays (Luceome Biotechniology),https://www.thesgc.org/chemical-probes/SGC-CLK-1,=,70,IC50,NanoBRET assay (HEK293T cells),,=,0,KinomeScan (DiscoverX),468,"Screened at 1 µM, closest targets as % of contr.: MAPK15 (21%), HIPK1 (31%), HIPK2 (34%), NEK7 (40%), PIP5K2B (50%), STK16 (53%), S(35) = 0.02; Follow-up IC50s in cellular NanoBRET assays: IC50(HIPK1/2) >10 µM, IC50(STK16) = 167 nM (partial inhibition), others NA;",https://www.thesgc.org/chemical-probes/SGC-CLK-1,Kinase set,1 µM
EUB0000724a_CLK4,SGC-CLK-1 (UNC-CAF-170 ),EUB0000724a,COC1=NN2N=CC(C3=NC(NC4=CC(C(F)(F)F)=CC(OC)=C4)=NC=C3)=C2C=C1,"InChI=1S/C19H15F3N6O2/c1-29-13-8-11(19(20,21)22)7-12(9-13)25-18-23-6-5-15(26-18)14-10-24-28-16(14)3-4-17(27-28)30-2/h3-10H,1-2H3,(H,23,25,26)",GJYVLTPTDBQQCY-UHFFFAOYSA-N,Protein Kinase,CLK4,57396,Q9HAZ1,,Inhibitor,SGC-CLK-1N (UNC-CAF-225 ),,,,,,100,IC50,NanoBRET assay (HEK293T cells),,=,0,KinomeScan (DiscoverX),468,"Screened at 1 µM, closest targets as % of contr.: MAPK15 (21%), HIPK1 (31%), HIPK2 (34%), NEK7 (40%), PIP5K2B (50%), STK16 (53%), S(35) = 0.02; Follow-up IC50s in cellular NanoBRET assays: IC50(HIPK1/2) >10 µM, IC50(STK16) = 167 nM (partial inhibition), others NA;",https://www.thesgc.org/chemical-probes/SGC-CLK-1,Kinase set,1 µM
EUB0000167b_CAMKK2,SGC-CAMKK2-1 (UNC-YL-36),EUB0000167b,Cc1cccc(-c2cnc3occ(-c4ccc(C(=O)O)c(C5CCCC5)c4)c3c2)c1,"InChI=1S/C26H23NO3/c1-16-5-4-8-18(11-16)20-13-23-24(15-30-25(23)27-14-20)19-9-10-21(26(28)29)22(12-19)17-6-2-3-7-17/h4-5,8-15,17H,2-3,6-7H2,1H3,(H,28,29)",TXIYVFVMXNFNRX-UHFFFAOYSA-N,Protein Kinase,CAMKK2,10645,Q96RR4,"CAMKK, KIAA0787, CAMKKB, MGC15254",Inhibitor,SGC-CAMKK2-1N (UNC-YL-83),30,IC50,Enzymatic activity assay,https://www.thesgc.org/chemical-probes/SGC-CAMKK2-1,=,,,,,,1,KinomeScan (DiscoverX),403,"Screened at 1 µM, off-target PoC of 12%",https://www.thesgc.org/chemical-probes/SGC-CAMKK2-1,Kinase set,1 µM
EUB0000303b_METAP2,TP-004,EUB0000303b,Cc1nc(N2CC[C@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12,"InChI=1S/C17H16F3N5O/c1-9-13(6-21-16(23-9)25-3-2-11(26)8-25)12-4-10(17(18,19)20)5-15-14(12)7-22-24-15/h4-7,11,26H,2-3,8H2,1H3,(H,22,24)/t11-/m0/s1",BNTAEJNPQLMGDJ-NSHDSACASA-N,Aminopeptidase,METAP2,10988,P50579,"METAP2, MNPEP, P67EIF2",Inhibitor,TPn-004,7,IC50,Biochemical activity assay (addition of Mn),"https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-004, https://doi.org/10.1016/j.bmcl.2016.04.073",=,,,,,,0,Ricerca panel,100,"Highly selective in panel of GPCRs, ion channels, transporters, enzymes and proteases, at 10 µM: METAP2/1 >1000-fold; Selectivity against other proteases: < 1000 -fold; Clean in KinomeScan (DiscoverX) against 468 targets at 1 µM, closest targets as % of contr.: LATS2 (26%), EPHB6 (36%), WNK2 (41%), GRK2 (42%), RPS6KA3 (48%), SGK1 (49%); Clean in screen against 45 GPCR targets (PDSP screen) at 10 µM, closest targets: Ki(SLC6A3) = 1679 nM, Ki(GABAA/BZP) = 4538 nM",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-004,Protease set,1 µM
EUB0000725a_MMP12,BAY-694,EUB0000725a,O=C(C1=C(N=N2)C=CC=C1)N2C[C@H]([C@H]3C(O)=O)CC[C@H]3C(C(C=C4)=CC=C4OCCC5CCOCC5)=O,"InChI=1S/C28H31N3O6/c32-26(19-5-8-21(9-6-19)37-16-13-18-11-14-36-15-12-18)23-10-7-20(25(23)28(34)35)17-31-27(33)22-3-1-2-4-24(22)29-30-31/h1-6,8-9,18,20,23,25H,7,10-17H2,(H,34,35)/t20-,23-,25-/m1/s1",ZGBAPSHWPBXEKN-QFZRFWILSA-N,MMP,MMP12,4321,P39900,"MMP12, HME",Negative control for BAY-7598,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-7598,,,,,,,,,,,,Protease set,100 nM
EUB0000726a_MMP13,T-26f,EUB0000726a,CN(Cc1ccccc1)Cc1csc2c1C(NC(C(NCc1cccc(c1)OC)=O)=N2)=O,"InChI=1S/C24H24N4O3S/c1-28(13-16-7-4-3-5-8-16)14-18-15-32-24-20(18)22(29)26-21(27-24)23(30)25-12-17-9-6-10-19(11-17)31-2/h3-11,15H,12-14H2,1-2H3,(H,25,30)(H,26,27,29)",FITQSJBSXMDHOS-UHFFFAOYSA-N,MMP,MMP13,4322,P45452,MMP13,Negative control for T-26c,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/T-26c,,,,,,,,,,,,Protease set,100 nM
EUB0000727a_MMP13,BI-4395,EUB0000727a,CN1C(C2=CC3=C(C=C2)NC=C3)=CC(C(NCC4=CC=C(C=C4)C(O)=O)=O)=N1,"InChI=1S/C21H18N4O3/c1-25-19(16-6-7-17-15(10-16)8-9-22-17)11-18(24-25)20(26)23-12-13-2-4-14(5-3-13)21(27)28/h2-11,22H,12H2,1H3,(H,23,26)(H,27,28)",FOIUQQUDMFDDDC-UHFFFAOYSA-N,MMP,MMP13,4322,P45452,MMP13,Negative control for BI-4394,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-4394,,,,,,,,,,,,Protease set,100 nM
EUB0000728a_MMP12,BAY-7598,EUB0000728a,O=C(C1=C(N=N2)C=CC=C1)N2C[C@@H]([C@@H]3C(O)=O)CC[C@@H]3C(C(C=C4)=CC=C4OCCC5CCOCC5)=O,"InChI=1S/C28H31N3O6/c32-26(19-5-8-21(9-6-19)37-16-13-18-11-14-36-15-12-18)23-10-7-20(25(23)28(34)35)17-31-27(33)22-3-1-2-4-24(22)29-30-31/h1-6,8-9,18,20,23,25H,7,10-17H2,(H,34,35)/t20-,23-,25-/m0/s1",ZGBAPSHWPBXEKN-OPHFCASCSA-N,MMP,MMP12,4321,P39900,"MMP12, HME",Inhibitor,BAY-694,0.085,IC50,"Biochemical assay (inhibition of human macrophage elastase (HME/hMMP-12), addition of 2% BSA)",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-7598,=,,,,,,4,Lead profiling screen (Eurofins),68,"Screened at 10 µM against 68 enzymes, transporters, GPCRs, ion chanels, closest targets: IC50(MMP2) = 44 nM, IC50(MMP10) = 13 nM, IC50(MMP8) = 15 nM, IC50(MMP13) = 67 nM, IC50(MMP14) = 250 nM, IC50(MMP3) = 360 nM, IC50(MMP9) = 460 nM, IC50(MMP7) = 600 nM, IC50(MMP16) = 940 nM; Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: EGFR(S752-I759del) (40%), TYK2 (41%), PNCK (46%); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest target as % inhibition: DRD2 (30%)","https://patents.google.com/patent/WO2015150350A1/en, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-7598",Protease set,100 nM
EUB0000729a_MMP13,T-26c,EUB0000729a,COc1cccc(CNC(C2NC(c3c(COCc4ccc(cc4)C(O)=O)csc3N=2)=O)=O)c1,"InChI=1S/C24H21N3O6S/c1-32-18-4-2-3-15(9-18)10-25-22(29)20-26-21(28)19-17(13-34-23(19)27-20)12-33-11-14-5-7-16(8-6-14)24(30)31/h2-9,13H,10-12H2,1H3,(H,25,29)(H,30,31)(H,26,27,28)",CDQRIIUMNLMHRH-UHFFFAOYSA-N,MMP,MMP13,4322,P45452,MMP13,Inhibitor,T-26f,0.0069,IC50,Enzyme inhibition assay,"https://doi.org/10.1016/j.bmc.2014.07.025, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/T-26c",=,,,,,,1,"MMPs panel, literature",10,">2600-fold selective over other MMPs: IC50(MMP1) >10 µM, IC50(MMP2) = 18 nM, IC50(MMP3) = 600 nM, IC50(MMP7) >10 µM, IC50(MMP8) = 780 nM, IC50(MMP9) >10 µM, IC50(MMP10) = 160 nM, IC50(MMP14) >10 mM, IC50(ADAM17) >10 µM; Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: LRRK2 (43%), CDK4 (43.5%), FLT3(D835V) (44.2%), NTRK1 (46.7%); Screended against 45 GPCR targets (PDSP screen) at 10 µM, closest targets: Ki(HRH1) = 98 nM, Ki(TMEM97) = 4553 nM; Clean profile in MSD Pharma/Taiwan screen against 118 enzymes and receptors","https://doi.org/10.1016/j.bmc.2014.07.025, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/T-26c",Protease set,100 nM
EUB0000730a_MMP13,BI-4394,EUB0000730a,CCOC(c1cc2cc(ccc2[nH]1)c1cc(C(NCc2ccc(cc2)C(O)=O)=O)nn1C)=O,"InChI=1S/C24H22N4O5/c1-3-33-24(32)20-11-17-10-16(8-9-18(17)26-20)21-12-19(27-28(21)2)22(29)25-13-14-4-6-15(7-5-14)23(30)31/h4-12,26H,3,13H2,1-2H3,(H,25,29)(H,30,31)",MMJPVSDTLGFIQW-UHFFFAOYSA-N,MMP,MMP13,4322,P45452,MMP13,Inhibitor,BI-4395,1,IC50,FRET assay,"https://doi.org/10.1021/jm201129m, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-4394",=,,,,,,0,"MMPs panel, literature",10,"Highly selective (> 1000-fold) against other matrix metalloproteinases (FRET assays): IC50(MMP1) >22 µM, IC50(MMP2) = 18 µM, IC50(MMP3) >22 µM, IC50(MMP7) >22 µM, IC50(MMP8) >22 µM, IC50(MMP9) = 8.9 µM, IC50(MMP10) = 16 µM, IC50(MMP12) >22 µM, IC50(MMP14) = 8.3 µM; Screened against 468 kinases (KinomeScan DiscoverX) at 100 nM, closest targets as % of contr.: CDK19 (0%), CDKL3 (0%), CDK3 (43%); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest targets: DRD5 (60% inhibition, Ki >10 µM); Screened against 56 targets (Invitrogen Panel) at 10 µM, closest targets: IC50(AURKA) = 1.3 µM, IC50(MAPKAPK2) = 1.1 µM, IC50(PRKAA1) = 1.9 µM, IC50(PRKACA) = 1.6 µM;","https://doi.org/10.1021/jm201129m, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-4394",Protease set,100 nM
EUB0000211b_WDR5,OICR-9429,EUB0000211b,CN1CCN(c2ccc(-c3cccc(CN4CCOCC4)c3)cc2NC(=O)c2c[nH]c(=O)cc2C(F)(F)F)CC1,"InChI=1S/C29H32F3N5O3/c1-35-7-9-37(10-8-35)26-6-5-22(21-4-2-3-20(15-21)19-36-11-13-40-14-12-36)16-25(26)34-28(39)23-18-33-27(38)17-24(23)29(30,31)32/h2-6,15-18H,7-14,19H2,1H3,(H,33,38)(H,34,39)",DJOVLOYCGXNVPI-UHFFFAOYSA-N,E3,WDR5,11091,P61964,"SWD3, CFAP89",Antagonist,OICR-0547,24,Kd,Biacore,https://www.thesgc.org/chemical-probes/OICR-9429,=,,,,,,0,"Protein methyltransferase panel, literature",22,"Screened at 50 µM, >1000-fold selective (IC50 >50 µM); Screened against 8 Methyl-Lysine/Arginine binder (DSF assay), dTm(WDR5) = 18.1 K, closest target: dTm(TDRD3) = 1.8 K; Screened in CEREP panel against 215 targets (kinases, GPCRs, ion channels, transporters) at 1 µM: no kinase with >50% inhibition (IC50 >1 µM)","https://doi.org/10.1038/nchembio.1859, https://www.thesgc.org/chemical-probes/OICR-9429",Epigenetic set,1 µM
EUB0000283b_MLLT1,NVS-MLLT-1,EUB0000283b,C[C@H]1CCCN1Cc1nc2cc(NC(=O)c3ccc4cnccc4c3)ccc2[nH]1,"InChI=1S/C23H23N5O/c1-15-3-2-10-28(15)14-22-26-20-7-6-19(12-21(20)27-22)25-23(29)17-4-5-18-13-24-9-8-16(18)11-17/h4-9,11-13,15H,2-3,10,14H2,1H3,(H,25,29)(H,26,27)/t15-/m0/s1",ZRTFTZCKJUNZIU-HNNXBMFYSA-N,YEATS,MLLT1,4298,Q03111,"ENL, LTG19, YEATS1",Inhibitor,NVS-iMLLT-C,150,IC50,AlphaScreen assay,https://www.thesgc.org/chemical-probes/NVS-MLLT-1,=,500,IC50,NanoBRET assay (HEK293T cells),,=,0,"Bromodomain panel, literature",42,"Selective across all bromodomains (IC50(CERC2) >40 µM, IC50(YESTS2/4) >20 µM (TR-FRET assay); Screened against 59 kinases (PSP kinase safety panel, Eurofins), closest targets: IC50(TRB2) = 3.5 µM, IC50(PIM1) = 8.6 µM, others >30 µM, Screened against 31 other targets (GPCRs, transporter and ion channels, PSP Principial panel 20118+, Eurofins), closest targets: IC50(ACES) = 250 nM, IC50(H3) = 290 nM, IC50(M2) = 1.8 µM, IC50(NET) = 8.7 µM, others >30 µM;",https://www.thesgc.org/chemical-probes/NVS-MLLT-1,Epigenetic set,1 µM
EUB0000283b_MLLT3,NVS-MLLT-1,EUB0000283b,C[C@H]1CCCN1Cc1nc2cc(NC(=O)c3ccc4cnccc4c3)ccc2[nH]1,"InChI=1S/C23H23N5O/c1-15-3-2-10-28(15)14-22-26-20-7-6-19(12-21(20)27-22)25-23(29)17-4-5-18-13-24-9-8-16(18)11-17/h4-9,11-13,15H,2-3,10,14H2,1H3,(H,25,29)(H,26,27)/t15-/m0/s1",ZRTFTZCKJUNZIU-HNNXBMFYSA-N,YEATS,MLLT3,4300,P42568,AF-9 AF9 YEATS3,Inhibitor,NVS-iMLLT-C,254,IC50,AlphaScreen assay,https://www.thesgc.org/chemical-probes/NVS-MLLT-1,=,,,,,,0,"Bromodomain panel, literature",42,"Selective across all bromodomains (IC50(CERC2) >40 µM, IC50(YESTS2/4) >20 µM (TR-FRET assay); Screened against 59 kinases (PSP kinase safety panel, Eurofins), closest targets: IC50(TRB2) = 3.5 µM, IC50(PIM1) = 8.6 µM, others >30 µM, Screened against 31 other targets (GPCRs, transporter and ion channels, PSP Principial panel 20118+, Eurofins), closest targets: IC50(ACES) = 250 nM, IC50(H3) = 290 nM, IC50(M2) = 1.8 µM, IC50(NET) = 8.7 µM, others >30 µM;",https://www.thesgc.org/chemical-probes/NVS-MLLT-1,Epigenetic set,1 µM
EUB0000731a_MLLT1,PFI-6,EUB0000731a,O=C(N(C)C)C1=C(O)C=C(C2=CC(C(N[C@@H]3CCC4=C3C=CC=C4)=O)=NO2)C=C1,"InChI=1S/C22H21N3O4/c1-25(2)22(28)16-9-7-14(11-19(16)26)20-12-18(24-29-20)21(27)23-17-10-8-13-5-3-4-6-15(13)17/h3-7,9,11-12,17,26H,8,10H2,1-2H3,(H,23,27)/t17-/m1/s1",IXWUILRSNIQHDM-QGZVFWFLSA-N,YEATS,MLLT1,4298,Q03111,"ENL, LTG19, YEATS1",Inhibitor,PFI-6N,140,IC50,HTRF-based inhibition assay,https://www.thesgc.org/chemical-probes/PFI-6,=,,,,,,,,,"Selective in SGC bromodomain panel; Screened in Invitrogen kinase panel against 40 kinases at 10 µM, clean profile; No activity in a panel of 25 PDEs, ion channels and GPCRS, IC50 >50 µM; IC50(YEATS2/4) > 40 µM (HTRF assay);",https://www.thesgc.org/chemical-probes/PFI-6,Epigenetic set,1 µM
EUB0000731a_MLLT3,PFI-6,EUB0000731a,O=C(N(C)C)C1=C(O)C=C(C2=CC(C(N[C@@H]3CCC4=C3C=CC=C4)=O)=NO2)C=C1,"InChI=1S/C22H21N3O4/c1-25(2)22(28)16-9-7-14(11-19(16)26)20-12-18(24-29-20)21(27)23-17-10-8-13-5-3-4-6-15(13)17/h3-7,9,11-12,17,26H,8,10H2,1-2H3,(H,23,27)/t17-/m1/s1",IXWUILRSNIQHDM-QGZVFWFLSA-N,YEATS,MLLT3,4300,P42568,AF-9 AF9 YEATS3,Inhibitor,PFI-6N,160,IC50,HTRF-based inhibition assay,https://www.thesgc.org/chemical-probes/PFI-6,=,760,IC50,NanoBRET assay (HEK293T cells),,=,,,,"Selective in SGC bromodomain panel; Screened in Invitrogen kinase panel against 40 kinases at 10 µM, clean profile; No activity in a panel of 25 PDEs, ion channels and GPCRS, IC50 >50 µM; IC50(YEATS2/4) > 40 µM (HTRF assay);",https://www.thesgc.org/chemical-probes/PFI-6,Epigenetic set,1 µM
EUB0000732a_MLLT1,PFI-6N,EUB0000732a,O=C(N(C)C)C1=C(O)C=C(C2=CC(C(N(C)C3CCCC3)=O)=NO2)C=C1,"InChI=1S/C19H23N3O4/c1-21(2)18(24)14-9-8-12(10-16(14)23)17-11-15(20-26-17)19(25)22(3)13-6-4-5-7-13/h8-11,13,23H,4-7H2,1-3H3",CKEICVFLYGXFOP-UHFFFAOYSA-N,YEATS,MLLT1,4298,Q03111,"ENL, LTG19, YEATS1",Negative control for PFI-6,,,Negative Control,,https://www.thesgc.org/chemical-probes/PFI-6,,,,,,,,,,,,Epigenetic set,1 µM
EUB0000732a_MLLT3,PFI-6N,EUB0000732a,O=C(N(C)C)C1=C(O)C=C(C2=CC(C(N(C)C3CCCC3)=O)=NO2)C=C1,"InChI=1S/C19H23N3O4/c1-21(2)18(24)14-9-8-12(10-16(14)23)17-11-15(20-26-17)19(25)22(3)13-6-4-5-7-13/h8-11,13,23H,4-7H2,1-3H3",CKEICVFLYGXFOP-UHFFFAOYSA-N,YEATS,MLLT3,4300,P42568,AF-9 AF9 YEATS3,Negative control for PFI-6,,,Negative Control,,https://www.thesgc.org/chemical-probes/PFI-6,,,,,,,,,,,,Epigenetic set,1 µM
EUB0000313b_CYP11B2 ,MSD-CYP11B2,EUB0000313b,CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1,"InChI=1S/C18H18FN3O/c1-18(2,23)12-7-11(9-20-10-12)17-21-15-6-3-13(19)8-16(15)22(17)14-4-5-14/h3,6-10,14,23H,4-5H2,1-2H3",OAMLIJKKGZLNHE-UHFFFAOYSA-N,P450,CYP11B2 ,1585,P19099,"CYP11BL, CPN2, P-450C18, P450aldo, ALDOS",Inhibitor,MSD-CYP11B2 negative control,,,,,,2.3,IC50,"HTRF-based assay (V79 cell lines, CisBio)",,=,0,KinomeScan (DiscoverX),468,"Screened at 1 µM, closest targets as % of control: DYRK1B (44%), DYRK1A (48%); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest targets: Ki(ADRA2C) = 625.6 nM, Ki(ADRA2B) = 1439.1 nM, Ki(HTR2B) = 1537.5 nM, Ki(ADRB1) = 2370.3 nM; Screened in Eurofins-Panlabs radioligand binding assays against 43 targets at 10 µM, closest targets: IC50(ADRA2B) = 4.7 nM, IC50(HTR2B) = 5.33 nM, IC50(ADRB1) =9.62 nM; ","https://doi.org/10.1021/acsmedchemlett.5b00054, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/MSD-CYP11B2, https://pubs.acs.org/doi/10.1021/acsmedchemlett.5b00054",Other targets,100 nM
EUB0000733a_CYP11B2 ,MSD-CYP11B2 negative control,EUB0000733a,FC(F)(F)C1=CC(N=C2C3=CN=CC=C3)=C(C=C1)N2C4CC4,"InChI=1S/C16H12F3N3/c17-16(18,19)11-3-6-14-13(8-11)21-15(22(14)12-4-5-12)10-2-1-7-20-9-10/h1-3,6-9,12H,4-5H2",RNBRMUYDOIRYOA-UHFFFAOYSA-N,P450,CYP11B2 ,1585,P19099,"CYP11BL, CPN2, P-450C18, P450aldo, ALDOS",Negative control for MSD-CYP11B2,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/MSD-CYP11B2,,,,,,,,,,,,Other targets,100 nM
EUB0000239b_MALT1,NVS-MALT1,EUB0000239b,CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12,"InChI=1S/C24H27ClF3N5O4S/c1-14(37-3)21-18(13-29-20-12-19(25)31-33(20)21)30-17-6-4-15(5-7-17)22(24(26,27)28)32(2)23(34)16-8-10-38(35,36)11-9-16/h4-7,12-14,16,22,30H,8-11H2,1-3H3/t14-,22-/m0/s1",NVGROBHDOYRPAN-FPTDNZKUSA-N,Protease,MALT1,10892,Q9UDY8,"MALT1, MLT",Allosteric inhibitor,NVS-MALT1-C,2.4,IC50,TR-FRET assay (high salt),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/NVS-MALT1,=,,,,,,0,"Protease assay, literature",16,"Screened at 10 µM, no cross reactivity among proteases owing to allosteric mechanism; Screened against 468 kinases(KinomeScan DiscoverX) at 1 µM, closest targets as % contr.: FLT3(N841I) (23%), CDK8 (39%), HIPK1 (40%), NEK3 (40%), MAST1 (43%), PIK3CA(E545K) (48%); Clean profile in screen against 45 GPCRs (PDSP screen) at 10 µM; Screened in kinase panel against 50 targets at 10 µM, closest targets: IC50(FLT3) = 3.5 µM; Screened against panel of 110 receptors, ion channels, enzymes and transporters, at 10 µM, closest target as % of inhibition: adenosine transporter AdT (52%);",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/NVS-MALT1,Other targets,1 µM
EUB0000262b_BCL2L1,A-1155463,EUB0000262b,CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1,"InChI=1S/C35H32FN5O4S2/c1-40(2)17-6-8-22-14-15-28(26(36)20-22)45-19-7-13-30-31(33(43)44)38-35(47-30)41-18-16-23-9-5-10-24(25(23)21-41)32(42)39-34-37-27-11-3-4-12-29(27)46-34/h3-5,9-12,14-15,20H,7,13,16-19,21H2,1-2H3,(H,43,44)(H,37,39,42)",SOYCFODXNRVBTI-UHFFFAOYSA-N,Apoptosis regulator,BCL2L1,598,Q07817,"BCL2L1, BCL2L, BCLX",Inhibitor,A-1107969,0.55,IC50,TR-FRET assay,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-1155463,=,,,,,,0,CEREP panel (Eurofins),71,"Screened at 10 µM (binding assay), closest targets as % inhibition: PPARG (99.1%), CCKAR (98.9%), UTS2R (94.9%), OPRD1 (77.9%), MAOA (74.5%), ADORA3 (71.6%), HRH1 (69.2%), PTGS2 (62.2%); Screened against 468 kinase targets (KinomeScan DiscoverX) at 1 µM, closest targets as % contr.: AURKC (9%), MARK3 (38%); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest targets: Ki(SIGMAR1) = 136.4 nM, Ki(GABA/PBR) = 793.96 nM, Ki(TMEM97) = 806.12 nM, Ki(HTR3A) = 1142.6 nM, Ki(HRH3) = 1806.76 nM, Ki(OPRD1) = 2118.36 nM; Screened in Eurofins-Cerep panel against 7 targets at 10 µM (enzymes and uptake assays): clean profile;",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-1155463,Other targets,1 µM
EUB0000263b_BCL2,A-1211212,EUB0000263b,CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,"InChI=1S/C47H54ClN7O7S/c1-47(2)18-16-34(41(27-47)32-6-8-35(48)9-7-32)30-53-20-22-54(23-21-53)36-10-14-40(44(25-36)62-38-24-33-17-19-49-45(33)51-29-38)46(56)52-63(59,60)39-13-15-42(43(26-39)55(57)58)50-28-31-4-11-37(61-3)12-5-31/h6-10,13-15,17,19,24-26,29,31,37,50H,4-5,11-12,16,18,20-23,27-28,30H2,1-3H3,(H,49,51)(H,52,56)/t31-,37-",CSBKUBOVPUXFLO-MAVVKCOWSA-N,Apoptosis regulator,BCL2,596,P10415,BCL2,Inhibitor,A-1210227,1.4,IC50,TR-FRET assay," https://doi.org/10.1126/scitranslmed.aaa4642, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-1211212",=,,,,,,0,CEREP panel (Eurofins),71,"Screened at 10 µM (binding assays), closest targets as % inhibition: Ca2+ channel (L, dihydropyridine site); Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: HIPK4 (4.4%), MAPK12 (47%); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest target: Ki(TMEM97) = 1491.08 nM; Screened in Eurofins-Cerep panel against 7 targets at 10 µM (enzymes and uptake assays): clean profile;",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-1211212,Other targets,1 µM
EUB0000289c_FNTB,ABT-100,EUB0000289c,CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC,"InChI=1S/C30H48N2O6/c1-7-10-13-31(14-11-8-2)26(33)19-32-18-22(21-15-24(36-6)28-25(16-21)37-20-38-28)27(29(34)35)23(32)17-30(4,5)12-9-3/h15-16,22-23,27H,7-14,17-20H2,1-6H3,(H,34,35)/t22-,23+,27-/m0/s1",OAEWNSKRLBVVBV-OBTVHEKISA-N,Transferase,FNTB,2342,P49356,FNTB,Inhibitor,A-108,0.05,IC50,Scintillation proximity assay (SPA),"https://doi.org/10.1097/00001813-200511000-00004, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/ABT-100",=,0.73,EC50,Western Blot (inhibition of Ras in NIH 3T3 H-Ras cells),,=,0,CEREP panel (Eurofins),75,"Screened at 3 µM against 75 ion channels, receptors, GPCRs and enzymes (ligand binding assay), closest target as % inhibition: PRCP (97%), >100 000-fold selective for FNTB over the closely related enzyme PGGT1B (GGTase I); Screened against 468 kinases (KinomeScan DiscoverX), at 1 µM, closest targets as % of contr.: EPHA1 (38%), NEK7 (46%), BRSK2 (48%), GRK3 (48%), follow-up Kd values: IC50(EPHA1/NEK7/BRSK2/GRK3) >10 µM; Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest target: Ki(HRH1) >10 µM;",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/ABT-100,Other targets,1 µM
EUB0000735a_ELANE,BAY-678,EUB0000735a,CC1=C(C(C)=O)[C@@H](c2ccc(C#N)nc2)NC(N1c1cccc(c1)C(F)(F)F)=O,"InChI=1S/C20H15F3N4O2/c1-11-17(12(2)28)18(13-6-7-15(9-24)25-10-13)26-19(29)27(11)16-5-3-4-14(8-16)20(21,22)23/h3-8,10,18H,1-2H3,(H,26,29)/t18-/m1/s1",PGIVGIFOWOVINL-GOSISDBHSA-N,Protease,ELANE,1991,P08246,"ELANE, ELA2",Inhibitor,BAY-677,20,IC50,Microtiter-based biochemical assay,"https://doi.org/10.1002/cmdc.201500131, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-678",=,,,,,,0,"Serine protease panel, literature",21,"> 30-fold selective over 21 serine proteases (for all IC50 > 30 µM); Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: RPS6KA4 (33.5%), PRKG1 (45.5%), PRKACB (48.7%); Screened against 45 GPCR targets (PSDP screen) at 10 µM, closest target: Ki(HRH3) = 3.07 µM, Ki(DTR1A) = 4.98 µM, Ki(ADRB1) = 5.45 µM; Radioligand binding assays (Lead Profiling Screen, Eurofins) against 64 receptors and transporters at 10 µM: > 30-fold selective","https://doi.org/10.1002/cmdc.201500131, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-678",Protease set,1 µM
EUB0000294b_FASN,BI 99179,EUB0000294b,CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1,"InChI=1S/C23H25N3O3/c1-3-21(27)24-17-11-8-16(14-17)23(28)26(2)18-12-9-15(10-13-18)22-25-19-6-4-5-7-20(19)29-22/h4-7,9-10,12-13,16-17H,3,8,11,14H2,1-2H3,(H,24,27)/t16-,17+/m1/s1",YNFDIGJKJPNFFD-SJORKVTESA-N,Synthase,FASN,2194,P49327,"FAS, OA-519, SDR27X1",Inhibitor,BI 99990,79,IC50,Human FAS enzyme assay (measuring consumption of NADPH),"https://doi.org/10.1016/j.bmcl.2011.07.083, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI%2099179",=,180,IC50,Cellular activity assay (inhibition of [14C]acetate incorporation into human H1975 cells),,=,,,,"Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: MAP2K5 (16%), NTRK3 (32%), AURKA (43%), LATS1 (48%); Screened against 30 GPCR, ion channels, receptors and other enzymes (MDS Pharma Service panel, radioligand binding assays) at 10 µM, closest target as % inhibition: Imidazoline I2, central (19%); Screened against 45 GPCRs (PDSP screen) at 10 µM, closest targets: SLC6A3 (77%)","https://doi.org/10.1016/j.bmcl.2011.07.083, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI%2099179",Other targets,1 µM
EUB0000301b_MIF,BTZO-1,EUB0000301b,O=c1nc(-c2ccccn2)sc2ccccc12,InChI=1S/C13H8N2OS/c16-12-9-5-1-2-7-11(9)17-13(15-12)10-6-3-4-8-14-10/h1-8H,GBAKVEWPYUIGHN-UHFFFAOYSA-N,Tautomerase,MIF,4282,P14174,"MIF, GLIF, MMIF",Activator,BTZO-4,68.6,Kd,Scintillation proximity assay (SPA; measurement of selective [83H]-BTZO-1 binding to human MIF-His),"https://doi.org/10.1016/j.chembiol.2010.10.011, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BTZO-1",=,,,,,,,,,"Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: CDK8 (36%), EIF2AK4 (47%); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest target: Ki(GABAA/BZP) = 934 nM; Selectivity against recently discovered D-Dopachrome Tautomerase (DDT) is unknown.",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BTZO-1,Other targets,1 µM
EUB0000315b_MGAT2,TP-020,EUB0000315b,Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1,"InChI=1S/C27H21ClF5N7O3S/c1-38-20(11-22(36-38)27(31,32)33)15-12-34-26(35-13-15)40-6-4-14-7-17(10-21(25(14)40)39-5-2-3-23(39)41)44(42,43)37-24-18(29)8-16(28)9-19(24)30/h7-13,37H,2-6H2,1H3",VSZRYLHBOKTNBO-UHFFFAOYSA-N,Transferase,MGAT2,4247,Q10469,MGAT2,Inhibitor,TP-020n,7.8,IC50,RapidFire/MS assay ,"https://doi.org/10.1016/j.bmc.2015.06.003, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-020",=,160,IC50,Cell-based assay,,=,,,,"High selectivity over other acyltransferases, >100-fold over mouse MGAT1 (IC50 = 2.6 µM), >1000-fold over human DGAT1 (IC50 > 30 µM), human DGAT2 (IC50 > 30 µM), human ACAT1 (IC50 = 19 µM); Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: MARK3 (12%), FLT3(ITD,F691L) (32%), SRPK2 (34%); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest target: Ki(HTR1D) = 4.65 µM","https://doi.org/10.1016/j.bmc.2015.06.003, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-020",Other targets,1 µM
EUB0000316c_BCL6,TP-021,EUB0000316c,O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1,"InChI=1S/C20H20ClN3O5/c21-15-10-18(24(26)27)19(29-14-5-7-28-8-6-14)11-17(15)22-13-2-3-16-12(9-13)1-4-20(25)23-16/h2-3,9-11,14,22H,1,4-8H2,(H,23,25)",RRELDGDKULRRDM-UHFFFAOYSA-N,Apoptosis regulator,BCL6,604,P41182,"BCL6, BCL5, LAZ3, ZBTB27, ZNF51",Inhibitor,TP-021n,100,IC50,Cell-free enzyme-linked immunosorbent assay (ELISA),"https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-021, https://doi.org/10.1016/j.bmc.2017.07.037",=,,,,,,0,KinomeScan (DiscoverX),468,"Screened at 1 µM, closest targets as % of contrl.: NEK1 (40%), STK38L (41%), EIF2AK2 (46%); Screen against 45 GPCR targets (PDSP screen) at 10 µM, closest target as % inhibition: CHRM4 (49%); Clean in Takeda in-house kinase panel against 344 targets, at 1 µM; compound is protein-protein inhibitor targetting non-conserved sites.","https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-021, https://doi.org/10.1016/j.bmc.2017.07.037",Epigenetic set,1 µM
EUB0000320b_SOS1,BAY-293,EUB0000320b,CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1,"InChI=1S/C25H28N4O2S/c1-15(24-10-18(14-32-24)19-9-7-6-8-17(19)13-26-3)27-25-20-11-22(30-4)23(31-5)12-21(20)28-16(2)29-25/h6-12,14-15,26H,13H2,1-5H3,(H,27,28,29)/t15-/m1/s1",WEGLOYDTDILXDA-OAHLLOKOSA-N,Guanine-nucleotide releasing factor,SOS1,6654,Q07889,SOS1,Inhibitor,BAY-294,21,IC50,KRASG12C–SOS1cat interaction assay,"https://doi.org/10.1073/pnas.1812963116, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-293",=,200,IC50,ELISA (Active RAS in Calu-1 cells (CLS 300141)) ,,=,0,KinomeScan (DiscoverX),468,"Screened at 1 µM, closest targets as % of contr.: STK33 (45%), MYO3B (47%), FLT3(ITD,D835V) (48%), BMX (49%); Screened against 358 kinases (Eurofins panel) at 1 µM, closest target as % of contr.: CK2A2 (67%); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest targets: Ki(HTR2A) = 133.44 nM, Ki(ADRA2C) = 130.87 nM, Ki(HRH2) = 139.82 nM, Ki(HTR1D) = 181.12 nM, Ki(TMEM97) = 179.81 nM, Ki(CHRM1) = 237.75 nM, Ki(ADRA1D) = 337.65 nM, further GPCRs and transporters inhibited but not considered causative for on-target and downstream cellular effects or antiproliferative activity; Lead profiling screen (Eurofins) against 77 GPCRs, transporters, nuclear receptors and enzymes at 10 µM, closest targets as % inhibition: HTR2A (110%), ADRA1A (106%), OPRK1 (105%),HTR2C (104%), HTR2B (100%); Screened against 358 targets (Eurofins Kinase panel) at 1 µM: clean profile (all tested kinases retain activity > 67%), GEFs: IC50 > 20 µM on SOS2 (KRAS(G12C)–SOS2(cat) activation assay) and MCF2L (CDC42 activation by DBS assay)",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-293,Other targets,1 µM
EUB0000736a_FNTB,A-108,EUB0000736a,CN1C=NC=C1[C@@](COC2=C(C3=CC=C(OC(F)(F)F)C=C3)C=C(C#N)C=C2)(C4=CC=C(C#N)C=C4)O,"InChI=1S/C27H19F3N4O3/c1-34-17-33-15-25(34)26(35,21-7-2-18(13-31)3-8-21)16-36-24-11-4-19(14-32)12-23(24)20-5-9-22(10-6-20)37-27(28,29)30/h2-12,15,17,35H,16H2,1H3/t26-/m1/s1",HEUVRFNVTLGKMZ-AREMUKBSSA-N,Transferase,FNTB,2342,P49356,FNTB,Negative control for ABT-100,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/ABT-100,,,,,,,,,,,,Other targets,1 µM
EUB0000737a_ELANE,BAY-677,EUB0000737a,CC(=O)C1=C(C)N(C(=O)N[C@H]1c2ccc(nc2)C#N)c3cccc(c3)C(F)(F)F,"InChI=1S/C20H15F3N4O2/c1-11-17(12(2)28)18(13-6-7-15(9-24)25-10-13)26-19(29)27(11)16-5-3-4-14(8-16)20(21,22)23/h3-8,10,18H,1-2H3,(H,26,29)/t18-/m0/s1",PGIVGIFOWOVINL-SFHVURJKSA-N,Protease,ELANE,1991,P08246,"ELANE, ELA2",Negative control for BAY-678,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-678,,,,,,,,,,,,Protease set,1 µM
EUB0000738a_FASN,BI 99990,EUB0000738a,CCC(=O)N[C@@H]1CC[C@@H](C1)C(=O)N(C)c2ccc(cc2)c3oc4ccccc4n3,"InChI=1S/C23H25N3O3/c1-3-21(27)24-17-11-8-16(14-17)23(28)26(2)18-12-9-15(10-13-18)22-25-19-6-4-5-7-20(19)29-22/h4-7,9-10,12-13,16-17H,3,8,11,14H2,1-2H3,(H,24,27)/t16-,17+/m0/s1",YNFDIGJKJPNFFD-DLBZAZTESA-N,Synthase,FASN,2194,P49327,"FAS, OA-519, SDR27X1",Negative control for BI 99179,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI%2099179,,,,,,,,,,,,Other targets,1 µM
EUB0000739a_PSEN1@Protease,GSM-NC,EUB0000739a,Cc1ccn(c2ccc(cc2OC)c2cn([C@H]3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)n1,"InChI=1S/C25H23F3N6O2/c1-16-11-12-33(30-16)21-9-8-18(13-23(21)36-2)19-14-34(31-29-19)22-10-7-17-5-3-4-6-20(17)32(24(22)35)15-25(26,27)28/h3-6,8-9,11-14,22H,7,10,15H2,1-2H3/t22-/m0/s1",LMWVEVSLAFDIRE-QFIPXVFZSA-N,Protease,PSEN1@Protease,5663,P49768,"ACNINV3, AD3, FAD, PS-1, PS1, S182",Negative control for GSM1,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/GSM1,,,,,,,,,,,,Protease set,1 µM
EUB0001135a_MIF,BTZO-4,EUB0001135a,c1ccc2c(c1)C(NC(c1ccccn1)S2)=O,"InChI=1S/C13H10N2OS/c16-12-9-5-1-2-7-11(9)17-13(15-12)10-6-3-4-8-14-10/h1-8,13H,(H,15,16)",VNQMNFPFGNMBPO-UHFFFAOYSA-N,Tautomerase,MIF,4282,P14174,"MIF, GLIF, MMIF",Negative control for BTZO-1,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BTZO-1,,,,,,,,,,,,Other targets,1 µM
EUB0000740a_ALOX5AP,BI-0153,EUB0000740a,CN(C)C(Cn1cc(cn1)c1nc(C2(CC2)c2ccc(cc2)c2cnc(N)nc2)no1)=O,"InChI=1S/C22H22N8O2/c1-29(2)18(31)13-30-12-16(11-26-30)19-27-20(28-32-19)22(7-8-22)17-5-3-14(4-6-17)15-9-24-21(23)25-10-15/h3-6,9-12H,7-8,13H2,1-2H3,(H2,23,24,25)",VAAPYECJHQQRAS-UHFFFAOYSA-N,PPi transporter,ALOX5AP,241,P20292,"ALOX5AP, FLAP",Negative control for BI 665915,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI%20665915,,,,,,,,,,,,Other targets,100 nM
EUB0000741a_PSEN1@Protease,GSI-NC,EUB0000741a,CC(C)(OC(N1CCCC1CN[C@@H]2CC[C@](c3c(F)ccc(F)c3)(S(c4ccc(Cl)cc4)(=O)=O)CC2)=O)C,"InChI=1S/C28H35ClF2N2O4S/c1-27(2,3)37-26(34)33-16-4-5-22(33)18-32-21-12-14-28(15-13-21,24-17-20(30)8-11-25(24)31)38(35,36)23-9-6-19(29)7-10-23/h6-11,17,21-22,32H,4-5,12-16,18H2,1-3H3/t21-,22?,28+",TTWGDSSADVBNQY-LMGRWQENSA-N,Protease,PSEN1@Protease,5663,P49768,"ACNINV3, AD3, FAD, PS-1, PS1, S182",Negative control for MRK-560,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/MRK-560,,,,,,,,,,,,Protease set,100 nM
EUB0000742a_BCL6,TP-021n,EUB0000742a,C(c1ccc(c(c1)[Cl])Nc1ccc2c(c1)NC(N2)=O)#N,"InChI=1S/C14H9ClN4O/c15-10-5-8(7-16)1-3-11(10)17-9-2-4-12-13(6-9)19-14(20)18-12/h1-6,17H,(H2,18,19,20)",BZXKWTWZOMZUEU-UHFFFAOYSA-N,Apoptosis regulator,BCL6,604,P41182,"BCL6, BCL5, LAZ3, ZBTB27, ZNF51",Negative control for TP-021,,,Negative Control,,"https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-021, https://doi.org/10.1016/j.bmc.2017.07.037",,,,,,,,,,,,Epigenetic set,1 µM
EUB0000743a_SOS1,BAY-294,EUB0000743a,CC1=NC(N[C@H](C2=CC(C3=CC=CC=C3CNC)=CS2)C)=C4C=C(OC)C(OC)=CC4=N1,"InChI=1S/C25H28N4O2S/c1-15(24-10-18(14-32-24)19-9-7-6-8-17(19)13-26-3)27-25-20-11-22(30-4)23(31-5)12-21(20)28-16(2)29-25/h6-12,14-15,26H,13H2,1-5H3,(H,27,28,29)/t15-/m0/s1",WEGLOYDTDILXDA-HNNXBMFYSA-N,Guanine-nucleotide releasing factor,SOS1,6654,Q07889,SOS1,Negative control for BAY-293,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-293,,,,,,,,,,,,Other targets,1 µM
EUB0000744a_PDE10A,THPP-1-NC,EUB0000744a,CC(CC(N1CCC2=C(C(N(CC3=CC=CC=C3)C)=NC(C4=CC=C(Br)C=C4)=N2)C1)=O)C,"InChI=1S/C26H29BrN4O/c1-18(2)15-24(32)31-14-13-23-22(17-31)26(30(3)16-19-7-5-4-6-8-19)29-25(28-23)20-9-11-21(27)12-10-20/h4-12,18H,13-17H2,1-3H3",HVYWAAXJQNGKRV-UHFFFAOYSA-N,PDE,PDE10A,10846,Q9Y233,PDE10A,Negative control for THPP-1,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/THPP-1,,,,,,,,,,,,Other targets,100 nM
EUB0000745a_DHODH,IPP/CNRS-A019,EUB0000745a,CC(OC1=NN(C2=NC=C(C3CC3)C=C2)C(C)=C1OC4=CC=C(F)C=C4)C,"InChI=1S/C21H22FN3O2/c1-13(2)26-21-20(27-18-9-7-17(22)8-10-18)14(3)25(24-21)19-11-6-16(12-23-19)15-4-5-15/h6-13,15H,4-5H2,1-3H3",RDNHAVKDNYIJLE-UHFFFAOYSA-N,Dehydrogenase,DHODH,1723,Q02127,DHODH,Negative control for IPP/CNRS-A017,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/IPP/CNRS-A017,,,,,,,,,,,,Other targets,100 nM
EUB0000746a_BCL2,A-1210227,EUB0000746a,C1COCCC1CNc1ccc(cc1[N+]([O-])=O)S(NC(c1ccc(cc1Oc1cc2cc[nH]c2nc1)N1CCN(CC1)Cc1ccc(cc1c1ccc(cc1)[Cl])C(F)(F)F)=O)(=O)=O,"InChI=1S/C44H41ClF3N7O7S/c45-33-5-2-29(3-6-33)38-22-32(44(46,47)48)4-1-31(38)27-53-15-17-54(18-16-53)34-7-9-37(41(23-34)62-35-21-30-11-14-49-42(30)51-26-35)43(56)52-63(59,60)36-8-10-39(40(24-36)55(57)58)50-25-28-12-19-61-20-13-28/h1-11,14,21-24,26,28,50H,12-13,15-20,25,27H2,(H,49,51)(H,52,56)",MIVWTBCJCNWAEJ-UHFFFAOYSA-N,Apoptosis regulator,BCL2,596,P10415,BCL2,Negative control for A-1211212,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-1211212,,,,,,,,,,,,Other targets,1 µM
EUB0000747a_MALT1,NVS-MALT1-C,EUB0000747a,C[C@H](OC)C1=C(NC2=CC=C([C@@H](N(C(C3CCS(CC3)(=O)=O)=O)C)C(F)(F)F)C=C2)C=NC4=CC(Cl)=NN14,"InChI=1S/C24H27ClF3N5O4S/c1-14(37-3)21-18(13-29-20-12-19(25)31-33(20)21)30-17-6-4-15(5-7-17)22(24(26,27)28)32(2)23(34)16-8-10-38(35,36)11-9-16/h4-7,12-14,16,22,30H,8-11H2,1-3H3/t14-,22+/m0/s1",NVGROBHDOYRPAN-RCDICMHDSA-N,Protease,MALT1,10892,Q9UDY8,"MALT1, MLT",Negative control for NVS-MALT1,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/NVS-MALT1,,,,,,,,,,,,Other targets,1 µM
EUB0000748a_NDUFS2,BAY-070,EUB0000748a,CN1C2=C(C=CC=C2)N=C1C3=CSC(C4CCN(CC4)CC5=NC6N=CC=CC6N5)=N3,"InChI=1S/C23H25N7S/c1-29-19-7-3-2-5-16(19)26-22(29)18-14-31-23(27-18)15-8-11-30(12-9-15)13-20-25-17-6-4-10-24-21(17)28-20/h2-7,10,14-15,17,21H,8-9,11-13H2,1H3,(H,25,28)",NSXFCOAQTRXPAW-UHFFFAOYSA-N,Dehydrogenase,NDUFS2,4720,O75306,"CI-49, MC1DN6",Negative control for BAY-179,,,Negative Control,,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-179,,,,,,,,,,,,Other targets,1 µM
EUB0000749a_ALOX5AP,BI-665915,EUB0000749a,C[C@@](C1CC1)(c1ccc(cc1)c1cnc(N)nc1)c1nc(c2cnn(CC(N(C)C)=O)c2)on1,"InChI=1S/C24H26N8O2/c1-24(19-8-9-19,18-6-4-15(5-7-18)16-10-26-23(25)27-11-16)22-29-21(34-30-22)17-12-28-32(13-17)14-20(33)31(2)3/h4-7,10-13,19H,8-9,14H2,1-3H3,(H2,25,26,27)/t24-/m0/s1",QGPXEIMWTKWHMH-DEOSSOPVSA-N,PPi transporter,ALOX5AP,241,P20292,"ALOX5AP, FLAP",Inhibitor,BI-0153,1.7,IC50,Binding assay (measuring radio-labeled ligand [125I]-L-691831(PE NEX084) displacement),"https://doi.org/10.1021/jm501185j, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI%20665915",=,,,,,,,,,"No closely related mammalian protein known; Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: ABL1(Q252H)-nonphosphorylated (0%), GRK7 (0%), CHUK (0%), PK5 (0%), JAK1 (33%), PRKCE (44%); Screened against 546 targets (Invitrogen kinase panel) at 3 µM: all kinases showed < 30% inhibition; Screened against 68 targets (Eurofins-Panlabs panel) at 10 µM: clean profile; Screened against 137 targets in CEREP screen at 20 µM, closest targets as % inhibition: FLT1 (64%), ABL1 (67%); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest target as % of inhibition: SLC6A3 (61%);",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI%20665915,Other targets,100 nM
EUB0000750a_PSEN1@Protease,MRK-560,EUB0000750a,O=S([C@]1(C2=C(C=CC(F)=C2)F)CC[C@H](NS(C(F)(F)F)(=O)=O)CC1)(C3=CC=C(Cl)C=C3)=O,"InChI=1S/C19H17ClF5NO4S2/c20-12-1-4-15(5-2-12)31(27,28)18(16-11-13(21)3-6-17(16)22)9-7-14(8-10-18)26-32(29,30)19(23,24)25/h1-6,11,14,26H,7-10H2/t14-,18+",WDZVWDXOIGQJIO-UJKQEGAGSA-N,Protease,PSEN1@Protease,5663,P49768,"ACNINV3, AD3, FAD, PS-1, PS1, S182",Inhibitor,GSI-NC,0.65,IC50,Radioligand binding assay for APP as target,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/MRK-560,=,,,,,,0,Enzyme and Receptor panel (MSD Pharma/Taiwan),171,"No near family aspartyl proteases detected, closest target: IC50(SLC18A2) = 213 nM, 6 additional targets between 2-10 µM; Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: CIT (0%), EGFR (0%), IKBKE (0%), LATS2 (0%), AKT1 (5%), PIK3CA(C420R) (36%); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest target: Ki(SLC6A3) = 3137 nM;",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/MRK-560,Protease set,100 nM
EUB0000751a_PDE10A,THPP-1,EUB0000751a,COCCOC1=NC(C2=CC=C(Cl)N=C2)=NC3=C1CN(C(C4=C5C=CC=CN5C=N4)=O)CC3,"InChI=1S/C23H21ClN6O3/c1-32-10-11-33-22-16-13-29(23(31)20-18-4-2-3-8-30(18)14-26-20)9-7-17(16)27-21(28-22)15-5-6-19(24)25-12-15/h2-6,8,12,14H,7,9-11,13H2,1H3",JBHLOPKIPKTRSU-UHFFFAOYSA-N,PDE,PDE10A,10846,Q9Y233,PDE10A,Inhibitor,THPP-1-NC,0.99,Ki,Fluorescence polarization assay,"https://doi.org/10.1016/j.neuropharm.2012.06.013, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/THPP-1",=,49,IC50,Cell-based assay,,=,1,"PDE panel, literature",11,"Targets tested in PDE activity assays, closest targets: Ki(PDE6) = 44 nM (44-fold selective), Ki(PDE5A) = 116 nM (116-fold selective), Ki(PDE298) = 298 nM (300-fold selective), others >1000-fold selective"," https://doi.org/10.1016/j.bmcl.2012.07.072, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/THPP-1",Other targets,100 nM
EUB0000752a_NDUFS2,BAY-179,EUB0000752a,N1(CC2=NC3=C(C=CC=N3)N2)CCC(c4scc(c(c5)oc6c5cccc6)n4)CC1,"InChI=1S/C23H21N5OS/c1-2-6-19-16(4-1)12-20(29-19)18-14-30-23(26-18)15-7-10-28(11-8-15)13-21-25-17-5-3-9-24-22(17)27-21/h1-6,9,12,14-15H,7-8,10-11,13H2,(H,24,25,27)",JOCPQSJABURDDD-UHFFFAOYSA-N,Dehydrogenase,NDUFS2,4720,O75306,"CI-49, MC1DN6",Inhibitor,BAY-070,,,,,,79,IC50,Cellular activity assay (measurement of ATP levels in presence of complex II substrate succinate in H1299 cells),,=,,,,"Biochemical bovine OxPhos activity assay: >30 µM for Complex 2, 3, 4 and 5; Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest targets:Ki(HTR2B) = 558.19 nM, Ki(TMEM97) = 1118.32 nM, Ki(SIGMAR1) = 1179.84 nM, Ki(ADRA2C) = 3499.92 nM; Screened in Eurofins-CEREP, GPCR panel at 10 µM, closest target as % inhibition: HTR2B (73.5%); Selectivity > 500 fold against numerous kinases tested;","https://doi.org/10.1021/acsmedchemlett.1c00666, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-179",Other targets,1 µM
EUB0000753a_PSEN1@Protease,GSM1,EUB0000753a,Cc1ncn(c2ccc(c3cn([C@@H]4C(N(c5cccc(F)c5CC4)CC(F)(F)F)=O)nn3)cc2OC)c1,"InChI=1S/C25H22F4N6O2/c1-15-11-33(14-30-15)21-8-6-16(10-23(21)37-2)19-12-35(32-31-19)22-9-7-17-18(26)4-3-5-20(17)34(24(22)36)13-25(27,28)29/h3-6,8,10-12,14,22H,7,9,13H2,1-2H3/t22-/m0/s1",AAHNBILIYONQLX-QFIPXVFZSA-N,Protease,PSEN1@Protease,5663,P49768,"ACNINV3, AD3, FAD, PS-1, PS1, S182",Allosteric modulator,GSM-NC,,,,,,,,,,,0,Enzyme and Receptor panel (MSD Pharma/Taiwan),165,"No near family aspartyl proteases, closest targets: IC50(SLC6A4) = 13 nM, IC50(SLC6A3) = 536 nM, IC50(Na channel site 2) = 1000 nM; Screened against 468 kinases (KinomeScan DiscoverX) at 1 µM, closest targets as % of contr.: ACVR2A (0%), EGFR (0%), MAP4K4 (0%), MAP4K5 (5.8%); Screened against 45 GPCR targets (PDSP screen) at 10 µM, closest targets: Ki(SLC6A4) = 24 nM, Ki(SLC6A3) = 191 nM, Ki(SLC6A2) = 808 nM;",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/GSM1,Protease set,1 µM
EUB0000484b_GPR35,PAMOIC ACID,EUB0000484b,OC(=O)C1=CC2=C(C=CC=C2)C(CC2=C3C=CC=CC3=CC(C(O)=O)=C2O)=C1O,"InChI=1S/C23H16O6/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29/h1-10,24-25H,11H2,(H,26,27)(H,28,29)",WLJNZVDCPSBLRP-UHFFFAOYSA-N,GPCR,GPR35,2859,Q9HC97,,,,23.99,EC50,Agonist activity at human GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay,23713606,=,,,,,,,,,,,,
EUB0000274cCl_P2RY14,PPTN,EUB0000274cCl,Cl.OC(=O)c1cc(-c2ccc(cc2)C2CCNCC2)c2ccc(cc2c1)-c1ccc(cc1)C(F)(F)F,"InChI=1S/C29H24F3NO2.ClH/c30-29(31,32)25-8-5-19(6-9-25)22-7-10-26-23(15-22)16-24(28(34)35)17-27(26)21-3-1-18(2-4-21)20-11-13-33-14-12-20;/h1-10,15-17,20,33H,11-14H2,(H,34,35);1H",FKMVYPCBLWYNAV-UHFFFAOYSA-N,GPCR,P2RY14,9934,Q15391,KIAA0001,Antagonist,,7.94,IC50,Antagonist activity human P2Y14R expressed in African green monkey COS7 cells assessed as inhibition of UDPG-induced [3H]inositol phosphate accumulation after 30 mins by liquid scintillation counting method,27331270,=,,,,,,,,,,,,
EUB0001184b_ACVR1,M4K2234,EUB0001184b,COc1cc(-c2cncc(-c3ccc(N4CCN(C(C)C)CC4)cc3)c2C)cc(F)c1C(N)=O,"InChI=1S/C27H31FN4O2/c1-17(2)31-9-11-32(12-10-31)21-7-5-19(6-8-21)22-15-30-16-23(18(22)3)20-13-24(28)26(27(29)33)25(14-20)34-4/h5-8,13-17H,9-12H2,1-4H3,(H2,29,33)",RIWTUJFFSTVYPW-UHFFFAOYSA-N,Protein Kinase,ACVR1,90,Q04771,"SKR1, ALK2, ACVR1A",inhibitor,M4K2234NC,14,IC50,Radiometric assay and ³³PanQinase™,https://www.thesgc.org/chemical-probes/m4k2234,=,13,IC50,NanoBRET assay (HEK293T cells),https://www.thesgc.org/chemical-probes/m4k2234,=,,Kinase panel (Reaction Biology),375,"Screened at 1 µM, closest targets as % of inhibition: TNIK (4.92%), ALK6 (27%), MAP4K4 (30%); In-vitro follow-up of closest targets and ALK family (biochemical assays, Reaction Biology, 10 mM ATP): IC50(ALK3) = 168 nM, IC50(ALK4) = 1660 nM, IC50(ALK5) 1950 nM, IC50(ALK6) = 88 nM, IC50(TNIK) = 41 nM; In-cellulo potency (NanoBRET assay in HEK293T cells): IC50(ALK3) = 536 nM, IC50(ALK4) = 8424 nM, IC50(ALK5) = 7932 nM, IC560(ALK6) = 1628 nM, https://www.thesgc.org/chemical-probes/m4k2234;",https://www.thesgc.org/chemical-probes/m4k2234,Kinase set,1 µM
EUB0001465a_ACVR1,M4K2234NC,EUB0001465a,COc1cc(-c2cncc(-c3ccc(N4CCN(C(C)C)CC4)cc3)c2C)cc(F)c1C(=O)N1CCCC1,"InChI=1S/C31H37FN4O2/c1-21(2)34-13-15-35(16-14-34)25-9-7-23(8-10-25)26-19-33-20-27(22(26)3)24-17-28(32)30(29(18-24)38-4)31(37)36-11-5-6-12-36/h7-10,17-21H,5-6,11-16H2,1-4H3",WFJOMSKCDAOJBT-UHFFFAOYSA-N,Protein Kinase,ACVR1,90,Q04771,"SKR1, ALK2, ACVR1A",negative control,,,,,,,5686,IC50,NanoBRET assay (HEK293T cells),https://www.thesgc.org/chemical-probes/m4k2234,=,,"ALK family panel (NanoBRET assay in HEK293T cells , in-house data SGC-Frankfurt)",6,"In-cellulo follow-up (NanoBRET assays in HEK293T cells): IC50(ALK3) >10 µM, IC50(ALK4) >10 µM, IC50(ALK5) >10 µM, IC560(ALK6) = >10 µM; https://www.thesgc.org/chemical-probes/m4k2234",https://www.thesgc.org/chemical-probes/m4k2234,Kinase set,1 µM
EUB0001184b_ACVRL1,M4K2234,EUB0001184b,COc1cc(-c2cncc(-c3ccc(N4CCN(C(C)C)CC4)cc3)c2C)cc(F)c1C(N)=O,"InChI=1S/C27H31FN4O2/c1-17(2)31-9-11-32(12-10-31)21-7-5-19(6-8-21)22-15-30-16-23(18(22)3)20-13-24(28)26(27(29)33)25(14-20)34-4/h5-8,13-17H,9-12H2,1-4H3,(H2,29,33)",RIWTUJFFSTVYPW-UHFFFAOYSA-N,Protein Kinase,ACVRL1,94,P37023,"HHT2, ALK1, HHT",inhibitor,M4K2234NC,7,IC50,Radiometric assay and ³³PanQinase™,https://www.thesgc.org/chemical-probes/m4k2234,=,83,IC50,NanoBRET assay (HEK293T cells),https://www.thesgc.org/chemical-probes/m4k2234,=,,Kinase panel (Reaction Biology),375,"Screened at 1 µM, closest targets as % of inhibition: TNIK (4.92%), ALK6 (27%), MAP4K4 (30%); In-vitro follow-up of closest targets and ALK family (biochemical assays, Reaction Biology, 10 mM ATP): IC50(ALK3) = 168 nM, IC50(ALK4) = 1660 nM, IC50(ALK5) 1950 nM, IC50(ALK6) = 88 nM, IC50(TNIK) = 41 nM; In-cellulo potency (NanoBRET assay in HEK293T cells): IC50(ALK3) = 536 nM, IC50(ALK4) = 8424 nM, IC50(ALK5) = 7932 nM, IC560(ALK6) = 1628 nM, https://www.thesgc.org/chemical-probes/m4k2234;",https://www.thesgc.org/chemical-probes/m4k2234,Kinase set,1 µM
EUB0001465a_ACVRL1,M4K2234NC,EUB0001465a,COc1cc(-c2cncc(-c3ccc(N4CCN(C(C)C)CC4)cc3)c2C)cc(F)c1C(=O)N1CCCC1,"InChI=1S/C31H37FN4O2/c1-21(2)34-13-15-35(16-14-34)25-9-7-23(8-10-25)26-19-33-20-27(22(26)3)24-17-28(32)30(29(18-24)38-4)31(37)36-11-5-6-12-36/h7-10,17-21H,5-6,11-16H2,1-4H3",WFJOMSKCDAOJBT-UHFFFAOYSA-N,Protein Kinase,ACVRL1,94,P37023,"HHT2, ALK1, HHT",negative control,,,,,,,10000,IC50,NanoBRET assay (HEK293T cells),https://www.thesgc.org/chemical-probes/m4k2234,>,,"ALK family panel (NanoBRET assay in HEK293T cells , in-house data SGC-Frankfurt)",6,"In-cellulo follow-up (NanoBRET assays in HEK293T cells): IC50(ALK3) >10 µM, IC50(ALK4) >10 µM, IC50(ALK5) >10 µM, IC560(ALK6) = >10 µM; https://www.thesgc.org/chemical-probes/m4k2234",https://www.thesgc.org/chemical-probes/m4k2234,Kinase set,1 µM
EUB0001560a_AKT1,BAY-940,EUB0001560a,NC1(c2ccc(-c3nc4c(O)ccnn4c3-c3ccccc3)cc2)CCC1,"InChI=1S/C22H20N4O/c23-22(12-4-13-22)17-9-7-15(8-10-17)19-20(16-5-2-1-3-6-16)26-21(25-19)18(27)11-14-24-26/h1-3,5-11,14,27H,4,12-13,23H2",DSWFCCRSSVVRIR-UHFFFAOYSA-N,Protein Kinase,AKT1,207,P31749,"RAC, PKB, PRKBA, AKT, RAC-alpha",Negative control for BAY-1125976,,3740,IC50,Enzymatic inhibition assay,"https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BAY1125976, https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BAY1125976",=,6000,IC50,NanoBRET assay (in HEK293T cells),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BAY1125976,=,,,,,,Kinase set,1 µM
EUB0001563a_AKT1,RL2578,EUB0001563a,C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5ccc6c(c5)NC(=O)CO6)cc4)CC3)c2c1,"InChI=1S/C30H29N5O4/c1-2-28(36)31-22-8-9-24-26(16-22)35(30(38)33-24)23-11-13-34(14-12-23)17-19-3-5-20(6-4-19)21-7-10-27-25(15-21)32-29(37)18-39-27/h2-10,15-16,23H,1,11-14,17-18H2,(H,31,36)(H,32,37)(H,33,38)",DHRJWFCFMBINAK-UHFFFAOYSA-N,Protein Kinase,AKT1,207,P31749,"RAC, PKB, PRKBA, AKT, RAC-alpha",Negative control for Borussertib,,920,IC50,HTFR assay,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/Borussertib,=,1900,IC50,NanoBRET assay (in HEK293T cells),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/Borussertib,=,,,,,,Kinase set,1 µM
EUB0001560a_AKT2,BAY-940,EUB0001560a,NC1(c2ccc(-c3nc4c(O)ccnn4c3-c3ccccc3)cc2)CCC1,"InChI=1S/C22H20N4O/c23-22(12-4-13-22)17-9-7-15(8-10-17)19-20(16-5-2-1-3-6-16)26-21(25-19)18(27)11-14-24-26/h1-3,5-11,14,27H,4,12-13,23H2",DSWFCCRSSVVRIR-UHFFFAOYSA-N,Protein Kinase,AKT2,208,P31751,PKBb,Negative control for BAY-1125976,,3840,IC50,Enzymatic inhibition assay,"https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BAY1125976,https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BAY1125976",=,10400,IC50,NanoBRET assay (in HEK293T cells),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BAY1125976,=,,,,,,Kinase set,1 µM
EUB0001563a_AKT2,RL2578,EUB0001563a,C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5ccc6c(c5)NC(=O)CO6)cc4)CC3)c2c1,"InChI=1S/C30H29N5O4/c1-2-28(36)31-22-8-9-24-26(16-22)35(30(38)33-24)23-11-13-34(14-12-23)17-19-3-5-20(6-4-19)21-7-10-27-25(15-21)32-29(37)18-39-27/h2-10,15-16,23H,1,11-14,17-18H2,(H,31,36)(H,32,37)(H,33,38)",DHRJWFCFMBINAK-UHFFFAOYSA-N,Protein Kinase,AKT2,208,P31751,PKBb,Negative control for Borussertib,,,,,,,8300,IC50,NanoBRET assay (in HEK293T cells),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/Borussertib,=,,,,,,Kinase set,1 µM
EUB0000041b_ACVR1B,Vactosertib,EUB0000041b,Cc1cccc(-c2[nH]c(CNc3ccccc3F)nc2-c2ccc3ncnn3c2)n1,"InChI=1S/C22H18FN7/c1-14-5-4-8-18(27-14)22-21(15-9-10-20-25-13-26-30(20)12-15)28-19(29-22)11-24-17-7-3-2-6-16(17)23/h2-10,12-13,24H,11H2,1H3,(H,28,29)",FJCDSQATIJKQKA-UHFFFAOYSA-N,Protein Kinase,ACVR1B,91,P36896,"ALK4, SKR2, ActRIB",Inhibitor,,17.2,IC50,Radiometric protein kinase assay (33PanQinase Activity Assay),https://aacrjournals.org/mct/article/13/7/1704/91906/EW-7197-a-Novel-ALK-5-Kinase-Inhibitor-Potently,=,,,,,,,"Kinase panel (radiometric 33ProQinase Activity Assays, singlicates, ProQinase)",320,"Screened at 1 µM, closest targets as % residual activity: RIPK2 (7%), VEGFR2 (11%), MINK1 (21%), VEGFR3 (28%), VEGFR1 (38%), MAP4K4 (41%), PDGFRA(V561D) (43%), PDGFRA (47%), TGFBR2 (47%); In-vitro follow-up of closest targets (radioisotopic protein kinase assay, 33PanQinase activity assay): IC50(RIPK2) = 54 nM, IC50(VEGFR2) = 97 nM (https://pubs.acs.org/doi/10.1021/jm500115w); Selectivity within ALK family (Radioisotopic protein kinase assay, HotSpot assay, Reaction Biology): IC50(ALK1) >10 µM, IC50(ALK2) >10 µM, IC50(ALK3) >10 µM, IC50(ALK4) = 0.013 µM, IC50(ALK5) = 0.011 µM, IC50(ALK6) >10 µM, IC50(ALK7) n.d. (https://pubs.acs.org/doi/10.1021/jm500115w);",https://aacrjournals.org/mct/article/13/7/1704/91906/EW-7197-a-Novel-ALK-5-Kinase-Inhibitor-Potently,Kinase set,100 nM
EUB0000041b_TGFBR1,Vactosertib,EUB0000041b,Cc1cccc(-c2[nH]c(CNc3ccccc3F)nc2-c2ccc3ncnn3c2)n1,"InChI=1S/C22H18FN7/c1-14-5-4-8-18(27-14)22-21(15-9-10-20-25-13-26-30(20)12-15)28-19(29-22)11-24-17-7-3-2-6-16(17)23/h2-10,12-13,24H,11H2,1H3,(H,28,29)",FJCDSQATIJKQKA-UHFFFAOYSA-N,Protein Kinase,TGFBR1,7046,P36897,"ALK-5, ACVRLK4, ALK5, TBRI, TBR-i",Inhibitor,,12.9,IC50,Radiometric protein kinase assay (33PanQinase Activity Assay),https://aacrjournals.org/mct/article/13/7/1704/91906/EW-7197-a-Novel-ALK-5-Kinase-Inhibitor-Potently,=,41,IC50,Cell-based Luciferase assay (ALK5 inhibition in HaCaT cells permanently transfected with p3TO-luciferase reporter construct),https://pubs.acs.org/doi/10.1021/jm500115w,=,,"Kinase panel (radiometric 33ProQinase Activity Assays, singlicates, ProQinase)",320,"Screened at 1 µM, closest targets as % residual activity: RIPK2 (7%), VEGFR2 (11%), MINK1 (21%), VEGFR3 (28%), VEGFR1 (38%), MAP4K4 (41%), PDGFRA(V561D) (43%), PDGFRA (47%), TGFBR2 (47%); In-vitro follow-up of closest targets (radioisotopic protein kinase assay, 33PanQinase activity assay): IC50(RIPK2) = 54 nM, IC50(VEGFR2) = 97 nM (https://pubs.acs.org/doi/10.1021/jm500115w); Selectivity within ALK family (Radioisotopic protein kinase assay, HotSpot assay, Reaction Biology): IC50(ALK1) >10 µM, IC50(ALK2) >10 µM, IC50(ALK3) >10 µM, IC50(ALK4) = 0.013 µM, IC50(ALK5) = 0.011 µM, IC50(ALK6) >10 µM, IC50(ALK7) n.d. (https://pubs.acs.org/doi/10.1021/jm500115w);",https://aacrjournals.org/mct/article/13/7/1704/91906/EW-7197-a-Novel-ALK-5-Kinase-Inhibitor-Potently,Kinase set,100 nM
EUB0000133b_STK6,Alisertib,EUB0000133b,COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC,"InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)",ZLHFILGSQDJULK-UHFFFAOYSA-N,Protein Kinase,STK6,6790,O14965,"BTAK, AurA, STK7, ARK1, PPP1R47, AIK",Inhibitor,,1.2,IC50,Radioactive Flashplate assay,https://aacrjournals.org/clincancerres/article/17/24/7614/204920/Characterization-of-Alisertib-MLN8237-an,=,6.7,IC50,Immunostaining (pThr288 autophosphorylation assay in HeLa cells),https://aacrjournals.org/clincancerres/article/17/24/7614/204920/Characterization-of-Alisertib-MLN8237-an,=,,SelectScreen kinase panel (Invitrogen),205,"Screened at 1 µM, closest targets as % of inhibition: BLK (92%), CAMK2A (95%), EPHA2 (100%), EPHA4 (94%), FGFR2 (90%), FGR (97%), MAPKAPK3 (91%), NTRK3 (91%); Proteomics (Kinobeads assays), in-vitro potencies of closest targets: Kdapp(AURKA) = 5 nM, Kdapp(ACAD10) = 78 nM, Kdapp(AURKB) = 195 nM, Kdapp(PDPK1) = 289 nM, Kdapp(EPHA2) = 309 nM, Kdapp(EPHA4) = 455 nM, Kdapp(DNAJA1) = 962 nM, Kd(ABL2) = 1009 nM, Kdapp(GNAI2) = 184 nM, Kdapp(PSMA7) = 405 nM, Kdapp(MCM4) = 629 nM, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542668/;",https://aacrjournals.org/clincancerres/article/17/24/7614/204920/Characterization-of-Alisertib-MLN8237-an,Kinase set,100 nM
EUB0000125b_AURKB,Barasertib-HQPA,EUB0000125b,CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO,"InChI=1S/C26H30FN7O3/c1-2-34(10-11-35)9-4-12-37-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(36)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17,35H,2,4,9-12,15H2,1H3,(H,30,36)(H2,28,29,31,32,33)",QYZOGCMHVIGURT-UHFFFAOYSA-N,Protein Kinase,AURKB,9212,Q96GD4,"Aik2, IPL1, AurB, AIM-1, ARK2, STK5, PPP1R48",Active inhibitor of prodrug AZD1152,,0.37,Ki,Enzymatic assay,https://pubmed.ncbi.nlm.nih.gov/17026809/,=,,,,,,,Kinase panel (DSF assay),100,"Screened at 20 µM, closest targets with dTm >3K: dTm(AURKB) = 13.8 K, dTm(STK6) = 9.08 K, dTm(FLT1) = 4.33 K;",https://pubmed.ncbi.nlm.nih.gov/17026809/,Kinase set,100 nM
EUB0000045b_BMX,BMX-IN-1,EUB0000045b,CC1=C(C=C(C=C1)N2C(=O)C=CC3=CN=C4C=CC(=CC4=C32)C5=CC=C(C=C5)NS(=O)(=O)C)NC(=O)C=C,"InChI=1S/C29H24N4O4S/c1-4-27(34)31-26-16-23(12-5-18(26)2)33-28(35)14-9-21-17-30-25-13-8-20(15-24(25)29(21)33)19-6-10-22(11-7-19)32-38(3,36)37/h4-17,32H,1H2,2-3H3,(H,31,34)",SFMJNHNUOVADRW-UHFFFAOYSA-N,Protein Kinase,BMX,660,P51813,"ETK, PSCTK3",Covalent inhibitor,,8,IC50,SelectScreen Z’lyte assay (Invitrogen),https://pubmed.ncbi.nlm.nih.gov/23594111/,=,138,IC50,BMX IP kinase assay in HEK293 cells,https://pubmed.ncbi.nlm.nih.gov/23594111/,=,,KinomeScan (DiscoverX),442,"Screened at 1 µM, S(10) = 0.01, closest targets as % of contr.: JAK3 (6.6%), PIP3CG (2.8%), PIP5K2C (5.6%), SBK1 (4.6%); ",https://pubmed.ncbi.nlm.nih.gov/23594111/,Kinase set,1 µM
EUB0001074a_BRD1,NI-198,EUB0001074a,O=S(NC1=CC=C2N(C(C(CC)=CC2=C1)=O)CC)(C3=CC=C(C=C3)C#N)=O,"InChI=1S/C20H19N3O3S/c1-3-15-11-16-12-17(7-10-19(16)23(4-2)20(15)24)22-27(25,26)18-8-5-14(13-21)6-9-18/h5-12,22H,3-4H2,1-2H3",QTIVTZLLONAWRR-UHFFFAOYSA-N,Bromodomain,BRD1,23774,O95696,"BRL, BRPF2",Negative control for NI-57,,100000,IC50,BROMOscan,https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00611#,>,,,,,,,,,,,Epigenetic set,1 µM
EUB0000102c_BRD2,I-BET151 (GSK1210151A),EUB0000102c,COc1cc2c(cc1-c1c(C)noc1C)ncc1nc(O)n([C@H](C)c3ccccn3)c12,"InChI=1S/C23H21N5O3/c1-12-21(14(3)31-27-12)16-9-18-15(10-20(16)30-4)22-19(11-25-18)26-23(29)28(22)13(2)17-7-5-6-8-24-17/h5-11,13H,1-4H3,(H,26,29)/t13-/m1/s1",VUVUVNZRUGEAHB-CYBMUJFWSA-N,Bromodomain,BRD2,6046,P25440,"KIAA9001, RING3, D6S113E, NAT, FSRG1",Inhibitor,,500,IC50,FP ligand displacement assays,https://pubmed.ncbi.nlm.nih.gov/21964340/,=,,,,,,,"Bromodomain panel (DSF assays, literature)",26,"Screened at 100 µM in DSF assay, closest target: dTm(CEREBBP) = 1-3 K; Screened in CEREP panel against 50 GPCRs, ion channels and transporters at 10 µM, closest target as % inhibition: NK2 (48%)",https://pubmed.ncbi.nlm.nih.gov/21964340/,Epigenetic set,1 µM
EUB0000200b_BRD2@BD1,(-)-JQ1,EUB0000200b,Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@H](CC(=O)OC(C)(C)C)c1nnc(C)n1-2,"InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m1/s1",DNVXATUJJDPFDM-QGZVFWFLSA-N,Bromodomain,BRD2@BD1,6046,P25440,"KIAA9001, RING3, D6S113E, NAT, FSRG1",Negative control for (+)-JQ1,,0.89,K,DSF-assay (Screened at 10 µM),https://www.thesgc.org/chemical-probes/JQ1,=,,,,,,,"Bromodomain panel (DSF assays, literature)",37,"Screened at 10 µM in DSF-assay, closest target: dTm(CREBBP) = 1.18 K;",https://www.nature.com/articles/nature09504,Epigenetic set,1 µM
EUB0000200b_BRD2@BD2,(-)-JQ1,EUB0000200b,Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@H](CC(=O)OC(C)(C)C)c1nnc(C)n1-2,"InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m1/s1",DNVXATUJJDPFDM-QGZVFWFLSA-N,Bromodomain,BRD2@BD2,6046,P25440,"KIAA9001, RING3, D6S113E, NAT, FSRG1",Negative control for (+)-JQ1,,0.91,K,DSF-assay (Screened at 10 µM),https://www.thesgc.org/chemical-probes/JQ1,=,,,,,,,"Bromodomain panel (DSF assays, literature)",37,"Screened at 10 µM in DSF-assay, closest target: dTm(CREBBP) = 1.18 K;",https://www.nature.com/articles/nature09504,Epigenetic set,1 µM
EUB0000102c_BRD3,I-BET151 (GSK1210151A),EUB0000102c,COc1cc2c(cc1-c1c(C)noc1C)ncc1nc(O)n([C@H](C)c3ccccn3)c12,"InChI=1S/C23H21N5O3/c1-12-21(14(3)31-27-12)16-9-18-15(10-20(16)30-4)22-19(11-25-18)26-23(29)28(22)13(2)17-7-5-6-8-24-17/h5-11,13H,1-4H3,(H,26,29)/t13-/m1/s1",VUVUVNZRUGEAHB-CYBMUJFWSA-N,Bromodomain,BRD3,8019,Q15059,"RING3L, ORFX, KIAA0043",Inhibitor,,250,IC50,FP ligand displacement assays,https://pubmed.ncbi.nlm.nih.gov/21964340/,=,,,,,,,"Bromodomain panel (DSF assays, literature)",26,"Screened at 100 µM in DSF assay, closest target: dTm(CEREBBP) = 1-3 K; Screened in CEREP panel against 50 GPCRs, ion channels and transporters at 10 µM, closest target as % inhibition: NK2 (48%)",https://pubmed.ncbi.nlm.nih.gov/21964340/,Epigenetic set,1 µM
EUB0000200b_BRD3@BD1,(-)-JQ1,EUB0000200b,Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@H](CC(=O)OC(C)(C)C)c1nnc(C)n1-2,"InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m1/s1",DNVXATUJJDPFDM-QGZVFWFLSA-N,Bromodomain,BRD3@BD1,8019,Q15059,"RING3L, ORFX, KIAA0043",Negative control for (+)-JQ1,,1.95,K,DSF-assay (Screened at 10 µM),https://www.thesgc.org/chemical-probes/JQ1,=,,,,,,,"Bromodomain panel (DSF assays, literature)",37,"Screened at 10 µM in DSF-assay, closest target: dTm(CREBBP) = 1.18 K;",https://www.nature.com/articles/nature09504,Epigenetic set,1 µM
EUB0000200b_BRD3@BD2,(-)-JQ1,EUB0000200b,Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@H](CC(=O)OC(C)(C)C)c1nnc(C)n1-2,"InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m1/s1",DNVXATUJJDPFDM-QGZVFWFLSA-N,Bromodomain,BRD3@BD2,8019,Q15059,"RING3L, ORFX, KIAA0043",Negative control for (+)-JQ1,,2.14,K,DSF-assay (Screened at 10 µM),https://www.thesgc.org/chemical-probes/JQ1,=,,,,,,,"Bromodomain panel (DSF assays, literature)",37,"Screened at 10 µM in DSF-assay, closest target: dTm(CREBBP) = 1.18 K;",https://www.nature.com/articles/nature09504,Epigenetic set,1 µM
EUB0000102c_BRD4,I-BET151 (GSK1210151A),EUB0000102c,COc1cc2c(cc1-c1c(C)noc1C)ncc1nc(O)n([C@H](C)c3ccccn3)c12,"InChI=1S/C23H21N5O3/c1-12-21(14(3)31-27-12)16-9-18-15(10-20(16)30-4)22-19(11-25-18)26-23(29)28(22)13(2)17-7-5-6-8-24-17/h5-11,13H,1-4H3,(H,26,29)/t13-/m1/s1",VUVUVNZRUGEAHB-CYBMUJFWSA-N,Bromodomain,BRD4,23476,O60885,"HUNKI, MCAP, CAP, HUNK1",Inhibitor,,790,IC50,FP ligand displacement assays,https://pubmed.ncbi.nlm.nih.gov/21964340/,=,,,,,,,"Bromodomain panel (DSF assays, literature)",26,"Screened at 100 µM in DSF assay, closest target: dTm(CEREBBP) = 1-3 K; Screened in CEREP panel against 50 GPCRs, ion channels and transporters at 10 µM, closest target as % inhibition: NK2 (48%)",https://pubmed.ncbi.nlm.nih.gov/21964340/,Epigenetic set,1 µM
EUB0000200b_BRD4@BD1,(-)-JQ1,EUB0000200b,Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@H](CC(=O)OC(C)(C)C)c1nnc(C)n1-2,"InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m1/s1",DNVXATUJJDPFDM-QGZVFWFLSA-N,Bromodomain,BRD4@BD1,23476,O60885,"HUNKI, MCAP, CAP, HUNK1",Negative control for (+)-JQ1,,10000,IC50,"Luminescence proximity homogeneous assay (alpha-screen, binding of a tetra-acetylated histone H4 peptide to BRD4)",https://www.nature.com/articles/s41586-020-1930-8,=,,,,,,,"Bromodomain panel (DSF assays, literature)",37,"Screened at 10 µM in DSF-assay, closest target: dTm(CREBBP) = 1.18 K;",https://www.nature.com/articles/nature09504,Epigenetic set,1 µM
EUB0000200b_BRD4@BD2,(-)-JQ1,EUB0000200b,Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@H](CC(=O)OC(C)(C)C)c1nnc(C)n1-2,"InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m1/s1",DNVXATUJJDPFDM-QGZVFWFLSA-N,Bromodomain,BRD4@BD2,23476,O60885,"HUNKI, MCAP, CAP, HUNK1",Negative control for (+)-JQ1,,10000,IC50,"Luminescence proximity homogeneous assay (alpha-screen, binding of a tetra-acetylated histone H4 peptide to BRD4)","https://www.thesgc.org/chemical-probes/JQ1, https://www.nature.com/articles/s41586-020-1930-8",=,,,,,,,"Bromodomain panel (DSF assays, literature)",37,"Screened at 10 µM in DSF-assay, closest target: dTm(CREBBP) = 1.18 K;",https://www.nature.com/articles/nature09504,Epigenetic set,1 µM
EUB0000102c_BRDT,I-BET151 (GSK1210151A),EUB0000102c,COc1cc2c(cc1-c1c(C)noc1C)ncc1nc(O)n([C@H](C)c3ccccn3)c12,"InChI=1S/C23H21N5O3/c1-12-21(14(3)31-27-12)16-9-18-15(10-20(16)30-4)22-19(11-25-18)26-23(29)28(22)13(2)17-7-5-6-8-24-17/h5-11,13H,1-4H3,(H,26,29)/t13-/m1/s1",VUVUVNZRUGEAHB-CYBMUJFWSA-N,Bromodomain,BRDT,676,Q58F21,"BRD6, CT9",Inhibitor,,,,,,,,,,,,,"Bromodomain panel (DSF assays, literature)",26,"Screened at 100 µM in DSF assay, closest target: dTm(CEREBBP) = 1-3 K; Screened in CEREP panel against 50 GPCRs, ion channels and transporters at 10 µM, closest target as % inhibition: NK2 (48%)",https://pubmed.ncbi.nlm.nih.gov/21964340/,Epigenetic set,1 µM
EUB0000200b_BRDT@BD1,(-)-JQ1,EUB0000200b,Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@H](CC(=O)OC(C)(C)C)c1nnc(C)n1-2,"InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m1/s1",DNVXATUJJDPFDM-QGZVFWFLSA-N,Bromodomain,BRDT@BD1,676,Q58F21,"BRD6, CT9",Negative control for (+)-JQ1,,0.38,K,DSF-assay (Screened at 10 µM),https://www.thesgc.org/chemical-probes/JQ1,=,,,,,,,"Bromodomain panel (DSF assays, literature)",37,"Screened at 10 µM in DSF-assay, closest target: dTm(CREBBP) = 1.18 K;",https://www.nature.com/articles/nature09504,Epigenetic set,1 µM
EUB0000200b_BRDT@BD2,(-)-JQ1,EUB0000200b,Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@H](CC(=O)OC(C)(C)C)c1nnc(C)n1-2,"InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m1/s1",DNVXATUJJDPFDM-QGZVFWFLSA-N,Bromodomain,BRDT@BD2,676,Q58F21,"BRD6, CT9",Negative control for (+)-JQ1,,,,,,,,,,,,,"Bromodomain panel (DSF assays, literature)",37,"Screened at 10 µM in DSF-assay, closest target: dTm(CREBBP) = 1.18 K;",https://www.nature.com/articles/nature09504,Epigenetic set,1 µM
EUB0001074a_BRPF1,NI-198,EUB0001074a,O=S(NC1=CC=C2N(C(C(CC)=CC2=C1)=O)CC)(C3=CC=C(C=C3)C#N)=O,"InChI=1S/C20H19N3O3S/c1-3-15-11-16-12-17(7-10-19(16)23(4-2)20(15)24)22-27(25,26)18-8-5-14(13-21)6-9-18/h5-12,22H,3-4H2,1-2H3",QTIVTZLLONAWRR-UHFFFAOYSA-N,Bromodomain,BRPF1,7862,P55201,BR140,Negative control for NI-57,,100000,IC50,BROMOscan,https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00611#,>,,,,,,,,,,,Epigenetic set,1 µM
EUB0001074a_BRPF3,NI-198,EUB0001074a,O=S(NC1=CC=C2N(C(C(CC)=CC2=C1)=O)CC)(C3=CC=C(C=C3)C#N)=O,"InChI=1S/C20H19N3O3S/c1-3-15-11-16-12-17(7-10-19(16)23(4-2)20(15)24)22-27(25,26)18-8-5-14(13-21)6-9-18/h5-12,22H,3-4H2,1-2H3",QTIVTZLLONAWRR-UHFFFAOYSA-N,Bromodomain,BRPF3,27154,Q9ULD4,KIAA1286,BRPF3@BRD,,100000,IC50,BROMOscan,https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00611#,>,,,,,,,,,,,Epigenetic set,1 µM
EUB0001868a_BTK,BIIB068,EUB0001868a,Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(OC(C)C)C1,"InChI=1S/C23H29N7O2/c1-15(2)32-20-13-30(14-20)23(31)25-10-18-6-5-17(9-16(18)3)21-7-8-24-22(28-21)27-19-11-26-29(4)12-19/h5-9,11-12,15,20H,10,13-14H2,1-4H3,(H,25,31)(H,24,27,28)",BMWMKGNVAMXXCH-UHFFFAOYSA-N,Protein Kinase,BTK,695,Q06187,"ATK, XLA, PSCTK1",inhibitor,,0.3,Kd,Competition-binding assay (DiscoverX),https://pubmed.ncbi.nlm.nih.gov/32696648/,=,,,,,,,KINOMEscan (DiscoverX),395,"Screened at 1 µM, closest targets as % of contr.: MAP3K19 (9%), AAK1 (22%), ABL1(21%), BMP2K (18%), BTK (2.9%), CDKL2 (15%), JAK1 (29%), MST4 (42%), NLK(46%), PIP5K1A (28%), RIOK1 (17%), RIOK3 (19%), RPS6KA5 (42%), SRC (31%), STK16 (23%), TEC (46%), TIE1 (46%), TYK2 (47%); In-vitro potency of closest targets (Competition-binding assay, DiscoverX): Kd(AAK1) = 430 nM, Kd(BMP2K) = 1100 nM, Kd(BTK) = 0.3 nM, Kd(CDKL2) = 420 nM, Kd(JAK2) = 460 nM, Kd(PIP5K1A) >10000 nM, Kd(RIOK1) = 1200 nM, Kd(RIOK2) = 2400 nM, Kd(CDK7) = 880 nM, Kd(MAP3K19) = 130 nM, https://pubmed.ncbi.nlm.nih.gov/32696648/; Screened at 10 µM against 68 non-kinase targets, in-vitro potency of closest targets: IC50(A3) = 4.2 µM, IC50(H2) = 26.5 µM, https://pubmed.ncbi.nlm.nih.gov/32696648/; ",https://pubmed.ncbi.nlm.nih.gov/32696648/,Kinase set,1 µM
EUB0000045b_BTK,BMX-IN-1,EUB0000045b,CC1=C(C=C(C=C1)N2C(=O)C=CC3=CN=C4C=CC(=CC4=C32)C5=CC=C(C=C5)NS(=O)(=O)C)NC(=O)C=C,"InChI=1S/C29H24N4O4S/c1-4-27(34)31-26-16-23(12-5-18(26)2)33-28(35)14-9-21-17-30-25-13-8-20(15-24(25)29(21)33)19-6-10-22(11-7-19)32-38(3,36)37/h4-17,32H,1H2,2-3H3,(H,31,34)",SFMJNHNUOVADRW-UHFFFAOYSA-N,Protein Kinase,BTK,695,Q06187,"ATK, XLA, PSCTK1",Covalent inhibitor,,10.4,IC50,SelectScreen Z’lyte assay (Invitrogen),https://pubmed.ncbi.nlm.nih.gov/23594111/,=,,,,,,,KinomeScan (DiscoverX),442,"Screened at 1 µM, S(10) = 0.01, closest targets as % of contr.: JAK3 (6.6%), PIP3CG (2.8%), PIP5K2C (5.6%), SBK1 (4.6%); ",https://pubmed.ncbi.nlm.nih.gov/23594111/,Kinase set,1 µM
EUB0001548a_BUB1,BAY 1816032,EUB0001548a,COc1cnccc1Nc1nc(-c2nn(Cc3c(F)cc(OCCO)cc3F)c3ccccc23)ncc1OC,"InChI=1S/C27H24F2N6O4/c1-37-23-13-30-8-7-21(23)32-26-24(38-2)14-31-27(33-26)25-17-5-3-4-6-22(17)35(34-25)15-18-19(28)11-16(12-20(18)29)39-10-9-36/h3-8,11-14,36H,9-10,15H2,1-2H3,(H,30,31,32,33)",QVOGVAVHOLLLAZ-UHFFFAOYSA-N,Protein Kinase,BUB1,699,O43683,"hBUB1, BUB1A",Inhibitor,BAY-283,6.5,IC50,TR-FRET kinase assay (at 10 µM ATP),https://aacrjournals.org/clincancerres/article/25/4/1404/10115/Inhibition-of-BUB1-Kinase-by-BAY-1816032,=,29,IC50,Phospho-histone assay (inhibition of histone H2A-Thr120 phosphorylation in nocodazole-arrested HeLa cells after 1 h),https://aacrjournals.org/clincancerres/article/25/4/1404/10115/Inhibition-of-BUB1-Kinase-by-BAY-1816032,=,,KinomeScan (DiscoverX),403,"Screened at 1 µM, closest targets as % of control: STK10 (0.6%), DYRK1B (6.7%); In-vitro potency of closest targets (Competition-binding assay, DiscoverX): Kd(STK10) = 57 nM, Kd(DYRK1B) >30 µM; Screened at 10 µM against 89 targets (Eurofins-Panlabs Screen), closest targets as % of inhibition: human Adenosine transporter (71%), ADORA2A (67%), GABAA chloride channel TBOB receptor (60%), PTGS1 (54%), sodium channel site 2 (53%), PDE4 (52%); In-vitro potency of closest target: IC50(human Adenosin transporter) = 370 nM (https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY%201816032);",https://aacrjournals.org/clincancerres/article/25/4/1404/10115/Inhibition-of-BUB1-Kinase-by-BAY-1816032,Kinase set,100 nM
EUB0001549a_BUB1,BAY-283,EUB0001549a,COc1ccccc1Nc1nc(-c2nn(Cc3c(F)cc(OCCCO)cc3F)c3ccccc23)ncc1OC,"InChI=1S/C29H27F2N5O4/c1-38-25-11-6-4-9-23(25)33-28-26(39-2)16-32-29(34-28)27-19-8-3-5-10-24(19)36(35-27)17-20-21(30)14-18(15-22(20)31)40-13-7-12-37/h3-6,8-11,14-16,37H,7,12-13,17H2,1-2H3,(H,32,33,34)",PYAFWWXPXHSNDM-UHFFFAOYSA-N,Protein Kinase,BUB1,699,O43683,"hBUB1, BUB1A",Negative control for BAY 1816032,,1700,IC50,TR-FRET kinase assay (at 10 µM ATP),https://aacrjournals.org/clincancerres/article/25/4/1404/10115/Inhibition-of-BUB1-Kinase-by-BAY-1816032,=,,,,,,,Kinase panel (Bayer),25,IC50 >20 µM for all targets tested,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY%201816032,Kinase set,100 nM
EUB0000878a_CAMK1,640,EUB0000878a,CC(C)c1cc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)cc(C(C)C)n1,"InChI=1S/C21H31N7O/c1-12(2)17-8-15(9-18(26-17)13(3)4)25-20-16(19(23)29)10-24-21(27-20)28-7-5-6-14(22)11-28/h8-10,12-14H,5-7,11,22H2,1-4H3,(H2,23,29)(H,24,25,26,27)/t14-/m0/s1",BWBUPDTUXQDHSX-AWEZNQCLSA-N,Protein Kinase,CAMK1,8536,Q14012,"CaMKI, CaMKI-alpha",Inhibitor,CS640s,1,IC50,Enzymatic assay (Reaction Biology),https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01803,=,23,IC50,NanoBRET assay (in HEK293T cells),https://www.thesgc.org/chemical-probes/cs-640,=,,KinomeScan (DiscoverX),450,"Screened at 1 µM, closest targets as % of control: PIP5K1C (0%), MEK5 (0.95%), RIPK4 (4.5%), MLK3 (99%); In-vitro potency of closest targets (enzymatic assay, Reaction Biology): IC50(PIP5K1C) = 11 µM, IC50(MEK5) = 0.025 µM, IC50(RIPK4) = 5.69 µM, IC50(MLK3) = 2.75 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01803#; Screened at 10 µM in Eurofins Cerep-Panlabs Safety Screen 44 (GPCRS, Transporters, Ion Channels, Nuclear Receptors, other enzymes), closest targets as % of inhibition or stimulation: dopamine transporter (100%), hERG channel (89%), norepinephrine transporter (87%), M1 (84%), M2(70%), M3(74%), acetylcholinesterase (84%), https://www.thesgc.org/chemical-probes/cs-640;",https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01803,Kinase set,100 nM
EUB0000878a_PNCK,640,EUB0000878a,CC(C)c1cc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)cc(C(C)C)n1,"InChI=1S/C21H31N7O/c1-12(2)17-8-15(9-18(26-17)13(3)4)25-20-16(19(23)29)10-24-21(27-20)28-7-5-6-14(22)11-28/h8-10,12-14H,5-7,11,22H2,1-4H3,(H2,23,29)(H,24,25,26,27)/t14-/m0/s1",BWBUPDTUXQDHSX-AWEZNQCLSA-N,Protein Kinase,PNCK,139728,Q6P2M8,"MGC45419, CaMK1b",Inhibitor,CS640s,3,IC50,Enzymatic assay (Reaction Biology),https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01803,=,8.2,IC50,NanoBRET assay (in HEK293T cells),https://www.thesgc.org/chemical-probes/cs-640,=,,KinomeScan (DiscoverX),450,"Screened at 1 µM, closest targets as % of control: PIP5K1C (0%), MEK5 (0.95%), RIPK4 (4.5%), MLK3 (99%); In-vitro potency of closest targets (enzymatic assay, Reaction Biology): IC50(PIP5K1C) = 11 µM, IC50(MEK5) = 0.025 µM, IC50(RIPK4) = 5.69 µM, IC50(MLK3) = 2.75 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01803#; Screened at 10 µM in Eurofins Cerep-Panlabs Safety Screen 44 (GPCRS, Transporters, Ion Channels, Nuclear Receptors, other enzymes), closest targets as % of inhibition or stimulation: dopamine transporter (100%), hERG channel (89%), norepinephrine transporter (87%), M1 (84%), M2(70%), M3(74%), acetylcholinesterase (84%), https://www.thesgc.org/chemical-probes/cs-640;",https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01803,Kinase set,100 nM
EUB0000878a_CAMK1D,640,EUB0000878a,CC(C)c1cc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)cc(C(C)C)n1,"InChI=1S/C21H31N7O/c1-12(2)17-8-15(9-18(26-17)13(3)4)25-20-16(19(23)29)10-24-21(27-20)28-7-5-6-14(22)11-28/h8-10,12-14H,5-7,11,22H2,1-4H3,(H2,23,29)(H,24,25,26,27)/t14-/m0/s1",BWBUPDTUXQDHSX-AWEZNQCLSA-N,Protein Kinase,CAMK1D,57118,Q8IU85,CKLiK,Inhibitor,CS640s,8,IC50,Enzymatic assay (Reaction Biology),https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01803,=,29,IC50,NanoBRET assay (in HEK293T cells),https://www.thesgc.org/chemical-probes/cs-640,=,,KinomeScan (DiscoverX),450,"Screened at 1 µM, closest targets as % of control: PIP5K1C (0%), MEK5 (0.95%), RIPK4 (4.5%), MLK3 (99%); In-vitro potency of closest targets (enzymatic assay, Reaction Biology): IC50(PIP5K1C) = 11 µM, IC50(MEK5) = 0.025 µM, IC50(RIPK4) = 5.69 µM, IC50(MLK3) = 2.75 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01803#; Screened at 10 µM in Eurofins Cerep-Panlabs Safety Screen 44 (GPCRS, Transporters, Ion Channels, Nuclear Receptors, other enzymes), closest targets as % of inhibition or stimulation: dopamine transporter (100%), hERG channel (89%), norepinephrine transporter (87%), M1 (84%), M2(70%), M3(74%), acetylcholinesterase (84%), https://www.thesgc.org/chemical-probes/cs-640;",https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01803,Kinase set,100 nM
EUB0000878a_CAMK1G,640,EUB0000878a,CC(C)c1cc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)cc(C(C)C)n1,"InChI=1S/C21H31N7O/c1-12(2)17-8-15(9-18(26-17)13(3)4)25-20-16(19(23)29)10-24-21(27-20)28-7-5-6-14(22)11-28/h8-10,12-14H,5-7,11,22H2,1-4H3,(H2,23,29)(H,24,25,26,27)/t14-/m0/s1",BWBUPDTUXQDHSX-AWEZNQCLSA-N,Protein Kinase,CAMK1G,57172,Q96NX5,"VWS1, CLICKIII, dJ272L16.1",Inhibitor,CS640s,1,IC50,Enzymatic assay (Reaction Biology),https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01803,=,55,IC50,NanoBRET assay (in HEK293T cells),https://www.thesgc.org/chemical-probes/cs-640,=,,KinomeScan (DiscoverX),450,"Screened at 1 µM, closest targets as % of control: PIP5K1C (0%), MEK5 (0.95%), RIPK4 (4.5%), MLK3 (99%); In-vitro potency of closest targets (enzymatic assay, Reaction Biology): IC50(PIP5K1C) = 11 µM, IC50(MEK5) = 0.025 µM, IC50(RIPK4) = 5.69 µM, IC50(MLK3) = 2.75 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01803#; Screened at 10 µM in Eurofins Cerep-Panlabs Safety Screen 44 (GPCRS, Transporters, Ion Channels, Nuclear Receptors, other enzymes), closest targets as % of inhibition or stimulation: dopamine transporter (100%), hERG channel (89%), norepinephrine transporter (87%), M1 (84%), M2(70%), M3(74%), acetylcholinesterase (84%), https://www.thesgc.org/chemical-probes/cs-640;",https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01803,Kinase set,100 nM
EUB0000261b_CARM1,MS094,EUB0000261b,CC(C)Oc1ccc(-c2c[nH]cc2CN(C)CCO)cc1,"InChI=1S/C17H24N2O2/c1-13(2)21-16-6-4-14(5-7-16)17-11-18-10-15(17)12-19(3)8-9-20/h4-7,10-11,13,18,20H,8-9,12H2,1-3H3",GNAKYUUZAXUXKB-UHFFFAOYSA-N,HMT,CARM1,10498,Q86X55,PRMT4,Negative control for MS023,,,,,,,,,,,,,,,,,Epigenetic set,1 µM
EUB0000230b_CARM1,TP-064,EUB0000230b,CNCCN1CCC(c2cc(CN(C)C(=O)c3cccc(Oc4ccccc4)c3)ccn2)CC1,"InChI=1S/C28H34N4O2/c1-29-15-18-32-16-12-23(13-17-32)27-19-22(11-14-30-27)21-31(2)28(33)24-7-6-10-26(20-24)34-25-8-4-3-5-9-25/h3-11,14,19-20,23,29H,12-13,15-18,21H2,1-2H3",VUIITYLFSAXKIQ-UHFFFAOYSA-N,HMT,CARM1,10498,Q86X55,PRMT4,Inhibitor,TP-064N,10,IC50,Scintillation proximity assay (SPA),https://www.oncotarget.com/article/24883/text/,<,43,IC50,"Western Blot (dimethylation of MED12, Med12me2a/Med12, in HEK293T cells) ",https://www.oncotarget.com/article/24883/text/,=,,Methyltransferase screen (Scintillation proximity assays),32,"In-vitro potencies of closest targets: IC50(PRMT6) = 1.3 µM, IC50(PRMT8) = 8.1 µM, IC50(PRMT4) <0.01 µM, IC50(PRMT1) >10 µM,  IC50(PRMT3) >10 µM,  IC50(PRMT5) >10 µM, IC50(PRMT7) >10 µM, IC50(PRMT9) >10 µM, IC50(G9a) >10 µM, IC50(GLP) >10 µM, IC50(SETDB1) >10 µM, IC50(SUV39H1) >10 µM, IC50(SUV39H2) >10 µM, IC50(PRDM9) >10 µM, IC50(SETD) >10 µM, IC50(SETD7) >10 µM, IC50(MLL1) >10 µM, IC50(MLL3) >10 µM, IC50(SETD2) >10 µM, IC50(PRC2) >10 µM, IC50(SUV420H1) >10 µM, IC50(SUV420H2) >10 µM, IC50(SMYD2) >10 µM, IC50(SMYD3) >10 µM, IC50(DNMT1) >10 µM, IC50(DNMT3A/3L) >10 µM, IC50(DNMT3B/3L) >10 µM, IC50(NSD1) >10 µM, IC50(NSD2) >10 µM, IC50(NSD3) >10 µM, IC50(ASH1L) >10 µM, IC50(DOT1L) >10 µM ",https://www.oncotarget.com/article/24883/text/,Epigenetic set,1 µM
EUB0000255b_CARM1,TP-064N,EUB0000255b,COCCN1CCC(c2cc(CN(C)C(=O)c3cccc(Oc4ccccc4)c3)ccn2)CC1,"InChI=1S/C28H33N3O3/c1-30(28(32)24-7-6-10-26(20-24)34-25-8-4-3-5-9-25)21-22-11-14-29-27(19-22)23-12-15-31(16-13-23)17-18-33-2/h3-11,14,19-20,23H,12-13,15-18,21H2,1-2H3",IQCHVVCQDZOLHI-UHFFFAOYSA-N,HMT,CARM1,10498,Q86X55,PRMT4,Negative control for TP-064,,2500,IC50,Scintillation proximity assay (SPA),"https://www.oncotarget.com/article/24883/text/, https://www.thesgc.org/chemical-probes/TP-064",=,10000,IC50,"Western Blot (dimethylation of MED12, Med12me2a/Med12, in HEK293T cells) ",https://www.oncotarget.com/article/24883/text/,>,,Methyltransferase screen (Scintillation proximity assays),32,"In-vitro potencies of closest targets: IC50(PRMT6) = 1.3 µM, IC50(PRMT8) = 8.1 µM, IC50(PRMT4) <0.01 µM, IC50(PRMT1) >10 µM,  IC50(PRMT3) >10 µM,  IC50(PRMT5) >10 µM, IC50(PRMT7) >10 µM, IC50(PRMT9) >10 µM, IC50(G9a) >10 µM, IC50(GLP) >10 µM, IC50(SETDB1) >10 µM, IC50(SUV39H1) >10 µM, IC50(SUV39H2) >10 µM, IC50(PRDM9) >10 µM, IC50(SETD) >10 µM, IC50(SETD7) >10 µM, IC50(MLL1) >10 µM, IC50(MLL3) >10 µM, IC50(SETD2) >10 µM, IC50(PRC2) >10 µM, IC50(SUV420H1) >10 µM, IC50(SUV420H2) >10 µM, IC50(SMYD2) >10 µM, IC50(SMYD3) >10 µM, IC50(DNMT1) >10 µM, IC50(DNMT3A/3L) >10 µM, IC50(DNMT3B/3L) >10 µM, IC50(NSD1) >10 µM, IC50(NSD2) >10 µM, IC50(NSD3) >10 µM, IC50(ASH1L) >10 µM, IC50(DOT1L) >10 µM ",https://www.oncotarget.com/article/24883/text/,Epigenetic set,1 µM
EUB0001632a_CDK12,SR-4835,EUB0001632a,Cn1cc(-n2cnc3c(NCc4nc5cc(Cl)c(Cl)cc5[nH]4)nc(N4CCOCC4)nc32)cn1,"InChI=1S/C21H20Cl2N10O/c1-31-10-12(8-26-31)33-11-25-18-19(29-21(30-20(18)33)32-2-4-34-5-3-32)24-9-17-27-15-6-13(22)14(23)7-16(15)28-17/h6-8,10-11H,2-5,9H2,1H3,(H,27,28)(H,24,29,30)",FSELUFUYNUNZKD-UHFFFAOYSA-N,Protein Kinase,CDK12,51755,Q9NYV4,"CRK7, CRKR, KIAA0904",inhibitor,,98,Kd,Competition- binding assay (DiscoverX),https://pubmed.ncbi.nlm.nih.gov/31668947/,=,,,,,,,Kinase panel (Z′-LYTE Assay),272,"Screened at 10 µM, closest targets as % of inhibition (using ATP = Km app): GSK3B (89%), GSK3A (82.2%), CSNK1E(48.9%); Screened at 10 µM against 31 kinases (Adapta Assay using ATP = Km app), closest targets as % of inhibition: LRRK2(I2020T, 100%), LRRK2 (100%), LRRK2(R1441C, 96.1%), LRRK2 (G2019S, 95%), SPHK2(67.7%), PIK3CD/PIK3R1 (p110 delta/p85 alpha, 66%), PIK3C2B (PI3K-C2 beta, 64.1%), CDK9/cyclin T1 (63.9%), SPHK1 (53.7%), GSG2 (45%), https://pubmed.ncbi.nlm.nih.gov/31668947/; In-vitro potency (enzymatic assay on full-lenght LRRK2): IC50(LRRK2) >10 µM, https://pubmed.ncbi.nlm.nih.gov/31668947/; Screened at 10 µM against 162 kinases (LanthaScreen Eu Kinase Binding Assay), closest targets as % of inhibition: TAOK1 (31.8%), CDK8/cyclinC (17%), CDK16(PCTK1)/cyclinY (15%), NLK(13.4%), CLK4(12.3%), SIK3(12.2%), https://pubmed.ncbi.nlm.nih.gov/31668947/; Screened at 10 µM against 20 kinases (Rxn Biology kinase assay using 10 µM ATP), targets as % of inhibition: GSK3B (96.5%), GSK3A (90.6%), CDK6/cyclin D1 (83.4%), CDK6/cyclin D3 (52.7%), CDK4/cyclin D1(46.7%), CDK4/cyclin D3(46.3%), MEK2(8.7%), AKT3(6.7%), MAPK1(5.8%), MEK1(4.5%), AXL(4.1%), EGFR(3.4%), ERBB2(2.6%), AKT2(1.6%), AKT1(0.2%), ERK1(-5.8%), MAPK15 (-25.6%), MAPK7(-29.8%), MET(-31.5%), MAPK7(-42.4%), https://pubmed.ncbi.nlm.nih.gov/31668947/; ",https://pubmed.ncbi.nlm.nih.gov/31668947/,Kinase set,1 µM
EUB0001632a_CDK13,SR-4835,EUB0001632a,Cn1cc(-n2cnc3c(NCc4nc5cc(Cl)c(Cl)cc5[nH]4)nc(N4CCOCC4)nc32)cn1,"InChI=1S/C21H20Cl2N10O/c1-31-10-12(8-26-31)33-11-25-18-19(29-21(30-20(18)33)32-2-4-34-5-3-32)24-9-17-27-15-6-13(22)14(23)7-16(15)28-17/h6-8,10-11H,2-5,9H2,1H3,(H,27,28)(H,24,29,30)",FSELUFUYNUNZKD-UHFFFAOYSA-N,Protein Kinase,CDK13,8621,Q14004,"CHED, CDC2L, KIAA1791",inhibitor,,4.9,Kd,Competition- binding assay (DiscoverX),https://pubmed.ncbi.nlm.nih.gov/31668947/,=,,,,,,,Kinase panel (Z′-LYTE Assay),272,"Screened at 10 µM, closest targets as % of inhibition (using ATP = Km app): GSK3B (89%), GSK3A (82.2%), CSNK1E(48.9%); Screened at 10 µM against 31 kinases (Adapta Assay using ATP = Km app), closest targets as % of inhibition: LRRK2(I2020T, 100%), LRRK2 (100%), LRRK2(R1441C, 96.1%), LRRK2 (G2019S, 95%), SPHK2(67.7%), PIK3CD/PIK3R1 (p110 delta/p85 alpha, 66%), PIK3C2B (PI3K-C2 beta, 64.1%), CDK9/cyclin T1 (63.9%), SPHK1 (53.7%), GSG2 (45%), https://pubmed.ncbi.nlm.nih.gov/31668947/; In-vitro potency (enzymatic assay on full-lenght LRRK2): IC50(LRRK2) >10 µM, https://pubmed.ncbi.nlm.nih.gov/31668947/; Screened at 10 µM against 162 kinases (LanthaScreen Eu Kinase Binding Assay), closest targets as % of inhibition: TAOK1 (31.8%), CDK8/cyclinC (17%), CDK16(PCTK1)/cyclinY (15%), NLK(13.4%), CLK4(12.3%), SIK3(12.2%), https://pubmed.ncbi.nlm.nih.gov/31668947/; Screened at 10 µM against 20 kinases (Rxn Biology kinase assay using 10 µM ATP), targets as % of inhibition: GSK3B (96.5%), GSK3A (90.6%), CDK6/cyclin D1 (83.4%), CDK6/cyclin D3 (52.7%), CDK4/cyclin D1(46.7%), CDK4/cyclin D3(46.3%), MEK2(8.7%), AKT3(6.7%), MAPK1(5.8%), MEK1(4.5%), AXL(4.1%), EGFR(3.4%), ERBB2(2.6%), AKT2(1.6%), AKT1(0.2%), ERK1(-5.8%), MAPK15 (-25.6%), MAPK7(-29.8%), MET(-31.5%), MAPK7(-42.4%), https://pubmed.ncbi.nlm.nih.gov/31668947/; ",https://pubmed.ncbi.nlm.nih.gov/31668947/,Kinase set,1 µM
EUB0000090b_CDK13,THZ531,EUB0000090b,CN(C)C/C=C/C(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)C2)cc1,"InChI=1S/C30H32ClN7O2/c1-37(2)15-6-10-27(39)34-21-13-11-20(12-14-21)29(40)38-16-5-7-22(19-38)35-30-33-18-25(31)28(36-30)24-17-32-26-9-4-3-8-23(24)26/h3-4,6,8-14,17-18,22,32H,5,7,15-16,19H2,1-2H3,(H,34,39)(H,33,35,36)/b10-6+",RUBYHLPRZRMTJO-UXBLZVDNSA-N,Protein Kinase,CDK13,8621,Q14004,"CHED, CDC2L, KIAA1791",Covalent inhibitor,,69,IC50,Radiometric kinase assay,https://www.nature.com/articles/nchembio.2166,=,,,,,,,Ambit KINOMEscanand KiNATiv profiling in Jurkat cells,211,"Screened at 1 µM, closest targets AURKA (54%), PLK(53%), CLK1(43%), all IC50 >3.5 µM, In-vitro potency of closest target (Radiometric kinase assay ): Kd(CDK12) = 158 nM, https://www.nature.com/articles/nchembio.2166;",https://www.nature.com/articles/nchembio.2166,Kinase set,1 µM
EUB0001326b_CDK4,Palbociclib,EUB0001326b,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",AHJRHEGDXFFMBM-UHFFFAOYSA-N,Protein Kinase,CDK4,1019,P11802,PSK-J3,inhibitor,,9,IC50,Radiometric kinase assay (using CDK4/cyclinD3 and 25 µM ATP),https://pubmed.ncbi.nlm.nih.gov/15542782/,=,,,,,,,CARNA Biosciences Kinase Panel (Caliper LabChip3000 mobility shift assay),274,"Screened at 1 µM using Km =ATP, closest targets as % of inhibition: CDK4(cyclinD3, 102.4%), CDK6(cyclinD3, 101.7%), CLK1 (100.3%), HIPK2(88.9%), MAP2K5 (84.8%), FLT3(84.5%), ERK5(77.9%), NTRK1(72.7%), CLK2(72.5%), PKD3(72.1%), PKD2(71.9%), PKR(71.4%), DYRK1B(70.5%), PKD1(69.1%), PEK(68.8%), HIPK3(63.4%), HIPK4(62.5%), NUAK2(61.9%), CDK9(cyclinT1, 59.8%), HIPK1(57.4%), CAMK2D(54%), TSSK1(53.5%), DYRK3(52.3%), MER(52.2%); In-vitro potency of closest targets (biochemical dose-responce assay using ATP = Km, Carna Biosciences): Ki(CLK1) = 16 nM, Ki(FLT3) = 53 nM, Ki(HIPK2) = 70 nM, Ki(MAP2K5) = 90 nM, Ki(ERK5) = 129 nM, Ki(DYRK1B) = 162 nM, Ki(CLK2) = 176 nM, Ki(PKD3) = 204 nM, Ki(PKR) = 241 nM, Ki(PKD2) = 277 nM, https://pubmed.ncbi.nlm.nih.gov/27496135/; Screened against 17 non-kinase proteins (CEREP ligand displacement assays), in-vitro potency of closest targets: EC50(Adren Alpha 1a) >10 µM, EC50(Dopamine 1) >10 µM, EC50(Histamine 1) >10 µM, EC50(Muscarinic 1) >10 µM, EC50(5HT2b) >10 µM, EC50(Adren Beta 2) >10 µM, EC50(Cannabinoid 1) >10 µM, EC50(Mu Opioid) >10 µM, EC50(SERT) >10 µM, EC50(DAT) >10 µM, EC50(NET) >10 µM, EC50(PDE3A1) >180 µM, EC50(PDE4D3) = 3.4 µM, EC50(PDE5A1) = 2.9 µM, EC50(L-Type Calcium) >20 µM, EC50(Sodium, Nav1.5) >10 µM, EC50(BRD4) >25 µM, https://pubmed.ncbi.nlm.nih.gov/27496135/; Screened at 1 µM against 140 kinases (Dundee kinase profiling), closest targets as % of contr.: HIPK2 (2%), PKD1 (44%), ERK8 (47%), https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00049; Screened at 10 µM against 140 kinases (Dundee kinase profiling), closest targets as % of contr.: HIPK2 (8%), DYRK1A (9%), ERK8 (13%), CK2 (13%), MELK (14%), GCK(15%), DYRK3 (16%), PKD1 (18%), PLK1 (18%), NTRK1(18%), TAK1(21%), PHK (22%), https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00049; Screened against 520 kinases (competition-binding assay), closest targets: Kd(CDK6) = 76 nM, Kd(PIP4K2A) = 208 nM, Kd(CLK1) = 276 nM, Kd(CSNK2B) = 448 nM, Kd(CSNK2A2) = 488 nM, Kd(CDK4) = 572 nM, Kd(EIF3J) = 701 nM, Kd(CSNK2A1/A3) = 760 nM, Kd(MAP2K4) = 1251 nM, Kd(CDK17) = 1272 nM, Kd(CCNT2) = 1665 nM, Kd(PIP4K2C) = 1721 nM, Kd(CCNT1) = 2676 nM, Kd(CDK16) = 2778 nM, Kd(MAPK9) = 2856 nM, Kd(MED23) = 2998 nM, Kd(AAK1) = 4216 nM, Kd(PRKD2) = 5623 nM, Kd(CDK9) = 9492 nM, Kd(STK16) = 9969 nM, Kd(TAOK3) = 15852 nM, Kd(PRKD3) = 16296 nM, Kd(BMP2K) = 26466 nM, Kd(Q6ZSR9) = 27334 nM, Kd(TAOK2) = 27973 nM,  https://pubmed.ncbi.nlm.nih.gov/29191878/;",https://pubmed.ncbi.nlm.nih.gov/27496135/,Kinase set,100 nM
EUB0001326b_CDK6,Palbociclib,EUB0001326b,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",AHJRHEGDXFFMBM-UHFFFAOYSA-N,Protein Kinase,CDK6,1021,Q00534,PLSTIRE,inhibitor,,15,IC50,Radiometric kinase assay (using CDK6/cyclinD3 and 25 µM ATP),https://pubmed.ncbi.nlm.nih.gov/15542782/,=,,,,,,,CARNA Biosciences Kinase Panel (Caliper LabChip3000 mobility shift assay),274,"Screened at 1 µM using Km =ATP, closest targets as % of inhibition: CDK4(cyclinD3, 102.4%), CDK6(cyclinD3, 101.7%), CLK1 (100.3%), HIPK2(88.9%), MAP2K5 (84.8%), FLT3(84.5%), ERK5(77.9%), NTRK1(72.7%), CLK2(72.5%), PKD3(72.1%), PKD2(71.9%), PKR(71.4%), DYRK1B(70.5%), PKD1(69.1%), PEK(68.8%), HIPK3(63.4%), HIPK4(62.5%), NUAK2(61.9%), CDK9(cyclinT1, 59.8%), HIPK1(57.4%), CAMK2D(54%), TSSK1(53.5%), DYRK3(52.3%), MER(52.2%); In-vitro potency of closest targets (biochemical dose-responce assay using ATP = Km, Carna Biosciences): Ki(CLK1) = 16 nM, Ki(FLT3) = 53 nM, Ki(HIPK2) = 70 nM, Ki(MAP2K5) = 90 nM, Ki(ERK5) = 129 nM, Ki(DYRK1B) = 162 nM, Ki(CLK2) = 176 nM, Ki(PKD3) = 204 nM, Ki(PKR) = 241 nM, Ki(PKD2) = 277 nM, https://pubmed.ncbi.nlm.nih.gov/27496135/; Screened against 17 non-kinase proteins (CEREP ligand displacement assays), in-vitro potency of closest targets: EC50(Adren Alpha 1a) >10 µM, EC50(Dopamine 1) >10 µM, EC50(Histamine 1) >10 µM, EC50(Muscarinic 1) >10 µM, EC50(5HT2b) >10 µM, EC50(Adren Beta 2) >10 µM, EC50(Cannabinoid 1) >10 µM, EC50(Mu Opioid) >10 µM, EC50(SERT) >10 µM, EC50(DAT) >10 µM, EC50(NET) >10 µM, EC50(PDE3A1) >180 µM, EC50(PDE4D3) = 3.4 µM, EC50(PDE5A1) = 2.9 µM, EC50(L-Type Calcium) >20 µM, EC50(Sodium, Nav1.5) >10 µM, EC50(BRD4) >25 µM, https://pubmed.ncbi.nlm.nih.gov/27496135/; Screened at 1 µM against 140 kinases (Dundee kinase profiling), closest targets as % of contr.: HIPK2 (2%), PKD1 (44%), ERK8 (47%), https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00049; Screened at 10 µM against 140 kinases (Dundee kinase profiling), closest targets as % of contr.: HIPK2 (8%), DYRK1A (9%), ERK8 (13%), CK2 (13%), MELK (14%), GCK(15%), DYRK3 (16%), PKD1 (18%), PLK1 (18%), NTRK1(18%), TAK1(21%), PHK (22%), https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00049; Screened against 520 kinases (competition-binding assay), closest targets: Kd(CDK6) = 76 nM, Kd(PIP4K2A) = 208 nM, Kd(CLK1) = 276 nM, Kd(CSNK2B) = 448 nM, Kd(CSNK2A2) = 488 nM, Kd(CDK4) = 572 nM, Kd(EIF3J) = 701 nM, Kd(CSNK2A1/A3) = 760 nM, Kd(MAP2K4) = 1251 nM, Kd(CDK17) = 1272 nM, Kd(CCNT2) = 1665 nM, Kd(PIP4K2C) = 1721 nM, Kd(CCNT1) = 2676 nM, Kd(CDK16) = 2778 nM, Kd(MAPK9) = 2856 nM, Kd(MED23) = 2998 nM, Kd(AAK1) = 4216 nM, Kd(PRKD2) = 5623 nM, Kd(CDK9) = 9492 nM, Kd(STK16) = 9969 nM, Kd(TAOK3) = 15852 nM, Kd(PRKD3) = 16296 nM, Kd(BMP2K) = 26466 nM, Kd(Q6ZSR9) = 27334 nM, Kd(TAOK2) = 27973 nM,  https://pubmed.ncbi.nlm.nih.gov/29191878/;",https://pubmed.ncbi.nlm.nih.gov/27496135/,Kinase set,100 nM
EUB0001635a_CDK7,YKL 5-124,EUB0001635a,C=CC(=O)Nc1ccc(C(=O)Nc2n[nH]c3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)cc1,"InChI=1S/C28H33N7O3/c1-6-23(36)29-20-14-12-19(13-15-20)26(37)31-25-21-16-35(28(2,3)24(21)32-33-25)27(38)30-22(17-34(4)5)18-10-8-7-9-11-18/h6-15,22H,1,16-17H2,2-5H3,(H,29,36)(H,30,38)(H2,31,32,33,37)/t22-/m1/s1",KPABJHHKKJIDGX-JOCHJYFZSA-N,Protein Kinase,CDK7,1022,P50613,"CAK1, CDKN7, MO15, STK1, CAK",Covalent inhibitor,,9.7,IC50,Adapta Eu kinase assay (for CDK7/CycH/MNAT1 using ATP = Km),https://pubmed.ncbi.nlm.nih.gov/30905681/,=,62.5,IC50,Radioactive in vitro kinase assays (from cellular wild-type CDK7 immunoprecipitated in HeLa cells),https://www.sciencedirect.com/science/article/pii/S2451945619300674?via%3Dihub,=,,Kinase panel (KiNativ target engagement assay in Jurkat cells),233,"Screened at 1 µM, closest targets as % of engagement: CDK7 (95.5%), MARK4(93.3%), AMPK1 (54.4%), AMPK2(53.5%), MST3(41.8%), CAMK2G (35.8%), CAMK2D(34.1%), TBK1(32.4%), SNRK(30.4%)",https://www.sciencedirect.com/science/article/pii/S2451945619300674?via%3Dihub,Kinase set,1 µM
EUB0000162b_CDK8,BI-1347,EUB0000162b,CN(C)C(=O)Cn1cc(-c2ccc(-c3cncc4ccccc34)cc2)cn1,"InChI=1S/C22H20N4O/c1-25(2)22(27)15-26-14-19(12-24-26)16-7-9-17(10-8-16)21-13-23-11-18-5-3-4-6-20(18)21/h3-14H,15H2,1-2H3",WULUGQONDYDNKY-UHFFFAOYSA-N,Protein Kinase,CDK8,1024,P49336,K35,Inhibitor,BI-1374,1,IC50,Lantha screen (CDK8/cyclinC inhibition),https://opnme.com/molecules/cdk8-bi-1347,=,,,,,,,Invitrogen® panel,369,In-vitro potency of closest target: IC50(CDK11)  = 1.7 nM,https://opnme.com/molecules/cdk8-bi-1347#,Kinase set,100 nM
EUB0000163b_CDK8,BI-1374,EUB0000163b,CN(C)C(=O)Cn1cc(-c2ccc(-c3nnc4ccccn34)cc2)cn1,"InChI=1S/C18H17ClN4O/c1-11-15-9-13(10-20-17(15)22-21-11)18(24)23-8-2-3-16(23)12-4-6-14(19)7-5-12/h4-7,9-10,16H,2-3,8H2,1H3,(H,20,21,22)/t16-/m0/s1",ODRITQGYYWHQGM-INIZCTEOSA-N,Protein Kinase,CDK8,1024,P49336,K35,Negative control for BI-1347,,671,IC50,Lantha screen (CDK8/cyclinC inhibition),https://opnme.com/molecules/cdk8-bi-1347,=,,,,,,,,,,,Kinase set,100 nM
EUB0001623a_CDK8,MSC2530818,EUB0001623a,Cc1n[nH]c2ncc(C(=O)N3CCC[C@H]3c3ccc(Cl)cc3)cc12,"InChI=1S/C18H17ClN4O/c1-11-15-9-13(10-20-17(15)22-21-11)18(24)23-8-2-3-16(23)12-4-6-14(19)7-5-12/h4-7,9-10,16H,2-3,8H2,1H3,(H,20,21,22)/t16-/m0/s1",ODRITQGYYWHQGM-INIZCTEOSA-N,Protein Kinase,CDK8,1024,P49336,K35,Inhibitor,,2.6,IC50,FRET-based Lanthascreen binding competition assay,https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00597#,=,6.5,IC50,7dF3 WNT-specific reporter gene assay,https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00597#,=,,Kinase panel (literature),264,"Screened at 1 µM, closest targets as % of inhibition: P70S6K (47%), SGK (39%), CDK1 (cyclinB, 2%), CDK2 (cyclinA, -7%), CDK2 (cyclinE, 18%), CDK3 (cyclinE, 2%), CDK5(p25, -1%), CDK5 (p35, -1%), CDK6 (cyclinD3, 12%), CDK7 (cyclinH/MAT1, 7%), CDK9 (cyclinT1, 13%); In-vitro potency of closest targets (enzymatic assays): IC50(GSK3A) = 691 nM, IC50(FLT3) >30 µM, IC50(NTRK3) >30 µM; Screened at 10 µM against 59 receptors and ion channels (CEREP panel, binding assay), closest targets as % of inhibition: A1 (48%), D2 (54%); In-vitro potency of closest targets (CEREP binding assay): IC50(D2) = 8.5 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00597#;",https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00597#,Kinase set,100 nM
EUB0001631a_CDK9,Atuveciclib,EUB0001631a,COc1cc(F)ccc1-c1ncnc(Nc2cccc(CS(C)(=N)=O)c2)n1,"InChI=1S/C18H18FN5O2S/c1-26-16-9-13(19)6-7-15(16)17-21-11-22-18(24-17)23-14-5-3-4-12(8-14)10-27(2,20)25/h3-9,11,20H,10H2,1-2H3,(H,21,22,23,24)",ACWKGTGIJRCOOM-UHFFFAOYSA-N,Protein Kinase,CDK9,1025,P50750,"PITALRE, C-2k, TAK",inhibitor,,13,IC50,TR-FRET assay (inhibition of CDK9/cyclinT1 phosphorylation using 10 µM ATP),https://pubmed.ncbi.nlm.nih.gov/28961375/,=,,,,,,,KinaseProfilerTM (Merck Millipore) ,230,"Screened at 10 µM, closest targets as % of contr.: GSK3B (3%), GSK3A (4%), KIT (6%), CDK3 (cyclinE, 10%), EPHB1 (11%), CAMK2B (13%), CDK2 (cyclinE, 13%), CDK1 (cyclinE, 14%), YES (14%), ARG (16%), CDK5(p35, 20%), EPHA1 (20%), NTRK1(20%), CAMK2G (21%), CAMK2D (22%), LYN(23%), FYN(24%), MLK1(24%), IRAK1(27%), SRC(28%), FGR(29%), FLT4(30%); In-vitro potency of closest targets (Merck Millipore kinase assay using 10 µM ATP): IC50(ARG) = 2843 nM, IC50(CAMK2B) = 1650 nM, IC50(CAMK2G) = 2081 nM, IC50(CAMK2D) = 3340 nM, IC50(SRC) = 5293 nM, IC50(EPHA1) = 1737 nM, IC50(EPHB1) = 2032 nM, IC50(FGR) = 7754 nM, IC50(GSK3A) = 45 nM, IC50(GSK3B) = 87 nM, IC50(IRAK1) = 5454 nM, IC50(LYN) = 3514 nM, IC50(MLK1) = 3010 nM, IC50(YES) = 1495 nM;",https://pubmed.ncbi.nlm.nih.gov/28961375/,Kinase set,1 µM
EUB0000734a_CENPE,GSK923295,EUB0000734a,O=C(C1=CC=C(OC(C)C)C(Cl)=C1)N[C@H](CNC(CN(C)C)=O)CC2=CC=C(C3=CN(C=CC=C4[C@H](C)O)C4=N3)C=C2,"InChI=1S/C32H38ClN5O4/c1-20(2)42-29-13-12-24(16-27(29)33)32(41)35-25(17-34-30(40)19-37(4)5)15-22-8-10-23(11-9-22)28-18-38-14-6-7-26(21(3)39)31(38)36-28/h6-14,16,18,20-21,25,39H,15,17,19H2,1-5H3,(H,34,40)(H,35,41)/t21-,25-/m0/s1",WHMXDBPHBVLYRC-OFVILXPXSA-N,Kinesin,CENPE,1062,Q02224,"CENP-E, KIF10, MCPH13, PPP1R61",Allosteric inhibitor,,2.2,Ki,Enzyme inhibition assay,https://pubmed.ncbi.nlm.nih.gov/20167803/,=,,,,,,,,,,,Other targets,100 nM
EUB0000008b_CLK1,MU1210,EUB0000008b,CN1C=C(C2=NC3=C(OC=C3C4=CC(C5=CC=NC=C5)=CC=C4)C=C2)C=N1,"InChI=1S/C22H16N4O/c1-26-13-18(12-24-26)20-5-6-21-22(25-20)19(14-27-21)17-4-2-3-16(11-17)15-7-9-23-10-8-15/h2-14H,1H3",HEAGNKNMQVIVMM-UHFFFAOYSA-N,Protein Kinase,CLK1,1195,P49759,,Inhibitor,MU140,8,IC50,Biochemical activity assay (Reaction Biology),https://onlinelibrary.wiley.com/doi/10.1002/anie.201810312,=,84,Ki,NanoBRET assay (in HEK293T cells),https://www.thesgc.org/chemical-probes/MU1210,=,,Eurofins kinase panel,210,"Screened at 1 µM, closest targets as % of activity: HIPK2 (99%), HIPK3 (94%), GSK3A (90%); Eurofins binding assay: IC50(HIPK1) = 187 nM, IC50(HIPK2) = 23 nM, IC50(CLK3) >3 µM; In-cellular potency (NanoBRET assay in HEK293T cells): Ki(HIPK2) >10 µM, Ki(HIPK4) = 5.41 µM",https://onlinelibrary.wiley.com/doi/10.1002/anie.201810312,Kinase set,1 µM
EUB0001049a_CLK1,SGC-CLK-1N,EUB0001049a,COC1=NN2N=CC(C3=NC(NC4=CC(C(F)(F)F)=CC(OC)=C4)=NC(C)=C3)=C2C=C1,"InChI=1S/C20H17F3N6O2/c1-11-6-16(15-10-24-29-17(15)4-5-18(28-29)31-3)27-19(25-11)26-13-7-12(20(21,22)23)8-14(9-13)30-2/h4-10H,1-3H3,(H,25,26,27)",BJVQXSHZMUFJBQ-UHFFFAOYSA-N,Protein Kinase,CLK1,1195,P49759,,Negative control for SGC-CLK-1 (UNC-CAF-170 ),,10000,IC50,Enzymatic assay (Eurofins),https://www.thesgc.org/chemical-probes/SGC-CLK-1,>,10000,IC50,NanoBRET assay (in HEK293T cells),https://www.thesgc.org/chemical-probes/SGC-CLK-1,>,,KinomeScan (DiscoverX),403,"Screened at 1 µM, no kinases with <45% of control; In-vitro potency (Eurofins Enzymatic assay): IC50(CLK3) >10 µM, IC50(DYRK1A) >10 µM, IC50(DYRK1B) >10 µM, IC50(DYRK2) >10 µM, IC50(DYRK3) >10 µM, IC50(HIPK1) >10 µM, IC50(HIPK2) >10 µM, IC50(HIPK3) >10µM, IC50(HIPK4) >10 µM, IC50(PIM2) >10 µM, https://www.thesgc.org/chemical-probes/SGC-CLK-1;",https://www.thesgc.org/chemical-probes/SGC-CLK-1,Kinase set,1 µM
EUB0000008b_CLK2,MU1210,EUB0000008b,CN1C=C(C2=NC3=C(OC=C3C4=CC(C5=CC=NC=C5)=CC=C4)C=C2)C=N1,"InChI=1S/C22H16N4O/c1-26-13-18(12-24-26)20-5-6-21-22(25-20)19(14-27-21)17-4-2-3-16(11-17)15-7-9-23-10-8-15/h2-14H,1H3",HEAGNKNMQVIVMM-UHFFFAOYSA-N,Protein Kinase,CLK2,1196,P49760,,Inhibitor,MU140,20,IC50,Biochemical activity assay (Reaction Biology),https://onlinelibrary.wiley.com/doi/10.1002/anie.201810312,=,91,Ki,NanoBRET assay (in HEK293T cells),https://www.thesgc.org/chemical-probes/MU1210,=,,Eurofins kinase panel,210,"Screened at 1 µM, closest targets as % of activity: HIPK2 (99%), HIPK3 (94%), GSK3A (90%); Eurofins binding assay: IC50(HIPK1) = 187 nM, IC50(HIPK2) = 23 nM, IC50(CLK3) >3 µM; In-cellular potency (NanoBRET assay in HEK293T cells): Ki(HIPK2) >10 µM, Ki(HIPK4) = 5.41 µM",https://onlinelibrary.wiley.com/doi/10.1002/anie.201810312,Kinase set,1 µM
EUB0001049a_CLK2,SGC-CLK-1N,EUB0001049a,COC1=NN2N=CC(C3=NC(NC4=CC(C(F)(F)F)=CC(OC)=C4)=NC(C)=C3)=C2C=C1,"InChI=1S/C20H17F3N6O2/c1-11-6-16(15-10-24-29-17(15)4-5-18(28-29)31-3)27-19(25-11)26-13-7-12(20(21,22)23)8-14(9-13)30-2/h4-10H,1-3H3,(H,25,26,27)",BJVQXSHZMUFJBQ-UHFFFAOYSA-N,Protein Kinase,CLK2,1196,P49760,,Negative control for SGC-CLK-1 (UNC-CAF-170 ),,10000,IC50,Enzymatic assay (Eurofins),https://www.thesgc.org/chemical-probes/SGC-CLK-1,>,10000,IC50,NanoBRET assay (in HEK293T cells),https://www.thesgc.org/chemical-probes/SGC-CLK-1,>,,KinomeScan (DiscoverX),403,"Screened at 1 µM, no kinases with <45% of control; In-vitro potency (Eurofins Enzymatic assay): IC50(CLK3) >10 µM, IC50(DYRK1A) >10 µM, IC50(DYRK1B) >10 µM, IC50(DYRK2) >10 µM, IC50(DYRK3) >10 µM, IC50(HIPK1) >10 µM, IC50(HIPK2) >10 µM, IC50(HIPK3) >10µM, IC50(HIPK4) >10 µM, IC50(PIM2) >10 µM, https://www.thesgc.org/chemical-probes/SGC-CLK-1;",https://www.thesgc.org/chemical-probes/SGC-CLK-1,Kinase set,1 µM
EUB0000008b_CLK4,MU1210,EUB0000008b,CN1C=C(C2=NC3=C(OC=C3C4=CC(C5=CC=NC=C5)=CC=C4)C=C2)C=N1,"InChI=1S/C22H16N4O/c1-26-13-18(12-24-26)20-5-6-21-22(25-20)19(14-27-21)17-4-2-3-16(11-17)15-7-9-23-10-8-15/h2-14H,1H3",HEAGNKNMQVIVMM-UHFFFAOYSA-N,Protein Kinase,CLK4,57396,Q9HAZ1,,Inhibitor,MU140,12,IC50,Eurofins radiometric assay,https://onlinelibrary.wiley.com/doi/10.1002/anie.201810312,=,23,Ki,NanoBRET assay (in HEK293T cells),https://www.thesgc.org/chemical-probes/MU1210,=,,Eurofins kinase panel,210,"Screened at 1 µM, closest targets as % of activity: HIPK2 (99%), HIPK3 (94%), GSK3A (90%); Eurofins binding assay: IC50(HIPK1) = 187 nM, IC50(HIPK2) = 23 nM, IC50(CLK3) >3 µM; In-cellular potency (NanoBRET assay in HEK293T cells): Ki(HIPK2) >10 µM, Ki(HIPK4) = 5.41 µM",https://onlinelibrary.wiley.com/doi/10.1002/anie.201810312,Kinase set,1 µM
EUB0001049a_CLK4,SGC-CLK-1N,EUB0001049a,COC1=NN2N=CC(C3=NC(NC4=CC(C(F)(F)F)=CC(OC)=C4)=NC(C)=C3)=C2C=C1,"InChI=1S/C20H17F3N6O2/c1-11-6-16(15-10-24-29-17(15)4-5-18(28-29)31-3)27-19(25-11)26-13-7-12(20(21,22)23)8-14(9-13)30-2/h4-10H,1-3H3,(H,25,26,27)",BJVQXSHZMUFJBQ-UHFFFAOYSA-N,Protein Kinase,CLK4,57396,Q9HAZ1,,Negative control for SGC-CLK-1 (UNC-CAF-170 ),,10000,IC50,Enzymatic assay (Eurofins),https://www.thesgc.org/chemical-probes/SGC-CLK-1,>,,,,,,,KinomeScan (DiscoverX),403,"Screened at 1 µM, no kinases with <45% of control; In-vitro potency (Eurofins Enzymatic assay): IC50(CLK3) >10 µM, IC50(DYRK1A) >10 µM, IC50(DYRK1B) >10 µM, IC50(DYRK2) >10 µM, IC50(DYRK3) >10 µM, IC50(HIPK1) >10 µM, IC50(HIPK2) >10 µM, IC50(HIPK3) >10µM, IC50(HIPK4) >10 µM, IC50(PIM2) >10 µM, https://www.thesgc.org/chemical-probes/SGC-CLK-1;",https://www.thesgc.org/chemical-probes/SGC-CLK-1,Kinase set,1 µM
EUB0001205a_CSNK1A1,MU1742,EUB0001205a,CN1CCC(F)(Cn2cnc(-c3ccc(F)cn3)c2-c2ccnc3[nH]ccc23)CC1,"InChI=1S/C22H22F2N6/c1-29-10-6-22(24,7-11-29)13-30-14-28-19(18-3-2-15(23)12-27-18)20(30)16-4-8-25-21-17(16)5-9-26-21/h2-5,8-9,12,14H,6-7,10-11,13H2,1H3,(H,25,26)",SWOIFXHMBKFCRM-UHFFFAOYSA-N,Protein Kinase,CSNK1A1,1452,P48729,"CK1, CK1a, CK1alpha, CKIa, CKIalpha",Inhibitor,MU2027,7.2,IC50,Eurofins radiometric assay,https://www.thesgc.org/chemical-probes/mu1742,=,3500,IC50,NanoBRET asssay (HEK293T cells),https://www.thesgc.org/chemical-probes/mu1742,=,,Kinase panel (Reaction Biology),415,"Screened at 1 µM, closest targets as % of inhibition: CSNK1A1 (6%), CSNK1D (-6%), CSNK1E (0%), TNIK (43%), ZAP-70 (71%);",https://www.thesgc.org/chemical-probes/mu1742,Kinase set,1 µM
EUB0001201a_CSNK1A1,MU2027,EUB0001201a,CCc1ccc(-c2ncn(CC3(F)CCN(C)CC3)c2-c2ccnc3[nH]ccc23)nc1,"InChI=1S/C24H27FN6/c1-3-17-4-5-20(28-14-17)21-22(18-6-10-26-23-19(18)7-11-27-23)31(16-29-21)15-24(25)8-12-30(2)13-9-24/h4-7,10-11,14,16H,3,8-9,12-13,15H2,1-2H3,(H,26,27)",SRSOVGVHVNSXTC-UHFFFAOYSA-N,Protein Kinase,CSNK1A1,1452,P48729,"CK1, CK1a, CK1alpha, CKIa, CKIalpha",Negative control for MU1742,,3000,IC50,"Tracer competition assays (Reaction Biology, 10 mM ATP)",https://www.thesgc.org/chemical-probes/mu1742,>,,,,,,,,,,,Kinase set,1 µM
EUB0001205a_CSNK1D,MU1742,EUB0001205a,CN1CCC(F)(Cn2cnc(-c3ccc(F)cn3)c2-c2ccnc3[nH]ccc23)CC1,"InChI=1S/C22H22F2N6/c1-29-10-6-22(24,7-11-29)13-30-14-28-19(18-3-2-15(23)12-27-18)20(30)16-4-8-25-21-17(16)5-9-26-21/h2-5,8-9,12,14H,6-7,10-11,13H2,1H3,(H,25,26)",SWOIFXHMBKFCRM-UHFFFAOYSA-N,Protein Kinase,CSNK1D,1453,P48730,"HCKID, CKID, CKIdelta",Inhibitor,MU2027,6.1,IC50,Eurofins radiometric assay,https://www.thesgc.org/chemical-probes/mu1742,=,47,IC50,NanoBRET asssay (HEK293T cells),https://www.thesgc.org/chemical-probes/mu1742,=,,Kinase panel (Reaction Biology),415,"Screened at 1 µM, closest targets as % of inhibition: CSNK1A1 (6%), CSNK1D (-6%), CSNK1E (0%), TNIK (43%), ZAP-70 (71%);",https://www.thesgc.org/chemical-probes/mu1742,Kinase set,1 µM
EUB0001201a_CSNK1D,MU2027,EUB0001201a,CCc1ccc(-c2ncn(CC3(F)CCN(C)CC3)c2-c2ccnc3[nH]ccc23)nc1,"InChI=1S/C24H27FN6/c1-3-17-4-5-20(28-14-17)21-22(18-6-10-26-23-19(18)7-11-27-23)31(16-29-21)15-24(25)8-12-30(2)13-9-24/h4-7,10-11,14,16H,3,8-9,12-13,15H2,1-2H3,(H,26,27)",SRSOVGVHVNSXTC-UHFFFAOYSA-N,Protein Kinase,CSNK1D,1453,P48730,"HCKID, CKID, CKIdelta",Negative control for MU1742,,3000,IC50,"Tracer competition assays (Reaction Biology, 10 mM ATP)",https://www.thesgc.org/chemical-probes/mu1742,>,50000,IC50,NanoBRET asssay (HEK293T cells),https://www.thesgc.org/chemical-probes/mu1742,>,,,,,,Kinase set,1 µM
EUB0001199aCl_CSNK1D,PF-05236216,EUB0001199aCl,CN1C=C(C2=CC=NC(CN3C)=C2C3=O)C(C4=CC=C(F)C=C4)=N1.Cl,"InChI=1S/C18H15FN4O.ClH/c1-22-10-15-16(18(22)24)13(7-8-20-15)14-9-23(2)21-17(14)11-3-5-12(19)6-4-11;/h3-9H,10H2,1-2H3;1H",CLDJMFXSCFWXDI-UHFFFAOYSA-N,Protein Kinase,CSNK1D,1453,P48730,"HCKID, CKID, CKIdelta",Inhibitor,,8,IC50,Kinase-Glo Plus Assay,https://doi.org/10.1021/acschemneuro.7b00155,=,58,EC50,Translocation Assay (CSNK1D mediated PER3 nuclear translocation in COS-7 cells),https://pubs.acs.org/doi/10.1021/acschemneuro.7b00155,=,,Kinase panel (literature),100,"Screened at 1 µM, closest targets as % of inhibition: MAP4K4 (65%), CSNK1A1 (51%), MINK1 (42%), MAPK14 (37%), in-vitro potencies of closest targets: IC50(MAP4K4) = 873 nM, IC50(CSNK1A1) = 630 nM, IC50(MINK1) = 1573 nM, IC50(MAPK14) = 861 nM (https://pubs.acs.org/doi/10.1021/acschemneuro.7b00155);",https://pubs.acs.org/doi/10.1021/acschemneuro.7b00155,Kinase set,1 µM
EUB0001205a_CSNK1E,MU1742,EUB0001205a,CN1CCC(F)(Cn2cnc(-c3ccc(F)cn3)c2-c2ccnc3[nH]ccc23)CC1,"InChI=1S/C22H22F2N6/c1-29-10-6-22(24,7-11-29)13-30-14-28-19(18-3-2-15(23)12-27-18)20(30)16-4-8-25-21-17(16)5-9-26-21/h2-5,8-9,12,14H,6-7,10-11,13H2,1H3,(H,25,26)",SWOIFXHMBKFCRM-UHFFFAOYSA-N,Protein Kinase,CSNK1E,1454,P49674,"HCKIE, CKIE, CKIepsilon",Inhibitor,MU2027,27.7,IC50,"Tracer competition assays (Reaction Biology, 10 mM ATP)",https://www.thesgc.org/chemical-probes/mu1742,=,220,IC50,NanoBRET asssay (HEK293T cells),https://www.thesgc.org/chemical-probes/mu1742,=,,Kinase panel (Reaction Biology),415,"Screened at 1 µM, closest targets as % of inhibition: CSNK1A1 (6%), CSNK1D (-6%), CSNK1E (0%), TNIK (43%), ZAP-70 (71%);",https://www.thesgc.org/chemical-probes/mu1742,Kinase set,1 µM
EUB0001201a_CSNK1E,MU2027,EUB0001201a,CCc1ccc(-c2ncn(CC3(F)CCN(C)CC3)c2-c2ccnc3[nH]ccc23)nc1,"InChI=1S/C24H27FN6/c1-3-17-4-5-20(28-14-17)21-22(18-6-10-26-23-19(18)7-11-27-23)31(16-29-21)15-24(25)8-12-30(2)13-9-24/h4-7,10-11,14,16H,3,8-9,12-13,15H2,1-2H3,(H,26,27)",SRSOVGVHVNSXTC-UHFFFAOYSA-N,Protein Kinase,CSNK1E,1454,P49674,"HCKIE, CKIE, CKIepsilon",Negative control for MU1742,,3000,IC50,"Tracer competition assays (Reaction Biology, 10 mM ATP)",https://www.thesgc.org/chemical-probes/mu1742,>,50000,IC50,NanoBRET asssay (HEK293T cells),https://www.thesgc.org/chemical-probes/mu1742,>,,,,,,Kinase set,1 µM
EUB0001199aCl_CSNK1E,PF-05236216,EUB0001199aCl,CN1C=C(C2=CC=NC(CN3C)=C2C3=O)C(C4=CC=C(F)C=C4)=N1.Cl,"InChI=1S/C18H15FN4O.ClH/c1-22-10-15-16(18(22)24)13(7-8-20-15)14-9-23(2)21-17(14)11-3-5-12(19)6-4-11;/h3-9H,10H2,1-2H3;1H",CLDJMFXSCFWXDI-UHFFFAOYSA-N,Protein Kinase,CSNK1E,1454,P49674,"HCKIE, CKIE, CKIepsilon",Inhibitor,,36,IC50,Kinase-Glo Plus Assay,https://doi.org/10.1021/acschemneuro.7b00155,=,318,EC50,Translocation Assay (CSNK1E mediated PER3 nuclear translocation in COS-7 cells),https://pubs.acs.org/doi/10.1021/acschemneuro.7b00155,=,,Kinase panel (literature),100,"Screened at 1 µM, closest targets as % of inhibition: MAP4K4 (65%), CSNK1A1 (51%), MINK1 (42%), MAPK14 (37%), in-vitro potencies of closest targets: IC50(MAP4K4) = 873 nM, IC50(CSNK1A1) = 630 nM, IC50(MINK1) = 1573 nM, IC50(MAPK14) = 861 nM (https://pubs.acs.org/doi/10.1021/acschemneuro.7b00155);",https://pubs.acs.org/doi/10.1021/acschemneuro.7b00155,Kinase set,1 µM
EUB0001183a_CSNK2A1,SGC-CK2-1,EUB0001183a,CC1=CC=C(NC2=NC3=C(C#N)C=NN3C(NC4CC4)=C2)C=C1NC(CC)=O,"InChI=1S/C20H21N7O/c1-3-19(28)25-16-8-15(5-4-12(16)2)23-17-9-18(24-14-6-7-14)27-20(26-17)13(10-21)11-22-27/h4-5,8-9,11,14,24H,3,6-7H2,1-2H3,(H,23,26)(H,25,28)",YKDZIFFKQUNVHH-UHFFFAOYSA-N,Protein Kinase,CSNK2A1,1457,P68400,"Cka1, Cka2",Inhibitor,SGC-CK2-1N,4.2,IC50,Enzymatic assay (Eurofins at 10 µM ATP),https://www.sciencedirect.com/science/article/pii/S2451945620305225?via%3Dihub,=,36,IC50,NanoBRET assay (in HEK293T cells),https://www.sciencedirect.com/science/article/pii/S2451945620305225?via%3Dihub,=,,ScanMAX (DiscoverX),468,"Screened at 1 µM, S-Score(10) = 0.007 at 1 µM, closest targets as % of inhibition: STK17A (100%), DYRK2 (86%), PLK4 (77%), HIPK2 (72%), MEK5 (72%), HIPK1 (68%), HIPK3 (66%); In-cellulo follow-up of closest targets (NanoBRET assay in HEK293T cells): IC50(STK17A) >10000 nM, IC50(DYRK2) = 440 nM, IC50(PLK4) >10000 nM, IC50(HIPK2) = 3400 nM, IC50(MEK5) n.d., IC50(HIPK1) = 3700 nM, IC50(HIPK3) = 8100 nM; In-vitro follow-up of MEK5 in enzymatic assay: 0% inhibition at 1 µM (https://www.sciencedirect.com/science/article/pii/S2451945620305225?via%3Dihub); ",https://www.sciencedirect.com/science/article/pii/S2451945620305225?via%3Dihub,Kinase set,100 nM
EUB0001183a_CSNK2A2,SGC-CK2-1,EUB0001183a,CC1=CC=C(NC2=NC3=C(C#N)C=NN3C(NC4CC4)=C2)C=C1NC(CC)=O,"InChI=1S/C20H21N7O/c1-3-19(28)25-16-8-15(5-4-12(16)2)23-17-9-18(24-14-6-7-14)27-20(26-17)13(10-21)11-22-27/h4-5,8-9,11,14,24H,3,6-7H2,1-2H3,(H,23,26)(H,25,28)",YKDZIFFKQUNVHH-UHFFFAOYSA-N,Protein Kinase,CSNK2A2,1459,P19784,"CSNK2A1, CK2alpha'",Inhibitor,SGC-CK2-1N,2.3,IC50,Enzymatic assay (Eurofins at 10 µM ATP),https://www.sciencedirect.com/science/article/pii/S2451945620305225?via%3Dihub,=,16,IC50,NanoBRET assay (in HEK293T cells),https://www.sciencedirect.com/science/article/pii/S2451945620305225?via%3Dihub,=,,ScanMAX (DiscoverX),468,"Screened at 1 µM, S-Score(10) = 0.007 at 1 µM, closest targets as % of inhibition: STK17A (100%), DYRK2 (86%), PLK4 (77%), HIPK2 (72%), MEK5 (72%), HIPK1 (68%), HIPK3 (66%); In-cellulo follow-up of closest targets (NanoBRET assay in HEK293T cells): IC50(STK17A) >10000 nM, IC50(DYRK2) = 440 nM, IC50(PLK4) >10000 nM, IC50(HIPK2) = 3400 nM, IC50(MEK5) n.d., IC50(HIPK1) = 3700 nM, IC50(HIPK3) = 8100 nM; In-vitro follow-up of MEK5 in enzymatic assay: 0% inhibition at 1 µM (https://www.sciencedirect.com/science/article/pii/S2451945620305225?via%3Dihub); ",https://www.sciencedirect.com/science/article/pii/S2451945620305225?via%3Dihub,Kinase set,100 nM
EUB0000276b_DHODH,IPP/CNRS-A017,EUB0000276b,Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F,"InChI=1S/C21H20F3N3O2/c1-11(2)28-21-18(29-19-15(22)5-4-6-16(19)23)12(3)27(26-21)20-17(24)9-14(10-25-20)13-7-8-13/h4-6,9-11,13H,7-8H2,1-3H3",JNAABFZPXJJMPX-UHFFFAOYSA-N,Dehydrogenase,DHODH,1723,Q02127,DHODH,Inhibitor,IPP/CNRS-A019,25,IC50,Activity assay,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/IPP/CNRS-A017,=,2.5,IC50,Measles Virus Inhibition Assay,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/IPP/CNRS-A017,=,,,,No related human family members,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/IPP/CNRS-A017,Other targets,100 nM
EUB0000008b_DYRK1A,MU1210,EUB0000008b,CN1C=C(C2=NC3=C(OC=C3C4=CC(C5=CC=NC=C5)=CC=C4)C=C2)C=N1,"InChI=1S/C22H16N4O/c1-26-13-18(12-24-26)20-5-6-21-22(25-20)19(14-27-21)17-4-2-3-16(11-17)15-7-9-23-10-8-15/h2-14H,1H3",HEAGNKNMQVIVMM-UHFFFAOYSA-N,Protein Kinase,DYRK1A,1859,Q13627,,Inhibitor,MU140,213,IC50,Eurofins radiometric assay,https://onlinelibrary.wiley.com/doi/10.1002/anie.201810312,=,6580,Ki,NanoBRET assay (in HEK293T cells),https://www.thesgc.org/chemical-probes/MU1210,=,,Eurofins kinase panel,210,"Screened at 1 µM, closest targets as % of activity: HIPK2 (99%), HIPK3 (94%), GSK3A (90%); Eurofins binding assay: IC50(HIPK1) = 187 nM, IC50(HIPK2) = 23 nM, IC50(CLK3) >3 µM; In-cellular potency (NanoBRET assay in HEK293T cells): Ki(HIPK2) >10 µM, Ki(HIPK4) = 5.41 µM",https://onlinelibrary.wiley.com/doi/10.1002/anie.201810312,Kinase set,1 µM
EUB0000008b_DYRK1B,MU1210,EUB0000008b,CN1C=C(C2=NC3=C(OC=C3C4=CC(C5=CC=NC=C5)=CC=C4)C=C2)C=N1,"InChI=1S/C22H16N4O/c1-26-13-18(12-24-26)20-5-6-21-22(25-20)19(14-27-21)17-4-2-3-16(11-17)15-7-9-23-10-8-15/h2-14H,1H3",HEAGNKNMQVIVMM-UHFFFAOYSA-N,Protein Kinase,DYRK1B,8445,Q92630,,Inhibitor,MU140,956,IC50,Eurofins radiometric assay,https://onlinelibrary.wiley.com/doi/10.1002/anie.201810312,=,10000,Ki,NanoBRET assay (in HEK293T cells),https://www.thesgc.org/chemical-probes/MU1210,=,,Eurofins kinase panel,210,"Screened at 1 µM, closest targets as % of activity: HIPK2 (99%), HIPK3 (94%), GSK3A (90%); Eurofins binding assay: IC50(HIPK1) = 187 nM, IC50(HIPK2) = 23 nM, IC50(CLK3) >3 µM; In-cellular potency (NanoBRET assay in HEK293T cells): Ki(HIPK2) >10 µM, Ki(HIPK4) = 5.41 µM",https://onlinelibrary.wiley.com/doi/10.1002/anie.201810312,Kinase set,1 µM
EUB0000008b_DYRK2,MU1210,EUB0000008b,CN1C=C(C2=NC3=C(OC=C3C4=CC(C5=CC=NC=C5)=CC=C4)C=C2)C=N1,"InChI=1S/C22H16N4O/c1-26-13-18(12-24-26)20-5-6-21-22(25-20)19(14-27-21)17-4-2-3-16(11-17)15-7-9-23-10-8-15/h2-14H,1H3",HEAGNKNMQVIVMM-UHFFFAOYSA-N,Protein Kinase,DYRK2,9149,Q9Y463,MIRK,Inhibitor,MU140,1309,IC50,Eurofins radiometric assay,https://onlinelibrary.wiley.com/doi/10.1002/anie.201810312,=,1700,Ki,NanoBRET assay (in HEK293T cells),https://www.thesgc.org/chemical-probes/MU1210,=,,Eurofins kinase panel,210,"Screened at 1 µM, closest targets as % of activity: HIPK2 (99%), HIPK3 (94%), GSK3A (90%); Eurofins binding assay: IC50(HIPK1) = 187 nM, IC50(HIPK2) = 23 nM, IC50(CLK3) >3 µM; In-cellular potency (NanoBRET assay in HEK293T cells): Ki(HIPK2) >10 µM, Ki(HIPK4) = 5.41 µM",https://onlinelibrary.wiley.com/doi/10.1002/anie.201810312,Kinase set,1 µM
EUB0001487a_EGFR ,Lapatinib,EUB0001487a,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,Protein Kinase,EGFR ,1956,P00533,ERBB1,inhibitor,,10.8,IC50,Radiometric kinase assay (10 µM ATP),https://aacrjournals.org/mct/article/1/2/85/233686/The-Effects-of-the-Novel-Reversible-Epidermal,=,80170,IC50,Western Blot (phosphorylation of EGFR in BT474 cells),https://aacrjournals.org/mct/article/1/2/85/233686/The-Effects-of-the-Novel-Reversible-Epidermal,=,,Kinase panel (literature),317,"In-vitro potency of closest targets: Kd(EGFR) = 2.4 nM, Kd(EGFR, E746-A750del) = 8.6 nM, Kd(EGFR, G719C) = 0.92 nM, Kd(EGFR, G719S) = 2.1 nM, Kd(EGFR, L747-E749del, A750P) = 2.2 nM, Kd(EGFR, L747-T751del, Sins) = 3.5 nM, Kd(EGFR, L747-S752del, P753S) = 3.9 nM, Kd(EGFR, L858R) = 2.8 nM, Kd(EGFR, L861Q) = 1.2 nM, Kd(EGFR, S752-I759del) = 4.2 nM, Kd(ERBB2) = 7 nM, Kd(ERBB4) = 54 nM, Kd(RIPK2) = 3600 nM,  Kd(STK10) = 4400 nM; In-vitro potencies of closest targets (Radiometric kinase assay (10 µM ATP)): IC50(ERBB4) = 367 nM, IC50(SRC) = 3500 nM, IC50(RAF1) >10000 nM, IC50(MAP2K1) >10000 nM, IC50(MAPK1) >10000 nM, IC50(CSF1R) >10000 nM, IC50(CDK1) >10000 nM, IC50(CDK2) >10000 nM, IC50(MAPK14) >10000 nM, IC50(TEK) >10000 nM, IC50(KDR) >10000 nM (https://aacrjournals.org/mct/article/1/2/85/233686/The-Effects-of-the-Novel-Reversible-Epidermal)",https://www.nature.com/articles/nbt1358,Kinase set,1 µM
EUB0000318b_ENPP2,BI-2545,EUB0000318b,O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2nn[nH]c2c1,"InChI=1S/C23H19F6N5O3/c24-22(25,26)13-3-11(4-14(6-13)23(27,28)29)10-37-21(36)34-8-16-15(17(16)9-34)7-30-20(35)12-1-2-18-19(5-12)32-33-31-18/h1-6,15-17H,7-10H2,(H,30,35)(H,31,32,33)/t15-,16-,17+",ZDOBSAPHUUUOHX-OSYLJGHBSA-N,Hydrolase,ENPP2,5168,Q13822,"ENPP2, ATX, PDNP2",Inhibitor,BI-3017,2.2,IC50,Biochemical assay (LPA measurement),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-2545,=,29,IC50,Inhibition of Autotaxin (whole blood assay),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-2545,=,,KinomeScan (DiscoverX),468,"Screened at 1 µM, closest targets as % of contr.: ASK (13%), NEK1 (44%); Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potencies of closest targets: Ki(GABA/PBR) = 2.56 µM, Ki(SIGMAR1) =3.55 µM; Screened at 10 µM against 44 other enzymes (CEREP selectivity screen), closest targets as % inhibition: CACNA1C (80%), SCN1B (66%), SLC6A2 (61%), HTR2A (55%)",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-2545,Other targets,1 µM
EUB0001066a_ENPP2,BI-3017,EUB0001066a,CC1=NC(COC(N2C[C@H]3[C@H](CNC(C4=CC5=C(C=C4)NN=N5)=O)[C@H]3C2)=O)=CC=N1,"InChI=1S/C20H21N7O3/c1-11-21-5-4-13(23-11)10-30-20(29)27-8-15-14(16(15)9-27)7-22-19(28)12-2-3-17-18(6-12)25-26-24-17/h2-6,14-16H,7-10H2,1H3,(H,22,28)(H,24,25,26)/t14-,15-,16+",ZDITZGRCUFFQRS-PHZGNYQRSA-N,Hydrolase,ENPP2,5168,Q13822,"ENPP2, ATX, PDNP2",Negative control for BI-2545,,8900,IC50,Biochemical assay (LPA measurement),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-2545,=,,,,,,,KinomeScan (DiscoverX),468,"Screened at 1 µM, closest targets as % of contr.: PIM2 (0%), VRK2 (29%), KIT(V55D,V654A) (41%), NLK (41%); Screened at 10 µM against 45 GPCRs (PDPS screen), closest targets as % of inhibition: HTR1E (31.76%), HTR2C (31.08%), ADRA1B (30.19%);",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-2545,Other targets,1 µM
EUB0001487a_ERBB2,Lapatinib,EUB0001487a,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,Protein Kinase,ERBB2,2064,P04626,"NEU, HER-2, CD340, HER2",inhibitor,,9.2,IC50,Radiometric kinase assay (10 µM ATP),https://aacrjournals.org/mct/article/1/2/85/233686/The-Effects-of-the-Novel-Reversible-Epidermal,=,80170,IC50,Western Blot (phosphorylation of ERBB2 in BT474 cells),https://aacrjournals.org/mct/article/1/2/85/233686/The-Effects-of-the-Novel-Reversible-Epidermal,=,,Kinase panel (literature),317,"In-vitro potency of closest targets: Kd(EGFR) = 2.4 nM, Kd(EGFR, E746-A750del) = 8.6 nM, Kd(EGFR, G719C) = 0.92 nM, Kd(EGFR, G719S) = 2.1 nM, Kd(EGFR, L747-E749del, A750P) = 2.2 nM, Kd(EGFR, L747-T751del, Sins) = 3.5 nM, Kd(EGFR, L747-S752del, P753S) = 3.9 nM, Kd(EGFR, L858R) = 2.8 nM, Kd(EGFR, L861Q) = 1.2 nM, Kd(EGFR, S752-I759del) = 4.2 nM, Kd(ERBB2) = 7 nM, Kd(ERBB4) = 54 nM, Kd(RIPK2) = 3600 nM,  Kd(STK10) = 4400 nM; In-vitro potencies of closest targets (Radiometric kinase assay (10 µM ATP)): IC50(ERBB4) = 367 nM, IC50(SRC) = 3500 nM, IC50(RAF1) >10000 nM, IC50(MAP2K1) >10000 nM, IC50(MAPK1) >10000 nM, IC50(CSF1R) >10000 nM, IC50(CDK1) >10000 nM, IC50(CDK2) >10000 nM, IC50(MAPK14) >10000 nM, IC50(TEK) >10000 nM, IC50(KDR) >10000 nM (https://aacrjournals.org/mct/article/1/2/85/233686/The-Effects-of-the-Novel-Reversible-Epidermal)",https://www.nature.com/articles/nbt1358,Kinase set,1 µM
EUB0000699a_FGFR1,PD173074,EUB0000699a,O=C(NC(C)(C)C)NC2=NC1=NC(NCCCCN(CC)CC)=NC=C1C=C2C3=CC(OC)=CC(OC)=C3,"InChI=1S/C28H41N7O3/c1-8-35(9-2)13-11-10-12-29-26-30-18-20-16-23(19-14-21(37-6)17-22(15-19)38-7)25(31-24(20)32-26)33-27(36)34-28(3,4)5/h14-18H,8-13H2,1-7H3,(H3,29,30,31,32,33,34,36)",DXCUKNQANPLTEJ-UHFFFAOYSA-N,Protein Kinase,FGFR1,2260,P11362,"H2, H3, H4, H5, CEK, FLG, BFGFR, N-SAM, CD331",Inhibitor,,21.5,IC50,Enzymatic inhibition assay (5 µM ATP),https://pubmed.ncbi.nlm.nih.gov/9774334/,=,15,IC50,Immunoblotting (inhibition of FGFR1 autophosphorylation in NIH 3T3 cells),https://pubmed.ncbi.nlm.nih.gov/9774334/,=,,KinomeScan (DiscoverX),317,"Screened at 10 μM, closest targets at % of contr.: DDR1 (1.1%), FLT4 (6.0%), CSF1R (6.6%), MST3 (7.0%), VEGFR1 (8.0%), YSK1 (9.4%);In-vitro potency of other targets: IC50(PDGFR, cytoplasmic domain) = 17.6 µM, IC50(c-Src) = 19.8 µM; ",https://lincs.hms.harvard.edu/db/datasets/20055/,Kinase set,100 nM
EUB0000699a_FGFR2,PD173074,EUB0000699a,O=C(NC(C)(C)C)NC2=NC1=NC(NCCCCN(CC)CC)=NC=C1C=C2C3=CC(OC)=CC(OC)=C3,"InChI=1S/C28H41N7O3/c1-8-35(9-2)13-11-10-12-29-26-30-18-20-16-23(19-14-21(37-6)17-22(15-19)38-7)25(31-24(20)32-26)33-27(36)34-28(3,4)5/h14-18H,8-13H2,1-7H3,(H3,29,30,31,32,33,34,36)",DXCUKNQANPLTEJ-UHFFFAOYSA-N,Protein Kinase,FGFR2,2263,P21802,"CEK3, TK14, TK25, ECT1, K-SAM, CD332",Inhibitor,,,,,,,25.1,IC50,NanoBRET assay (in HEK293T cells),https://pubmed.ncbi.nlm.nih.gov/9774334/,=,,KinomeScan (DiscoverX),317,"Screened at 10 μM, closest targets at % of contr.: DDR1 (1.1%), FLT4 (6.0%), CSF1R (6.6%), MST3 (7.0%), VEGFR1 (8.0%), YSK1 (9.4%); In-vitro potency of other targets: IC50(PDGFR, cytoplasmic domain) = 17.6 µM, IC50(c-Src) = 19.8 µM; ",https://lincs.hms.harvard.edu/db/datasets/20055/,Kinase set,100 nM
EUB0000699a_FGFR3,PD173074,EUB0000699a,O=C(NC(C)(C)C)NC2=NC1=NC(NCCCCN(CC)CC)=NC=C1C=C2C3=CC(OC)=CC(OC)=C3,"InChI=1S/C28H41N7O3/c1-8-35(9-2)13-11-10-12-29-26-30-18-20-16-23(19-14-21(37-6)17-22(15-19)38-7)25(31-24(20)32-26)33-27(36)34-28(3,4)5/h14-18H,8-13H2,1-7H3,(H3,29,30,31,32,33,34,36)",DXCUKNQANPLTEJ-UHFFFAOYSA-N,Protein Kinase,FGFR3,2261,P22607,"CEK2, JTK4, CD333",Inhibitor,,,,,,,58.4,IC50,NanoBRET assay (in HEK293T cells),https://pubmed.ncbi.nlm.nih.gov/9774334/,=,,KinomeScan (DiscoverX),317,"Screened at 10 μM, closest targets at % of contr.: DDR1 (1.1%), FLT4 (6.0%), CSF1R (6.6%), MST3 (7.0%), VEGFR1 (8.0%), YSK1 (9.4%); In-vitro potency of other targets: IC50(PDGFR, cytoplasmic domain) = 17.6 µM, IC50(c-Src) = 19.8 µM; ",https://lincs.hms.harvard.edu/db/datasets/20055/,Kinase set,100 nM
EUB0001485a_FLT3,JNJ-47117096,EUB0001485a,COc1cc(-c2cn[nH]c2)ccc1C(=O)Nc1ccc2c(c1)CCNCC2.Cl,"InChI=1S/C21H22N4O2.ClH/c1-27-20-11-15(17-12-23-24-13-17)3-5-19(20)21(26)25-18-4-2-14-6-8-22-9-7-16(14)10-18;/h2-5,10-13,22H,6-9H2,1H3,(H,23,24)(H,25,26);1H",OXRWZUUCCUDKJJ-UHFFFAOYSA-N,Protein Kinase,FLT3,2322,P36888,"STK1, FLK2, CD135",inhibitor,,18,IC50,Radioactive filter binding assay (10 µM ATP),https://pubs.acs.org/doi/10.1021/ml5001245,=,,,,,,,KinaseProfile service (Milipore),235,"Screened at 1 µM, closest targets as % of contr.: CAMK2D (60%), CAMK2G (59%), MKNK2 (55%), MYLK (54%); In-vitro follow-up (enzymatic assays, Milipore): IC50(CAMK2D) = 810 nM, IC50(MKNK2) = 760 nM, IC50(CAMK2G) = 1000 nM, IC50(MYLK) = 1000 nM;",https://pubs.acs.org/doi/10.1021/ml5001245,Kinase set,1 µM
EUB0000229b_GAK,SGC-GAK-1N,EUB0000229b,COc1cc(N(C)c2ccnc3ccc(C(F)(F)F)cc23)cc(OC)c1OC,"InChI=1S/C20H19F3N2O3/c1-25(13-10-17(26-2)19(28-4)18(11-13)27-3)16-7-8-24-15-6-5-12(9-14(15)16)20(21,22)23/h5-11H,1-4H3",PVTQCCFMFWASHK-UHFFFAOYSA-N,Protein Kinase,GAK,2580,O14976,DNAJC26,Negative control for SGC-GAK-1,,,,,,,5000,IC50,NanoBRET assay (HEK293T cells),https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01213,>,,,,,,Kinase set,1 µM
EUB0001492b_IKBKB,BI 605906,EUB0001492b,CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12,"InChI=1S/C17H22F2N4O3S2/c1-3-17(18,19)10-8-11(23-6-4-9(5-7-23)28(2,25)26)22-16-12(10)13(20)14(27-16)15(21)24/h8-9H,3-7,20H2,1-2H3,(H2,21,24)",IYHHRZBKXXKDDY-UHFFFAOYSA-N,Protein Kinase,IKBKB,3551,O14920,"IKK2, NFKBIKB, IKK-beta, IKKB",inhibitor,BI-5026,49,IC50,Enzymatic inhibition assay,https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BI%20605906,=,900,EC50,Cellular assay (inhibition of phospho-IKBKB in HeLa cells),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BI%20605906,=,,Kinase panel (Boehringer Ingelheim),397,"Screened at 10 µM, in-vitro potencies of closest targets (enzymatic assays): IC50(AAK1) = 188 nM, IC50(GAK) = 272 nM, IC50(IRAK3) = 921 nM; In-cellulo follow-up of closest targets (NanoBRET assay in HEK293T cells): IC50(AAK1) = 7 µM, IC50(GAK) = 6.5 µM, IC50(IRAK3) >20 µM (https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BI%20605906); Screened at 10 µM in Panlabs panel, closest targets as % of contr.: PDE3A (31%), all other targets >50% (https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BI%20605906); Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potencies of closest targets: Ki(DRD3) = 428.07 nM, Ki(DRD2) = 341.44 nM, Ki(GABA/PBR) = 2622.51 nM (https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BI%20605906); ",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BI%20605906,Kinase set,1 µM
EUB0001576a_IKBKB,BI-5026,EUB0001576a,CN(C)C(=O)c1sc2nc(N3CCC(S(C)(=O)=O)CC3)cc(C(F)(F)F)c2c1N,"InChI=1S/C17H21F3N4O3S2/c1-23(2)16(25)14-13(21)12-10(17(18,19)20)8-11(22-15(12)28-14)24-6-4-9(5-7-24)29(3,26)27/h8-9H,4-7,21H2,1-3H3",HHYGVXHXNNIDJF-UHFFFAOYSA-N,Protein Kinase,IKBKB,3551,O14920,"IKK2, NFKBIKB, IKK-beta, IKKB",Negative control for BI 605906,,10000,IC50,Enzymatic inhibition assay,https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BI%20605906,>,20000,IC50,NanoBRET assay (HEK293T cells),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BI%20605906,>,,GPCR panel (PDSP screen),45,"Screened at 10 µM, in-vitro potencies of closest targets: Ki(SLC6A3) = 4270.11 nM, Ki(TMEM97) = 7307.71 nM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BI%20605906,Kinase set,1 µM
EUB0001558a_IRAK4,GNE-2256,EUB0001558a,CC(C)(O)[C@H](F)CN1Cc2cc(NC(=O)c3cnn4cccnc34)c(N3CCOCC3)cc2C1=O,"InChI=1S/C24H27FN6O4/c1-24(2,34)20(25)14-30-13-15-10-18(19(11-16(15)23(30)33)29-6-8-35-9-7-29)28-22(32)17-12-27-31-5-3-4-26-21(17)31/h3-5,10-12,20,34H,6-9,13-14H2,1-2H3,(H,28,32)/t20-/m1/s1",AUYCSWFYKYVCLD-HXUWFJFHSA-N,Protein Kinase,IRAK4,51135,Q9NWZ3,NY-REN-64,Inhibitor,GNE-6689,1.4,Ki,Biochemical assay,https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/GNE-2256,=,3,EC50,NanoBRET assay (HEK293T cells),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/GNE-2256,=,,SelectScreen Kinase Profiling (Thermo Fisher Scientific),221,"Screened at 1 µM, closest targets as % of inhibition: FLT3 (90.8%), MAP4K4 (86.3%), MINK1 (80.5%), NTRK1 (71%), NTRK2 (86%), JAK1 (83.5%), JAK2 (80.5%), LRRK2 (91.4%), TAK-TAB (74.5%); In-vitro potency of closest targets (Z'-Lyte kinase biochemical assay, conc. ATP = Km(app), Thermo Fisher Scientific): IC50(FLT3) = 177 nM, IC50(MAP4K4) = 680 nM, IC50(MINK1) = 879 nM, IC50(NTRK1) = 313 nM, IC50(NTRK2) = 259 nM, IC50(JAK1) = 282 nM, IC50(JAK2) = 486 nM, IC50(LRRK2) = 198 nM, IC50(TAK-TAB) = 966 nM (https://pubs.acs.org/doi/10.1021/acsmedchemlett.9b00380); In-cellulo follow-up of closest targets (NanoBRET assay, HEK293T cells): EC50(LRRK2) = 5.2 µM, EC50(NTRK2) = 5.6 µM, EC50(NTRK1) = 11 µM, EC50(FLT3) >50 µM, EC50(JAK1) >50 µM, EC50(JAK2) >50 µM (https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/GNE-2256);",https://pubs.acs.org/doi/10.1021/acsmedchemlett.9b00380,Kinase set,1 µM
EUB0001559a_IRAK4,GNE-6689,EUB0001559a,CN(C(=O)c1cnn2cccnc12)c1cc2c(cc1N1CCOCC1)C(=O)N(C[C@@H](F)C(C)(C)O)C2,"InChI=1S/C25H29FN6O4/c1-25(2,35)21(26)15-31-14-16-11-19(20(12-17(16)24(31)34)30-7-9-36-10-8-30)29(3)23(33)18-13-28-32-6-4-5-27-22(18)32/h4-6,11-13,21,35H,7-10,14-15H2,1-3H3/t21-/m1/s1",JREVKKCSBRLATM-OAQYLSRUSA-N,Protein Kinase,IRAK4,51135,Q9NWZ3,NY-REN-64,Negative control for GNE-2256,,,,,,,9500,EC50,NanoBRET assay (HEK293T cells),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/GNE-2256,=,,,,,,Kinase set,1 µM
EUB0000639a_IRAK4,PF-06650833,EUB0000639a,COC(C(C(N)=O)=C1)=CC2=C1C=CN=C2OC[C@H]3NC([C@@H](F)[C@H]3CC)=O,"InChI=1S/C18H20FN3O4/c1-3-10-13(22-17(24)15(10)19)8-26-18-11-7-14(25-2)12(16(20)23)6-9(11)4-5-21-18/h4-7,10,13,15H,3,8H2,1-2H3,(H2,20,23)(H,22,24)/t10-,13+,15-/m0/s1",JKDGKIBAOAFRPJ-ZBINZKHDSA-N,Protein Kinase,IRAK4,51135,Q9NWZ3,NY-REN-64,Inhibitor,,0.2,IC50,Dissociation-Enhanced Lanthanide Fluorescent Immunoassay,https://pubmed.ncbi.nlm.nih.gov/28498658/,=,0.29,IC50,NanoBRET assay (in HEK293T cells),https://pubmed.ncbi.nlm.nih.gov/28498658/,=,,Invitrogen panel (inhibition),278,"Screened at 200 nM, closest targets with >90% inhibition: IRAK1, targets with >70% inhibition: MNK2, LRRK2, CLK4, CK1g; Screened in KiNativ kinome screen (ActivX) in THP1 cell lysates at 10, 50, 200, 1000, and 5000 nM against 270 kinases; closest targets >50% inhibition at 200 nM: CSNK1G2, IRAK3, PIPK2C, CKSNK1D/E, https://pubmed.ncbi.nlm.nih.gov/28498658/; Cellular potency (NanoBRET assay in HEK293T cells): IC50(CSNK1G2) = 7.1 µM (SGC-Frankfurt, in-house data)",https://pubmed.ncbi.nlm.nih.gov/28498658/,Kinase set,100 nM
EUB0000651a_ITK,BMS 509744,EUB0000651a,COC1=CC(C)=C(SC3=CN=C(NC(C4=CC=C(CNC(C)C(C)(C)C)C=C4)=O)S3)C=C1C(N2CCN(C(C)=O)CC2)=O,"InChI=1S/C32H41N5O4S2/c1-20-16-26(41-7)25(30(40)37-14-12-36(13-15-37)22(3)38)17-27(20)42-28-19-34-31(43-28)35-29(39)24-10-8-23(9-11-24)18-33-21(2)32(4,5)6/h8-11,16-17,19,21,33H,12-15,18H2,1-7H3,(H,34,35,39)",ZHXNIYGJAOPMSO-UHFFFAOYSA-N,Protein Kinase,ITK,3702,Q08881,"EMT, PSCTK2, LYK",inhibitor,,19,IC50,Enzymatic radiometric assay,https://pubmed.ncbi.nlm.nih.gov/15323564/,=,,,,,,,"Kinase Tm panel, in-house SGC Frankfurt",100,"Tm panel screened at 20 µM, closest targets (dTm >5 K): dTm (CAMKK2) = 7.2 K, dTm(CLK1) = 6.4 K, dTm(EPHA2) = 6.2 K, dTm(NEK2) = 5.1 K, dTm(SRPK1) = 5.1 K, dTm(PHKG2) = 5.5 K, dTm(STK10) =  5.8 K, dTm(STK6) = 10.1 K, dTm(STK4) = 5.2 K, dTm(ULK3) = 5.8 K; Screened against 19 kinases (Radiometric inhibition assays): no target within 30-fold (PMID: 15323564)",https://pubmed.ncbi.nlm.nih.gov/15323564/,Kinase set,1 µM
EUB0001542aTs_JAK1,PF-06700841,EUB0001542aTs,Cc1ccc(S(=O)(=O)O)cc1.Cn1cc(Nc2nccc(N3CC4CCC(C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1,"InChI=1S/C18H21F2N7O.C7H8O3S/c1-25-8-11(7-22-25)23-17-21-5-4-15(24-17)26-9-12-2-3-13(10-26)27(12)16(28)14-6-18(14,19)20;1-6-2-4-7(5-3-6)11(8,9)10/h4-5,7-8,12-14H,2-3,6,9-10H2,1H3,(H,21,23,24);2-5H,1H3,(H,8,9,10)/t12?,13?,14-;/m0./s1",FAKGOYNHHHOTEN-WTMFEIAXSA-N,Protein Kinase,JAK1,3716,P23458,"JAK1A, JTK3",inhibitor,,17,IC50,"Microfluidic assay (phosphorylation of synthetic peptide by recombinant human JAK1, at 1 mM ATP, Caliper Life Science)",https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00917,=,,,,,,,Kinase panel (Carna Biosciences),306,"Screened at 1 µM, conc. ATP = Km, closest targets >90% of inhibition: AURKA/TPX2 (97%), TNK1 (94%), JAK3(92%), QIK(91%); Screened at 10 µM against a broad panel of receptors, ion channels, and transporters (CEREP Wide Ligand Profile screen), in-vitro potency of closest target: IC50(KDR) = 1600 nM, others <50% inhibition, IC50 follow-up in cell-based assay (NovaScreen): IC50(KDR) >30 µM (https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00917);",https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b00917,Kinase set,1 µM
EUB0001542aTs_JAK2,PF-06700841,EUB0001542aTs,Cc1ccc(S(=O)(=O)O)cc1.Cn1cc(Nc2nccc(N3CC4CCC(C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1,"InChI=1S/C18H21F2N7O.C7H8O3S/c1-25-8-11(7-22-25)23-17-21-5-4-15(24-17)26-9-12-2-3-13(10-26)27(12)16(28)14-6-18(14,19)20;1-6-2-4-7(5-3-6)11(8,9)10/h4-5,7-8,12-14H,2-3,6,9-10H2,1H3,(H,21,23,24);2-5H,1H3,(H,8,9,10)/t12?,13?,14-;/m0./s1",FAKGOYNHHHOTEN-WTMFEIAXSA-N,Protein Kinase,JAK2,3717,O60674,JTK10,inhibitor,,77,IC50,"Microfluidic assay (phosphorylation of synthetic peptide by recombinant human JAK2, at 1 mM ATP, Caliper Life Science)",https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00917,=,,,,,,,Kinase panel (Carna Biosciences),306,"Screened at 1 µM, conc. ATP = Km, closest targets >90% of inhibition: AURKA/TPX2 (97%), TNK1 (94%), JAK3(92%), QIK(91%); Screened at 10 µM against a broad panel of receptors, ion channels, and transporters (CEREP Wide Ligand Profile screen), in-vitro potency of closest target: IC50(KDR) = 1600 nM, others <50% inhibition, IC50 follow-up in cell-based assay (NovaScreen): IC50(KDR) >30 µM (https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00917);",https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b00917,Kinase set,1 µM
EUB0001072a_KISS1R,KISS1-543,EUB0001072a,CC(C[C@H](NC(NNC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](NC([C@H](N)Cc1ccc(O)cc1)=O)CC2=CC=NC=C2)=O)CC(N)=O)=O)CO)=O)Cc3ccccc3)=O)=O)C(N[C@H](C(N[C@@H](CC4=CC=CC=C4)C(NCC)=O)=O)CCCNC(NC)=N)=O)C,"InChI=1S/C58H80N16O12/c1-5-64-50(79)43(29-35-13-8-6-9-14-35)68-51(80)41(17-12-24-65-57(61)62-4)66-52(81)42(27-34(2)3)72-58(86)74-73-56(85)45(30-36-15-10-7-11-16-36)69-55(84)47(33-75)71-54(83)46(32-48(60)77)70-53(82)44(31-38-22-25-63-26-23-38)67-49(78)40(59)28-37-18-20-39(76)21-19-37/h6-11,13-16,18-23,25-26,34,40-47,75-76H,5,12,17,24,27-33,59H2,1-4H3,(H2,60,77)(H,64,79)(H,66,81)(H,67,78)(H,68,80)(H,69,84)(H,70,82)(H,71,83)(H,73,85)(H3,61,62,65)(H2,72,74,86)/t40-,41+,42+,43+,44-,45+,46+,47+/m1/s1",KSPGBAVXLLOLOZ-FIWWHSBNSA-N,GPCR,KISS1R,84634,Q969F8,"HOT7T175, AXOR12",Negative control for KISS1-305,,,,,,,,,,,,,GPCR panel (PDSP screen),45,"Screened at 1 µM, closest target as % of inhibition: CHRM2 (40.7%)",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/KISS1-305,GPCR set,1 µM
EUB0001619a_LRRK2,PF-06447475,EUB0001619a,N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1,"InChI=1S/C17H15N5O/c18-9-12-2-1-3-13(8-12)14-10-19-16-15(14)17(21-11-20-16)22-4-6-23-7-5-22/h1-3,8,10-11H,4-7H2,(H,19,20,21)",BHTWDJBVZQBRKP-UHFFFAOYSA-N,Protein Kinase,LRRK2,120892,Q5S007,"ROCO2, DKFZp434H2111, FLJ45829, RIPK7",Inhibitor,,3,IC50,"Lanthascreen assay (Invitrogen, using 117 µM ATP)",https://pubs.acs.org/doi/10.1021/jm5014055,=,84,IC50,NanoBRET assay (in HEK293T cells),https://pubs.acs.org/doi/epdf/10.1021/acs.jmedchem.1c00804,=,,KinomeScan (DiscoverX),360,"Screened at 1 µM, closest targets as % of contr: MAP3K3(8.2%), MAP4K2(3.4%), JAK3(2.7%), MST2(1.8%), MAP4K3(4.8%), RIOK3(4.8%), RSK4(9.8%), MST4(7%), PRKCE(12%), MEK1(13%), EGFR(L747-E749del, 14%), EGFR(L747-S752del,14%), MEK5(14%), MEST1(18%), MEK2(19%), PIP5K1A(20%); In-vitro potency of closest targets (Z-Lyte assay assay, Invitrogen, using 7.75 µM ATP): IC50(MST4) = 178 nM, https://pubs.acs.org/doi/10.1021/jm5014055;",https://pubs.acs.org/doi/10.1021/jm5014055,Kinase set,100 nM
EUB0000124b_MAP2K1,Trametinib,EUB0000124b,CC(NC1=CC(N2C(C(C(N(C3CC3)C2=O)=O)=C(NC4=CC=C(I)C=C4F)N5C)=C(C)C5=O)=CC=C1)=O,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,Protein Kinase,MAP2K1,5604,Q02750,"MEK1, MAPKK1",Inhibitor,,1.8,IC50,"ELISA (Raf-MEK-ERK cascade kinase assay, activated with c-Raf, 10 µM ATP)",https://www.spandidos-publications.com/10.3892/ijo.2011.1015,=,,,,,,,Millipor'e kinase profiler,99,"Screened at 10 µM, closest targets as % of contr.: NTRK1 (59%); Screened against 300 proteins in Kinobeads assays, in-vitro potencies of closest targets: Kdapp(BRD4) = 1915 nM, Kdapp(MAP2K1) = 62 nM, Kdapp(MAP2K2) = 9 nM (https://www.science.org/doi/10.1126/science.aan4368)",https://www.spandidos-publications.com/10.3892/ijo.2011.1015,Kinase set,100 nM
EUB0000124b_MAP2K2,Trametinib,EUB0000124b,CC(NC1=CC(N2C(C(C(N(C3CC3)C2=O)=O)=C(NC4=CC=C(I)C=C4F)N5C)=C(C)C5=O)=CC=C1)=O,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,Protein Kinase,MAP2K2,5605,P36507,MEK2,Inhibitor,,0.92,IC50,"ELISA (Raf-MEK-ERK cascade kinase assay, activated with c-Raf, 10 µM ATP)",https://www.spandidos-publications.com/10.3892/ijo.2011.1015,=,,,,,,,Millipor'e kinase profiler,99,"Screened at 10 µM, closest targets as % of contr.: NTRK1 (59%); Screened against 300 proteins in Kinobeads assays, in-vitro potencies of closest targets: Kdapp(BRD4) = 1915 nM, Kdapp(MAP2K1) = 62 nM, Kdapp(MAP2K2) = 9 nM (https://www.science.org/doi/10.1126/science.aan4368)",https://www.spandidos-publications.com/10.3892/ijo.2011.1015,Kinase set,100 nM
EUB0000623aCl_MAP3K5,ASK1 Inhibitor 10,EUB0000623aCl,O=C(C1=CC=C(C(C)(C)C)C=C1)NC2=CN3C=C(N4C=CN=C4)C=CC3=N2.Cl.Cl,"InChI=1S/C21H21N5O.2ClH/c1-21(2,3)16-6-4-15(5-7-16)20(27)24-18-13-26-12-17(8-9-19(26)23-18)25-11-10-22-14-25;;/h4-14H,1-3H3,(H,24,27);2*1H",IKKLFEDUYFZNBO-UHFFFAOYSA-N,Protein Kinase,MAP3K5,4217,Q99683,"MAPKKK5, ASK1",Inhibitor,,14,IC50,Enzymatic inhibition assay,https://pubmed.ncbi.nlm.nih.gov/23147077/,=,,,,,,,"Kinase panel (Invitrogen, enzymatic assay)",195,"Screened at 1 µM, in-vitro potency of closest targets: IC50(ASK2)= 510 nM, IC50(MEKK1) >10 µM, IC50(TAK1) >10 µM, IC50(IKKB) >10 µM, IC50(ERK1) >10 µM, IC50(JNK1) >10µM, IC50(MAPK14) >10 µM, IC50(GSK3B) >10 µM, IC50(PRKCT) >10 µM; Screened against 12 kinases (Invitrogen, enzymatic assays), in-vitro potency of closest targets: IC50(CDK2) = 0.158 µM, IC50(EGFR) <20 µM, IC50(EPHA3) <20 µM, IC50(ERBB4) <20 µM, IC50(GSK3B) = 0.832 µM, IC50(ITK) = 5.5 µM, IC50(MER) = 6.5 µM, IC50(MAPK14) <20 µM, IC50(PRKAA1) = 13.8 µM, IC50(RET) = 11.5 µM, IC50(ROCK1) = 4.9 µM, IC50(RON) <20 µM, https://pubmed.ncbi.nlm.nih.gov/28291695/; Screened at 20 µM against 100 kinases, DSF panel, closest targets with dTm >5 K: dTm(MAP3K5) = 12.41 K, dTm(CLK1) = 5.46 K, closest targets with dTm 3-5 K: dTm(CAMKK2) = 4.55 K, dTm(RPS6KA5) = 3.13 K, in-house data SGC Frankfurt; ",https://pubmed.ncbi.nlm.nih.gov/23147077/,Kinase set,1 µM
EUB0001068a_MAPK11,FM-743,EUB0001068a,O=C(C1=CC=CC=C1)N(C)C1=C(F)C=CC(N(C)C2C=CC(=C(C=2)CC2)C(C(=C23)C=C(C(NCCN2CCOCC2)=O)C=C3)=O)=C1,"InChI=1S/C37H37FN4O4/c1-40(30-13-15-33(38)34(24-30)41(2)37(45)26-6-4-3-5-7-26)29-12-14-31-27(22-29)10-8-25-9-11-28(23-32(25)35(31)43)36(44)39-16-17-42-18-20-46-21-19-42/h3-7,9,11-15,22-24H,8,10,16-21H2,1-2H3,(H,39,44)",RHXKLUBQGQKHCH-UHFFFAOYSA-N,Protein Kinase,MAPK11,5600,Q15759,"p38-2, p38Beta, SAPK2",Negative control for FS-694 and L-Skepinone,,,,,,,16200,IC50,NanoBRET assay (HEK293T cells),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/FS-694,=,,KinomeScan (DiscoverX),468,"Screened at 1 µM, closest targets as % of control: NEK1(45%), STK38L (47%), BMX(50%)",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/FS-694,Kinase set,1 µM
EUB0001068a_MAPK14,FM-743,EUB0001068a,O=C(C1=CC=CC=C1)N(C)C1=C(F)C=CC(N(C)C2C=CC(=C(C=2)CC2)C(C(=C23)C=C(C(NCCN2CCOCC2)=O)C=C3)=O)=C1,"InChI=1S/C37H37FN4O4/c1-40(30-13-15-33(38)34(24-30)41(2)37(45)26-6-4-3-5-7-26)29-12-14-31-27(22-29)10-8-25-9-11-28(23-32(25)35(31)43)36(44)39-16-17-42-18-20-46-21-19-42/h3-7,9,11-15,22-24H,8,10,16-21H2,1-2H3,(H,39,44)",RHXKLUBQGQKHCH-UHFFFAOYSA-N,Protein Kinase,MAPK14,1432,Q16539,"PRKM14, p38, Mxi2, PRKM15",Negative control for FS-694 and L-Skepinone,,,,,,,11300,IC50,NanoBRET assay (HEK293T cells),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/FS-694,=,,KinomeScan (DiscoverX),468,"Screened at 1 µM, closest targets as % of control: NEK1(45%), STK38L (47%), BMX(50%)",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/FS-694,Kinase set,1 µM
EUB0001485a_MELK,JNJ-47117096,EUB0001485a,COc1cc(-c2cn[nH]c2)ccc1C(=O)Nc1ccc2c(c1)CCNCC2.Cl,"InChI=1S/C21H22N4O2.ClH/c1-27-20-11-15(17-12-23-24-13-17)3-5-19(20)21(26)25-18-4-2-14-6-8-22-9-7-16(14)10-18;/h2-5,10-13,22H,6-9H2,1H3,(H,23,24)(H,25,26);1H",OXRWZUUCCUDKJJ-UHFFFAOYSA-N,Protein Kinase,MELK,9833,Q14680,KIAA0175,inhibitor,,23,IC50,Radioactive filter binding assay (10 µM ATP),https://pubs.acs.org/doi/10.1021/ml5001245,=,,,,,,,KinaseProfile service (Milipore),235,"Screened at 1 µM, closest targets as % of contr.: CAMK2D (60%), CAMK2G (59%), MKNK2 (55%), MYLK (54%); In-vitro follow-up (enzymatic assays, Milipore): IC50(CAMK2D) = 810 nM, IC50(MKNK2) = 760 nM, IC50(CAMK2G) = 1000 nM, IC50(MYLK) = 1000 nM;",https://pubs.acs.org/doi/10.1021/ml5001245,Kinase set,1 µM
EUB0001079a_MGAT2,TP-020n,EUB0001079a,NC1=CN=C(N2CCC3=C2C(N4CCCC4=O)=CC(S(=O)(NC5=C(F)C=C(Cl)C=C5F)=O)=C3)N=C1,"InChI=1S/C22H19ClF2N6O3S/c23-13-7-16(24)20(17(25)8-13)29-35(33,34)15-6-12-3-5-31(22-27-10-14(26)11-28-22)21(12)18(9-15)30-4-1-2-19(30)32/h6-11,29H,1-5,26H2",SBCFKMYFTAVDHK-UHFFFAOYSA-N,Transferase,MGAT2,4247,Q10469,MGAT2,Negative control for TP-020,,3300,IC50,RapidFire/MS assay (using full-length human protein),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-020,=,,,,,,,,,,,Other targets,1 µM
EUB0001619a_STK3,PF-06447475,EUB0001619a,N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1,"InChI=1S/C17H15N5O/c18-9-12-2-1-3-13(8-12)14-10-19-16-15(14)17(21-11-20-16)22-4-6-23-7-5-22/h1-3,8,10-11H,4-7H2,(H,19,20,21)",BHTWDJBVZQBRKP-UHFFFAOYSA-N,Protein Kinase,STK3,6788,Q13188,"MST2, KRS1",Inhibitor,,22,IC50,"Z-Lyte assay assay (Invitrogen, using 7.75 µM ATP)",https://pubs.acs.org/doi/10.1021/jm5014055,=,197,IC50,NanoBRET assay (in HEK293T cells),https://pubs.acs.org/doi/epdf/10.1021/acs.jmedchem.1c00804,=,,KinomeScan (DiscoverX),360,"Screened at 1 µM, closest targets as % of contr: MAP3K3(8.2%), MAP4K2(3.4%), JAK3(2.7%), MST2(1.8%), MAP4K3(4.8%), RIOK3(4.8%), RSK4(9.8%), MST4(7%), PRKCE(12%), MEK1(13%), EGFR(L747-E749del, 14%), EGFR(L747-S752del,14%), MEK5(14%), MEST1(18%), MEK2(19%), PIP5K1A(20%); In-vitro potency of closest targets (Z-Lyte assay assay, Invitrogen, using 7.75 µM ATP): IC50(MST4) = 178 nM, https://pubs.acs.org/doi/10.1021/jm5014055;",https://pubs.acs.org/doi/10.1021/jm5014055,Kinase set,100 nM
EUB0000270b_NSD3@PWWP1,BI-9466,EUB0000270b,Cc1cc(CN)cc(C)c1-c1ncn(C)c1-c1cncn1C,"InChI=1S/C17H21N5/c1-11-5-13(7-18)6-12(2)15(11)16-17(22(4)10-20-16)14-8-19-9-21(14)3/h5-6,8-10H,7,18H2,1-4H3",SFZHMKDAVPIXRB-UHFFFAOYSA-N,HMT,NSD3@PWWP1,54904,Q9BZ95,"FLJ20353, WHISTLE, KMT3F",Negative control for BI-9321,,120000,IC50,TR-FRET binding assay (NSD3-PWWP1),https://www.nature.com/articles/s41589-019-0310-x,=,10000,IC50,NanoBRET assay (Nluc-NSD3-PWWP1 fusion protein in U2OS cells),https://www.nature.com/articles/s41589-019-0310-x,>,,"PWWP, WD40, and Tudor domain panel (DSLS measurements, literature)",20,"Screened at 500 µM against 10 PWWP, 4 WD40, 3 Tudor and 4 MBT domains of 20 proteins (DSLS measurements): dTagg(NSD3@PWWP1) = 0.7 K, dTagg(NSD2@PWWP1) = 0.1 K, dTagg(NSD3@PWWP2) = 0.5 K, dTagg(BRPF1@PWWP) = 0.0 K, dTagg(BRD1@PWWP) = -2.2 K, dTagg(BRPF3@PWWP) = 0.3 K, dTagg(ZCWPW1@PWWP) = 0.0 K, dTagg(DNMT3A@PWWP1) = -0.1 K, dTagg(DNMT3B@PWWP1) = 0.0 K, dTagg(MSH6@PWWP) = -0.2 K, dTagg(WDR20@PWWP) = 0.0 K, dTagg(WDR5@PWWP) = - 0.7 K, dTagg(WDR48@PWWP) = 0.1 K, dTagg(EED@PWWP) = 0.2 K, dTagg(53BP1@PWWP1) = 0.1 K, dTagg(SETDB1@PWWP) = 0.9 K, dTagg(TDRD3@PWWP) = 0.8 K, dTagg(L3MBTL3@PWWP) = 0.2 K, dTagg(L3MBTL1@PWWP1) = 0.2 K, dTagg(SCML2@PWWP1) = 0.1 K (https://www.nature.com/articles/s41589-019-0310-x); Screened at 1 µM and 10 µM against 34 protein, RNA and DNA methyltransferases and EP300 (acetyltransferase): highly selective with >80% remaining activity on all proteins tested (https://www.nature.com/articles/s41589-019-0310-x); Screened at 100 µM against 48 bromodomains (DSF assay): clean selectivity profile with all targets dTm <2K (https://www.nature.com/articles/s41589-019-0310-x)",https://www.nature.com/articles/s41589-019-0310-x,Epigenetic set,1 µM
EUB0001070aCl_PADI4,GSK106,EUB0001070aCl,CCn1c(-c2nc3cc(C(=O)N4CC[C]C(N)C4)ccc3n2C)cc2ccccc21.[Cl],"InChI=1S/C24H25N5O.Cl/c1-3-29-20-9-5-4-7-16(20)14-22(29)23-26-19-13-17(10-11-21(19)27(23)2)24(30)28-12-6-8-18(25)15-28;/h4-5,7,9-11,13-14,18H,3,6,12,15,25H2,1-2H3;",PLCVQSIOQUTHPT-UHFFFAOYSA-N,Hydrolase,PADI4,23569,Q9UM07,"PAD, PAD4, PADI5, PDI4, PDI5",Negative control for GSK484,,100000,IC50,Fluorescence polarization binding assay (0 mM Ca),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397581/,>,,,,,,,,,,,Other targets,1 µM
EUB0001071aCl_PADI4,GSK484,EUB0001071aCl,COc1cc(C(=O)N2CC[C@@H](O)[C@@H](N)C2)cc2nc(-c3cc4ccccc4n3CC3CC3)n(C)c12.Cl,"InChI=1S/C27H31N5O3.ClH/c1-30-25-20(11-18(13-24(25)35-2)27(34)31-10-9-23(33)19(28)15-31)29-26(30)22-12-17-5-3-4-6-21(17)32(22)14-16-7-8-16;/h3-6,11-13,16,19,23,33H,7-10,14-15,28H2,1-2H3;1H/t19-,23+;/m0./s1",MULKOGJHUZTANI-ADMBKAPUSA-N,Hydrolase,PADI4,23569,Q9UM07,"PAD, PAD4, PADI5, PDI4, PDI5",Inhibitor,GSK106,50,IC50,Fluorescence polarization binding assay (0 mM Ca),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397581/,=,,,,,,,"Panel of kinases, GPCRs, ion channels and transporters (literature)",50,"Various assays types used, i.e. TR-FRET, Luminescence assay, FLINT, Electrophysiological assay, LEADseeker SPA; No activation across HDACs 1–11 at 100 μM; Selective for PADI4 over PADI1-3 (tested with recombinant enzymes and cell lysates).",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397581/,Other targets,1 µM
EUB0001075a_PAK1,NVS-PAK1-C,EUB0001075a,O=C(N1CC[C@@H](C1)NC2=NC3=C(N(C4=C2C=C(Cl)C=C4)CC(F)F)C=CC(F)=C3)N(C)C,"InChI=1S/C22H23ClF3N5O/c1-29(2)22(32)30-8-7-15(11-30)27-21-16-9-13(23)3-5-18(16)31(12-20(25)26)19-6-4-14(24)10-17(19)28-21/h3-6,9-10,15,20H,7-8,11-12H2,1-2H3,(H,27,28)/t15-/m0/s1",RVHZFZVJXGIAJF-HNNXBMFYSA-N,Protein Kinase,PAK1,5058,Q13153,,Negative control for NVS-PAK1-1,,1500,IC50,Caliper in-vitro dephosphorylation assay (PAK1 phos.),https://www.thesgc.org/chemical-probes/mu1742,=,,,,,,,,,,,Kinase set,1 µM
EUB0000621a_PIK3CB,AZD 6482,EUB0000621a,CC1=CN2C(=O)C=C(N=C2C(=C1)[C@@H](C)NC3=CC=CC=C3C(=O)O)N4CCOCC4,"InChI=1S/C22H24N4O4/c1-14-11-17(15(2)23-18-6-4-3-5-16(18)22(28)29)21-24-19(12-20(27)26(21)13-14)25-7-9-30-10-8-25/h3-6,11-13,15,23H,7-10H2,1-2H3,(H,28,29)/t15-/m1/s1",IRTDIKMSKMREGO-OAHLLOKOSA-N,Protein Kinase,PIK3CB,5291,P42338,,Inhibitor,,10,IC50,Alphascreen assay,https://pubmed.ncbi.nlm.nih.gov/22906130/,=,,,,,,,Kinase panel (DSF assay),100,"Screened at 20 µM, closest targets with dTm >1K: dTm(MARK3) = 1.76 K, dTm(MST4) = 1.33 K, dTm(GSK3B) = 1.33 K; Screened against 88 targets in functional assays (AstraZeneca): >200-fold with exception of PIK3 isoforms, PIK3CA (86-fold) and PIK3CG (108-fold), as well as DNA-PK (42-fold), IC50(PIK3CA) = 0.87 µM (AlphaScreen), IC50(PIK3CG) = 1.09 µM (AlphaScreen), IC50(DNA-PK) = 0.42 µM (ELISA), https://pubmed.ncbi.nlm.nih.gov/22906130/;",https://pubmed.ncbi.nlm.nih.gov/22906130/,Kinase set,1 µM
EUB0000621a_PIK3CD,AZD 6482,EUB0000621a,CC1=CN2C(=O)C=C(N=C2C(=C1)[C@@H](C)NC3=CC=CC=C3C(=O)O)N4CCOCC4,"InChI=1S/C22H24N4O4/c1-14-11-17(15(2)23-18-6-4-3-5-16(18)22(28)29)21-24-19(12-20(27)26(21)13-14)25-7-9-30-10-8-25/h3-6,11-13,15,23H,7-10H2,1-2H3,(H,28,29)/t15-/m1/s1",IRTDIKMSKMREGO-OAHLLOKOSA-N,Protein Kinase,PIK3CD,5293,O00329,p110D,Inhibitor,,80,IC50,Alphascreen assay,https://pubmed.ncbi.nlm.nih.gov/22906130/,=,,,,,,,Kinase panel (DSF assay),100,"Screened at 20 µM, closest targets with dTm >1K: dTm(MARK3) = 1.76 K, dTm(MST4) = 1.33 K, dTm(GSK3B) = 1.33 K; Screened against 88 targets in functional assays (AstraZeneca): >200-fold with exception of PIK3 isoforms, PIK3CA (86-fold) and PIK3CG (108-fold), as well as DNA-PK (42-fold), IC50(PIK3CA) = 0.87 µM (AlphaScreen), IC50(PIK3CG) = 1.09 µM (AlphaScreen), IC50(DNA-PK) = 0.42 µM (ELISA), https://pubmed.ncbi.nlm.nih.gov/22906130/;",https://pubmed.ncbi.nlm.nih.gov/22906130/,Kinase set,1 µM
EUB0000877a_PIK3CD,Leniolisib,EUB0000877a,COC1=NC=C(N2CC(C(N[C@H]3CCN(C(CC)=O)C3)=NC=N4)=C4CC2)C=C1C(F)(F)F,"InChI=1S/C21H25F3N6O2/c1-3-18(31)30-6-4-13(10-30)28-19-15-11-29(7-5-17(15)26-12-27-19)14-8-16(21(22,23)24)20(32-2)25-9-14/h8-9,12-13H,3-7,10-11H2,1-2H3,(H,26,27,28)/t13-/m0/s1",MWKYMZXCGYXLPL-ZDUSSCGKSA-N,Protein Kinase,PIK3CD,5293,O00329,p110D,Inhibitor,,11,IC50,Adapta™ TR-FRET assay,https://pubs.acs.org/doi/10.1021/acsmedchemlett.7b00293,=,,,,,,,KinomeScan (DiscoverX),442,"Screened at 10 µM, closest targets as % of contr.: RPS6KA5 (76%); Screened against 50 related targets (GPCRs, ion channels, transporters): in-vitro potency of closest targets IC50(hPDE4D) = 4.7 µM, IC50(5HT2B) = 7.7 µM; No activity when tested against CYP isoforms (CYP3A3, CYP2D9, CYP2D6,CYP2C9)",https://pubs.acs.org/doi/10.1021/acsmedchemlett.7b00293,Kinase set,1 µM
EUB0001550a_PIKFYVE,SGC-PIKFYVE-1,EUB0001550a,CN(C)CC#Cc1ccc2[nH]c3c(c2c1)-c1nc(N)ncc1CCC3,"InChI=1S/C20H21N5/c1-25(2)10-4-5-13-8-9-16-15(11-13)18-17(23-16)7-3-6-14-12-22-20(21)24-19(14)18/h8-9,11-12,23H,3,6-7,10H2,1-2H3,(H2,21,22,24)",DORZPJWJOBMQKC-UHFFFAOYSA-N,Protein Kinase,PIKFYVE,200576,Q9Y2I7,"CFD, FAB1, HEL37, PIP5K, PIP5K3, ZFYVE29",Inhibitor,SGC-PIKFYVE-1N,6.9,IC50,Enzymatic assay (SignalChem),https://www.thesgc.org/chemical-probes/sgc-pikfyve-1,=,4,IC50,NanoBRET assay (HEK293T cells),https://www.thesgc.org/chemical-probes/sgc-pikfyve-1,=,,Kinome Scan (DiscoverX),403,"Screened at 1 µM, closest targets as % of contr.: MYLK4 (1.8%), MEK1 (4.5%), RIPK5 (5.2%), IRAK3 (9.2%), MEK2 (9.6%), DYRK1A (9.9%), YSK4 (9.9%), ULK3(11%), MEK4 (12%), HASPIN (13%), STK16 (14%), CLK2 (20%), CDK7 (20%), IRAK4 (21%), AURKB (23%), DYRK1B (26%), CLK1 (30%), RIOK2 (32%), CLK4 (34%), PIP4K2C (53%), MAP4K5 (96%); In-vitro follow-up of closest targets: IC50(MYLK4) = 66 nM, IC50(MEK1) >10000 nM, IC50(RIPK5) >10000 nM, IC50(MEK2) >10000 nM, IC50(DYRK1A) = 2040 nM, IC50(YSK4) = 4020 nM, IC50(ULK3) >10000 nM, IC50(MEK4) >10000 nM, IC50(HASPIN) = 1400 nM, IC50(STK16) = 560 nM, IC50(CLK2) = 290 nM, IC50(CDK7) >10000 nM, IC50(IRAK4) = 4500 nM, IC50(AURKB) = 1400 nM, IC50(DYRK1B) = 380 nM, IC50(CLK1) = 420 nM, IC50(CLK4) = 440 nM, IC50(PIP4K2C) = 1900 nM, IC50(MAP4K5) = 89 nM; In-cellulo follow-up of closest targets (NanoBRET assay in HEK293T cells): IC50(MYLK4) = 270 nM, IC50(PIP4K2C) >10000 nM, IC50(MAP4K5) >10000 nM (https://www.thesgc.org/chemical-probes/sgc-pikfyve-1)",https://www.thesgc.org/chemical-probes/sgc-pikfyve-1,Kinase set,100 nM
EUB0001877a_PIKFYVE,SGC-PIKFYVE-1N,EUB0001877a,NC1=NC2=C(CCCCC3=C2C4=C(C=CC(C5CC5)=C4)N3)C=N1,"InChI=1S/C19H20N4/c20-19-21-10-13-3-1-2-4-16-17(18(13)23-19)14-9-12(11-5-6-11)7-8-15(14)22-16/h7-11,22H,1-6H2,(H2,20,21,23)",XIVFOAKTTGQHLJ-UHFFFAOYSA-N,Protein Kinase,PIKFYVE,200576,Q9Y2I7,"CFD, FAB1, HEL37, PIP5K, PIP5K3, ZFYVE29",Negative control for SGC-PIKFYVE,,715,IC50,Enzymatic assay,https://www.thesgc.org/chemical-probes/sgc-pikfyve-1,=,10000,IC50,NanoBRET assay (HEK293T cells),https://www.thesgc.org/chemical-probes/sgc-pikfyve-1,>,,Kinome Scan (DiscoverX),403,"Screened at 1 µM, closest target as % of contr.: MAST1 (32%), S-score(35) = 0.002 at 1 µM;",https://www.thesgc.org/chemical-probes/sgc-pikfyve-1,Kinase set,100 nM
EUB0001547a_PIM1,AZD1208,EUB0001547a,N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1,"InChI=1S/C21H21N3O2S/c22-16-9-5-11-24(13-16)19-15(12-18-20(25)23-21(26)27-18)8-4-10-17(19)14-6-2-1-3-7-14/h1-4,6-8,10,12,16H,5,9,11,13,22H2,(H,23,25,26)/t16-/m1/s1",MCUJKPPARUPFJM-MRXNPFEDSA-N,Protein Kinase,PIM1,5292,P11309,,inhibitor,,0.4,IC50,"Mobility shift assay (Caliper Life Sciences, conc. ATP = Km)","https://ashpublications.org/blood/article/123/6/905/32601/AZD1208-a-potent-and-selective-pan-Pim-kinase, https://ashpublications.org/blood/article/123/6/905/32601/AZD1208-a-potent-and-selective-pan-Pim-kinase, https://ashpublications.org/blood/article/123/6/905/32601/AZD1208-a-potent-and-selective-pan-Pim-kinase",=,10,IC50,Enzyme-linked immunosorbent assay (phosphorylation of BAD in U2OS cells),https://ashpublications.org/blood/article/123/6/905/32601/AZD1208-a-potent-and-selective-pan-Pim-kinase,=,,KinomeScan (DiscoverX),442,"Screened at 1 µM, 16 kinases with >50% inhibition, in-vitro follow-up of closest targets: Kd(CDK7) = 38 nM, Kd(MAPK15) = 53 nM, others Kd(CAMK4) = 360 nM, Kd(DAPK1) = 420 nM, Kd(HIPK3) = 480 nM, Kd(STK17B) = 930 nM;",https://ashpublications.org/blood/article/123/6/905/32601/AZD1208-a-potent-and-selective-pan-Pim-kinase,Kinase set,100 nM
EUB0001581a_PIM1,PIM447,EUB0001581a,C[C@@H]1C[C@H](N)C[C@H](c2ccncc2NC(=O)c2ccc(F)c(-c3c(F)cccc3F)n2)C1,"InChI=1S/C24H23F3N4O/c1-13-9-14(11-15(28)10-13)16-7-8-29-12-21(16)31-24(32)20-6-5-19(27)23(30-20)22-17(25)3-2-4-18(22)26/h2-8,12-15H,9-11,28H2,1H3,(H,31,32)/t13-,14+,15-/m0/s1",VRQXRVAKPDCRCI-ZNMIVQPWSA-N,Protein Kinase,PIM1,5292,P11309,,inhibitor,,0.006,Ki,AlphaScreen assay (2800 μM ATP),https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01275,=,,,,,,,KinomeScan (DiscoverX),442,"Screened at 1 µM, closest targets as % of control: MAPK15 (2.5%), others >20%;",https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01275,Kinase set,1 µM
EUB0001547a_PIM2,AZD1208,EUB0001547a,N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1,"InChI=1S/C21H21N3O2S/c22-16-9-5-11-24(13-16)19-15(12-18-20(25)23-21(26)27-18)8-4-10-17(19)14-6-2-1-3-7-14/h1-4,6-8,10,12,16H,5,9,11,13,22H2,(H,23,25,26)/t16-/m1/s1",MCUJKPPARUPFJM-MRXNPFEDSA-N,Protein Kinase,PIM2,11040,Q9P1W9,,inhibitor,,5,IC50,"Mobility shift assay (Caliper Life Sciences, conc. ATP = Km)","https://ashpublications.org/blood/article/123/6/905/32601/AZD1208-a-potent-and-selective-pan-Pim-kinase, https://ashpublications.org/blood/article/123/6/905/32601/AZD1208-a-potent-and-selective-pan-Pim-kinase, https://ashpublications.org/blood/article/123/6/905/32601/AZD1208-a-potent-and-selective-pan-Pim-kinase",=,151,IC50,Enzyme-linked immunosorbent assay (phosphorylation of BAD in U2OS cells),https://ashpublications.org/blood/article/123/6/905/32601/AZD1208-a-potent-and-selective-pan-Pim-kinase,=,,KinomeScan (DiscoverX),442,"Screened at 1 µM, 16 kinases with >50% inhibition, in-vitro follow-up of closest targets: Kd(CDK7) = 38 nM, Kd(MAPK15) = 53 nM, others Kd(CAMK4) = 360 nM, Kd(DAPK1) = 420 nM, Kd(HIPK3) = 480 nM, Kd(STK17B) = 930 nM;",https://ashpublications.org/blood/article/123/6/905/32601/AZD1208-a-potent-and-selective-pan-Pim-kinase,Kinase set,100 nM
EUB0001581a_PIM2,PIM447,EUB0001581a,C[C@@H]1C[C@H](N)C[C@H](c2ccncc2NC(=O)c2ccc(F)c(-c3c(F)cccc3F)n2)C1,"InChI=1S/C24H23F3N4O/c1-13-9-14(11-15(28)10-13)16-7-8-29-12-21(16)31-24(32)20-6-5-19(27)23(30-20)22-17(25)3-2-4-18(22)26/h2-8,12-15H,9-11,28H2,1H3,(H,31,32)/t13-,14+,15-/m0/s1",VRQXRVAKPDCRCI-ZNMIVQPWSA-N,Protein Kinase,PIM2,11040,Q9P1W9,,inhibitor,,0.018,Ki,AlphaScreen assay (500 µM ATP),https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01275,=,,,,,,,KinomeScan (DiscoverX),442,"Screened at 1 µM, closest targets as % of control: MAPK15 (2.5%), others >20%;",https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01275,Kinase set,1 µM
EUB0001547a_PIM3,AZD1208,EUB0001547a,N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1,"InChI=1S/C21H21N3O2S/c22-16-9-5-11-24(13-16)19-15(12-18-20(25)23-21(26)27-18)8-4-10-17(19)14-6-2-1-3-7-14/h1-4,6-8,10,12,16H,5,9,11,13,22H2,(H,23,25,26)/t16-/m1/s1",MCUJKPPARUPFJM-MRXNPFEDSA-N,Protein Kinase,PIM3,415116,Q86V86,,inhibitor,,1.9,IC50,"Mobility shift assay (Caliper Life Sciences, conc. ATP = Km)","https://ashpublications.org/blood/article/123/6/905/32601/AZD1208-a-potent-and-selective-pan-Pim-kinase, https://ashpublications.org/blood/article/123/6/905/32601/AZD1208-a-potent-and-selective-pan-Pim-kinase, https://ashpublications.org/blood/article/123/6/905/32601/AZD1208-a-potent-and-selective-pan-Pim-kinase",=,102,IC50,Enzyme-linked immunosorbent assay (phosphorylation of BAD in U2OS cells),https://ashpublications.org/blood/article/123/6/905/32601/AZD1208-a-potent-and-selective-pan-Pim-kinase,=,,KinomeScan (DiscoverX),442,"Screened at 1 µM, 16 kinases with >50% inhibition, in-vitro follow-up of closest targets: Kd(CDK7) = 38 nM, Kd(MAPK15) = 53 nM, others Kd(CAMK4) = 360 nM, Kd(DAPK1) = 420 nM, Kd(HIPK3) = 480 nM, Kd(STK17B) = 930 nM;",https://ashpublications.org/blood/article/123/6/905/32601/AZD1208-a-potent-and-selective-pan-Pim-kinase,Kinase set,100 nM
EUB0001581a_PIM3,PIM447,EUB0001581a,C[C@@H]1C[C@H](N)C[C@H](c2ccncc2NC(=O)c2ccc(F)c(-c3c(F)cccc3F)n2)C1,"InChI=1S/C24H23F3N4O/c1-13-9-14(11-15(28)10-13)16-7-8-29-12-21(16)31-24(32)20-6-5-19(27)23(30-20)22-17(25)3-2-4-18(22)26/h2-8,12-15H,9-11,28H2,1H3,(H,31,32)/t13-,14+,15-/m0/s1",VRQXRVAKPDCRCI-ZNMIVQPWSA-N,Protein Kinase,PIM3,415116,Q86V86,,inhibitor,,0.009,Ki,AlphaScreen assay (2800 μM ATP),https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01275,=,,,,,,,KinomeScan (DiscoverX),442,"Screened at 1 µM, closest targets as % of control: MAPK15 (2.5%), others >20%;",https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01275,Kinase set,1 µM
EUB0001565a_PIP4K2A,BAY-0361,EUB0001565a,CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O,"InChI=1S/C26H21FN4O2/c1-3-21(26(32)33)30-25-19-11-12-29-14-22(19)31-24(20(25)13-28)17-9-7-16(8-10-17)18-6-4-5-15(2)23(18)27/h4-12,14,21H,3H2,1-2H3,(H,30,31)(H,32,33)/t21-/m1/s1",DVIVLYHDLNAXAT-OAQYLSRUSA-N,Protein Kinase,PIP4K2A,5305,P48426,"PIP5KIIA, PIP5KIIalpha",Negative control for BAY-091,,271,IC50,Enzymatic assay (Eurofins),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BAY-091,=,30000,EC50,CETSA (intact K-562 cells),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BAY-091,>,,,,,,Kinase set,1 µM
EUB0001564a_PIP4K2A,BAY-091,EUB0001564a,CC[C@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O,"InChI=1S/C26H21FN4O2/c1-3-21(26(32)33)30-25-19-11-12-29-14-22(19)31-24(20(25)13-28)17-9-7-16(8-10-17)18-6-4-5-15(2)23(18)27/h4-12,14,21H,3H2,1-2H3,(H,30,31)(H,32,33)/t21-/m0/s1",DVIVLYHDLNAXAT-NRFANRHFSA-N,Protein Kinase,PIP4K2A,5305,P48426,"PIP5KIIA, PIP5KIIalpha",Inhibitor,BAY-0361,21,IC50,Enzymatic assay (Eurofins),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BAY-091,=,1100,EC50,CETSA (intact K-562 cells),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BAY-091,=,,Kinase panel (Eurofins),373,"Screened at 1 µM, clean selectivity profile with no kinase inhibited >60%; Screened at 10 µM against 77 targets outside the target family (Eurofins safety panel), closest targets as % of inhibition: TBXAS1 (98%), HTR2B (98%), MAOB (81%), PDE3 (74%), PDE5A (62%);",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BAY-091,Kinase set,1 µM
EUB0000311b_PRKAA1,BAY-3827,EUB0000311b,CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12,"InChI=1S/C27H25FN6O/c1-6-17-9-7-8-10-18(17)27(35)31-26-20-11-19(24(28)14(2)25(20)32-33-26)23-21(12-29)15(3)34(5)16(4)22(23)13-30/h7-11,23H,6H2,1-5H3,(H2,31,32,33,35)",OZFFKOSQNBBYCA-UHFFFAOYSA-N,Protein Kinase,PRKAA1,5562,Q13131,AMPKa1,Inhibitor,BAY-974,7,IC50,Enzymatic inhibition assay,https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BAY-3827,=,,,,,,,KinomeScan (DiscoverX),468,"Screened at 1 µM, in-vitro potencies of closest targets: Kd(RPS6KA3) = 52 nM, Kd(RPS6KA2) = 24 nM, Kd(RPS6KA6) = 36 nM, Kd(FLT3) = 124 nM, Kd(RPS6KA5) = 43 nM, Kd(MST3) = 94 nM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BAY-3827,Kinase set,100 nM
EUB0000261b_PRMT1,MS094,EUB0000261b,CC(C)Oc1ccc(-c2c[nH]cc2CN(C)CCO)cc1,"InChI=1S/C17H24N2O2/c1-13(2)21-16-6-4-14(5-7-16)17-11-18-10-15(17)12-19(3)8-9-20/h4-7,10-11,13,18,20H,8-9,12H2,1-3H3",GNAKYUUZAXUXKB-UHFFFAOYSA-N,HMT,PRMT1,3276,Q99873,"HCP1, ANM1",Negative control for MS023,,,,,,,,,,,,,,,,,Epigenetic set,1 µM
EUB0000261b_PRMT3,MS094,EUB0000261b,CC(C)Oc1ccc(-c2c[nH]cc2CN(C)CCO)cc1,"InChI=1S/C17H24N2O2/c1-13(2)21-16-6-4-14(5-7-16)17-11-18-10-15(17)12-19(3)8-9-20/h4-7,10-11,13,18,20H,8-9,12H2,1-3H3",GNAKYUUZAXUXKB-UHFFFAOYSA-N,HMT,PRMT3,10196,O60678,,Negative control for MS023,,,,,,,,,,,,,,,,,Epigenetic set,1 µM
EUB0000271b_PRMT6,SGC6870,EUB0000271b,Cc1cc(C)cc([C@@H]2c3cc(C)ccc3NC(=O)CN2C(=O)c2ccc(Br)s2)c1,"InChI=1S/C23H21BrN2O2S/c1-13-4-5-18-17(11-13)22(16-9-14(2)8-15(3)10-16)26(12-21(27)25-18)23(28)19-6-7-20(24)29-19/h4-11,22H,12H2,1-3H3,(H,25,27)/t22-/m1/s1",NIPTUMFVYBXSMZ-JOCHJYFZSA-N,HMT,PRMT6,55170,Q96LA8,FLJ10559,Allosteric inhibitor,SGC6870N,77,IC50,Radioactive biochemical assay ,https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02160,=,,,,,,,Methyltransferase screen (radiometric assays),32,"Screened at 1 µM and 10 µM, clean against a panel of 8 PRMTs, 21 protein lysine methyltransferases, 3 DNA methyltransferases, and one RNA methyltransferase, targets as % of activity in the screen at 1 µM: PRMT6 (17%), PRMT1 (>90%), PRMT3 (>90%), PRMT4 (>90%), PRMT5 (>90%), PRMT7 (>90%), PRMT8 (>90%), PRMT9 (>90%), G9a (>90%), GLP (>90%), SETDB1 (>90%), SUV39H1 (>90%), SUV39H2 (>90%), SUV420H1 (>90%), SUV420H2 (>90%), SETD7 (>90%), SETD8 (>90%), MLL1 (>90%), MLL3 (>90%), PRDM9 (>90%), PRC2 (>90%), SETD2 (>90%), SMYD2 (>90%), SMYD3 (>90%), BCDN3D (>90%), DNMT1 (>90%), DNMT3A/3L (>90%), DNMT3B/3L (>90%), DOT1L (>90%), ASH1L (>90%), NSD1 (>90%), NSD2(>90%),NSD3(>90%); Targets as % of activity in the screen at 10 µM: PRMT6 (8%), PRMT1 (>90%), PRMT3 (>90%), PRMT4 (>90%), PRMT5 (>90%), PRMT7 (>90%), PRMT8 (>90%), PRMT9 (>90%), G9a (>90%), GLP (>90%), SETDB1 (>90%), SUV39H1 (>90%), SUV39H2 (>90%), SUV420H1 (>90%), SUV420H2 (>90%), SETD7 (>90%), SETD8 (>90%), MLL1 (>90%), MLL3 (>90%), PRDM9 (>90%), PRC2 (>90%), SETD2 (>90%), SMYD2 (>90%), SMYD3 (>90%), BCDN3D (>90%), DNMT1 (>90%), DNMT3A/3L (>90%), DNMT3B/3L (>90%), DOT1L (>90%), ASH1L (>90%), NSD1 (>90%), NSD2(>90%),NSD3(>90%); Screened against 44 non-epigenetic targets by Eurofins (kinases, GPCRs, ion channels and transporters) at 1 μM, closest target as % of inhibition: KOP (20%), COX1 (17%), GR (15%), 5-HT2A (12%), M3 (12%), MAOA (12%), D1 (9%), acetylcholinesterase (7%), https://pubmed.ncbi.nlm.nih.gov/33591753/;",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02160,Epigenetic set,1 µM
EUB0000272b_PRMT6,SGC6870N,EUB0000272b,Cc1cc(C)cc([C@H]2c3cc(C)ccc3NC(=O)CN2C(=O)c2ccc(Br)s2)c1,"InChI=1S/C23H21BrN2O2S/c1-13-4-5-18-17(11-13)22(16-9-14(2)8-15(3)10-16)26(12-21(27)25-18)23(28)19-6-7-20(24)29-19/h4-11,22H,12H2,1-3H3,(H,25,27)/t22-/m0/s1",NIPTUMFVYBXSMZ-QFIPXVFZSA-N,HMT,PRMT6,55170,Q96LA8,FLJ10559,Negative control for SGC6870,,50000,IC50,Radioactive biochemical assay ,https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02160,>,,,,,,,Methyltransferase screen (radiometric assays),32,"Screened at 1 µM and 10 µM, clean against a panel of 8 PRMTs, 21 protein lysine methyltransferases, 3 DNA methyltransferases, and one RNA methyltransferase, targets as % of activity in the screen at 1 µM: PRMT6 (17%), PRMT1 (>90%), PRMT3 (>90%), PRMT4 (>90%), PRMT5 (>90%), PRMT7 (>90%), PRMT8 (>90%), PRMT9 (>90%), G9a (>90%), GLP (>90%), SETDB1 (>90%), SUV39H1 (>90%), SUV39H2 (>90%), SUV420H1 (>90%), SUV420H2 (>90%), SETD7 (>90%), SETD8 (>90%), MLL1 (>90%), MLL3 (>90%), PRDM9 (>90%), PRC2 (>90%), SETD2 (>90%), SMYD2 (>90%), SMYD3 (>90%), BCDN3D (>90%), DNMT1 (>90%), DNMT3A/3L (>90%), DNMT3B/3L (>90%), DOT1L (>90%), ASH1L (>90%), NSD1 (>90%), NSD2(>90%),NSD3(>90%); Targets as % of activity in the screen at 10 µM: PRMT6 (8%), PRMT1 (>90%), PRMT3 (>90%), PRMT4 (>90%), PRMT5 (>90%), PRMT7 (>90%), PRMT8 (>90%), PRMT9 (>90%), G9a (>90%), GLP (>90%), SETDB1 (>90%), SUV39H1 (>90%), SUV39H2 (>90%), SUV420H1 (>90%), SUV420H2 (>90%), SETD7 (>90%), SETD8 (>90%), MLL1 (>90%), MLL3 (>90%), PRDM9 (>90%), PRC2 (>90%), SETD2 (>90%), SMYD2 (>90%), SMYD3 (>90%), BCDN3D (>90%), DNMT1 (>90%), DNMT3A/3L (>90%), DNMT3B/3L (>90%), DOT1L (>90%), ASH1L (>90%), NSD1 (>90%), NSD2(>90%),NSD3(>90%); Screened against 44 non-epigenetic targets by Eurofins (kinases, GPCRs, ion channels and transporters) at 1 μM, closest target as % of inhibition: KOP (20%), COX1 (17%), GR (15%), 5-HT2A (12%), M3 (12%), MAOA (12%), D1 (9%), acetylcholinesterase (7%), https://pubmed.ncbi.nlm.nih.gov/33591753/;",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02160,Epigenetic set,1 µM
EUB0000236b_PRMT7,SGC3027N,EUB0000236b,CC1=C(C)C(=O)C(C(C)(C)CC(=O)N(CCCCSC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)[C@@H]3OC(C)(C)O[C@H]23)Cc2cccc(-c3ccc(Cl)cc3)c2)=C(C)C1=O,"InChI=1S/C44H51ClN6O6S/c1-25-26(2)37(54)34(27(3)36(25)53)43(4,5)20-33(52)50(21-28-11-10-12-30(19-28)29-13-15-31(45)16-14-29)17-8-9-18-58-22-32-38-39(57-44(6,7)56-38)42(55-32)51-24-49-35-40(46)47-23-48-41(35)51/h10-16,19,23-24,32,38-39,42H,8-9,17-18,20-22H2,1-7H3,(H2,46,47,48)/t32-,38-,39-,42-/m1/s1",FJBPSCVGHZASPG-LJVHFRCJSA-N,HMT,PRMT7,54496,Q9NVM4,"FLJ10640, KIAA1933",Negative control for SGC3027,,,,,,,,,,,,,,,,,Epigenetic set,1 µM
EUB0000261b_PRMT8,MS094,EUB0000261b,CC(C)Oc1ccc(-c2c[nH]cc2CN(C)CCO)cc1,"InChI=1S/C17H24N2O2/c1-13(2)21-16-6-4-14(5-7-16)17-11-18-10-15(17)12-19(3)8-9-20/h4-7,10-11,13,18,20H,8-9,12H2,1-3H3",GNAKYUUZAXUXKB-UHFFFAOYSA-N,HMT,PRMT8,56341,Q9NR22,,Negative control for MS023,,,,,,,,,,,,,,,,,Epigenetic set,1 µM
EUB0000311b_RPS6KA1,BAY-3827,EUB0000311b,CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12,"InChI=1S/C27H25FN6O/c1-6-17-9-7-8-10-18(17)27(35)31-26-20-11-19(24(28)14(2)25(20)32-33-26)23-21(12-29)15(3)34(5)16(4)22(23)13-30/h7-11,23H,6H2,1-5H3,(H2,31,32,33,35)",OZFFKOSQNBBYCA-UHFFFAOYSA-N,Protein Kinase,RPS6KA1,6196,Q15349,"RSK3, HU-2",Inhibitor,BAY-974,9.1,IC50,Enzymatic inhibition assay,https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BAY-3827,=,,,,,,,KinomeScan (DiscoverX),468,"Screened at 1 µM, in-vitro potencies of closest targets: Kd(RPS6KA3) = 52 nM, Kd(RPS6KA2) = 24 nM, Kd(RPS6KA6) = 36 nM, Kd(FLT3) = 124 nM, Kd(RPS6KA5) = 43 nM, Kd(MST3) = 94 nM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BAY-3827,Kinase set,100 nM
EUB0001479a_SIK1,MR7,EUB0001479a,CN(C)c1ncc2cc(-c3ccc(-c4ncccc4F)cc3Cl)c(=O)n(C[C@H]3OC[C@H](N)CO3)c2n1,"InChI=1S/C25H24ClFN6O3/c1-32(2)25-30-10-15-8-18(17-6-5-14(9-19(17)26)22-20(27)4-3-7-29-22)24(34)33(23(15)31-25)11-21-35-12-16(28)13-36-21/h3-10,16,21H,11-13,28H2,1-2H3/t16-,21-",RRFFBKGCCWPMLK-OQIWPSSASA-N,Protein Kinase,SIK1,150094,P57059,msk,Negative control for MRIA9,,,,,,,,,,,,,"Kinase panel (DSF assay, SGC-Frankfurt)",100,"Screened at 20 µM, clean selectivity profile, dTm(MST3) = 0.2 K, dTm(MST4) = 0.8 K, dTM(PAK1) = 0.9 K",https://www.thesgc.org/chemical-probes/mria9,Kinase set,1 µM
EUB0001107a_SIK1,MRIA9,EUB0001107a,CNc1ncc2cc(-c3ccc(-c4ncccc4F)cc3Cl)c(=O)n(C[C@H]3OC[C@H](N)CO3)c2n1,"InChI=1S/C24H22ClFN6O3/c1-28-24-30-9-14-7-17(16-5-4-13(8-18(16)25)21-19(26)3-2-6-29-21)23(33)32(22(14)31-24)10-20-34-11-15(27)12-35-20/h2-9,15,20H,10-12,27H2,1H3,(H,28,30,31)/t15-,20-",QKNBRNSGPNCARD-SGNKCFNYSA-N,Protein Kinase,SIK1,150094,P57059,msk,Inhibitor,MR7,55,IC50,Radiometric 33PanQinase Assay ,https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02144,=,516,IC50,NanoBRET assay (HEK293T cells),https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02144,=,,33PanQinase Assay (Reaction Biology),443,"Screened at 1 μM inhibition, closest targets as % of residual activity: MAP4K5 (8%), PAK3 (9%), PAK2 (10%), NLK (13%), PKN3 (35%), PAK1 (36%), MAP2K4 (37%), TIE2 (39%), MST4 (45%), MELK (48%); In-vitro follow-up of closest targets (33PanQinase assay, Reaction Biology): IC50(MAP4K5) = 210 nM, IC50(PAK3) = 140 nM, IC50(PAK2) = 41 nM, IC50(NLK) = 13 nM, IC50(PKN3) = 1400 nM, IC50(PAK1) = 580 nM, IC50(MAP2K4) = 830 nM, IC50(TIE2) = 3100 nM, IC50(MST4) = 1600 nM, IC50(MELK) = 2200 nM (https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02144); In-cellulo follow-up of closest targets (NanoBRET assay in HEK293T cells): IC50(MAP4K5) = 13 µM, IC50(NLK) = 0.25 µM, IC50(PKN3) = 6.7 µM, IC50(TIE2) = 6 µM, IC50(MST4) = 34 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02144;",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02144,Kinase set,1 µM
EUB0001479a_SIK2,MR7,EUB0001479a,CN(C)c1ncc2cc(-c3ccc(-c4ncccc4F)cc3Cl)c(=O)n(C[C@H]3OC[C@H](N)CO3)c2n1,"InChI=1S/C25H24ClFN6O3/c1-32(2)25-30-10-15-8-18(17-6-5-14(9-19(17)26)22-20(27)4-3-7-29-22)24(34)33(23(15)31-25)11-21-35-12-16(28)13-36-21/h3-10,16,21H,11-13,28H2,1-2H3/t16-,21-",RRFFBKGCCWPMLK-OQIWPSSASA-N,Protein Kinase,SIK2,23235,Q9H0K1,"KIAA0781, QIK, DKFZp434K1115, LOH11CR1I",Negative control for MRIA9,,,,,,,14000,IC50,NanoBRET assay (HEK293T cells),https://www.thesgc.org/chemical-probes/mria9,=,,"Kinase panel (DSF assay, SGC-Frankfurt)",100,"Screened at 20 µM, clean selectivity profile, dTm(MST3) = 0.2 K, dTm(MST4) = 0.8 K, dTM(PAK1) = 0.9 K",https://www.thesgc.org/chemical-probes/mria9,Kinase set,1 µM
EUB0001107a_SIK2,MRIA9,EUB0001107a,CNc1ncc2cc(-c3ccc(-c4ncccc4F)cc3Cl)c(=O)n(C[C@H]3OC[C@H](N)CO3)c2n1,"InChI=1S/C24H22ClFN6O3/c1-28-24-30-9-14-7-17(16-5-4-13(8-18(16)25)21-19(26)3-2-6-29-21)23(33)32(22(14)31-24)10-20-34-11-15(27)12-35-20/h2-9,15,20H,10-12,27H2,1H3,(H,28,30,31)/t15-,20-",QKNBRNSGPNCARD-SGNKCFNYSA-N,Protein Kinase,SIK2,23235,Q9H0K1,"KIAA0781, QIK, DKFZp434K1115, LOH11CR1I",Inhibitor,MR7,48,IC50,Radiometric 33PanQinase Assay ,https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02144,=,180,IC50,NanoBRET assay (HEK293T cells),https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02144,=,,33PanQinase Assay (Reaction Biology),443,"Screened at 1 μM inhibition, closest targets as % of residual activity: MAP4K5 (8%), PAK3 (9%), PAK2 (10%), NLK (13%), PKN3 (35%), PAK1 (36%), MAP2K4 (37%), TIE2 (39%), MST4 (45%), MELK (48%); In-vitro follow-up of closest targets (33PanQinase assay, Reaction Biology): IC50(MAP4K5) = 210 nM, IC50(PAK3) = 140 nM, IC50(PAK2) = 41 nM, IC50(NLK) = 13 nM, IC50(PKN3) = 1400 nM, IC50(PAK1) = 580 nM, IC50(MAP2K4) = 830 nM, IC50(TIE2) = 3100 nM, IC50(MST4) = 1600 nM, IC50(MELK) = 2200 nM (https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02144); In-cellulo follow-up of closest targets (NanoBRET assay in HEK293T cells): IC50(MAP4K5) = 13 µM, IC50(NLK) = 0.25 µM, IC50(PKN3) = 6.7 µM, IC50(TIE2) = 6 µM, IC50(MST4) = 34 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02144;",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02144,Kinase set,1 µM
EUB0001479a_SIK3,MR7,EUB0001479a,CN(C)c1ncc2cc(-c3ccc(-c4ncccc4F)cc3Cl)c(=O)n(C[C@H]3OC[C@H](N)CO3)c2n1,"InChI=1S/C25H24ClFN6O3/c1-32(2)25-30-10-15-8-18(17-6-5-14(9-19(17)26)22-20(27)4-3-7-29-22)24(34)33(23(15)31-25)11-21-35-12-16(28)13-36-21/h3-10,16,21H,11-13,28H2,1-2H3/t16-,21-",RRFFBKGCCWPMLK-OQIWPSSASA-N,Protein Kinase,SIK3,23387,Q9Y2K2,"FLJ12240, L19, KIAA0999, QSK",Negative control for MRIA9,,,,,,,,,,,,,"Kinase panel (DSF assay, SGC-Frankfurt)",100,"Screened at 20 µM, clean selectivity profile, dTm(MST3) = 0.2 K, dTm(MST4) = 0.8 K, dTM(PAK1) = 0.9 K",https://www.thesgc.org/chemical-probes/mria9,Kinase set,1 µM
EUB0001107a_SIK3,MRIA9,EUB0001107a,CNc1ncc2cc(-c3ccc(-c4ncccc4F)cc3Cl)c(=O)n(C[C@H]3OC[C@H](N)CO3)c2n1,"InChI=1S/C24H22ClFN6O3/c1-28-24-30-9-14-7-17(16-5-4-13(8-18(16)25)21-19(26)3-2-6-29-21)23(33)32(22(14)31-24)10-20-34-11-15(27)12-35-20/h2-9,15,20H,10-12,27H2,1H3,(H,28,30,31)/t15-,20-",QKNBRNSGPNCARD-SGNKCFNYSA-N,Protein Kinase,SIK3,23387,Q9Y2K2,"FLJ12240, L19, KIAA0999, QSK",Inhibitor,MR7,22,IC50,Radiometric 33PanQinase Assay ,https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02144,=,127,IC50,NanoBRET assay (HEK293T cells),https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02144,=,,33PanQinase Assay (Reaction Biology),443,"Screened at 1 μM inhibition, closest targets as % of residual activity: MAP4K5 (8%), PAK3 (9%), PAK2 (10%), NLK (13%), PKN3 (35%), PAK1 (36%), MAP2K4 (37%), TIE2 (39%), MST4 (45%), MELK (48%); In-vitro follow-up of closest targets (33PanQinase assay, Reaction Biology): IC50(MAP4K5) = 210 nM, IC50(PAK3) = 140 nM, IC50(PAK2) = 41 nM, IC50(NLK) = 13 nM, IC50(PKN3) = 1400 nM, IC50(PAK1) = 580 nM, IC50(MAP2K4) = 830 nM, IC50(TIE2) = 3100 nM, IC50(MST4) = 1600 nM, IC50(MELK) = 2200 nM (https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02144); In-cellulo follow-up of closest targets (NanoBRET assay in HEK293T cells): IC50(MAP4K5) = 13 µM, IC50(NLK) = 0.25 µM, IC50(PKN3) = 6.7 µM, IC50(TIE2) = 6 µM, IC50(MST4) = 34 µM, https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02144;",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02144,Kinase set,1 µM
EUB0001046a_SRPK1,MSC2705360A,EUB0001046a,Clc4cc1c([nH]c(c1)-c2nc(ccn2)NCc3c(nccc3)N(S(=O)(=O)C)C)cc4,"InChI=1S/C20H19ClN6O2S/c1-27(30(2,28)29)20-13(4-3-8-23-20)12-24-18-7-9-22-19(26-18)17-11-14-10-15(21)5-6-16(14)25-17/h3-11,25H,12H2,1-2H3,(H,22,24,26)",MXAVRMOXZMBKGE-UHFFFAOYSA-N,Protein Kinase,SRPK1,6732,Q96SB4,SFRSK1,Negative control for MSC2711186A,,10000,IC50,Biochemical activity assay (Reaction Biology),https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c01705,>,50000,IC50,"NanoBRET assay (in HEK293T cells, lysed mode)",https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c01705,>,,,,,,Kinase set,1 µM
EUB0001048a_SRPK1,MSC2711186A,EUB0001048a,Fc2c1nc([nH]c1ccc2Cl)-c3nc(ccn3)NCc4c(nccc4)N(S(=O)(=O)C)C,"InChI=1S/C19H17ClFN7O2S/c1-28(31(2,29)30)19-11(4-3-8-23-19)10-24-14-7-9-22-17(26-14)18-25-13-6-5-12(20)15(21)16(13)27-18/h3-9H,10H2,1-2H3,(H,25,27)(H,22,24,26)",WBFJDKLBAAHKIL-UHFFFAOYSA-N,Protein Kinase,SRPK1,6732,Q96SB4,SFRSK1,Inhibitor,MSC2705360A,2.7,IC50,Biochemical activity assay (Reaction Biology),https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c01705,=,44,IC50,"NanoBRET assay (in HEK293T cells, lysed mode)",https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c01705,=,,Kinome Scan (Reaction Biology),395,"Screened at 1 µM, closest targets as % of control: STK2 (3.83%), SRPK1 (8.76%), SRPK2 (13.94%), PIM1 (54.68%), PKCe(55.07%), PKN1(55.56%); In-vitro potency of closest targets (Radioactive assay, Reaction Biology): IC50(CLK1) >10 µM, IC50(CLK2) >10 µM, IC50(CLK3) >10 µM, IC50(CLK4) >10 µM, IC50(DYRK1A) >10 µM, IC50(DYRK1B) >10 µM, IC50(DYRK2) >10 µM, IC50(DYRK3) >10 µM, https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c01705#;",https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c01705,Kinase set,1 µM
EUB0001046a_SRPK2,MSC2705360A,EUB0001046a,Clc4cc1c([nH]c(c1)-c2nc(ccn2)NCc3c(nccc3)N(S(=O)(=O)C)C)cc4,"InChI=1S/C20H19ClN6O2S/c1-27(30(2,28)29)20-13(4-3-8-23-20)12-24-18-7-9-22-19(26-18)17-11-14-10-15(21)5-6-16(14)25-17/h3-11,25H,12H2,1-2H3,(H,22,24,26)",MXAVRMOXZMBKGE-UHFFFAOYSA-N,Protein Kinase,SRPK2,6733,P78362,SFRSK2,Negative control for MSC2711186A,,10000,IC50,Biochemical activity assay (Reaction Biology),https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c01705,>,50000,IC50,"NanoBRET assay (in HEK293T cells, lysed mode)",https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c01705,>,,,,,,Kinase set,1 µM
EUB0001048a_SRPK2,MSC2711186A,EUB0001048a,Fc2c1nc([nH]c1ccc2Cl)-c3nc(ccn3)NCc4c(nccc4)N(S(=O)(=O)C)C,"InChI=1S/C19H17ClFN7O2S/c1-28(31(2,29)30)19-11(4-3-8-23-19)10-24-14-7-9-22-17(26-14)18-25-13-6-5-12(20)15(21)16(13)27-18/h3-9H,10H2,1-2H3,(H,25,27)(H,22,24,26)",WBFJDKLBAAHKIL-UHFFFAOYSA-N,Protein Kinase,SRPK2,6733,P78362,SFRSK2,Inhibitor,MSC2705360A,81,IC50,Biochemical activity assay (Reaction Biology),https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c01705,=,149,IC50,"NanoBRET assay (in HEK293T cells, lysed mode)",https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c01705,=,,Kinome Scan (Reaction Biology),395,"Screened at 1 µM, closest targets as % of control: STK2 (3.83%), SRPK1 (8.76%), SRPK2 (13.94%), PIM1 (54.68%), PKCe(55.07%), PKN1(55.56%); In-vitro potency of closest targets (Radioactive assay, Reaction Biology): IC50(CLK1) >10 µM, IC50(CLK2) >10 µM, IC50(CLK3) >10 µM, IC50(CLK4) >10 µM, IC50(DYRK1A) >10 µM, IC50(DYRK1B) >10 µM, IC50(DYRK2) >10 µM, IC50(DYRK3) >10 µM, https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c01705#;",https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c01705,Kinase set,1 µM
EUB0001046a_SRPK3,MSC2705360A,EUB0001046a,Clc4cc1c([nH]c(c1)-c2nc(ccn2)NCc3c(nccc3)N(S(=O)(=O)C)C)cc4,"InChI=1S/C20H19ClN6O2S/c1-27(30(2,28)29)20-13(4-3-8-23-20)12-24-18-7-9-22-19(26-18)17-11-14-10-15(21)5-6-16(14)25-17/h3-11,25H,12H2,1-2H3,(H,22,24,26)",MXAVRMOXZMBKGE-UHFFFAOYSA-N,Protein Kinase,SRPK3,26576,Q9UPE1,MSSK1,Negative control for MSC2711186A,,3500,IC50,Biochemical activity assay (Reaction Biology),https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c01705,=,9962,IC50,"NanoBRET assay (in HEK293T cells, lysed mode)",https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c01705,=,,,,,,Kinase set,1 µM
EUB0001048a_SRPK3,MSC2711186A,EUB0001048a,Fc2c1nc([nH]c1ccc2Cl)-c3nc(ccn3)NCc4c(nccc4)N(S(=O)(=O)C)C,"InChI=1S/C19H17ClFN7O2S/c1-28(31(2,29)30)19-11(4-3-8-23-19)10-24-14-7-9-22-17(26-14)18-25-13-6-5-12(20)15(21)16(13)27-18/h3-9H,10H2,1-2H3,(H,25,27)(H,22,24,26)",WBFJDKLBAAHKIL-UHFFFAOYSA-N,Protein Kinase,SRPK3,26576,Q9UPE1,MSSK1,Inhibitor,MSC2705360A,0.59,IC50,Biochemical activity assay (Reaction Biology),https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c01705,=,20,IC50,"NanoBRET assay (in HEK293T cells, lysed mode)",https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c01705,=,,Kinome Scan (Reaction Biology),395,"Screened at 1 µM, closest targets as % of control: STK2 (3.83%), SRPK1 (8.76%), SRPK2 (13.94%), PIM1 (54.68%), PKCe(55.07%), PKN1(55.56%); In-vitro potency of closest targets (Radioactive assay, Reaction Biology): IC50(CLK1) >10 µM, IC50(CLK2) >10 µM, IC50(CLK3) >10 µM, IC50(CLK4) >10 µM, IC50(DYRK1A) >10 µM, IC50(DYRK1B) >10 µM, IC50(DYRK2) >10 µM, IC50(DYRK3) >10 µM, https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c01705#;",https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c01705,Kinase set,1 µM
EUB0001489b_STK17A,CKJB71,EUB0001489b,CN1CCN(C(=O)c2ccc3cc2OCCOCCNc2ccn4ncc-3c4n2)CC1,"InChI=1S/C22H26N6O3/c1-26-7-9-27(10-8-26)22(29)17-3-2-16-14-19(17)31-13-12-30-11-5-23-20-4-6-28-21(25-20)18(16)15-24-28/h2-4,6,14-15H,5,7-13H2,1H3,(H,23,25)",DDXOMWWURGFLKK-UHFFFAOYSA-N,Protein Kinase,STK17A,9263,Q9UEE5,DRAK1,Negative control for CK156,,,,,,,45000,IC50,Nano BRET assay (intact HEK293T cells),https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c00173,>,,"Kinase panel (DSF assay, in-house data SGC Frankfurt)",90,"Screened at 20 µM, dTm values of closest targets: dTm(BMP2K) = 6.8 K, dTm(AAK1) = 4.2 K, dTm(STK6) = 4.2 K, dTm(PLK4) = 4.0 K, dTm(STK3) = 3.4 K, dTm(MAP3K5) = 3.32 K, dTm(FLT1) = 2.9 K, dTm(CLK1) = 2.9 K, dTm(STK10) = 2.3 K, dTm(PIM3) = 2.1 K, dTm(STK17A) = 1.5K;",https://www.thesgc.org/chemical-probes/ck156,Kinase set,1 µM
EUB0000620a_TNK2,AIM 100,EUB0000620a,C1(NC[C@H]2OCCC2)=C(C(C3=CC=CC=C3)=C(C4=CC=CC=C4)O5)C5=NC=N1,"InChI=1S/C23H21N3O2/c1-3-8-16(9-4-1)19-20-22(24-14-18-12-7-13-27-18)25-15-26-23(20)28-21(19)17-10-5-2-6-11-17/h1-6,8-11,15,18H,7,12-14H2,(H,24,25,26)/t18-/m0/s1",XNFHHOXCDUAYSR-SFHVURJKSA-N,Protein Kinase,TNK2,10188,Q07912,"p21cdc42Hs, ACK, ACK1",Inhibitor,,21.58,IC50,"Radiometric enzyme assay (HotSpot assay, Reaction Biology)",https://pubmed.ncbi.nlm.nih.gov/22566699/,=,,,,,,,Kinase panel (DSF assay),100,"Screened at 20 µM, closest targets with dTm >5K: dTm(STK6) = 8.23K, dTm(STK10) = 7.64 K, dTm(PLK4) = 5.33 K, further targets dTm 3-5K: dTm(BMX) = 4.14 K, dTm(ULK3) = 4.13 K, dTm(SLK) = 3.82 K, dTm(AURKB) = 3.81 K, dTm(ABL1) = 3.52 K; HotSpot assay (Reaction Biology), 30 targets, in-vitro potencies of closest targets: IC50(ABL1) = 705.9 nM, IC50(BTK) = 871.7 nM, IC50(LCK) = 432.3 nM, IC50(LYN) = 346.7 nM, https://pubmed.ncbi.nlm.nih.gov/22566699/;",https://pubmed.ncbi.nlm.nih.gov/22566699/,Kinase set,100 nM
EUB0001543a_TYK2,BMS 986165,EUB0001543a,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,"InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3",BZZKEPGENYLQSC-FIBGUPNXSA-N,Protein Kinase,TYK2,7297,P29597,JTK1,Allosteric inhibitor,,0.2,IC50,"HTRF assay (TYK2, JH2 domain with 1 mM ATP)",https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00444,=,2,IC50,"STAT-dependent luciferase reporter assay in PBMCs (IFNα-stimulation, measuring STAT5 phosphorylation in CD3+ T-cells as end point, TYK2/JAK1 dependent signaling)",https://pubmed.ncbi.nlm.nih.gov/31318208/,=,,Kinase panel (literature),249,"All >1000-fold selective except BMPR2 (IC50 = 193 nM, ~960-fold selective); Selective within JAK family (HTRF assay, 1 mM ATP): IC50(JAK1) >10 µM, IC50(JAK2) >10 µM, IC50(JAK3) >10 µM, IC50(TYK2, JH1 domain) >10 µM, IC50(TYK2, JH2 domain) = 0.2 nM (https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00444);",https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00444,Kinase set,100 nM
EUB0001542aTs_TYK2,PF-06700841,EUB0001542aTs,Cc1ccc(S(=O)(=O)O)cc1.Cn1cc(Nc2nccc(N3CC4CCC(C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1,"InChI=1S/C18H21F2N7O.C7H8O3S/c1-25-8-11(7-22-25)23-17-21-5-4-15(24-17)26-9-12-2-3-13(10-26)27(12)16(28)14-6-18(14,19)20;1-6-2-4-7(5-3-6)11(8,9)10/h4-5,7-8,12-14H,2-3,6,9-10H2,1H3,(H,21,23,24);2-5H,1H3,(H,8,9,10)/t12?,13?,14-;/m0./s1",FAKGOYNHHHOTEN-WTMFEIAXSA-N,Protein Kinase,TYK2,7297,P29597,JTK1,inhibitor,,23,IC50,"Microfluidic assay (phosphorylation of synthetic peptide by recombinant human TYK2, at 1 mM ATP, Caliper Life Science)",https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00917,=,,,,,,,Kinase panel (Carna Biosciences),306,"Screened at 1 µM, conc. ATP = Km, closest targets >90% of inhibition: AURKA/TPX2 (97%), TNK1 (94%), JAK3(92%), QIK(91%); Screened at 10 µM against a broad panel of receptors, ion channels, and transporters (CEREP Wide Ligand Profile screen), in-vitro potency of closest target: IC50(KDR) = 1600 nM, others <50% inhibition, IC50 follow-up in cell-based assay (NovaScreen): IC50(KDR) >30 µM (https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00917);",https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b00917,Kinase set,1 µM
EUB0000116c_CTNNB1,ICG-001,EUB0000116c,O=C1[C@H](Cc2ccc(O)cc2)N2C(=O)CCN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2ccccc12,"InChI=1S/C33H32N4O4/c38-27-15-13-23(14-16-27)19-29-32(40)35(21-26-11-6-10-25-9-4-5-12-28(25)26)22-30-36(18-17-31(39)37(29)30)33(41)34-20-24-7-2-1-3-8-24/h1-16,29-30,38H,17-22H2,(H,34,41)/t29-,30+/m0/s1",HQWTUOLCGKIECB-XZWHSSHBSA-N,Apoptosis regulator,CTNNB1,1499,P35222,"CTNNB, MRD19, EVR7",Inhibitor,,,,,,,3000,IC50,TOPFLASH reporter assay (using SW480 colon carcinoma cells),https://www.pnas.org/doi/10.1073/pnas.0404875101?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed,=,,,,"No inhibition of AP-1 and CRE (IC50 >100 µM, TOPFLASH reporter assay); no interaction with the beta-catenin transcriptional coactivator p300.",https://www.pnas.org/doi/10.1073/pnas.0404875101?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed,Other targets,1 µM
EUB0001574a_UCHL1@Protease,8RK64,EUB0001574a,N#CN1CC[C@H](C(=O)Nc2nc3c(s2)CN(C(=O)CN=[N+]=[N-])CC3)C1,"InChI=1S/C14H16N8O2S/c15-8-21-3-1-9(6-21)13(24)19-14-18-10-2-4-22(7-11(10)25-14)12(23)5-17-20-16/h9H,1-7H2,(H,18,19,24)/t9-/m0/s1",KIWKRCCIHSGWQS-VIFPVBQESA-N,,UCHL1@Protease,7345,P09936,"HEL-117, HEL-S-53, NDGOA, PARK5, PGP 9.5, PGP9.5, PGP95, SPG79, Uch-L1",covalent inhibitor,JYQ88,320,IC50,Biochemical activity assay using a fluorogenic Ub-Rho-morpholine (inhibition of UCHL1 using 2 mM cysteine),https://pubs.acs.org/doi/10.1021/jacs.0c07726,0,3000,IC50,"Activity-based protein profiling assay (ABPP experiment, inhibition of UCHL1 in HEK293 cells)",https://pubs.acs.org/doi/10.1021/jacs.0c07726,<,0,GPCR panel (PDSD screen),45,"Screened at 10 µM, in-vitro potency of closest target: Ki(SIGMAR1) = 3.429 µM; No inhibition of other deubiquitylating enzymes in activity-based protein profiling assay (ABPP) experiment; Selectivity outside target family (2‐step labeling Pull‐down proteomics experiment): off-target PARK7 (has cysteine in active site) identified",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!gpcrscandataview/8RK64,Other targets set,1 µM
EUB0001486a_GLS,A-426,EUB0001486a,O=C(Cc1ccccc1)Nc1nnc(N2CC[C@@H]3[C@H]2CN3c2cccnn2)s1,"InChI=1S/C19H19N7OS/c27-17(11-13-5-2-1-3-6-13)21-18-23-24-19(28-18)25-10-8-14-15(25)12-26(14)16-7-4-9-20-22-16/h1-7,9,14-15H,8,10-12H2,(H,21,23,27)/t14-,15-/m1/s1",VCDTXROFDBHEIP-HUUCEWRRSA-N,,GLS,2744,O94925,"GLS, GLS1, KIAA0838",Negative control for A-446,,30000,IC50,GLS Enzyme activity assay,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-446,>,,,,,,,,,Selectivity within target family (GLS2 enzyme activity assay): IC50 >30 µM (>1000 fold),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-446,Other targets set,100 nM
EUB0001120a_GLS,A-446,EUB0001120a,C(C(Nc1nnc(N2C[C@H]3C[C@@H]2CN3c2cccnn2)s1)=O)c1ccccc1,"InChI=1S/C19H19N7OS/c27-17(9-13-5-2-1-3-6-13)21-18-23-24-19(28-18)26-12-14-10-15(26)11-25(14)16-7-4-8-20-22-16/h1-8,14-15H,9-12H2,(H,21,23,27)/t14-,15-/m1/s1",DLNFTRSEHUWEGO-HUUCEWRRSA-N,,GLS,2744,O94925,"GLS, GLS1, KIAA0838",Inhibitor,A-426,31,IC50,GLS Enzyme activity assay,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-446,0,10.5,IC50,CTG assay in A549 cells,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-446,0,0,GPCR panel (PDSD screen),45,"Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potency of closest targets: Ki(HTR7) >10 µM, Ki(GABA/PBR) >10 µM, Ki(HTR1D) = 6453.57 nM; Selectivity within target family (GLS2 enzyme activity assay): IC50 >30 µM (> 1000 fold); Selectivity outside target family (probe selectivity observed in Proteome Integral Stability Assay): closest targets in CEREP binding assay at 10 μM (percent inhibition of control specific binding): ADORA3 (agonist radioligand) = 76.6%, CHRM1 (antagonist radioligand) = 92.6%, CHRM2 (antagonist radioligand) = 71.5% ",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-446,Other targets set,100 nM
EUB0000246b_BRD4@BD2,ABBV-744,EUB0000246b,CCNC(=O)c1cc2c(-c3cc(C(C)(C)O)ccc3Oc3c(C)cc(F)cc3C)cn(C)c(=O)c2[nH]1,"InChI=1S/C28H30FN3O4/c1-7-30-26(33)22-13-20-21(14-32(6)27(34)24(20)31-22)19-12-17(28(4,5)35)8-9-23(19)36-25-15(2)10-18(29)11-16(25)3/h8-14,31,35H,7H2,1-6H3,(H,30,33)",OEDSFMUSNZDJFD-UHFFFAOYSA-N,Bromodomain,BRD4@BD2,23476,O60885,"HUNKI, MCAP, CAP, HUNK1",Inhibitor,,1.6,Ki,TR-FRET binding assay (BD2),https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00628,0,27.5,IC50,NanoBRET assay (BD2),https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00628,0,0,BROMOScan (Discoverx),22,"290-fold selectivity relative to the BD1 domains of BRD2, BRD3 and BRD4; Clean in screen against 75 kinases",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00628,Epigenetic set,1 µM
EUB0000246b_BRD2@BD2,ABBV-744,EUB0000246b,CCNC(=O)c1cc2c(-c3cc(C(C)(C)O)ccc3Oc3c(C)cc(F)cc3C)cn(C)c(=O)c2[nH]1,"InChI=1S/C28H30FN3O4/c1-7-30-26(33)22-13-20-21(14-32(6)27(34)24(20)31-22)19-12-17(28(4,5)35)8-9-23(19)36-25-15(2)10-18(29)11-16(25)3/h8-14,31,35H,7H2,1-6H3,(H,30,33)",OEDSFMUSNZDJFD-UHFFFAOYSA-N,Bromodomain,BRD2@BD2,6046,P25440,"KIAA9001, RING3, D6S113E, NAT, FSRG1",Inhibitor,,4.6,Ki,TR-FRET binding assay (BD2),https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00628,0,,,,,,0,BROMOScan (Discoverx),22,"290-fold selectivity relative to the BD1 domains of BRD2, BRD3 and BRD4; Clean in screen against 75 kinases",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00628,Epigenetic set,1 µM
EUB0000246b_BRD3@BD2,ABBV-744,EUB0000246b,CCNC(=O)c1cc2c(-c3cc(C(C)(C)O)ccc3Oc3c(C)cc(F)cc3C)cn(C)c(=O)c2[nH]1,"InChI=1S/C28H30FN3O4/c1-7-30-26(33)22-13-20-21(14-32(6)27(34)24(20)31-22)19-12-17(28(4,5)35)8-9-23(19)36-25-15(2)10-18(29)11-16(25)3/h8-14,31,35H,7H2,1-6H3,(H,30,33)",OEDSFMUSNZDJFD-UHFFFAOYSA-N,Bromodomain,BRD3@BD2,8019,Q15059,"RING3L, ORFX, KIAA0043",Inhibitor,,4.9,Ki,TR-FRET binding assay (BD2),https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00628,0,,,,,,0,BROMOScan (Discoverx),22,"290-fold selectivity relative to the BD1 domains of BRD2, BRD3 and BRD4; Clean in screen against 75 kinases",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00628,Epigenetic set,1 µM
EUB0000246b_BRDT@BD2,ABBV-744,EUB0000246b,CCNC(=O)c1cc2c(-c3cc(C(C)(C)O)ccc3Oc3c(C)cc(F)cc3C)cn(C)c(=O)c2[nH]1,"InChI=1S/C28H30FN3O4/c1-7-30-26(33)22-13-20-21(14-32(6)27(34)24(20)31-22)19-12-17(28(4,5)35)8-9-23(19)36-25-15(2)10-18(29)11-16(25)3/h8-14,31,35H,7H2,1-6H3,(H,30,33)",OEDSFMUSNZDJFD-UHFFFAOYSA-N,Bromodomain,BRDT@BD2,676,Q58F21,"BRD6, CT9",Inhibitor,,1,Ki,TR-FRET binding assay (BD2),https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00628,0,,,,,,0,BROMOScan (Discoverx),22,"290-fold selectivity relative to the BD1 domains of BRD2, BRD3 and BRD4; Clean in screen against 75 kinases",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00628,Epigenetic set,1 µM
EUB0001109a_BCAT1,BAY-069,EUB0001109a,Cc1ccccc1Oc1cc(c2ccccc2c1[Cl])N1C(C=C(C(F)(F)F)NC1=O)=O,"InChI=1S/C22H14ClF3N2O3/c1-12-6-2-5-9-16(12)31-17-10-15(13-7-3-4-8-14(13)20(17)23)28-19(29)11-18(22(24,25)26)27-21(28)30/h2-11H,1H3,(H,27,30)",UNSHMXUHOHBLIQ-UHFFFAOYSA-N,,BCAT1,586,P54687,"BCAT1, BCT1, ECA39",Inhibitor,BAY-771,27,IC50,Biochemical assay,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-069,0,358,IC50,"Cellular mechanistic assay (BCAA measurement in U-87-MG, high BCAT1 expressing cells)",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-069,0,0,Safety screen (Eurofins),77,"Clean selectivity profile with no target activity >50%; Screened in enzymatic assays against other transaminases: IC50(GOT1/2) >50 µM; Screened at 6 µM against 30 proteases, all targets IC50 >10 µM; Screened at 2 µM against 45 kinases (enzymatic assays), clean selectivity profile with all kinases IC50 >7 µM",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-069,Other targets set,1 µM
EUB0001109a_BCAT2,BAY-069,EUB0001109a,Cc1ccccc1Oc1cc(c2ccccc2c1[Cl])N1C(C=C(C(F)(F)F)NC1=O)=O,"InChI=1S/C22H14ClF3N2O3/c1-12-6-2-5-9-16(12)31-17-10-15(13-7-3-4-8-14(13)20(17)23)28-19(29)11-18(22(24,25)26)27-21(28)30/h2-11H,1H3,(H,27,30)",UNSHMXUHOHBLIQ-UHFFFAOYSA-N,,BCAT2,587,O15382,"BCAT2, BCATM, BCT2, ECA40",Inhibitor,BAY-771,130,IC50,Biochemical assay,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-069,0,874,IC50,"Cellular mechanistic assay (BCAA measurement in MDA-MB-231, high BCAT2 expressing cells)",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-069,0,0,Safety screen (Eurofins),77,"Clean selectivity profile with no target activity >50%; Screened in enzymatic assays against other transaminases: IC50(GOT1/2) >50 µM; Screened at 6 µM against 30 proteases, all targets IC50 >10 µM; Screened at 2 µM against 45 kinases (enzymatic assays), clean selectivity profile with all kinases IC50 >7 µM",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-069,Other targets set,1 µM
EUB0001121a_CCR1,BAY-3153,EUB0001121a,CCOc1cc(ccc1[Cl])N1C2CN(CC1COC2)C([C@H]1C[C@@H](CN1c1ccc(cc1)[Cl])O)=O,"InChI=1S/C25H29Cl2N3O4/c1-2-34-24-9-18(7-8-22(24)27)30-19-11-28(12-20(30)15-33-14-19)25(32)23-10-21(31)13-29(23)17-5-3-16(26)4-6-17/h3-9,19-21,23,31H,2,10-15H2,1H3/t19?,20?,21-,23+/m0/s1",LZSPYTNDRPEZBK-OXYJHPMESA-N,GPCR,CCR1,1230,P32246,"CKR-1, MIP1aR, CD191",Antagonist,BAY-173,,,,,,3,IC50,CCR1 cellular Ca2+-flux assay (using calcium-optimized stable cell line #HTS005C),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-3153,0,0,GPCR panel (PDSP screen),45,"Screened at 10 µM, in-vitro potencies of closest targets: Ki(TMEM97) = 1476.05 nM, Ki(SIGMAR1) = 1828.52 nM, Ki(GABA/PBR) = 1805.52 nM, Ki(OPRK1) = 3005.38 nM; Screened in enzymatic assays against other CCR family members: inactive on hCCR3, IC50(hCCR2) >30 µM, IC50(hCCR4) >30 µM, IC50(hCCR%) >30 µM, IC50(hCCR6) >30 µM, IC50(hCCR7) >30 µM, IC50(hCCR8) >30 µM, IC50(hCCR9) >30 µM, IC50(hCCR10) >30 µM, IC50(hCXCR1) >30 µM, IC50(hCXCR2) >30 µM, IC50(hCXCR3) >30 µM, IC50(hCXCR4) >30 µM,  IC50(hCXCR5) >30 µM",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-3153,GPCR set,100 nM
EUB0001110a_TRPA1,BAY-390,EUB0001110a,FC1=CC=C(N[C@H]2[C@](O)(CCCC2)C(F)(F)F)C=C1,"InChI=1S/C13H15F4NO/c14-9-4-6-10(7-5-9)18-11-3-1-2-8-12(11,19)13(15,16)17/h4-7,11,18-19H,1-3,8H2/t11-,12-/m1/s1",IESAJAZKMLPVIB-VXGBXAGGSA-N,Ion Channel,TRPA1,8989,O75762,"TRPA1, ANKTM1",Inhibitor,BAY-9897,16,IC50,FLIPR Ca2+ assay (human TRPA1 overexpressing cell line CHO hTRPA1 GCaMP6),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-390,0,82,IC50,"Ephys (Patchliner, CHO cells)",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-390,0,0,GPCR panel (PDSD screen),45,"Screened at 10 µM, in vitro-potencies of closest targets: Ki(SLC6A3) = 1377.15 nM, Ki(HTR2A) = 2576.32 nM; Selectivity against family members in biochemical assays, all >30 fold: IC50(hTRPV1) >25 µM, IC50(hTRPV4) >25 µM, IC50(hTRPC3) >25 µM, IC50(hTRPC5) = 5.6 µM, IC50(hTRPC6) >25 µM, IC50(hKCNK9, TASK-3) >30 µM, IC50(hCACNA1H, Cav3.2) >25 µM; Selectivity screen in Eurofins Lead Profiling Screen, GPCR Profiling Screen and Bayer Kinase Panel was performed, in-vitro potencies of closest targets: Ki (SLC6A3, human) = 0.9 μM, Ki(PGR, human) = 4 μM, EC50(ESR1) = 2.1 μM",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-390,Ion Channel,100 nM
EUB0001131a_PTGFR,BAY-403,EUB0001131a,Cc1c(N2CCNCC2)nc2ccc(Br)cc2c1C(=O)NC[C@H](CCC(=O)O)c1ccccc1Cl,"InChI=1S/C26H28BrClN4O3/c1-16-24(20-14-18(27)7-8-22(20)31-25(16)32-12-10-29-11-13-32)26(35)30-15-17(6-9-23(33)34)19-4-2-3-5-21(19)28/h2-5,7-8,14,17,29H,6,9-13,15H2,1H3,(H,30,35)(H,33,34)/t17-/m0/s1",ZZSNHHKTFMLWFY-KRWDZBQOSA-N,GPCR,PTGFR,5737,P43088,FP,Negative control for BAY-6672,,10000,IC50,Panlabs hFP-R binding assay,https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BAY-6672,>,1200,IC50,"Human FP-R assay (Chem-1 cells expressing human FP receptor, Eurofins)",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00834,0,0,GPCR panel (PDSP screen),45,"Screened at 10 µM, in-vitro potencies of closest targets: Ki(HTR3A) = 584.83 nM, Ki(TMEM97) = 1099.22 nM, Ki(ADRA2A) = 8468.01 nM",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00834,GPCR set,100 nM
EUB0000220b_SMYD2,BAY-598,EUB0000220b,CCN(C(CO)=O)[C@H]1CN(C(Nc2cccc(c2)OC(F)F)=NC#N)N=C1c1ccc(c(c1)[Cl])[Cl],"InChI=1S/C22H20Cl2F2N6O3/c1-2-31(19(34)11-33)18-10-32(30-20(18)13-6-7-16(23)17(24)8-13)22(28-12-27)29-14-4-3-5-15(9-14)35-21(25)26/h3-9,18,21,33H,2,10-11H2,1H3,(H,28,29)/t18-/m0/s1",OTTJIRVZJJGFTK-SFHVURJKSA-N,HMT,SMYD2,56950,Q9NRG4,"HSKM-B, KMT3C, ZMYND14",Inhibitor,BAY-369 (racemate),27,IC50,Scintillation proximity assay,https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01890,0,,,,,,0,KinomeScan (DiscoverX),456,"Screened at 1 µM, closest target as % of contr.: RIOK3 (46%); Screened at 10 µM against Eurofins-Panlabs screen against 68 targets, closest targets as % of inhibition: SLC6A2 (NET, 78%), SLC6A3 (DAT, 71 %); Screened at 1 µM, 10 µM, and 50 µM, against 32 methyltransferases (enzyme activity assays, including closely related family members SMYD3, SUV420H1, and SUV420H2) >100-fold selective; IC50(SMYD3) = 3 μM, IC50(PAR1) = 1.7 µM",https://www.thesgc.org/chemical-probes/BAY-598,Epigenetic set,1 µM
EUB0001111a_PTGFR,BAY-6672,EUB0001111a,Cc1c(N2CCCC2)nc2ccc(Br)cc2c1C(=O)NC[C@H](CCC(=O)O)c1ccccc1Cl.Cl.O,"InChI=1S/C26H27BrClN3O3/c1-16-24(20-14-18(27)9-10-22(20)30-25(16)31-12-4-5-13-31)26(34)29-15-17(8-11-23(32)33)19-6-2-3-7-21(19)28/h2-3,6-7,9-10,14,17H,4-5,8,11-13,15H2,1H3,(H,29,34)(H,32,33)/t17-/m0/s1",YQOLEILXOBUDMU-KRWDZBQOSA-N,GPCR,PTGFR,5737,P43088,FP,Antagonist,BAY-403,22,IC50,Panlabs hFP-R binding assay,https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BAY-6672,0,11,IC50,"Human FP-R assay (Chem-1 cells expressing human FP receptor, Eurofins)",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00834,0,0,GPCR panel (PDSP screen),45,"Screened at 10 µM, closest target as % of inhibition: HTR3A (38%); Screened against other human prostanoid receptor (binding assay, Eurofins/Panlabs): IC50(PTGFR) = 22 nM, IC50(EP1) >10 µM, IC50(EP2) >10 µM, IC50(EP3) >10 µM, IC50(EP4) >10 µM, IC50(IP) >10 µM, IC50(DP) >10 µM, IC50(CRTH2) >10 µM, >420-fold selective; Screened in cell-based assay (Eurofins/Panlabs): IC50(TBXA2R) = 2.2 µM, 200-fold selective; Screened at 10 µM against 77 other targets (Leadprofiling Screen, Panlabs), closest target as % of inhibition: TBXAS1 (33%); Screened at 10 µM against 8 ion channels (Ion channel profiler, Eurofins): IC20(Nav1.5) >10 μM, IC20(Kv4.3/KChIP2) >10 μM, IC20(Cav1.2) >10 μM, IC20(Kv1.5) >10 μM, IC20(KCNQ/minK) >10 μM, IC20(herG) >10 μM, IC20(HCN4) >10 μM, IC20(Kir2.1) >10 μM",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00834,GPCR set,100 nM
EUB0002354aCl_PDE9A,BAY-7081,EUB0002354aCl,CCC[C@H]1CNCC2=C1NC(C(C#N)=C2N3CCC4(CC4)CC3)=O.Cl,"InChI=1S/C19H26N4O/c1-2-3-13-11-21-12-15-16(13)22-18(24)14(10-20)17(15)23-8-6-19(4-5-19)7-9-23/h13,21H,2-9,11-12H2,1H3,(H,22,24)/t13-/m0/s1",NPPMVTBTTJNVKP-ZDUSSCGKSA-N,Hydrolase,PDE9A,5152,O76083,HSPDE9A2,inhibitor,BAY-7081,15,IC50,Scintillation Proximity Assay,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791655/,0,995,EC50,Cellular PDE9A assay (using recombinant CHO cell line stably expressing murine PDE9A),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791655/,0,0,Eurofins Panlabs screen,75,"Screened at 10 µM (panel of GPCRs, ion channels, transporters), closest targets as % of inhibition: PDE1A (7.7%), PDE2A (3.5%), PDE3A (-1.3%), PDE3B (0.8%), PDE4A (6.8%), PDE4B (10.6%), PDE4C (28.6%), PDE4D (19.1%), PDE5A (12.2%), PDE6 (16.7%), PDE7A (-1.6%), PDE7B (-2.1%), PDE8A (2.9%), PDE10A (1.6%), PDE11A (1.3%); In-vitro potency (Scintillation Proximity Assay): IC50(PDE1) = 0.753 nM, IC50(PDE2A) >10000 nM, IC50(PDE3B) >10000 nM, IC50(PDE4B) = 3960 nM, IC50(PDE5A) = 2980 nM, IC50(PDE6) = 1560 nM, IC50(PDE7B) >10000 nM, IC50(PDE8A) = 1490 nM, IC50(PDE10A) >10000 nM, IC50(PDE11A) = 6600 nM",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791655/,Other targets set,1 µM
EUB0002186bCl_PDE9A,BAY-7424,EUB0002186bCl,CCC[C@@H]1CNCc2c1[nH]c(=O)c(C#N)c2N1CCC2(CC1)CC2.Cl,"InChI=1S/C19H26N4O/c1-2-3-13-11-21-12-15-16(13)22-18(24)14(10-20)17(15)23-8-6-19(4-5-19)7-9-23/h13,21H,2-9,11-12H2,1H3,(H,22,24)/t13-/m1/s1",NPPMVTBTTJNVKP-CYBMUJFWSA-N,Hydrolase,PDE9A,5152,O76083,HSPDE9A2,Negative control for BAY-7081,,10000,IC50,Scintillation Proximity Assay,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-7081,>,10000,EC50,Cellular PDE9A assay (using recombinant CHO cell line stably expressing murine PDE9A),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791655/,>,0,Eurofins Panlabs screen,15,"Screened at 10 µM against PDE1A, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6, PDE7A, PDE7B, PDE8A, PDE10A, PDE11A, closest target as % of inhibiton: PDE9A(62%)",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-7081,Other targets set,1 µM
EUB0001132a_TRPA1,BAY-9897,EUB0001132a,COc1cc(N[C@@H]2CCCC[C@]2(O)C(F)(F)F)ccc1F,"InChI=1S/C14H17F4NO2/c1-21-11-8-9(5-6-10(11)15)19-12-4-2-3-7-13(12,20)14(16,17)18/h5-6,8,12,19-20H,2-4,7H2,1H3/t12-,13-/m1/s1",CWRARANSONEPBZ-CHWSQXEVSA-N,Ion Channel,TRPA1,8989,O75762,"TRPA1, ANKTM1",Negative control for BAY-390,,25000,IC50,FLIPR Ca2+ assay (human TRPA1 overexpressing cell line CHO hTRPA1 GCaMP6),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-390,>,,,,,,0,GPCR panel (PDSD screen),45,"Screened at 10 µM, in-vitro potency of closest target: Ki(HRH2) = 9781.38 nM; Selectivity against family members in biochemical assays, all >30 fold: IC50(hTRPV1) >25 µM, IC50(hTRPV4) >25 µM, IC50(hTRPC3) n.d., IC50(hTRPC5) = 10.0 µM, IC50(hTRPC6) >30 µM, IC50(hKCNK9 (TASK-3)) n.d., IC50(hCACNA1H (Cav3.2)) n.d.",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BAY-390,Ion Channel,100 nM
EUB0000314c_NR3C1,BI 653048,EUB0000314c,CCS(c1cc2cc(C[C@](CC(C)(C)c3ccc(cc3C(N)=O)F)(C(F)(F)F)O)[nH]c2cn1)(=O)=O,"InChI=1S/C19H26N4OS/c1-13-7-17(8-14(2)21-13)9-16-5-4-6-23(11-16)12-18-10-20-19(25-18)22-15(3)24/h7-8,10,16H,4-6,9,11-12H2,1-3H3,(H,20,22,24)/t16-/m1/s1",CYFBRQHYEQKYHH-MRXNPFEDSA-N,Nuclear Receptor,NR3C1,2908,P04150,GR,Agonist,BI-3047,55,IC50,Fluorescence polarization assay,https://pubmed.ncbi.nlm.nih.gov/25516791/,0,23,IC50,Fibroblast IL-6 assay (suppression of IL-1 induced IL-6 production in human foreskin fibroblasts),https://pubmed.ncbi.nlm.nih.gov/25516791/,0,0,Eurofins-Panlabs screen,49,"Screened at 10 µM; >100 fold selective against related nuclear receptors (PGR, NR3C2, ESR1, AR); Screened at 10 µM against 45 GPCRs, closest targets >30% of inhibition: DRD5 (34%), HTR3A (32%); Screened at 1 µM against 468 kinases (KinomeScan, DiscoverX), closest targets <45% of control: LATS2 (40%), NDR2 (45%), NEK1 (45%)",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI%20653048,NR set,1 µM
EUB0002187a_HSD17B13,BI-0955,EUB0002187a,CCn1c(=O)c(C)cn(Cc2nnc(-c3ccc(F)c(OC)c3F)s2)c1=O,"InChI=1S/C17H16F2N4O3S/c1-4-23-16(24)9(2)7-22(17(23)25)8-12-20-21-15(27-12)10-5-6-11(18)14(26-3)13(10)19/h5-7H,4,8H2,1-3H3",TVCKWZATGBVYEN-UHFFFAOYSA-N,Oxidoreductase,HSD17B13,345275,Q7Z5P4,"FLDP, HMFN0376, NIIL497, SCDR9, SDR16C3",Negative control for BI-3231,,10000,Ki,Enzyme activity assay,https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c01884,>,10000,IC50,Cellular human HSD17B13 assay (custom-made stably overexpressing hHSD17B13-Myc/DDK HEK293 cells),https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c01884,>,0,SafetyScreen44™ (Eurofins),44,"Screened at 10 µM, closest targets as % of control: COX2 (49%), 5HT2B/H agonist (45%)",https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/BI-3231,Other targets set,1 µM
EUB0001182a_HCV:NS3,BI-1230,EUB0001182a,CC(C(Nc1scc(c(cc2O[C@@H]3C[C@H]4C(N[C@]5(C(O)=O)CC5/C=C/CCCCC[C@H](NC(OC6CCCC6)=O)C(N4C3)=O)=O)nc7c2ccc(OC)c7C)n1)=O)C,"InChI=1S/C42H52N6O9S/c1-23(2)36(49)46-40-44-31(22-58-40)30-19-34(28-16-17-33(55-4)24(3)35(28)43-30)56-27-18-32-37(50)47-42(39(52)53)20-25(42)12-8-6-5-7-9-15-29(38(51)48(32)21-27)45-41(54)57-26-13-10-11-14-26/h8,12,16-17,19,22-23,25-27,29,32H,5-7,9-11,13-15,18,20-21H2,1-4H3,(H,45,54)(H,47,50)(H,52,53)(H,44,46,49)/b12-8-/t25?,27-,29+,32+,42-/m1/s1",YQCVJBZPFAJZFJ-DVUQJCTJSA-N,Protease,HCV:NS3,,P26662,,Inhibitor,BI-1675,6.7,IC50,Enzymatic assay (using a NS3-NS4A heterodimer and a fluorogenic substrate),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-1230,0,1.8,EC50,"HCVPV RNA replication Luciferase reporter assay (genotype 1b, Huh-7 cells, 3-day incubation)",https://pubs.acs.org/doi/full/10.1021/ol303498m,<,0,Cerep panel (Eurofins),6,"Screened at 10 µM against 6 human serine proteases, closest target as % inhibition: CTSG (63%), estimated IC50 = 6 µM; Clean Eurofins-Cerep panel for non-serine proteases tested at 10 µM; Screened at 1 µM against 468 kinases (KinomeScan, DiscoverX), closest targets as % of control: STK38L (43%), MELK (44%); Screened at 10 µM against 45 GPCRs (PDSP panel), in-vitro potencies of closest targets: Ki(ADRA2C) = 3.29 µM, Ki(ADRB3) = 3.62 µM, Ki(ADRA2B) = 4.49 µM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BI-1230,Protease set,100 nM
EUB0000319b_HCV:NS3,BI-1675,EUB0000319b,O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1,"InChI=1S/C29H38N4O7/c34-25-24-16-22(39-21-12-14-30-15-13-21)18-33(24)26(35)23(31-28(38)40-20-9-6-7-10-20)11-5-3-1-2-4-8-19-17-29(19,32-25)27(36)37/h4,8,12-15,19-20,22-24H,1-3,5-7,9-11,16-18H2,(H,31,38)(H,32,34)(H,36,37)/b8-4-/t19?,22-,23+,24+,29-/m1/s1",WJXNVDYYZYLOAF-GILVJNHZSA-N,Protease,HCV:NS3,,P26662,,Negative control for BI-1230,,4870,IC50,Enzymatic assay (using a NS3-NS4A heterodimer and a fluorogenic substrate),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-1230,0,,,,,,0,KinomeScan (DiscoverX),468,"Screened at 1 µM, closest targets as % of contr.: MYO3B (38%), MATK(41%), DYRK1B (46%); Screened at 10 µM against 45 GPCRs (PDSP screen), closest targets as % of inhibition: ADRA1A(25.68%), HRH1(23.9%), TMEM97(18.5%)",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BI-1230,Protease set,100 nM
EUB0001112a_CMA1@Protease,BI-1942,EUB0001112a,CC[C@H](CC(O)=O)N1C(c2c(cccn2)N(Cc2cn(C)c3cc(C)cc(C)c23)C1=O)=O,"InChI=1S/C24H26N4O4/c1-5-17(11-20(29)30)28-23(31)22-18(7-6-8-25-22)27(24(28)32)13-16-12-26(4)19-10-14(2)9-15(3)21(16)19/h6-10,12,17H,5,11,13H2,1-4H3,(H,29,30)/t17-/m1/s1",PCJVXTDIDUMIRR-QGZVFWFLSA-N,Protease,CMA1@Protease,1215,P23946,"CYH, MCT1, chymase",Inhibitor,No control available for probe,0.4,IC50,Enzymatic assay (inhibition of recombinant human chymase CMA1),https://pubmed.ncbi.nlm.nih.gov/23659209/,0,,,,,,1,Protease panel (Eurofins),35,"Screened at 10 µM, in-vitro potency of closest target: IC50(CTSG, cathepsin G) = 110 nM, >100-fold selective; Screened at 10 µM against 44 targets outside target family (Eurofins Safety Screen44TM), clean selectivity profile; Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potencies of closest targets: Ki(HTR1D) = 1130.61 nM, Ki(OPRK1) = 4948.48 nM",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-1942,Protease set,1 µM
EUB0001577a_HCV:NS5B,BI-207127,EUB0001577a,Cn1c(C2(NC(=O)c3ccc4c(C5CCCC5)c(-c5ncc(Br)cn5)n(C)c4c3)CCC2)nc2ccc(/C=C/C(=O)O)cc21,"InChI=1S/C34H33BrN6O3/c1-40-26-17-22(10-11-24(26)29(21-6-3-4-7-21)30(40)31-36-18-23(35)19-37-31)32(44)39-34(14-5-15-34)33-38-25-12-8-20(9-13-28(42)43)16-27(25)41(33)2/h8-13,16-19,21H,3-7,14-15H2,1-2H3,(H,39,44)(H,42,43)/b13-9+",BMAIGAHXAJEULY-UKTHLTGXSA-N,,HCV:NS5B,951475,P27958,p23,Inhibitor,BI-7656,19,IC50,Enzymatic assay (using HCV NS5B polymerase D21),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BI%20207127,0,23,IC50,"Cell-based replication assay (Genotyp 1a, Huh7 cells)",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BI%20207127,0,0,SafetyScreen44TM (Eurofins),44,"Screened at 10 µM, closest targets as % of contr.: CCKA/H (12%), DELTA2/H (47%)",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BI%20207127,Protease set,100 nM
EUB0001578a_HIV:NNRT,BI-2540,EUB0001578a,Cc1c(NC(=O)COc2ccc(Cl)cc2C(=O)c2cc(F)cc(C(F)(F)F)c2)ccc(C(=O)O)c1F,"InChI=1S/C24H15ClF5NO5/c1-11-18(4-3-16(21(11)27)23(34)35)31-20(32)10-36-19-5-2-14(25)9-17(19)22(33)12-6-13(24(28,29)30)8-15(26)7-12/h2-9H,10H2,1H3,(H,31,32)(H,34,35)",WPEKGNGDNFRRMH-UHFFFAOYSA-N,,HIV:NNRT,155348,P04585,Pr160Gag-Pol,Inhibitor,BI-2439,12,IC50,Enzymatic assay (HIV1 reverse transcriptase picogreen fluorescence assay),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BI-2540,0,0.76,IC50,ELISA (HIV viral replication assay in C8166 cells),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BI-2540,0,0,SafetyScreen44TM (Eurofins),44,"Screened at 10 µM, clean selectivity profile with no target <80% of contrl.",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/BI-2540,Other targets set,100 nM
EUB0002188a_HSD17B13,BI-3231,EUB0002188a,CCn1c(=O)c(C)cn(Cc2nnc(-c3ccc(F)c(O)c3F)s2)c1=O,"InChI=1S/C16H14F2N4O3S/c1-3-22-15(24)8(2)6-21(16(22)25)7-11-19-20-14(26-11)9-4-5-10(17)13(23)12(9)18/h4-6,23H,3,7H2,1-2H3",XKDHFIPNTTUSIA-UHFFFAOYSA-N,Oxidoreductase,HSD17B13,345275,Q7Z5P4,"FLDP, HMFN0376, NIIL497, SCDR9, SDR16C3",inhibitor,BI-0955,0.7,Ki,Enzyme activity assay,https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c01884,0,11,IC50,Cellular human HSD17B13 assay (custom-made stably overexpressing hHSD17B13-Myc/DDK HEK293 cells),https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c01884,0,0,SafetyScreen44™ (Eurofins),44,"Screened at 10 µM, closest targets as % of control: COX2 (49%), NA+/SITE2/R(73%)",https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c01884,Other targets set,1 µM
EUB0002206a_BCL6,CCT369260,EUB0002206a,C[C@H]1CN(c2ncc(Cl)c(Nc3ccc4c(c3)n(CCC(C)(C)O)c(=O)n4C)n2)C[C@@H](C)C1(F)F,"InChI=1S/C24H31ClF2N6O2/c1-14-12-32(13-15(2)24(14,26)27)21-28-11-17(25)20(30-21)29-16-6-7-18-19(10-16)33(22(34)31(18)5)9-8-23(3,4)35/h6-7,10-11,14-15,35H,8-9,12-13H2,1-5H3,(H,28,29,30)/t14-,15+",VFNPUAOAEFMXQI-GASCZTMLSA-N,Apoptosis regulator,BCL6,604,P41182,"BCL6, BCL5, LAZ3, ZBTB27, ZNF51",degrader,CCT393732,520,IC50,TR-FRET assay,https://pubmed.ncbi.nlm.nih.gov/32275432/,0,90,DC50,Immunofluorescence-based BCL6 degradation assay (in SUDHL-4 cells),https://pubmed.ncbi.nlm.nih.gov/32275432/,0,1,GPCR panel (PDSP screen),45,"Screened at 10 µM, closest targets as % of inhibition: OPRM1 (86%), GABA/PBR (59.57%), ADORA1 (93.08%), HRH3 (60.67%), TMEM97 (85.65%), ADRB3 (65.27%), SLC6A3 (50.76%), HTR1D (56.54%), AVPR1A (78.62%), SIGMAR1 (47.38%); In-vitro potency (enzymatic assay): Ki(OPRM1) = 872.47 nM, Ki(GABA/PBR) = 1113.88 nM, Ki(ADORA1) = 1630.55 nM, Ki(HRH3) = 2333.56 nM, Ki(TMEM97) = 2503.46 nM, Ki(ADRB3) = 3994.88 nM, Ki(SLC6A3) = 5087.69 nM, Ki(HTR1D) = 6174.88 nM",https://www.sgc-ffm.uni-frankfurt.de/#!gpcrscandataview/CCT369260,Other targets set,1 µM
EUB0002207a_BCL6,CCT393732,EUB0002207a,C[C@H]1CN(c2nccc(Nc3ccc4c(c3)n(CCC(C)(C)O)c(=O)n4C)n2)C[C@@H](C)C1(F)F,"InChI=1S/C24H32F2N6O2/c1-15-13-31(14-16(2)24(15,25)26)21-27-10-8-20(29-21)28-17-6-7-18-19(12-17)32(22(33)30(18)5)11-9-23(3,4)34/h6-8,10,12,15-16,34H,9,11,13-14H2,1-5H3,(H,27,28,29)/t15-,16+",MLRMGHITRSOINN-IYBDPMFKSA-N,Apoptosis regulator,BCL6,604,P41182,"BCL6, BCL5, LAZ3, ZBTB27, ZNF51",Negative control for CCT369260,,21000,IC50,TR-FRET assay,https://www.sgc-ffm.uni-frankfurt.de/#!usageview/CCT369260,0,10000,DC50,MSD degrader assay (OCI-LY1 cells),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/CCT369260,>,,,,,,Other targets set,1 µM
EUB0002216a_CAMK1D,CS640s,EUB0002216a,CNC(=O)c1cnc(N2CCC[C@H](N)C2)nc1Nc1cc(C(C)C)nc(C(C)C)c1,"InChI=1S/C22H33N7O/c1-13(2)18-9-16(10-19(27-18)14(3)4)26-20-17(21(30)24-5)11-25-22(28-20)29-8-6-7-15(23)12-29/h9-11,13-15H,6-8,12,23H2,1-5H3,(H,24,30)(H,25,26,27,28)/t15-/m0/s1",BULCCNLYFBCNHQ-HNNXBMFYSA-N,Protein Kinase,CAMK1D,57118,Q8IU85,CKLiK,Negative control for CS640,,1.71,dTm,DSF assay,https://www.thesgc.org/chemical-probes/cs-640,0,,,,,,0,Kinase panel (DSF assay),100,"Screened at 20 µM, closest targets as shift in temperature: dTm(DCAMKL1) = 1.69 K, dTm(DMPK1) = 1.16 K, dTm(EPHA7) = 1.33 K, dTm(CAMK1D) = 1.71 K, dTm(CAMK1G) = 2.02 K, dTm(TIF1) = 2.74 K, dTm(TLK1) = 1.18K",https://www.thesgc.org/chemical-probes/cs-640,Kinase set,100 nM
EUB0002216a_PNCK,CS640s,EUB0002216a,CNC(=O)c1cnc(N2CCC[C@H](N)C2)nc1Nc1cc(C(C)C)nc(C(C)C)c1,"InChI=1S/C22H33N7O/c1-13(2)18-9-16(10-19(27-18)14(3)4)26-20-17(21(30)24-5)11-25-22(28-20)29-8-6-7-15(23)12-29/h9-11,13-15H,6-8,12,23H2,1-5H3,(H,24,30)(H,25,26,27,28)/t15-/m0/s1",BULCCNLYFBCNHQ-HNNXBMFYSA-N,Protein Kinase,PNCK,139728,Q6P2M8,"MGC45419, CaMK1b",Negative control for CS640,,,,,,0,,,,,,0,Kinase panel (DSF assay),100,"Screened at 20 µM, closest targets as shift in temperature: dTm(DCAMKL1) = 1.69 K, dTm(DMPK1) = 1.16 K, dTm(EPHA7) = 1.33 K, dTm(CAMK1D) = 1.71 K, dTm(CAMK1G) = 2.02 K, dTm(TIF1) = 2.74 K, dTm(TLK1) = 1.18K",https://www.thesgc.org/chemical-probes/cs-640,Kinase set,100 nM
EUB0002216a_CAMK1,CS640s,EUB0002216a,CNC(=O)c1cnc(N2CCC[C@H](N)C2)nc1Nc1cc(C(C)C)nc(C(C)C)c1,"InChI=1S/C22H33N7O/c1-13(2)18-9-16(10-19(27-18)14(3)4)26-20-17(21(30)24-5)11-25-22(28-20)29-8-6-7-15(23)12-29/h9-11,13-15H,6-8,12,23H2,1-5H3,(H,24,30)(H,25,26,27,28)/t15-/m0/s1",BULCCNLYFBCNHQ-HNNXBMFYSA-N,Protein Kinase,CAMK1,8536,Q14012,"CaMKI, CaMKI-alpha",Negative control for CS640,,,,,,0,,,,,,0,Kinase panel (DSF assay),100,"Screened at 20 µM, closest targets as shift in temperature: dTm(DCAMKL1) = 1.69 K, dTm(DMPK1) = 1.16 K, dTm(EPHA7) = 1.33 K, dTm(CAMK1D) = 1.71 K, dTm(CAMK1G) = 2.02 K, dTm(TIF1) = 2.74 K, dTm(TLK1) = 1.18K",https://www.thesgc.org/chemical-probes/cs-640,Kinase set,100 nM
EUB0002216a_CAMK1G,CS640s,EUB0002216a,CNC(=O)c1cnc(N2CCC[C@H](N)C2)nc1Nc1cc(C(C)C)nc(C(C)C)c1,"InChI=1S/C22H33N7O/c1-13(2)18-9-16(10-19(27-18)14(3)4)26-20-17(21(30)24-5)11-25-22(28-20)29-8-6-7-15(23)12-29/h9-11,13-15H,6-8,12,23H2,1-5H3,(H,24,30)(H,25,26,27,28)/t15-/m0/s1",BULCCNLYFBCNHQ-HNNXBMFYSA-N,Protein Kinase,CAMK1G,57172,Q96NX5,"VWS1, CLICKIII, dJ272L16.1",Negative control for CS640,,2.02,dTm,DSF assay,https://www.thesgc.org/chemical-probes/cs-640,0,,,,,,0,Kinase panel (DSF assay),100,"Screened at 20 µM, closest targets as shift in temperature: dTm(DCAMKL1) = 1.69 K, dTm(DMPK1) = 1.16 K, dTm(EPHA7) = 1.33 K, dTm(CAMK1D) = 1.71 K, dTm(CAMK1G) = 2.02 K, dTm(TIF1) = 2.74 K, dTm(TLK1) = 1.18K",https://www.thesgc.org/chemical-probes/cs-640,Kinase set,100 nM
EUB0001553_FKBP5,ddSAFit2,EUB0001553,COc1ccc(CC[C@@H](OC(=O)[C@H]2CCCCN2C(=O)[C@@H](c2cc(OC)c(OC)c(OC)c2)C2CCCCC2)c2cccc(OCCN3CCOCC3)c2)cc1OC,"InChI=1S/C46H62N2O10/c1-51-39-20-18-32(28-40(39)52-2)17-19-38(34-14-11-15-36(29-34)57-27-24-47-22-25-56-26-23-47)58-46(50)37-16-9-10-21-48(37)45(49)43(33-12-7-6-8-13-33)35-30-41(53-3)44(55-5)42(31-35)54-4/h11,14-15,18,20,28-31,33,37-38,43H,6-10,12-13,16-17,19,21-27H2,1-5H3/t37-,38-,43-/m1/s1",ZDBWLRLGUBSLPG-FFUXEPPCSA-N,,FKBP5,2289,Q13451,"AIG6, FKBP51, FKBP54, P54, PPIase, Ptg-10",Negative control for SAFit2,,20000,Kd,Competitive fluorescence polarization binding assay,https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/SAFit2,>,,,,,,,,,,,Other targets set,1 µM
EUB0002234a_SMARCA2@BRD,FHT-2344,EUB0002234a,COC[C@H](NC(=O)c1ccn(S(C)(=O)=O)c1)C(=O)Nc1nc(-c2cccc(-c3ccn(C)n3)c2)cs1,"InChI=1S/C23H24N6O5S2/c1-28-9-8-18(27-28)15-5-4-6-16(11-15)20-14-35-23(25-20)26-22(31)19(13-34-2)24-21(30)17-7-10-29(12-17)36(3,32)33/h4-12,14,19H,13H2,1-3H3,(H,24,30)(H,25,26,31)/t19-/m0/s1",APLVGTKXOIMODQ-IBGZPJMESA-N,Bromodomain,SMARCA2@BRD,6595,P51531,"BAF190, hSNF2a, hBRM, Sth1p, SNF2LA, BRM, SNF2, SWI2",inhibitor,FHT-5908,13.8,IC50,ADP-Glo assay ,https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/FHT-2344,0,29.8,IC50,Luciferase transporter assay (SMARCA-mutant cell line),https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/FHT-2344,0,0,GPCR panel (PDSP screen),45,"Screened at 10 µM, closest targets as % of inhibition: SLC6A3 (-87.78%), HTR2B (48.2%); In-vitro potency (enzymatic assay): Ki(SLC6A3) >10000 nM",https://www.sgc-ffm.uni-frankfurt.de/#!usageview/FHT-2344,Epigenetic set,1 µM
EUB0002234a_SMARCA4@BRD,FHT-2344,EUB0002234a,COC[C@H](NC(=O)c1ccn(S(C)(=O)=O)c1)C(=O)Nc1nc(-c2cccc(-c3ccn(C)n3)c2)cs1,"InChI=1S/C23H24N6O5S2/c1-28-9-8-18(27-28)15-5-4-6-16(11-15)20-14-35-23(25-20)26-22(31)19(13-34-2)24-21(30)17-7-10-29(12-17)36(3,32)33/h4-12,14,19H,13H2,1-3H3,(H,24,30)(H,25,26,31)/t19-/m0/s1",APLVGTKXOIMODQ-IBGZPJMESA-N,Bromodomain,SMARCA4@BRD,6597,P51532,"hSNF2b, BRG1, BAF190, SNF2, SWI2, SNF2-BETA, SNF2LB, FLJ39786",inhibitor,FHT-5908,26.1,IC50,ADP-Glo assay ,https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/FHT-2344,0,30.2,IC50,Luciferase transporter assay (SMARCA-mutant cell line),https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/FHT-2344,0,0,GPCR panel (PDSP screen),45,"Screened at 10 µM, closest targets as % of inhibition: SLC6A3 (-87.78%), HTR2B (48.2%); In-vitro potency (enzymatic assay): Ki(SLC6A3) >10000 nM",https://www.sgc-ffm.uni-frankfurt.de/#!usageview/FHT-2344,Epigenetic set,1 µM
EUB0002235a_SMARCA2@BRD,FHT-5908,EUB0002235a,C[C@H](NC(=O)c1cn(C2(C#N)CC2)cn1)C(=O)Nc1nc(-c2cccc(-c3ccn(C)n3)c2)cs1,"InChI=1S/C24H22N8O2S/c1-15(27-22(34)19-11-32(14-26-19)24(13-25)7-8-24)21(33)29-23-28-20(12-35-23)17-5-3-4-16(10-17)18-6-9-31(2)30-18/h3-6,9-12,14-15H,7-8H2,1-2H3,(H,27,34)(H,28,29,33)/t15-/m0/s1",DMEDHHKXKVEBDF-HNNXBMFYSA-N,Bromodomain,SMARCA2@BRD,6595,P51531,"BAF190, hSNF2a, hBRM, Sth1p, SNF2LA, BRM, SNF2, SWI2",Negative control for FHT-2344,,1880,IC50,ADP-Glo assay ,https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/FHT-2344,0,4350,IC50,Luciferase transporter assay (SMARCA-mutant cell line),https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/FHT-2344,0,3,GPCR panel (PDSP screen),45,"Screened at 10 µM, closest targets as % of inhibition: SLC6A3 (-151.28%), SIGMAR1 (83.25%), HTR2B (86.81%), GABA/PBR (64.56%), SLC6A2 (69.81%); In-vitro potency (enzymatic assay): Ki(SLC6A3) >10000 nM, Ki(SIGMAR1) = 416.9 nM, Ki(HTR2B) = 507.65 nM, Ki(GABA/PBR) = 1583.39 nM, Ki(SLC6A2) = 8271.8 nM",https://www.sgc-ffm.uni-frankfurt.de/#!usageview/FHT-2344,Epigenetic set,1 µM
EUB0002235a_SMARCA4@BRD,FHT-5908,EUB0002235a,C[C@H](NC(=O)c1cn(C2(C#N)CC2)cn1)C(=O)Nc1nc(-c2cccc(-c3ccn(C)n3)c2)cs1,"InChI=1S/C24H22N8O2S/c1-15(27-22(34)19-11-32(14-26-19)24(13-25)7-8-24)21(33)29-23-28-20(12-35-23)17-5-3-4-16(10-17)18-6-9-31(2)30-18/h3-6,9-12,14-15H,7-8H2,1-2H3,(H,27,34)(H,28,29,33)/t15-/m0/s1",DMEDHHKXKVEBDF-HNNXBMFYSA-N,Bromodomain,SMARCA4@BRD,6597,P51532,"hSNF2b, BRG1, BAF190, SNF2, SWI2, SNF2-BETA, SNF2LB, FLJ39786",Negative control for FHT-2344,,3990,IC50,ADP-Glo assay ,https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/FHT-2344,0,2370,IC50,Luciferase transporter assay (SMARCA-mutant cell line),https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/FHT-2344,0,3,GPCR panel (PDSP screen),45,"Screened at 10 µM, closest targets as % of inhibition: SLC6A3 (-151.28%), SIGMAR1 (83.25%), HTR2B (86.81%), GABA/PBR (64.56%), SLC6A2 (69.81%); In-vitro potency (enzymatic assay): Ki(SLC6A3) >10000 nM, Ki(SIGMAR1) = 416.9 nM, Ki(HTR2B) = 507.65 nM, Ki(GABA/PBR) = 1583.39 nM, Ki(SLC6A2) = 8271.8 nM",https://www.sgc-ffm.uni-frankfurt.de/#!usageview/FHT-2344,Epigenetic set,1 µM
EUB0001114a_BRD2@BD2,GSK046,EUB0001114a,CC(Nc1c(cc(cc1F)C(N[C@H]1CC[C@@H](CC1)O)=O)O[C@@H](C)c1ccccc1)=O,"InChI=1S/C23H27FN2O4/c1-14(16-6-4-3-5-7-16)30-21-13-17(12-20(24)22(21)25-15(2)27)23(29)26-18-8-10-19(28)11-9-18/h3-7,12-14,18-19,28H,8-11H2,1-2H3,(H,25,27)(H,26,29)/t14-,18-,19-/m0/s1",FRBRZGLUFOZRGD-JVPBZIDWSA-N,Bromodomain,BRD2@BD2,6046,P25440,"KIAA9001, RING3, D6S113E, NAT, FSRG1",Inhibitor,No control available for probe,251,IC50,BET mutant TR-FRET assay (BD2),https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00605,0,,,,,,0,BROMOScan (DiscoverX) ,40,"In-vitro potencies of closest targets in BROMOScan (DiscoverX): Kd(BRD2, BD1) = 1621 nM, Kd(BRD2, BD2) = 35 nM (64-fold selective), Kd(BRD3, BD1) = 2082 nM, Kd(BRD3, BD2) = 32 nM (63-fold selective), Kd(BRD4, BD1) = 769 nM, Kd(BRD4, BD2) = 9 nM (85-fold selective), Kd(BRDT, BD1) = 2454 nM, Kd(BRDT, BD2) = 15 nM (164-fold selective); In-vitro potencies (SPR measurements): Kd(BRD4, BD1) >10 µM, Kd(BRD4, BD2) = 30 nM, excellent selectivity against other BCPs, Kd >30 µM for TAF1(BD2), BRD9, TAF1L(BD2), BAZ2A, CECR2, BAZ2B; Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potency of closest target: Ki(HTR1D) = 3438.75 nM  ",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00605,Epigenetic set,1 µM
EUB0001114a_BRD3@BD2,GSK046,EUB0001114a,CC(Nc1c(cc(cc1F)C(N[C@H]1CC[C@@H](CC1)O)=O)O[C@@H](C)c1ccccc1)=O,"InChI=1S/C23H27FN2O4/c1-14(16-6-4-3-5-7-16)30-21-13-17(12-20(24)22(21)25-15(2)27)23(29)26-18-8-10-19(28)11-9-18/h3-7,12-14,18-19,28H,8-11H2,1-2H3,(H,25,27)(H,26,29)/t14-,18-,19-/m0/s1",FRBRZGLUFOZRGD-JVPBZIDWSA-N,Bromodomain,BRD3@BD2,8019,Q15059,"RING3L, ORFX, KIAA0043",Inhibitor,No control available for probe,100,IC50,BET mutant TR-FRET assay (BD2),https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00605,0,,,,,,0,BROMOScan (DiscoverX) ,40,"In-vitro potencies of closest targets in BROMOScan (DiscoverX): Kd(BRD2, BD1) = 1621 nM, Kd(BRD2, BD2) = 35 nM (64-fold selective), Kd(BRD3, BD1) = 2082 nM, Kd(BRD3, BD2) = 32 nM (63-fold selective), Kd(BRD4, BD1) = 769 nM, Kd(BRD4, BD2) = 9 nM (85-fold selective), Kd(BRDT, BD1) = 2454 nM, Kd(BRDT, BD2) = 15 nM (164-fold selective); In-vitro potencies (SPR measurements): Kd(BRD4, BD1) >10 µM, Kd(BRD4, BD2) = 30 nM, excellent selectivity against other BCPs, Kd >30 µM for TAF1(BD2), BRD9, TAF1L(BD2), BAZ2A, CECR2, BAZ2B; Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potency of closest target: Ki(HTR1D) = 3438.75 nM  ",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00605,Epigenetic set,1 µM
EUB0001114a_BRD4@BD2,GSK046,EUB0001114a,CC(Nc1c(cc(cc1F)C(N[C@H]1CC[C@@H](CC1)O)=O)O[C@@H](C)c1ccccc1)=O,"InChI=1S/C23H27FN2O4/c1-14(16-6-4-3-5-7-16)30-21-13-17(12-20(24)22(21)25-15(2)27)23(29)26-18-8-10-19(28)11-9-18/h3-7,12-14,18-19,28H,8-11H2,1-2H3,(H,25,27)(H,26,29)/t14-,18-,19-/m0/s1",FRBRZGLUFOZRGD-JVPBZIDWSA-N,Bromodomain,BRD4@BD2,23476,O60885,"HUNKI, MCAP, CAP, HUNK1",Inhibitor,No control available for probe,50,IC50,BET mutant TR-FRET assay (BD2),https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00605,0,,,,,,0,BROMOScan (DiscoverX) ,40,"In-vitro potencies of closest targets in BROMOScan (DiscoverX): Kd(BRD2, BD1) = 1621 nM, Kd(BRD2, BD2) = 35 nM (64-fold selective), Kd(BRD3, BD1) = 2082 nM, Kd(BRD3, BD2) = 32 nM (63-fold selective), Kd(BRD4, BD1) = 769 nM, Kd(BRD4, BD2) = 9 nM (85-fold selective), Kd(BRDT, BD1) = 2454 nM, Kd(BRDT, BD2) = 15 nM (164-fold selective); In-vitro potencies (SPR measurements): Kd(BRD4, BD1) >10 µM, Kd(BRD4, BD2) = 30 nM, excellent selectivity against other BCPs, Kd >30 µM for TAF1(BD2), BRD9, TAF1L(BD2), BAZ2A, CECR2, BAZ2B; Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potency of closest target: Ki(HTR1D) = 3438.75 nM  ",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00605,Epigenetic set,1 µM
EUB0001114a_BRDT@BD2,GSK046,EUB0001114a,CC(Nc1c(cc(cc1F)C(N[C@H]1CC[C@@H](CC1)O)=O)O[C@@H](C)c1ccccc1)=O,"InChI=1S/C23H27FN2O4/c1-14(16-6-4-3-5-7-16)30-21-13-17(12-20(24)22(21)25-15(2)27)23(29)26-18-8-10-19(28)11-9-18/h3-7,12-14,18-19,28H,8-11H2,1-2H3,(H,25,27)(H,26,29)/t14-,18-,19-/m0/s1",FRBRZGLUFOZRGD-JVPBZIDWSA-N,Bromodomain,BRDT@BD2,676,Q58F21,"BRD6, CT9",Inhibitor,No control available for probe,200,IC50,BET mutant TR-FRET assay (BD2),https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00605,0,,,,,,0,BROMOScan (DiscoverX) ,40,"In-vitro potencies of closest targets in BROMOScan (DiscoverX): Kd(BRD2, BD1) = 1621 nM, Kd(BRD2, BD2) = 35 nM (64-fold selective), Kd(BRD3, BD1) = 2082 nM, Kd(BRD3, BD2) = 32 nM (63-fold selective), Kd(BRD4, BD1) = 769 nM, Kd(BRD4, BD2) = 9 nM (85-fold selective), Kd(BRDT, BD1) = 2454 nM, Kd(BRDT, BD2) = 15 nM (164-fold selective); In-vitro potencies (SPR measurements): Kd(BRD4, BD1) >10 µM, Kd(BRD4, BD2) = 30 nM, excellent selectivity against other BCPs, Kd >30 µM for TAF1(BD2), BRD9, TAF1L(BD2), BAZ2A, CECR2, BAZ2B; Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potency of closest target: Ki(HTR1D) = 3438.75 nM  ",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00605,Epigenetic set,1 µM
EUB0001117a_BRD2@BD2,GSK620,EUB0001117a,CNC(C1=CC(=CN(Cc2ccccc2)C1=O)C(NC1CC1)=O)=O,"InChI=1S/C18H19N3O3/c1-19-17(23)15-9-13(16(22)20-14-7-8-14)11-21(18(15)24)10-12-5-3-2-4-6-12/h2-6,9,11,14H,7-8,10H2,1H3,(H,19,23)(H,20,22)",QZZCUOVXHPAQRQ-UHFFFAOYSA-N,Bromodomain,BRD2@BD2,6046,P25440,"KIAA9001, RING3, D6S113E, NAT, FSRG1",Inhibitor,No control available for probe,316,IC50,BET mutant TR-FRET assay (BD2),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/GSK620,0,,,,,,0,BROMOScan (DiscoverX) ,40,"In-vitro potencies of closest targets in BROMOScan (DiscoverX): pKd(TAF1, BD2) = 5.4, pKd(EP300) = 5.1, pKd(CREBBP) = 5.0, pKd(EP300) = 5.1; Cross screening in liability panel against 48 targets (GPCRs, transporter, ion-channels, and other targets), closest target: pEC50(CB2 receptor) <5; Selective for BD2 domain of BET proteins; Screened at 10 µM against 45 GPCRs (PDSP screen), closest target as % inhibition: OPRK1(40%);",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/GSK620,Epigenetic set,1 µM
EUB0001117a_BRD3@BD2,GSK620,EUB0001117a,CNC(C1=CC(=CN(Cc2ccccc2)C1=O)C(NC1CC1)=O)=O,"InChI=1S/C18H19N3O3/c1-19-17(23)15-9-13(16(22)20-14-7-8-14)11-21(18(15)24)10-12-5-3-2-4-6-12/h2-6,9,11,14H,7-8,10H2,1H3,(H,19,23)(H,20,22)",QZZCUOVXHPAQRQ-UHFFFAOYSA-N,Bromodomain,BRD3@BD2,8019,Q15059,"RING3L, ORFX, KIAA0043",Inhibitor,No control available for probe,79,IC50,BET mutant TR-FRET assay (BD2),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/GSK620,0,,,,,,0,BROMOScan (DiscoverX) ,40,"In-vitro potencies of closest targets in BROMOScan (DiscoverX): pKd(TAF1, BD2) = 5.4, pKd(EP300) = 5.1, pKd(CREBBP) = 5.0, pKd(EP300) = 5.1; Cross screening in liability panel against 48 targets (GPCRs, transporter, ion-channels, and other targets), closest target: pEC50(CB2 receptor) <5; Selective for BD2 domain of BET proteins; Screened at 10 µM against 45 GPCRs (PDSP screen), closest target as % inhibition: OPRK1(40%);",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/GSK620,Epigenetic set,1 µM
EUB0001117a_BRD4@BD2,GSK620,EUB0001117a,CNC(C1=CC(=CN(Cc2ccccc2)C1=O)C(NC1CC1)=O)=O,"InChI=1S/C18H19N3O3/c1-19-17(23)15-9-13(16(22)20-14-7-8-14)11-21(18(15)24)10-12-5-3-2-4-6-12/h2-6,9,11,14H,7-8,10H2,1H3,(H,19,23)(H,20,22)",QZZCUOVXHPAQRQ-UHFFFAOYSA-N,Bromodomain,BRD4@BD2,23476,O60885,"HUNKI, MCAP, CAP, HUNK1",Inhibitor,No control available for probe,97,IC50,BET mutant TR-FRET assay (BD2),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/GSK620,0,,,,,,0,BROMOScan (DiscoverX) ,40,"In-vitro potencies of closest targets in BROMOScan (DiscoverX): pKd(TAF1, BD2) = 5.4, pKd(EP300) = 5.1, pKd(CREBBP) = 5.0, pKd(EP300) = 5.1; Cross screening in liability panel against 48 targets (GPCRs, transporter, ion-channels, and other targets), closest target: pEC50(CB2 receptor) <5; Selective for BD2 domain of BET proteins; Screened at 10 µM against 45 GPCRs (PDSP screen), closest target as % inhibition: OPRK1(40%);",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/GSK620,Epigenetic set,1 µM
EUB0001117a_BRDT@BD2,GSK620,EUB0001117a,CNC(C1=CC(=CN(Cc2ccccc2)C1=O)C(NC1CC1)=O)=O,"InChI=1S/C18H19N3O3/c1-19-17(23)15-9-13(16(22)20-14-7-8-14)11-21(18(15)24)10-12-5-3-2-4-6-12/h2-6,9,11,14H,7-8,10H2,1H3,(H,19,23)(H,20,22)",QZZCUOVXHPAQRQ-UHFFFAOYSA-N,Bromodomain,BRDT@BD2,676,Q58F21,"BRD6, CT9",Inhibitor,No control available for probe,200,IC50,BET mutant TR-FRET assay (BD2),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/GSK620,0,,,,,,0,BROMOScan (DiscoverX) ,40,"In-vitro potencies of closest targets in BROMOScan (DiscoverX): pKd(TAF1, BD2) = 5.4, pKd(EP300) = 5.1, pKd(CREBBP) = 5.0, pKd(EP300) = 5.1; Cross screening in liability panel against 48 targets (GPCRs, transporter, ion-channels, and other targets), closest target: pEC50(CB2 receptor) <5; Selective for BD2 domain of BET proteins; Screened at 10 µM against 45 GPCRs (PDSP screen), closest target as % inhibition: OPRK1(40%);",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/GSK620,Epigenetic set,1 µM
EUB0001115a_BRD2@BD1,GSK778,EUB0001115a,Cc1c(c2cc3c(cc2OC[C@H]2CCNC2)c2c(cn3)nc(COC)n2[C@H](C)c2ccccc2)c(C)on1,"InChI=1S/C30H33N5O3/c1-18-29(20(3)38-34-18)24-12-25-23(13-27(24)37-16-21-10-11-31-14-21)30-26(15-32-25)33-28(17-36-4)35(30)19(2)22-8-6-5-7-9-22/h5-9,12-13,15,19,21,31H,10-11,14,16-17H2,1-4H3/t19-,21+/m1/s1",ZORLJXWXFABTPZ-CTNGQTDRSA-N,Bromodomain,BRD2@BD1,6046,P25440,"KIAA9001, RING3, D6S113E, NAT, FSRG1",Inhibitor,No control available for probe,79,IC50,BET mutant TR-FRET assay (BD1),https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00566,0,,,,,,0,BROMOScan (DiscoverX) ,40,"In-vitro potencies of closest targets in BROMOScan (DiscoverX): Kd(BRD2, BD1) = 13 nM, Kd(BRD3, BD1) = 5 nM, Kd(BRD4, BD1) = 5.9 nM, Kd(BRDT, BD1) = 18 nM; Selectivity screen against 50 targets (GPCRs, ion-channels, other targets), in-vitro potencies of closest targets: pIC50(CHRNA1) = 6, pIC50(CYP3A4) = 6; Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potencies of closest targets: Ki(DRD3) = 485.92 nM, Ki(DRD4) = 856.99 nM, Ki(GABAA) = 1595.89 nM, Ki(GABAA/BZP) = 1970.29 nM",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00566,Epigenetic set,1 µM
EUB0001115a_BRD3@BD1,GSK778,EUB0001115a,Cc1c(c2cc3c(cc2OC[C@H]2CCNC2)c2c(cn3)nc(COC)n2[C@H](C)c2ccccc2)c(C)on1,"InChI=1S/C30H33N5O3/c1-18-29(20(3)38-34-18)24-12-25-23(13-27(24)37-16-21-10-11-31-14-21)30-26(15-32-25)33-28(17-36-4)35(30)19(2)22-8-6-5-7-9-22/h5-9,12-13,15,19,21,31H,10-11,14,16-17H2,1-4H3/t19-,21+/m1/s1",ZORLJXWXFABTPZ-CTNGQTDRSA-N,Bromodomain,BRD3@BD1,8019,Q15059,"RING3L, ORFX, KIAA0043",Inhibitor,No control available for probe,40,IC50,BET mutant TR-FRET assay (BD1),https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00566,0,,,,,,0,BROMOScan (DiscoverX) ,40,"In-vitro potencies of closest targets in BROMOScan (DiscoverX): Kd(BRD2, BD1) = 13 nM, Kd(BRD3, BD1) = 5 nM, Kd(BRD4, BD1) = 5.9 nM, Kd(BRDT, BD1) = 18 nM; Selectivity screen against 50 targets (GPCRs, ion-channels, other targets), in-vitro potencies of closest targets: pIC50(CHRNA1) = 6, pIC50(CYP3A4) = 6; Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potencies of closest targets: Ki(DRD3) = 485.92 nM, Ki(DRD4) = 856.99 nM, Ki(GABAA) = 1595.89 nM, Ki(GABAA/BZP) = 1970.29 nM",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00566,Epigenetic set,1 µM
EUB0001115a_BRD4@BD1,GSK778,EUB0001115a,Cc1c(c2cc3c(cc2OC[C@H]2CCNC2)c2c(cn3)nc(COC)n2[C@H](C)c2ccccc2)c(C)on1,"InChI=1S/C30H33N5O3/c1-18-29(20(3)38-34-18)24-12-25-23(13-27(24)37-16-21-10-11-31-14-21)30-26(15-32-25)33-28(17-36-4)35(30)19(2)22-8-6-5-7-9-22/h5-9,12-13,15,19,21,31H,10-11,14,16-17H2,1-4H3/t19-,21+/m1/s1",ZORLJXWXFABTPZ-CTNGQTDRSA-N,Bromodomain,BRD4@BD1,23476,O60885,"HUNKI, MCAP, CAP, HUNK1",Inhibitor,No control available for probe,40,IC50,BET mutant TR-FRET assay (BD1),https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00566,0,50.1,IC50,NanoBRET assay (nanoluciferase-BRD4 fusion protein in HEK293 cells),https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00566,0,0,BROMOScan (DiscoverX) ,40,"In-vitro potencies of closest targets in BROMOScan (DiscoverX): Kd(BRD2, BD1) = 13 nM, Kd(BRD3, BD1) = 5 nM, Kd(BRD4, BD1) = 5.9 nM, Kd(BRDT, BD1) = 18 nM; Selectivity screen against 50 targets (GPCRs, ion-channels, other targets), in-vitro potencies of closest targets: pIC50(CHRNA1) = 6, pIC50(CYP3A4) = 6; Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potencies of closest targets: Ki(DRD3) = 485.92 nM, Ki(DRD4) = 856.99 nM, Ki(GABAA) = 1595.89 nM, Ki(GABAA/BZP) = 1970.29 nM",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00566,Epigenetic set,1 µM
EUB0001115a_BRDT@BD1,GSK778,EUB0001115a,Cc1c(c2cc3c(cc2OC[C@H]2CCNC2)c2c(cn3)nc(COC)n2[C@H](C)c2ccccc2)c(C)on1,"InChI=1S/C30H33N5O3/c1-18-29(20(3)38-34-18)24-12-25-23(13-27(24)37-16-21-10-11-31-14-21)30-26(15-32-25)33-28(17-36-4)35(30)19(2)22-8-6-5-7-9-22/h5-9,12-13,15,19,21,31H,10-11,14,16-17H2,1-4H3/t19-,21+/m1/s1",ZORLJXWXFABTPZ-CTNGQTDRSA-N,Bromodomain,BRDT@BD1,676,Q58F21,"BRD6, CT9",Inhibitor,No control available for probe,158,IC50,BET mutant TR-FRET assay (BD1),https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00566,0,,,,,,0,BROMOScan (DiscoverX) ,40,"In-vitro potencies of closest targets in BROMOScan (DiscoverX): Kd(BRD2, BD1) = 13 nM, Kd(BRD3, BD1) = 5 nM, Kd(BRD4, BD1) = 5.9 nM, Kd(BRDT, BD1) = 18 nM; Selectivity screen against 50 targets (GPCRs, ion-channels, other targets), in-vitro potencies of closest targets: pIC50(CHRNA1) = 6, pIC50(CYP3A4) = 6; Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potencies of closest targets: Ki(DRD3) = 485.92 nM, Ki(DRD4) = 856.99 nM, Ki(GABAA) = 1595.89 nM, Ki(GABAA/BZP) = 1970.29 nM",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00566,Epigenetic set,1 µM
EUB0001116a_BRD2@BD1,GSK789,EUB0001116a,CC1=Cc2c(cnc(c2NC1=O)N[C@@H]1CCN(C)C[C@H]1C(NC1CCCCC1)=O)c1ccco1,"InChI=1S/C26H33N5O3/c1-16-13-18-19(22-9-6-12-34-22)14-27-24(23(18)30-25(16)32)29-21-10-11-31(2)15-20(21)26(33)28-17-7-4-3-5-8-17/h6,9,12-14,17,20-21H,3-5,7-8,10-11,15H2,1-2H3,(H,27,29)(H,28,33)(H,30,32)/t20-,21-/m1/s1",NDEORODKVUYMFQ-NHCUHLMSSA-N,Bromodomain,BRD2@BD1,6046,P25440,"KIAA9001, RING3, D6S113E, NAT, FSRG1",Inhibitor,GSK791,100,IC50,BET mutant TR-FRET assay (BD1),https://pubmed.ncbi.nlm.nih.gov/32691589/,0,,,,,,0,BROMOScan (DiscoverX) ,40,"In-vitro potencies of closest targets in BROMOScan (DiscoverX): pKd(TAF1, BD2) = 7.3, pKd(TAF1L, BD2) = 6.4, selective for the BD1 domain of BET proteins; Follow-up of closest targets (FRET assay): pIC50(TAF1, BD1) = 5.0 ± 0.1, n = 3 (BRD4, BD1 selectivity = 500-fold); Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potency of closest target: Ki(DRD4) = 1013.12 nM",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00614,Epigenetic set,1 µM
EUB0001116a_BRD3@BD1,GSK789,EUB0001116a,CC1=Cc2c(cnc(c2NC1=O)N[C@@H]1CCN(C)C[C@H]1C(NC1CCCCC1)=O)c1ccco1,"InChI=1S/C26H33N5O3/c1-16-13-18-19(22-9-6-12-34-22)14-27-24(23(18)30-25(16)32)29-21-10-11-31(2)15-20(21)26(33)28-17-7-4-3-5-8-17/h6,9,12-14,17,20-21H,3-5,7-8,10-11,15H2,1-2H3,(H,27,29)(H,28,33)(H,30,32)/t20-,21-/m1/s1",NDEORODKVUYMFQ-NHCUHLMSSA-N,Bromodomain,BRD3@BD1,8019,Q15059,"RING3L, ORFX, KIAA0043",Inhibitor,GSK791,158,IC50,BET mutant TR-FRET assay (BD1),https://pubmed.ncbi.nlm.nih.gov/32691589/,0,,,,,,0,BROMOScan (DiscoverX) ,40,"In-vitro potencies of closest targets in BROMOScan (DiscoverX): pKd(TAF1, BD2) = 7.3, pKd(TAF1L, BD2) = 6.4, selective for the BD1 domain of BET proteins; Follow-up of closest targets (FRET assay): pIC50(TAF1, BD1) = 5.0 ± 0.1, n = 3 (BRD4, BD1 selectivity = 500-fold); Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potency of closest target: Ki(DRD4) = 1013.12 nM",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00614,Epigenetic set,1 µM
EUB0001116a_BRD4@BD1,GSK789,EUB0001116a,CC1=Cc2c(cnc(c2NC1=O)N[C@@H]1CCN(C)C[C@H]1C(NC1CCCCC1)=O)c1ccco1,"InChI=1S/C26H33N5O3/c1-16-13-18-19(22-9-6-12-34-22)14-27-24(23(18)30-25(16)32)29-21-10-11-31(2)15-20(21)26(33)28-17-7-4-3-5-8-17/h6,9,12-14,17,20-21H,3-5,7-8,10-11,15H2,1-2H3,(H,27,29)(H,28,33)(H,30,32)/t20-,21-/m1/s1",NDEORODKVUYMFQ-NHCUHLMSSA-N,Bromodomain,BRD4@BD1,23476,O60885,"HUNKI, MCAP, CAP, HUNK1",Inhibitor,GSK791,32,IC50,BET mutant TR-FRET assay (BD1),https://pubmed.ncbi.nlm.nih.gov/32691589/,0,,,,,,0,BROMOScan (DiscoverX) ,40,"In-vitro potencies of closest targets in BROMOScan (DiscoverX): pKd(TAF1, BD2) = 7.3, pKd(TAF1L, BD2) = 6.4, selective for the BD1 domain of BET proteins; Follow-up of closest targets (FRET assay): pIC50(TAF1, BD1) = 5.0 ± 0.1, n = 3 (BRD4, BD1 selectivity = 500-fold); Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potency of closest target: Ki(DRD4) = 1013.12 nM",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00614,Epigenetic set,1 µM
EUB0001116a_BRDT@BD1,GSK789,EUB0001116a,CC1=Cc2c(cnc(c2NC1=O)N[C@@H]1CCN(C)C[C@H]1C(NC1CCCCC1)=O)c1ccco1,"InChI=1S/C26H33N5O3/c1-16-13-18-19(22-9-6-12-34-22)14-27-24(23(18)30-25(16)32)29-21-10-11-31(2)15-20(21)26(33)28-17-7-4-3-5-8-17/h6,9,12-14,17,20-21H,3-5,7-8,10-11,15H2,1-2H3,(H,27,29)(H,28,33)(H,30,32)/t20-,21-/m1/s1",NDEORODKVUYMFQ-NHCUHLMSSA-N,Bromodomain,BRDT@BD1,676,Q58F21,"BRD6, CT9",Inhibitor,GSK791,631,IC50,BET mutant TR-FRET assay (BD1),https://pubmed.ncbi.nlm.nih.gov/32691589/,0,,,,,,0,BROMOScan (DiscoverX) ,40,"In-vitro potencies of closest targets in BROMOScan (DiscoverX): pKd(TAF1, BD2) = 7.3, pKd(TAF1L, BD2) = 6.4, selective for the BD1 domain of BET proteins; Follow-up of closest targets (FRET assay): pIC50(TAF1, BD1) = 5.0 ± 0.1, n = 3 (BRD4, BD1 selectivity = 500-fold); Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potency of closest target: Ki(DRD4) = 1013.12 nM",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00614,Epigenetic set,1 µM
EUB0001133a_BRD2@BD1,GSK791,EUB0001133a,Cc1cc2c(-c3ccco3)cnc(N[C@H]3CCN(C)C[C@@H]3C(=O)NC3CCCCC3)c2[nH]c1=O,"InChI=1S/C26H33N5O3/c1-16-13-18-19(22-9-6-12-34-22)14-27-24(23(18)30-25(16)32)29-21-10-11-31(2)15-20(21)26(33)28-17-7-4-3-5-8-17/h6,9,12-14,17,20-21H,3-5,7-8,10-11,15H2,1-2H3,(H,27,29)(H,28,33)(H,30,32)/t20-,21-/m0/s1",NDEORODKVUYMFQ-SFTDATJTSA-N,Bromodomain,BRD2@BD1,6046,P25440,"KIAA9001, RING3, D6S113E, NAT, FSRG1",Negative control for GSK789,,2512,IC50,BET mutant TR-FRET assay (BD1),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/GSK789,0,,,,,,0,GPCR panel (PDSP screen),45,"Screened at 10 µM, in-vitro potency of closest target: KI(GABA/BZP) = 2539.22 nM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/GSK789,Epigenetic set,1 µM
EUB0001133a_BRD3@BD1,GSK791,EUB0001133a,Cc1cc2c(-c3ccco3)cnc(N[C@H]3CCN(C)C[C@@H]3C(=O)NC3CCCCC3)c2[nH]c1=O,"InChI=1S/C26H33N5O3/c1-16-13-18-19(22-9-6-12-34-22)14-27-24(23(18)30-25(16)32)29-21-10-11-31(2)15-20(21)26(33)28-17-7-4-3-5-8-17/h6,9,12-14,17,20-21H,3-5,7-8,10-11,15H2,1-2H3,(H,27,29)(H,28,33)(H,30,32)/t20-,21-/m0/s1",NDEORODKVUYMFQ-SFTDATJTSA-N,Bromodomain,BRD3@BD1,8019,Q15059,"RING3L, ORFX, KIAA0043",Negative control for GSK789,,3981,IC50,BET mutant TR-FRET assay (BD1),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/GSK789,0,,,,,,0,GPCR panel (PDSP screen),45,"Screened at 10 µM, in-vitro potency of closest target: KI(GABA/BZP) = 2539.22 nM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/GSK789,Epigenetic set,1 µM
EUB0001133a_BRD4@BD1,GSK791,EUB0001133a,Cc1cc2c(-c3ccco3)cnc(N[C@H]3CCN(C)C[C@@H]3C(=O)NC3CCCCC3)c2[nH]c1=O,"InChI=1S/C26H33N5O3/c1-16-13-18-19(22-9-6-12-34-22)14-27-24(23(18)30-25(16)32)29-21-10-11-31(2)15-20(21)26(33)28-17-7-4-3-5-8-17/h6,9,12-14,17,20-21H,3-5,7-8,10-11,15H2,1-2H3,(H,27,29)(H,28,33)(H,30,32)/t20-,21-/m0/s1",NDEORODKVUYMFQ-SFTDATJTSA-N,Bromodomain,BRD4@BD1,23476,O60885,"HUNKI, MCAP, CAP, HUNK1",Negative control for GSK789,,1585,IC50,BET mutant TR-FRET assay (BD1),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/GSK789,0,,,,,,0,GPCR panel (PDSP screen),45,"Screened at 10 µM, in-vitro potency of closest target: KI(GABA/BZP) = 2539.22 nM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/GSK789,Epigenetic set,1 µM
EUB0001133a_BRDT@BD1,GSK791,EUB0001133a,Cc1cc2c(-c3ccco3)cnc(N[C@H]3CCN(C)C[C@@H]3C(=O)NC3CCCCC3)c2[nH]c1=O,"InChI=1S/C26H33N5O3/c1-16-13-18-19(22-9-6-12-34-22)14-27-24(23(18)30-25(16)32)29-21-10-11-31(2)15-20(21)26(33)28-17-7-4-3-5-8-17/h6,9,12-14,17,20-21H,3-5,7-8,10-11,15H2,1-2H3,(H,27,29)(H,28,33)(H,30,32)/t20-,21-/m0/s1",NDEORODKVUYMFQ-SFTDATJTSA-N,Bromodomain,BRDT@BD1,676,Q58F21,"BRD6, CT9",Negative control for GSK789,,7943,IC50,BET mutant TR-FRET assay (BD1),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/GSK789,0,,,,,,0,GPCR panel (PDSP screen),45,"Screened at 10 µM, in-vitro potency of closest target: KI(GABA/BZP) = 2539.22 nM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/GSK789,Epigenetic set,1 µM
EUB0001134a_BRD2@BD2,GSK943,EUB0001134a,CNC(=O)c1cc(C(=O)N[C@@H]2[C@H]3COC[C@H]32)cc2c1O[C@@H](CF)[C@@H]2c1ccccc1,"InChI=1S/C23H23FN2O4/c1-25-23(28)15-8-13(22(27)26-20-16-10-29-11-17(16)20)7-14-19(12-5-3-2-4-6-12)18(9-24)30-21(14)15/h2-8,16-20H,9-11H2,1H3,(H,25,28)(H,26,27)/t16-,17+,18-,19+,20+/m0/s1",WZQLVEPIBAOOGF-PXTPFGJHSA-N,Bromodomain,BRD2@BD2,6046,P25440,"KIAA9001, RING3, D6S113E, NAT, FSRG1",Negative control for GSK973,,,,,,,,,,,,0,GPCR panel (PDSP screen),45,"Screened at 10 µM, in-vitro potency of closest target: Ki(GABA/BZP) = 473.91 nM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/GSK973,Epigenetic set,1 µM
EUB0001134a_BRD3@BD2,GSK943,EUB0001134a,CNC(=O)c1cc(C(=O)N[C@@H]2[C@H]3COC[C@H]32)cc2c1O[C@@H](CF)[C@@H]2c1ccccc1,"InChI=1S/C23H23FN2O4/c1-25-23(28)15-8-13(22(27)26-20-16-10-29-11-17(16)20)7-14-19(12-5-3-2-4-6-12)18(9-24)30-21(14)15/h2-8,16-20H,9-11H2,1H3,(H,25,28)(H,26,27)/t16-,17+,18-,19+,20+/m0/s1",WZQLVEPIBAOOGF-PXTPFGJHSA-N,Bromodomain,BRD3@BD2,8019,Q15059,"RING3L, ORFX, KIAA0043",Negative control for GSK973,,,,,,,,,,,,0,GPCR panel (PDSP screen),45,"Screened at 10 µM, in-vitro potency of closest target: Ki(GABA/BZP) = 473.91 nM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/GSK973,Epigenetic set,1 µM
EUB0001134a_BRD4@BD2,GSK943,EUB0001134a,CNC(=O)c1cc(C(=O)N[C@@H]2[C@H]3COC[C@H]32)cc2c1O[C@@H](CF)[C@@H]2c1ccccc1,"InChI=1S/C23H23FN2O4/c1-25-23(28)15-8-13(22(27)26-20-16-10-29-11-17(16)20)7-14-19(12-5-3-2-4-6-12)18(9-24)30-21(14)15/h2-8,16-20H,9-11H2,1H3,(H,25,28)(H,26,27)/t16-,17+,18-,19+,20+/m0/s1",WZQLVEPIBAOOGF-PXTPFGJHSA-N,Bromodomain,BRD4@BD2,23476,O60885,"HUNKI, MCAP, CAP, HUNK1",Negative control for GSK973,,7943,IC50,BET mutant TR-FRET assay (BD2),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/GSK973,0,,,,,,0,GPCR panel (PDSP screen),45,"Screened at 10 µM, in-vitro potency of closest target: Ki(GABA/BZP) = 473.91 nM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/GSK973,Epigenetic set,1 µM
EUB0001134a_BRDT@BD2,GSK943,EUB0001134a,CNC(=O)c1cc(C(=O)N[C@@H]2[C@H]3COC[C@H]32)cc2c1O[C@@H](CF)[C@@H]2c1ccccc1,"InChI=1S/C23H23FN2O4/c1-25-23(28)15-8-13(22(27)26-20-16-10-29-11-17(16)20)7-14-19(12-5-3-2-4-6-12)18(9-24)30-21(14)15/h2-8,16-20H,9-11H2,1H3,(H,25,28)(H,26,27)/t16-,17+,18-,19+,20+/m0/s1",WZQLVEPIBAOOGF-PXTPFGJHSA-N,Bromodomain,BRDT@BD2,676,Q58F21,"BRD6, CT9",Negative control for GSK973,,,,,,,,,,,,0,GPCR panel (PDSP screen),45,"Screened at 10 µM, in-vitro potency of closest target: Ki(GABA/BZP) = 473.91 nM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/GSK973,Epigenetic set,1 µM
EUB0001113a_BRD2@BD2,GSK973,EUB0001113a,[H][C@@]12COC[C@@]2([H])[C@@H]1NC(c1cc(C(NC)=O)c2c(c1)[C@H](c1ccccc1)[C@@H](CF)O2)=O,"InChI=1S/C23H23FN2O4/c1-25-23(28)15-8-13(22(27)26-20-16-10-29-11-17(16)20)7-14-19(12-5-3-2-4-6-12)18(9-24)30-21(14)15/h2-8,16-20H,9-11H2,1H3,(H,25,28)(H,26,27)/t16-,17+,18-,19+,20+/m1/s1",WZQLVEPIBAOOGF-RMMWZPCPSA-N,Bromodomain,BRD2@BD2,6046,P25440,"KIAA9001, RING3, D6S113E, NAT, FSRG1",Inhibitor,GSK943,31.6,IC50,BET mutant TR-FRET assay (BD2),https://pubs.acs.org/doi/10.1021/acsmedchemlett.0c00247,0,,,,,,0,BROMOScan (DiscoverX) ,40,"In-vitro potencies of closest targets in BROMOScan (DiscoverX): pKd(TAF1, BD2) = 6.4, pKd(TAF1L, BD2) = 5.7, pKd(BRD9) = 5.7, pKd(CECR2) = 5.5, pKd(BAZ2A) = 5.5, pKd(BAZ2B) = 5.1; Selective for the BD2 domain of BET proteins; Clean in selectivity screen against 48 targets (GPCRs, ion-channels, other targets); Chemoproteomics data (3 vectors) showed excellent non BCPs selectivity; Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potencies of closest targets: Ki(DRD3) = 257.47 nM, Ki(DRD4) = 982.65 nM, Ki(DRD2) = 964.05 nM",https://pubs.acs.org/doi/10.1021/acsmedchemlett.0c00247,Epigenetic set,1 µM
EUB0001113a_BRD3@BD2,GSK973,EUB0001113a,[H][C@@]12COC[C@@]2([H])[C@@H]1NC(c1cc(C(NC)=O)c2c(c1)[C@H](c1ccccc1)[C@@H](CF)O2)=O,"InChI=1S/C23H23FN2O4/c1-25-23(28)15-8-13(22(27)26-20-16-10-29-11-17(16)20)7-14-19(12-5-3-2-4-6-12)18(9-24)30-21(14)15/h2-8,16-20H,9-11H2,1H3,(H,25,28)(H,26,27)/t16-,17+,18-,19+,20+/m1/s1",WZQLVEPIBAOOGF-RMMWZPCPSA-N,Bromodomain,BRD3@BD2,8019,Q15059,"RING3L, ORFX, KIAA0043",Inhibitor,GSK943,15.8,IC50,BET mutant TR-FRET assay (BD2),https://pubs.acs.org/doi/10.1021/acsmedchemlett.0c00247,0,,,,,,0,BROMOScan (DiscoverX) ,40,"In-vitro potencies of closest targets in BROMOScan (DiscoverX): pKd(TAF1, BD2) = 6.4, pKd(TAF1L, BD2) = 5.7, pKd(BRD9) = 5.7, pKd(CECR2) = 5.5, pKd(BAZ2A) = 5.5, pKd(BAZ2B) = 5.1; Selective for the BD2 domain of BET proteins; Clean in selectivity screen against 48 targets (GPCRs, ion-channels, other targets); Chemoproteomics data (3 vectors) showed excellent non BCPs selectivity; Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potencies of closest targets: Ki(DRD3) = 257.47 nM, Ki(DRD4) = 982.65 nM, Ki(DRD2) = 964.05 nM",https://pubs.acs.org/doi/10.1021/acsmedchemlett.0c00247,Epigenetic set,1 µM
EUB0001113a_BRD4@BD2,GSK973,EUB0001113a,[H][C@@]12COC[C@@]2([H])[C@@H]1NC(c1cc(C(NC)=O)c2c(c1)[C@H](c1ccccc1)[C@@H](CF)O2)=O,"InChI=1S/C23H23FN2O4/c1-25-23(28)15-8-13(22(27)26-20-16-10-29-11-17(16)20)7-14-19(12-5-3-2-4-6-12)18(9-24)30-21(14)15/h2-8,16-20H,9-11H2,1H3,(H,25,28)(H,26,27)/t16-,17+,18-,19+,20+/m1/s1",WZQLVEPIBAOOGF-RMMWZPCPSA-N,Bromodomain,BRD4@BD2,23476,O60885,"HUNKI, MCAP, CAP, HUNK1",Inhibitor,GSK943,15.8,IC50,BET mutant TR-FRET assay (BD2),https://pubs.acs.org/doi/10.1021/acsmedchemlett.0c00247,0,,,,,,0,BROMOScan (DiscoverX) ,40,"In-vitro potencies of closest targets in BROMOScan (DiscoverX): pKd(TAF1, BD2) = 6.4, pKd(TAF1L, BD2) = 5.7, pKd(BRD9) = 5.7, pKd(CECR2) = 5.5, pKd(BAZ2A) = 5.5, pKd(BAZ2B) = 5.1; Selective for the BD2 domain of BET proteins; Clean in selectivity screen against 48 targets (GPCRs, ion-channels, other targets); Chemoproteomics data (3 vectors) showed excellent non BCPs selectivity; Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potencies of closest targets: Ki(DRD3) = 257.47 nM, Ki(DRD4) = 982.65 nM, Ki(DRD2) = 964.05 nM",https://pubs.acs.org/doi/10.1021/acsmedchemlett.0c00247,Epigenetic set,1 µM
EUB0001113a_BRDT@BD2,GSK973,EUB0001113a,[H][C@@]12COC[C@@]2([H])[C@@H]1NC(c1cc(C(NC)=O)c2c(c1)[C@H](c1ccccc1)[C@@H](CF)O2)=O,"InChI=1S/C23H23FN2O4/c1-25-23(28)15-8-13(22(27)26-20-16-10-29-11-17(16)20)7-14-19(12-5-3-2-4-6-12)18(9-24)30-21(14)15/h2-8,16-20H,9-11H2,1H3,(H,25,28)(H,26,27)/t16-,17+,18-,19+,20+/m1/s1",WZQLVEPIBAOOGF-RMMWZPCPSA-N,Bromodomain,BRDT@BD2,676,Q58F21,"BRD6, CT9",Inhibitor,GSK943,39.8,IC50,BET mutant TR-FRET assay (BD2),https://pubs.acs.org/doi/10.1021/acsmedchemlett.0c00247,0,,,,,,0,BROMOScan (DiscoverX) ,40,"In-vitro potencies of closest targets in BROMOScan (DiscoverX): pKd(TAF1, BD2) = 6.4, pKd(TAF1L, BD2) = 5.7, pKd(BRD9) = 5.7, pKd(CECR2) = 5.5, pKd(BAZ2A) = 5.5, pKd(BAZ2B) = 5.1; Selective for the BD2 domain of BET proteins; Clean in selectivity screen against 48 targets (GPCRs, ion-channels, other targets); Chemoproteomics data (3 vectors) showed excellent non BCPs selectivity; Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potencies of closest targets: Ki(DRD3) = 257.47 nM, Ki(DRD4) = 982.65 nM, Ki(DRD2) = 964.05 nM",https://pubs.acs.org/doi/10.1021/acsmedchemlett.0c00247,Epigenetic set,1 µM
EUB0001122a_WDR5,Homer,EUB0001122a,CC1=C(C2=CC=C(CNC([C@@H]3C[C@@H](O)CN3C([C@H](C(C)(C)C)NC(CCCCNC(C4=CC=C(C5=CC=C(N6CCN(C)CC6)C(NC(C7=CNC(C=C7C(F)(F)F)=O)=O)=C5)C=C4)=O)=O)=O)=O)C=C2)SC=N1 ,"InChI=1S/C52H60F3N9O7S/c1-31-45(72-30-59-31)34-11-9-32(10-12-34)27-58-49(70)42-25-37(65)29-64(42)50(71)46(51(2,3)4)61-43(66)8-6-7-19-56-47(68)35-15-13-33(14-16-35)36-17-18-41(63-22-20-62(5)21-23-63)40(24-36)60-48(69)38-28-57-44(67)26-39(38)52(53,54)55/h9-18,24,26,28,30,37,42,46,65H,6-8,19-23,25,27,29H2,1-5H3,(H,56,68)(H,57,67)(H,58,70)(H,60,69)(H,61,66)/t37-,42+,46-/m1/s1",OFNZESNEBSQKSE-BQGOKDIQSA-N,,WDR5,11091,P61964,"SWD3, CFAP89","PROTAC, degrader",nc_WDR5 and nc_VHL,18,Kd,ITC,https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00146,0,53,DC50,HiBit assay (WDR5 degradation in MV4-11 cells),https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00146,0,,Proteomics,,"Screened at 1 µM in quantitative proteomic studies, clean selectivty profile",https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00146,Epigenetic set,1 µM
EUB0000227d_EGLN1,IOX2,EUB0000227d,CC(CS(=O)(N[C@H]1CCC(N(C2=CC3=C(C(C)=CC(N3C)=O)C=C2)[C@@H]1C4=CC=C(C=C4)Cl)=O)=O)C,"InChI=1S/C26H30ClN3O4S/c1-16(2)15-35(33,34)28-22-11-12-24(31)30(26(22)18-5-7-19(27)8-6-18)20-9-10-21-17(3)13-25(32)29(4)23(21)14-20/h5-10,13-14,16,22,26,28H,11-12,15H2,1-4H3/t22-,26+/m0/s1",LVDRREOUMKACNJ-BKMJKUGQSA-N,Hydroxylase,EGLN1,54583,Q9GZT9,"C1orf12, ECYT3, HALAH, HIF-PH2, HIFPH2, HPH-2, HPH2, PHD2, SM20, ZMYND6",Inhibitor,No control available for probe,22,IC50,AlphaScreen assay,https://www.thesgc.org/chemical-probes/IOX2,0,,,,,,0,CEREP panel (receptors and ion channels) ,55,"Screened at 10 µM, closest targets as % control binding: Cl-channel, GABA gated (70%), Adenosine A1 (82%); Selectivity against histone demethylases, in-vitro potency (AlphaScreen assay): IC50(KDM4A) = 100 µM, IC50(KDM4C) = 100 µM, IC50(KDM4E) >100 µM, IC50(KDM6B) >100 µM, IC50(KDM3A) >100 µM, IC50(KDM2A) = 52 µM, IC50(KDM5C) = 159 µM",https://www.thesgc.org/chemical-probes/IOX2,Other targets set,1 µM
EUB0002255a_CDK14,JA314,EUB0002255a,CNC(=O)c1cc(Nc2ccnc(Nc3ccc(CCNC(=O)OC(C)(C)C)cc3)n2)n[nH]1,"InChI=1S/C22H28N8O3/c1-22(2,3)33-21(32)25-11-9-14-5-7-15(8-6-14)26-20-24-12-10-17(28-20)27-18-13-16(29-30-18)19(31)23-4/h5-8,10,12-13H,9,11H2,1-4H3,(H,23,31)(H,25,32)(H3,24,26,27,28,29,30)",VJWCJKXRULCPCJ-UHFFFAOYSA-N,Protein Kinase,CDK14,5218,O94921,PFTAIRE1,Negative control for JA397,,,,,,,,,,,,0,Kinase panel (DSF assay),100,"Screened at 20 µM, closest targets: dTm(MAPK8) = 4.8 K, dTm(AAK1) = 4.6&), dTm(TTK) = 4K, dTm(STK6) = 4 K, dTm(BMP2K) = 3.8 K, dTm(STK17A) = 3.5 K, dTm(GAK) = 3 K, dTm(MAPK10) = 3 K, dTm(CDK16) = 0.9 K  ",https://www.thesgc.org/chemical-probes/ja397,Kinase set,1 µM
EUB0002255a_CDK15,JA314,EUB0002255a,CNC(=O)c1cc(Nc2ccnc(Nc3ccc(CCNC(=O)OC(C)(C)C)cc3)n2)n[nH]1,"InChI=1S/C22H28N8O3/c1-22(2,3)33-21(32)25-11-9-14-5-7-15(8-6-14)26-20-24-12-10-17(28-20)27-18-13-16(29-30-18)19(31)23-4/h5-8,10,12-13H,9,11H2,1-4H3,(H,23,31)(H,25,32)(H3,24,26,27,28,29,30)",VJWCJKXRULCPCJ-UHFFFAOYSA-N,Protein Kinase,CDK15,65061,Q96Q40,PFTAIRE2,Negative control for JA397,,,,,,,,,,,,0,Kinase panel (DSF assay),100,"Screened at 20 µM, closest targets: dTm(MAPK8) = 4.8 K, dTm(AAK1) = 4.6&), dTm(TTK) = 4K, dTm(STK6) = 4 K, dTm(BMP2K) = 3.8 K, dTm(STK17A) = 3.5 K, dTm(GAK) = 3 K, dTm(MAPK10) = 3 K, dTm(CDK16) = 0.9 K  ",https://www.thesgc.org/chemical-probes/ja397,Kinase set,1 µM
EUB0002255a_CDK16,JA314,EUB0002255a,CNC(=O)c1cc(Nc2ccnc(Nc3ccc(CCNC(=O)OC(C)(C)C)cc3)n2)n[nH]1,"InChI=1S/C22H28N8O3/c1-22(2,3)33-21(32)25-11-9-14-5-7-15(8-6-14)26-20-24-12-10-17(28-20)27-18-13-16(29-30-18)19(31)23-4/h5-8,10,12-13H,9,11H2,1-4H3,(H,23,31)(H,25,32)(H3,24,26,27,28,29,30)",VJWCJKXRULCPCJ-UHFFFAOYSA-N,Protein Kinase,CDK16,5127,Q00536,"PCTAIRE, PCTAIRE1, PCTGAIRE, FLJ16665",Negative control for JA397,,,,,,,4165,EC50,"NanoBRET assay (lysed mode, HEK293T cells)",https://pubmed.ncbi.nlm.nih.gov/36499165/,0,0,Kinase panel (DSF assay),100,"Screened at 20 µM, closest targets: dTm(MAPK8) = 4.8 K, dTm(AAK1) = 4.6&), dTm(TTK) = 4K, dTm(STK6) = 4 K, dTm(BMP2K) = 3.8 K, dTm(STK17A) = 3.5 K, dTm(GAK) = 3 K, dTm(MAPK10) = 3 K, dTm(CDK16) = 0.9 K  ",https://www.thesgc.org/chemical-probes/ja397,Kinase set,1 µM
EUB0002255a_CDK17,JA314,EUB0002255a,CNC(=O)c1cc(Nc2ccnc(Nc3ccc(CCNC(=O)OC(C)(C)C)cc3)n2)n[nH]1,"InChI=1S/C22H28N8O3/c1-22(2,3)33-21(32)25-11-9-14-5-7-15(8-6-14)26-20-24-12-10-17(28-20)27-18-13-16(29-30-18)19(31)23-4/h5-8,10,12-13H,9,11H2,1-4H3,(H,23,31)(H,25,32)(H3,24,26,27,28,29,30)",VJWCJKXRULCPCJ-UHFFFAOYSA-N,Protein Kinase,CDK17,5128,Q00537,PCTAIRE2,Negative control for JA397,,,,,,,,,,,,0,Kinase panel (DSF assay),100,"Screened at 20 µM, closest targets: dTm(MAPK8) = 4.8 K, dTm(AAK1) = 4.6&), dTm(TTK) = 4K, dTm(STK6) = 4 K, dTm(BMP2K) = 3.8 K, dTm(STK17A) = 3.5 K, dTm(GAK) = 3 K, dTm(MAPK10) = 3 K, dTm(CDK16) = 0.9 K  ",https://www.thesgc.org/chemical-probes/ja397,Kinase set,1 µM
EUB0002255a_CDK18,JA314,EUB0002255a,CNC(=O)c1cc(Nc2ccnc(Nc3ccc(CCNC(=O)OC(C)(C)C)cc3)n2)n[nH]1,"InChI=1S/C22H28N8O3/c1-22(2,3)33-21(32)25-11-9-14-5-7-15(8-6-14)26-20-24-12-10-17(28-20)27-18-13-16(29-30-18)19(31)23-4/h5-8,10,12-13H,9,11H2,1-4H3,(H,23,31)(H,25,32)(H3,24,26,27,28,29,30)",VJWCJKXRULCPCJ-UHFFFAOYSA-N,Protein Kinase,CDK18,5129,Q07002,PCTAIRE3,Negative control for JA397,,,,,,,,,,,,0,Kinase panel (DSF assay),100,"Screened at 20 µM, closest targets: dTm(MAPK8) = 4.8 K, dTm(AAK1) = 4.6&), dTm(TTK) = 4K, dTm(STK6) = 4 K, dTm(BMP2K) = 3.8 K, dTm(STK17A) = 3.5 K, dTm(GAK) = 3 K, dTm(MAPK10) = 3 K, dTm(CDK16) = 0.9 K  ",https://www.thesgc.org/chemical-probes/ja397,Kinase set,1 µM
EUB0002256a_CDK14,JA397,EUB0002256a,CC(C)(C)OC(=O)Nc1ccc(CNc2nccc(Nc3cc(C(=O)OC(C)(C)C)[nH]n3)n2)cc1,"InChI=1S/C24H31N7O4/c1-23(2,3)34-20(32)17-13-19(31-30-17)28-18-11-12-25-21(29-18)26-14-15-7-9-16(10-8-15)27-22(33)35-24(4,5)6/h7-13H,14H2,1-6H3,(H,27,33)(H3,25,26,28,29,30,31)",JQLMEZBHIJSVKR-UHFFFAOYSA-N,Protein Kinase,CDK14,5218,O94921,PFTAIRE1,Inhibitor,JA314,,,,,,27.1,EC50,"NanoBRET assay (lysed mode, HEK293T cells)",https://pubmed.ncbi.nlm.nih.gov/36499165/,0,0,Kinase panel (Reaction Biology) ,340,"Screened at 1 µM, closest targets as % of control: CDK16 (cyclin Y, 28.4%),  NTRK1 (44.8%), NTRK2 (47.5%), CDK12 (cyclin K, 49.8%), CDK17 (p35NCK, 50.9%), CDK18 (cyclin Y, 54.3%); Screened against 100 kinases (DSF assay), closest targets: dTm(CDK16) = 9.2 K, dTm(MAPK15) = 5.8 K, dTm(PLK4) = 5.5 K, dTm(STK6) = 4.0 K, dTm(ULK3) = 3.3 K, dTm(CDK2) = 3.2 K, dTm(MAP2K6) = 3 K, dTm(GSK3B) = 2.9 K, dTm(MAPK10) = -1.6 K",https://www.thesgc.org/chemical-probes/ja397,Kinase set,1 µM
EUB0002256a_CDK15,JA397,EUB0002256a,CC(C)(C)OC(=O)Nc1ccc(CNc2nccc(Nc3cc(C(=O)OC(C)(C)C)[nH]n3)n2)cc1,"InChI=1S/C24H31N7O4/c1-23(2,3)34-20(32)17-13-19(31-30-17)28-18-11-12-25-21(29-18)26-14-15-7-9-16(10-8-15)27-22(33)35-24(4,5)6/h7-13H,14H2,1-6H3,(H,27,33)(H3,25,26,28,29,30,31)",JQLMEZBHIJSVKR-UHFFFAOYSA-N,Protein Kinase,CDK15,65061,Q96Q40,PFTAIRE2,Inhibitor,JA314,,,,,,252,EC50,"NanoBRET assay (lysed mode, HEK293T cells)",https://pubmed.ncbi.nlm.nih.gov/36499165/,0,0,Kinase panel (Reaction Biology) ,340,"Screened at 1 µM, closest targets as % of control: CDK16 (cyclin Y, 28.4%),  NTRK1 (44.8%), NTRK2 (47.5%), CDK12 (cyclin K, 49.8%), CDK17 (p35NCK, 50.9%), CDK18 (cyclin Y, 54.3%); Screened against 100 kinases (DSF assay), closest targets: dTm(CDK16) = 9.2 K, dTm(MAPK15) = 5.8 K, dTm(PLK4) = 5.5 K, dTm(STK6) = 4.0 K, dTm(ULK3) = 3.3 K, dTm(CDK2) = 3.2 K, dTm(MAP2K6) = 3 K, dTm(GSK3B) = 2.9 K, dTm(MAPK10) = -1.6 K",https://www.thesgc.org/chemical-probes/ja397,Kinase set,1 µM
EUB0002256a_CDK16,JA397,EUB0002256a,CC(C)(C)OC(=O)Nc1ccc(CNc2nccc(Nc3cc(C(=O)OC(C)(C)C)[nH]n3)n2)cc1,"InChI=1S/C24H31N7O4/c1-23(2,3)34-20(32)17-13-19(31-30-17)28-18-11-12-25-21(29-18)26-14-15-7-9-16(10-8-15)27-22(33)35-24(4,5)6/h7-13H,14H2,1-6H3,(H,27,33)(H3,25,26,28,29,30,31)",JQLMEZBHIJSVKR-UHFFFAOYSA-N,Protein Kinase,CDK16,5127,Q00536,"PCTAIRE, PCTAIRE1, PCTGAIRE, FLJ16665",Inhibitor,JA314,,,,,,39,EC50,"NanoBRET assay (lysed mode, HEK293T cells)",https://pubmed.ncbi.nlm.nih.gov/36499165/,0,0,Kinase panel (Reaction Biology) ,340,"Screened at 1 µM, closest targets as % of control: CDK16 (cyclin Y, 28.4%),  NTRK1 (44.8%), NTRK2 (47.5%), CDK12 (cyclin K, 49.8%), CDK17 (p35NCK, 50.9%), CDK18 (cyclin Y, 54.3%); Screened against 100 kinases (DSF assay), closest targets: dTm(CDK16) = 9.2 K, dTm(MAPK15) = 5.8 K, dTm(PLK4) = 5.5 K, dTm(STK6) = 4.0 K, dTm(ULK3) = 3.3 K, dTm(CDK2) = 3.2 K, dTm(MAP2K6) = 3 K, dTm(GSK3B) = 2.9 K, dTm(MAPK10) = -1.6 K",https://www.thesgc.org/chemical-probes/ja397,Kinase set,1 µM
EUB0002256a_CDK17,JA397,EUB0002256a,CC(C)(C)OC(=O)Nc1ccc(CNc2nccc(Nc3cc(C(=O)OC(C)(C)C)[nH]n3)n2)cc1,"InChI=1S/C24H31N7O4/c1-23(2,3)34-20(32)17-13-19(31-30-17)28-18-11-12-25-21(29-18)26-14-15-7-9-16(10-8-15)27-22(33)35-24(4,5)6/h7-13H,14H2,1-6H3,(H,27,33)(H3,25,26,28,29,30,31)",JQLMEZBHIJSVKR-UHFFFAOYSA-N,Protein Kinase,CDK17,5128,Q00537,PCTAIRE2,Inhibitor,JA314,,,,,,77.2,EC50,"NanoBRET assay (lysed mode, HEK293T cells)",https://pubmed.ncbi.nlm.nih.gov/36499165/,0,0,Kinase panel (Reaction Biology) ,340,"Screened at 1 µM, closest targets as % of control: CDK16 (cyclin Y, 28.4%),  NTRK1 (44.8%), NTRK2 (47.5%), CDK12 (cyclin K, 49.8%), CDK17 (p35NCK, 50.9%), CDK18 (cyclin Y, 54.3%); Screened against 100 kinases (DSF assay), closest targets: dTm(CDK16) = 9.2 K, dTm(MAPK15) = 5.8 K, dTm(PLK4) = 5.5 K, dTm(STK6) = 4.0 K, dTm(ULK3) = 3.3 K, dTm(CDK2) = 3.2 K, dTm(MAP2K6) = 3 K, dTm(GSK3B) = 2.9 K, dTm(MAPK10) = -1.6 K",https://www.thesgc.org/chemical-probes/ja397,Kinase set,1 µM
EUB0002256a_CDK18,JA397,EUB0002256a,CC(C)(C)OC(=O)Nc1ccc(CNc2nccc(Nc3cc(C(=O)OC(C)(C)C)[nH]n3)n2)cc1,"InChI=1S/C24H31N7O4/c1-23(2,3)34-20(32)17-13-19(31-30-17)28-18-11-12-25-21(29-18)26-14-15-7-9-16(10-8-15)27-22(33)35-24(4,5)6/h7-13H,14H2,1-6H3,(H,27,33)(H3,25,26,28,29,30,31)",JQLMEZBHIJSVKR-UHFFFAOYSA-N,Protein Kinase,CDK18,5129,Q07002,PCTAIRE3,Inhibitor,JA314,,,,,,172,EC50,"NanoBRET assay (lysed mode, HEK293T cells)",https://pubmed.ncbi.nlm.nih.gov/36499165/,0,0,Kinase panel (Reaction Biology) ,340,"Screened at 1 µM, closest targets as % of control: CDK16 (cyclin Y, 28.4%),  NTRK1 (44.8%), NTRK2 (47.5%), CDK12 (cyclin K, 49.8%), CDK17 (p35NCK, 50.9%), CDK18 (cyclin Y, 54.3%); Screened against 100 kinases (DSF assay), closest targets: dTm(CDK16) = 9.2 K, dTm(MAPK15) = 5.8 K, dTm(PLK4) = 5.5 K, dTm(STK6) = 4.0 K, dTm(ULK3) = 3.3 K, dTm(CDK2) = 3.2 K, dTm(MAP2K6) = 3 K, dTm(GSK3B) = 2.9 K, dTm(MAPK10) = -1.6 K",https://www.thesgc.org/chemical-probes/ja397,Kinase set,1 µM
EUB0002257a_CSNK1D,JNJ-0293,EUB0002257a,Cn1ncc2c(-c3c(-c4ccc(F)cn4)nn4c3COC(C)(C)C4)ccnc21,"InChI=1S/C20H19FN6O/c1-20(2)11-27-16(10-28-20)17(18(25-27)15-5-4-12(21)8-23-15)13-6-7-22-19-14(13)9-24-26(19)3/h4-9H,10-11H2,1-3H3",OOIXWMIRURMFRS-UHFFFAOYSA-N,Protein Kinase,CSNK1D,1453,P48730,"HCKID, CKID, CKIdelta",Negative control for JNJ-6204,,,,,,,,,,,,0,GPCR panel (PDSP screen),45,"Screened at 10 µM, against 45 GPCRs, closest targets as % of inhibition: SLC6A3 (72.51%), HTR1A (-28.41%), DRD3(71.05%), in-vitro potency of closest targets: Ki(SLC6A3) = 7216.06 nM, Ki(HTR1A) = 7661.26 nM, Ki(DRD3) = 8625.81 nM",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/JNJ-6204,Kinase set,1 µM
EUB0002257a_CSNK1E,JNJ-0293,EUB0002257a,Cn1ncc2c(-c3c(-c4ccc(F)cn4)nn4c3COC(C)(C)C4)ccnc21,"InChI=1S/C20H19FN6O/c1-20(2)11-27-16(10-28-20)17(18(25-27)15-5-4-12(21)8-23-15)13-6-7-22-19-14(13)9-24-26(19)3/h4-9H,10-11H2,1-3H3",OOIXWMIRURMFRS-UHFFFAOYSA-N,Protein Kinase,CSNK1E,1454,P49674,"HCKIE, CKIE, CKIepsilon",Negative control for JNJ-6204,,6900,IC50,ADP-Glo assay ,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/JNJ-6204,0,10000,IC50,BRET assay (whole cell binding assay using full-length human CSNK1D in CHO cells),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/JNJ-6204,>,0,GPCR panel (PDSP screen),45,"Screened at 10 µM, against 45 GPCRs, closest targets as % of inhibition: SLC6A3 (72.51%), HTR1A (-28.41%), DRD3(71.05%), in-vitro potency of closest targets: Ki(SLC6A3) = 7216.06 nM, Ki(HTR1A) = 7661.26 nM, Ki(DRD3) = 8625.81 nM",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/JNJ-6204,Kinase set,1 µM
EUB0001571a_PDE10A,JNJ-40573663,EUB0001571a,c1ccc(C2CCN(c3cnc4c(N5CCOCC5)nccn34)CC2)cc1,"InChI=1S/C21H25N5O/c1-2-4-17(5-3-1)18-6-9-24(10-7-18)19-16-23-21-20(22-8-11-26(19)21)25-12-14-27-15-13-25/h1-5,8,11,16,18H,6-7,9-10,12-15H2",OKTXMSSTNJXZII-UHFFFAOYSA-N,,PDE10A,10846,Q9Y233,PDE10A,Negative control for JNJ-42396302,,10000,IC50,In-vitro assay (recombinant human PDE10A),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/JNJ-42396302,>,,,,,,0,GPCR panel (PDSP screen),45,"Screened at 10 µM, in-vitro potencies of closest targets: Ki(GABAA) = 1.822 µM, Ki(SLC6A3) = 4.132 µM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/JNJ-42396302,Other targets set,1 µM
EUB0001570a_PDE10A,JNJ-42396302,EUB0001570a,COCCc1ccc(-c2c(C)nc3c(N4CCOCC4)ccnn23)cn1,"InChI=1S/C19H23N5O2/c1-14-18(15-3-4-16(20-13-15)6-10-25-2)24-19(22-14)17(5-7-21-24)23-8-11-26-12-9-23/h3-5,7,13H,6,8-12H2,1-2H3",BPLVDYJDAVYLRQ-UHFFFAOYSA-N,,PDE10A,10846,Q9Y233,PDE10A,Inhibitor,JNJ-40573663,13,Ki,Scintillation proximity assay with human PDE10A,https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/JNJ-42396302,0,2.3,fold,Luciferase activity assay (measuring increase in cAMP level at 1 µM in HEK293 cells stably transfected with mouse PDE10A1 and transiently co-transfected with pCRE-Luc plasmid),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!detailedpotencydataview/JNJ-42396302,0,0,PDE panel (in-house data Janssen),11,"Selective versus other PDE family members (>250 fold in Scintillation proximity assays): Ki(hPDE1B1) = 3.4 µM, Ki(hPDE2A) = 32 µM, Ki(hPDE3A) = 49 µM, Ki(hPDE4D3) = 15 µM, Ki(hPDE5A3) = 8.5 µM, Ki(hPDE6AB) = 85 µM, Ki(hPDE7A1) = 23 µM, Ki(hPDE8A1) = 41 µM, Ki(hPDE9A) >33 µM, Ki(hPDE10A2) = 0.013 µM, Ki(hPDE11A4) = 46 µM; Screened at 10 µM in CEREP panel against 50 receptors and other enzymes: clean selectivity profile; Screened at 10 µM against 230 kinases (Millipore panel): clean selectivity profile with no inhibition of kinases <50%; Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potencies of closest targets: Ki(ADRA2B) >10 µM, Ki(HTR2C) = 2.197 µM, Ki(HTR2B) = 2.293 µM, Ki(HTR7) = 8.745 µM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/JNJ-42396302,Other targets set,1 µM
EUB0001569a_RORC,JNJ-53721590,EUB0001569a,COc1nc2ccc([C@@](O)(c3ccc(Cl)cc3)c3cncn3C)cc2c(Cl)c1Cc1ccc(-n2cccn2)cc1,"InChI=1S/C31H25Cl2N5O2/c1-37-19-34-18-28(37)31(39,21-6-9-23(32)10-7-21)22-8-13-27-25(17-22)29(33)26(30(36-27)40-2)16-20-4-11-24(12-5-20)38-15-3-14-35-38/h3-15,17-19,39H,16H2,1-2H3/t31-/m0/s1",UWOBQISTECYGOP-HKBQPEDESA-N,Nuclear Receptor,RORC,6097,P51449,"RZRG, RORG, NR1F3, TOR",Negative control for JNJ-54119936, ,515.7,qKd,ThermoFlour binding assay (RORC),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!detailedpotencydataview/JNJ-54119936,0,670,IC50,"One-hybrid reporter assay (HEK293T cells co-transfected with pFR-Luc reporter and pRL-CMV reporter, pCMV-BD containing the GAL4 DNA-binding domain fused with full-length human RORγt using 6 µM compound)",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155022/,0,,,,,,NR set,1 µM
EUB0001568a_RORC,JNJ-54119936,EUB0001568a,COc1nc2ccc([C@@](O)(c3ccccc3)C3CCN(C(C)=O)CC3)cc2c(Cl)c1Cc1ccc(-n2cccn2)cc1,"InChI=1S/C34H33ClN4O3/c1-23(40)38-19-15-26(16-20-38)34(41,25-7-4-3-5-8-25)27-11-14-31-29(22-27)32(35)30(33(37-31)42-2)21-24-9-12-28(13-10-24)39-18-6-17-36-39/h3-14,17-18,22,26,41H,15-16,19-21H2,1-2H3/t34-/m1/s1",QBIGUDRHHJTXKG-UUWRZZSWSA-N,Nuclear Receptor,RORC,6097,P51449,"RZRG, RORG, NR1F3, TOR",Inverse agonist,JNJ-53721590,5.3,qKd,ThermoFlour binding assay (RORC),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!detailedpotencydataview/JNJ-54119936,0,30,IC50,"One-hybrid reporter assay (HEK293T cells co-transfected with pFR-Luc reporter and pRL-CMV reporter, pCMV-BD containing the GAL4 DNA-binding domain fused with full-length human RORγt using 6 µM compound)",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155022/,0,0,Nuclear receptor panel (in-house data Janssen),15,"Screened at 3 µM against PPARa/d/g, LXRa/b, CAR, FXR, GR, Era/b, Tra/b, VDR, PXR, RXRa: clean selectivity profile with no significant agonism/antagonism detected; Screened at 1 µM and 10 µM in CEREP panel against 50 receptors and other enzymes: clean selectivity profile with no target inhibited >50%; Screened at 10 µM against 50 kinases (DiscoverX), clean selectivity profile with no target inhibited >50%; Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potencies of closest targets: Ki(TMEM97) = 636.99 nM, Ki(SIGMAR1) = 3125.58 nM, Ki(ADRA2B) = 9223.59 nM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/JNJ-54119936,NR set,1 µM
EUB0002260a_CSNK1D,JNJ-6204,EUB0002260a,[2H]C([2H])([2H])C1(C([2H])([2H])[2H])Cn2nc(-c3ccc(F)cn3)c(-c3ccnc4[nH]ncc34)c2CO1,"InChI=1S/C19H17FN6O/c1-19(2)10-26-15(9-27-19)16(12-5-6-21-18-13(12)8-23-24-18)17(25-26)14-4-3-11(20)7-22-14/h3-8H,9-10H2,1-2H3,(H,21,23,24)/i1D3,2D3",WZMIWVZGYMKUDV-WFGJKAKNSA-N,Protein Kinase,CSNK1D,1453,P48730,"HCKID, CKID, CKIdelta",inhibitor,JNJ-0293,,,,,,,,,,,1,Kinome Scan,373,"Screened at 1 µM, in-vitro potency of closest targets: IC50(TNIK) = 1663 nM, IC50(AMPKA2) >10000 nM, IC50(DCAMKL2) >10000 nM, IC50(FMS) >10000 nM, IC50(NDR2) >10000 nM, IC50(TGFBR1) >10000 nM, IC50(SAPK2A) >10000 nM, IC50(SAPK2B) >10000 nM; Screened at 10 µM, against 45 GPCRs (PDSP screen), closest targets as % of inhibition: GABA/PBR (50.86%), SLC6A3 (43.78%), HTR1D (33.37%), in-vitro potency of closest targets: Ki(GABA/PBR) = 4525.85 nM",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/JNJ-6204,Kinase set,1 µM
EUB0002260a_CSNK1E,JNJ-6204,EUB0002260a,[2H]C([2H])([2H])C1(C([2H])([2H])[2H])Cn2nc(-c3ccc(F)cn3)c(-c3ccnc4[nH]ncc34)c2CO1,"InChI=1S/C19H17FN6O/c1-19(2)10-26-15(9-27-19)16(12-5-6-21-18-13(12)8-23-24-18)17(25-26)14-4-3-11(20)7-22-14/h3-8H,9-10H2,1-2H3,(H,21,23,24)/i1D3,2D3",WZMIWVZGYMKUDV-WFGJKAKNSA-N,Protein Kinase,CSNK1E,1454,P49674,"HCKIE, CKIE, CKIepsilon",inhibitor,JNJ-0293,137,IC50,ADP-Glo assay ,https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/JNJ-6204,0,72,IC50,BRET assay (whole cell binding assay using full-length human CSNK1D in CHO cells),https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/JNJ-6204,0,1,Kinome Scan,373,"Screened at 1 µM, in-vitro potency of closest targets: IC50(TNIK) = 1663 nM, IC50(AMPKA2) >10000 nM, IC50(DCAMKL2) >10000 nM, IC50(FMS) >10000 nM, IC50(NDR2) >10000 nM, IC50(TGFBR1) >10000 nM, IC50(SAPK2A) >10000 nM, IC50(SAPK2B) >10000 nM; Screened at 10 µM, against 45 GPCRs (PDSP screen), closest targets as % of inhibition: GABA/PBR (50.86%), SLC6A3 (43.78%), HTR1D (33.37%), in-vitro potency of closest targets: Ki(GABA/PBR) = 4525.85 nM",https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/JNJ-6204,Kinase set,1 µM
EUB0001561a_OGA,JNJ-65355394,EUB0001561a,CC(=O)Nc1ncc(CN2CCC[C@H](Cc3cc(C)nc(C)c3)C2)s1,"InChI=1S/C19H26N4OS/c1-13-7-17(8-14(2)21-13)9-16-5-4-6-23(11-16)12-18-10-20-19(25-18)22-15(3)24/h7-8,10,16H,4-6,9,11-12H2,1-3H3,(H,20,22,24)/t16-/m1/s1",CYFBRQHYEQKYHH-MRXNPFEDSA-N,,OGA,10724,O60502,"OGA, HEXC, KIAA0679, MEA5, MGEA5",Agonist/inhibitor,JNJ-73924149,1.3,IC50,"Fluorescence-based enzymatic assay (recombinant full-length OGA, inhibition of the hydrolysis of fluorescein mono-β-D-N5 Acetyl-Glucosamine (FM-GlcNAc) by OGA)",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!detailedpotencydataview/JNJ-65355394,0,3.9,IC50,"Cell-based OGA assay (in HEK293 cells overexpressing P301L mutant human Tau, OGA inhibition is evaluated through the immunocytochemical (ICC) detection of O-GlcNAcylated proteins by the use of a monoclonal antibody (CTD110.6))",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!detailedpotencydataview/JNJ-65355394,0,0,CEREP panel (in-house data Janssen),54,"Screened at 10 µM, closest targets as % of inhibition: OPRK1 (78%), rat ADORA2A (69%), human OPRM1 (55%); Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potency of closest target: Ki(OPRK1) = 773.3 nM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!gpcrscandataview/JNJ-65355394,Other targets set,1 µM
EUB0001562a_OGA,JNJ-73924149,EUB0001562a,CC(=O)Nc1nc(CN2CCC[C@H](Cc3cc(C)nc(C)c3)C2)cs1,"InChI=1S/C19H26N4OS/c1-13-7-17(8-14(2)20-13)9-16-5-4-6-23(10-16)11-18-12-25-19(22-18)21-15(3)24/h7-8,12,16H,4-6,9-11H2,1-3H3,(H,21,22,24)/t16-/m1/s1",VKYYOTCDIVOPRO-MRXNPFEDSA-N,,OGA,10724,O60502,"OGA, HEXC, KIAA0679, MEA5, MGEA5",negative control for JNJ-65355394,,10000,IC50,"Fluorescence-based enzymatic assay (recombinant full-length OGA, inhibition of the hydrolysis of fluorescein mono-β-D-N5 Acetyl-Glucosamine (FM-GlcNAc) by OGA)",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!detailedpotencydataview/JNJ-65355394,>,1000,IC50,"Cell-based OGA assay (in HEK293 cells overexpressing P301L mutant human Tau, OGA inhibition is evaluated through the immunocytochemical (ICC) detection of O-GlcNAcylated proteins by the use of a monoclonal antibody (CTD110.6))",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!detailedpotencydataview/JNJ-65355394,>,1,GPCR panel (PDSP screen),45,"Screened at 10 µM, in-vitro potencies of closest targets: Ki(SIGMAR1) = 63.33 nM, Ki(TMEM97) = 1399.16 nM, Ki(SLC6A4) = 2614.09 nM, Ki(ADRA2B) = 3691.26 nM, Ki(SLC6A3) = 5284.45 nM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!gpcrscandataview/JNJ-65355394,Other targets set,1 µM
EUB0001575a_UCHL1@Protease,JYQ88,EUB0001575a,N#CN1CC[C@@H](C(=O)Nc2nc3c(s2)CN(C(=O)CN=[N+]=[N-])CC3)C1,"InChI=1S/C14H16N8O2S/c15-8-21-3-1-9(6-21)13(24)19-14-18-10-2-4-22(7-11(10)25-14)12(23)5-17-20-16/h9H,1-7H2,(H,18,19,24)/t9-/m1/s1",KIWKRCCIHSGWQS-SECBINFHSA-N,,UCHL1@Protease,7345,P09936,"HEL-117, HEL-S-53, NDGOA, PARK5, PGP 9.5, PGP9.5, PGP95, SPG79, Uch-L1",Negative control for 8RK64,,12900,IC50,Biochemical activity-assay using a fluorogenic Ub-Rho-morpholine (inhibition of UCHL1 using 2 mM cysteine),https://pubs.acs.org/doi/10.1021/jacs.0c07726,0,,,,,,0,GPCR panel (PDSD screen),45,"Screened at 10 µM, in-vitro potency of closest target: Ki(SLC6A3) >10 µM, Ki(ADRA2A) >10 µM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!gpcrscandataview/8RK64,Other targets set,1 µM
EUB0001484a_PRMT5,LLY-284,EUB0001484a,Nc1ncnc2c1ccn2[C@@H]1O[C@H]([C@@H](O)c2ccccc2)[C@@H](O)[C@H]1O,"InChI=1S/C17H18N4O4/c18-15-10-6-7-21(16(10)20-8-19-15)17-13(24)12(23)14(25-17)11(22)9-4-2-1-3-5-9/h1-8,11-14,17,22-24H,(H2,18,19,20)/t11-,12-,13+,14+,17+/m0/s1",WWOOWAHTEXIWBO-CNUKPYSBSA-N,,PRMT5,10419,O14744,"HRMT1L5, HSL7, IBP72, JBP1, SKB1, SKB1Hs",Negative control for LLY-283,,1074,IC50,Radioactivity-based assay (measuring transfer of the methyl group from 3H-SAM to peptide substrate),https://pubs.acs.org/doi/10.1021/acsmedchemlett.8b00014,0,30000,IC50,Western Blot (monitoring SmBB′-Rme2s levels in MCF7 cells),https://pubs.acs.org/doi/10.1021/acsmedchemlett.8b00014,>,0,Methyltransferase panel,32,"Screened at 1 µM, highly selective with all targets >55% remaining activity, PRMT5 (55%), other targets >90%",https://pubs.acs.org/doi/10.1021/acsmedchemlett.8b00014,Epigenetic set,1 µM
EUB0001567a_SLC16A3,MSC-0516,EUB0001567a,COc1cc(C(=O)O)ncc1C#Cc1ccccc1NS(=O)(=O)c1cccc2c(N(C)C)ccnc12,"InChI=1S/C26H22N4O5S/c1-30(2)22-13-14-27-25-19(22)8-6-10-24(25)36(33,34)29-20-9-5-4-7-17(20)11-12-18-16-28-21(26(31)32)15-23(18)35-3/h4-10,13-16,29H,1-3H3,(H,31,32)",MMSNEMMBFRAGPO-UHFFFAOYSA-N,Ion Channel,SLC16A3,9123,O15427,MCT 3 MCT 4 MCT-3 MCT-4 MCT3 MCT4,Negative control for MSC-4381,,,,,,,506,IC50,Lactate efflux inhibition assay (MDA-MB-231 cells expressing SLC16A3),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!detailedpotencydataview/MSC-4381,0,2,GPCR panel (PDSP screen),45,"Screened at 10 µM, in-vitro potencies of closest targets: Ki(OPRD1) = 597.96 nM, Ki(GABA/PBR) = 733.68 nM, Ki(HTR6) = 1523.62 nM, Ki(SLC6A3) = 9585.29 nM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/MSC-4381,Ion Channel,1 µM
EUB0001566aK_SLC16A3,MSC-4381,EUB0001566aK,CCOc1ccc(S(=O)(=O)Nc2ccc(Cl)cc2C#Cc2cnc(C(=O)[O-])cc2OC)c2ncccc12.[K+],"InChI=1S/C26H20ClN3O6S.K/c1-3-36-22-10-11-24(25-19(22)5-4-12-28-25)37(33,34)30-20-9-8-18(27)13-16(20)6-7-17-15-29-21(26(31)32)14-23(17)35-2;/h4-5,8-15,30H,3H2,1-2H3,(H,31,32);/q;+1/p-1",HBYQBJCBPAXCBO-UHFFFAOYSA-M,Ion Channel,SLC16A3,9123,O15427,MCT 3 MCT 4 MCT-3 MCT-4 MCT3 MCT4,Inhibitor,MSC-0516,11,Ki,Fluorescence cross-correlation spectroscopy (FCCS),https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00448,0,1,IC50,Lactate efflux inhibition assay (MDA-MB-231 cells expressing SLC16A3),https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00448,0,0,CEREP panel (in-house data Merck),58,"Screened at 10 µM, in-vitro potencies of closest targets: IC50(HTR6) = 4.6 µM, IC50(AVPR1A, human) = 7.1 µM, IC50(PTGER1) >30 µM, IC50(PTGER2) >30 µM; Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potencies of closest targets: Ki(HTR1E) >10 µM, Ki(HTR5A) = 1.625 µM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/MSC-4381,Ion Channel,1 µM
EUB0000322b_BRD2@BD1,PFI-1,EUB0000322b,CN1Cc2cc(ccc2NC1=O)NS(c1ccccc1OC)(=O)=O ,"InChI=1S/C16H17N3O4S/c1-19-10-11-9-12(7-8-13(11)17-16(19)20)18-24(21,22)15-6-4-3-5-14(15)23-2/h3-9,18H,10H2,1-2H3,(H,17,20)",TXZPMHLMPKIUGK-UHFFFAOYSA-N,Bromodomain,BRD2@BD1,6046,P25440,"KIAA9001, RING3, D6S113E, NAT, FSRG1",Inhibitor,No control available for probe,107.9,Kd,ITC,https://aacrjournals.org/cancerres/article/73/11/3336/584303/PFI-1-a-Highly-Selective-Protein-Interaction,0,,,,,,0,Bromodomain panel (DSF assays),42,"Screened in DSF assays, dTm values of closest targets: dTm(EP300) = 2.71 K, dTm(CREBBP) = 2.66 K, dTm of main targets: dTm(BRD2, BD1) = 4.61 K, dTm(BRD2, BD2) = 5.32 K, dTm(BRD3, BD1) = 5.24 K, dTm(BRD3, BD2) = 5.45 K, dTm(BRD4, BD1) = 6.84 K, dTm(BRD4, BD2) = 3.79 K, dTm(BRDT, BD1) = 2.08 K; Screened at 1 µM against 38 protein kinases (Invitrogen kinase panel), closest targets as % of inhibition: NTRK1 (28.5%), CHEK1 (16%); Screened at 10 µM against 14 membrane receptors, closest targets as % of inhibition: PDE3B (46.3%), H1 (6.5%)",https://www.thesgc.org/chemical-probes/PFI-1,Epigenetic set,1 µM
EUB0000322b_BRD2@BD2,PFI-1,EUB0000322b,CN1Cc2cc(ccc2NC1=O)NS(c1ccccc1OC)(=O)=O ,"InChI=1S/C16H17N3O4S/c1-19-10-11-9-12(7-8-13(11)17-16(19)20)18-24(21,22)15-6-4-3-5-14(15)23-2/h3-9,18H,10H2,1-2H3,(H,17,20)",TXZPMHLMPKIUGK-UHFFFAOYSA-N,Bromodomain,BRD2@BD2,6046,P25440,"KIAA9001, RING3, D6S113E, NAT, FSRG1",Inhibitor,No control available for probe,143.7,Kd,ITC,https://aacrjournals.org/cancerres/article/73/11/3336/584303/PFI-1-a-Highly-Selective-Protein-Interaction,0,,,,,,0,Bromodomain panel (DSF assays),42,"Screened in DSF assays, dTm values of closest targets: dTm(EP300) = 2.71 K, dTm(CREBBP) = 2.66 K, dTm of main targets: dTm(BRD2, BD1) = 4.61 K, dTm(BRD2, BD2) = 5.32 K, dTm(BRD3, BD1) = 5.24 K, dTm(BRD3, BD2) = 5.45 K, dTm(BRD4, BD1) = 6.84 K, dTm(BRD4, BD2) = 3.79 K, dTm(BRDT, BD1) = 2.08 K; Screened at 1 µM against 38 protein kinases (Invitrogen kinase panel), closest targets as % of inhibition: NTRK1 (28.5%), CHEK1 (16%); Screened at 10 µM against 14 membrane receptors, closest targets as % of inhibition: PDE3B (46.3%), H1 (6.5%)",https://www.thesgc.org/chemical-probes/PFI-1,Epigenetic set,1 µM
EUB0000322b_BRD3@BD1,PFI-1,EUB0000322b,CN1Cc2cc(ccc2NC1=O)NS(c1ccccc1OC)(=O)=O ,"InChI=1S/C16H17N3O4S/c1-19-10-11-9-12(7-8-13(11)17-16(19)20)18-24(21,22)15-6-4-3-5-14(15)23-2/h3-9,18H,10H2,1-2H3,(H,17,20)",TXZPMHLMPKIUGK-UHFFFAOYSA-N,Bromodomain,BRD3@BD1,8019,Q15059,"RING3L, ORFX, KIAA0043",Inhibitor,No control available for probe,80,Kd,ITC,https://aacrjournals.org/cancerres/article/73/11/3336/584303/PFI-1-a-Highly-Selective-Protein-Interaction,0,,,,,,0,Bromodomain panel (DSF assays),42,"Screened in DSF assays, dTm values of closest targets: dTm(EP300) = 2.71 K, dTm(CREBBP) = 2.66 K, dTm of main targets: dTm(BRD2, BD1) = 4.61 K, dTm(BRD2, BD2) = 5.32 K, dTm(BRD3, BD1) = 5.24 K, dTm(BRD3, BD2) = 5.45 K, dTm(BRD4, BD1) = 6.84 K, dTm(BRD4, BD2) = 3.79 K, dTm(BRDT, BD1) = 2.08 K; Screened at 1 µM against 38 protein kinases (Invitrogen kinase panel), closest targets as % of inhibition: NTRK1 (28.5%), CHEK1 (16%); Screened at 10 µM against 14 membrane receptors, closest targets as % of inhibition: PDE3B (46.3%), H1 (6.5%)",https://www.thesgc.org/chemical-probes/PFI-1,Epigenetic set,1 µM
EUB0000322b_BRD3@BD2,PFI-1,EUB0000322b,CN1Cc2cc(ccc2NC1=O)NS(c1ccccc1OC)(=O)=O ,"InChI=1S/C16H17N3O4S/c1-19-10-11-9-12(7-8-13(11)17-16(19)20)18-24(21,22)15-6-4-3-5-14(15)23-2/h3-9,18H,10H2,1-2H3,(H,17,20)",TXZPMHLMPKIUGK-UHFFFAOYSA-N,Bromodomain,BRD3@BD2,8019,Q15059,"RING3L, ORFX, KIAA0043",Inhibitor,No control available for probe,76.3,Kd,ITC,https://aacrjournals.org/cancerres/article/73/11/3336/584303/PFI-1-a-Highly-Selective-Protein-Interaction,0,,,,,,0,Bromodomain panel (DSF assays),42,"Screened in DSF assays, dTm values of closest targets: dTm(EP300) = 2.71 K, dTm(CREBBP) = 2.66 K, dTm of main targets: dTm(BRD2, BD1) = 4.61 K, dTm(BRD2, BD2) = 5.32 K, dTm(BRD3, BD1) = 5.24 K, dTm(BRD3, BD2) = 5.45 K, dTm(BRD4, BD1) = 6.84 K, dTm(BRD4, BD2) = 3.79 K, dTm(BRDT, BD1) = 2.08 K; Screened at 1 µM against 38 protein kinases (Invitrogen kinase panel), closest targets as % of inhibition: NTRK1 (28.5%), CHEK1 (16%); Screened at 10 µM against 14 membrane receptors, closest targets as % of inhibition: PDE3B (46.3%), H1 (6.5%)",https://www.thesgc.org/chemical-probes/PFI-1,Epigenetic set,1 µM
EUB0000322b_BRD4@BD1,PFI-1,EUB0000322b,CN1Cc2cc(ccc2NC1=O)NS(c1ccccc1OC)(=O)=O ,"InChI=1S/C16H17N3O4S/c1-19-10-11-9-12(7-8-13(11)17-16(19)20)18-24(21,22)15-6-4-3-5-14(15)23-2/h3-9,18H,10H2,1-2H3,(H,17,20)",TXZPMHLMPKIUGK-UHFFFAOYSA-N,Bromodomain,BRD4@BD1,23476,O60885,"HUNKI, MCAP, CAP, HUNK1",Inhibitor,No control available for probe,47.4,Kd,ITC,https://aacrjournals.org/cancerres/article/73/11/3336/584303/PFI-1-a-Highly-Selective-Protein-Interaction,0,,,,,,0,Bromodomain panel (DSF assays),42,"Screened in DSF assays, dTm values of closest targets: dTm(EP300) = 2.71 K, dTm(CREBBP) = 2.66 K, dTm of main targets: dTm(BRD2, BD1) = 4.61 K, dTm(BRD2, BD2) = 5.32 K, dTm(BRD3, BD1) = 5.24 K, dTm(BRD3, BD2) = 5.45 K, dTm(BRD4, BD1) = 6.84 K, dTm(BRD4, BD2) = 3.79 K, dTm(BRDT, BD1) = 2.08 K; Screened at 1 µM against 38 protein kinases (Invitrogen kinase panel), closest targets as % of inhibition: NTRK1 (28.5%), CHEK1 (16%); Screened at 10 µM against 14 membrane receptors, closest targets as % of inhibition: PDE3B (46.3%), H1 (6.5%)",https://www.thesgc.org/chemical-probes/PFI-1,Epigenetic set,1 µM
EUB0000322b_BRD4@BD2,PFI-1,EUB0000322b,CN1Cc2cc(ccc2NC1=O)NS(c1ccccc1OC)(=O)=O ,"InChI=1S/C16H17N3O4S/c1-19-10-11-9-12(7-8-13(11)17-16(19)20)18-24(21,22)15-6-4-3-5-14(15)23-2/h3-9,18H,10H2,1-2H3,(H,17,20)",TXZPMHLMPKIUGK-UHFFFAOYSA-N,Bromodomain,BRD4@BD2,23476,O60885,"HUNKI, MCAP, CAP, HUNK1",Inhibitor,No control available for probe,194.9,Kd,ITC,https://aacrjournals.org/cancerres/article/73/11/3336/584303/PFI-1-a-Highly-Selective-Protein-Interaction,0,,,,,,0,Bromodomain panel (DSF assays),42,"Screened in DSF assays, dTm values of closest targets: dTm(EP300) = 2.71 K, dTm(CREBBP) = 2.66 K, dTm of main targets: dTm(BRD2, BD1) = 4.61 K, dTm(BRD2, BD2) = 5.32 K, dTm(BRD3, BD1) = 5.24 K, dTm(BRD3, BD2) = 5.45 K, dTm(BRD4, BD1) = 6.84 K, dTm(BRD4, BD2) = 3.79 K, dTm(BRDT, BD1) = 2.08 K; Screened at 1 µM against 38 protein kinases (Invitrogen kinase panel), closest targets as % of inhibition: NTRK1 (28.5%), CHEK1 (16%); Screened at 10 µM against 14 membrane receptors, closest targets as % of inhibition: PDE3B (46.3%), H1 (6.5%)",https://www.thesgc.org/chemical-probes/PFI-1,Epigenetic set,1 µM
EUB0000322b_BRDT@BD1,PFI-1,EUB0000322b,CN1Cc2cc(ccc2NC1=O)NS(c1ccccc1OC)(=O)=O ,"InChI=1S/C16H17N3O4S/c1-19-10-11-9-12(7-8-13(11)17-16(19)20)18-24(21,22)15-6-4-3-5-14(15)23-2/h3-9,18H,10H2,1-2H3,(H,17,20)",TXZPMHLMPKIUGK-UHFFFAOYSA-N,Bromodomain,BRDT@BD1,676,Q58F21,"BRD6, CT9",Inhibitor,No control available for probe,85.5,Kd,ITC,https://aacrjournals.org/cancerres/article/73/11/3336/584303/PFI-1-a-Highly-Selective-Protein-Interaction,0,,,,,,0,Bromodomain panel (DSF assays),42,"Screened in DSF assays, dTm values of closest targets: dTm(EP300) = 2.71 K, dTm(CREBBP) = 2.66 K, dTm of main targets: dTm(BRD2, BD1) = 4.61 K, dTm(BRD2, BD2) = 5.32 K, dTm(BRD3, BD1) = 5.24 K, dTm(BRD3, BD2) = 5.45 K, dTm(BRD4, BD1) = 6.84 K, dTm(BRD4, BD2) = 3.79 K, dTm(BRDT, BD1) = 2.08 K; Screened at 1 µM against 38 protein kinases (Invitrogen kinase panel), closest targets as % of inhibition: NTRK1 (28.5%), CHEK1 (16%); Screened at 10 µM against 14 membrane receptors, closest targets as % of inhibition: PDE3B (46.3%), H1 (6.5%)",https://www.thesgc.org/chemical-probes/PFI-1,Epigenetic set,1 µM
EUB0000322b_BRDT@BD2,PFI-1,EUB0000322b,CN1Cc2cc(ccc2NC1=O)NS(c1ccccc1OC)(=O)=O ,"InChI=1S/C16H17N3O4S/c1-19-10-11-9-12(7-8-13(11)17-16(19)20)18-24(21,22)15-6-4-3-5-14(15)23-2/h3-9,18H,10H2,1-2H3,(H,17,20)",TXZPMHLMPKIUGK-UHFFFAOYSA-N,Bromodomain,BRDT@BD2,676,Q58F21,"BRD6, CT9",Inhibitor,No control available for probe,220.8,Kd,ITC,https://aacrjournals.org/cancerres/article/73/11/3336/584303/PFI-1-a-Highly-Selective-Protein-Interaction,0,,,,,,0,Bromodomain panel (DSF assays),42,"Screened in DSF assays, dTm values of closest targets: dTm(EP300) = 2.71 K, dTm(CREBBP) = 2.66 K, dTm of main targets: dTm(BRD2, BD1) = 4.61 K, dTm(BRD2, BD2) = 5.32 K, dTm(BRD3, BD1) = 5.24 K, dTm(BRD3, BD2) = 5.45 K, dTm(BRD4, BD1) = 6.84 K, dTm(BRD4, BD2) = 3.79 K, dTm(BRDT, BD1) = 2.08 K; Screened at 1 µM against 38 protein kinases (Invitrogen kinase panel), closest targets as % of inhibition: NTRK1 (28.5%), CHEK1 (16%); Screened at 10 µM against 14 membrane receptors, closest targets as % of inhibition: PDE3B (46.3%), H1 (6.5%)",https://www.thesgc.org/chemical-probes/PFI-1,Epigenetic set,1 µM
EUB0001124aAE_SMYD2,PFI-5,EUB0001124aAE,[H][C@]1(CCCCC=C1)N1CCC(CC1)Cn1ccc(c1)C(N1CC(C)(C1)n1cnc2c(N)nc(C)cc12)=O.CC(O)=O,"InChI=1S/C29H39N7O.C2H4O2/c1-21-15-25-26(27(30)32-21)31-20-36(25)29(2)18-35(19-29)28(37)23-11-12-33(17-23)16-22-9-13-34(14-10-22)24-7-5-3-4-6-8-24;1-2(3)4/h5,7,11-12,15,17,20,22,24H,3-4,6,8-10,13-14,16,18-19H2,1-2H3,(H2,30,32);1H3,(H,3,4)/t24-;/m0./s1",TZMQFZRIXDLOHW-JIDHJSLPSA-N,,SMYD2,56950,Q9NRG4,"HSKM-B, KMT3C, ZMYND14",Inhibitor,PFI-5N,9,IC50,Inhibition of in vitro methylation of p53K370,https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00112#,0,900,IC50,Inhibition of the methylation of p53K370 in cells,https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00112#,0,0,Enzyme panel (Scintillation proximity assay),35,"Screened at 1 µM, 10 µM, and 50 µM (methyltransferase activity of G9a, GLP, SUV39H1, SUV39H2, SETDB1, SETD8, SUV420H1, SUV420H2, SETD7, MLL1 pentameric complex, MLL3 pentameric complex, EZH2 trimeric complex, PRMT1, PRMT3, PRMT4, PRMT5-MEP50 complex, PRMT6, PRMT7, PRMT8, PRMT9, PRDM9, SETD2, SMYD2, SMYD3, BCDIN3D, METTL3-14, and DNMT1), closest targets SUV420H1 (60% activity at 1 µM), SUV420H2 (62% activity at 1 µM); In-cellular follow-up by western blot assay (effect on H4K20me2/3 cellular mark modulated by SUVH420H1/H2 using MCF7 cells): EC50(SUVH420H1) >50 µM, EC50(SUV420H2) >50 µM; Screened at 1 µM against 40 kinases (enzymatic assay), closest target as % of inhibition: MAP4K4 (10.42%), clean selectivity profile; Screened against 15 diverse protein targets, all targets >10 µM, clean selectivity profile",https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00112#,Epigenetic set,1 µM
EUB0001127a_GID4,PFI-7,EUB0001127a,C1C[C@H](CC[C@H]1c1nc2ccccc2[nH]1)NC(CNCc1cc2ccccc2[nH]1)=O,"InChI=1S/C24H27N5O/c30-23(15-25-14-19-13-17-5-1-2-6-20(17)26-19)27-18-11-9-16(10-12-18)24-28-21-7-3-4-8-22(21)29-24/h1-8,13,16,18,25-26H,9-12,14-15H2,(H,27,30)(H,28,29)/t16-,18+",HLHNFJNSQZZUNW-MAEOIBBWSA-N,,GID4,79018,Q8IVV7,"C17orf39, VID2, VID24",Inhibitor,PFI-7N,80,Kd,SPR measurement,https://www.thesgc.org/chemical-probes/PFI-7,0,600,EC50,NanoBRET assay (interaction between NanoLuc® tagged degrons and full-length GID4),https://www.thesgc.org/chemical-probes/PFI-7,0,,,,,,Other targets set,100 nM
EUB0001552a_FKBP5,SAFit2,EUB0001552a,COc1ccc(CC[C@@H](OC(=O)[C@@H]2CCCCN2C(=O)[C@H](c2cc(OC)c(OC)c(OC)c2)C2CCCCC2)c2cccc(OCCN3CCOCC3)c2)cc1OC,"InChI=1S/C46H62N2O10/c1-51-39-20-18-32(28-40(39)52-2)17-19-38(34-14-11-15-36(29-34)57-27-24-47-22-25-56-26-23-47)58-46(50)37-16-9-10-21-48(37)45(49)43(33-12-7-6-8-13-33)35-30-41(53-3)44(55-5)42(31-35)54-4/h11,14-15,18,20,28-31,33,37-38,43H,6-10,12-13,16-17,19,21-27H2,1-5H3/t37-,38+,43-/m0/s1",ZDBWLRLGUBSLPG-FDHYQTMZSA-N,,FKBP5,2289,Q13451,"AIG6, FKBP51, FKBP54, P54, PPIase, Ptg-10",Inhibitor,ddSAFit2,6,Kd,Competitive fluorescence polarization binding assay,https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/SAFit2,0,493,IC50,NanoBRET assay (HEK293T cells),https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cbic.202100113,0,0,GPCR panel (PDSD screen),45,"Screened at 10 µM, in-vitro potencies of closest targets: Ki(TMEM97) = 226 nM, Ki(HRH4) = 3382 nM, Ki(HTR2C) >10000 nM, Ki(DRD2) >10000 nM; Selectivity within target family (competition fluorescence polarization binding assay): Kd(FKBP1A) = 116.4 nM, Kd(FKBP1B) = 38.9 nM, Kd(FKBP2) = 1053 nM, Kd(FKBP3) >10 µM, Kd(FKBP4) >50 µM; In-cellular follow up of closest targets within family (NanoBRET assay in HEK293T cells, FKBP51-NLuc): IC50(FKBP1A) = 771 nM, IC50(FKBP1B) = 80 nM, IC05(FKBP4) = 1409 nM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/SAFit2,Other targets set,1 µM
EUB0002311a_CDKL5,SGC-CAF268-1N,EUB0002311a,CN1CCN(c2cc(C(=O)Nc3ncc(SCc4cccc(C(F)(F)F)c4)s3)ccn2)CC1,"InChI=1S/C22H22F3N5OS2/c1-29-7-9-30(10-8-29)18-12-16(5-6-26-18)20(31)28-21-27-13-19(33-21)32-14-15-3-2-4-17(11-15)22(23,24)25/h2-6,11-13H,7-10,14H2,1H3,(H,27,28,31)",RUYKDMMLESXEOA-UHFFFAOYSA-N,Protein Kinase,CDKL5,6792,O76039,"EIEE2, CFAP247",Negative control for SGC-CAF382-1,,,,,,,10000,IC50,NanoBRET assay (HEK293T cells),https://www.thesgc.org/chemical-probes/SGC-CAF382-1,>,0,DiscoverX (scanMAX),403,"Screened at 1 µM, closest targets as % of control: DYRK1B (18%), MAPK12 (34%); In-cellular potency (NanoBRET assay, HEK293T cells): IC50(DYRK1B) >10000 nM, IC50(CDK9, cyclin K) > 10000 nM, IC50(CDK16, cyclin Y) >10000 nM, IC50(CDK17, cyclin Y) >10000 nM, IC50(CDK18, cyclin Y) >10000 nM",https://www.thesgc.org/chemical-probes/SGC-CAF382-1,Kinase set,100 nM
EUB0002312a_CDKL5,SGC-CAF382-1,EUB0002312a,CC(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,"InChI=1S/C16H22N4O2S2/c1-10(2)12-7-18-13(22-12)9-23-14-8-19-16(24-14)20-15(21)11-3-5-17-6-4-11/h7-8,10-11,17H,3-6,9H2,1-2H3,(H,19,20,21)",MCLDWKVRXDHDEI-UHFFFAOYSA-N,Protein Kinase,CDKL5,6792,O76039,"EIEE2, CFAP247",Inhibitor,SGC-CAF268-1N,6.7,IC50,Competition binding assay (Luceome Biotechnologies),https://pubmed.ncbi.nlm.nih.gov/37162893/,0,10,IC50,NanoBRET assay (HEK293T cells),https://www.thesgc.org/chemical-probes/SGC-CAF382-1,0,5,DiscoverX (scanMAX),403,"Screened at 1 µM, closest targets as % of control: GSK3A (0.7%), CDKL5 (0.7%), CDK17 (1.3%), CDK7 (1.9%), CDK16 (5.5%), CDK13 (5.9%), CDK9 (8.3%), YSK4 (14%), CDK18 (17%), CDK4 (20%), GSK3B (51%); In-vitro potency (radiometric enzymatic assays, Eurofins): IC50(GSK3A) = 470 nM, IC50(CDKL5) = 11 nM, IC50(CDK17) = 89 nM, IC50(CDK7) = 300 nM, IC50(CDK16) = 62 nM, IC50(CDK13) >10000 nM, IC50(CDK9) = 20 nM, IC50(YSK4) >10000 nM, IC50(CDK18) = 100 nM, IC50(CDK4) = 1900 nM, IC50(GSK3B) = 2250 nM; In-cellular potency (NanoBRET assay, HEK293T cells): IC50(GSK3A) = 1500 nM, IC50(CDKL5) = 10 nM, IC50(CDK17) = 240 nM, IC50(CDK16) = 390 nM, IC50(CDK9) = 280 nM, IC50(CDK18) = 260 nM, IC50(GSK3B) = 2400 nM",https://www.thesgc.org/chemical-probes/SGC-CAF382-1,Kinase set,100 nM
EUB0002313a_CDKL5,SGC-CDKL5/GSK3-1N,EUB0002313a,Cn1cc(NC(=O)c2cc(F)cc(F)c2)c(C(=O)NC2CCNCC2)n1,"InChI=1S/C17H19F2N5O2/c1-24-9-14(22-16(25)10-6-11(18)8-12(19)7-10)15(23-24)17(26)21-13-2-4-20-5-3-13/h6-9,13,20H,2-5H2,1H3,(H,21,26)(H,22,25)",ODZBDODDFLVDQZ-UHFFFAOYSA-N,Protein Kinase,CDKL5,6792,O76039,"EIEE2, CFAP247",Negative control for SGC-CDKL5_GSK3,,,,,,,10000,IC50,NanoBRET assay (HEK293T cells),https://www.thesgc.org/chemical-probes/SGC-CDKL5_GSK3,>,,,,,,Kinase set,100 nM
EUB0002313a_GSK3A,SGC-CDKL5/GSK3-1N,EUB0002313a,Cn1cc(NC(=O)c2cc(F)cc(F)c2)c(C(=O)NC2CCNCC2)n1,"InChI=1S/C17H19F2N5O2/c1-24-9-14(22-16(25)10-6-11(18)8-12(19)7-10)15(23-24)17(26)21-13-2-4-20-5-3-13/h6-9,13,20H,2-5H2,1H3,(H,21,26)(H,22,25)",ODZBDODDFLVDQZ-UHFFFAOYSA-N,Protein Kinase,GSK3A,2931,P49840,,Negative control for SGC-CDKL5_GSK3,,,,,,,10000,IC50,NanoBRET assay (HEK293T cells),https://www.thesgc.org/chemical-probes/SGC-CDKL5_GSK3,>,,,,,,Kinase set,100 nM
EUB0002313a_GSK3B,SGC-CDKL5/GSK3-1N,EUB0002313a,Cn1cc(NC(=O)c2cc(F)cc(F)c2)c(C(=O)NC2CCNCC2)n1,"InChI=1S/C17H19F2N5O2/c1-24-9-14(22-16(25)10-6-11(18)8-12(19)7-10)15(23-24)17(26)21-13-2-4-20-5-3-13/h6-9,13,20H,2-5H2,1H3,(H,21,26)(H,22,25)",ODZBDODDFLVDQZ-UHFFFAOYSA-N,Protein Kinase,GSK3B,2932,P49841,,Negative control for SGC-CDKL5_GSK3,,,,,,,10000,IC50,NanoBRET assay (HEK293T cells),https://www.thesgc.org/chemical-probes/SGC-CDKL5_GSK3,>,,,,,,Kinase set,100 nM
EUB0002314a_CDKL5,SGC-CDKL5_GSK3,EUB0002314a,O=C(Nc1c[nH]nc1C(=O)NC1CCNCC1)c1cc(F)cc(F)c1,"InChI=1S/C16H17F2N5O2/c17-10-5-9(6-11(18)7-10)15(24)22-13-8-20-23-14(13)16(25)21-12-1-3-19-4-2-12/h5-8,12,19H,1-4H2,(H,20,23)(H,21,25)(H,22,24)",NIHAFOURWLZLFN-UHFFFAOYSA-N,Protein Kinase,CDKL5,6792,O76039,"EIEE2, CFAP247",inhibitor,SGC-CDKL5/GSK3-1N,6.5,IC50,KinaseSeeker homogenous competition binding assay (Luceome Biotechnologies),https://pubmed.ncbi.nlm.nih.gov/37084253/,0,3.5,IC50,NanoBRET assay (HEK293T cells),https://pubmed.ncbi.nlm.nih.gov/37084253/,0,2,DiscoverX (scanMAX),403,"Screened at  1 µM, closest targets as % of control: CDKL5 (0.2%), GSK3B (0.5%), DYRK2 (4.8%), CDK7 (5.6%), CDK16 (12%), GSK3A (14%), DYRK1A (19%), CDK17 (20%), HIPK1 (33%), HIPK2 (33%), RPS6KA4 (34%); In-vitro potency (enzymatic radiometric assays, Eurofins): IC50(DYRK2) = 770 nM, IC50(CDK7) >10000 nM, IC50(CDK16) = 590 nM, IC50(DYRK1A) = 1100 nM, IC50(CDK17) = 1000 nM, IC50(HIPK1) = 7900 nM, IC50(HIPK2) = 2300 nM, IC50(RPS6KA4) >10000 nM",https://pubmed.ncbi.nlm.nih.gov/37084253/,Kinase set,100 nM
EUB0002314a_GSK3A,SGC-CDKL5_GSK3,EUB0002314a,O=C(Nc1c[nH]nc1C(=O)NC1CCNCC1)c1cc(F)cc(F)c1,"InChI=1S/C16H17F2N5O2/c17-10-5-9(6-11(18)7-10)15(24)22-13-8-20-23-14(13)16(25)21-12-1-3-19-4-2-12/h5-8,12,19H,1-4H2,(H,20,23)(H,21,25)(H,22,24)",NIHAFOURWLZLFN-UHFFFAOYSA-N,Protein Kinase,GSK3A,2931,P49840,,inhibitor,SGC-CDKL5/GSK3-1N,4,IC50,Enzymatic radiometric assays (Eurofins),https://pubmed.ncbi.nlm.nih.gov/37084253/,0,10,IC50,NanoBRET assay (HEK293T cells),https://pubmed.ncbi.nlm.nih.gov/37084253/,0,2,DiscoverX (scanMAX),403,"Screened at  1 µM, closest targets as % of control: CDKL5 (0.2%), GSK3B (0.5%), DYRK2 (4.8%), CDK7 (5.6%), CDK16 (12%), GSK3A (14%), DYRK1A (19%), CDK17 (20%), HIPK1 (33%), HIPK2 (33%), RPS6KA4 (34%); In-vitro potency (enzymatic radiometric assays, Eurofins): IC50(DYRK2) = 770 nM, IC50(CDK7) >10000 nM, IC50(CDK16) = 590 nM, IC50(DYRK1A) = 1100 nM, IC50(CDK17) = 1000 nM, IC50(HIPK1) = 7900 nM, IC50(HIPK2) = 2300 nM, IC50(RPS6KA4) >10000 nM",https://pubmed.ncbi.nlm.nih.gov/37084253/,Kinase set,100 nM
EUB0002314a_GSK3B,SGC-CDKL5_GSK3,EUB0002314a,O=C(Nc1c[nH]nc1C(=O)NC1CCNCC1)c1cc(F)cc(F)c1,"InChI=1S/C16H17F2N5O2/c17-10-5-9(6-11(18)7-10)15(24)22-13-8-20-23-14(13)16(25)21-12-1-3-19-4-2-12/h5-8,12,19H,1-4H2,(H,20,23)(H,21,25)(H,22,24)",NIHAFOURWLZLFN-UHFFFAOYSA-N,Protein Kinase,GSK3B,2932,P49841,,inhibitor,SGC-CDKL5/GSK3-1N,9,IC50,Enzymatic radiometric assays (Eurofins),https://pubmed.ncbi.nlm.nih.gov/37084253/,0,35,IC50,NanoBRET assay (HEK293T cells),https://pubmed.ncbi.nlm.nih.gov/37084253/,0,2,DiscoverX (scanMAX),403,"Screened at  1 µM, closest targets as % of control: CDKL5 (0.2%), GSK3B (0.5%), DYRK2 (4.8%), CDK7 (5.6%), CDK16 (12%), GSK3A (14%), DYRK1A (19%), CDK17 (20%), HIPK1 (33%), HIPK2 (33%), RPS6KA4 (34%); In-vitro potency (enzymatic radiometric assays, Eurofins): IC50(DYRK2) = 770 nM, IC50(CDK7) >10000 nM, IC50(CDK16) = 590 nM, IC50(DYRK1A) = 1100 nM, IC50(CDK17) = 1000 nM, IC50(HIPK1) = 7900 nM, IC50(HIPK2) = 2300 nM, IC50(RPS6KA4) >10000 nM",https://pubmed.ncbi.nlm.nih.gov/37084253/,Kinase set,100 nM
EUB0002315a_GSK3A,SGC-GSK3-1,EUB0002315a,O=C(NCC1CCOCC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F,"InChI=1S/C17H18F2N4O3/c18-11-2-1-3-12(19)14(11)16(24)22-13-9-21-23-15(13)17(25)20-8-10-4-6-26-7-5-10/h1-3,9-10H,4-8H2,(H,20,25)(H,21,23)(H,22,24)",OCQCKUTZHBQNEI-UHFFFAOYSA-N,Protein Kinase,GSK3A,2931,P49840,,inhibitor,SGC-CDKL5/GSK3-1N,1,IC50,Enzymatic radiometric assays (Eurofins),https://pubmed.ncbi.nlm.nih.gov/37084253/,0,4.6,IC50,NanoBRET assay (HEK293T cells),https://pubmed.ncbi.nlm.nih.gov/37084253/,0,8,DiscoverX (scanMAX),403,"Screened at 1 µM, closest targets as % of control: GSK3A (0%), GSK3B (0.2%), DYRK1A (0.4%), ICK(5.7%), DYRK2 (8.3%), DYRK1B (10%), MAPK8 (16%), CDK4 (20%), RPS6KA4 (29%), CLK1 (30%), CDKL5 (30%), CDK7 (31%), MAPK10 (31%), CLK4 (32%), CLK2 (34%), CDKL2 (77%), CDKL1(93%), CDKL3(100%); In-vitro potency of closest targets (enzymatic radiometric assays, Eurofins): IC50(DYRK1A) = 170 nM, IC50(ICK) = 520 nM, IC50(DYRK2) = 800 nM, IC50(DYRK1B) = 47 nM, IC50(MAPK8) >10000 nM, IC50(CDK4) = 3800 nM, IC50(RPS6KA4) >10000 nM, IC50(CLK1) = 620 nM, IC50(CDKL5) = 840 nM, IC50(CDK7) >10000 nM, IC50(MAPK10) = 2900 nM, IC50(CLK4) = 760 nM, IC50(CLK2) = 800 nM; In-cellular potency (NanoBRET assay, HEK293T cells): IC50(DYRK1B) = 2400 nM, IC50(CDKL5) = 1400 nM",https://pubmed.ncbi.nlm.nih.gov/37084253/,Kinase set,100 nM
EUB0002315a_GSK3B,SGC-GSK3-1,EUB0002315a,O=C(NCC1CCOCC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F,"InChI=1S/C17H18F2N4O3/c18-11-2-1-3-12(19)14(11)16(24)22-13-9-21-23-15(13)17(25)20-8-10-4-6-26-7-5-10/h1-3,9-10H,4-8H2,(H,20,25)(H,21,23)(H,22,24)",OCQCKUTZHBQNEI-UHFFFAOYSA-N,Protein Kinase,GSK3B,2932,P49841,,inhibitor,SGC-CDKL5/GSK3-1N,2,IC50,Enzymatic radiometric assays (Eurofins),https://pubmed.ncbi.nlm.nih.gov/37084253/,0,12,IC50,NanoBRET assay (HEK293T cells),https://pubmed.ncbi.nlm.nih.gov/37084253/,0,8,DiscoverX (scanMAX),403,"Screened at 1 µM, closest targets as % of control: GSK3A (0%), GSK3B (0.2%), DYRK1A (0.4%), ICK(5.7%), DYRK2 (8.3%), DYRK1B (10%), MAPK8 (16%), CDK4 (20%), RPS6KA4 (29%), CLK1 (30%), CDKL5 (30%), CDK7 (31%), MAPK10 (31%), CLK4 (32%), CLK2 (34%), CDKL2 (77%), CDKL1(93%), CDKL3(100%); In-vitro potency of closest targets (enzymatic radiometric assays, Eurofins): IC50(DYRK1A) = 170 nM, IC50(ICK) = 520 nM, IC50(DYRK2) = 800 nM, IC50(DYRK1B) = 47 nM, IC50(MAPK8) >10000 nM, IC50(CDK4) = 3800 nM, IC50(RPS6KA4) >10000 nM, IC50(CLK1) = 620 nM, IC50(CDKL5) = 840 nM, IC50(CDK7) >10000 nM, IC50(MAPK10) = 2900 nM, IC50(CLK4) = 760 nM, IC50(CLK2) = 800 nM; In-cellular potency (NanoBRET assay, HEK293T cells): IC50(DYRK1B) = 2400 nM, IC50(CDKL5) = 1400 nM",https://pubmed.ncbi.nlm.nih.gov/37084253/,Kinase set,100 nM
EUB0001118a_SMARCA2@BRD,SGC-SMARCA-BRDVIII,EUB0001118a,OC1=CC=CC=C1C2=CC(N3CCN(C(OC(C)(C)C)=O)CC3)=C(N)N=N2,"InChI=1S/C19H25N5O3/c1-19(2,3)27-18(26)24-10-8-23(9-11-24)15-12-14(21-22-17(15)20)13-6-4-5-7-16(13)25/h4-7,12,25H,8-11H2,1-3H3,(H2,20,22)",AQTNUGRRZDRZIA-UHFFFAOYSA-N,Bromodomain,SMARCA2@BRD,6595,P51531,"BAF190, hSNF2a, hBRM, Sth1p, SNF2LA, BRM, SNF2, SWI2",Inhibitor,SGC-BRDVIII-NC,35,Kd,ITC,https://www.thesgc.org/chemical-probes/SGC-SMARCA-BRDVIII,0,,,,,,0,Bromodomain panel (DSF assays),25,"Screened at 20 µM, dTm(SMARCA2) = 7.7 K, dTm(SMARCA4) = 7.4 K, dTm(PBRM1,BD5) = 11.3 K, other targets <2.7 K; Screened at 20 µM against 85 protein kinases (DSF assay), clean selectivity profile with all targets dTm <0.5 K",https://www.thesgc.org/chemical-probes/SGC-SMARCA-BRDVIII,Epigenetic set,1 µM
EUB0001118a_SMARCA4@BRD,SGC-SMARCA-BRDVIII,EUB0001118a,OC1=CC=CC=C1C2=CC(N3CCN(C(OC(C)(C)C)=O)CC3)=C(N)N=N2,"InChI=1S/C19H25N5O3/c1-19(2,3)27-18(26)24-10-8-23(9-11-24)15-12-14(21-22-17(15)20)13-6-4-5-7-16(13)25/h4-7,12,25H,8-11H2,1-3H3,(H2,20,22)",AQTNUGRRZDRZIA-UHFFFAOYSA-N,Bromodomain,SMARCA4@BRD,6597,P51532,"hSNF2b, BRG1, BAF190, SNF2, SWI2, SNF2-BETA, SNF2LB, FLJ39786",Inhibitor,SGC-BRDVIII-NC,36,Kd,ITC,https://www.thesgc.org/chemical-probes/SGC-SMARCA-BRDVIII,0,,,,,,0,Bromodomain panel (DSF assays),25,"Screened at 20 µM, dTm(SMARCA2) = 7.7 K, dTm(SMARCA4) = 7.4 K, dTm(PBRM1,BD5) = 11.3 K, other targets <2.7 K; Screened at 20 µM against 85 protein kinases (DSF assay), clean selectivity profile with all targets dTm <0.5 K",https://www.thesgc.org/chemical-probes/SGC-SMARCA-BRDVIII,Epigenetic set,1 µM
EUB0001118a_PBRM1@BRD,SGC-SMARCA-BRDVIII,EUB0001118a,OC1=CC=CC=C1C2=CC(N3CCN(C(OC(C)(C)C)=O)CC3)=C(N)N=N2,"InChI=1S/C19H25N5O3/c1-19(2,3)27-18(26)24-10-8-23(9-11-24)15-12-14(21-22-17(15)20)13-6-4-5-7-16(13)25/h4-7,12,25H,8-11H2,1-3H3,(H2,20,22)",AQTNUGRRZDRZIA-UHFFFAOYSA-N,Bromodomain,PBRM1@BRD,55193,Q86U86,"BAF180, PB1",Inhibitor,SGC-BRDVIII-NC,13,Kd,ITC,https://www.thesgc.org/chemical-probes/SGC-SMARCA-BRDVIII,0,,,,,,0,Bromodomain panel (DSF assays),25,"Screened at 20 µM, dTm(SMARCA2) = 7.7 K, dTm(SMARCA4) = 7.4 K, dTm(PBRM1,BD5) = 11.3 K, other targets <2.7 K; Screened at 20 µM against 85 protein kinases (DSF assay), clean selectivity profile with all targets dTm <0.5 K",https://www.thesgc.org/chemical-probes/SGC-SMARCA-BRDVIII,Epigenetic set,1 µM
EUB0001060a_DDR1,SR301,EUB0001060a,CS(N1CCCC(NC([C@@H](NC(C2=CC=C(CNC3=NC=NC4=C3[N][N]N4C5=CC=CC=C5)C=C2)=O)CCC6CCCCC6)=O)C1)(=O)=O,"InChI=1S/C34H43N9O4S/c1-48(46,47)42-20-8-11-27(22-42)38-34(45)29(19-16-24-9-4-2-5-10-24)39-33(44)26-17-14-25(15-18-26)21-35-31-30-32(37-23-36-31)43(41-40-30)28-12-6-3-7-13-28/h3,6-7,12-15,17-18,23-24,27,29H,2,4-5,8-11,16,19-22H2,1H3,(H,38,45)(H,39,44)(H,35,36,37)/t27?,29-/m0/s1",JINDDPNTLQVRRX-ACEFPKFPSA-N,Protein Kinase,DDR1,780,Q08345,"RTK6, CD167",Negative control for SR-302,,,,,,,21900,IC50,NanoBRET assay (HEK293T cells),https://pubmed.ncbi.nlm.nih.gov/34506142/,0,0,KinomeScan (DiscoverX),468,"Screened at 100 nM, closest targets as % of control: STK38L (24%), SRPK2 (34%), PIK3CA (44%), TNIK(45%), LRRK2(51%), NEK1(51%), RIOK1(54%), EIF2AK2 (55%), FYN (56%), STK32A (57%), RIPK2 (59%), FRK (60%), NIM1K (60%), PRPF4B (60%)",https://pubmed.ncbi.nlm.nih.gov/34506142/,Kinase set,100 nM
EUB0001060a_DDR2,SR301,EUB0001060a,CS(N1CCCC(NC([C@@H](NC(C2=CC=C(CNC3=NC=NC4=C3[N][N]N4C5=CC=CC=C5)C=C2)=O)CCC6CCCCC6)=O)C1)(=O)=O,"InChI=1S/C34H43N9O4S/c1-48(46,47)42-20-8-11-27(22-42)38-34(45)29(19-16-24-9-4-2-5-10-24)39-33(44)26-17-14-25(15-18-26)21-35-31-30-32(37-23-36-31)43(41-40-30)28-12-6-3-7-13-28/h3,6-7,12-15,17-18,23-24,27,29H,2,4-5,8-11,16,19-22H2,1H3,(H,38,45)(H,39,44)(H,35,36,37)/t27?,29-/m0/s1",JINDDPNTLQVRRX-ACEFPKFPSA-N,Protein Kinase,DDR2,4921,Q16832,TKT,Negative control for SR-302,,,,,,,15500,IC50,NanoBRET assay (HEK293T cells),https://pubmed.ncbi.nlm.nih.gov/34506142/,0,0,KinomeScan (DiscoverX),468,"Screened at 100 nM, closest targets as % of control: STK38L (24%), SRPK2 (34%), PIK3CA (44%), TNIK(45%), LRRK2(51%), NEK1(51%), RIOK1(54%), EIF2AK2 (55%), FYN (56%), STK32A (57%), RIPK2 (59%), FRK (60%), NIM1K (60%), PRPF4B (60%)",https://pubmed.ncbi.nlm.nih.gov/34506142/,Kinase set,100 nM
EUB0001060a_MAPK11,SR301,EUB0001060a,CS(N1CCCC(NC([C@@H](NC(C2=CC=C(CNC3=NC=NC4=C3[N][N]N4C5=CC=CC=C5)C=C2)=O)CCC6CCCCC6)=O)C1)(=O)=O,"InChI=1S/C34H43N9O4S/c1-48(46,47)42-20-8-11-27(22-42)38-34(45)29(19-16-24-9-4-2-5-10-24)39-33(44)26-17-14-25(15-18-26)21-35-31-30-32(37-23-36-31)43(41-40-30)28-12-6-3-7-13-28/h3,6-7,12-15,17-18,23-24,27,29H,2,4-5,8-11,16,19-22H2,1H3,(H,38,45)(H,39,44)(H,35,36,37)/t27?,29-/m0/s1",JINDDPNTLQVRRX-ACEFPKFPSA-N,Protein Kinase,MAPK11,5600,Q15759,"p38-2, p38Beta, SAPK2",Negative control for SR-302,,,,,,,1630,IC50,NanoBRET assay (HEK293T cells),https://pubmed.ncbi.nlm.nih.gov/34506142/,0,0,KinomeScan (DiscoverX),468,"Screened at 100 nM, closest targets as % of control: STK38L (24%), SRPK2 (34%), PIK3CA (44%), TNIK(45%), LRRK2(51%), NEK1(51%), RIOK1(54%), EIF2AK2 (55%), FYN (56%), STK32A (57%), RIPK2 (59%), FRK (60%), NIM1K (60%), PRPF4B (60%)",https://pubmed.ncbi.nlm.nih.gov/34506142/,Kinase set,100 nM
EUB0001060a_MAPK14,SR301,EUB0001060a,CS(N1CCCC(NC([C@@H](NC(C2=CC=C(CNC3=NC=NC4=C3[N][N]N4C5=CC=CC=C5)C=C2)=O)CCC6CCCCC6)=O)C1)(=O)=O,"InChI=1S/C34H43N9O4S/c1-48(46,47)42-20-8-11-27(22-42)38-34(45)29(19-16-24-9-4-2-5-10-24)39-33(44)26-17-14-25(15-18-26)21-35-31-30-32(37-23-36-31)43(41-40-30)28-12-6-3-7-13-28/h3,6-7,12-15,17-18,23-24,27,29H,2,4-5,8-11,16,19-22H2,1H3,(H,38,45)(H,39,44)(H,35,36,37)/t27?,29-/m0/s1",JINDDPNTLQVRRX-ACEFPKFPSA-N,Protein Kinase,MAPK14,1432,Q16539,"PRKM14, p38, Mxi2, PRKM15",Negative control for SR-302,,,,,,,5390,IC50,NanoBRET assay (HEK293T cells),https://pubmed.ncbi.nlm.nih.gov/34506142/,0,0,KinomeScan (DiscoverX),468,"Screened at 100 nM, closest targets as % of control: STK38L (24%), SRPK2 (34%), PIK3CA (44%), TNIK(45%), LRRK2(51%), NEK1(51%), RIOK1(54%), EIF2AK2 (55%), FYN (56%), STK32A (57%), RIPK2 (59%), FRK (60%), NIM1K (60%), PRPF4B (60%)",https://pubmed.ncbi.nlm.nih.gov/34506142/,Kinase set,100 nM
EUB0001572a_OGA,TP-040,EUB0001572a,CC1CCN(c2ccnc(NCc3cn(C)cn3)n2)CC1,"InChI=1S/C15H22N6/c1-12-4-7-21(8-5-12)14-3-6-16-15(19-14)17-9-13-10-20(2)11-18-13/h3,6,10-12H,4-5,7-9H2,1-2H3,(H,16,17,19)",PWKAYICUBVNJAZ-UHFFFAOYSA-N,,OGA,10724,O60502,"OGA, HEXC, KIAA0679, MEA5, MGEA5",Inhibitor,TP-040n,46,IC50,Fluorescent enzymatic assay,https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01712,0,450,EC50,In-cell western assay (measuring induction of glycosylation by an increase in O-GlcNAcylated protein levels in human neuroblastoma SH-SY5Y cells),https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01712,0,0,Kinase panel (literature),277,"Screened at 1 µM, clean selectivity profile with no kinase inhibited >50%; Screened at 10 µM against 45 GPCRs (PDSP screen), in vitro-potencies of closest targets: Ki(HTR2C) = 373.79 nM, Ki(GABAA/BZP) = 511.7 nM, Ki(HTR1D) = 417.5 nM, Ki(HTR2B) = 699.39 nM, Ki(SLC6A2) = 1935.54 nM, Ki(ADRA2B) = 2570.64 nM, Ki(ADRA2C) = 3432.79 nM",https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01712,Other targets set,1 µM
EUB0001573a_OGA,TP-040n,EUB0001573a,CN1CCN(c2ccnc(NCCc3ccccc3)n2)CC1,"InChI=1S/C17H23N5/c1-21-11-13-22(14-12-21)16-8-10-19-17(20-16)18-9-7-15-5-3-2-4-6-15/h2-6,8,10H,7,9,11-14H2,1H3,(H,18,19,20)",BNXNWRSVYQHTOH-UHFFFAOYSA-N,,OGA,10724,O60502,"OGA, HEXC, KIAA0679, MEA5, MGEA5",Negative control for TP-040,,10000,IC50,Fluorescent enzymatic assay,https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/TP-040,>,,,,,,1,GPCR panel (PDSP screen),45,"Screened at 10 µM, in-vitro potencies of closest targets: Ki(HRH3) = 92.76 nM, Ki(SIGMAR1) = 125.1 nM, Ki(HRH2) = 148.82, Ki(HTR2C) = 266.79 nM, Ki(HTR2B) = 290.75 nM, Ki(HTR7) = 334.53 nM, Ki(ADRA2C) = 414.29 nM, Ki(ADRA2B) = 475.35 nM, Ki(HTR6) = 606.4 nM, Ki(HTR2A) = 757.58 nM, Ki(HRH4) = 711.87 nM, Ki(SLC6A3) = 864.98 nM, Ki(TMEM97) = 1463.21 nM, Ki(HTR1D) = 2037.31, Ki(SLC6A2) = 3112.25 nM, Ki(HTR5A) = 6131.61 nM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!gpcrscandataview/TP-040,Other targets set,1 µM
EUB0001556a_GRIN2A,TP-050,EUB0001556a,Cc1cn([C@H](C)CC#N)c(=O)c2cc(Cn3nc(C(F)F)cc3Cl)nn12,"InChI=1S/C16H15ClF2N6O/c1-9(3-4-20)23-7-10(2)25-13(16(23)26)5-11(21-25)8-24-14(17)6-12(22-24)15(18)19/h5-7,9,15H,3,8H2,1-2H3/t9-/m1/s1",BEBDKSYNJJVZSO-SECBINFHSA-N,Ion Channel,GRIN2A,2903,Q12879,"EPND, FESD, GluN2A, LKS, NMDAR2A, NR2A",Positive allosteric modulator,TP-050n,,,,,,510,EC50,Ca2+ influx assay (using CHO cells expressing GluN2A/GluN1a in the presence of glutamate at an EC30 concentration),https://www.sciencedirect.com/science/article/pii/S0968089621005848?via%3Dihub,0,0,NMDA receptor panel,3,"Screened in Ca2+ influx assay (using CHO cells expressing NMDA receptor subtype in the presence of glutamate at an EC30 concentration): EC50(GluN2A) = 0.51 µM, max potentiation at 30 µM = 350%; EC50(GluN2B) n.d., max potentiation at 30 µM <150%, EC50(GluN2C) >30 µM, max potentiation at 30 µM = 200%, EC50(GluN2D) = 9.6 µM, max potentiation at 30 µM = 260%; AMPA binding (scintillation proximity assay, SPA, with 100 µM glutamate): IC50 >30 µM; Screened at 10 µM against 47 targets (SAFETYscan assays, DiscoverX), in-vitro potencies of targets: IC50(PDE3A) = 7.9 µM (56% inhibition), others IC50 >10 µM",https://www.sciencedirect.com/science/article/pii/S0968089621005848?via%3Dihub,Ion Channel,1 µM
EUB0001557a_GRIN2A,TP-050n,EUB0001557a,Cc1cn([C@@H](C)CC#N)c(=O)c2cc(Cn3nc(C(F)F)cc3Cl)nn12,"InChI=1S/C16H15ClF2N6O/c1-9(3-4-20)23-7-10(2)25-13(16(23)26)5-11(21-25)8-24-14(17)6-12(22-24)15(18)19/h5-7,9,15H,3,8H2,1-2H3/t9-/m0/s1",BEBDKSYNJJVZSO-VIFPVBQESA-N,Ion Channel,GRIN2A,2903,Q12879,"EPND, FESD, GluN2A, LKS, NMDAR2A, NR2A",Negative control for TP-050,,,,,,,30000,EC50,Ca2+ influx assay (using CHO cells expressing GluN2A/GluN1a in the presence of glutamate at an EC30 concentration),https://www.sciencedirect.com/science/article/pii/S0968089621005848?via%3Dihub,>,,,,"Screened in Ca2+ influx assay (using CHO cells expressing NMDA receptor subtype in the presence of glutamate at an EC30 concentration): EC50(GluN2A)>30 µM, max potentiation at 30 µM <150%; AMPA binding (scintillation proximity assay (SPA) with 100 µM glutamate): IC50 >30 µM",https://www.sciencedirect.com/science/article/pii/S0968089621005848?via%3Dihub,Ion Channel,1 µM
EUB0001554a_FFAR1,TP-051,EUB0001554a,Cc1cc(OC2CCS(=O)(=O)CC2)cc(C)c1-c1cccc(COc2ccc(CCC(=O)O)c(F)c2)c1,"InChI=1S/C29H31FO6S/c1-19-14-26(36-24-10-12-37(33,34)13-11-24)15-20(2)29(19)23-5-3-4-21(16-23)18-35-25-8-6-22(27(30)17-25)7-9-28(31)32/h3-6,8,14-17,24H,7,9-13,18H2,1-2H3,(H,31,32)",RPAHCZZXEGWBDL-UHFFFAOYSA-N,GPCR,FFAR1,2864,O14842,FFA1R,agonist,TP-051n,16,Ki,Radiometric GPR40 receptor binding assay,https://pubs.acs.org/doi/10.1021/jm2016123,0,25,EC50,FLIPR assay (Ca influx activity of CHO cells expressing human GPR40),https://pubs.acs.org/doi/10.1021/jm2016123,0,0,Eurofins Panlabs panel,118,"Screened at 10 µM, closest targets as % of inhibition: ALOX5 (85%), TBXAS1 (64%), EGFR (61%), MAPK14 (60%), TBXA2R (60%), others >10 µM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/TP-051,GPCR set,1 µM
EUB0001555_FFAR1,TP-051n,EUB0001555,Cc1cc(OC2CCS(=O)(=O)CC2)cc(C)c1-c1cccc(COc2ccc(C(=O)O)c(F)c2)c1,"InChI=1S/C27H27FO6S/c1-17-12-23(34-21-8-10-35(31,32)11-9-21)13-18(2)26(17)20-5-3-4-19(14-20)16-33-22-6-7-24(27(29)30)25(28)15-22/h3-7,12-15,21H,8-11,16H2,1-2H3,(H,29,30)",OLFCZVVFPNDHIW-UHFFFAOYSA-N,GPCR,FFAR1,2864,O14842,FFA1R,Negative control for TP-051,,10000,Ki,Radiometric GPR40 receptor binding assay,https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/TP-051,>,10000,EC50,FLIPR assay (Ca influx activity of CHO cells expressing human GPR40),https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/TP-051,>,0,Eurofins Panlabs panel,118,"Screened at 10 µM, closest targets as % of inhibition: LYN (70%), MAPK14 (66%), PKC non-selective (-114%), others >10 µM",https://www.sgc-ffm.uni-frankfurt.de/chemProbes#!specificprobeoverview/TP-051,GPCR set,1 µM
